FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Schulz, A
Cohen-Pfeffer, J
Crystal, R
de los Reyes, E
Eto, Y
Guelbert, N
Heron, B
Mikhailova, S
Miller, N
Mink, JW
Perez-Poyato, MS
Simonati, A
Sims, K
Williams, RE
AF Schulz, Angela
Cohen-Pfeffer, Jessica
Crystal, Ronald
de los Reyes, Emily
Eto, Yoshikatsu
Guelbert, Norberto
Heron, Benedicte
Mikhailova, Svetlana
Miller, Nicole
Mink, Jonathan W.
Socorro Perez-Poyato, Maria
Simonati, Alessandro
Sims, Katherine
Williams, Ruth E.
TI NEURONAL CEROID LIPOFUSCINOSIS-2 (CLN2) DISEASE, A TYPE OF BATTEN
DISEASE CAUSED BY TPP1 ENZYME DEFICIENCY: CURRENT KNOWLEDGE OF THE
NATURAL HISTORY FROM INTERNATIONAL EXPERTS
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Meeting Abstract
CT 39th Annual Meeting of the Society-for-Inherited-Metabolic-Disorders
(SIMD)
CY APR 03-06, 2016
CL Ponte Vedra Beach, FL
SP Soc Inherited Metab Disorders
C1 [Schulz, Angela] Univ Med Ctr Hamburg Eppendorf, Dept Paediat, Hamburg, Germany.
[Cohen-Pfeffer, Jessica; Miller, Nicole] BioMarin Pharmaceut Inc, Global Med Affairs, Novato, CA USA.
[Crystal, Ronald] Weill Cornell Med Coll, Dept Med Genet, New York, NY USA.
[de los Reyes, Emily] Nationwide Childrens Hosp, Dept Pediat Neurol, Columbus, OH USA.
[Eto, Yoshikatsu] Southern Tohoku Brain Res Ctr, Adv Clin Res Ctr, Kawasaki, Kanagawa, Japan.
[Guelbert, Norberto] Hosp Ninos Cordoba, Cordoba, Argentina.
[Heron, Benedicte] CHU Paris Est Hop Enfants Armand Trousseau, Serv Neuropediat, Paris, France.
[Mikhailova, Svetlana] Russian Pediat Reg Hosp, Dept Med Genet, Moscow, Russia.
[Mink, Jonathan W.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
[Socorro Perez-Poyato, Maria] Hosp Univ Marques de Valdecilla, Unit Pediat Neurol, Santander, Cantabria, Spain.
[Simonati, Alessandro] Univ Verona, Dept Neurol & Movement Sci Neurol, I-37100 Verona, Italy.
[Sims, Katherine] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Williams, Ruth E.] Guys & St Thomas NHS Fdn Trust, Childrens Neurosci, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD MAR
PY 2016
VL 117
IS 3
MA 101
BP 283
EP 284
PG 2
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
Medicine
GA DH3JP
UT WOS:000372683600120
ER
PT J
AU Williams, RE
Cohen-Pfeffer, J
Adams, H
Blohm, M
de los Reyes, E
Denecke, J
Drago, K
Fairhurst, C
Frazier, M
Guelbert, N
Kiss, S
Kofler, A
Lawson, J
Lehwald, L
Leung, MA
Mikhailova, S
Mink, J
Nickel, M
Shediac, R
Sims, K
Specchio, N
Topcu, M
von Lobbecke, I
West, A
Schulz, A
AF Williams, Ruth E.
Cohen-Pfeffer, Jessica
Adams, Heather
Blohm, Martin
de los Reyes, Emily
Denecke, Jonas
Drago, Kristen
Fairhurst, Charlie
Frazier, Margie
Guelbert, Norberto
Kiss, Szilard
Kofler, Annamaria
Lawson, John
Lehwald, Lenora
Leung, Mary-Anne
Mikhailova, Svetlana
Mink, Jonathan
Nickel, Miriam
Shediac, Renee
Sims, Katherine
Specchio, Nicola
Topcu, Meral
von Lobbecke, Ina
West, Andrea
Schulz, Angela
TI EXPERT OPINION ON THE MANAGEMENT OF CLN2 DISEASE
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Meeting Abstract
CT 39th Annual Meeting of the Society-for-Inherited-Metabolic-Disorders
(SIMD)
CY APR 03-06, 2016
CL Ponte Vedra Beach, FL
SP Soc Inherited Metab Disorders
C1 [Williams, Ruth E.; Fairhurst, Charlie; Leung, Mary-Anne] Evelina London Childrens Hosp, London, England.
[Cohen-Pfeffer, Jessica; Shediac, Renee] BioMarin Pharmaceut Inc, Novato, CA USA.
[Adams, Heather; Mink, Jonathan] Univ Rochester, Sch Med, Rochester, NY USA.
[Blohm, Martin; Denecke, Jonas; Nickel, Miriam; Schulz, Angela] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany.
[de los Reyes, Emily; Lehwald, Lenora] Nationwide Childrens Hosp, Columbus, OH USA.
[Drago, Kristen] Journeycare Children, Chicago, IL USA.
[Frazier, Margie] BDSRA, Columbus, OH USA.
[Guelbert, Norberto] Childrens Hosp Cordoba, Cordoba, Argentina.
[Kiss, Szilard] Weill Cornell Med Coll, New York, NY USA.
[Kofler, Annamaria; Specchio, Nicola] IRCCS, Bambino Gesu Childrens Hosp, Rome, Italy.
[Lawson, John] Sydney Childrens Hosp, Sydney, NSW, Australia.
[Mikhailova, Svetlana] Russian Reg Pediat Hosp, Moscow, Russia.
[Sims, Katherine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Topcu, Meral] Hacettepe Univ, Ankara, Turkey.
[West, Andrea] BDFA, Farnborough, Hants, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD MAR
PY 2016
VL 117
IS 3
MA 122
BP 293
EP 293
PG 1
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
Medicine
GA DH3JP
UT WOS:000372683600141
ER
PT J
AU Blakeley, JO
Coons, SJ
Corboy, JR
Leidy, NK
Mendoza, TR
Wefel, JS
AF Blakeley, Jaishri O.
Coons, Stephen Joel
Corboy, John R.
Leidy, Nancy Kline
Mendoza, Tito R.
Wefel, Jeffrey S.
TI Clinical outcome assessment in malignant glioma trials: measuring signs,
symptoms, and functional limitations
SO NEURO-ONCOLOGY
LA English
DT Article
DE clinical outcome assessment; clinical trials; endpoints; malignant
glioma
ID QUALITY-OF-LIFE; NEWLY-DIAGNOSED GLIOBLASTOMA; KARNOFSKY PERFORMANCE
STATUS; MODULE EORTC QLQ-BN20; RANDOMIZED PHASE-III; BRAIN-TUMOR MODULE;
HIGH-GRADE GLIOMAS; EUROPEAN-ORGANIZATION; NEUROCOGNITIVE FUNCTION;
COGNITIVE FUNCTION
AB The shared goal of all parties developing therapeutics against malignant gliomas is to positively impact the lives of people affected by these cancers. Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall survival and radiographic endpoints. This review examines the properties of various COA measures used in malignant glioma clinical trials to date and cross references their content to the priority signs, symptoms, and functional limitations defined through a community survey conducted by the National Brain Tumor Society. The overarching goal of this initiative is to identify COA measures that are feasible and have appropriate psychometric properties for use in this patient population as well as highlight where further development is needed.
C1 [Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.
[Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21287 USA.
[Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA.
[Coons, Stephen Joel] Crit Path Inst, 1730 E River Rd, Tucson, AZ USA.
[Corboy, John R.] Univ Colorado, Sch Med, Denver Vet Affairs Med Ctr, 12631 East 17th Ave B185, Aurora, CO USA.
[Leidy, Nancy Kline] Evidera, 7101Wisconsin Ave,Suite 1400, Bethesda, MD USA.
[Mendoza, Tito R.; Wefel, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Bld, Houston, TX 77030 USA.
RP Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.; Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21287 USA.; Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA.
EM jblakel3@jhmi.edu
NR 57
TC 0
Z9 0
U1 2
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD MAR
PY 2016
VL 18
SU 2
BP 13
EP 20
DI 10.1093/neuonc/nov291
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA DH9KO
UT WOS:000373115200002
ER
PT J
AU Helfer, JL
Wen, PY
Blakeley, J
Gilbert, MR
Armstrong, TS
AF Helfer, Jennifer L.
Wen, Patrick Y.
Blakeley, Jaishri
Gilbert, Mark R.
Armstrong, Terri S.
TI Report of the Jumpstarting Brain Tumor Drug Development Coalition and
FDA clinical trials clinical outcome assessment endpoints workshop
(October 15, 2014, Bethesda MD)
SO NEURO-ONCOLOGY
LA English
DT Article
DE brain tumor; clinical outcome assessment; endpoints; high-grade gliomas;
patient-reported outcomes
ID NEWLY-DIAGNOSED GLIOBLASTOMA; SYMPTOM INVENTORY; RANDOMIZED-TRIAL;
MODULE; CANCER; MYELOFIBROSIS; RUXOLITINIB; BEVACIZUMAB; VALIDATION;
THERAPY
AB On October 15, 2014, a workshop was held on the use of clinical outcome assessments in clinical trials for high-grade glioma of the brain. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, the Musella Foundation for Brain Tumor Research and Information, and Accelerate Brain Cancer Cure. It was planned and carried out with participation from the US Food and Drug Administration. The workshop also included stakeholders from all aspects of the brain tumor community, including clinicians, researchers, industry, clinical research organizations, patients and patient advocates, and the National Cancer Institute. This report summarizes the presentations and discussions of that workshop and the proposals that emerged to move the field forward and toward greater inclusion of these endpoints in future clinical trials for high-grade gliomas.
C1 [Helfer, Jennifer L.] Natl Brain Tumor Soc, 55 Chapel St,Suite 200, Newton, MA 02458 USA.
[Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA.
[Blakeley, Jaishri] Johns Hopkins Univ, Brain Canc Program, Dept Neurooncol, Baltimore, MD USA.
[Gilbert, Mark R.] NCI, Ctr Canc Res, Neurooncol Branch, Bethesda, MD 20892 USA.
[Armstrong, Terri S.] Univ Texas Houston, Hlth Sci Ctr, Sch Nursing, Dept Family Hlth, Houston, TX USA.
RP Helfer, JL (reprint author), Natl Brain Tumor Soc, 55 Chapel St,Suite 200, Newton, MA 02458 USA.
EM jhelfer@braintumor.org
RI Gilbert, Mark/J-7494-2016
OI Gilbert, Mark/0000-0003-2556-9722
FU Angiochem; Astra Zeneca; Genentech/Roche; GlaxoSmith Kline; Merck;
Novartis; Sanofi-Aventis; Vascular Biogenics; Abbvie
FX P.Y.W. has received research support from Angiochem, Astra Zeneca,
Genentech/Roche, GlaxoSmith Kline, Merck, Novartis, Sanofi-Aventis, and
Vascular Biogenics; serves on the advisory board of Abbvie, Celldex,
Foundation Medicine, Genentech/Roche, Novartis, SigmaTau, Vascular
Biogenics, Midatech, and Momenta; and has been a speaker for Merck. J.B.
reports grants from GlaxoSmith Kline and served as a paid consultant for
Abbvie. T.S.A. served as a consultant for Abbvie, Immunocellular
Therapeutics, and Tocagen. J.L.H. and M.R.G. report no conflicts.
NR 23
TC 0
Z9 0
U1 2
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD MAR
PY 2016
VL 18
SU 2
BP 26
EP 36
DI 10.1093/neuonc/nov270
PG 11
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA DH9KO
UT WOS:000373115200004
ER
PT J
AU Chabner, BA
AF Chabner, Bruce A.
TI While We're at It, Let's Whack the FDA
SO ONCOLOGIST
LA English
DT Editorial Material
C1 [Chabner, Bruce A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Chabner, BA (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM bchabner@partners.org
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD MAR
PY 2016
VL 21
IS 3
BP 259
EP 260
DI 10.1634/theoncologist.2016-0041
PG 2
WC Oncology
SC Oncology
GA DH9MR
UT WOS:000373120700001
PM 26869585
ER
PT J
AU Greer, JA
Amoyal, N
Nisotel, L
Fishbein, JN
MacDonald, J
Stagl, J
Lennes, I
Temel, JS
Safren, SA
Pirl, WF
AF Greer, Joseph A.
Amoyal, Nicole
Nisotel, Lauren
Fishbein, Joel N.
MacDonald, James
Stagl, Jamie
Lennes, Inga
Temel, Jennifer S.
Safren, Steven A.
Pirl, William F.
TI A Systematic Review of Adherence to Oral Antineoplastic Therapies
SO ONCOLOGIST
LA English
DT Review
DE Patient adherence; Medication adherence; Oral drug administration;
Antineoplastic agents; Chemotherapy; Endocrine therapy
ID CHRONIC MYELOID-LEUKEMIA; BREAST-CANCER PATIENTS; ADJUVANT ENDOCRINE
THERAPY; GASTROINTESTINAL STROMAL TUMORS; PATIENTS ANASTROZOLE
COMPLIANCE; HORMONAL-THERAPY; AROMATASE INHIBITORS; POSTMENOPAUSAL
WOMEN; ANTICANCER AGENTS; IMATINIB THERAPY
AB Background. Oral antineoplastic therapies not only improve survival but also reduce the burden of care for patients. Yet patients and clinicians face new challenges in managing adherence to these oral therapies. We conducted a systematic literature review to assess rates and correlates of adherence to oral antineoplastic therapies and interventions aimed at improving adherence.
Methods. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a comprehensive literature search of the Ovid MEDLINE database from January 1, 2003 to June 30, 2015, using relevant terminology for oral antineoplastic agents. We included observational, database, and intervention studies. At least two researchers evaluated each paper to ensure accuracy of results and determine risk of bias.
Results. We identified 927 records from the search and screened 214 abstracts. After conducting a full-text review of 167 papers, we included in the final sample 51 papers on rates/correlates of adherence to oral antineoplastic therapy and 12 papers on intervention studies to improve adherence. Rates of adherence varied widely, from 46% to 100%, depending on patient sample, medication type, follow-up period, assessment measure, and calculation of adherence. Of the intervention studies, only 1 of the randomized trials and 2 of the cohort studies showed benefit regarding adherence, with the majority suffering high risk of bias.
Conclusions. Although no reliable estimate of adherence to oral antineoplastic therapies can be gleaned from the literature, a substantial proportion of patients struggle to adhere to these medications as prescribed. The few intervention studies for adherence have notable methodological concerns, thereby limiting the evidence to guide practice in promoting medication adherence among patients with cancer.
C1 [Greer, Joseph A.; Amoyal, Nicole; Nisotel, Lauren; Fishbein, Joel N.; MacDonald, James; Stagl, Jamie; Lennes, Inga; Temel, Jennifer S.; Pirl, William F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Greer, Joseph A.; Amoyal, Nicole; Nisotel, Lauren; Fishbein, Joel N.; MacDonald, James; Stagl, Jamie; Lennes, Inga; Temel, Jennifer S.; Pirl, William F.] Harvard Univ, Sch Med, Boston, MA USA.
[Safren, Steven A.] Univ Miami, Coral Gables, FL 33124 USA.
RP Greer, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Psychiat Oncol & Behav Sci, Yawkey Bldg,Suite 10B,55 Fruit St, Boston, MA 02114 USA.
EM jgreer2@mgh.harvard.edu
OI Jacobs, Jamie M./0000-0001-9740-624X
FU Patient-Centered Outcomes Research Institute [IHS-1306-03616]
FX Funding for this study was supported by the Patient-Centered Outcomes
Research Institute (IHS-1306-03616, PI: Greer). PROSPERO registration
number is CRD42014014785.
NR 92
TC 3
Z9 3
U1 2
U2 6
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD MAR
PY 2016
VL 21
IS 3
BP 354
EP 376
DI 10.1634/theoncologist.2015-0405
PG 23
WC Oncology
SC Oncology
GA DH9MR
UT WOS:000373120700015
PM 26921292
ER
PT J
AU McInnis, KC
Ramey, LN
AF McInnis, Kelly C.
Ramey, Lindsay N.
TI High-Risk Stress Fractures: Diagnosis and Management
SO PM&R
LA English
DT Review
ID YOUNG MALE-ADULTS; FEMORAL-NECK; BONE STRESS; 5TH-METATARSAL FRACTURES;
SURGICAL-TREATMENT; MEDIAL MALLEOLUS; VITAMIN-D; CONSERVATIVE
MANAGEMENT; RADIOGRAPHIC EVALUATION; MILITARY RECRUITS
AB Stress fractures are common overuse injuries in athletes. They occur during periods of increased training without adequate rest, disrupting normal bone reparative mechanisms. There are a host of intrinsic and extrinsic factors, including biochemical and biomechanical, that put athletes at risk. In most stress fractures, the diagnosis is primarily clinical, with imaging indicated at times, and management focused on symptom-free relative rest with advancement of activity as tolerated. Overall, stress fractures in athletes have an excellent prognosis for return to sport, with little risk of complication. There is a subset of injuries that have a greater risk of fracture progression, delayed healing, and nonunion and are generally more challenging to treat with nonoperative care. Specific locations of high-risk stress fracture include the femoral neck (tension side), patella, anterior tibia, medial malleolus, talus, tarsal navicular, proximal fifth metatarsal, and great toe sesamoids. These sites share a characteristic region of high tensile load and low blood flow. High-risk stress fractures require a more aggressive approach to evaluation, with imaging often necessary, to confirm early and accurate diagnosis and initiate immediate treatment. Treatment consists of nonweight-bearing immobilization, often with a prolonged period away from sport, and a more methodic and careful reintroduction to athletic activity. These stress fractures may require surgical intervention. A high index of suspicion is essential to avoid delayed diagnosis and optimize outcomes in this subset of stress fractures.
C1 [McInnis, Kelly C.; Ramey, Lindsay N.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA.
[McInnis, Kelly C.] Harvard Univ, Sch Med, Ctr Sports Med, Boston, MA USA.
[McInnis, Kelly C.] Massachusetts Gen Hosp, Sports Med Serv, 175 Cambridge St, Boston, MA 02114 USA.
[Ramey, Lindsay N.] Harvard Univ, Sch Med, Boston, MA USA.
RP McInnis, KC (reprint author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA.; McInnis, KC (reprint author), Harvard Univ, Sch Med, Ctr Sports Med, Boston, MA USA.; McInnis, KC (reprint author), Massachusetts Gen Hosp, Sports Med Serv, 175 Cambridge St, Boston, MA 02114 USA.
EM kcmcinnis@partners.org
NR 105
TC 4
Z9 4
U1 16
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD MAR
PY 2016
VL 8
IS 3
SU S
BP S113
EP S124
DI 10.1016/j.pmrj.2015.09.019
PG 12
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA DH5UZ
UT WOS:000372858900014
PM 26972260
ER
PT J
AU Reiff, ES
Little, SE
Dobson, L
Wilkins-Haug, L
Bromley, B
AF Reiff, Emily S.
Little, Sarah E.
Dobson, Lori
Wilkins-Haug, Louise
Bromley, Bryann
TI What is the role of the 11-to 14-week ultrasound in women with negative
cell-free DNA screening for aneuploidy?
SO PRENATAL DIAGNOSIS
LA English
DT Article
ID INCREASED NUCHAL TRANSLUCENCY; FETAL STRUCTURAL ANOMALIES; CHROMOSOMAL
MICROARRAY; ABNORMALITIES; GESTATION; DIAGNOSIS; 1ST-TRIMESTER; FETUSES;
SCAN
AB ObjectiveThis study aimed to examine the role of the 11- to 14-week ultrasound in women with negative cell-free DNA screening.
MethodsA retrospective cohort study of women at increased risk for aneuploidy based on age or medical history and negative cell-free DNA screening between March 2012 and March 2014 was conducted. Patients were included if they had an 11- to 14-week ultrasound and obstetrical care at our center(s). Primary outcome was an unexpected finding at ultrasound. Imaging findings were compared with obstetrical outcome by medical record review.
ResultsStudy group was composed of 1739 patients. An unexpected finding was identified in 60/1739 (3.5%). An abnormal fetal finding occurred in 37 living fetuses (2.1%); 33 had a nuchal translucency (NT)3mm, including four isolated' cystic hygroma and three with a structural abnormality. Four fetuses had a structural anomaly without a thick NT. Karyotype confirmed euploidy in 98.7% of available cases. Pregnancy termination was chosen by 63.6% of those with cystic hygroma or anomaly at the 11- to 14-week scan. Unexpected multiples were identified in 13 (0.7%) women and a fetal demise in 10 (0.6%).
ConclusionUnexpected findings at the 11- to 14-week scan occur in 3.5% of patients with negative cell-free DNA. Recognition provides options for comprehensive testing, consultation, and management. (c) 2016 John Wiley & Sons, Ltd.
What's already known about this topic? Noninvasive prenatal screening for aneuploidy by cell-free DNA has superior performance metrics for detection of targeted trisomies when compared with standard aneuploidy screening methods and does not require an 11- to 14-week fetal scan.
What does this study add? The 11- to 14-week scan demonstrates unexpected findings in 3.5% of patients with negative noninvasive prenatal screening by cell-free DNA including 2.1% with fetal findings that place them at increased risk for other genetic and/or structural anomalies.
C1 [Reiff, Emily S.; Little, Sarah E.; Dobson, Lori; Wilkins-Haug, Louise; Bromley, Bryann] Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA.
[Reiff, Emily S.; Bromley, Bryann] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Bromley, Bryann] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
[Reiff, Emily S.; Little, Sarah E.; Wilkins-Haug, Louise; Bromley, Bryann] Harvard Univ, Sch Med, Boston, MA USA.
[Bromley, Bryann] Diagnost Ultrasound Associates PC, Boston, MA USA.
RP Reiff, ES (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA.; Reiff, ES (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.; Reiff, ES (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
EM ereiff@partners.org
NR 35
TC 4
Z9 4
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0197-3851
EI 1097-0223
J9 PRENATAL DIAG
JI Prenat. Diagn.
PD MAR
PY 2016
VL 36
IS 3
BP 260
EP 265
DI 10.1002/pd.4774
PG 6
WC Genetics & Heredity; Obstetrics & Gynecology
SC Genetics & Heredity; Obstetrics & Gynecology
GA DH1OR
UT WOS:000372555000009
PM 26748490
ER
PT J
AU Zgibor, JC
Schlenk, EA
Vater, L
Kola, S
Vander Bilt, J
Woody, S
Jacob, ME
Lo-Ciganic, WH
Brenckle, A
Brandenstein, J
Kwoh, CK
Boudreau, R
Albert, S
Conroy, M
Rodgers, E
Newman, AB
AF Zgibor, Janice C.
Schlenk, Elizabeth A.
Vater, Laura
Kola, Sushma
Vander Bilt, Joni
Woody, Sarah
Jacob, Mini E.
Lo-Ciganic, Wei-Hsuan
Brenckle, Allison
Brandenstein, Jane
Kwoh, C. Kent
Boudreau, Robert
Albert, Steven
Conroy, Margaret
Rodgers, Elizabeth
Newman, Anne B.
TI Partnership Building and Implementation of an Integrated Healthy-Aging
Program
SO PROGRESS IN COMMUNITY HEALTH PARTNERSHIPS-RESEARCH EDUCATION AND ACTION
LA English
DT Article
DE Community; partnership; exercise; preventive behavior; prevention;
healthy aging
ID LOWER-EXTREMITY FUNCTION; PREVENTION PROGRAM; PHYSICAL-ACTIVITY;
EXERCISE PROGRAM; SELF-MANAGEMENT; CHRONIC DISEASE; 10 KEYS; COMMUNITY;
ARTHRITIS; DISABILITY
AB Background: Evidence-based interventions exist for prevention of chronic disease in older adults. Partnering with community organizations may provide a mechanism for disseminating these interventions.
Objective: To describe the partnership and program implementation by the Arthritis Foundation (AF) and the University of Pittsburgh.
Methods: The AF Exercise Program (AFEP; an existing evidence-based program) was enhanced with the "10 Keys"(TM) to Healthy Aging (a prevention-focused program bundling the most common risk factors for chronic disease and disability in older adults and applies behavior change strategies to enhance prevention). The program was delivered in 20 sessions over 10 weeks by community health workers in a cluster-randomized trial.
Lessons Learned: Partnering with an organization having an existing infrastructure supports program delivery at the community level. This partnership provided programming in 54 sites across Pittsburgh and surrounding communities.
Conclusions: This collaborative partnership created a productive synergy maximizing strengths in both research and program delivery.
C1 [Zgibor, Janice C.] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL 33620 USA.
[Schlenk, Elizabeth A.] Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15260 USA.
[Vater, Laura] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Kola, Sushma] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
[Vander Bilt, Joni; Boudreau, Robert; Rodgers, Elizabeth; Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
[Woody, Sarah] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21218 USA.
[Jacob, Mini E.] VA Boston Healthcare Syst, New England GRECC, Boston, MA USA.
[Jacob, Mini E.] Boston Univ, Hlth & Disabil Res Inst, Sch Publ Hlth, Boston, MA 02215 USA.
[Jacob, Mini E.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA.
[Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA.
[Brenckle, Allison; Brandenstein, Jane] Arthrit Fdn, Pittsburgh, PA USA.
[Kwoh, C. Kent] Coll Med, Dept Med, Div Rheumatol & Clin Rheumatol, Boston, MA USA.
[Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ 85721 USA.
[Albert, Steven] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15260 USA.
[Conroy, Margaret] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA.
RP Zgibor, JC (reprint author), Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL 33620 USA.
OI Albert, Steven/0000-0001-6786-9956; Schlenk,
Elizabeth/0000-0001-7361-1951; Boudreau, Robert/0000-0003-0162-5187
FU Centers for Disease Control and Prevention, Health Promotion and Disease
Prevention Research Center [U48DP001918]
FX This study was funded by the Centers for Disease Control and Prevention,
Health Promotion and Disease Prevention Research Center, U48DP001918.
NR 32
TC 0
Z9 0
U1 4
U2 4
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1557-0541
EI 1557-055X
J9 PROG COMM HLTH PARTN
JI Prog. Community Health Partnersh.
PD SPR
PY 2016
VL 10
IS 1
BP 123
EP 132
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DH3JB
UT WOS:000372682200016
PM 27018361
ER
PT J
AU Vohringer, PA
Perlis, RH
AF Voehringer, Paul A.
Perlis, Roy H.
TI Discriminating Between Bipolar Disorder and Major Depressive Disorder
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Diagnosis; Nosology; Misdiagnosis; Bipolar disorder; Major depressive
disorder; Irritability
ID COMORBIDITY SURVEY REPLICATION; TREATMENT ENHANCEMENT PROGRAM; LIFETIME
PREVALENCE; ANTIDEPRESSANT USE; CLINICAL-FEATURES; SPECTRUM DISORDER; II
DISORDER; STEP-BD; UNIPOLAR; ONSET
AB Rates of misdiagnosis between major depressive disorder and bipolar disorder have been reported to be substantial, and the consequence of such misdiagnosis is likely to be a delay in achieving effective control of symptoms, in some cases spanning many years. Particularly in the midst of a depressive episode, or early in the illness course, it may be challenging to distinguish the 2 mood disorders purely on the basis of cross-sectional features. To date, no useful biological markers have been reliably shown to distinguish between bipolar disorder and major depressive disorder.
C1 [Voehringer, Paul A.] Tufts Univ, Sch Med, Dept Psychiat, 800 Washington St, Boston, MA 02111 USA.
[Voehringer, Paul A.] Univ Chile, Dept Psychiat, Av Independencia 1027, Santiago 8071146, Chile.
[Perlis, Roy H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Expt Drugs & Diagnost,Dept Psychiat, 185 Cambridge St, Boston, MA 02114 USA.
RP Perlis, RH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Expt Drugs & Diagnost,Dept Psychiat, 185 Cambridge St, Boston, MA 02114 USA.
EM rperlis@mgh.harvard.edu
OI Vohringer, Paul A/0000-0002-2460-4680
NR 53
TC 1
Z9 1
U1 4
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
EI 1558-3147
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD MAR
PY 2016
VL 39
IS 1
BP 1
EP +
DI 10.1016/j.psc.2015.10.001
PG 11
WC Psychiatry
SC Psychiatry
GA DH8GV
UT WOS:000373032400002
PM 26876315
ER
PT J
AU Phillippe, M
Adeli, S
AF Phillippe, Mark
Adeli, Sharareh
TI Cell-Free DNA Production by Human Trophoblast Cells
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Phillippe, Mark; Adeli, Sharareh] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA T-073
BP 124A
EP 124A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200232
ER
PT J
AU Mitchell, C
Gaur, N
Kalsy, A
AF Mitchell, Caroline
Gaur, Nidhi
Kalsy, Anuj
TI Lactobacillus Crispatus Protects Vaginal Epithelial Cells from
Leptotrichia Amnionii-Induced Damage.
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Mitchell, Caroline; Gaur, Nidhi; Kalsy, Anuj] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA T-214
BP 167A
EP 167A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200372
ER
PT J
AU Reed, SD
Newton, KM
Larson, JC
Anawalt, BD
Booth-LaForce, CC
Woods, NF
Landis, CA
Freeman, EW
Joffe, H
Carpenter, JS
Guthrie, KA
AF Reed, Susan D.
Newton, Katherine M.
Larson, Joseph C.
Anawalt, Bradley D.
Booth-LaForce, Catherine C.
Woods, Nancy F.
Landis, Carol A.
Freeman, Ellen W.
Joffe, Hadine
Carpenter, Janet S.
Guthrie, Katherine A.
TI Daily Salivary Cortisol Patterns in Midlife Women with Hot Flashes.
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Reed, Susan D.; Anawalt, Bradley D.; Booth-LaForce, Catherine C.; Woods, Nancy F.; Landis, Carol A.] Univ Washington, Seattle, WA 98195 USA.
[Newton, Katherine M.] Grp Hlth Res Inst, Seattle, WA USA.
[Larson, Joseph C.; Guthrie, Katherine A.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Freeman, Ellen W.] Perleman SOM, Philadelphia, PA USA.
[Joffe, Hadine] Harvard, Dana Farber, Brigham & Womens, Boston, MA USA.
[Carpenter, Janet S.] Indiana Univ, Indianapolis, IN 46204 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA T-248
BP 177A
EP 178A
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200406
ER
PT J
AU Bellio, C
Foster, R
Growdon, WB
Rueda, BR
AF Bellio, Chiara
Foster, Rosemary
Growdon, Whitfield B.
Rueda, Bo R.
TI PARP Inhibitors for Treatment of Ovarian Cancer: The Downside of Good
Intentions.
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Bellio, Chiara; Foster, Rosemary; Growdon, Whitfield B.; Rueda, Bo R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bellio, Chiara; Foster, Rosemary; Growdon, Whitfield B.; Rueda, Bo R.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA T-252
BP 179A
EP 179A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200410
ER
PT J
AU Elias, KM
Lindsey, JS
Ng, NWC
Ginsburg, ES
Drapkin, R
Anchan, RM
AF Elias, Kevin M.
Lindsey, Jennifer S.
Ng, Nicholas W. C.
Ginsburg, Elizabeth S.
Drapkin, Ronny
Anchan, Raymond M.
TI Protection Against Chemotherapy Induced Premature Ovarian Failure Using
Granulosa Cell-Derived Induced Pluripotent Stem Cells.
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Elias, Kevin M.; Lindsey, Jennifer S.; Ng, Nicholas W. C.; Ginsburg, Elizabeth S.; Anchan, Raymond M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Elias, Kevin M.; Ginsburg, Elizabeth S.; Drapkin, Ronny; Anchan, Raymond M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 6
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA T-260
BP 181A
EP 181A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200418
ER
PT J
AU Peress, DA
Miller, ES
Bortoletto, P
Gossett, DR
AF Peress, Danielle A.
Miller, Emily S.
Bortoletto, Pietro
Gossett, Dana R.
TI Is Third Stage Oxytocin Administration Associated with an Increased Risk
of Retained Placentas?
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Peress, Danielle A.; Miller, Emily S.; Gossett, Dana R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Bortoletto, Pietro] Brigham & Womens Massachusetts Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA F-010
BP 189A
EP 189A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200445
ER
PT J
AU Liff, I
Adeli, S
Romero, R
Phillippe, M
AF Liff, Ingrid
Adeli, Sharareh
Romero, Roberto
Phillippe, Mark
TI Mechanism Underlying Progesterone Prolongation of Gestation in the Mouse
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Liff, Ingrid; Adeli, Sharareh; Phillippe, Mark] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Romero, Roberto] Wayne State Univ, Detroit, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA F-074
BP 209A
EP 209A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200509
ER
PT J
AU Cardozo, ER
Karmon, AE
Gatune, L
Foster, R
Rueda, BR
Styer, AK
AF Cardozo, Eden R.
Karmon, Anatte E.
Gatune, Leah
Foster, Rosemary
Rueda, Bo R.
Styer, Aaron K.
TI The Impact of MicroRNA 21a-5p on Mediators of Extracellular Matrix
Formation in Uterine Leiomyoma
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Cardozo, Eden R.; Karmon, Anatte E.; Gatune, Leah; Foster, Rosemary; Rueda, Bo R.; Styer, Aaron K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cardozo, Eden R.; Karmon, Anatte E.; Foster, Rosemary; Rueda, Bo R.; Styer, Aaron K.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA F-206
BP 250A
EP 250A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200641
ER
PT J
AU Hariton, E
Bortoletto, P
Cardozo, ER
Hochberg, EP
Sabatini, ME
AF Hariton, Eduardo
Bortoletto, Pietro
Cardozo, Eden R.
Hochberg, Ephraim P.
Sabatini, Mary E.
TI The Role of Oncofertility Clinics in Facilitating Access to Reproductive
Specialists.
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Hariton, Eduardo; Bortoletto, Pietro; Cardozo, Eden R.; Hochberg, Ephraim P.; Sabatini, Mary E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA F-251
BP 263A
EP 263A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200686
ER
PT J
AU Naqvi, M
Bryant, A
Kaimal, A
AF Naqvi, Mariam
Bryant, Allison
Kaimal, Anjali
TI Second Stage Length and Third and Fourth Degree Lacerations Among
Nulliparous Women
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Naqvi, Mariam; Bryant, Allison; Kaimal, Anjali] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA S-031
BP 279A
EP 279A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200738
ER
PT J
AU Naqvi, M
Scourtas, A
Hanmer, K
Khattaby, I
Roberts, D
AF Naqvi, Mariam
Scourtas, Aristana
Hanmer, Kaitlin
Khattaby, Ingy
Roberts, Drucilla
TI Placental Pathology and Ischemic Perinatal Stroke.
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 63rd Annual Scientific Meeting of the
Society-for-Reproductive-Investigation
CY MAR 16-19, 2016
CL Montreal, CANADA
SP Soc Reprod Invest
C1 [Naqvi, Mariam; Scourtas, Aristana; Hanmer, Kaitlin; Khattaby, Ingy; Roberts, Drucilla] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2016
VL 23
SU 1
MA S-183
BP 325A
EP 326A
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DH6CS
UT WOS:000372879200889
ER
PT J
AU Ingelfinger, JR
Kalantar-Zadeh, K
Schaefer, F
AF Ingelfinger, Julie R.
Kalantar-Zadeh, Kamyar
Schaefer, Franz
CA World Kidney Day Steering Comm
TI Averting the legacy of kidney disease - Focus on childhood
SO SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION
LA English
DT Editorial Material
ID NEPHROLOGY ASSOCIATION IPNA; RENAL REPLACEMENT THERAPY;
LOW-BIRTH-WEIGHT; NONCOMMUNICABLE DISEASES; INTERNATIONAL SOCIETY;
CONSENSUS STATEMENT; PROSPECTIVE COHORT; BLOOD-PRESSURE; GLOBAL HEALTH;
CHILDREN
AB World Kidney Day 2016 focuses on kidney disease in childhood and the antecedents of adult kidney disease that can begin in earliest childhood. Chronic kidney disease (CKD) in childhood differs from that in adults, as the largest diagnostic group among children includes congenital anomalies and inherited disorders, with glomerulopathies and kidney disease in the setting of diabetes being relatively uncommon. In addition, many children with acute kidney injury will ultimately develop sequelae that may lead to hypertension and CKD in later childhood or in adult life. Children born early or who are small-for date newborns have relatively increased risk for the development of CKD later in life. Persons with a high-risk birth and early childhood history should be watched closely in order to help detect early signs of kidney disease in time to provide effective prevention or treatment. Successful therapy is feasible for advanced CKD in childhood; there is evidence that children fare better than adults, if they receive kidney replacement therapy including dialysis and transplantation, while only a minority of children may require this ultimate intervention Because there are disparities in access to care, effort is needed so that those children with kidney disease, wherever they live, may be treated effectively, irrespective of their geographic or economic circumstances. Our hope is that World Kidney Day will inform the general public, policy makers and caregivers about the needs and possibilities surrounding kidney disease in childhood.
C1 [Ingelfinger, Julie R.] Massachusetts Gen Hosp, MassGen Hosp Children, Dept Pediat Nephrol, Boston, MA 02114 USA.
[Schaefer, Franz] Heidelberg Univ, Div Pediat Nephrol, Ctr Pediat & Adolescent Med, Heidelberg, Germany.
[Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Sch Med, Div Nephrol & Hypertens, Med Pediat & Publ Hlth, Irvine, CA 92717 USA.
[Kalantar-Zadeh, Kamyar] Vet Affairs VA Long Beach Healthcare Syst, Long Beach, CA USA.
[Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA USA.
RP Ingelfinger, JR (reprint author), Massachusetts Gen Hosp, MassGen Hosp Children, Dept Pediat Nephrol, Boston, MA 02114 USA.; Ingelfinger, JR (reprint author), World Kidney Day, Int Federat Kidney Fdn, Int Soc Nephrol, Rue Fabr 1B, B-1000 Brussels, Belgium.
OI Kalantar-Zadeh, Kamyar/0000-0002-8666-0725
NR 33
TC 0
Z9 0
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 1319-2442
EI 2320-3838
J9 SAUDI J KIDNEY DIS T
JI Saudi J. Kidney Dis. Transplant.
PD MAR-APR
PY 2016
VL 27
IS 2
BP 219
EP 226
DI 10.4103/1319-2442.178201
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA DI1YN
UT WOS:000373293000001
PM 26997373
ER
PT J
AU Biehn, TL
Contractor, AA
Elhai, JD
Tamburrino, M
Fine, TH
Cohen, G
Shirley, E
Chan, PK
Liberzon, I
Calabrese, JR
Galea, S
AF Biehn, Tracey L.
Contractor, Ateka A.
Elhai, Jon D.
Tamburrino, Marijo
Fine, Thomas H.
Cohen, Gregory
Shirley, Edwin
Chan, Philip K.
Liberzon, Israel
Calabrese, Joseph R.
Galea, Sandro
TI Latent dimensions of posttraumatic stress disorder and their relations
with alcohol use disorder
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Posttraumatic stress disorder; Alcohol use disorder; Cormorbidity;
Confirmatory factor analysis
ID SUBSTANCE-USE DISORDERS; CONFIRMATORY FACTOR-ANALYSIS; PTSD SYMPTOMS;
UNDERLYING DIMENSIONS; COMORBIDITY; SOLDIERS; DRINKING; TRAUMA; SAMPLE;
MODEL
AB The objective of this study was to evaluate the relationship between factors of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) using confirmatory factor analysis (CFA) in order to further our understanding of the substantial comorbidity between these two disorders.
CFA was used to examine which factors of PTSD's dysphoria model were most related to AUD in a military sample. Ohio National Guard soldiers with a history of overseas deployment participated in the survey (n = 1215). Participants completed the PTSD Checklist and a 12-item survey from the National Survey on Drug Use used to diagnosis AUD.
The results of the CFA indicated that a combined model of PTSD's four factors and a single AUD factor fit the data very well. Correlations between PTSD's factors and a latent AUD factor ranged from correlation coefficients of 0.258-0.285, with PTSD's dysphoria factor demonstrating the strongest correlation. However, Wald tests of parameter constraints revealed that AUD was not more correlated with PTSD's dysphoria than other PTSD factors.
All four factors of PTSD's dysphoria model demonstrate comparable correlations with AUD. The role of dysphoria to the construct of PTSD is discussed.
C1 [Biehn, Tracey L.] St Cloud VA Hlth Care Syst, 4801 Vet Dr, St Cloud, MN 56303 USA.
[Biehn, Tracey L.; Contractor, Ateka A.; Elhai, Jon D.] Univ Toledo, Dept Psychol, Mail Stop 948,2801 W Bancroft St, Toledo, OH 43606 USA.
[Elhai, Jon D.; Tamburrino, Marijo; Fine, Thomas H.] Univ Toledo, Dept Psychiat, Mail Stop 948,2801 W Bancroft St, Toledo, OH 43606 USA.
[Cohen, Gregory; Galea, Sandro] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
[Cohen, Gregory; Shirley, Edwin] Case Western Reserve Univ, Univ Hosp, Dept Psychiat, Case Med Ctr, Cleveland, OH 44106 USA.
[Liberzon, Israel] Univ Michigan, Dept Psychiat, Mental Hlth Serv, VA Ann Arbor Hlth Syst, Ann Arbor, MI 48109 USA.
[Calabrese, Joseph R.] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA.
[Contractor, Ateka A.] Massachusetts Vet Epidemiol Res & Informat Ctr, VA Boston Healthcare Syst, Boston, MA USA.
RP Biehn, TL (reprint author), St Cloud VA Hlth Care Syst, 4801 Vet Dr, St Cloud, MN 56303 USA.; Biehn, TL (reprint author), Univ Toledo, Dept Psychol, Mail Stop 948,2801 W Bancroft St, Toledo, OH 43606 USA.
EM tlbiehn02@gmail.com
OI Liberzon, Israel/0000-0002-4990-556X
FU Department of Defense Congressionally Directed Medical Research Program,
"Combat Mental Health Initiative" [W81XWH-O7-1-0409]
FX This project was funded by the Department of Defense Congressionally
Directed Medical Research Program W81XWH-O7-1-0409, the "Combat Mental
Health Initiative."
NR 63
TC 1
Z9 1
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
EI 1433-9285
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD MAR
PY 2016
VL 51
IS 3
BP 421
EP 429
DI 10.1007/s00127-015-1135-x
PG 9
WC Psychiatry
SC Psychiatry
GA DI1CA
UT WOS:000373232400011
PM 26520448
ER
PT J
AU Celano, CM
Healy, B
Suarez, L
Levy, DE
Mastromauro, C
Januzzi, JL
Huffman, JC
AF Celano, Christopher M.
Healy, Brian
Suarez, Laura
Levy, Douglas E.
Mastromauro, Carol
Januzzi, James L.
Huffman, Jeff C.
TI Cost-Effectiveness of a Collaborative Care Depression and Anxiety
Treatment Program in Patients with Acute Cardiac Illness
SO VALUE IN HEALTH
LA English
DT Article
DE anxiety; cardiovascular disease; collaborative care; cost-effectiveness;
depression
ID RANDOMIZED-CONTROLLED-TRIAL; BYPASS GRAFT-SURGERY;
CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; MAJOR DEPRESSION; PANIC
DISORDER; HEALTH STATES; INTERVENTION; MANAGEMENT; VALIDITY
AB Objective: To use data from a randomized trial to determine the cost-effectiveness of a collaborative care (CC) depression and anxiety treatment program and to assess effects of the CC program on health care utilization. Methods: The CC intervention's impact on health related quality of life, depression-free days (DFDs), and anxiety-free days (AFDs) over the 24-week postdischarge period was calculated and compared with the enhanced usual care (EUC) condition using independent samples t tests and random-effects regression models. Costs for both the CC and EUC conditions were calculated on the basis of staff time, overhead expenses, and treatment materials. Using this information, incremental cost-effectiveness ratios were calculated. A cost-effectiveness acceptability plot was created using nonparametric bootstrapping with 10,000 replications, and the likelihood of the CC intervention's cost-effectiveness was assessed using standard cutoffs. As a secondary analysis, we determined whether the CC intervention led to reductions in postdischarge health care utilization and costs. Results: The CC intervention was more costly than the EUC intervention ($209.86 vs. $34.59; z = -11.71; P < 0.001), but was associated with significantly greater increases in quality adjusted life-years (t = -2.49; P = 0.01) and DFDs (t = -2.13; P = 0.03), but not AFDs (t = -1.92; P = 0.057). This translated into an incremental cost-effectiveness ratio of $3337.06 per quality adjusted life-year saved, $13.36 per DFD, and $13.74 per AFD. Compared with the EUC intervention, the CC intervention was also associated with fewer emergency department visits but no differences in overall costs. Conclusions: This CC intervention was associated with clinically relevant improvements, was cost-effective, and was associated with fewer emergency department visits in the 24 weeks after discharge.
C1 [Celano, Christopher M.; Healy, Brian; Levy, Douglas E.; Januzzi, James L.; Huffman, Jeff C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Celano, Christopher M.; Suarez, Laura; Mastromauro, Carol; Huffman, Jeff C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Healy, Brian; Januzzi, James L.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Levy, Douglas E.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
RP Celano, CM (reprint author), Massachusetts Gen Hosp, Blake 11,55 Fruit St, Boston, MA 02114 USA.
EM ccelano@partners.org
FU American Heart Association [10GRNT3450015]
FX American Heart Association Grant-in-Aid (grant no. 10GRNT3450015 to J.C.
Huffman).
NR 40
TC 3
Z9 3
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAR-APR
PY 2016
VL 19
IS 2
BP 185
EP 191
DI 10.1016/j.jval.2015.12.015
PG 7
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA DH8WY
UT WOS:000373078800009
PM 27021752
ER
PT J
AU Singh, S
Rejai, S
Antongiorgi, Z
Gonzalez, N
Stelzner, M
AF Singh, Sumit
Rejai, Sepehr
Antongiorgi, Zarah
Gonzalez, Nestor
Stelzner, Matthias
TI Misconnections in the Critically Ill: Injection of High-Dose Gadolinium
into an External Ventricular Drain
SO A & A CASE REPORTS
LA English
DT Article
ID INTRATHECAL GADOLINIUM; GADOPENTETATE DIMEGLUMINE; ENCEPHALOPATHY;
CISTERNOGRAPHY
AB We report an unfortunate case of accidental administration of intrathecal gadolinium through an external ventricular drain in a postcraniotomy patient during magnetic resonance imaging of the brain. The incident occurred after the venous contrast line was connected mistakenly to the ventricular drainage catheter. The patient subsequently developed confusion, aphasia, and right facial droop with new computed tomography evidence of diffuse cerebral edema and stroke. Review of the magnetic resonance image revealed the inappropriate presence of subarachnoid gadolinium. Despite all interventions, the patient developed irreversible neurologic disability. We address the clinical sequelae, management strategies, and factors contributing to the catheter misconnection that led to this event.
C1 [Singh, Sumit; Rejai, Sepehr; Antongiorgi, Zarah] Univ Calif Los Angeles, Med Ctr, Dept Anesthesiol & Perioperat Med, Los Angeles, CA 90024 USA.
[Gonzalez, Nestor] Univ Calif Los Angeles, Med Ctr, Neurosurg, Los Angeles, CA 90024 USA.
[Stelzner, Matthias] Univ Calif Los Angeles, Med Ctr, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90024 USA.
RP Singh, S (reprint author), Univ Calif Los Angeles, Dept Anesthesiol & Perioperat Med, 757 Westwood Plaza, Los Angeles, CA 90024 USA.
EM SPSingh@mednet.ucla.edu
OI Gonzalez, Nestor/0000-0002-8277-6317
NR 14
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2325-7237
J9 A A CASE REP
JI A A Case Rep.
PD MAR 1
PY 2016
VL 6
IS 5
BP 121
EP 123
DI 10.1213/XAA.0000000000000230
PG 3
WC Anesthesiology
SC Anesthesiology
GA DH2OT
UT WOS:000372626400004
PM 26462163
ER
PT J
AU Melillo, B
Liang, SY
Park, J
Schon, A
Courter, JR
LaLonde, JM
Wendler, DJ
Princiotto, AM
Seaman, MS
Freire, E
Sodroski, J
Madani, N
Hendrickson, WA
Smith, AB
AF Melillo, Bruno
Liang, Shuaiyi
Park, Jongwoo
Schoen, Arne
Courter, Joel R.
LaLonde, Judith M.
Wendler, Daniel J.
Princiotto, Amy M.
Seaman, Michael S.
Freire, Ernesto
Sodroski, Joseph
Madani, Navid
Hendrickson, Wayne A.
Smith, Amos B., III
TI Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry
Inhibition
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV; gp120; CD4; entry inhibitor; structure-based drug design;
thermodynamics; X-ray crystallography; viral inhibition; protein-protein
interactions
ID STRUCTURE-BASED DESIGN; CD4; VALIDATION; DOCKING
AB The optimization, based on computational, thermodynamic, and crystallographic data, of a series of small-molecule ligands of the Phe43 cavity of the envelope glycoprotein gp120 of human immunodeficiency virus (HIV) has been achieved. Importantly, biological evaluation revealed that the small-molecule CD4 mimics (4-7) inhibit HIV-1 entry into target cells with both significantly higher potency and neutralization breadth than previous congeners, while maintaining high selectivity for the target virus. Their binding mode was characterized via thermodynamic and crystallographic studies.
C1 [Melillo, Bruno; Park, Jongwoo; Courter, Joel R.; Wendler, Daniel J.; Smith, Amos B., III] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
[Liang, Shuaiyi; Hendrickson, Wayne A.] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.
[Hendrickson, Wayne A.] Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA.
[Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
[LaLonde, Judith M.] Bryn Mawr Coll, Dept Chem, Bryn Mawr, PA 19010 USA.
[Princiotto, Amy M.; Sodroski, Joseph; Madani, Navid] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA.
[Seaman, Michael S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.
[Sodroski, Joseph] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA.
[Sodroski, Joseph] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Park, Jongwoo] LG Chem, Daejeon, South Korea.
[Courter, Joel R.] Seattle Genet, Bothell, WA 98021 USA.
[LaLonde, Judith M.] Teva Pharmaceut USA Inc, Horsham, PA 19044 USA.
[Wendler, Daniel J.] Max Planck Florida Inst Neurosci, Jupiter, FL 33458 USA.
RP Smith, AB (reprint author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
EM smithab@sas.upenn.edu
FU Program Project (NIH) [GM 56550]
FX Funding was provided by a Program Project (NIH GM 56550) to J.L., E.F.,
W.A.H., A.B.S., and J.S.
NR 18
TC 10
Z9 10
U1 2
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD MAR
PY 2016
VL 7
IS 3
BP 330
EP 334
DI 10.1021/acsmedchemlett.5b00471
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA DG4LE
UT WOS:000372042900025
PM 26985324
ER
PT J
AU Bourgeois, S
Bounoure, L
Mouro-Chanteloup, I
Aronovicz, YC
Brown, D
Wagner, CA
AF Bourgeois, S.
Bounoure, L.
Mouro-Chanteloup, I.
Aronovicz, Y. Colin
Brown, D.
Wagner, C. A.
TI The ammonia transporter RhCG modulates vacuolar H+-ATPase function in
renal collecting duct cells
SO ACTA PHYSIOLOGICA
LA English
DT Meeting Abstract
C1 [Bourgeois, S.; Bounoure, L.; Wagner, C. A.] Univ Zurich, Inst Physiol, CH-8006 Zurich, Switzerland.
[Mouro-Chanteloup, I.; Aronovicz, Y. Colin] INSERM, UMR665, Paris, France.
[Mouro-Chanteloup, I.; Aronovicz, Y. Colin] Univ Paris Diderot, Paris, France.
[Brown, D.] Massachusetts Gen Hosp, Dept Med, Ctr Syst Biol, Program Membrane Biol, Boston, MA 02114 USA.
[Brown, D.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1748-1708
EI 1748-1716
J9 ACTA PHYSIOL
JI Acta Physiol.
PD MAR
PY 2016
VL 216
SU 707
SI SI
MA OS13-1
PG 1
WC Physiology
SC Physiology
GA DG7TA
UT WOS:000372285400175
ER
PT J
AU Dubois, B
Hampel, H
Feldman, HH
Scheltens, P
Aisen, P
Andrieu, S
Bakardjian, H
Benali, H
Bertram, L
Blennow, K
Broich, K
Cavedo, E
Crutch, S
Dartigues, JF
Duyckaerts, C
Epelbaum, S
Frisoni, GB
Gauthier, S
Genthon, R
Gouw, AA
Habert, MO
Holtzman, DM
Kivipelto, M
Lista, S
Molinuevo, JL
O'Bryant, SE
Rabinovici, GD
Rowe, C
Salloway, S
Schneider, LS
Sperling, R
Teichmann, M
Carrillo, MC
Cummings, J
Jack, CR
AF Dubois, Bruno
Hampel, Harald
Feldman, Howard H.
Scheltens, Philip
Aisen, Paul
Andrieu, Sandrine
Bakardjian, Hovagim
Benali, Habib
Bertram, Lars
Blennow, Kaj
Broich, Karl
Cavedo, Enrica
Crutch, Sebastian
Dartigues, Jean-Francois
Duyckaerts, Charles
Epelbaum, Stephane
Frisoni, Giovanni B.
Gauthier, Serge
Genthon, Remy
Gouw, Alida A.
Habert, Marie-Odile
Holtzman, David M.
Kivipelto, Miia
Lista, Simone
Molinuevo, Jose-Luis
O'Bryant, Sid E.
Rabinovici, Gil D.
Rowe, Christopher
Salloway, Stephen
Schneider, Lon S.
Sperling, Reisa
Teichmann, Marc
Carrillo, Maria C.
Cummings, Jeffrey
Jack, Cliff R., Jr.
CA IWG
Amer Alzheimer's Assoc Preclinical
TI Preclinical Alzheimer's disease: Definition, natural history, and
diagnostic criteria
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Preclinical; Asymptomatic; Diagnostic criteria;
Biomarkers; Pathophysiology; Genetics; CSF biomarkers; Blood biomarkers;
MRI; Amyloid PET; Tau PET
ID MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY;
CEREBROSPINAL-FLUID BIOMARKERS; BLOOD-BASED BIOMARKERS; NORMAL
OLDER-ADULTS; BETA-AMYLOID 1-42; SECONDARY PREVENTION TRIALS; RANDOMIZED
CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; GINKGO-BILOBA EXTRACT
AB During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
C1 [Dubois, Bruno; Hampel, Harald; Epelbaum, Stephane; Teichmann, Marc] Univ Paris 06, Pitie Salpetriere Univ Hosp, AP HP, Inst Memory & Alzheimers Dis IM2A, Paris, France.
[Dubois, Bruno; Hampel, Harald; Epelbaum, Stephane; Teichmann, Marc] Univ Paris 06, Pitie Salpetriere Univ Hosp, AP HP, Brain & Spine Inst ICM,Frontlab,Dept Neurol,UMR S, Paris, France.
[Hampel, Harald; Cavedo, Enrica; Lista, Simone] AXA Res Fund, Paris, France.
[Hampel, Harald; Cavedo, Enrica; Lista, Simone] UPMC, Paris, France.
[Feldman, Howard H.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Scheltens, Philip] Vrije Univ Amsterdam Med Ctr, Dept Neurol & Alzheimer Ctr, Amsterdam, Netherlands.
[Scheltens, Philip] Neurosci Campus, Dept Neurol & Alzheimer Ctr, Amsterdam, Netherlands.
[Aisen, Paul] Univ Southern Calif San Diego, San Diego, CA USA.
[Andrieu, Sandrine; Gouw, Alida A.] Univ Toulouse 3, Toulouse Univ Hosp, INSERM, UMR1027, F-31062 Toulouse, France.
[Bakardjian, Hovagim] Inst Neurosci Translat Paris, IIIU A ICM, Paris, France.
[Benali, Habib] UPMC UM CR2, CNRS UMR 7371, INSERM U1146, Site Pitie Salpetriere, Paris, France.
[Bertram, Lars] Med Univ Lubeck, Inst Neurogenet, Lubeck Interdisciplinary Platform Genome Analyt L, D-23538 Lubeck, Germany.
[Bertram, Lars] Med Univ Lubeck, Inst Integrat & Expt Genom, Lubeck Interdisciplinary Platform Genome Analyt L, D-23538 Lubeck, Germany.
[Bertram, Lars] Univ London Imperial Coll Sci Technol & Med, Fac Med, Sch Publ Hlth, London, England.
[Blennow, Kaj] Univ Gothenburg, Molndal Hosp, Sahlgrenska Univ Hosp, Clin Neurochem Lab,Dept Neurosci & Physiol, Molndal, Sweden.
[Broich, Karl] Fed Inst Drugs & Med Devices, Bonn, Germany.
[Cavedo, Enrica] IRCCS Ctr San Giovanni di Dio Fatebenefratelli, Lab Alzheimers Neuroimaging & Epidemiol, Brescia, Italy.
[Crutch, Sebastian] UCL, UCL Inst Neurol, Dept Neurodegenerat Dis, Dementia Res Ctr, London, England.
[Dartigues, Jean-Francois] Univ Bordeaux, INSERM U1219, Bordeaux, France.
[Duyckaerts, Charles] Univ Paris 06, AP HP, Alzheimer Prion Team, ICM, Paris, France.
[Frisoni, Giovanni B.] Univ Hosp Geneva, Geneva, Switzerland.
[Frisoni, Giovanni B.] Univ Geneva, Geneva, Switzerland.
[Frisoni, Giovanni B.] IRCCS Fatebenefratelli, Brescia, Italy.
[Gauthier, Serge] McGill Ctr Studies Aging, Douglas Mental Hlth Res Inst, Montreal, PQ, Canada.
[Genthon, Remy] Hop La Pitie Salpetriere, Fdn Rech Alzheimer, Paris, France.
[Gouw, Alida A.] Vrije Univ Amsterdam Med Ctr, MEG Ctr, Dept Clin Neurophysiol, Amsterdam, Netherlands.
[Habert, Marie-Odile] Univ Paris 06, Sorbonne Univ, CNRS, INSERM,Lab Imagerie Biomed, Paris, France.
[Habert, Marie-Odile] Hop La Pitie Salpetriere, AP HP, Dept Nucl Med, Paris, France.
[Holtzman, David M.] Washington Univ, Dept Neurol, Hope Ctr Neurol Disorders, St Louis, MO USA.
[Holtzman, David M.] Washington Univ, Dept Neurol, Knight Alzheimers Dis Res Ctr St, St Louis, MO USA.
[Kivipelto, Miia] Karolinska Univ Hosp, Dept Geriatr Med, Karolinska Inst, Ctr Alzheimer Res, Stockholm, Sweden.
[Kivipelto, Miia] Univ Eastern Finland, Inst Clin Med Neurol, Kuopio, Finland.
[Molinuevo, Jose-Luis] Hosp Clin Barcelona, IDIBAPS, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona, Spain.
[Molinuevo, Jose-Luis] Pasqual Maragall Fdn, Barcelonabeta Brain Res Ctr, Barcelona, Spain.
[O'Bryant, Sid E.] Univ N Texas, Hlth Sci Ctr, Ctr Alzheimers & Neurodegenerat Dis Res, Denton, TX 76203 USA.
[Rabinovici, Gil D.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA.
[Rowe, Christopher] Univ Melbourne, Austin Hlth, Dept Mol Imaging, Melbourne, Vic 3010, Australia.
[Salloway, Stephen] Brown Univ, Alpert Med Sch, Butler Hosp, Memory & Aging Program, Providence, RI 02912 USA.
[Salloway, Stephen] Brown Univ, Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA.
[Salloway, Stephen] Brown Univ, Alpert Med Sch, Dept Psychiat, Providence, RI 02912 USA.
[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Sperling, Reisa] Harvard Univ, Brigham & Womens Hosp, Sch Med, Memory Disorders Unit,Ctr Alzheimer Res & Treatme, Boston, MA 02115 USA.
[Sperling, Reisa] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Memory Disorders Unit,Ctr Alzheimer Res & Treatme, Boston, MA USA.
[Carrillo, Maria C.] Alzheimers Assoc Div Med & Sci Relat, Chicago, IL USA.
[Cummings, Jeffrey] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA.
[Jack, Cliff R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA.
RP Dubois, B (reprint author), Univ Paris 06, Pitie Salpetriere Univ Hosp, AP HP, Inst Memory & Alzheimers Dis IM2A, Paris, France.; Dubois, B (reprint author), Univ Paris 06, Pitie Salpetriere Univ Hosp, AP HP, Brain & Spine Inst ICM,Frontlab,Dept Neurol,UMR S, Paris, France.
EM bruno.dubois@aphp.fr
RI Bertram, Lars/K-3889-2015; Frisoni, Giovanni B/K-1360-2016; ,
Enrica/K-2652-2016;
OI Feldman, Howard/0000-0002-9258-4538; Bertram, Lars/0000-0002-0108-124X;
Frisoni, Giovanni B/0000-0002-6419-1753; , enrica/0000-0003-2127-816X; ,
Enrica/0000-0003-2306-0164; Molinuevo, Jose Luis/0000-0003-0485-6001;
O'Bryant, Sid/0000-0003-0582-5266
FU AXA Research Fund; Fondation Universite Pierre et Marie Curie;
"Fondation pour la Recherche sur Alzheimer", Paris, France; program
"Investissements d'avenir" [ANR-10-IAIHU-06]; European Medical
Information Framework (EMIF); National Institute on Aging; French
International Foundation for Research in Alzheimer's disease (IFRAD);
Alzheimer's Association
FX H.H. is supported by the AXA Research Fund, the Fondation Universite
Pierre et Marie Curie, and the "Fondation pour la Recherche sur
Alzheimer", Paris, France. The research leading to these results has
received funding from the program "Investissements d'avenir"
ANR-10-IAIHU-06. S.L. is supported by the European Medical Information
Framework (EMIF). R.S. is supported by the National Institute on Aging
and Alzheimer's Association.r The authors acknowledge the helpful
contribution of Zaven Khachaturian as an advisor to the Working Group in
charge of the article. The meeting was supported by the French
International Foundation for Research in Alzheimer's disease (IFRAD).
NR 297
TC 38
Z9 38
U1 15
U2 46
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAR
PY 2016
VL 12
IS 3
BP 292
EP 323
DI 10.1016/j.jalz.2016.02.002
PG 32
WC Clinical Neurology
SC Neurosciences & Neurology
GA DH3VP
UT WOS:000372715200010
PM 27012484
ER
PT J
AU Goldberg, J
Magruder, KM
Forsberg, CW
Friedman, MJ
Litz, BT
Vaccarino, V
Heagerty, PJ
Gleason, TC
Huang, GD
Smith, NL
AF Goldberg, Jack
Magruder, Kathryn M.
Forsberg, Christopher W.
Friedman, Matthew J.
Litz, Brett T.
Vaccarino, Viola
Heagerty, Patrick J.
Gleason, Theresa C.
Huang, Grant D.
Smith, Nicholas L.
TI Prevalence of Post-Traumatic Stress Disorder in Aging Vietnam-Era
Veterans: Veterans Administration Cooperative Study 569: Course and
Consequences of Post-Traumatic Stress Disorder in Vietnam-Era Veteran
Twins
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Epidemiology; geriatric/aging/elderly; PTSD/posttraumatic stress
disorder; twin studies; trauma
ID DIAGNOSTIC INTERVIEW CIDI; ADMINISTERED PTSD SCALE; LATE-LIFE PTSD;
COMBAT EXPOSURE; REGISTRY; HEALTH; CHECKLIST; VERSION
AB Objective: The prevalence of post-traumatic stress disorder (PTSD) among aging Vietnam-era veterans is not well characterized. Methods: In a cross-sectional study, 5,598 male Vietnam-era veterans and members of the Vietnam Era Twin Registry were assessed for PTSD using the Composite International Diagnostic Interview. Current symptoms were measured with the PTSD Checklist (PCL). PTSD was estimated according to age (<60 or >= 60) and Vietnam theater service. Results: The lifetime prevalence of PTSD in theater veterans aged at least 60 years was 16.9% (95% CI: 13.9%-20.5%) and higher than the 5.5% (95% CI: 4.3%-7.0%) among nontheater veterans. Among veterans younger than 60 years, the comparable prevalence was 22.0% for theater (95% CI: 16.7%-28.4%) and 15.7% for nontheater (95% CI: 13.4%-18.2%) veterans. Similar results were found for theater service and current PTSD prevalence (past 12 months). PCL scores were significantly higher in theater compared with nontheater veterans in both younger and older cohorts. In both the younger and older cohorts significant differences in lifetime and current PTSD prevalence and PCL scores persisted in theater service discordant twin pairs. Conclusion: Vietnam service is related to elevated PTSD prevalence and current symptom burden in aging veterans. More than 30 years after the end of the Vietnam conflict, many veterans continue to suffer from PTSD, which highlights the need for continuing outreach throughout the life course.
C1 [Goldberg, Jack; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Goldberg, Jack; Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Heagerty, Patrick J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Magruder, Kathryn M.] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA.
[Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[Friedman, Matthew J.] Natl Ctr Posttraumat Stress Disorder, Dept Vet Affairs, White River Jct, VT USA.
[Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA.
[Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA.
[Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Epidemiol Res & Informat Ctr, Boston, MA USA.
[Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Vaccarino, Viola] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
[Vaccarino, Viola] Emory Univ, Dept Med, Atlanta, GA 30322 USA.
[Gleason, Theresa C.; Huang, Grant D.] VA Off Res & Dev, Clin Sci Res & Dev, Cooperat Studies Program, Washington, DC USA.
RP Goldberg, J (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr S 152 E, 1600 South Columbian Way, Seattle, WA 98108 USA.
EM jack.goldberg@va.gov
FU Cooperative Studies Program of the Office of Research and Development,
Clinical Science Research and Development, of the U.S. Department of
Veterans Affairs; National Institutes of Health [K24 HL077506]
FX The Cooperative Studies Program of the Office of Research and
Development, Clinical Science Research and Development, of the U.S.
Department of Veterans Affairs provided financial support for
Cooperative Study 569 and the development and maintenance of the VET
Registry. Dr. Viola Vaccarino was supported in part by a National
Institutes of Health award (K24 HL077506).
NR 35
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2016
VL 24
IS 3
BP 181
EP 191
DI 10.1016/j.jagp.2015.05.004
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DG8CF
UT WOS:000372309300002
PM 26560508
ER
PT J
AU Beristianos, MH
Yaffe, K
Cohen, B
Byers, AL
AF Beristianos, Matthew H.
Yaffe, Kristine
Cohen, Beth
Byers, Amy L.
TI PTSD and Risk of Incident Cardiovascular Disease in Aging Veterans
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE PTSD; cardiovascular disease; veterans
ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; PERIPHERAL
ARTERIAL-DISEASE; MENTAL-HEALTH PROBLEMS; VIETNAM VETERANS; US VETERANS;
SYMPTOMS; AFGHANISTAN; PREVALENCE; IRAQ
AB Objectives: To determine if late-life posttraumatic stress disorder (PTSD) is associated with cardiovascular disease in a sample of older veterans, and whether the association is independent of medical and psychiatric comorbities. Design: Retrospective cohort study conducted using the Department of Veterans Affairs (VA) National Patient Care Database (2000-2011). Setting: VA medical centers in the United States. Participants: A total of 138,341 veterans 55 years and older without cardiovascular disease at study baseline (2000-2003). Measurements: PTSD and cardiovascular disease (as defined by diagnoses of: cerebrovascular disease [CVD], congestive heart failure [CHF], myocardial infarction [MI], and peripheral vascular disease [PVD]) were identified by ICD-9 codes during study baseline (2000-2003) and follow-up (2004-2011), respectively. Results: 3% of veterans (N = 4,041) had a baseline diagnosis of PTSD. Unadjusted increased risk of incidence of CVD was 80%, CHF was 56%, MI was 82%, and PVD was 60% in veterans with PTSD compared with those without PTSD. After adjustment for demographics, medical comorbidities, substance use, and psychiatric comorbidities, veterans with late-life PTSD were at a 45% increased risk for incident CVD, 26% increased risk for incident CHF, 49% increased risk for incident MI, and 35% increased risk for PVD compared with veterans without late-life PTSD. Conclusions: Findings highlight the longitudinal impact of PTSD on increasing the incidence of cardiovascular disease in older adults. This study implies the need for greater monitoring and treatment of PTSD in older persons, particularly older veterans, to assist in preventing adverse outcomes, such as cardiovascular disease, over the long term.
C1 [Beristianos, Matthew H.; Yaffe, Kristine; Byers, Amy L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Cohen, Beth] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Beristianos, Matthew H.; Yaffe, Kristine; Cohen, Beth; Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Beristianos, Matthew H.] Alliant Int Univ, Calif Sch Profess Psychol, San Francisco, CA USA.
RP Beristianos, MH (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, 4150 Clement St,116H, San Francisco, CA 94121 USA.
EM Matthew.Beristianos@ucsf.edu
FU U.S. Department of Defense [W81XWH-11-2-0189]; K24 Midcareer
Investigator Award from the National Institute on Aging [AG031155];
National Heart, Lung, and Blood Institute [K23 HL 094765-0]; American
Heart Association [12CRP11810021]; Takeda, Inc.; National Institute on
Aging
FX This study was funded by U.S. Department of Defense grant
W81XWH-11-2-0189 (principal investigator: Dr. Byers). Dr. Yaffe is
supported in part by a K24 Midcareer Investigator Award from the
National Institute on Aging (AG031155). Dr. Cohen is supported in part
by the National Heart, Lung, and Blood Institute grant K23 HL 094765-0
and grant 12CRP11810021 from the American Heart Association.; Mr.
Beristianos, Dr. Cohen, and Dr. Byers report no financial relationships
with commercial interests. Dr. Yaffe reports having served as a
consultant to Novartis, Inc., and Pfizer for reasons not related to the
current project. She serves on DSMB committees for Takeda, Inc., and a
National Institute on Aging-sponsored study, and also serves on the
Beeson Scientific Advisory Board. The authors have no competing
interests, including specific financial interests or relationships or
affiliations relevant to the subject of this article.
NR 41
TC 6
Z9 6
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2016
VL 24
IS 3
BP 192
EP 200
DI 10.1016/j.jagp.2014.12.003
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DG8CF
UT WOS:000372309300003
PM 25555625
ER
PT J
AU Diem, SJ
Blackwell, TL
Stone, KL
Yaffe, K
Tranah, G
Cauley, JA
Ancoli-Israel, S
Redline, S
Spira, AP
Hillier, TA
Ensrud, KE
AF Diem, Susan J.
Blackwell, Terri L.
Stone, Katie L.
Yaffe, Kristine
Tranah, Greg
Cauley, Jane A.
Ancoli-Israel, Sonia
Redline, Susan
Spira, Adam P.
Hillier, Teresa A.
Ensrud, Kristine E.
TI Measures of Sleep-Wake Patterns and Risk of Mild Cognitive Impairment or
Dementia in Older Women
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE cognitive aging; sleep disorders; older women; dementia; actigraphy
ID OSTEOPOROTIC FRACTURES; ALZHEIMERS-DISEASE; DECLINE; ADULTS;
FRAGMENTATION; QUESTIONNAIRE; RELIABILITY; ACTIGRAPHY; DURATION; RHYTHMS
AB Objective: Sleep disturbances are common in older adults. Little is known about the sleep of cognitively intact older adults and its relationship to subsequent cognitive impairment. The objective of this study was to examine the association between objective sleep-wake measures and risk of incident cognitive impairment. Methods: In this prospective cohort study encompassing four U.S. sites, 1,245 women (mean age: 82.6 years) without dementia participated in the Study of Osteoporotic Fractures and completed actigraphy at the baseline visit and comprehensive cognitive assessment at follow-up. The association between sleep-wake patterns measured by actigraphy and risk of incident mild cognitive impairment (MCI) and dementia was examined. Results: A total of 473 women (38%) developed cognitive impairment during an average (SD) follow-up of 4.9 (0.6) years; 290 (23.3%) developed MCI and 183 (14.7%) developed dementia. After controlling for multiple potential confounders, women in the lowest quartile of average sleep efficiency (<74%) had a 1.5-fold higher odds of developing MCI or dementia compared with women in the highest quartile of sleep efficiency (>86%) (odds ratio: Q1 versus Q4 1.53; 95% CI: 1.07, 2.19; Wald chi(2) [1, N = 1,223] = 5.34 for p for trend = 0.03). Longer average sleep latency, but not total sleep time, was also associated with higher odds of developing cognitive impairment. Greater variability in both sleep efficiency and total sleep time was associated with an increased odds of developing MCI or dementia. Conclusion: Lower average sleep efficiency, longer average sleep latency, and greater variability in sleep efficiency and total sleep time are associated with increased odds of developing cognitive impairment. Further research is needed to explore the mechanisms underlying these associations.
C1 [Diem, Susan J.; Ensrud, Kristine E.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
[Diem, Susan J.; Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55415 USA.
[Blackwell, Terri L.; Stone, Katie L.; Tranah, Greg] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, 75 Francis St, Boston, MA 02115 USA.
[Redline, Susan] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Spira, Adam P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Ensrud, Kristine E.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
RP Diem, SJ (reprint author), Univ Minnesota, 1100 Washington Ave S, Minneapolis, MN 55415 USA.
EM sdiem@umn.edu
RI Cauley, Jane/N-4836-2015
OI Cauley, Jane/0000-0003-0752-4408
FU National Institute on Aging [RO1 AG005407, RO1 AR35582, ROA AR35583, RO1
AR35584, RO1 AG005394, RO1 AG027574, RO1 AG027576, KO1 AG033195]
FX The Study of Osteoporotic Fractures is supported by grants RO1 AG005407,
RO1 AR35582, ROA AR35583, RO1 AR35584, RO1 AG005394, RO1 AG027574, RO1
AG027576, and KO1 AG033195 from the National Institute on Aging. The
funding agencies had no direct role in the conduct of the study; the
collection, management, analyses and interpretation of the data; or
preparation or approval of the manuscript. All authors have nothing to
disclose.
NR 49
TC 2
Z9 2
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2016
VL 24
IS 3
BP 248
EP 258
DI 10.1016/j.jagp.2015.12.002
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DG8CF
UT WOS:000372309300009
PM 26964485
ER
PT J
AU Hamilos, DL
AF Hamilos, Daniel L.
TI Problem-based learning discussion: Medical treatment of pediatric
chronic rhinosinusitis
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article; Proceedings Paper
CT North American Rhinology and Allergy Conference
CY FEB 05-07, 2015
CL Boca Raton, FL
ID ENDOSCOPIC SINUS SURGERY; CYSTIC-FIBROSIS; LONG-TERM; CONTROLLED-TRIAL;
RETROSPECTIVE ANALYSIS; NASAL POLYPS; CHILDREN; OUTCOMES; MANAGEMENT;
METAANALYSIS
AB This problem-based learning case focused on the approach to evaluation and management of a 5-year old girl who was "always sick" with sinus infections. The discussion unfolds in a "real life" scenario, i.e., based on information available to the clinician initially and after the acquisition of laboratory data, and, ultimately, after sinus surgery. Emphasis is placed on the differential diagnosis of the patient's symptoms, discussion of the initial management strategy for chronic rhinosinusitis (CRS), evolution from acute rhinosinusitis to CRS, the prevalence of and differential diagnosis of nasal polyps in children, treatment considerations specific for CRS with nasal polyps, the significance of Pseudomonas aeruginosa sinus infection, the significance of an abnormal sweat chloride test in a young child with nasal polyposis, special considerations in children with CRS who have cystic fibrosis, treatment considerations after endoscopic sinus surgery, and, finally, prognostic factors that impact the outcomes of endoscopic sinus surgery. This problem-based learning case highlights many facets of managing refractory CRS in children.
C1 [Hamilos, Daniel L.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA.
RP Hamilos, DL (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA.
EM dhamilos@partners.org
NR 60
TC 1
Z9 1
U1 1
U2 2
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
EI 1945-8932
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAR-APR
PY 2016
VL 30
IS 2
BP 113
EP 121
DI 10.2500/ajra.2016.30.4270
PG 9
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DG8PL
UT WOS:000372346000017
PM 26980392
ER
PT J
AU Schlosser, RJ
Storck, K
Cortese, BM
Uhde, TW
Rudmik, L
Soler, ZM
AF Schlosser, Rodney J.
Storck, Kristina
Cortese, Bernadette M.
Uhde, Thomas W.
Rudmik, Luke
Soler, Zachary M.
TI Depression in chronic rhinosinusitis: A controlled cohort study
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID ENDOSCOPIC SINUS SURGERY; QUALITY-OF-LIFE; INVENTORY-II;
DIABETES-MELLITUS; DISEASE SEVERITY; SYMPTOMS; OUTCOMES; HEALTH; IMPACT;
ASSOCIATION
AB Background: Depression in patients with chronic rhinosinusitis (CRS) is underdiagnosed but significantly impacts treatment outcomes and health care utilization.
Objective: To compare undiagnosed depression in a CRS cohort with a healthy, non-CRS control cohort.
Methods: A case-control study of patients with symptomatic CRS and a non-CRS control cohort was performed. Demographic and comorbidity factors were correlated to depression-specific outcomes by using the Beck Depression Inventory II (BDI).
Results: We enrolled 42 patients with CRS and 88 control patients with no history of CRS. Physician-diagnosed depression was equivalent in CRS and control patients (6% and 9%, respectively). BDI-detected depression was higher among patients with CRS compared with controls (31% versus 14.8%, respectively; p = 0.031). BDI scores were higher in patients with CRS even when controlling for comorbid asthma, allergy, and aspirin sensitivity. When examined by polyp status, the patients without polyps had more depression than did the controls (38% versus 14.8%; p = 0.048). The somatic subscale scores of the BDI were worse in patients with CRS (p = 0.004), whereas the cognitive subscale trended toward significance (p = 0.081).
Conclusion: Depression may be more common in CRS than previously recognized, especially in patients without polyps. Somatic subscale scores of the BDI are increased in CRS and may impact future treatment outcomes.
C1 [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA.
[Schlosser, Rodney J.; Storck, Kristina; Soler, Zachary M.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
[Cortese, Bernadette M.; Uhde, Thomas W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Rudmik, Luke] Univ Calgary, Dept Surg, Div Otolaryngol Head & Neck Surg, Calgary, AB, Canada.
RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.
EM schlossr@musc.edu
FU Flight Attendant Medical Research Institute [ID113042_CIA]; National
Institute on Deafness and Other Communication Disorders, one of the
National Institutes of Health, Bethesda, Maryland [R01 DC005805, R03
DC013651-01]; National Institute of Mental Health [K01 MH090548];
Entellus; IntersectENT; OptiNose
FX Supported by a grant from the Flight Attendant Medical Research
Institute (ID113042_CIA). Z.M. Soler is also supported by grants from
the National Institute on Deafness and Other Communication Disorders,
one of the National Institutes of Health, Bethesda, Maryland (R01
DC005805; R03 DC013651-01). B.M. Cortese is supported by a grant from
the National Institute of Mental Health (K01 MH090548).; Z.M. Soler is a
consultant for Olympus, which is not affiliated with this manuscript,
and has grant support from Entellus and IntersectENT. R.J. Schlosser is
supported by grants from OptiNose, Entellus, and IntersectENT, which are
not associated with this manuscript, and is a consultant for Olympus,
Meda, and Arrinex, which are not affiliated with this study. The
remaining authors have no conflicts of interest pertaining to this
article
NR 33
TC 4
Z9 4
U1 1
U2 3
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
EI 1945-8932
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAR-APR
PY 2016
VL 30
IS 2
BP 128
EP 133
DI 10.2500/ajra.2016.30.4290
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DG8PL
UT WOS:000372346000019
PM 26980393
ER
PT J
AU Xia, W
Chiu, YH
Afeiche, MC
Williams, PL
Ford, JB
Tanrikut, C
Souter, I
Hauser, R
Chavarro, JE
AF Xia, Wei
Chiu, Yu-Han
Afeiche, Myriam C.
Williams, Paige L.
Ford, Jennifer B.
Tanrikut, Cigdem
Souter, Irene
Hauser, Russ
Chavarro, Jorge E.
CA EARTH Study Team
TI Impact of men's dairy intake on assisted reproductive technology
outcomes among couples attending a fertility clinic
SO ANDROLOGY
LA English
DT Article
DE assisted reproductive technology; cohort studies; dairy intake;
infertility; men
ID FOOD FREQUENCY QUESTIONNAIRE; YOUNG DANISH MEN; SEMEN QUALITY;
DIETARY-INTAKE; UNITED-STATES; SOY FOOD; INFERTILITY; POPULATION;
REPRODUCIBILITY; PARAMETERS
AB Intake of full-fat dairy has been linked to lower semen quality but whether this leads to decreased fertility is unknown. To address this question, we prospectively evaluated the association of men's dairy intake with treatment outcomes of subfertile couples undergoing assisted reproductive technology (ART). We followed 142 men from couples undergoing infertility treatment with ART at an academic fertility centre between 2007 and 2014. Couples completed dietary assessments prior to treatment, and the female partners underwent a total of 248 ART cycles. Multivariable generalized linear mixed models were used to examine the association of dairy intake with fertilization, implantation, clinical pregnancy and live birth rates adjusting for age, body mass index, smoking status, total exercise time, dietary patterns, alcohol, caffeine, total energy intake, and female dairy intake. Intake of dairy foods, regardless of their fat content, was not associated with fertilization, implantation, clinical pregnancy or live birth rates. The adjusted live birth rates (95% confidence interval) for couples in increasing quartiles of men's dairy intake were 0.42 (0.25, 0.60), 0.25 (0.13, 0.42), 0.26 (0.15, 0.41), and 0.44 (0.27, 0.63) (p linear trend=0.73). Results remained similar after adjustment for female partner intake of dairy foods. Overall, men's dairy intake was not associated with treatment outcomes of couples undergoing ART.
C1 [Xia, Wei; Chiu, Yu-Han; Chavarro, Jorge E.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA USA.
[Xia, Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Family Planning Res Inst, Wuhan 430074, Peoples R China.
[Xia, Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Reprod Med Ctr, Wuhan 430074, Peoples R China.
[Afeiche, Myriam C.; Ford, Jennifer B.; Hauser, Russ] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Williams, Paige L.; Hauser, Russ; Chavarro, Jorge E.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Williams, Paige L.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Tanrikut, Cigdem] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Tanrikut, Cigdem; Souter, Irene; Hauser, Russ; Chavarro, Jorge E.] Harvard Univ, Sch Med, Boston, MA USA.
[Souter, Irene; Hauser, Russ] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA.
[Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Lab, 75 Francis St, Boston, MA 02115 USA.
RP Chavarro, JE (reprint author), Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA USA.
EM jchavarr@hsph.harvard.edu
FU NIH [R01ES009718, R01ES022955, P30ES000002, P30DK46200]; China
Scholarship Council
FX The authors acknowledge all members of the EARTH study team,
specifically the Harvard T.H. Chan School of Public Health research
nurses Jennifer B. Ford and Myra G. Keller, research staff Ramace Dadd
and Patricia Morey, physicians and staff at Massachusetts General
Hospital Fertility Center and extend a special thanks to all the study
participants. This work was supported by NIH grants R01ES009718,
R01ES022955, P30ES000002 and P30DK46200. Dr Xia was supported by the
China Scholarship Council.
NR 36
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-2919
EI 2047-2927
J9 ANDROLOGY-US
JI Andrology
PD MAR
PY 2016
VL 4
IS 2
BP 277
EP 283
DI 10.1111/andr.12151
PG 7
WC Andrology
SC Endocrinology & Metabolism
GA DG9PT
UT WOS:000372417000011
PM 26825777
ER
PT J
AU Lin, JE
Neylan, TC
Epel, E
O'Donovan, A
AF Lin, Joy E.
Neylan, Thomas C.
Epel, Elissa
O'Donovan, Aoife
TI Associations of childhood adversity and adulthood trauma with C-reactive
protein: A cross-sectional population-based study
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Childhood adversity; Adulthood trauma; C-reactive protein; Immune
system; Inflammation
ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; EARLY-LIFE
STRESS; ELEVATED INFLAMMATION; MENTAL-HEALTH; CARDIOVASCULAR-DISEASE;
PSYCHIATRIC-DISORDERS; PSYCHOLOGICAL STRESS; GENE-EXPRESSION; RISK
AB Mounting evidence highlights specific forms of psychological stress as risk factors for ill health. Particularly strong evidence indicates that childhood adversity and adulthood trauma exposure increase risk for physical and psychiatric disorders, and there is emerging evidence that inflammation may play a key role in these relationships. In a population-based sample from the Health and Retirement Study (n = 11,198, mean age 69 +/- 10), we examine whether childhood adversity, adulthood trauma, and the interaction between them are associated with elevated levels of the systemic inflammatory marker high sensitivity C-reactive protein (hsCRP). All models were adjusted for age, gender, race, education, and year of data collection, as well as other possible confounds in follow-up sensitivity analyses. In our sample, 67% of individuals had experienced at least one traumatic event during adulthood, and those with childhood adversity were almost three times as likely to have experienced trauma as an adult. Childhood adversities and adulthood traumas were independently associated with elevated levels of hsCRP (beta = 0.03, p = 0.01 and beta = 0.05, p < 0.001, respectively). Those who had experienced both types of stress had higher levels of hsCRP than those with adulthood trauma alone, Estimate = -0.06, 95% CI [-0.003, -0.12], p = 0.04, but not compared to those with childhood adversity alone, Estimate = -0.06, 95% CI [0.03, -0.16], p = 0.19. There was no interaction between childhood and adulthood trauma exposure. To our knowledge, this is the first study to examine adulthood trauma exposure and inflammation in a large population-based sample, and the first to explore the interaction of childhood adversity and adulthood trauma with inflammation. Our study demonstrates the prevalence of trauma-related inflammation in the general population and suggests that childhood adversity and adulthood trauma are independently associated with elevated inflammation. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Lin, Joy E.] Univ Calif San Francisco, Sch Med, 500 Parnassus Ave, San Francisco, CA 94143 USA.
[Neylan, Thomas C.; Epel, Elissa; O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, 500 Parnassus Ave, San Francisco, CA 94143 USA.
[Lin, Joy E.; Neylan, Thomas C.; O'Donovan, Aoife] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
RP Lin, JE (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St 116C-1, San Francisco, CA 94121 USA.
EM joy.lin@ucsf.edu; thomas.neylan@ucsf.edu; elissa.epel@ucsf.edu;
aoife.odonovan@ucsf.edu
FU National Institute on Aging [NIA U01AG009740]; National Center for
Advancing Translational Sciences Career Development Award at the
University of California, San Francisco [KL2 TR000143]; Society in
Science-Branco Weiss Fellowship; UCSF Dean's Office Medical Student
Research Program
FX The HRS (Health and Retirement Study) is sponsored by the National
Institute on Aging (grant number NIA U01AG009740) and was conducted by
the University of Michigan. A.O.D. was supported by a National Center
for Advancing Translational Sciences Career Development Award at the
University of California, San Francisco (KL2 TR000143) and a Society in
Science-Branco Weiss Fellowship. J.E.L. was supported by the UCSF Dean's
Office Medical Student Research Program. The authors would like to
acknowledge Tom Metzler for statistical support in preparation of this
manuscript.
NR 79
TC 1
Z9 1
U1 4
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD MAR
PY 2016
VL 53
BP 105
EP 112
DI 10.1016/j.bbi.2015.11.015
PG 8
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DG9BJ
UT WOS:000372377500012
PM 26616398
ER
PT J
AU Franco, W
Gutierrez-Herrera, E
Kollias, N
Doukas, A
AF Franco, W.
Gutierrez-Herrera, E.
Kollias, N.
Doukas, A.
TI Review of applications of fluorescence excitation spectroscopy to
dermatology
SO BRITISH JOURNAL OF DERMATOLOGY
LA English
DT Review
ID IRRITANT CONTACT-DERMATITIS; IN-VIVO FLUORESCENCE; HUMAN-SKIN; EPIDERMAL
PROLIFERATION; NONINVASIVE EVALUATION; REACTION-PRODUCTS; DANSYL
CHLORIDE; COLLAGEN; AGE; AUTOFLUORESCENCE
AB Endogenous molecules that exhibit fluorescence hold the potential to serve as reporters of tissue structure, activity and physiology. Fluorescence excitation spectroscopy is one means to measure and express tissue's innate fluorescence. This review focuses on the application of endogenous fluorescence ultraviolet excitation spectroscopy to dermatology.
C1 [Franco, W.; Gutierrez-Herrera, E.; Doukas, A.] Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Kollias, N.] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC V5Z 1M9, Canada.
[Gutierrez-Herrera, E.] Univ Nacl Autonoma Mexico, Ctr Ciencias Aplicadas & Desarrollo Tecnol, Mexico City 04510, DF, Mexico.
RP Franco, W (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM wfranco@mgh.harvard.edu
NR 34
TC 4
Z9 4
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-0963
EI 1365-2133
J9 BRIT J DERMATOL
JI Br. J. Dermatol.
PD MAR
PY 2016
VL 174
IS 3
BP 499
EP 504
DI 10.1111/bjd.14221
PG 6
WC Dermatology
SC Dermatology
GA DH5DJ
UT WOS:000372805100018
PM 26471781
ER
PT J
AU Singh, JA
Ramachandran, R
AF Singh, Jasvinder A.
Ramachandran, Rekha
TI Sex differences in characteristics, utilization, and outcomes of patient
undergoing total elbow arthroplasty: a study of the US nationwide
inpatient sample
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Discharge; Hospital stay; Mortality; Outcomes; Sex; TEA; Total elbow
arthroplasty; Utilization
ID SURGEON PROCEDURE VOLUME; TOTAL KNEE ARTHROPLASTY; UNITED-STATES;
SHOULDER ARTHROPLASTY; HIP-REPLACEMENT; HOME; ASSOCIATION; DISCHARGE;
MORTALITY; SUPPORT
AB The aim of this study was to compare patient characteristics, utilization rates, and outcomes after total elbow arthroplasty (TEA) by sex. We used the nationwide inpatient sample from 1998 to 2011 to study sex-related time trends in patient characteristics, comorbidity, and outcomes after TEA. We used chi-squared test, analysis of variance, and the Cochran-Armitage test to assess differences in utilization rates and characteristics over time by sex and logistic regression to compare mortality, discharge disposition, and the length of hospital stay by sex. Overall TEA utilization 0.45 in 1998 to 0.96 per 100,000 in 2011 (p < 0.0001). The utilization rates were significantly higher in females compared to males throughout the study period: 0.62 vs. 0.29 in 1998 (p < 0.0001) and 1.31 vs. 0.70 in 2011 (p < 0.0001). Compared to males, females undergoing TEA were more likely to be white (79.7 vs. 71.4 %; p < 0.0001), have rheumatoid arthritis (16.7 vs. 8.1 %; p < 0.0001), and have Deyo-Charlson index of 2 or more (11.3 vs. 5.9 %; p < 0.0001) and were older (63.5 vs. 51.4 years; p < 0.0001). Compared to males undergoing TEA, females had significantly lower mortality, 0.1 vs. 0.4 % (p = 0.03); lower proportion were discharged to home, 81.9 vs. 89.6 % (p < 0.0001), and fewer had has index hospital stay above the median, 30.0 vs. 33.0 % (p = 0.01); most differences were significant after multivariable adjustment. TEA utilization in the USA more than doubled in the last 14 years, with rates higher in females than males. Females had better outcomes after TEA than men. Preoperative risk communication should be sex-specific based on these data.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
FU Agency for Health Quality and Research Center for Education and Research
on Therapeutics (CERTs); National Institute of Arthritis,
Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging
(NIA); National Cancer Institute (NCI)
FX This material is the result of work supported by the resources and use
of facilities at the Birmingham VA Medical Center, Alabama, USA. J.A.S.
is also supported by grants from the Agency for Health Quality and
Research Center for Education and Research on Therapeutics (CERTs),
National Institute of Arthritis, Musculoskeletal and Skin Diseases
(NIAMS), National Institute of Aging (NIA), and National Cancer
Institute (NCI).
NR 19
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD MAR
PY 2016
VL 35
IS 3
BP 723
EP 731
DI 10.1007/s10067-014-2778-9
PG 9
WC Rheumatology
SC Rheumatology
GA DG9UJ
UT WOS:000372429000022
PM 25316506
ER
PT J
AU Burge, SK
Katerndahl, DA
Wood, RC
Becho, J
Ferrer, RL
Talamantes, M
AF Burge, Sandra K.
Katerndahl, David A.
Wood, Robert C.
Becho, Johanna
Ferrer, Robert L.
Talamantes, Melissa
TI Using Complexity Science to Examine Three Dynamic Patterns of Intimate
Partner Violence
SO FAMILIES SYSTEMS & HEALTH
LA English
DT Article
DE spouse abuse; battered women; domestic violence; nonlinear dynamics;
longitudinal studies
ID PRIMARY-CARE; LYAPUNOV EXPONENTS; TIME-SERIES; RELIABILITY; SEVERITY;
VALIDITY; SYSTEMS; HEALTH; CHAOS; MOOD
AB Introduction: The partner violence literature describes 3 dominant models of dynamics of partner aggression: cycle of violence, family systems theory, and Duluth model (power and control wheel). Complexity science describes 3 patterns of system dynamics: periodic, chaotic, and random. Are these parallel patterns? In this analysis, investigators calculated dynamic patterns (periodic, chaotic, and random) using 84 daily reports of male-to-female aggression and assessed the "fit" between time-series-derived patterns of male partners' violent behaviors and literature-based models of violence dynamics. Method: Participants were 200 women in moderately violent intimate relationships who completed a telephone survey about their relationships every day for 12 weeks. They also completed baseline and end-of-study surveys and maintained telephone contact with the study team weekly. Of 200 participants, 135 women provided enough data to be assigned to period, chaotic, or random groups. Results: Group membership included 16 women in periodic, 40 in chaotic, and 79 in random groups. Consistent with the cycle of violence, periodic women found violence to be predictable and controllable. Consistent with the Duluth model, women in the random group found violence to be unpredictable and out of their control, occurring with high frequency. The chaotic group had the lowest frequency and severity of violence, lowest stress and arguments, and the highest marital satisfaction. Discussion: The most common dynamic pattern in partner violence is random, which exhibits high frequency and unpredictability of aggression. Complexity science suggests interventions in random systems have unpredictable outcomes, posing great challenges for clinicians who work with victims of violence.
C1 [Burge, Sandra K.; Katerndahl, David A.; Wood, Robert C.; Becho, Johanna; Ferrer, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA.
[Talamantes, Melissa] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Burge, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA.
EM burge@uthscsa.edu
FU "Dynamics of Human Behavior" program, National Science Foundation
[0525026]
FX This study was funded with a grant from the "Dynamics of Human Behavior"
program, National Science Foundation, Award 0525026. Automated data
collection was provided by the University of Colorado, Department of
Family Medicine Information Services group. We thank Stephanie Mitchell,
Kelli Giacomini, and Wilson Pace for their invaluable assistance with
IVR. We also express appreciation to Norma Cantu and Diandrea Garza for
their commitment to screening and enrolling women for this study.
NR 39
TC 1
Z9 1
U1 1
U2 5
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1091-7527
EI 1939-0602
J9 FAM SYST HEALTH
JI Fam. Syst. Health
PD MAR
PY 2016
VL 34
IS 1
BP 4
EP 14
DI 10.1037/fsh0000170
PG 11
WC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
SC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
GA DG8WG
UT WOS:000372363700002
PM 26618639
ER
PT J
AU Kentta, TV
Nearing, BD
Porthan, K
Tikkanen, JT
Viitasalo, M
Nieminen, MS
Salomaa, V
Oikarinen, L
Jula, A
Kontula, K
Newton-Cheh, C
Huikuri, HV
Verrier, RL
AF Kentta, Tuomas V.
Nearing, Bruce D.
Porthan, Kimmo
Tikkanen, Jani T.
Viitasalo, Matti
Nieminen, Markku S.
Salomaa, Veikko
Oikarinen, Lasse
Jula, Antti
Kontula, Kimmo
Newton-Cheh, Chris
Huikuri, Heikki V.
Verrier, Richard L.
TI Prediction of sudden cardiac death with automated high-throughput
analysis of heterogeneity in standard resting 12-lead electrocardiograms
SO HEART RHYTHM
LA English
DT Editorial Material
DE Sudden cardiac death; Ventricular arrhythmias; Depolarization;
Repolarization; Electrocardiogram; Heterogeneity
ID T-WAVE MORPHOLOGY; QT DISPERSION; MYOCARDIAL-INFARCTION; REPOLARIZATION
HETEROGENEITY; VENTRICULAR REPOLARIZATION; CARDIOVASCULAR MORTALITY;
RISK STRATIFICATION; ARRHYTHMIA RISK; INTERVAL; POPULATION
AB BACKGROUND Heterogeneity of depolarization and repolarization underlies the development of lethal arrhythmias.
OBJECTIVE We investigated whether quantification of spatial depolarization and repolarization heterogeneity identifies individuals at risk for sudden cardiac death (SCD).
METHODS Spatial R-, J-, and T-wave heterogeneity (RWH, JWH, and TWH, respectively) was analyzed using automated second central moment analysis of standard digital 12-lead electrocardiograms in 5618 adults (2588, 46% men; mean +/- SEM age 50.9 +/- 0.2 years), who took part in the epidemiological Health 2000 Survey as representative of the entire Finnish adult population.
RESULTS During the follow-up period of 7.7 +/- 0.2 years, a total of 72 SCDs occurred (1.3%), with an average yearly incidence rate of 0.17% per year. Increased RWH, JWH, and TWH in left precordial leads (V-4-V-6) were univariately associated with SCD (P < .001 for each). When adjusted with standard clinical risk markers, JWH and TWH remained independent predictors of SCD. Increased TWH (>= 102 mu V) was associated with a 1.7-fold adjusted relative risk for SCD (95% confidence interval [CI] 1.0-2.9; P = .048) and increased JWH (>= 123 mu V) with a 2.0-fold adjusted relative risk for SCD (95% CI 1.2-3.3; P = .006). When both TWH and JWH were above the threshold, the adjusted relative risk for SCD was 2.9-fold (95% CI 1.5-5.7; P = .002). When RWH (>= 470 mu V), JWH, and TWH were all above the threshold, the adjusted relative risk for SCD was 3.2-fold (95% CI 1.4-7.1; P = .009).
CONCLUSION Second central moment analysis of standard resting 12-lead electrocardiographic morphology provides an ultrarapid means for the automated measurement of spatial RWH, JWH, and TWH, enabling analysis of high subject volumes and screening for SCD risk in the general population.
C1 [Kentta, Tuomas V.; Tikkanen, Jani T.; Huikuri, Heikki V.] Univ Oulu, Med Res Ctr Oulu, Oulu, Finland.
[Kentta, Tuomas V.; Tikkanen, Jani T.; Huikuri, Heikki V.] Univ Hosp Oulu, Oulu, Finland.
[Kentta, Tuomas V.; Nearing, Bruce D.; Verrier, Richard L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Nearing, Bruce D.; Verrier, Richard L.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Porthan, Kimmo; Viitasalo, Matti; Nieminen, Markku S.; Oikarinen, Lasse] Univ Helsinki, Cent Hosp, Div Cardiol, Heart & Lung Ctr, Helsinki, Finland.
[Tikkanen, Jani T.] Haartman Hosp, Emergency Dept, Helsinki, Finland.
[Salomaa, Veikko; Jula, Antti] Natl Inst Hlth & Welf, Helsinki, Finland.
[Kontula, Kimmo] Univ Helsinki, Dept Med, Helsinki, Finland.
[Newton-Cheh, Chris] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Newton-Cheh, Chris] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Newton-Cheh, Chris] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
RP Verrier, RL (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, 99 Brookline Ave,RN 301, Boston, MA 02215 USA.
EM rverrier@bidmc.harvard.edu
NR 35
TC 3
Z9 3
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD MAR
PY 2016
VL 13
IS 3
BP 713
EP 720
DI 10.1016/j.hrthm.2015.11.035
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG8XV
UT WOS:000372367800015
PM 26616400
ER
PT J
AU Libbus, I
Nearing, BD
Amurthur, B
KenKnight, BH
Verrier, RL
AF Libbus, Imad
Nearing, Bruce D.
Amurthur, Badri
KenKnight, Bruce H.
Verrier, Richard L.
TI Autonomic regulation therapy suppresses quantitative T-wave alternans
and improves baroreflex sensitivity in patients with heart failure
enrolled in the ANTHEM-HF study
SO HEART RHYTHM
LA English
DT Editorial Material
DE Heart failure; T-wave alternans; Baroreceptor sensitivity; Vagus nerve
stimulation; Autonomic regulation therapy; Heart rate turbulence;
Ventricular tachycardia; Heart rate variability; Autonomic tone;
Autonomic reflexes
ID VAGUS NERVE-STIMULATION; PHYSIOLOGICAL INTERPRETATION; CLINICAL-USE;
SUDDEN; SYSTEM; DEATH; STANDARDS; MORTALITY; EPILEPSY; HOLTER
AB BACKGROUND Autonomic regulation therapy (ART) with chronic vagus nerve stimulation improves ventricular function in patients with chronic heart failure, but its effects on quantitative T-wave alternans (TWA), ventricular tachycardia (VT), baroreflex sensitivity, and autonomic tone remained unknown.
OBJECTIVE Effects on TWA, a marker of risk of life-threatening arrhythmias; heart rate turbulence (HRT), an indicator of baroreflex sensitivity; heart rate variability; and VT incidence were studied in 25 patients with chronic symptomatic heart failure and reduced ejection fraction enrolled in the ANTHEM-HF study (NCT01823887).
METHODS Twenty-four-hour ambulatory electrocardiographic recordings made before ART system (Cyberonics, Inc., Houston, TX) implantation involving the left or right vagus nerve and after 6 and 12 months of chronic therapy (10-Hz frequency, 250-mu s pulse width, maximum tolerable current amplitude after 10 weeks of titration) at low-intensity (<2 mA; n = 10, 40%) or high-intensity (>= 2 mA; n = 15, 60%) stimulation levels were analyzed.
RESULTS At 12 months, peak TWA levels were reduced by 29% from 71.0 +/- 4.6 to 50.5 +/- 1.8 mu V (P < .0001). The number of patients with severely abnormal TWA (>= 60 mu V) was reduced by 76% from 17 to 4 (P < .0005), and the number of patients with nonsustained VT decreased by 73% from 11 to 3 (P < .025). HRT slope (P < .025), high frequency heart rate variability (HRV) (P =.05), and square root of the mean squared differences of successive normal-to-normal interval HRV (P =.013) increased. The mean heart rate derived from 24-hour Hotter electrocardiograms decreased by 10% from 77 +/- 2 to 69 +/- 2 beats/min (P = .0002). HRT onset was unchanged.
CONCLUSION Chronic ART in patients with symptomatic heart failure improves cardiac electrical stability, as reflected by reduced TWA levels and heart rate, suppresses VT, and increases baroreceptor sensitivity. These observations deserve study in a larger population.
C1 [Libbus, Imad; Amurthur, Badri; KenKnight, Bruce H.] Cyberonics Inc, Houston, TX USA.
[Nearing, Bruce D.; Verrier, Richard L.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Verrier, RL (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Sch Med,Harvard Thomdike Electrophysiol Inst, 99 Brookline Ave,RN 301, Boston, MA 02215 USA.
EM rverrier@bidmc.harvard.edu
NR 24
TC 6
Z9 6
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD MAR
PY 2016
VL 13
IS 3
BP 721
EP 728
DI 10.1016/j.hrthm.2015.11.030
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG8XV
UT WOS:000372367800016
PM 26601770
ER
PT J
AU Afeiche, MC
Chiu, YH
Gaskins, AJ
Williams, PL
Souter, I
Wright, DL
Hauser, R
Chavarro, JE
AF Afeiche, M. C.
Chiu, Y. -H.
Gaskins, A. J.
Williams, P. L.
Souter, I.
Wright, D. L.
Hauser, R.
Chavarro, J. E.
CA EARTH Study Team
TI Dairy intake in relation to in vitro fertilization outcomes among women
from a fertility clinic
SO HUMAN REPRODUCTION
LA English
DT Article
DE diet; dairy; in vitro fertilization outcomes; assisted reproductive
technology; live birth rate
ID GROWTH-FACTOR-I; MILK CONSUMPTION; DIETARY PATTERNS; SEMEN QUALITY;
PREGNANCY; FOOD; MEN; QUESTIONNAIRE; INFERTILITY; PRODUCTS
AB Is dairy food consumption associated with live birth among women undergoing infertility treatment?
There was a positive association between total dairy food consumption and live birth among women a parts per thousand yen35 years of age.
Dairy food intake has been previously related to infertility risk and measures of fertility potential but its relation to infertility treatment outcomes are unknown.
Our study population comprised a total of 232 women undergoing 353 in vitro fertilization (IVF) treatment cycles between February 2007 and May 2013, from the Environment and Reproductive Health study, an ongoing prospective cohort.
Diet was assessed before assisted reproductive technology (ART) treatment using a validated food frequency questionnaire. Study outcomes included ovarian stimulation outcomes (endometrial thickness, estradiol levels and oocyte yield), fertilization rates, embryo quality measures and clinical outcomes (implantation, clinical pregnancy and live birth rates). We used generalized linear mixed models with random intercepts to account for multiple ART cycles per woman while simultaneously adjusting for age, caloric intake, BMI, race, smoking status, infertility diagnosis, protocol type, alcohol intake and dietary patterns.
The age- and calorie-adjusted difference in live birth between women in the highest (> 3.0 servings/day) and lowest (< 1.34 servings/day) quartile of dairy intake was 21% (P = 0.02). However, after adjusting for additional covariates, this association was observed only among women a parts per thousand yen35 years (P, interaction = 0.04). The multivariable-adjusted live birth (95% CI) in increasing quartiles of total dairy intake was 23% (11, 42%), 39% (24, 56%), 29% (17, 47%) and 55% (39, 69%) (P, trend = 0.02) among women a parts per thousand yen35 years old, and ranged from 46 to 54% among women < 35 years old (P, trend = 0.69). There was no association between dairy intake and any of the intermediate outcomes.
The lack of a known biological mechanism linking dairy intake to infertility treatment outcomes calls for caution when interpreting these results and for additional work to corroborate or refute them.
Dairy intake does not appear to harm IVF outcomes and, if anything, is associated with higher chances of live birth.
This work was supported by NIH grants R01-ES009718 and R01ES000002 from NIEHS, P30 DK046200 from NIDDK and T32HD060454 from NICHD. M.C.A. was supported by a Ruth L. Kirschstein National Research Service Award T32 DK 007703-16 from NIDDK. She is currently employed at the Nestl, Research Center, Switzerland and completed this work while at the Harvard School of Public Health. The other authors declare no conflicts of interest.
C1 [Afeiche, M. C.; Hauser, R.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Chiu, Y. -H.; Gaskins, A. J.; Chavarro, J. E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Chiu, Y. -H.; Gaskins, A. J.; Williams, P. L.; Hauser, R.; Chavarro, J. E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Williams, P. L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Souter, I.; Wright, D. L.; Hauser, R.] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA.
[Souter, I.; Wright, D. L.; Hauser, R.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Chavarro, J. E.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA.
[Chavarro, J. E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Afeiche, MC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM mafeiche@hsph.harvard.edu
FU NIH [R01-ES009718]; NIEHS [R01ES000002]; NIDDK [P30 DK046200]; NICHD
[T32HD060454]; Ruth L. Kirschstein National Research Service Award from
NIDDK [T32 DK 007703-16]
FX This work was supported by NIH grants R01-ES009718 and R01ES000002 from
NIEHS, P30 DK046200 from NIDDK, and T32HD060454 from NICHD. M.C.A. was
supported by a Ruth L. Kirschstein National Research Service Award T32
DK 007703-16 from NIDDK.
NR 31
TC 2
Z9 2
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD MAR
PY 2016
VL 31
IS 3
BP 563
EP 571
DI 10.1093/humrep/dev344
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DG9QN
UT WOS:000372419000009
PM 26787645
ER
PT J
AU Neilan, TG
Kwong, R
AF Neilan, Tomas G.
Kwong, Raymond
TI How to Distinguish Between Myocarditis and Sarcoidosis Based on CMR
Imaging REPLY
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Letter
ID LATE GADOLINIUM ENHANCEMENT; CARDIAC SARCOIDOSIS
C1 [Neilan, Tomas G.] Massachusetts Gen Hosp, Dept Cardiol, 55 Fruit St,Yawkey 5, Boston, MA 02114 USA.
RP Neilan, TG (reprint author), Massachusetts Gen Hosp, Dept Cardiol, 55 Fruit St,Yawkey 5, Boston, MA 02114 USA.
EM tneilan@partners.org
NR 5
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD MAR
PY 2016
VL 9
IS 3
BP 327
EP 328
DI 10.1016/j.jcmg.2015.05.016
PG 4
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA DH0EN
UT WOS:000372455400021
PM 26965735
ER
PT J
AU Schulman, JM
Oh, DH
Sanborn, JZ
Pincus, L
McCalmont, TH
Cho, RJ
AF Schulman, Joshua M.
Oh, Dennis H.
Sanborn, J. Zachary
Pincus, Laura
McCalmont, Timothy H.
Cho, Raymond J.
TI Multiple Hereditary Infundibulocystic Basal Cell Carcinoma Syndrome
Associated With a Germline SUFU Mutation
SO JAMA DERMATOLOGY
LA English
DT Article
ID GORLIN SYNDROME; MEDULLOBLASTOMA
AB IMPORTANCE Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC) is a rare genodermatosis in which numerous indolent, well-differentiated basal cell carcinomas develop primarily on the face and genitals, without other features characteristic of basal cell nevus syndrome. The cause is unknown. The purpose of the study was to identify a genetic basis for the syndrome and a mechanism by which the associated tumors develop.
OBSERVATIONS Whole-exome sequencing of 5 tumors and a normal buccal mucosal sample from a patient with MHIBCC was performed. A conserved splice-site mutation in 1 copy of the suppressor of fused gene (SUFU) was identified in all tumor and normal tissue samples. Additional distinct deletions of the trans SUFU allele were identified in all tumor samples, none of which were present in the normal sample.
CONCLUSIONS AND RELEVANCE A germline SUFU mutation was present in a patient with MHIBCC, and additional acquired SUFU mutations underlie the development of infundibulocystic basal cell carcinomas. The downstream location of the SUFU gene within the sonic hedgehog pathway may explain why its loss is associated with relatively well-differentiated tumors and suggests that MHIBCC will not respond to therapeutic strategies, such as smoothened inhibitors, that target upstream components of this pathway.
C1 [Schulman, Joshua M.; Oh, Dennis H.; Pincus, Laura; McCalmont, Timothy H.; Cho, Raymond J.] Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,S431, San Francisco, CA 94115 USA.
[Schulman, Joshua M.; Pincus, Laura; McCalmont, Timothy H.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA.
[Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA USA.
[Sanborn, J. Zachary] NantOmics LLC, Santa Cruz, CA USA.
RP Cho, RJ (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,S431, San Francisco, CA 94115 USA.
EM chorj@derm.ucsf.edu
FU Well Aging Research Center, Samsung Advanced Institute of Technology;
National Cancer Institute, National Institutes of Health [K08 CA169865]
FX This study was supported by the Well Aging Research Center, Samsung
Advanced Institute of Technology, under the auspices of Sang Chul Park,
MD, PhD, and by grant K08 CA169865 from the National Cancer Institute,
National Institutes of Health (Dr Cho).
NR 15
TC 2
Z9 2
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD MAR
PY 2016
VL 152
IS 3
BP 323
EP 327
DI 10.1001/jamadermatol.2015.4233
PG 5
WC Dermatology
SC Dermatology
GA DH0GH
UT WOS:000372460300019
PM 26677003
ER
PT J
AU Morone, NE
Greco, CM
Moore, CG
Rollman, BL
Lane, B
Morrow, LA
Glynn, NW
Weiner, DK
AF Morone, Natalia E.
Greco, Carol M.
Moore, Charity G.
Rollman, Bruce L.
Lane, Bridget
Morrow, Lisa A.
Glynn, Nancy W.
Weiner, Debra K.
TI A Mind-Body Program for Older Adults With Chronic Low Back Pain A
Randomized Clinical Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID SELF-EFFICACY; PSYCHOMETRIC PROPERTIES; NATIONAL-HEALTH; SCALE;
METAANALYSIS; MINDFULNESS; VALIDATION; MEDITATION; DISABILITY; INTENSITY
AB IMPORTANCE Treatment of chronic low back pain (LBP) in older adults is limited by the adverse effects of analgesics. Effective nonpharmacologic treatment options are needed.
OBJECTIVE To determine the effectiveness of a mind-body program at increasing function and reducing pain in older adults with chronic LBP.
DESIGN, SETTING, AND PARTICIPANTS This single-blind, randomized clinical trial compared a mind-body program (n = 140) with a health education program (n = 142). Community-dwelling older adults residing within the Pittsburgh metropolitan area were recruited from February 14, 2011, to June 30, 2014, with 6-month follow-up completed by April 9, 2015. Eligible participants were 65 years or older with functional limitations owing to their chronic LBP (>= 11 points on the Roland and Morris Disability Questionnaire) and chronic pain (duration >= 3 months) of moderate intensity. Data were analyzed from March 1 to July 1, 2015.
INTERVENTIONS The intervention and control groups received an 8-week group program followed by 6 monthly sessions. The intervention was modeled on the Mindfulness-Based Stress Reduction program; the control program, on the "10 Keys" to Healthy Aging.
MAIN OUTCOMES AND MEASURES Follow-up occurred at program completion and 6 months later. The score on the Roland and Morris Disability Questionnaire was the primary outcome and measured functional limitations owing to LBP. Pain (current, mean, and most severe in the past week) was measured with the Numeric Pain Rating Scale. Secondary outcomes included quality of life, pain self-efficacy, and mindfulness. Intent-to-treat analyses were conducted.
RESULTS Of 1160 persons who underwent screening, 282 participants enrolled in the trial (95 men [33.7%] and 187 women [66.3%]; mean [SD] age, 74.5 [6.6] years). The baseline mean (SD) Roland and Morris Disability Questionnaire scores for the intervention and control groups were 15.6 (3.0) and 15.4 (3.0), respectively. Compared with the control group, intervention participants improved an additional -1.1 (mean, 12.1 vs 13.1) points at 8 weeks and -0.04 (mean, 12.2 vs 12.6) points at 6 months (effect sizes, -0.23 and -0.08, respectively) on the Roland and Morris Disability Questionnaire. By 6 months, the intervention participants improved on the Numeric Pain Rating Scale current and most severe pain measures an additional -1.8 points (95% CI, -3.1 to -0.05 points; effect size, -0.33) and -1.0 points (95% CI, -2.1 to 0.2 points; effect size, -0.19), respectively. The changes in Numeric Pain Rating Scale mean pain measure after the intervention were not significant (-0.1 [95% CI, -1.1 to 1.0] at 8 weeks and -1.1 [95% CI, -2.2 to -0.01] at 6 months; effect size, -0.01 and -0.22, respectively).
CONCLUSIONS AND RELEVANCE A mind-body program for chronic LBP improved short-term function and long-term current and most severe pain. The functional improvement was not sustained, suggesting that future development of the intervention could focus on durability.
C1 [Morone, Natalia E.; Rollman, Bruce L.; Lane, Bridget] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.
[Morone, Natalia E.; Rollman, Bruce L.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15213 USA.
[Morone, Natalia E.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Greco, Carol M.] Univ Pittsburgh, Sch Med, UPMC, Dept Psychiat,Ctr Integrat Med, Pittsburgh, PA 15213 USA.
[Moore, Charity G.] Carolinas HealthCare Syst, Dickson Adv Analyt, Charlotte, NC USA.
[Morrow, Lisa A.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Glynn, Nancy W.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA.
[Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
RP Morone, NE (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.
EM moronene@upmc.edu
OI Glynn, Nancy/0000-0003-2265-0162
FU National Institutes of Health [R01 AG034078]
FX This study was supported by grant R01 AG034078 from the National
Institutes of Health.
NR 29
TC 12
Z9 12
U1 5
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 329
EP 337
DI 10.1001/jamainternmed.2015.8033
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500010
PM 26903081
ER
PT J
AU Auer, R
Vittinghoff, E
Yaffe, K
Kunzi, A
Kertesz, SG
Levine, DA
Albanese, E
Whitmer, RA
Jacobs, DR
Sidney, S
Glymour, MM
Pletcher, MJ
AF Auer, Reto
Vittinghoff, Eric
Yaffe, Kristine
Kuenzi, Arnaud
Kertesz, Stefan G.
Levine, Deborah A.
Albanese, Emiliano
Whitmer, Rachel A.
Jacobs, David R., Jr.
Sidney, Stephen
Glymour, M. Maria
Pletcher, Mark J.
TI Association Between Lifetime Marijuana Use and Cognitive Function in
Middle Age The Coronary Artery Risk Development in Young Adults (CARDIA)
Study
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID POPULATION-BASED COHORT; HEAVY CANNABIS USERS; SOCIOECONOMIC-STATUS;
DRUG-USE; DECLINE; HEALTH; IQ; INTERFERENCE; EXPOSURE; MIDLIFE
AB IMPORTANCE Marijuana use is increasingly common in the United States. It is unclear whether it has long-term effects on memory and other domains of cognitive function.
OBJECTIVE To study the association between cumulative lifetime exposure to marijuana use and cognitive performance in middle age.
DESIGN, SETTING, AND PARTICIPANTS We used data from the Coronary Artery Risk Development in Young Adults (CARDIA) study, a cohort of 5115 black and white men and women aged 18 to 30 years at baseline from March 25, 1985, to June 7, 1986 (year 0), and followed up over 25 years from June 7, 1986, to August 31, 2011, to estimate cumulative years of exposure to marijuana (1 year = 365 days of marijuana use) using repeated measures and to assess associations with cognitive function at year 25. Linear regression was used to adjust for demographic factors, cardiovascular risk factors, tobacco smoking, use of alcohol and illicit drugs, physical activity, depression, and results of the mirror star tracing test (a measure of cognitive function) at year 2. Data analysis was conducted from June 7, 1986, to August 31, 2011.
MAIN OUTCOMES AND MEASURES Three domains of cognitive function were assessed at year 25 using the Rey Auditory Verbal Learning Test (verbal memory), the Digit Symbol Substitution Test (processing speed), and the Stroop Interference Test (executive function).
RESULTS Among 3385 participants with cognitive function measurements at the year 25 visit, 2852 (84.3%) reported past marijuana use, but only 392 (11.6%) continued to use marijuana into middle age. Current use of marijuana was associated with worse verbal memory and processing speed; cumulative lifetime exposure was associated with worse performance in all 3 domains of cognitive function. After excluding current users and adjusting for potential confounders, cumulative lifetime exposure to marijuana remained significantly associated with worse verbal memory. For each 5 years of past exposure, verbal memory was 0.13 standardized units lower (95% CI, -0.24 to -0.02; P =.02), corresponding to a mean of 1 of 2 participants remembering 1 word fewer from a list of 15 words for every 5 years of use. After adjustment, we found no associations with lower executive function (-0.03 [95% CI, -0.12 to 0.07]; P =.56) or processing speed (-0.04 [95% CI, -0.16 to 0.08]; P =.51).
CONCLUSIONS AND RELEVANCE Past exposure to marijuana is associated with worse verbal memory but does not appear to affect other domains of cognitive function.
C1 [Auer, Reto; Vittinghoff, Eric; Yaffe, Kristine; Glymour, M. Maria; Pletcher, Mark J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Auer, Reto; Kuenzi, Arnaud] Univ Lausanne, Dept Ambulatory Care & Community Med, Lausanne, Switzerland.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat & Neurol, San Francisco, CA 94143 USA.
[Kertesz, Stefan G.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med & Acute Care Res, Birmingham, AL USA.
[Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA.
[Levine, Deborah A.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Levine, Deborah A.] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Levine, Deborah A.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
[Levine, Deborah A.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA.
[Levine, Deborah A.] Univ Michigan, Stroke Program, Ann Arbor, MI 48109 USA.
[Albanese, Emiliano] Univ Geneva, Dept Psychiat, Geneva, Switzerland.
[Whitmer, Rachel A.; Sidney, Stephen] Kaiser Permanente, Div Res, Oakland, CA USA.
[Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
RP Auer, R (reprint author), Univ Lausanne, Dept Ambulatory Care & Community Med, Rue Bugnon 44, CH-1011 Lausanne, Switzerland.
EM reto.auer@hospvd.ch
OI Glymour, M. Maria/0000-0001-9644-3081
FU National Heart, Lung, and Blood Institute (NHLBI); University of Alabama
at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern
University [HHSN268201300027C]; University of Minnesota
[HHSN268201300028C]; Kaiser Foundation Research Institute
[HHSN268201300029C]; Johns Hopkins University School of Medicine
[HHSN268200900041C]; Intramural Research Program of the National
Institute on Aging (NIA); NIA [AG0005]; NHLBI [AG0005]
FX The Coronary Artery Risk Development in Young Adults (CARDIA) study is
conducted and supported by the National Heart, Lung, and Blood Institute
(NHLBI) in collaboration with the University of Alabama at Birmingham
(grants HHSN268201300025C and HHSN268201300026C), Northwestern
University (grant HHSN268201300027C), University of Minnesota (grant
HHSN268201300028C), Kaiser Foundation Research Institute (grant
HHSN268201300029C), and The Johns Hopkins University School of Medicine
(grant HHSN268200900041C). The CARDIA study is also partially supported
by the Intramural Research Program of the National Institute on Aging
(NIA) and an intra-agency agreement between the NIA and the NHLBI
(AG0005).
NR 45
TC 12
Z9 12
U1 9
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 352
EP 361
DI 10.1001/jamainternmed.2015.7841
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500014
PM 26831916
ER
PT J
AU Widera, E
Talebreza, S
AF Widera, Eric
Talebreza, Shaida
TI Variability in Hospice Care at the Very End of Life
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Widera, Eric] Univ Calif San Francisco, Dept Internal Med, Div Geriatr, San Francisco, CA 94143 USA.
[Widera, Eric] San Francisco VA Med Ctr, 4150 Clement St,Campus Box 181G, San Francisco, CA 94121 USA.
[Talebreza, Shaida] Univ Utah, Sch Med, Dept Internal Med, Div Geriatr, Salt Lake City, UT USA.
[Talebreza, Shaida] George E Wahlen Salt Lake City Vet Affairs Med Ct, Salt Lake City, UT USA.
[Talebreza, Shaida] Inspirat Hosp, Salt Lake City, UT USA.
RP Widera, E (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Campus Box 181G, San Francisco, CA 94121 USA.
EM eric.widera@ucsf.edu
NR 2
TC 2
Z9 2
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 370
EP 371
DI 10.1001/jamainternmed.2015.7931
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500017
PM 26856885
ER
PT J
AU Kim, TY
Schafer, AL
AF Kim, Tiffany Y.
Schafer, Anne L.
TI Variability in DXA Reporting and Other Challenges in Osteoporosis
Evaluation
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID PREVENTION; FRACTURE; THERAPY
C1 [Kim, Tiffany Y.; Schafer, Anne L.] San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA.
RP Schafer, AL (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA.
EM anne.schafer@ucsf.edu
FU CSRD VA [IK2 CX000549]
NR 7
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 393
EP 395
DI 10.1001/jamainternmed.2015.7550
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500025
PM 26746871
ER
PT J
AU Lehman, C
AF Lehman, Constance
TI Potential Benefits of Computer-Aided Detection for Cancer Identification
and Treatment Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID SCREENING MAMMOGRAPHY
C1 [Lehman, Constance] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Ste 240, Boston, MA 02114 USA.
RP Lehman, C (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Ste 240, Boston, MA 02114 USA.
EM clehman@mgh.harvard.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 411
EP 411
DI 10.1001/jamainternmed.2015.8474
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500038
PM 26954046
ER
PT J
AU Sun, JK
Aiello, LP
AF Sun, Jennifer K.
Aiello, Lloyd Paul
TI The Future of Ultrawide Field Imaging for Diabetic Retinopathy Pondering
the Retinal Periphery
SO JAMA OPHTHALMOLOGY
LA English
DT Editorial Material
C1 [Sun, Jennifer K.; Aiello, Lloyd Paul] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.
[Sun, Jennifer K.; Aiello, Lloyd Paul] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA.
RP Aiello, LP (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Beetham Eye Inst,Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
EM lpaiello@joslin.harvard.edu
NR 7
TC 2
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2016
VL 134
IS 3
BP 247
EP 248
DI 10.1001/jamaophthalmol.2015.5384
PG 2
WC Ophthalmology
SC Ophthalmology
GA DH1JN
UT WOS:000372540300005
PM 26720171
ER
PT J
AU Kang, JH
Willett, WC
Rosner, BA
Buys, E
Wiggs, JL
Pasquale, LR
AF Kang, Jae H.
Willett, Walter C.
Rosner, Bernard A.
Buys, Emmanuel
Wiggs, Janey L.
Pasquale, Louis R.
TI Association of Dietary Nitrate Intake With Primary Open-Angle Glaucoma A
Prospective Analysis From the Nurses' Health Study and Health
Professionals Follow-up Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; FOOD FREQUENCY QUESTIONNAIRE; NORMAL-TENSION
GLAUCOMA; VISUAL-FIELD CHARACTERISTICS; OCULAR BLOOD-FLOW; OSTEOPOROTIC
FRACTURES; INTRAOCULAR-PRESSURE; POSTURE CHANGE; EXERCISE; RISK
AB IMPORTANCE Nitric oxide signaling alterations in outflow facility and retinal blood flow autoregulation are implicated in primary open-angle glaucoma (POAG). Nitric oxide donation has emerged as a POAG therapeutic target. An exogenous source of nitric oxide is dietary nitrates.
OBJECTIVE To evaluate the association between dietary nitrate intake, derived mainly from green leafy vegetables, and POAG.
DESIGN, SETTING, AND PARTICIPANTS We followed up participants biennially in the prospective cohorts of the Nurses' Health Study (63 893 women; 1984-2012) and the Health Professionals Follow-up Study (41 094 men; 1986-2012) at each 2-year risk period. Eligible participants were 40 years or older, were free of POAG, and reported eye examinations.
EXPOSURES The primary exposure was dietary nitrate intake. Information on diet and potential confounders was updated with validated questionnaires.
MAIN OUTCOMES AND MEASURES The main outcome was the incidence of POAG and POAG subtypes; 1483 cases were confirmed with medical records and classified into subtypes defined by intraocular pressure (IOP) (>22 or <22 mm Hg) or by visual field (VF) loss pattern at diagnosis (peripheral loss only or early paracentral loss). Cohort-specific and pooled multivariable rate ratios (MVRRs) and 95% CIs were estimated.
RESULTS During 1 678 713 person-years of follow-up, 1483 incident cases of POAG were identified. The mean (SD) age for the 1483 cases was 66.8 (8.3). Compared with the lowest quintile of dietary nitrate intake (quintile 1: approximately 80 mg/d), the pooled MVRR for the highest quintile (quintile 5: approximately 240 mg/d) was 0.79 (95% CI, 0.66-0.93; P for trend = .02). The dose response was stronger (P for heterogeneity = .01) for POAG with early paracentral VF loss (433 cases; quintile 5 vs quintile 1 MVRR = 0.56; 95% CI, 0.40-0.79; P for trend < .001) than for POAG with peripheral VF loss only (835 cases; quintile 5 vs quintile 1 MVRR = 0.85; 95% CI, 0.68-1.06; P for trend = .50). The association did not differ (P for heterogeneity = .75) by POAG subtypes defined by IOP (997 case patients with IOP >= 22 mm Hg: quintile 5 vs quintile 1 MVRR = 0.82; 95% CI, 0.67-1.01; P for trend = .11; 486 case patients with IOP <22 mm Hg: quintile 5 vs quintile 1 MVRR = 0.71; 95% CI, 0.53-0.96; P for trend = .12). Green leafy vegetables accounted for 56.7% of nitrate intake variation. Compared with consuming 0.31 servings per day, the MVRR for consuming 1.45 or more servings per day was 0.82 for all POAG (95% CI, 0.69-0.97; P for trend = .02) and 0.52 for POAG with paracentral VF loss (95% CI, 0.29-0.96; P for trend < .001).
CONCLUSIONS AND RELEVANCE Higher dietary nitrate and green leafy vegetable intake was associated with a lower POAG risk, particularly POAG with early paracentral VF loss at diagnosis.
C1 [Kang, Jae H.; Willett, Walter C.; Rosner, Bernard A.; Pasquale, Louis R.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
[Kang, Jae H.; Willett, Walter C.; Rosner, Bernard A.; Pasquale, Louis R.] Harvard Univ, Sch Med, 181 Longwood Ave, Boston, MA 02115 USA.
[Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Rosner, Bernard A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Buys, Emmanuel] Massachusetts Gen Hosp, Res Inst, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Wiggs, Janey L.; Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Glaucoma Serv, Boston, MA 02114 USA.
RP Kang, JH (reprint author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.; Kang, JH (reprint author), Harvard Univ, Sch Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM nhjhk@channing.harvard.edu
FU National Institutes of Health [R21 EY022766]; Arthur Ashley Foundation;
Harvard Glaucoma Center of Excellence; Harvard Medical Distinguished
Ophthalmology Scholar Award; [UM1 CA186107]; [UM1 CA167552];
[EY09611]; [EY015473]
FX This work was supported by grants UM1 CA186107, UM1 CA167552, EY09611,
and EY015473 (Dr Pasquale) and grant R21 EY022766 (Dr Wiggs) from the
National Institutes of Health and the Arthur Ashley Foundation, the
Harvard Glaucoma Center of Excellence (Drs Pasquale and Wiggs), and a
Harvard Medical Distinguished Ophthalmology Scholar Award (Dr Pasquale).
NR 87
TC 1
Z9 1
U1 1
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2016
VL 134
IS 3
BP 294
EP 303
DI 10.1001/jamaophthalmol.2015.5601
PG 10
WC Ophthalmology
SC Ophthalmology
GA DH1JN
UT WOS:000372540300016
PM 26767881
ER
PT J
AU Silva, PS
Cavallerano, JD
Haddad, NMN
Tolls, D
Thakore, K
Patel, B
Sehizadeh, M
Tolson, AM
Sun, JK
Aiello, LP
AF Silva, Paolo S.
Cavallerano, Jerry D.
Haddad, Nour Maya N.
Tolls, Dorothy
Thakore, Komal
Patel, Bina
Sehizadeh, Mina
Tolson, Ann M.
Sun, Jennifer K.
Aiello, Lloyd Paul
TI Comparison of Nondiabetic Retinal Findings Identified With Nonmydriatic
Fundus Photography vs Ultrawide Field Imaging in an Ocular Telehealth
Program
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPY; DIABETIC-RETINOPATHY; LESIONS;
ANGIOGRAPHY
AB IMPORTANCE Ultrawide field imaging (UWFI) is increasingly being used in teleophthalmology settings. Given the greater area of the retina imaged, we evaluated the ability of UWFI vs nonmydriatic fundus photography (NMFP) to detect nondiabetic retinal findings in a teleophthalmology program.
OBSERVATION We conducted a retrospective single-center comparative cohort study from January 1, 2011, to June 30, 2013, imaging 3864 and 3971 consecutive teleophthalmology patients (7728 and 7942 eyes) using NMFP and UWFI, respectively. Standard diabetic retinopathy evaluation and nondiabetic findings were compared between the 2 imaging modalities. In patients without diabetic retinopathy (2243 by NMFP and 2252 by UWFI), the rate of identification of nondiabetic findings by NMFP (451 patients [20.1%]) and UWFI (490 [21.8%]) were comparable (P = .19). Ultrawide field imaging increased the identification of choroidal nevi by 27%(406 eyes [5.3%] by NMFP vs 545 eyes [6.9%] by UWFI; P < .001) and chorioretinal atrophy or scarring by 116%(50 eyes [0.6%] by NMFP vs 101 eyes [1.3%] by UWFI; P < .001). No peripheral retinal findings were identified with NMFP, while UWFI detected 25 retinal tears (0.3%; P < .001), 54 lattice and peripheral degenerations (0.7%; P < .001), and 142 cases of vitreous detachment or floaters (1.8%; P < .001). Data analysis was performed from November 1, 2013, to May 1, 2014.
CONCLUSIONS AND RELEVANCE In eyes without diabetic retinopathy, approximately 20% may have ocular findings identified on retinal imaging, which emphasizes the role of retinal imaging in patients with diabetes mellitus type 1 and type 2 regardless of the severity of retinopathy. In this cohort, UWFI increased the identification of peripheral retinal and vitreous pathologic findings.
C1 [Silva, Paolo S.; Cavallerano, Jerry D.; Haddad, Nour Maya N.; Tolls, Dorothy; Thakore, Komal; Patel, Bina; Sehizadeh, Mina; Tolson, Ann M.; Sun, Jennifer K.; Aiello, Lloyd Paul] Joslin Diabet Ctr, Beetham Eye Inst, One Joslin Pl, Boston, MA 02215 USA.
[Silva, Paolo S.; Cavallerano, Jerry D.; Aiello, Lloyd Paul] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Silva, Paolo S.] Univ Philippines, Philippine Eye Res Inst, Teleophthalmol & Image Reading Ctr, Manila, Philippines.
[Patel, Bina] New England Coll Optometry, Boston, MA USA.
RP Silva, PS (reprint author), Joslin Diabet Ctr, Beetham Eye Inst, One Joslin Pl, Boston, MA 02215 USA.
EM paoloantonio.silva@joslin.harvard.edu
FU Massachusetts Lions Eye Research Fund
FX This study was supported by the Massachusetts Lions Eye Research Fund
(Drs Silva and Aiello). Temporary loan of 2 ultrawide field imaging
devices was provided to the Joslin Diabetes Center by Optos plc.
NR 15
TC 3
Z9 3
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2016
VL 134
IS 3
BP 330
EP 334
DI 10.1001/jamaophthalmol.2015.5605
PG 5
WC Ophthalmology
SC Ophthalmology
GA DH1JN
UT WOS:000372540300020
PM 26795026
ER
PT J
AU Stryjewski, TP
Papakostas, TD
Vavvas, D
AF Stryjewski, Tomasz P.
Papakostas, Thanos D.
Vavvas, Demetrios
TI Proliferative Hypertensive Retinopathy
SO JAMA OPHTHALMOLOGY
LA English
DT Letter
C1 [Stryjewski, Tomasz P.; Papakostas, Thanos D.; Vavvas, Demetrios] Massachusetts Eye & Ear Infirm, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
[Papakostas, Thanos D.; Vavvas, Demetrios] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Vavvas, D (reprint author), Massachusetts Eye & Ear Infirm, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM vavvas@meei.harvard.edu
NR 4
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2016
VL 134
IS 3
BP 345
EP 346
DI 10.1001/jamaophthalmol.2015.5583
PG 3
WC Ophthalmology
SC Ophthalmology
GA DH1JN
UT WOS:000372540300026
PM 26767543
ER
PT J
AU Suh, I
Yingling, C
Randolph, GW
Duh, QY
AF Suh, Insoo
Yingling, Charles
Randolph, Gregory W.
Duh, Quan-Yang
TI A Novel Method of Neuromonitoring in Thyroidectomy and Parathyroidectomy
Using Transcutaneous Intraoperative Vagal Stimulation
SO JAMA SURGERY
LA English
DT Letter
ID RECURRENT LARYNGEAL NERVE; INJURY; IONM
C1 [Suh, Insoo; Duh, Quan-Yang] Univ Calif San Francisco, Dept Surg, Endocrine Surg Sect, Mt Zion Med Ctr, 1600 Divisadero St,Room A-725, San Francisco, CA 94115 USA.
[Suh, Insoo; Duh, Quan-Yang] Vet Affairs Med Ctr, Surg Serv, San Francisco, CA 94121 USA.
[Yingling, Charles] Golden Gate Neuromonitoring, San Francisco, CA USA.
[Randolph, Gregory W.] Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
RP Suh, I (reprint author), Univ Calif San Francisco, Dept Surg, Endocrine Surg Sect, Mt Zion Med Ctr, 1600 Divisadero St,Room A-725, San Francisco, CA 94115 USA.
EM insoo.suh@ucsf.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD MAR
PY 2016
VL 151
IS 3
BP 290
EP 292
DI 10.1001/jamasurg.2015.3249
PG 4
WC Surgery
SC Surgery
GA DG7TI
UT WOS:000372286200023
PM 26535804
ER
PT J
AU Waltz, P
Luciano, J
Peitzman, A
Zuckerbraun, BS
AF Waltz, Paul
Luciano, Jason
Peitzman, Andrew
Zuckerbraun, Brian S.
TI Femoral Hernias in Patients Undergoing Total Extraperitoneal
Laparoscopic Hernia Repair: Including Routine Evaluation of the Femoral
Canal in Approaches to Inguinal Hernia Repair
SO JAMA SURGERY
LA English
DT Letter
C1 [Waltz, Paul; Luciano, Jason; Peitzman, Andrew; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.
[Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Dept Surg, VA Pittsburgh Healthcare Syst, F1267 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM zuckerbraunbs@upmc.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD MAR
PY 2016
VL 151
IS 3
BP 292
EP 293
DI 10.1001/jamasurg.2015.3402
PG 3
WC Surgery
SC Surgery
GA DG7TI
UT WOS:000372286200024
PM 26558846
ER
PT J
AU Lehman, CD
Lee, JM
DeMartini, WB
Hippe, DS
Rendi, MH
Kalish, G
Porter, P
Gralow, J
Partridge, SC
AF Lehman, Constance D.
Lee, Janie M.
DeMartini, Wendy B.
Hippe, Daniel S.
Rendi, Mara H.
Kalish, Grace
Porter, Peggy
Gralow, Julie
Partridge, Savannah C.
TI Screening MRI in Women With a Personal History of Breast Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID PROSPECTIVE MULTICENTER COHORT; HIGH FAMILIAL RISK; FOLLOW-UP;
CONSERVATION THERAPY; MAMMOGRAPHY; TRIAL; SURVEILLANCE; TAMOXIFEN;
ULTRASOUND; SOCIETY
AB Screening MRI is recommended for individuals at high risk for breast cancer, based on genetic risk or family history (GFH); however, there is insufficient evidence to support screening MRI for women with a personal history (PH) of breast cancer. We compared screening MRI performance in women with PH vs GFH of breast cancer.
We analyzed case-series registry data, collected at time of MRI and at 12-month follow-up, from our regional Clinical Oncology Data Integration project. MRI performance was compared in women with PH with those with GFH. Chi-square testing was used to identify associations between age, prior history of MRI, and clinical indication with MRI performance; logistic regression was used to determine the combined contribution of these variables in predicting risk of a false-positive exam. All statistical tests were two-sided.
Of 1521 women who underwent screening MRI from July 2004 to November 2011, 915 had PH and 606 had GFH of breast cancer. Overall, MRI sensitivity was 79.4% for all cancers and 88.5% for invasive cancers. False-positive exams were lower in the PH vs GFH groups (12.3% vs 21.6%, P < .001), specificity was higher (94.0% vs 86.0%, P < .001), and sensitivity and cancer detection rate were not statistically different (P > .99). Age (P < .001), prior MRI (P < .001), and clinical indication (P < .001) were individually associated with initial false-positive rate; age and prior MRI remained statistically significant in multivariable modeling (P = .001 and P < .001, respectively).
MRI performance is superior in women with PH compared with women with GFH. Screening MRI warrants consideration as an adjunct to mammography in women with a PH of breast cancer.
C1 [Lehman, Constance D.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Lee, Janie M.; Hippe, Daniel S.; Kalish, Grace; Partridge, Savannah C.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA.
[Lee, Janie M.; Partridge, Savannah C.] Seattle Canc Care Alliance, Seattle, WA USA.
[DeMartini, Wendy B.] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA.
[Rendi, Mara H.] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA.
[Porter, Peggy; Gralow, Julie] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Gralow, Julie] Univ Washington, Med Ctr, Dept Med Oncol, Seattle, WA 98195 USA.
RP Lehman, CD (reprint author), Massachusetts Gen Hosp, Dept Radiol, Breast Imaging, Avon Comprehens Breast Evaluat Ctr, Suite 240,55 Fruit St, Boston, MA 02114 USA.
EM clehman@mgh.harvard.edu
NR 40
TC 4
Z9 4
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD MAR
PY 2016
VL 108
IS 3
AR djv349
DI 10.1093/jnci/djv349
PG 8
WC Oncology
SC Oncology
GA DH2BP
UT WOS:000372589400015
ER
PT J
AU Marler, S
Ferguson, BJ
Lee, EB
Peters, B
Williams, KC
McDonnell, E
Macklin, EA
Levitt, P
Gillespie, CH
Anderson, GM
Margolis, KG
Beversdorf, DQ
Veenstra-VanderWeele, J
AF Marler, Sarah
Ferguson, Bradley J.
Lee, Evon Batey
Peters, Brittany
Williams, Kent C.
McDonnell, Erin
Macklin, Eric A.
Levitt, Pat
Gillespie, Catherine Hagan
Anderson, George M.
Margolis, Kara Gross
Beversdorf, David Q.
Veenstra-VanderWeele, Jeremy
TI Brief Report: Whole Blood Serotonin Levels and Gastrointestinal Symptoms
in Autism Spectrum Disorder
SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
LA English
DT Article
DE Serotonin; 5-HT; Gastrointestinal (GI); IL-6; Medical comorbidities;
Autism Treatment Network
ID MENTAL-RETARDATION; METAANALYSIS; CHILDREN; BEHAVIOR
AB Elevated whole blood serotonin levels are observed in more than 25 % of children with autism spectrum disorder (ASD). Co-occurring gastrointestinal (GI) symptoms are also common in ASD but have not previously been examined in relationship with hyperserotonemia, despite the synthesis of serotonin in the gut. In 82 children and adolescents with ASD, we observed a correlation between a quantitative measure of lower GI symptoms and whole blood serotonin levels. No significant association was seen between functional constipation diagnosis and serotonin levels in the hyperserotonemia range, suggesting that this correlation is not driven by a single subgroup. More specific assessment of gut function, including the microbiome, will be necessary to evaluate the contribution of gut physiology to serotonin levels in ASD.
C1 [Marler, Sarah; Peters, Brittany] Vanderbilt Univ, Dept Psychiat, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Ferguson, Bradley J.] Univ Missouri, Thompson Ctr Autism & Neurodev Disorders, Interdisciplinary Neurosci Program, Columbia, MO USA.
[Lee, Evon Batey] Vanderbilt Univ, Dept Pediat, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Lee, Evon Batey] Vanderbilt Univ, Dept Psychol, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Lee, Evon Batey] Vanderbilt Univ, Dept Psychiat, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Williams, Kent C.] Nationwide Childrens, Dept Gastroenterol Hepatol & Nutr, Columbus, OH USA.
[McDonnell, Erin; Macklin, Eric A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Levitt, Pat] Childrens Hosp Los Angeles, Inst Developing Mind, Dev Neurogenet, Los Angeles, CA 90027 USA.
[Levitt, Pat] Univ So Calif, Keck Sch Med, Dept Neurogenet, Los Angeles, CA 90033 USA.
[Levitt, Pat] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA.
[Levitt, Pat] Univ So Calif, Keck Sch Med, Dept Neurosci, Los Angeles, CA 90033 USA.
[Levitt, Pat] Univ So Calif, Keck Sch Med, Dept Pharm, Los Angeles, CA 90033 USA.
[Levitt, Pat] Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA.
[Levitt, Pat] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
[Levitt, Pat] Univ So Calif, Keck Sch Med, Dept Psychol, Los Angeles, CA 90033 USA.
[Gillespie, Catherine Hagan] Univ Missouri, Coll Vet Med, Dept Vet Pathobiol, Columbia, MO USA.
[Anderson, George M.] Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT USA.
[Margolis, Kara Gross] Columbia Univ, Dept Pediat, Div Pediat Gastroenterol Hepatol & Nutr, New York, NY 10027 USA.
[Beversdorf, David Q.] Univ Missouri, Thompson Ctr Autism & Neurodev Disorder, Interdisciplinary Neurosci Program, Dept Radiol, Columbia, MO USA.
[Beversdorf, David Q.] Univ Missouri, Thompson Ctr Autism & Neurodev Disorder, Interdisciplinary Neurosci Program, Dept Neurol, Columbia, MO USA.
[Beversdorf, David Q.] Univ Missouri, Thompson Ctr Autism & Neurodev Disorder, Interdisciplinary Neurosci Program, Dept Psychol Sci, Columbia, MO USA.
[Veenstra-VanderWeele, Jeremy] Columbia Univ, Dept Psychiat, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.
[Veenstra-VanderWeele, Jeremy] Columbia Univ, Sackler Inst Dev Psychobiol, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.
[Veenstra-VanderWeele, Jeremy] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Veenstra-VanderWeele, Jeremy] New York Presbyterian Hosp, Ctr Autism & Developing Brain, White Plains, NY USA.
RP Veenstra-VanderWeele, J (reprint author), Columbia Univ, Dept Psychiat, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.; Veenstra-VanderWeele, J (reprint author), Columbia Univ, Sackler Inst Dev Psychobiol, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.; Veenstra-VanderWeele, J (reprint author), New York State Psychiat Inst & Hosp, New York, NY 10032 USA.; Veenstra-VanderWeele, J (reprint author), New York Presbyterian Hosp, Ctr Autism & Developing Brain, White Plains, NY USA.
EM sarah.marler@vanderbilt.edu; fergusonbj@health.missouri.edu;
evon.lee@vanderbilt.edu; brittany.peters@vanderbilt.edu;
kent.williams@nationwidechildrens.org; eimcdonnell@mgh.harvard.edu;
emacklin@mgh.harvard.edu; plevitt@med.usc.edu; haganc@missouri.edu;
george.anderson@yale.edu; kjg2133@cumc.columbia.edu;
beversdorfd@health.missouri.edu; jeremy.vvw@gmail.com
RI Beversdorf, David/M-2786-2016;
OI Beversdorf, David/0000-0002-0298-0634; Macklin, Eric/0000-0003-1618-3502
FU [UA3MC11054]
FX We would like to thank the children and families who participated in
this study. This research was supported by a Grant given to the Autism
Treatment Network, Autism Intervention Research Network on Physical
Health by the Health Resources Services Administration (HRSA Grant#
UA3MC11054). This article was reviewed by the funding body prior to
submission.
NR 24
TC 2
Z9 3
U1 5
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0162-3257
EI 1573-3432
J9 J AUTISM DEV DISORD
JI J. Autism Dev. Disord.
PD MAR
PY 2016
VL 46
IS 3
BP 1124
EP 1130
DI 10.1007/s10803-015-2646-8
PG 7
WC Psychology, Developmental
SC Psychology
GA DG7RO
UT WOS:000372281600035
PM 26527110
ER
PT J
AU Perrotta, L
Kandala, J
Di Biase, L
Valleggi, A
Michelotti, F
Pieragnoli, P
Ricciardi, G
Mascioli, G
Lakkireddy, D
Pillarisetti, J
Emdin, M
Natale, A
Singh, JP
Padeletti, L
AF Perrotta, Laura
Kandala, Jagdesh
Di Biase, Luigi
Valleggi, Alessandro
Michelotti, Federica
Pieragnoli, Paolo
Ricciardi, Giuseppe
Mascioli, Giosue
Lakkireddy, Dhanunjaya
Pillarisetti, Jayasree
Emdin, Michele
Natale, Andrea
Singh, Jagmeet P.
Padeletti, Luigi
TI Prognostic Impact of QRS Axis Deviation in Patients Treated With Cardiac
Resynchronization Therapy
SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
LA English
DT Article
DE cardiac resynchronization therapy; heart failure; left bundle branch
block; QRS axis deviation
ID BUNDLE-BRANCH-BLOCK; RANDOMIZED CONTROLLED-TRIALS; LEFT-VENTRICULAR
DYSFUNCTION; HEART-FAILURE; MORPHOLOGY; DURATION; OUTCOMES;
METAANALYSIS; PREDICTORS; CARDIOLOGY
AB Prognosis of QRS Axis Deviation in CRT-D
IntroductionQRS duration and morphology are currently recognized as recommended criteria for the selection of CRT candidates. It has recently been shown that patients with left bundle branch block (LBBB) derive substantial clinical benefit from CRT. The aim of this study is to investigate the prognostic impact of QRS axis deviation (AD) in HF patients with LBBB undergoing CRT.
Methods and ResultsWe retrospectively evaluated 707 HF patients with LBBB who underwent CRT at five centers. Baseline QRS axis was defined as normal (NA: -30 degrees to 90 degrees), right axis deviation (RAD: 90 degrees to 180 degrees) and left axis deviation (LAD: <-30 degrees). The primary endpoint was a composite of all cause death/HF hospitalization. The risk of endpoint by AD was evaluated with both Kaplan-Meier and Cox proportional hazard analysis. Among 707 patients (73% M, median age: 71 [62,77] years), 323 (46%) had NA, 359 (51%) LAD, and 25 (3.5%) RAD. Baseline clinical characteristics were similar between the three groups. Over a mean follow-up of 32 25 months, 141 deaths occurred (21%) and 36% (n = 255) met with the composite endpoint. A significantly higher proportion of RAD patients (52%) reached the endpoint (LAD 40%, NA 30%). KM analysis showed that RAD and LAD patients had worse event free survival and in multivariate analysis both LAD (HR: 1.40; 95% CI: 1.05-1.86; P = 0.021) and RAD (HR: 2.49; 95% CI: 1.31-4.74; P = 0.005) were independently associated with worse clinical outcome.
ConclusionsRight or left axis deviation in the presence of LBBB in HF patients undergoing CRT are independent predictors of poor prognosis.
C1 [Perrotta, Laura; Michelotti, Federica; Pieragnoli, Paolo; Ricciardi, Giuseppe; Padeletti, Luigi] Univ Florence, Viale Morgagni 85, I-50134 Florence, Italy.
[Kandala, Jagdesh; Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Di Biase, Luigi; Natale, Andrea] Texas Cardiac Arrhythmia Inst, Austin, TX USA.
[Valleggi, Alessandro; Emdin, Michele] Fdn Monasterio, Pisa, Italy.
[Michelotti, Federica; Mascioli, Giosue] Gavazzeni Hosp, Bergamo, Italy.
[Lakkireddy, Dhanunjaya; Pillarisetti, Jayasree] Univ Kansas, Bloch Heart Rhythm Ctr, Div Cardiovasc Dis, Cardiovasc Res Inst,Hosp & Med Ctr, Kansas City, KS USA.
[Padeletti, Luigi] IRCCS MultiMed, Milan, Italy.
RP Perrotta, L (reprint author), Univ Florence, Viale Morgagni 85, I-50134 Florence, Italy.
EM laura_perrotta81@hotmail.com
OI Di Biase, Luigi/0000-0001-6508-4047
FU EHRA (European Heart Rhythm Association) fellowship grant; Biotronik;
Boston Scientific; Sorin; St. Jude Medical; Medtronic
FX L. Perrotta was supported by an EHRA (European Heart Rhythm Association)
fellowship grant.; L. Di Biase serves as a consultant/advisory board
member of Biosense Webster, St. Jude Medical, Hansen, Medtronic,
Biotronik, and Boston Scientific. A. Natale reports honoraria from
Biosense Webster and serving as consultant/advisory board member of
Janssen, Boston Scientific, Medtronic, and St. Jude Medical. J. P. Singh
serves as an advisor/consultant for Biotronik, Boston Scientific,
Medtronic, Sorin, St. Jude Medical, Respicardia, and CardioInsight; he
has received honoraria for participating in educational symposiums
sponsored by Biotronik, Boston Scientific, Sorin, and St. Jude Medical;
and received grants for clinical research from Biotronik, Boston
Scientific, Medtronic, and St. Jude Medical. L. Padeletti is consultant
for Medtronic, St. Jude Medical, Biotronik, and Boston Scientific.
NR 19
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-3873
EI 1540-8167
J9 J CARDIOVASC ELECTR
JI J. Cardiovasc. Electrophysiol.
PD MAR
PY 2016
VL 27
IS 3
BP 315
EP 320
DI 10.1111/jce.12887
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DH2WT
UT WOS:000372648600014
PM 26640084
ER
PT J
AU Maron, BA
Stephens, TE
Farrell, LA
Oldham, WM
Loscalzo, J
Leopold, JA
Lewis, GD
AF Maron, Bradley A.
Stephens, Thomas E.
Farrell, Laurie A.
Oldham, William M.
Loscalzo, Joseph
Leopold, Jane A.
Lewis, Gregory D.
TI Elevated pulmonary arterial and systemic plasma aldosterone levels
associate with impaired cardiac reserve capacity during exercise in left
ventricular systolic heart failure patients: A pilot study
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
DE aldosterone; exercise; heart failure; cardiac reserve; reduced ejection
fraction
ID SMOOTH-MUSCLE-CELLS; HYPERTENSION; HEMODYNAMICS; SILDENAFIL; ENDOTHELIN;
FIBROSIS; RECEPTOR
AB BACKGROUND: Elevated levels of aldosterone are a modifiable contributor to clinical worsening in heart failure with reduced ejection fraction (HFrEF). Endothelin-1 (ET-1), which is increased in HFrEF, induces pulmonary endothelial aldosterone synthesis in vitro. However, whether transpulmonary aldosterone release occurs in humans or aldosterone relates to functional capacity in HFrEF is not known. Therefore, we aimed to characterize ET-1 and transpulmonary aldosterone levels in HFrEF and determine if aldosterone levels relate to peak volume of oxygen uptake (pVO(2)).
METHODS: Data from 42 consecutive HFrEF patients and 18 controls referred for invasive cardiopulmonary exercise testing were analyzed retrospectively.
RESULTS: Radial ET-1 levels (median [interquartile range]) were higher in HFrEF patients compared with controls (17.5 [11.5-31.4] vs 11.5 [4.4-19.0] pg/ml, p = 0.04). A significant ET-1 transpulmonary gradient (pulmonary arterial [PA] radial arterial levels) was present in HFrEF (p < 0.001) but not in controls (p = 0.24). Compared with controls, aldosterone levels (median [interquartile range]) were increased in HFrEF patients in the PA (364 [250-489] vs 581 [400-914] ng/dl, p < 0.01) and radial compartments (366 [273-466] vs 702 [443-1223] ng/dl, p < 0.001). Akin to ET-1, a transpulmonary increase (median [interquartile range]) in aldosterone concentration was also observed between controls and HFrEF patients at rest (7.5 [-54 to 40] vs 61.6 [-13.6 to 165] ng/dl, p = 0.01) and peak exercise (-20.7 [-39.6 to 79.1] vs 25.8 [-29.2 to 109.3] ng/dl, p = 0.02). The adjusted pVO(2) correlated inversely with aldosterone levels at peak activity in the PA (r = -0.31, p = 0.01) and radial artery (r = -0.32, p = 0.01).
CONCLUSIONS: These data provide preliminary evidence in support of increased transpulmonary aldosterone levels in HFrEF and suggest an inverse relationship between circulating aldosterone arid pVO(2). Future prospective studies are needed to characterize the functional effects of transpulmonary and circulating aldosterone on cardiac reserve capacity in HFrEF. Published by Elsevier Inc.
C1 [Maron, Bradley A.; Stephens, Thomas E.; Loscalzo, Joseph; Leopold, Jane A.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
[Maron, Bradley A.; Stephens, Thomas E.; Farrell, Laurie A.; Oldham, William M.; Loscalzo, Joseph; Leopold, Jane A.; Lewis, Gregory D.] Harvard Univ, Sch Med, Boston, MA USA.
[Maron, Bradley A.] Vet Affairs Boston Healthcare Syst, Dept Cardiol, West Roxbury, MA USA.
[Farrell, Laurie A.; Lewis, Gregory D.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Oldham, William M.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.
RP Lewis, GD (reprint author), Massachusetts Gen Hosp, Heart Failure & Cardiac Transplantat Unit, 800 Fruit St, Boston, MA 02114 USA.
EM glewis@partners.orrg
FU Gilead Sciences Inc; National Institutes of Health [HL061795, HL108630,
HL048743, GM107618, R01-105301, U01-1252151, R01-HL1-19154,
U10-HL1-10337, T32-HL-007633, K08-HL1-11207-01A1]; American Heart
Association [15GRNT25080016]; Pulmonary Hypertension Association; Gilead
Research Scholars Fund; Cardiovascular Medical Research and Education
Foundation; Klarman Foundation (Boston, MA) at Brigham; Women's Hospital
FX B.A.M. receives funding from Gilead Sciences Inc to study pulmonary
hypertension. None of the other authors has a financial relationship
with a commercial entity that has an interest in the subject of the
presented manuscript or other conflicts of interest to disclose.; This
work was supported by National Institutes of Health (HL061795, HL108630,
HL048743, and GM107618 to J.L.; R01-105301 and U01-1252151 to J.A.L.;
R01-HL1-19154, U10-HL1-10337, and Hassenfeld Clinical Scholar Award to
G.D.L.; T32-HL-007633 to W.M.O.; K08-HL1-11207-01A1 to B.A.M.), and the
American Heart Association (15GRNT25080016), Pulmonary Hypertension
Association, Gilead Research Scholars Fund, Cardiovascular Medical
Research and Education Foundation, and the Klarman Foundation (Boston,
MA) at Brigham and Women's Hospital to B.A.M.
NR 24
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD MAR
PY 2016
VL 35
IS 3
BP 342
EP 351
DI 10.1016/j.healun.2015.10.019
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA DH3JI
UT WOS:000372682900011
PM 26586488
ER
PT J
AU Kansagara, D
Chiovaro, JC
Kagen, D
Jencks, S
Rhyne, K
O'Neil, M
Kondo, K
Relevo, R
Motu'apuaka, M
Freeman, M
Englander, H
AF Kansagara, Devan
Chiovaro, Joseph C.
Kagen, David
Jencks, Stephen
Rhyne, Kerry
O'Neil, Maya
Kondo, Karli
Relevo, Rose
Motu'apuaka, Makalapua
Freeman, Michele
Englander, Honora
TI So many options, where do we start? An overview of the care transitions
literature
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Review
ID RANDOMIZED CLINICAL-TRIAL; ACUTE CORONARY SYNDROME; HEART-FAILURE;
FOLLOW-UP; HOSPITAL DISCHARGE; SYSTEMATIC REVIEWS; METAANALYSIS; HOME;
INTERVENTIONS; READMISSIONS
AB BACKGROUNDHealth systems are faced with a large array of transitional care interventions and patient populations to whom such activities might apply.
PURPOSETo summarize the health and utilization effects of transitional care interventions, and to identify common themes about intervention types, patient populations, or settings that modify these effects.
DATA SOURCESPubMed and Cochrane Database of Systematic Reviews (January 1950-May 2014), reference lists, and technical advisors.
STUDY SELECTIONSystematic reviews of transitional care interventions that reported hospital readmission as an outcome.
DATA EXTRACTIONWe extracted transitional care procedures, patient populations, settings, readmissions, and health outcomes. We identified commonalities and compiled a narrative synthesis of emerging themes.
DATA SYNTHESISAmong 10 reviews of mixed patient populations, there was consistent evidence that enhanced discharge planning and hospital-at-home interventions reduced readmissions. Among 7 reviews in specific patient populations, transitional care interventions reduced readmission in patients with congestive heart failure and general medical populations. In general, interventions that reduced readmission addressed multiple aspects of the care transition, extended beyond hospital stay, and had the flexibility to accommodate individual patient needs. There was insufficient evidence on how caregiver involvement, transition to sites other than home, staffing, patient selection practices, or care settings modified intervention effects.
CONCLUSIONSSuccessful interventions are comprehensive, extend beyond hospital stay, and have the flexibility to respond to individual patient needs. The strength of evidence should be considered low because of heterogeneity in the interventions studied, patient populations, clinical settings, and implementation strategies. Journal of Hospital Medicine 2016;11:221-230. (c) 2015 Society of Hospital Medicine.
C1 [Kansagara, Devan; Chiovaro, Joseph C.; Kagen, David; Rhyne, Kerry; Freeman, Michele] VA Portland Hlth Care Syst, Dept Med, Portland, OR USA.
[Kansagara, Devan; Chiovaro, Joseph C.; Kagen, David; Rhyne, Kerry; Englander, Honora] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Kansagara, Devan; O'Neil, Maya; Kondo, Karli; Relevo, Rose; Motu'apuaka, Makalapua; Freeman, Michele] Portland VA Evidence Based Synth Program, Portland, OR USA.
RP Kansagara, D (reprint author), Portland VA Med Ctr, Mailcode RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM kansagar@ohsu.edu
FU Department of Veterans Affairs, Veterans Health Administration (VHA)
[ESP 05-225, 01-0206]; Quality Enhancement Research Initiative,
Department of Veterans Affairs [05-225]
FX The research reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration (VHA) Project ESP 05-225,
VA#01-0206. Dr. Jencks' work on this project was supported in part by a
grant from the Quality Enhancement Research Initiative (05-225),
Department of Veterans Affairs. Dr. Jencks has reported prior consulting
work with the following entities: Inovalon, Care Centrix, Affymax,
Curaspan, Reinforced Care, Health Services Advisory Group, Delmarva
Foundation, Connecticut Peer Review Organization, Maryland Health
Services Cost Review Commission, Institute for Healthcare Improvement,
American Association for Respiratory Care, Monaghan Medical, Iowa
Society for Respiratory Care.
NR 38
TC 5
Z9 5
U1 6
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD MAR
PY 2016
VL 11
IS 3
BP 221
EP 230
DI 10.1002/jhm.2502
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG8JQ
UT WOS:000372330500011
PM 26551918
ER
PT J
AU Llibre, A
Lopez-Macias, C
Marafioti, T
Mehta, H
Partridge, A
Kanzig, C
Rivellese, F
Galson, JD
Walker, LJ
Milne, P
Phillips, RE
Kelly, DF
Freeman, GJ
El Shikh, ME
Klenerman, P
Willberg, CB
AF Llibre, Alba
Lopez-Macias, Constantino
Marafioti, Teresa
Mehta, Hema
Partridge, Amy
Kanzig, Carina
Rivellese, Felice
Galson, Jacob D.
Walker, Lucy J.
Milne, Paul
Phillips, Rodney E.
Kelly, Dominic F.
Freeman, Gordon J.
El Shikh, Mohey Eldin
Klenerman, Paul
Willberg, Christian B.
TI LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell
Activation and CXCR4 Downregulation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID FOLLICULAR DENDRITIC CELLS; C-TYPE LECTIN; OSTEOCLAST INHIBITORY LECTIN;
FUNCTION IN-VITRO; HUMAN T-CELLS; IMMUNE-RESPONSES; HUMAN NKR-P1A;
SOMATIC MUTATION; CUTTING EDGE; HELPER-CELLS
AB Germinal centers (GCs) are microanatomical structures critical for the development of high-affinity Abs and B cell memory. They are organized into two zones, light and dark, with coordinated roles, controlled by local signaling. The innate lectin-like transcript 1 (LLT1) is known to be expressed on B cells, but its functional role in the GC reaction has not been explored. In this study, we report high expression of LLT1 on GC-associated B cells, early plasmablasts, and GC-derived lymphomas. LLT1 expression was readily induced via BCR, CD40, and CpG stimulation on B cells. Unexpectedly, we found high expression of the LLT1 ligand, CD161, on follicular dendritic cells. Triggering of LLT1 supported B cell activation, CD83 upregulation, and CXCR4 downregulation. Overall, these data suggest that LLT1-CD161 interactions play a novel and important role in B cell maturation within the GC in humans.
C1 [Llibre, Alba; Mehta, Hema; Partridge, Amy; Kanzig, Carina; Phillips, Rodney E.; Klenerman, Paul; Willberg, Christian B.] Univ Oxford, Peter Medawar Bldg Pathogen Res,South Parks Rd, Oxford OX1 3SY, England.
[Lopez-Macias, Constantino] Specialties Hosp, Mexican Inst Social Secur, Natl Med Ctr Siglo 21, Med Res Unit Immunochem, Mexico City 06720, DF, Mexico.
[Marafioti, Teresa] UCL, Dept Histopathol, London WC1E 6JJ, England.
[Rivellese, Felice; El Shikh, Mohey Eldin] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Expt Med & Rheumatol, London EC1M 6BQ, England.
[Galson, Jacob D.; Kelly, Dominic F.] Univ Oxford, Oxford Biomed Res Ctr, Natl Inst Hlth Res, Oxford Vaccine Grp,Dept Paediat, S Parks Rd, Oxford OX3 7LJ, England.
[Walker, Lucy J.; Milne, Paul] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Klenerman, Paul; Willberg, Christian B.] Oxford Natl Inst Hlth Res, Biomed Res Ctr, Oxford OX3 9DU, England.
RP Willberg, CB (reprint author), Univ Oxford, Peter Medawar Bldg Pathogen Res,South Parks Rd, Oxford OX1 3SY, England.; El Shikh, ME (reprint author), Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Expt Med & Rheumatol, London EC1M 6BQ, England.
EM m.elshikh@qmul.ac.uk; chris.willberg@ndm.ox.uk
OI Willberg, Christian/0000-0001-5299-9344; Galson,
Jacob/0000-0003-4916-800X
FU University College London Hospitals/University College London National
Institute for Health Research Comprehensive Biomedical Research Centre;
National Institute for Health Research Biomedical Research Centre,
Oxford; National Institutes of Health/National Institute of Allergy and
Infectious Diseases U19 Bio-Defense Program (National Institutes of
Health/National Institute of Allergy and Infectious Diseases)
[1U19AI082630-01, U19 AI082630]; Wellcome Trust Senior Fellowship
[WT091663MA]; Obra Social La Caixa
FX This work was supported by grants from the University College London
Hospitals/University College London National Institute for Health
Research Comprehensive Biomedical Research Centre (to T.M.), the
National Institute for Health Research Biomedical Research Centre,
Oxford (to C.B.W. and P.K.), National Institutes of Health/National
Institute of Allergy and Infectious Diseases U19 Bio-Defense Program
(National Institutes of Health/National Institute of Allergy and
Infectious Diseases Grants 1U19AI082630-01 and U19 AI082630) (to C.B.W.
and P.K.), and by Wellcome Trust Senior Fellowship WT091663MA (to P.K.)
and Obra Social La Caixa (to A.L.).
NR 71
TC 2
Z9 2
U1 1
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2016
VL 196
IS 5
BP 2085
EP 2094
DI 10.4049/jimmunol.1502462
PG 10
WC Immunology
SC Immunology
GA DG8LT
UT WOS:000372336300013
PM 26829983
ER
PT J
AU Nowakowska, DJ
Kissler, S
AF Nowakowska, Dominika J.
Kissler, Stephan
TI Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID LOW-DOSE INTERLEUKIN-2; OF-FUNCTION VARIANT; TYROSINE-PHOSPHATASE;
ALLELIC VARIANT; B-CELLS; RECEPTOR; AUTOIMMUNITY; LIGAND; PROLIFERATION;
SUPPRESSION
AB PTPN22 gene variation associates with multiple autoimmune diseases, including type 1 diabetes and rheumatoid arthritis. Loss of function studies have demonstrated that PTPN22 impinges on the homeostatic behavior of regulatory T (Treg) cells, a lineage critical for immune tolerance. The frequency and absolute number of Treg cells is increased in Ptpn22-deficient mice, but the mechanism driving this increase is unknown. In this study, we show that Ptpn22 knockdown (KD) promoted the expansion of the Treg cell compartment by upregulating the glucocorticoid-induced TNFR family-related protein (GITR) and increasing GITR signaling. Ptpn22 KD did not accelerate cell division but instead prolonged Treg cell survival, as measured by a decrease in the frequency of apoptotic Treg cells. Loss of Ptpn22 caused a concomitant increase in the proportion of CD44(hi)CD62L(lo) effector Treg cells, at the expense of CD44(lo)CD62L(hi) central Treg cells. The increase in Treg cell numbers, but not their differentiation toward an effector phenotype, was dependent on GITR signaling, because blockade of GITR ligand prevented Treg cell expansion caused by Ptpn22 KD. These findings indicate that GITR plays a key role in regulating the overall size of the Treg cell pool. Our results suggest that the size and composition of the Treg cell compartment are independently controlled and have implications for the design of immunotherapies that seek to improve Treg cell function.
C1 [Nowakowska, Dominika J.; Kissler, Stephan] Harvard Univ, Sch Med, Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
RP Kissler, S (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
EM Stephan.Kissler@joslin.harvard.edu
OI , /0000-0003-3062-7800
FU JDRF Career Development Award [2-2010-383]; Iacocca Foundation; Diabetes
Research Center award (National Institutes of Health) [P30DK036836]
FX This work was supported in part by JDRF Career Development Award
2-2010-383 (to S.K.), by a Mary K. Iacocca fellowship from the Iacocca
Foundation (to D.J.N.), and by a Diabetes Research Center award
(National Institutes of Health Grant P30DK036836) to the Joslin Diabetes
Center.
NR 29
TC 2
Z9 2
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2016
VL 196
IS 5
BP 2145
EP 2152
DI 10.4049/jimmunol.1501877
PG 8
WC Immunology
SC Immunology
GA DG8LT
UT WOS:000372336300018
PM 26810223
ER
PT J
AU Khan, NS
Kasperkovitz, PV
Timmons, AK
Mansour, MK
Tam, JM
Seward, MW
Reedy, JL
Puranam, S
Feliu, M
Vyas, JM
AF Khan, Nida S.
Kasperkovitz, Pia V.
Timmons, Allison K.
Mansour, Michael K.
Tam, Jenny M.
Seward, Michael W.
Reedy, Jennifer L.
Puranam, Sravanthi
Feliu, Marianela
Vyas, Jatin M.
TI Dectin-1 Controls TLR9 Trafficking to Phagosomes Containing beta-1,3
Glucan
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTORS; ASPERGILLUS-FUMIGATUS; CANDIDA-ALBICANS; IMMUNE
RECOGNITION; DENDRITIC CELLS; INNATE IMMUNITY; PROTEOLYTIC CLEAVAGE;
CYTOKINE PRODUCTION; FUNGAL-INFECTIONS; HOST-DEFENSE
AB Dectin-1 and TLR9 play distinct roles in the recognition and induction of innate immune responses to Aspergillus fumigatus and Candida albicans. Dectin-1 is a receptor for the major fungal cell wall carbohydrate beta-1,3 glucan that induces inflammatory cytokines and controls phagosomal maturation through spleen tyrosine kinase activation. TLR9 is an endosomal TLR that also modulates the inflammatory cytokine response to fungal pathogens. In this study, we demonstrate that beta-1,3 glucan beads are sufficient to induce dynamic redistribution and accumulation of cleaved TLR9 to phagosomes. Trafficking of TLR9 to A. fumigatus and C. albicans phagosomes requires Dectin-1 recognition. Inhibition of phagosomal acidification blocks TLR9 accumulation on phagosomes containing beta-1,3 glucan beads. Dectin-1-mediated spleen tyrosine kinase activation is required for TLR9 trafficking to beta-1,3 glucan-, A. fumigatus-, and C. albicans-containing phagosomes. In addition, Dectin-1 regulates TLR9-dependent gene expression. Collectively, our study demonstrates that recognition of beta-1,3 glucan by Dectin-1 triggers TLR9 trafficking to beta-1,3 glucan-containing phagosomes, which may be critical in coordinating innate antifungal defense.
C1 [Khan, Nida S.; Timmons, Allison K.; Mansour, Michael K.; Tam, Jenny M.; Seward, Michael W.; Reedy, Jennifer L.; Puranam, Sravanthi; Feliu, Marianela; Vyas, Jatin M.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA.
[Khan, Nida S.] Univ Massachusetts, Biomed Engn & Biotechnol, Lowell, MA 01854 USA.
[Kasperkovitz, Pia V.] Alnylam Pharmaceut, Cambridge, MA 02142 USA.
[Mansour, Michael K.; Reedy, Jennifer L.; Vyas, Jatin M.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Feliu, Marianela] Boston Univ, Nutr & Metab, Boston, MA 02118 USA.
[Vyas, Jatin M.] Harvard Univ, Sch Med, Program Immunol, Boston, MA 02115 USA.
RP Vyas, JM (reprint author), Massachusetts Gen Hosp, Dept Med, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA.
EM jvyas@partners.org
FU National Institutes of Health [5R01 A1 092084, 1R01 A1 097519]; National
Institutes of Health/National Institute of Allergy and Infectious
Diseases [1K08AI110655, T32 A1007061-35, KL2 TR001100]
FX This work was supported by National Institutes of Health Grants 5R01 A1
092084 and 1R01 A1 097519 and National Institutes of Health/National
Institute of Allergy and Infectious Diseases Grants 1K08AI110655 (to
M.K.M.), T32 A1007061-35 (to J.L.R.), and KL2 TR001100 (to J.L.R.).
NR 61
TC 5
Z9 5
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2016
VL 196
IS 5
BP 2249
EP 2261
DI 10.4049/jimmunol.1401545
PG 13
WC Immunology
SC Immunology
GA DG8LT
UT WOS:000372336300027
PM 26829985
ER
PT J
AU Caballero-Franco, C
Guma, M
Choo, MK
Sano, Y
Enzler, T
Karin, M
Mizoguchi, A
Park, JM
AF Caballero-Franco, Celia
Guma, Monica
Choo, Min-Kyung
Sano, Yasuyo
Enzler, Thomas
Karin, Michael
Mizoguchi, Atsushi
Park, Jin Mo
TI Epithelial Control of Gut-Associated Lymphoid Tissue Formation through
p38 alpha-Dependent Restraint of NF-kappa B Signaling
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID LYMPHOTOXIN BETA-RECEPTOR; CHEMOKINE RECEPTOR; FOLLICLE FORMATION;
LARGE-INTESTINE; INDUCER CELLS; PROTEIN-KINASE; T-CELLS; HOMEOSTASIS;
P38-ALPHA; PROLIFERATION
AB The protein kinase p38 alpha mediates cellular responses to environmental and endogenous cues that direct tissue homeostasis and immune responses. Studies of mice lacking p38 alpha in several different cell types have demonstrated that p38 alpha signaling is essential to maintaining the proliferation-differentiation balance in developing and steady-state tissues. The mechanisms underlying these roles involve cell-autonomous control of signaling and gene expression by p38 alpha. In this study, we show that p38 alpha regulates gut-associated lymphoid tissue (GALT) formation in a noncell-autonomous manner. From an investigation of mice with intestinal epithelial cell-specific deletion of the p38 alpha gene, we find that p38 alpha serves to limit NF-kappa B signaling and thereby attenuate GALT-promoting chemokine expression in the intestinal epithelium. Loss of this regulation results in GALT hyperplasia and, in some animals, mucosa-associated B cell lymphoma. These anomalies occur independently of luminal microbial stimuli and are most likely driven by direct epithelial-lymphoid interactions. Our study illustrates a novel p38 alpha-dependent mechanism preventing excessive generation of epithelial-derived signals that drive lymphoid tissue overgrowth and malignancy.
C1 [Caballero-Franco, Celia; Choo, Min-Kyung; Sano, Yasuyo; Enzler, Thomas; Park, Jin Mo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, 149 Thirteenth St, Charlestown, MA 02129 USA.
[Caballero-Franco, Celia; Choo, Min-Kyung; Sano, Yasuyo; Enzler, Thomas; Mizoguchi, Atsushi; Park, Jin Mo] Harvard Univ, Sch Med, 149 Thirteenth St, Charlestown, MA 02129 USA.
[Guma, Monica; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Guma, Monica] Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA.
[Enzler, Thomas] Univ Arizona, Ctr Canc, Dept Med, Tucson, AZ 85724 USA.
[Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA.
[Mizoguchi, Atsushi] Massachusetts Gen Hosp, Dept Pathol, Mol Pathol Unit, Charlestown, MA 02129 USA.
RP Park, JM (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, 149 Thirteenth St, Charlestown, MA 02129 USA.; Park, JM (reprint author), Harvard Univ, Sch Med, 149 Thirteenth St, Charlestown, MA 02129 USA.
EM jmpark@cbrc2.mgh.harvard.edu
FU National Institutes of Health [AI074957, AI043477]
FX This work was supported by National Institutes of Health Grants AI074957
(to J.M.P.) and AI043477 (to M.K.).
NR 53
TC 0
Z9 0
U1 1
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2016
VL 196
IS 5
BP 2368
EP 2376
DI 10.4049/jimmunol.1501724
PG 9
WC Immunology
SC Immunology
GA DG8LT
UT WOS:000372336300039
PM 26792803
ER
PT J
AU Scully, E
Lockhart, A
Huang, L
Robles, Y
Becerril, C
Romero-Tejeda, M
Albrecht, MA
Palmer, CD
Bosch, RJ
Altfeld, M
Kuritzkes, DR
Lin, NH
AF Scully, Eileen
Lockhart, Ainsley
Huang, Lisa
Robles, Yvonne
Becerril, Carlos
Romero-Tejeda, Marisol
Albrecht, Mary A.
Palmer, Christine D.
Bosch, Ronald J.
Altfeld, Marcus
Kuritzkes, Daniel R.
Lin, Nina H.
TI Elevated Levels of Microbial Translocation Markers and CCL2 Among Older
HIV-1-Infected Men
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; inflammation; monocytes; chemokine
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; HIV-INFECTION; ATHEROSCLEROSIS;
PREDICT; DISEASE; RISK
AB The aging of the human immunodeficiency virus type 1 (HIV-1)-infected population obligates a focus on the interaction between aging, comorbid conditions, and HIV-1. We recruited a cohort of HIV-1-infected men aged <= 35 years or >= 50 years who were receiving fully suppressive antiretroviral therapy (ART). We analyzed plasma markers of inflammation; T-cell activation, exhaustion, proliferation; and innate cellular subsets and functional capacity. Levels of lipopolysaccharide and the plasma marker of chemokine (C-C motif) ligand 2 were significantly elevated in older HIV-infected men despite comparable cellular phenotypes. Compared with similarly age-stratified uninfected subjects, older HIV-1-infected adults were also more frequently in the upper quartile of soluble CD14 expression.
C1 [Scully, Eileen; Lockhart, Ainsley; Romero-Tejeda, Marisol; Palmer, Christine D.; Altfeld, Marcus] MIT & Harvard, Ragon Inst MGH, Cambridge, MA USA.
[Scully, Eileen; Robles, Yvonne; Kuritzkes, Daniel R.] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.
[Huang, Lisa; Becerril, Carlos] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Albrecht, Mary A.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA USA.
[Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
[Altfeld, Marcus] Heinrich Pette Inst, Hamburg, Germany.
[Lin, Nina H.] Boston Univ, Sch Med, Boston Med Ctr, Div Infect Dis, Boston, MA 02118 USA.
RP Lin, NH (reprint author), Boston Univ, Sch Med, Boston Med Ctr, Div Infect Dis, Boston, MA 02118 USA.
EM nina.lin@bmc.org
FU National Institute of Allergy and Infectious Diseases [5 K08 AI081545];
Harvard University Center for AIDS Research; National Institutes of
Health (NIH) [P30 A1060354]; Ragon Institute Immune Monitoring Core; NIH
[P01 AI074415]
FX This work was supported by the National Institute of Allergy and
Infectious Diseases (grant 5 K08 AI081545 to N. H. L.); the Harvard
University Center for AIDS Research, a National Institutes of Health
(NIH)-funded program (grant P30 A1060354; supplemental award to N. H.
L.); and the Ragon Institute Immune Monitoring Core and NIH (grant P01
AI074415).
NR 15
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 1
PY 2016
VL 213
IS 5
BP 771
EP 775
DI 10.1093/infdis/jiv501
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DG9XY
UT WOS:000372438300013
PM 26494772
ER
PT J
AU Lyerly, MJ
Wu, TC
Mullen, MT
Albright, KC
Wolff, C
Boehme, AK
Branas, CC
Grotta, JC
Savitz, SI
Carr, BG
AF Lyerly, Michael J.
Wu, Tzu-Ching
Mullen, Michael T.
Albright, Karen C.
Wolff, Catherine
Boehme, Amelia K.
Branas, Charles C.
Grotta, James C.
Savitz, Sean I.
Carr, Brendan G.
TI The effects of telemedicine on racial and ethnic disparities in access
to acute stroke care
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
DE Teleneurology; tele-stroke; healthcare access; racial minorities; ethnic
minorities; telemedicine
ID TISSUE-PLASMINOGEN ACTIVATOR; AMERICAN-HEART-ASSOCIATION; ACUTE
ISCHEMIC-STROKE; UNITED-STATES; OUTCOMES; CENTERS; TIME;
RECOMMENDATIONS; THROMBOLYSIS; TELESTROKE
AB Racial and ethnic disparities have been previously reported in acute stroke care. We sought to determine the effect of telemedicine (TM) on access to acute stroke care for racial and ethnic minorities in the state of Texas. Data were collected from the US Census Bureau, The Joint Commission and the American Hospital Association. Access for racial and ethnic minorities was determined by summing the population that could reach a primary stroke centre (PSC) or telemedicine spoke within specified time intervals using validated models. TM extended access to stroke expertise by 1.5 million residents. The odds of providing 60-minute access via TM were similar in Blacks and Whites (prevalence odds ratios (POR) 1.000, 95% CI 1.000-1.000), even after adjustment for urbanization (POR 1.000, 95% CI 1.000-1.001). The odds of providing access via TM were also similar for Hispanics and non-Hispanics (POR 1.000, 95% CI 1.000-1.000), even after adjustment for urbanization (POR 1.000, 95% CI 1.000-1.000). We found that telemedicine increased access to acute stroke care for 1.5 million Texans. While racial and ethnic disparities exist in other components of stroke care, we did not find evidence of disparities in access to the acute stroke expertise afforded by telemedicine.
C1 [Lyerly, Michael J.] Univ Alabama Birmingham, Dept Neurol, 1813 6th Ave South,RWUH M226, Birmingham, AL 35294 USA.
[Lyerly, Michael J.] Birmingham Vet Affairs Med Ctr, Stroke Program, Birmingham, AL USA.
[Wu, Tzu-Ching; Grotta, James C.; Savitz, Sean I.] Univ Texas Houston, Mem Hermann Med Ctr, Dept Neurol, Houston, TX USA.
[Mullen, Michael T.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Albright, Karen C.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
[Albright, Karen C.] Univ Alabama Birmingham, Hlth Serv & Outcomes Res Ctr Outcome & Effectiven, Birmingham, AL 35294 USA.
[Albright, Karen C.] Univ Alabama Birmingham, Ctr Excellence Comparat Effectiveness Res Elimina, Minor Hlth & Hlth Dispar Res Ctr MHRC, Birmingham, AL 35294 USA.
[Albright, Karen C.] Birmingham Vet Affairs Med Ctr, GRECC, Birmingham, AL USA.
[Wolff, Catherine] Duke Univ, Sch Med, Durham, NC USA.
[Boehme, Amelia K.] Columbia Univ, Dept Neurol, Gertrude Sergievsky Ctr, New York, NY USA.
[Branas, Charles C.] Univ Penn, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Carr, Brendan G.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA.
RP Lyerly, MJ (reprint author), Univ Alabama Birmingham, Dept Neurol, 1813 6th Ave South,RWUH M226, Birmingham, AL 35294 USA.
EM mjlyerly@uab.edu
OI Lyerly, Michael/0000-0003-4236-1018
FU AHRQ HHS [5 T32 HS013852-10]; NIMHD NIH HHS [3 P60 MD000502-08S1, P60
MD000502]; None [HS013852]
NR 52
TC 3
Z9 3
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1357-633X
EI 1758-1109
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PD MAR
PY 2016
VL 22
IS 2
BP 114
EP 120
DI 10.1177/1357633X15589534
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DG4XG
UT WOS:000372075900005
PM 26116854
ER
PT J
AU Vedire, K
Joselow, AL
Markham, CM
Raugi, GJ
AF Vedire, Kirtana
Joselow, Andrew L.
Markham, Craig M.
Raugi, Gregory J.
TI Teledermatology-directed surgical care is safe and reduces travel
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
DE Telemedicine; teledermatology; melanoma; severely dysplastic nevi;
primary care clinicians
ID GENERAL-PRACTITIONERS; MELANOMA; EXCISION; REFERRALS; PROGRAM
AB Methods: We conducted a retrospective chart review and identified 186 Veterans in the VA Corporate Data Warehouse as having malignant melanomas or severely dysplastic nevi during the four-year period of observation from 1 July 2009 to 30 June 2013 and met inclusion and exclusion criteria for analysis.
Results: Three hundred and sixty-six surgical procedures were performed for diagnosis and treatment of these conditions including biopsy and wide-local excision, of which 189 carefully selected cases were performed by primary care clinicians with 2.0% biopsy complication rate and a 7.7% wide-local excision complication rate. Cases not performed by primary care providers were referred to specialists (e.g. dermatologists, general surgeons or specialty surgeons) who had a 2.5% complication rate in biopsies and wide-local excision complication rate of 13.5% in severely dysplastic nevi and pTis and pT1a lesions and a 10.7% complication rate for lesions pT1b and greater.
Discussion: These results show that a significant fraction of surgical procedures for diagnosis and treatment of malignant melanoma and severely dysplastic nevi can be safely performed in rural clinics by trained primary care providers.
C1 [Vedire, Kirtana; Joselow, Andrew L.; Markham, Craig M.; Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Seattle Div, Washington, DC USA.
[Joselow, Andrew L.] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
[Raugi, Gregory J.] Univ Washington, Dept Med Dermatol, Seattle, WA 98195 USA.
RP Raugi, GJ (reprint author), VISN20 Teledermatol,Fed Off Bldg,Suite 630, Seattle, WA 98104 USA.
EM gregory.raugi@va.gov
FU US Department of Veterans Affairs; VISN20 Office of Rural Health
Services; Office of Rural Health
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: US
Department of Veterans Affairs, VISN20 Office of Rural Health Services,
and the Office of Rural Health.
NR 17
TC 0
Z9 0
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1357-633X
EI 1758-1109
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PD MAR
PY 2016
VL 22
IS 2
BP 121
EP 126
DI 10.1177/1357633X15589861
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DG4XG
UT WOS:000372075900006
PM 26116856
ER
PT J
AU Martinod, K
Witsch, T
Farley, K
Gallant, M
Remold-O'Donnell, E
Wagner, DD
AF Martinod, K.
Witsch, T.
Farley, K.
Gallant, M.
Remold-O'Donnell, E.
Wagner, D. D.
TI Neutrophil elastase-deficient mice form neutrophil extracellular traps
in an experimental model of deep vein thrombosis
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE extracellular traps; eukocyte elastase; neutrophils; serine proteases;
venous thrombosis
ID PULMONARY-FIBROSIS; INNATE IMMUNITY; NET FORMATION; DNA TRAPS;
INHIBITOR; RELEASE; MOUSE; PAD4
AB Neutrophil elastase (NE) plays a role in extracellular trap formation (NETosis) triggered by microbes. The contribution of NE was evaluated in mouse NETosis models of sterile inflammation and thrombosis. NE is not required for mouse neutrophil NET production in vitro with non-infectious stimuli. NE deficiency had no significant effect on thrombosis in the inferior vena cava stenosis model.
Summary Background Neutrophil serine proteases have been implicated in coagulation and neutrophil extracellular trap (NET) formation. In human neutrophils, neutrophil elastase (NE) translocates to the nucleus during NETosis and cleaves histones, thus aiding in chromatin decondensation. NE-/- mice were shown not to release NETs in response to microbes. However, mouse studies evaluating the role of NE in NET formation in sterile inflammation and thrombosis are lacking.
Objective We wished to establish if neutrophils from NE-/- mice have a defect in NETosis, similar to peptidylarginine deiminase 4 (PAD4(-/-)) mice, and how this might have an impact on venous thrombosis, a model where NETs are produced and are crucial to thrombus development.
Methods We performed in vitro NET assays using neutrophils from wild-type (WT), NE-/-, SerpinB1 (SB1)(-/-) and NE(-/-)SB1(-/-) mice. We compared WT and NE-/- animals using the inferior vena cava stenosis model of deep vein thrombosis (DVT).
Results Neutrophil elastase deficiency resulted in a small reduction in ionomycin-induced NET formation in vitro without affecting histone citrullination. However, NET production in response to phorbol 12-myristate 13-acetate or platelet activating factor was normal in neutrophils from two independent NE-deficient mouse lines, and in NE(-/-)SB1(-/-) as compared with SB1(-/-) neutrophils. NE deficiency or inhibition did not prevent NETosis in vivo or DVT outcome.
Conclusions Neutrophil elastase is not required for NET formation in mice. NE-/- mice, which form pathological venous thrombi containing NETs, do not phenocopy PAD4(-/-) mice in in vitro NETosis assays or experimental venous thrombosis. Our study suggests that NET-targeted therapies need to be highly effective to have an impact on DVT.
C1 [Martinod, K.; Witsch, T.; Farley, K.; Gallant, M.; Remold-O'Donnell, E.; Wagner, D. D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Martinod, K.; Witsch, T.; Farley, K.; Remold-O'Donnell, E.; Wagner, D. D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Remold-O'Donnell, E.; Wagner, D. D.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
RP Wagner, DD (reprint author), Boston Childrens Hosp, 3 Blackfan Circle,Third Floor, Boston, MA 02115 USA.
EM denisa.wagner@childrens.harvard.edu
OI Martinod, Kimberly/0000-0002-1026-6107
FU National Heart, Lung, and Blood Institute of the National Institutes of
Health [R01HL102101, R01HL125501, 5T32HL066987-13]; National Institute
of Allergy and Infectious Diseases [R21AI103407]; German Cardiac Society
(Deutsche Gesellschaft fuer Kardiologie)
FX We thank J. Roes (University College London) and H. Luo (Boston
Children's Hospital) for providing neutrophil elastase-deficient mice to
E.R.O. We also thank M. Demers and S. Ling Wong for helpful discussions.
This work was supported by the National Heart, Lung, and Blood Institute
of the National Institutes of Health grants R01HL102101 and R01HL125501
(to D.D.W.) and 5T32HL066987-13 (K.M.), and the National Institute of
Allergy and Infectious Diseases grant R21AI103407 (to E.R.O.). T.W. was
a recipient of a fellowship of the German Cardiac Society (Deutsche
Gesellschaft fuer Kardiologie).
NR 28
TC 16
Z9 16
U1 3
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD MAR
PY 2016
VL 14
IS 3
BP 551
EP 558
DI 10.1111/jth.13239
PG 8
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA DH1DR
UT WOS:000372525100017
PM 26712312
ER
PT J
AU Baruch, NF
O'Donnell, EH
Glanz, BI
Benedict, RHB
Musallam, AJ
Healy, BC
Rintell, D
Chitnis, T
AF Baruch, Natalie F.
O'Donnell, Ellen H.
Glanz, Bonnie I.
Benedict, Ralph H. B.
Musallam, Alexander J.
Healy, Brian C.
Rintell, David
Chitnis, Tanuja
TI Cognitive and patient-reported outcomes in adults with pediatric-onset
multiple sclerosis
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE Multiple sclerosis; pediatric; cognition; quality of life; outcomes
ID QUALITY-OF-LIFE; DIGIT MODALITIES TEST; PSYCHOSOCIAL FEATURES; JUVENILE
MS; NEUROPSYCHOLOGICAL ASSESSMENT; UNITED-STATES; IMPACT; DYSFUNCTION;
IMPAIRMENT; CHILDHOOD
AB Background: Little is known about long-term cognitive and patient-reported outcomes of pediatric-onset multiple sclerosis (POMS).
Objective: The objective of this paper is to compare cognitive and patient-reported outcomes in adults with POMS vs. adult-onset MS (AOMS).
Methods: We compared standardized patient-reported measures MSQOL54, MFIS, CES-D and SDMT in adult patients with MS onset prior to and after age 18, using data gathered in the Comprehensive Longitudinal Investigations in MS at Brigham and Women's Hospital (CLIMB) study.
Results: Fifty-one POMS and 550 AOMS patients were compared. SDMT scores were significantly lower in POMS after adjusting for age (-7.57 (-11.72, -3.43; p < 0.001), but not after adjusting for disease duration. Estimated group difference demonstrated lower normative z scores in POMS vs. AOMS in unadjusted analysis (-0.74 (95% CI: -1.18, -0.30; p = 0.0009) and after adjusting for disease duration (-0.60; 95%CI: -1.05, -0.15; p = 0.0097). Findings were unchanged in a subset of POMS diagnosed prior to age 18. In unadjusted and adjusted analyses, no significant differences were observed in health-related quality-of-life, fatigue, depression or social support between POMS and AOMS.
Conclusions: Younger age of onset was associated with more impairment in information-processing speed in adults with POMS compared to AOMS, and remained significant when controlling for disease duration in age-normed analysis. The two groups were similar in terms of patient-reported outcomes, suggesting similar qualitative experiences of MS.
C1 [Baruch, Natalie F.; Glanz, Bonnie I.; Musallam, Alexander J.; Healy, Brian C.; Rintell, David; Chitnis, Tanuja] Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Boston, MA 02115 USA.
[O'Donnell, Ellen H.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Benedict, Ralph H. B.] SUNY Buffalo, Dept Neurol, Buffalo, NY 14260 USA.
[Healy, Brian C.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
RP Chitnis, T (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Massachusetts Gen Hosp, 1 Brookline Pl,Suite 602, Brookline, MA 02445 USA.
EM tchitnis@partners.org
NR 36
TC 2
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD MAR
PY 2016
VL 22
IS 3
BP 354
EP 361
DI 10.1177/1352458515588781
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DG7CM
UT WOS:000372242400012
PM 26041802
ER
PT J
AU Bararia, D
Kwok, HS
Welner, RS
Numata, A
Sarosi, MB
Yang, H
Wee, S
Tschuri, S
Ray, D
Weigert, O
Levantini, E
Ebralidze, AK
Gunaratne, J
Tenen, DG
AF Bararia, Deepak
Kwok, Hui Si
Welner, Robert S.
Numata, Akihiko
Sarosi, Menyhart B.
Yang, Henry
Wee, Sheena
Tschuri, Sebastian
Ray, Debleena
Weigert, Oliver
Levantini, Elena
Ebralidze, Alexander K.
Gunaratne, Jayantha
Tenen, Daniel G.
TI Acetylation of C/EBP alpha inhibits its granulopoietic function
SO NATURE COMMUNICATIONS
LA English
DT Article
ID BINDING PROTEIN-ALPHA; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS;
GENE-EXPRESSION; LYSINE ACETYLATION; HISTONE ACETYLTRANSFERASE;
PROTEOMIC IDENTIFICATION; MOLECULAR-DYNAMICS; TRANSCRIPTION;
DIFFERENTIATION
AB CCAAT/enhancer-binding protein alpha (C/EBP alpha) is an essential transcription factor for myeloid lineage commitment. Here we demonstrate that acetylation of C/EBP alpha at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBP alpha DNA-binding ability and modulates C/EBP alpha transcriptional activity. Acetylated C/EBP alpha is enriched in human myeloid leukaemia cell lines and acute myeloid leukaemia (AML) samples, and downregulated upon granulocyte-colony stimulating factor (G-CSF)-mediated granulocytic differentiation of 32Dcl3 cells. C/EBP alpha mutants that mimic acetylation failed to induce granulocytic differentiation in C/EBP alpha-dependent assays, in both cell lines and in primary hematopoietic cells. Our data uncover GCN5 as a negative regulator of C/EBP alpha and demonstrate the importance of C/EBP alpha acetylation in myeloid differentiation.
C1 [Bararia, Deepak; Kwok, Hui Si; Numata, Akihiko; Yang, Henry; Tenen, Daniel G.] Natl Univ Singapore, Canc Sci Inst, Singapore 117599, Singapore.
[Bararia, Deepak; Levantini, Elena; Ebralidze, Alexander K.; Tenen, Daniel G.] Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA.
[Bararia, Deepak; Tschuri, Sebastian; Weigert, Oliver] Univ Munich, Univ Hosp, Dept Internal Med 3, Marchioninistr 15, D-81377 Munich, Germany.
[Bararia, Deepak; Tschuri, Sebastian; Weigert, Oliver] Univ Munich, Expt Leukamie & Lymphomforsch ELLF, Marchioninistr 15, D-81377 Munich, Germany.
[Bararia, Deepak; Tschuri, Sebastian; Weigert, Oliver] German Canc Consortium DKTK, D-69120 Heidelberg, Germany.
[Bararia, Deepak; Tschuri, Sebastian; Weigert, Oliver] German Canc Res Ctr, D-69120 Heidelberg, Germany.
[Kwok, Hui Si] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore.
[Welner, Robert S.; Levantini, Elena; Ebralidze, Alexander K.; Tenen, Daniel G.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02215 USA.
[Welner, Robert S.] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA.
[Sarosi, Menyhart B.] Univ Leipzig, Fac Chem & Mineral, Inst Inorgan Chem, D-04103 Leipzig, Germany.
[Wee, Sheena; Gunaratne, Jayantha] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Translat Biomed Prote Lab, Singapore 138673, Singapore.
[Ray, Debleena] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore.
[Levantini, Elena] CNR, Inst Biomed Technol, I-56124 Pisa, Italy.
[Gunaratne, Jayantha] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117594, Singapore.
RP Bararia, D; Tenen, DG (reprint author), Natl Univ Singapore, Canc Sci Inst, Singapore 117599, Singapore.; Bararia, D; Tenen, DG (reprint author), Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA.; Bararia, D (reprint author), Univ Munich, Univ Hosp, Dept Internal Med 3, Marchioninistr 15, D-81377 Munich, Germany.; Bararia, D (reprint author), Univ Munich, Expt Leukamie & Lymphomforsch ELLF, Marchioninistr 15, D-81377 Munich, Germany.; Bararia, D (reprint author), German Canc Consortium DKTK, D-69120 Heidelberg, Germany.; Bararia, D (reprint author), German Canc Res Ctr, D-69120 Heidelberg, Germany.; Tenen, DG (reprint author), Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02215 USA.
EM deepak.bararia@med.uni-muenchen.de; daniel.tenen@nus.edu.sg
RI Sarosi, Menyhart/B-8886-2012
OI Sarosi, Menyhart/0000-0003-4222-0717
FU National Research Foundation Singapore; Singapore Translational Research
Award from the Singapore National Medical Research Council
[NMRC/STaR/0001/2008]; Singapore Ministry of Education; National
Research Foundation; National Institutes of Health [CA66996, HL112719];
Max-Eder Program of the Deutsche Krebshilfe [110659]; European Social
Fund (ESF) of the European Union (EU); Free State of Saxony; Singapore
Ministry of Education under its Research Centres of Excellence
initiative
FX We thank Pere Puigserver (Dana Farber Cancer Institute, Boston, USA) for
GCN5 and PCAF constructs, Georg W. Bornkamm (Helmholtz Center, Munich,
Germany) for p300 construct. Wee Joo Chng (Cancer Science Institute,
Singapore) for AML samples and cell lines, Yoon-Pin Lim (National
University of Singapore, Singapore) and Shirly Chong Poh Kuan (National
University of Singapore, Singapore) for synthetic peptides analysis used
for rabbit immunization, Alan Friedman (John Hopkins University,
Maryland, USA) for the pBabe-ER vector, Axel Imhof
(Ludwig-Maximilians-University, Munich, Germany) for GST-tagged GCN5 HAT
domain expression construct, Sharon Y. R. Dent (MD Anderson Cancer
Center, Texas, USA) for Gcn5fl/fl mice, Motomi Osato (Cancer
Science Institute, Singapore) for Vav-iCre mice, r many helpfuCelestina
Chin Ai Qi (Cancer Science Institute, Singapore) for proofreading of the
manuscript, and members of the Tenen laboratory fol discussions and
technical support. This research is supported by the National Research
Foundation Singapore and the Singapore Ministry of Education under its
Research Centres of Excellence initiative, Singapore Translational
Research Award from the Singapore National Medical Research Council
(NMRC/STaR/0001/2008 to D.G.T) and grants from the Singapore Ministry of
Education and National Research Foundation and the National Institutes
of Health (CA66996 and HL112719 to D.G.T). This research was supported
by the Max-Eder Program of the Deutsche Krebshilfe (#110659 to O.W.).
The molecular modelling studies were funded by the European Social Fund
(ESF) of the European Union (EU) and the Free State of Saxony (M.B.S.).
NR 63
TC 1
Z9 1
U1 4
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10968
DI 10.1038/ncomms10968
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH3XY
UT WOS:000372721300001
PM 27005833
ER
PT J
AU Kettunen, J
Demirkan, A
Wurtz, P
Draisma, HHM
Haller, T
Rawal, R
Vaarhorst, A
Kangas, AJ
Lyytikainen, LP
Pirinen, M
Pool, R
Sarin, AP
Soininen, P
Tukiainen, T
Wang, Q
Tiainen, M
Tynkkynen, T
Amin, N
Zeller, T
Beekman, M
Deelen, J
van Dijk, KW
Esko, T
Hottenga, JJ
van Leeuwen, EM
Lehtimaki, T
Mihailov, E
Rose, RJ
de Craen, AJM
Gieger, C
Kahonen, M
Perola, M
Blankenberg, S
Savolainen, MJ
Verhoeven, A
Viikari, J
Willemsen, G
Boomsma, DI
van Duijn, CM
Eriksson, J
Jula, A
Jarvelin, MR
Kaprio, J
Metspalu, A
Raitakari, O
Salomaa, V
Slagboom, PE
Waldenberger, M
Ripatti, S
Ala-Korpela, M
AF Kettunen, Johannes
Demirkan, Ayse
Wurtz, Peter
Draisma, Harmen H. M.
Haller, Toomas
Rawal, Rajesh
Vaarhorst, Anika
Kangas, Antti J.
Lyytikaeinen, Leo-Pekka
Pirinen, Matti
Pool, Rene
Sarin, Antti-Pekka
Soininen, Pasi
Tukiainen, Taru
Wang, Qin
Tiainen, Mika
Tynkkynen, Tuulia
Amin, Najaf
Zeller, Tanja
Beekman, Marian
Deelen, Joris
van Dijk, Ko Willems
Esko, Tonu
Hottenga, Jouke-Jan
van Leeuwen, Elisabeth M.
Lehtimaki, Terho
Mihailov, Evelin
Rose, Richard J.
de Craen, Anton J. M.
Gieger, Christian
Kahonen, Mika
Perola, Markus
Blankenberg, Stefan
Savolainen, Markku J.
Verhoeven, Aswin
Viikari, Jorma
Willemsen, Gonneke
Boomsma, Dorret I.
van Duijn, Cornelia M.
Eriksson, Johan
Jula, Antti
Jarvelin, Marjo-Riitta
Kaprio, Jaakko
Metspalu, Andres
Raitakari, Olli
Salomaa, Veikko
Slagboom, P. Eline
Waldenberger, Melanie
Ripatti, Samuli
Ala-Korpela, Mika
TI Genome-wide study for circulating metabolites identifies 62 loci and
reveals novel systemic effects of LPA
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; EVALUATING ROSUVASTATIN; GENETIC-DETERMINANTS;
INTERVENTION TRIAL; JUPITER TRIAL; ASSOCIATION; LIPOPROTEIN(A); THERAPY;
RISK; JUSTIFICATION
AB Genome-wide association studies have identified numerous loci linked with complex diseases, for which the molecular mechanisms remain largely unclear. Comprehensive molecular profiling of circulating metabolites captures highly heritable traits, which can help to uncover metabolic pathophysiology underlying established disease variants. We conduct an extended genome-wide association study of genetic influences on 123 circulating metabolic traits quantified by nuclear magnetic resonance metabolomics from up to 24,925 individuals and identify eight novel loci for amino acids, pyruvate and fatty acids. The LPA locus link with cardiovascular risk exemplifies how detailed metabolic profiling may inform underlying aetiology via extensive associations with very-low-density lipoprotein and triglyceride metabolism. Genetic fine mapping and Mendelian randomization uncover wide-spread causal effects of lipoprotein(a) on overall lipoprotein metabolism and we assess potential pleiotropic consequences of genetically elevated lipoprotein(a) on diverse morbidities via electronic health-care records. Our findings strengthen the argument for safe LPA-targeted intervention to reduce cardiovascular risk.
C1 [Kettunen, Johannes; Wurtz, Peter; Kangas, Antti J.; Soininen, Pasi; Wang, Qin; Tiainen, Mika; Tynkkynen, Tuulia; Ala-Korpela, Mika] Univ Oulu, Fac Med, Computat Med, POB 5000, Oulu 90014, Finland.
[Kettunen, Johannes; Sarin, Antti-Pekka; Perola, Markus; Eriksson, Johan; Jula, Antti; Salomaa, Veikko; Ripatti, Samuli] Natl Inst Hlth & Welf, POB 30, FI-00271 Helsinki, Finland.
[Kettunen, Johannes; Soininen, Pasi; Wang, Qin; Tiainen, Mika; Tynkkynen, Tuulia; Ala-Korpela, Mika] Univ Eastern Finland, Sch Pharm, NMR Metabol Lab, Yliopistonranta 1C, Kuopio 70210, Finland.
[Kettunen, Johannes; Savolainen, Markku J.; Jarvelin, Marjo-Riitta; Ala-Korpela, Mika] Univ Oulu, Bioctr Oulu, POB 5000, FI-90014 Oulu, Finland.
[Demirkan, Ayse; van Dijk, Ko Willems] Leiden Univ, Med Ctr, Dept Human Genet, POB 9600, NL-2300 RC Leiden, Netherlands.
[Demirkan, Ayse; Amin, Najaf; van Leeuwen, Elisabeth M.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
[Draisma, Harmen H. M.; Pool, Rene; Hottenga, Jouke-Jan; Willemsen, Gonneke; Boomsma, Dorret I.] Vrije Univ Amsterdam, Dept Biol Psychol, Boechorststr 1,Room 2B 29, NL-1081 BT Amsterdam, Netherlands.
[Draisma, Harmen H. M.; Pool, Rene; Hottenga, Jouke-Jan; Willemsen, Gonneke; Boomsma, Dorret I.] EMGO Inst Hlth & Care Res, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
[Draisma, Harmen H. M.] Neurosci Campus Amsterdam, Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.
[Haller, Toomas; Esko, Tonu; Mihailov, Evelin; Perola, Markus; Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, Riia 23b, EE-51010 Tartu, Estonia.
[Rawal, Rajesh; Gieger, Christian; Waldenberger, Melanie] Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.
[Rawal, Rajesh; Gieger, Christian; Waldenberger, Melanie] Helmholtz Zentrum Munchen, Inst Epidemiol 2, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.
[Vaarhorst, Anika; Beekman, Marian; Deelen, Joris; Slagboom, P. Eline] Leiden Univ, Med Ctr, Dept Mol Epidemiol, POB 9600, NL-2300 RC Leiden, Netherlands.
[Lyytikaeinen, Leo-Pekka; Lehtimaki, Terho] Tampere Univ, Univ Tampere Sch Med, Dept Clin Chem, Fimlab Labs, Kalevantie 4, Tampere 33014, Finland.
[Pirinen, Matti; Sarin, Antti-Pekka; Perola, Markus; Kaprio, Jaakko; Ripatti, Samuli] Univ Helsinki, Inst Mol Med FIMM, Biomedicum 2,Tukholmankatu 8, FIN-00290 Helsinki, Finland.
[Tukiainen, Taru] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, 55 Fruit St, Boston, MA 02114 USA.
[Tukiainen, Taru] Broad Inst, Program Med & Populat Genet, 415 Main St, Cambridge, MA 02142 USA.
[Tukiainen, Taru] Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.
[Zeller, Tanja; Blankenberg, Stefan] Partner Site Hamburg Lubeck Kiel, German Ctr Cardiovasc Res DZHK eV, Martinistr 52, D-20246 Hamburg, Germany.
[Zeller, Tanja; Blankenberg, Stefan] Univ Heart Ctr Hamburg, Clin Gen & Intervent Cardiol, Martinistr 52, D-20246 Hamburg, Germany.
[van Dijk, Ko Willems] Leiden Univ, Med Ctr, Dept Endocrinol, POB 9600, NL-2300 RC Leiden, Netherlands.
[Rose, Richard J.; Kaprio, Jaakko; Ripatti, Samuli] Univ Helsinki, Dept Publ Hlth, Hjelt Inst, POB 41,Maannerheimintie 172, FIN-00014 Helsinki, Finland.
[Rose, Richard J.] Indiana Univ, Dept Psychol & Brain Sci, 1101 E 10th St, Bloomington, IN 47405 USA.
[de Craen, Anton J. M.] Leiden Univ, Med Ctr, Dept Geriatr & Gerontol, Postzone C7-Q,POB 9600, NL-2300 RC Leiden, Netherlands.
[Kahonen, Mika] Univ Tampere, Dept Clin Physiol, POB 2000, FIN-33521 Tampere, Finland.
[Kahonen, Mika] Tampere Univ Hosp, POB 2000, FIN-33521 Tampere, Finland.
[Savolainen, Markku J.] Univ Oulu, Oulu Univ Hosp, Med Res Ctr, Internal Med, Aapistie 5A, FI-90220 Oulu, Finland.
[Verhoeven, Aswin] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
[Viikari, Jorma] Univ Turku, Dept Med, PB 52, Turku 20521, Finland.
[Viikari, Jorma] Turku Univ Hosp, PB 52, Turku 20521, Finland.
[Eriksson, Johan] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, PL 20,Tukholmankatu 8B, Helsinki 00029, Finland.
[Eriksson, Johan] Helsingfors Univ, Folkhalsan Res Ctr, PB 63, Helsinki 00014, Finland.
[Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC PHE Ctr Environm & Hlth, London SW7 2AZ, England.
[Jarvelin, Marjo-Riitta] Univ Oulu, Fac Med, Ctr Life Course & Syst Epidemiol, PL 5000, Oulu 90014, Finland.
[Jarvelin, Marjo-Riitta] Oulu Univ Hosp, Unit Primary Care, OYS, POB 20, Oulu 90029, Finland.
[Kaprio, Jaakko] Natl Inst Hlth & Welf, Dept Mental Hlth, POB 30,Mannerheimintie 166, Helsinki 00300, Finland.
[Kaprio, Jaakko] Natl Inst Hlth & Welf, Subst Abuse Serv, POB 30,Mannerheimintie 166, Helsinki 00300, Finland.
[Raitakari, Olli] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Kiinamyllynkatu 4-8, Turku 20521, Finland.
[Raitakari, Olli] Turku Univ Hosp, Dept Clin Physiol, Kiinamyllynkatu 4-8, Turku 20521, Finland.
[Ripatti, Samuli] Wellcome Trust Sanger Inst, Human Genet, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.
[Ala-Korpela, Mika] Oulu Univ Hosp, Kajaanintie 50, Oulu 90220, Finland.
[Ala-Korpela, Mika] Univ Bristol, Sch Social & Community Med, Computat Med, Senate House,Tyndall Ave, Bristol BS8 1TH, Avon, England.
[Ala-Korpela, Mika] Univ Bristol, MRC, Integrat Epidemiol Unit, Bristol BS8 1TH, Avon, England.
[Demirkan, Ayse; van Dijk, Ko Willems] LUMC, Bldg 2,Einthovenweg 20, NL-2333 ZC Leiden, Netherlands.
RP Kettunen, J (reprint author), Univ Oulu, Fac Med, Computat Med, POB 5000, Oulu 90014, Finland.; Kettunen, J (reprint author), Natl Inst Hlth & Welf, POB 30, FI-00271 Helsinki, Finland.; Kettunen, J (reprint author), Univ Eastern Finland, Sch Pharm, NMR Metabol Lab, Yliopistonranta 1C, Kuopio 70210, Finland.; Kettunen, J (reprint author), Univ Oulu, Bioctr Oulu, POB 5000, FI-90014 Oulu, Finland.
EM johannes.kettunen@oulu.fi
RI Pool, Rene/B-3652-2009; Waldenberger, Melanie/B-5355-2014; Slagboom, P.
Eline/R-4790-2016;
OI Pirinen, Matti/0000-0002-1664-1350; Pool, Rene/0000-0001-5579-0933;
Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Kaprio,
Jaakko/0000-0002-3716-2455; Waldenberger, Melanie/0000-0003-0583-5093;
Slagboom, P. Eline/0000-0002-2875-4723; Kettunen,
Johannes/0000-0002-3345-491X; Gieger, Christian/0000-0001-6986-9554
NR 31
TC 8
Z9 8
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 11122
DI 10.1038/ncomms11122
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH4DP
UT WOS:000372736000001
PM 27005778
ER
PT J
AU Ananian, L
AF Ananian, Lillian
TI Relationship Based Care: Exploring the Manifestations of Health as
Expanding Consciousness Within a Patient and Family Centered Medical
Intensive Care Unit
SO NURSING RESEARCH
LA English
DT Meeting Abstract
C1 [Ananian, Lillian] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2016
VL 65
IS 2
BP E92
EP E93
PG 2
WC Nursing
SC Nursing
GA DG6SA
UT WOS:000372215200253
ER
PT J
AU Carroll, D
Albert, J
Drucker, A
AF Carroll, Diane
Albert, Jenn
Drucker, Adienne
TI A National Study of Intravenous Medication Errors - Understanding How to
Improve Intravenous Safety with Smart Pumps: An Academic Medical Center
Experience
SO NURSING RESEARCH
LA English
DT Meeting Abstract
C1 [Carroll, Diane; Albert, Jenn] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Drucker, Adienne] Partners HealthCare, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2016
VL 65
IS 2
BP E101
EP E102
PG 2
WC Nursing
SC Nursing
GA DG6SA
UT WOS:000372215200277
ER
PT J
AU Moriarty, H
Winter, L
Piersol, C
Vause-Earland, T
Robinson, K
Newhart, B
AF Moriarty, Helene
Winter, Laraine
Piersol, Catherine
Vause-Earland, Tracey
Robinson, Keith
Newhart, Brian
TI Patient-Centered and Family-Centered Outcomes in Intervention Research:
Use of Target Outcomes in a Study with Veterans with Traumatic Brain
Injury and Their Family Members
SO NURSING RESEARCH
LA English
DT Meeting Abstract
C1 [Moriarty, Helene] Villanova Univ, Villanova, PA 19085 USA.
[Winter, Laraine; Robinson, Keith; Newhart, Brian] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Piersol, Catherine; Vause-Earland, Tracey] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2016
VL 65
IS 2
BP E71
EP E71
PG 1
WC Nursing
SC Nursing
GA DG6SA
UT WOS:000372215200194
ER
PT J
AU Perkins, JM
Subramanian, SV
Smith, GD
Ozaltin, E
AF Perkins, Jessica M.
Subramanian, S. V.
Smith, George Davey
Ozaltin, Emreo
TI Adult height, nutrition, and population health
SO NUTRITION REVIEWS
LA English
DT Review
DE genetics; height; intergenerational; life course; mortality; morbidity;
nutrition; population health; socioeconomic status; stature
ID BODY-MASS INDEX; LABOR-MARKET OUTCOMES; GENOME-WIDE ASSOCIATION;
CORONARY-HEART-DISEASE; INDIVIDUAL PARTICIPANT METAANALYSIS;
GESTATIONAL-AGE INFANTS; MIDDLE-INCOME COUNTRIES; LOW-BIRTH-WEIGHT;
RISK-FACTORS; PROSPECTIVE COHORT
AB In this review, the potential causes and consequences of adult height, a measure of cumulative net nutrition, in modern populations are summarized. The mechanisms linking adult height and health are examined, with a focus on the role of potential confounders. Evidence across studies indicates that short adult height (reflecting growth retardation) in low- and middle-income countries is driven by environmental conditions, especially net nutrition during early years. Some of the associations of height with health and social outcomes potentially reflect the association between these environmental factors and such outcomes. These conditions are manifested in the substantial differences in adult height that exist between and within countries and over time. This review suggests that adult height is a useful marker of variation in cumulative net nutrition, biological deprivation, and standard of living between and within populations and should be routinely measured. Linkages between adult height and health, within and across generations, suggest that adult height may be a potential tool for monitoring health conditions and that programs focused on offspring outcomes may consider maternal height as a potentially important influence.
C1 [Perkins, Jessica M.; Subramanian, S. V.] Harvard Ctr Populat & Dev Studies, Cambridge, MA USA.
[Perkins, Jessica M.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
[Perkins, Jessica M.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Subramanian, S. V.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA.
[Smith, George Davey] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England.
[Ozaltin, Emreo] World Bank, Hlth Nutr & Populat Global Practice, 1818 H St NW,MSN J 600, Washington, DC 20433 USA.
RP Ozaltin, E (reprint author), World Bank, Hlth Nutr & Populat Global Practice, 1818 H St NW,MSN J 600, Washington, DC 20433 USA.
EM eozaltin@worldbank.org
RI Davey Smith, George/A-7407-2013
OI Davey Smith, George/0000-0002-1407-8314
FU Harvard Center of Population and Development Studies; Robert Wood
Johnson Foundation; MRC Integrative Epidemiology Unit (IEU) at the
University of Bristol [MC_UU_12013/1-9]
FX This work was partially supported by a grant from the Harvard Center of
Population and Development Studies. S.V.S. is partially supported by the
Robert Wood Johnson Foundation Investigator Award in Health Policy
Research. G.D S. works within the MRC Integrative Epidemiology Unit
(IEU) at the University of Bristol. Grant Reference: MC_UU_12013/1-9.
NR 223
TC 3
Z9 3
U1 4
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD MAR
PY 2016
VL 74
IS 3
BP 149
EP 165
DI 10.1093/nutrit/nuv105
PG 17
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DH2HN
UT WOS:000372605600001
PM 26928678
ER
PT J
AU Junior, JA
Katz, AM
Ahn, R
AF Junior, Jean A.
Katz, Arlene M.
Ahn, Roy
TI The Perspectives of Young Women in Rural Western Kenya on Unconditional
Cash Transfers
SO POVERTY & PUBLIC POLICY
LA English
DT Article
DE sub-Saharan Africa; Kenya; women; cash transfers; subjective well-being
ID SUB-SAHARAN AFRICA; TRANSFER PROGRAM; QUALITATIVE RESEARCH; VULNERABLE
CHILDREN; MENTAL-HEALTH; POVERTY; IMPACT; COUNTRIES; SERVICES; SUPPORT
AB Unconditional cash transfers (UCTs) provide money to eligible individuals, without dictating how they spend the money or tasks they must do to receive it. This study explored how UCTs affected the lives of young, impoverished women in rural western Kenya. Qualitative methods were used, including in-depth interviews with 30 women: 10 receiving $1,000, 10 receiving $500, and 10 not receiving a UCT. UCTs were positively viewed by interviewees, and had nuanced and varied effects on aspirations, money management, relationships, and subjective well-being in social context. The perspectives of interviewees offer programmatic suggestions and question major assumptions concerning UCTs. The perspectives of interviewees offer programmatic suggestions and question major assumptions concerning UCTs. This qualitative study augments the primarily quantitative research on UCTs that has been done to date.
C1 [Junior, Jean A.] Harvard Univ, Sch Med, Boston, MA USA.
[Katz, Arlene M.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Ahn, Roy] Massachusetts Gen Hosp, Div Global Hlth & Human Rights, Dept Emergency Med, Boston, MA 02114 USA.
RP Junior, JA (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
NR 75
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1944-2858
J9 Poverty Public Polic
JI Poverty Public Policy
PD MAR
PY 2016
VL 8
IS 1
BP 72
EP 94
DI 10.1002/pop4.127
PG 23
WC Social Work
SC Social Work
GA DG9OH
UT WOS:000372412700006
ER
PT J
AU Nelson, S
Rustad, JK
Catalano, G
Stern, TA
Kozel, FA
AF Nelson, Scott
Rustad, James K.
Catalano, Glenn
Stern, Theodore A.
Kozel, F. Andrew
TI Depressive Symptoms Before, During, and After Delirium: A Literature
Review
SO PSYCHOSOMATICS
LA English
DT Review
ID CONFUSION ASSESSMENT METHOD; CORONARY-BYPASS SURGERY; HIP FRACTURE
PATIENTS; POSTOPERATIVE DELIRIUM; ELDERLY-PATIENTS; CARDIAC-SURGERY;
RISK-FACTORS; COGNITIVE IMPAIRMENT; PROSPECTIVE COHORT; FUNCTIONAL
STATUS
AB Background: Delirium and depression are often thought of as mutually exclusive conditions. However, several studies cite depression as a risk factor for delirium whereas others note that patients with delirium often manifest depressive symptoms. Whether these depressive symptoms persist after delirium resolves remains unclear. Objectives: This article reviews published studies that have investigated the relationship between depression and delirium. Methods: Literature searches on PubMed, CINAHL, Cochrane Library, and PsycInfo were conducted using search criteria "delirium" AND "depress*" as keywords or MeSH terms. Results: Of 722 search results, 10 prospective cohort studies were identified for inclusion. These studies were categorized regarding the time of assessment for depressive symptoms. Included studies varied greatly (regarding their index population, their methods of assessment, and their timing of assessments). Of the studies, 3 involved patients undergoing hip fracture repair. They demonstrated more severe depressive symptoms both during delirium and after delirium ended. Conversely, the other studies did not find any statistically significant correlations between the 2 conditions. Conclusions: The literature suggests a correlation between depression and delirium in patients with hip fracture. Whether other specific populations have higher comorbidity is unclear. Unfortunately, studies varied widely in their methods, precluding a meta-analysis. Nonetheless, our review provides a foundation for future research.
C1 [Nelson, Scott; Rustad, James K.; Catalano, Glenn; Kozel, F. Andrew] James A Haley Vet Hosp & Clin, Mental Hlth & Behav Sci, Tampa, FL USA.
[Nelson, Scott; Rustad, James K.; Catalano, Glenn; Kozel, F. Andrew] Univ S Florida, Dept Psychiat & Behav Sci, 12901 Bruce B Downs Blvd,MDC 41, Tampa, FL 33612 USA.
[Stern, Theodore A.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Kozel, F. Andrew] James A Haley Vet Hosp & Clin, HSR&D Ctr Innovat Disabil & Rehabil Res CINDRR, Tampa, FL USA.
RP Nelson, S (reprint author), Univ S Florida, Dept Psychiat & Behav Sci, 12901 Bruce B Downs Blvd,MDC 41, Tampa, FL 33612 USA.
EM snelson5@health.usf.edu
NR 64
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD MAR-APR
PY 2016
VL 57
IS 2
BP 131
EP 141
PG 11
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA DH4OY
UT WOS:000372766500002
PM 26805588
ER
PT J
AU Burk, KS
Singh, AK
Vagefi, PA
Sahani, D
AF Burk, Kristine S.
Singh, Ajay K.
Vagefi, Parsia A.
Sahani, Dushyant
TI Pretransplantation Imaging Workup of the Liver Donor and Recipient
SO RADIOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Liver transplantation; Preliving donor liver transplant imaging; Hepatic
artery anatomy and variants; Portal vein anatomy and variants; Hepatic
vein anatomy and variants; Biliary anatomy and variants
ID 2 ADULT RECIPIENTS; HEPATOCELLULAR-CARCINOMA; RIGHT HEPATECTOMY;
TRANSPLANTATION; SPLIT; CT; DISEASE; OUTCOMES; ANATOMY; SURGERY
AB Liver transplantation requires thorough preoperative imaging. Contrast enhanced computed tomography (CT) and MR imaging are the main modalities utilized for this purpose. Radiation-reducing protocols, advanced imaging techniques for evaluation of parenchymal fat and iron content, and 3-dimenionsal and volumetric reformations are routinely used. The helpful diagnostic radiologist has a complete understanding of indications for transplant, the indications for bridging and/or down-staging therapies for hepatocellular carcinoma, and the components of the transplant operation. With this information at hand, the radiologist can craft a thorough, yet succinct report that will help the surgeon plan and execute successful donor and recipient transplant operations.
C1 [Burk, Kristine S.] Massachusetts Gen Hosp, Dept Radiol, Radiol Founders 205, 55 Fruit St, Boston, MA 02114 USA.
[Singh, Ajay K.; Sahani, Dushyant] Massachusetts Gen Hosp, Dept Radiol, Radiol WHT 270, 55 Fruit St, Boston, MA 02114 USA.
[Vagefi, Parsia A.] Massachusetts Gen Hosp, Dept Radiol, White 521c,55 Fruit St, Boston, MA 02114 USA.
RP Sahani, D (reprint author), Massachusetts Gen Hosp, Dept Radiol, Radiol WHT 270, 55 Fruit St, Boston, MA 02114 USA.
EM dsahani@partners.org
NR 42
TC 0
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-8389
EI 1557-8275
J9 RADIOL CLIN N AM
JI Radiol. Clin. N. Am.
PD MAR
PY 2016
VL 54
IS 2
BP 185
EP +
DI 10.1016/j.rcl.2015.09.010
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DH4QN
UT WOS:000372770600002
PM 26896219
ER
PT J
AU Moreno, CC
Mittal, PK
Ghonge, NP
Bhargava, P
Heller, MT
AF Moreno, Courtney Coursey
Mittal, Pardeep K.
Ghonge, Nitin P.
Bhargava, Puneet
Heller, Matthew T.
TI Imaging Complications of Renal Transplantation
SO RADIOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Renal transplantation; Complications of renal transplantation; Renal
artery stenosis; Renal vein thrombosis; Collecting system injury;
Lymphocele; Urinoma; Posttransplant lymphoproliferative disorder
ID CHRONIC ALLOGRAFT NEPHROPATHY; DELAYED GRAFT FUNCTION; ARTERY-STENOSIS;
RISK-FACTORS; KIDNEY-TRANSPLANTATION; VASCULAR COMPLICATIONS;
MULTIVARIATE-ANALYSIS; DOPPLER SONOGRAPHY; RESISTIVE INDEX; ACUTE
REJECTION
AB Renal transplant complications are categorized as those related to the transplant vasculature, collecting system, perinephric space, renal parenchyma, and miscellaneous complications including posttransplant lymphoproliferative disorder. Many of these renal transplant complications are diagnosed with imaging. Medical complications including rejection, acute tubular necrosis, and drug toxicity also can impair renal function. These medical complications are typically indistinguishable at imaging, and biopsy may be performed to establish a diagnosis. Normal transplant anatomy, imaging techniques, and the appearances of renal transplant complications at ultrasound, computed tomography, and MR imaging are reviewed.
C1 [Moreno, Courtney Coursey; Mittal, Pardeep K.] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
[Ghonge, Nitin P.] Indraprastha Apollo Hosp, Dept Radiol, Delhi Mathura Rd, New Delhi 110076, India.
[Bhargava, Puneet] Univ Washington, Med Ctr, Dept Radiol, VA Puget Sound Hlth Care Syst, 1959 NE Pacific St,Room BB308,Box 357115, Seattle, WA 98195 USA.
[Heller, Matthew T.] Univ Pittsburgh, Sch Med, Dept Radiol, 200 Lothrop St,Suite 174E PUH, Pittsburgh, PA 15213 USA.
RP Moreno, CC (reprint author), Emory Univ, Sch Med, Dept Radiol & Imaging Sci, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
EM courtney.moreno@emoryhealthcare.org
OI Mittal, Pardeep/0000-0002-3302-8590
NR 62
TC 2
Z9 2
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-8389
EI 1557-8275
J9 RADIOL CLIN N AM
JI Radiol. Clin. N. Am.
PD MAR
PY 2016
VL 54
IS 2
BP 235
EP +
DI 10.1016/j.rcl.2015.09.007
PG 17
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DH4QN
UT WOS:000372770600005
PM 26896222
ER
PT J
AU Backhus, LM
Mulligan, MS
Ha, R
Shriki, JE
Mohammed, TLH
AF Backhus, Leah M.
Mulligan, Michael S.
Ha, Richard
Shriki, Jabi E.
Mohammed, Tan-Lucien H.
TI Imaging in Lung Transplantation Surgical Considerations of Donor and
Recipient
SO RADIOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Lung transplant; Transplant evaluation; Transplant surgery; Computed
tomography
ID IDIOPATHIC PULMONARY-FIBROSIS; TRAUMATIC CARDIOPULMONARY ARREST; VOLUME
REDUCTION SURGERY; INTERNATIONAL-SOCIETY; CYSTIC-FIBROSIS; ORGAN
DONATION; FLEISCHNER-SOCIETY; SIZE MISMATCH; BRAIN-DEATH; MANAGEMENT
AB Modifications in recipient and donor criteria and innovations in donor management hold promise for increasing rates of lung transplantation, yet availability of donors remains a limiting resource. Imaging is critical in the work-up of donor and recipient including identification of conditions that may portend to poor posttransplant outcomes or necessitate modifications in surgical technique. This article describes the radiologic principles that guide selection of patients and surgical procedures in lung transplantation.
C1 [Backhus, Leah M.; Ha, Richard] Stanford Univ, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Bldg, Stanford, CA 94304 USA.
[Mulligan, Michael S.] Univ Washington, Dept Surg, Div Cardiothorac Surg, Seattle, WA 98195 USA.
[Shriki, Jabi E.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Shriki, Jabi E.] VA Puget Sound Hlth Care Syst, Diagnost Imaging Serv, Seattle, WA USA.
[Mohammed, Tan-Lucien H.] Univ Florida, Coll Med, Dept Radiol, Gainesville, FL 32610 USA.
RP Backhus, LM (reprint author), Stanford Univ, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Bldg, Stanford, CA 94304 USA.
EM lbackhus@stanford.edu
NR 67
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-8389
EI 1557-8275
J9 RADIOL CLIN N AM
JI Radiol. Clin. N. Am.
PD MAR
PY 2016
VL 54
IS 2
BP 339
EP +
DI 10.1016/j.rcl.2015.09.013
PG 16
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DH4QN
UT WOS:000372770600011
PM 26896228
ER
PT J
AU Bahney, CS
Jacobs, L
Tamai, R
Hu, D
Luan, TF
Wang, MQ
Reddy, S
Park, M
Limburg, S
Kim, HT
Marcucio, R
Kuo, AC
AF Bahney, Chelsea S.
Jacobs, Linsey
Tamai, Robert
Hu, Diane
Luan, Tammy F.
Wang, Miqi
Reddy, Sanjay
Park, Michelle
Limburg, Sonja
Kim, Hubert T.
Marcucio, Ralph
Kuo, Alfred C.
TI Promoting Endochondral Bone Repair Using Human Osteoarthritic Articular
Chondrocytes
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; IN-VIVO; CARTILAGE REPAIR; GENE-EXPRESSION;
OSSIFICATION; HYDROGELS; DEFECTS; CULTURE
AB Introduction: Current tissue engineering strategies to heal critical-size bone defects through direct bone formation are limited by incomplete integration of grafts with host bone and incomplete graft vascularization. An alternative strategy for bone regeneration is the use of cartilage grafts that form bone through endochondral ossification. Endochondral cartilages stimulate angiogenesis and are remodeled into bone, but are found in very small quantities in growth plates and healing fractures. We sought to develop engineered endochondral cartilage grafts using osteoarthritic (OA) articular chondrocytes as a cell source. Such chondrocytes often undergo hypertrophy, which is a characteristic of endochondral cartilages.
Materials and Methods: We compared the ability of unmodified human OA (hOA) cartilage and cartilage grafts formed in vitro from hOA chondrocytes to undergo endochondral ossification in mice. Scaffold-free engineered chondrocyte grafts were generated by pelleting chondrocytes, followed by culture with transforming growth factor-beta 1 (TGF-beta 1) and bone morphogenetic protein 4. Samples derived from either primary or passaged chondrocytes were implanted subcutaneously into immunocompromised mice. Grafts derived from passaged chondrocytes from three patients were implanted into critical-size tibial defects in mice. Bone formation was assessed with histology after 4 weeks of implantation. The composition of tibial repair tissue was quantified with histomorphometry.
Results: Engineered cartilage grafts generated from passaged OA chondrocytes underwent endochondral ossification after implantation either subcutaneously or in bone. Cartilage grafts integrated with host bone at 15 out of 16 junctions. Grafts variably remodeled into woven bone, with the proportion of bony repair tissue in tibial defects ranging from 22% to 85% (average 48%). Bony repair tissue bridged the tibial defects in half of the animals. In contrast, unmodified OA cartilage and engineered grafts formed from primary chondrocytes did not undergo endochondral ossification in vivo.
Conclusions: hOA chondrocytes can adopt an endochondral phenotype after passaging and TGF-beta superfamily treatment. Engineered endochondral cartilage grafts can integrate with host bone, undergo ossification, and heal critical-size long-bone defects in a mouse model. However, additional methods to further enhance ossification of these grafts are required before the clinical translation of this approach.
C1 [Bahney, Chelsea S.; Hu, Diane; Marcucio, Ralph] Univ Calif San Francisco, Orthopaed Trauma Inst, San Francisco Gen Hosp, San Francisco, CA 94121 USA.
[Jacobs, Linsey; Tamai, Robert; Luan, Tammy F.; Wang, Miqi; Reddy, Sanjay; Park, Michelle; Limburg, Sonja; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 112, San Francisco, CA 94121 USA.
RP Kuo, AC (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 112, San Francisco, CA 94121 USA.
EM kuoac@orthosurg.ucsf.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Disease
(NIAMS) of the National Institutes of Health (NIH) [5F32AR062469];
Musculoskeletal Transplant Foundation; UCSF Graduate Education in
Medical Sciences (GEMS); UCSF Department of Orthopaedic Surgery; San
Francisco Veterans Affairs Medical Center
FX Research reported in this publication was supported by the National
Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS) of
the National Institutes of Health (NIH) under the following award
numbers: CSB (#5F32AR062469). Additional research support was provided
by the Musculoskeletal Transplant Foundation (CSB: MTF Junior
Investigator Award), the UCSF Graduate Education in Medical Sciences
(GEMS), the UCSF Department of Orthopaedic Surgery, and the San
Francisco Veterans Affairs Medical Center.
NR 31
TC 0
Z9 1
U1 5
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAR 1
PY 2016
VL 22
IS 5-6
BP 427
EP 435
DI 10.1089/ten.tea.2014.0705
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA DH0FL
UT WOS:000372457800005
PM 26830207
ER
PT J
AU Park, KM
Hussein, KH
Hong, SH
Ahn, C
Yang, SR
Park, SM
Kweon, OK
Kim, BM
Woo, HM
AF Park, Kyung-Mee
Hussein, Kamal Hany
Hong, Seok-Ho
Ahn, Cheol
Yang, Se-Ran
Park, Sung-Min
Kweon, Oh-Kyeong
Kim, Byeong-Moo
Woo, Heung-Myong
TI Decellularized Liver Extracellular Matrix as Promising Tools for
Transplantable Bioengineered Liver Promotes Hepatic Lineage Commitments
of Induced Pluripotent Stem Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID LONG-TERM CULTURE; PORCINE LIVER; ENDOTHELIAL-CELLS; GROWTH-FACTORS;
HUMAN IPS; IN-VITRO; ORGAN; DISEASE; DIFFERENTIATION; PLATFORM
AB Liver transplantation is the last resort for liver failure patients. However, due to the shortage of donor organs, bioengineered liver generated from decellularized whole liver scaffolds and induced pluripotent stem cell (iPSC)-derived hepatocytes (iPSC-Heps) is being studied as an alternative approach to treat liver disease. Nevertheless, there has been no report on both the interaction of iPSC-Heps with a liver extracellular matrix (ECM) and the analysis of recellularized iPSC-Heps into the whole liver scaffolds. In this study, we produced porcine iPSC-Heps, which strongly expressed the hepatic markers alpha-fetoprotein and albumin and exhibited hepatic functionalities, including glycogen storage, lipid accumulation, low-density lipoprotein uptake, and indocyanine green metabolism. Supplementation of ECM from porcine decellularized liver containing liver-derived growth factors stimulated the albumin expression of porcine iPSC-Heps during differentiation procedures. The iPSC-Heps were reseeded into decellularized liver scaffolds, and the recellularized liver was cultured using a continuous perfusion system. The recellularized liver scaffolds were transplanted into rats for a short term, and the grafts expressed hepatocyte markers and did not rupture. These results provide a foundation for development of bioengineered liver using stem cell and decellularized scaffolds.
C1 [Park, Kyung-Mee; Hussein, Kamal Hany; Hong, Seok-Ho; Ahn, Cheol; Yang, Se-Ran; Park, Sung-Min; Woo, Heung-Myong] Kangwon Natl Univ, Stem Cell Inst KNU, Chunchon 200701, Gangwon, South Korea.
[Park, Kyung-Mee; Hussein, Kamal Hany; Woo, Heung-Myong] Kangwon Natl Univ, Sch Vet Med, Chunchon 200701, Gangwon, South Korea.
[Hong, Seok-Ho; Yang, Se-Ran; Park, Sung-Min] Kangwon Natl Univ, Sch Med, Chunchon 200701, Gangwon, South Korea.
[Ahn, Cheol] Kangwon Natl Univ, Sch Biomed Technol, Chunchon 200701, Gangwon, South Korea.
[Kweon, Oh-Kyeong] Seoul Natl Univ, Sch Vet Med, Seoul, South Korea.
[Kim, Byeong-Moo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,GI Unit, Boston, MA USA.
RP Woo, HM (reprint author), Kangwon Natl Univ, Sch Vet Med, Chunchon 200701, Gangwon, South Korea.
EM woohm@kangwon.ac.kr
FU "Cooperative Research Program for Agriculture Science & Technology
Development" Rural Development Administration, Republic of Korea
[PJ0110022015]
FX This work was carried out with the support of "Cooperative Research
Program for Agriculture Science & Technology Development (Project No.
PJ0110022015)" Rural Development Administration, Republic of Korea
NR 56
TC 1
Z9 2
U1 9
U2 19
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAR 1
PY 2016
VL 22
IS 5-6
BP 449
EP 460
DI 10.1089/ten.tea.2015.0313
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA DH0FL
UT WOS:000372457800007
PM 26801816
ER
PT J
AU Lindau, A
Hardtner, C
Hergeth, SP
Blanz, KD
Dufner, B
Hoppe, N
Anto-Michel, N
Kornemann, J
Zou, J
Gerhardt, LMS
Heidt, T
Willecke, F
Geis, S
Stachon, P
Wolf, D
Libby, P
Swirski, FK
Robbins, CS
McPheat, W
Hawley, S
Braddock, M
Gilsbach, R
Hein, L
von zur Muhlen, C
Bode, C
Zirlik, A
Hilgendorf, I
AF Lindau, Alexandra
Haerdtner, Carmen
Hergeth, Sonja P.
Blanz, Kelly Daryll
Dufner, Bianca
Hoppe, Natalie
Anto-Michel, Nathaly
Kornemann, Jan
Zou, Jiadai
Gerhardt, Louisa M. S.
Heidt, Timo
Willecke, Florian
Geis, Serjosha
Stachon, Peter
Wolf, Dennis
Libby, Peter
Swirski, Filip K.
Robbins, Clinton S.
McPheat, William
Hawley, Shaun
Braddock, Martin
Gilsbach, Ralf
Hein, Lutz
von zur Muehlen, Constantin
Bode, Christoph
Zirlik, Andreas
Hilgendorf, Ingo
TI Atheroprotection through SYK inhibition fails in established disease
when local macrophage proliferation dominates lesion progression
SO BASIC RESEARCH IN CARDIOLOGY
LA English
DT Article
DE Atherosclerosis; SYK; Monocytes; Macrophages; Progenitors;
Proliferation; Egress
ID TYROSINE KINASE INHIBITOR; STEM-CELL PROLIFERATION;
RHEUMATOID-ARTHRITIS; ATHEROSCLEROTIC LESIONS; INADEQUATE RESPONSE;
PARALLEL-GROUP; DOUBLE-BLIND; PHASE-III; ACCUMULATION; FOSTAMATINIB
AB Macrophages in the arterial intima sustain chronic inflammation during atherogenesis. Under hypercholesterolemic conditions murine Ly6C(high) monocytes surge in the blood and spleen, infiltrate nascent atherosclerotic plaques, and differentiate into macrophages that proliferate locally as disease progresses. Spleen tyrosine kinase (SYK) may participate in downstream signaling of various receptors that mediate these processes. We tested the effect of the SYK inhibitor fostamatinib on hypercholesterolemia-associated myelopoiesis and plaque formation in Apoe(-/-) mice during early and established atherosclerosis. Mice consuming a high cholesterol diet supplemented with fostamatinib for 8 weeks developed less atherosclerosis. Histologic and flow cytometric analysis of aortic tissue showed that fostamatinib reduced the content of Ly6C(high) monocytes and macrophages. SYK inhibition limited Ly6C(high) monocytosis through interference with GM-CSF/IL-3 stimulated myelopoiesis, attenuated cell adhesion to the intimal surface, and blocked M-CSF stimulated monocyte to macrophage differentiation. In Apoe(-/-) mice with established atherosclerosis, however, fostamatinib treatment did not limit macrophage accumulation or lesion progression despite a significant reduction in blood monocyte counts, as lesional macrophages continued to proliferate. Thus, inhibition of hypercholesterolemia-associated monocytosis, monocyte infiltration, and differentiation by SYK antagonism attenuates early atherogenesis but not established disease when local macrophage proliferation dominates lesion progression.
C1 [Lindau, Alexandra; Haerdtner, Carmen; Hergeth, Sonja P.; Blanz, Kelly Daryll; Dufner, Bianca; Hoppe, Natalie; Anto-Michel, Nathaly; Kornemann, Jan; Zou, Jiadai; Gerhardt, Louisa M. S.; Heidt, Timo; Willecke, Florian; Geis, Serjosha; Stachon, Peter; Wolf, Dennis; von zur Muehlen, Constantin; Bode, Christoph; Zirlik, Andreas; Hilgendorf, Ingo] Univ Heart Ctr Freiburg, Dept Cardiol & Angiol 1, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Blanz, Kelly Daryll] Univ Freiburg, Spemann Grad Sch Biol & Med, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Blanz, Kelly Daryll] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Libby, Peter] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Swirski, Filip K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
[Robbins, Clinton S.] Peter Munk Cardiac Ctr, Toronto, ON, Canada.
[McPheat, William] AstraZeneca R&D, Gothenburg, Sweden.
[Hawley, Shaun; Braddock, Martin] AstraZeneca R&D, Alderley Pk, Macclesfield, Cheshire, England.
[Gilsbach, Ralf; Hein, Lutz] Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, Hugstetter Str 55, D-79106 Freiburg, Germany.
RP Zirlik, A; Hilgendorf, I (reprint author), Univ Heart Ctr Freiburg, Dept Cardiol & Angiol 1, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM andreas.zirlik@universitaets-herzzentrum.de;
ingo.hilgendorf@universitaets-herzzentrum.de
FU Department of Cardiology and Angiology I, University Heart Center
Freiburg; Astra Zeneca; German Research Foundation [HI 1573/2-1];
Excellence Initiative of the German Research Foundation (Spemann
Graduate School) [GSC-4]
FX This work was supported by internal funds of the Department of
Cardiology and Angiology I, University Heart Center Freiburg, and Astra
Zeneca to A.Z., the German Research Foundation to I.H. (HI 1573/2-1) and
the Excellence Initiative of the German Research Foundation (GSC-4,
Spemann Graduate School) to K.D.B.
NR 20
TC 4
Z9 4
U1 1
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8428
EI 1435-1803
J9 BASIC RES CARDIOL
JI Basic Res. Cardiol.
PD MAR
PY 2016
VL 111
IS 2
AR 20
DI 10.1007/s00395-016-0535-8
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG7LE
UT WOS:000372265000011
PM 26891724
ER
PT J
AU Sinha, I
Zhu, D
Ojomo, K
Gfrerer, L
Sawh-Martinez, R
Patel, A
Chan, RK
Watkins, JF
AF Sinha, Indranil
Zhu, Dagny
Ojomo, Kristin
Gfrerer, Lisa
Sawh-Martinez, Rajendra
Patel, Anup
Chan, Rodney K.
Watkins, James F.
TI Functional and subjective assessment of burn contracture release in a
mission setting
SO BURNS
LA English
DT Article; Proceedings Paper
CT Meeting of the American-Burn-Association
CY 2015
CL Chicago, IL
SP Amer Burn Assoc
DE Burn reconstruction; Contractors; Surgical missions
ID SF-36 HEALTH SURVEY; QUALITY-OF-LIFE; INJURY; TRANSLATION; ADAPTATION;
PREVENTION; MANAGEMENT; BARRIERS; IMPACT; RETURN
AB Objective: Burns and subsequent contractures are common in developing nations. Contracture release is performed to treat such patients with functional limitations. The aim of this study is to evaluate post-operative functional and psychosocial outcomes following contracture release in a mission setting.
Methods: During a surgical mission in Mumbai, India, 39 patients burn contractures underwent surgical release. A total of 31 patients (64% female, mean age 27 years) chose to participate in the study. Patients were scored preoperatively and postoperatively using a SF-36 validated survey and AMA impairment guideline assessment.
Results: Thirty-one patients completed questionnaires pre-operative and 6-weeks post operatively. Twenty-four patients completed a survey 3-months post operatively (77.4%). Among those enrolled, 67% were women with the majority sustaining <20% total body surface area burns (70.7%) but had multiple contractures (80.6%). SF-36 physical component score increased from a mean score of 49.8 preoperatively to 55.6 by 3 months following contracture release (P < 0.001). The SF-36 mental component score similarly increased from 38.8 to 51.1 by 3 months (P < 0.001). AMA Whole Person Impairment (WPI) scores improved from 40.3% impairment pre-operative to 26.6% at 6-weeks post-operative (P < 0.001).
Conclusions: Patients SF-36 and WPI scores improved following burn contracture release, confirming both functional and psychologic improvement following surgery. During the acute post-operative period, this study suggests that contracture release in a mission setting is of benefit to patients. (C) 2015 Elsevier Ltd and ISBI. All rights reserved.
C1 [Sinha, Indranil; Ojomo, Kristin] Brigham & Womens Hosp, Div Plast Surg, 75 Francis St, Boston, MA 02115 USA.
[Sinha, Indranil; Ojomo, Kristin] Brigham & Womens Hosp, Div Trauma & Burn Surg, 75 Francis St, Boston, MA 02115 USA.
[Zhu, Dagny] Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90089 USA.
[Gfrerer, Lisa] Massachusetts Gen Hosp, Div Plast Surg, Boston, MA 02114 USA.
[Sawh-Martinez, Rajendra; Patel, Anup] Yale Univ, Sch Med, Div Plast Surg, 333 Cedar St, New Haven, CT 06520 USA.
[Chan, Rodney K.] San Antonio Mil Med Ctr, Clin Div, San Antonio, TX 78234 USA.
[Chan, Rodney K.] San Antonio Mil Med Ctr, Burn Ctr, San Antonio, TX 78234 USA.
[Watkins, James F.] VA Eastern Colorado Healthcare Syst, Div Trauma & Crit Care, Denver, CO 80220 USA.
RP Sinha, I (reprint author), Dept Surg, Div Plast Surg, Div Trauma Burn Surg, 75 Francis St, Boston, MA 02115 USA.
EM isinha@partners.org
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0305-4179
EI 1879-1409
J9 BURNS
JI Burns
PD MAR
PY 2016
VL 42
IS 2
BP 466
EP 470
DI 10.1016/j.burns.2015.07.009
PG 5
WC Critical Care Medicine; Dermatology; Surgery
SC General & Internal Medicine; Dermatology; Surgery
GA DG6FW
UT WOS:000372179600035
PM 26778704
ER
PT J
AU Allott, EH
Howard, LE
Aronson, WJ
Terris, MK
Kane, CJ
Amling, CL
Cooperberg, MR
Freedland, SJ
AF Allott, Emma H.
Howard, Lauren E.
Aronson, William J.
Terris, Martha K.
Kane, Christopher J.
Amling, Christopher L.
Cooperberg, Matthew R.
Freedland, Stephen J.
TI Racial Differences in the Association Between Preoperative Serum
Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH
Database
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID AFRICAN-AMERICAN; RISK; MEN; COHORT; ATHEROSCLEROSIS; MORTALITY; IMPACT;
GRADE; CELLS
AB Background: Black men are disproportionately affected by both cardiovascular disease and prostate cancer. Epidemiologic evidence linking dyslipidemia, an established cardiovascular risk factor, and prostate cancer progression is mixed. As existing studies were conducted in predominantly non-black populations, research on black men is lacking.
Methods: We identified 628 black and 1,020 non-black men who underwent radical prostatectomy and never used statins before surgery in the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Median follow-up was 2.9 years. The impact of preoperative hypercholesterolemia on risk of biochemical recurrence was examined using multivariable, race-stratified proportional hazards. In secondary analysis, we examined associations with low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides, overall and among men with dyslipidemia.
Results: High cholesterol was associated with increased risk of recurrence in black [HRper10 (mg/dL) 1.06; 95% confidence interval (CI), 1.02-1.11] but not non-black men (HRper10 mg/dL 0.99; 95% CI, 0.95-1.03; P-interaction = 0.011). Elevated triglycerides were associated with increased risk in both black and non-black men (HRper10 mg/dL 1.02; 95% CI, 1.00-1.03 and 1.02; 95% CI, 1.00-1.02, respectively; P-interaction = 0.458). There were no significant associations between LDL or HDL and recurrence risk in either race. Associations with cholesterol, LDL, and triglycerides were similar among men with dyslipidemia, but low HDL was associated with increased risk of recurrence in black, but not non-black men with dyslipidemia (P-interaction = 0.047).
Conclusion: Elevated cholesterol was a risk factor for recurrence in black but not non-black men, whereas high triglycerides were associated with increased risk regardless of race.
Impact: Significantly contrasting associations by race may provide insight into prostate cancer racial disparities. (C) 2016 AACR.
C1 [Allott, Emma H.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Allott, Emma H.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Howard, Lauren E.] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA.
[Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Kane, Christopher J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA.
[Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA.
[Freedland, Stephen J.] Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA.
[Freedland, Stephen J.] Vet Affairs Med Ctr, Div Urol, Durham, NC USA.
RP Freedland, SJ (reprint author), Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA.
EM stephen.freedland@cshs.org
FU NIH [1K24CA160653, P50CA92131]; University Cancer Research Fund of North
Carolina
FX This study was supported by grants from NIH [1K24CA160653 (to S.J.
Freedland) and P50CA92131 (to W.J. Aronson)] and by the University
Cancer Research Fund of North Carolina (to E.H. Allott).
NR 32
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD MAR
PY 2016
VL 25
IS 3
BP 547
EP 554
DI 10.1158/1055-9965.EPI-15-0876
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA DG6EA
UT WOS:000372173900015
PM 26809276
ER
PT J
AU Boros, E
Holland, JP
Kenton, N
Rotile, N
Caravan, P
AF Boros, Eszter
Holland, Jason P.
Kenton, Nathaniel
Rotile, Nicholas
Caravan, Peter
TI Macrocycle-Based Hydroxamate Ligands for Complexation and
Immunoconjugation of (89)Zirconium for Positron Emission Tomography
(PET) Imaging
SO CHEMPLUSCHEM
LA English
DT Article
DE antitumor agents; imaging agents; macrocycles; radiopharmaceuticals;
zirconium
ID P-ISOTHIOCYANATOBENZYL-DESFERRIOXAMINE; EFFECTIVE CORE POTENTIALS;
IMMUNO-PET; MONOCLONAL-ANTIBODIES; MOLECULAR CALCULATIONS; BIFUNCTIONAL
CHELATE; SIDEROPHORE ANALOGS; ZR-89; ZIRCONIUM-89; CANCER
AB Four novel chelators (L1-L4) and their (89)zirconium complexes were prepared and compared with the (89)zirconium desferrioxamineB (DFO) complex. The new chelates are based on 1,4,7,10-tetraazacyclododecane (cyclen) and 1,4,8,11-tetraazacyclotetradecane (cyclam) scaffolds and present either three or four hydroxamate arms for coordination with Zr4+ ions with coordination numbers between six and eight. The Zr-89-L4 complex showed similar stability to that of Zr-89-DFO when incubated in either rat blood plasma or ethylenediaminetetraacetic acid challenge experiments. Positron imaging and biodistribution studies in mice showed that Zr-89-L4 had similar pharmacokinetic behavior to that of Zr-89-DFO, with rapid renal elimination and low residual activity in background tissues. A bifunctional version of L4 (L5) was synthesized and conjugated to trastuzumab; an anti-HER2/neu antibody. Immunopositron emission tomography imaging and biodistribution with Zr-89-L5-trastuzumab revealed high tumor to background ratios (tumor/blood ratio: 14.2 +/- 2.25) and a high tumor specificity that was comparable to the performance of Zr-89-DFO-trastuzumab.
C1 [Boros, Eszter; Kenton, Nathaniel; Rotile, Nicholas; Caravan, Peter] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, 149 Thirteenth St,Suite 2301, Charlestown, MA 02129 USA.
[Holland, Jason P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Nucl Med & Mol Imaging, 55 Fruit St,White 427, Boston, MA 02114 USA.
RP Boros, E (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, 149 Thirteenth St,Suite 2301, Charlestown, MA 02129 USA.
EM eboros@nmr.mgh.harvard.edu
FU NIH [K99HL125728, R01EB009062]
FX Fang Qian, Dingyi Wen, Yuting Huang, Susan Foley, and Paul Weinreb of
Biogen Inc. are acknowledged for MS analysis of antibody conjugates.
Chongzhao Ran and Anna Moore are acknowledged for providing access to
the Sofie Biosciences G4 PET scanner. Shadi Esfahani and Umar Mahmood
are acknowledged for a donation of BT474 cells and providing guidance on
tumor implantation. Neil Vasdev is acknowledged for providing
89Zr(oxalate) in house for early experiments. The NIH is
acknowledged for funding support to E.B. (K99HL125728) and P.C.
(R01EB009062).
NR 46
TC 5
Z9 5
U1 13
U2 22
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2192-6506
J9 CHEMPLUSCHEM
JI ChemPlusChem
PD MAR
PY 2016
VL 81
IS 3
BP 274
EP 281
DI 10.1002/cplu.201600003
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA DG6EL
UT WOS:000372175000003
PM 27630807
ER
PT J
AU Hsue, PY
Tawakol, A
AF Hsue, Priscilla Y.
Tawakol, Ahmed
TI Inflammation and Fibrosis in HIV Getting to the Heart of the Matter
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Editorial Material
DE Editorials; cardiovascular diseases; fibrosis; HIV; heart failure;
inflammation
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CARDIOVASCULAR MAGNETIC-RESONANCE;
ARTERIAL INFLAMMATION; INFECTION; RISK; ECHOCARDIOGRAPHY;
CYTOMEGALOVIRUS; COAGULATION; DYSFUNCTION; MYOCARDITIS
C1 Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
RP Hsue, PY (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, 1001 Potrero Ave, San Francisco, CA 94110 USA.
EM Priscilla.Hsue@ucsf.edu
FU NIAID NIH HHS [K24 AI112393, K24AI112393]
NR 29
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD MAR
PY 2016
VL 9
IS 3
AR e004427
DI 10.1161/CIRCIMAGING.116.004427
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA DG3PN
UT WOS:000371982100001
PM 26951604
ER
PT J
AU Fifer, MA
AF Fifer, Michael A.
TI Through Thick and Thin What Are the Septal Thickness Limits for Alcohol
Septal Ablation?
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
DE Editorials; catheter ablation; cardiomyopathy; hypertrophic obstructive;
heart septal defects; ventricular; hypertrophy; left ventricular;
magnetic resonance imaging; ventricular outflow obstruction; ventricular
septum
ID HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; TASK-FORCE; MANAGEMENT;
GUIDELINES; PREDICTORS; DIAGNOSIS; MYECTOMY
C1 [Fifer, Michael A.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Cardiol Div, Boston, MA USA.
RP Fifer, MA (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 800, Boston, MA 02114 USA.
EM mfifer@mgh.harvard.edu
NR 19
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7640
EI 1941-7632
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD MAR
PY 2016
VL 9
IS 3
AR e003588
DI 10.1161/CIRCINTERVENTIONS.116.003588
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG3QV
UT WOS:000371985700001
PM 26884613
ER
PT J
AU Shinagare, AB
Keraliya, A
Somarouthu, B
Tirumani, SH
Ramaiya, NH
Kantoff, PW
AF Shinagare, A. B.
Keraliya, A.
Somarouthu, B.
Tirumani, S. H.
Ramaiya, N. H.
Kantoff, P. W.
TI Imaging yield from 133 consecutive patients with prostate cancer and low
trigger PSA from a single institution
SO CLINICAL RADIOLOGY
LA English
DT Article
ID RADIONUCLIDE BONE-SCINTIGRAPHY; RADICAL PROSTATECTOMY; BIOCHEMICAL
FAILURE; FOLLOW-UP; COMPUTED-TOMOGRAPHY; INCREASED SURVIVAL;
NATURAL-HISTORY; ANTIGEN LEVEL; MEN; PROGRESSION
AB AIM: To investigate the yield of imaging in patients with relapsed prostate cancer (PC) with a low trigger prostate-specific antigen (PSA).
MATERIALS AND METHODS: This institutional review board (IRB)-approved, Health Insurance Portability and Accountability Act (HIPAA)-compliant retrospective study included all 133 patients (mean age 68 years; range 45-88; median 69 months since original diagnosis; interquartile range [IQR]: 32-139) with hormone-sensitive PC (HSPC, n = 28) or castration-resistant PC (CRPC, n = 105) and trigger PSA < 4 ng/ml, who underwent same-day bone scintigraphy and computed tomography (CT; total 224 time points) at Dana-Farber Cancer Institute from January to December 2013. Clinical and pathological data were obtained by manual review of the electronic medical records. All the included bone scintigraphs and CT images were reviewed by a fellowship-trained oncoradiologist to record the metastatic pattern and any clinically significant non-metastatic findings.
RESULTS: Ninety-four of the 133 (71%) patients had metastatic disease (18/28 [64%] with HSPC, 76/105 [72%] with CRPC). Forty-one of the 133 (31%) patients developed new metastatic disease and 23/133 (17%) developed new clinically significant non-metastatic findings. The incidence of osseous, nodal, and visceral metastases, and clinically significant non-metastatic findings was similar across the HSPC and CRPC groups (p>0.05 for all). Fifty-seven of the 133 (43%) patients had findings seen only at CT, of which 37 had new extra-osseous findings. Only 2/133 (2%) had findings at bone scintigraphy not seen at CT, both in areas not covered on CT.
CONCLUSION: Imaging frequently demonstrated new metastatic and non-metastatic findings in patients with a low trigger PSA. CT is valuable in these patients because extra-osseous findings not visible at bone scintigraphy are frequently seen. (C) 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Shinagare, A. B.; Keraliya, A.; Somarouthu, B.; Tirumani, S. H.; Ramaiya, N. H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
[Shinagare, A. B.; Keraliya, A.; Somarouthu, B.; Tirumani, S. H.; Ramaiya, N. H.; Kantoff, P. W.] Harvard Univ, Sch Med, 75 Francis St, Boston, MA 02115 USA.
[Kantoff, P. W.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA.
RP Shinagare, AB (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
EM ashinagare@partners.org
NR 35
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0009-9260
EI 1365-229X
J9 CLIN RADIOL
JI Clin. Radiol.
PD MAR
PY 2016
VL 71
IS 3
BP E143
EP E149
DI 10.1016/j.crad.2015.12.006
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DG3UK
UT WOS:000371995700001
PM 26767544
ER
PT J
AU Mackin, RS
Vigil, O
Insel, P
Kivowitz, A
Kupferman, E
Hough, CM
Fekri, S
Crothers, R
Bickford, D
Delucchi, KL
Mathews, CA
AF Mackin, R. Scott
Vigil, Ofilio
Insel, Philip
Kivowitz, Alana
Kupferman, Eve
Hough, Christina M.
Fekri, Shiva
Crothers, Ross
Bickford, David
Delucchi, Kevin L.
Mathews, Carol A.
TI PATTERNS OF CLINICALLY SIGNIFICANT COGNITIVE IMPAIRMENT IN HOARDING
DISORDER
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE hoarding disorder; cognitive impairment; executive dysfunction;
categorization; information processing speed; memory; attention
ID OBSESSIVE-COMPULSIVE DISORDER; SYMPTOM DIMENSIONS; OLDER-ADULTS;
EXECUTIVE FUNCTION; DECISION-MAKING; DEPRESSION; INVENTORY; ATTENTION;
VALIDITY; THERAPY
AB ObjectivesThe cognitive characteristics of individuals with hoarding disorder (HD) are not well understood. Existing studies are relatively few and somewhat inconsistent but suggest that individuals with HD may have specific dysfunction in the cognitive domains of categorization, speed of information processing, and decision making. However, there have been no studies evaluating the degree to which cognitive dysfunction in these domains reflects clinically significant cognitive impairment (CI).
MethodsParticipants included 78 individuals who met DSM-V criteria for HD and 70 age- and education-matched controls. Cognitive performance on measures of memory, attention, information processing speed, abstract reasoning, visuospatial processing, decision making, and categorization ability was evaluated for each participant. Rates of clinical impairment for each measure were compared, as were age- and education-corrected raw scores for each cognitive test.
ResultsHD participants showed greater incidence of CI on measures of visual memory, visual detection, and visual categorization relative to controls. Raw-score comparisons between groups showed similar results with HD participants showing lower raw-score performance on each of these measures. In addition, in raw-score comparisons HD participants also demonstrated relative strengths compared to control participants on measures of verbal and visual abstract reasoning.
ConclusionsThese results suggest that HD is associated with a pattern of clinically significant CI in some visually mediated neurocognitive processes including visual memory, visual detection, and visual categorization. Additionally, these results suggest HD individuals may also exhibit relative strengths, perhaps compensatory, in abstract reasoning in both verbal and visual domains.
C1 [Mackin, R. Scott; Vigil, Ofilio; Kivowitz, Alana; Kupferman, Eve; Hough, Christina M.; Crothers, Ross; Bickford, David; Delucchi, Kevin L.; Mathews, Carol A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Mackin, R. Scott; Insel, Philip] San Francisco VA Med Ctr, San Francisco, CA USA.
[Fekri, Shiva] Univ Colorado, Dept Psychol, Denver, CO 80202 USA.
RP Mackin, RS (reprint author), Univ Calif San Francisco, Langley Porter Psychiat Inst, Dept Psychiat, 401 Parnassus Ave,Box F-0984, San Francisco, CA 94143 USA.
EM Scott.Mackin@ucsf.edu
RI Hough, Christina/K-2416-2016
OI Hough, Christina/0000-0002-8864-5262
FU NIMH [R21 MH087748, K08 MH081065, R01 0977669]; Patient-Centered
Outcomes Research Institute (PCORI) Award [6000]
FX Contract grant sponsor: NIMH; Grant numbers: R21 MH087748, K08 MH081065,
R01 0977669. The Althea Foundation and a Patient-Centered Outcomes
Research Institute (PCORI) Award; Contract number: 6000.
NR 46
TC 3
Z9 3
U1 6
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD MAR
PY 2016
VL 33
IS 3
BP 211
EP 218
DI 10.1002/da.22439
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA DG6FY
UT WOS:000372179800005
PM 26474146
ER
PT J
AU McGuire, JF
Orr, SP
Wu, MS
Lewin, AB
Small, BJ
Phares, V
Murphy, TK
Wilhelm, S
Pine, DS
Geller, D
Storch, EA
AF McGuire, Joseph F.
Orr, Scott P.
Wu, Monica S.
Lewin, Adam B.
Small, Brent J.
Phares, Vicky
Murphy, Tanya K.
Wilhelm, Sabine
Pine, Daniel S.
Geller, Daniel
Storch, Eric A.
TI FEAR CONDITIONING AND EXTINCTION IN YOUTH WITH OBSESSIVE-COMPULSIVE
DISORDER
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE fear conditioning; extinction; skin conductance; inhibitory learning;
obsessive-compulsive disorder; children
ID COGNITIVE-BEHAVIORAL THERAPY; ANXIETY DISORDERS; FUNCTIONAL IMPAIRMENT;
TREATMENT RESPONSE; BIAS MODIFICATION; CHILD VERSION; ADOLESCENTS;
PREDICTORS; ADULTS; RELIABILITY
AB BackgroundFear acquisition and extinction are central constructs in the cognitive-behavioral model of obsessive-compulsive disorder (OCD), which underlies exposure-based cognitive-behavioral therapy (CBT). Youth with OCD may have impairments in fear acquisition and extinction that carry treatment implications. We examined these processes using a differential conditioning procedure.
MethodsForty-one youth (19 OCD, 22 community comparisons) completed a battery of clinical interviews, rating scales, and a differential conditioning task that included habituation, acquisition, and extinction phases. Skin conductance response (SCR) served as the primary dependent measure.
ResultsDuring habituation, no difference between groups was observed. During acquisition, differential fear conditioning was observed across participants as evidenced by larger SCRs to the CS+ compared to CS-; there were no between-group differences. Across participants, the number and frequency of OCD symptoms and anxiety severity was associated with greater reactivity to stimuli during acquisition. During extinction, a three-way interaction and follow-up tests revealed that youth with OCD showed a different pattern of SCR extinction compared to the community comparison group.
ConclusionsYouth with OCD exhibit a different pattern of fear extinction relative to community comparisons. This may be attributed to impaired inhibitory learning and contingency awareness in extinction. Findings suggest the potential benefit of utilizing inhibitory-learning principles in CBT for youth with OCD, and/or augmentative retraining interventions prior to CBT to reduce threat bias and improve contingency detection.
C1 [McGuire, Joseph F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Pl,48-228B, Los Angeles, CA 90095 USA.
[Orr, Scott P.; Wilhelm, Sabine; Geller, Daniel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Wu, Monica S.; Lewin, Adam B.; Phares, Vicky; Storch, Eric A.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
[Wu, Monica S.; Lewin, Adam B.; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, Dept Pediat, Tampa, FL 33620 USA.
[Lewin, Adam B.; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA.
[Lewin, Adam B.; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, All Childrens Hosp, Johns Hopkins Med, St Petersburg, FL 33701 USA.
[Small, Brent J.] Univ S Florida, Sch Aging Studies, Tampa, FL USA.
[Pine, Daniel S.] NIMH, Sect Dev & Affect Neurosci, Rockville, MD 20857 USA.
[Storch, Eric A.] Rogers Behav Hlth Tampa Bay, Tampa, FL USA.
[Storch, Eric A.] Univ S Florida, Dept Hlth Policy & Management, Tampa, FL USA.
RP McGuire, JF (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Pl,48-228B, Los Angeles, CA 90095 USA.
EM jfmcguire@mednet.ucla.edu
FU National Institute of Mental Health (NIMH) of the National Institutes of
Health (NIH) [R01MH093381-02S1]; NIMH Intramural Research Program
FX Contract grant sponsor: Support for this article comes in part from the
National Institute of Mental Health (NIMH) of the National Institutes of
Health (NIH) as a research supplement to promote diversity in
health-related research (R01MH093381-02S1). Dr. Pine is supported by the
NIMH Intramural Research Program. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the NIMH or NIH.
NR 54
TC 4
Z9 4
U1 5
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD MAR
PY 2016
VL 33
IS 3
BP 229
EP 237
DI 10.1002/da.22468
PG 9
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA DG6FY
UT WOS:000372179800007
PM 26799264
ER
PT J
AU Achuko, O
Walker, RJ
Campbell, JA
Dawson, AZ
Egede, LE
AF Achuko, Obinna
Walker, Rebekah J.
Campbell, Jennifer A.
Dawson, Aprill Z.
Egede, Leonard E.
TI Pathways Between Discrimination and Quality of Life in Patients with
Type 2 Diabetes
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID REPORTED RACIAL-DISCRIMINATION; RANDOMIZED CONTROLLED-TRIAL; PERCEIVED
DISCRIMINATION; SOCIAL DETERMINANTS; AFRICAN-AMERICAN; GLYCEMIC CONTROL;
HEALTH-CARE; EVERYDAY DISCRIMINATION; PSYCHOLOGICAL DISTRESS; WEIGHT
DISCRIMINATION
AB Background: Discrimination is a social determinant that has been linked to poor physical and mental health outcomes. This study aimed to examine the pathway whereby discrimination influences quality of life in patients with type 2 diabetes.
Subjects and Methods: Six hundred fifteen patients were recruited from two adult primary care clinics in the southeastern United States. Measures included perceived discrimination, perceived stress, social support, and social cohesion and were based on a theoretical model for the pathways by which perceived discrimination influences mental and physical health. Quality of life was measured using the SF-12 questionnaire.
Results: The final model [chi(2)(106) = 157.35, P = 0.009, R-2 = 0.99, root mean square error of approximation = 0.03, comparative fit index = 0.99] indicates direct effects of higher perceived stress (r = -1.02, P < 0.05) and lower social support (r = 0.36, P < 0.001) significantly related to decreased mental health component score (MCS) of quality of life. Discrimination and social cohesion were not significantly directly related to MCS. However, higher discrimination (r = 0.47, P < 0.001), higher social cohesion (r = 0.14, P < 0.05), and lower social support (r = -0.43, P < 0.001) were significantly directly related to increased stress. No significant paths were found for the physical component score of quality of life.
Conclusions: Perceived discrimination was significantly associated with stress and served as a pathway to influence the mental health component of quality of life (MCS). Social support had a direct and an indirect effect on MCS through a negative association with stress. These results suggest that future interventions should be developed to decrease stress and increase social support surrounding discrimination to improve the MCS of quality of life in patients with diabetes.
C1 [Achuko, Obinna; Walker, Rebekah J.; Campbell, Jennifer A.; Dawson, Aprill Z.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA.
[Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA Hlth Serv Res & Dev COIN, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA.
[Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU National Institute of Diabetes and Digestive and Kidney Disease
[K24DK093699-01]
FX This study was supported by grant K24DK093699-01 from the National
Institute of Diabetes and Digestive and Kidney Disease (Principal
Investigator: L.E.E.).
NR 58
TC 0
Z9 0
U1 2
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
EI 1557-8593
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD MAR 1
PY 2016
VL 18
IS 3
BP 151
EP 158
DI 10.1089/dia.2015.0305
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DG6HE
UT WOS:000372183700008
PM 26866351
ER
PT J
AU Marneros, AG
AF Marneros, Alexander G.
TI Increased VEGF-A promotes multiple distinct aging diseases of the eye
through shared pathomechanisms
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; aging; cataract; NLRP3 inflammasome;
VEGF-A
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; EXPERIMENTAL
CHOROIDAL NEOVASCULARIZATION; MEMBRANE ATTACK COMPLEX; AGE-RELATED
CATARACT; DISMUTASE-NULL MICE; MACULAR-DEGENERATION;
SUPEROXIDE-DISMUTASE; NLRP3 INFLAMMASOME; OXIDATIVE-STRESS
AB While increased VEGF-A has been associated with neovascular age-related macular degeneration (AMD), it is not known whether VEGF-A may also promote other age-related eye diseases. Here, we show that an increase in VEGF-A is sufficient to cause multiple distinct common aging diseases of the eye, including cataracts and both neovascular and non-exudative AMD-like pathologies. In the lens, increased VEGF-A induces age-related opacifications that are associated with ERK hyperactivation, increased oxidative damage, and higher expression of the NLRP3 inflammasome effector cytokine IL-1. Similarly, increased VEGF-A induces oxidative stress and IL-1 expression also in the retinal pigment epithelium (RPE). Targeting NLRP3 inflammasome components or Il1r1 strongly inhibited not only VEGF-A-induced cataract formation, but also both neovascular and non-exudative AMD-like pathologies. Moreover, increased VEGF-A expression specifically in the RPE was sufficient to cause choroidal neovascularization (CNV) as in neovascular AMD, which could be inhibited by RPE-specific inactivation of Flk1, while Tlr2 inactivation strongly reduced CNV. These findings suggest a shared pathogenic role of VEGF-A-induced andNLRP3 inflammasome-mediated IL-1 activation for multiple distinct ocular aging diseases.
C1 [Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.
[Marneros, Alexander G.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
RP Marneros, AG (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.; Marneros, AG (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
EM amarneros@mgh.harvard.edu
FU NEI [R01-EY019297]; BrightFocus Foundation
FX For some technical assistance, I would like to thank Oscar Morales and
Karin Strittmatter. This work was supported by grants to A.G.M. from the
NEI (R01-EY019297) and from the BrightFocus Foundation.
NR 66
TC 1
Z9 1
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD MAR
PY 2016
VL 8
IS 3
BP 208
EP 231
PG 24
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DG5WT
UT WOS:000372151100004
PM 26912740
ER
PT J
AU Teplyuk, NM
Uhlmann, EJ
Gabriely, G
Volfovsky, N
Wang, Y
Teng, J
Karmali, P
Marcusson, E
Peter, M
Mohan, A
Kraytsberg, Y
Cialic, R
Chiocca, EA
Godlewski, J
Tannous, B
Krichevsky, AM
AF Teplyuk, Nadiya M.
Uhlmann, Erik J.
Gabriely, Galina
Volfovsky, Natalia
Wang, Yang
Teng, Jian
Karmali, Priya
Marcusson, Eric
Peter, Merlene
Mohan, Athul
Kraytsberg, Yevgenya
Cialic, Ron
Chiocca, E. Antonio
Godlewski, Jakub
Tannous, Bakhos
Krichevsky, Anna M.
TI Therapeutic potential of targeting microRNA-10b in established
intracranial glioblastoma: first steps toward the clinic
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE alternative splicing; brain tumor; microRNA; oligonucleotide
therapeutics; stem cells
ID CANCER-CELL-PROLIFERATION; PRE-MESSENGER-RNA; GENE-EXPRESSION; MIR-B-10
EXPRESSION; BRAIN-TUMORS; INVASION; GLIOMA; PROTEINS; PROMOTES;
RESISTANCE
AB MicroRNA-10b (miR-10b) is a unique oncogenic miRNA that is highly expressed in all GBM subtypes, while absent in normal neuroglial cells of the brain. miR-10b inhibition strongly impairs proliferation and survival of cultured glioma cells, including glioma-initiating stem-like cells (GSC). Although several miR-10b targets have been identified previously, the common mechanism conferring the miR-10b-sustained viability of GSC is unknown. Here, we demonstrate that in heterogeneous GSC, miR-10b regulates cell cycle and alternative splicing, often through the non-canonical targeting via 5UTRs of its target genes, including MBNL1-3, SART3, and RSRC1. We have further assessed the inhibition of miR-10b in intracranial human GSC-derived xenograft and murine GL261 allograft models in athymic and immunocompetent mice. Three delivery routes for the miR-10b antisense oligonucleotide inhibitors (ASO), direct intratumoral injections, continuous osmotic delivery, and systemic intravenous injections, have been explored. In all cases, the treatment with miR-10b ASO led to targets' derepression, and attenuated growth and progression of established intracranial GBM. No significant systemic toxicity was observed upon ASO administration by local or systemic routes. Our results indicate that miR-10b is a promising candidate for the development of targeted therapies against all GBM subtypes.
C1 [Teplyuk, Nadiya M.; Uhlmann, Erik J.; Gabriely, Galina; Wang, Yang; Peter, Merlene; Mohan, Athul; Kraytsberg, Yevgenya; Cialic, Ron; Krichevsky, Anna M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Ann Romney Ctr Neurol Dis, Boston, MA USA.
[Volfovsky, Natalia] Simons Fdn, New York, NY USA.
[Teng, Jian; Tannous, Bakhos] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Karmali, Priya; Marcusson, Eric] Regulus Therapeut Inc, San Diego, CA USA.
[Chiocca, E. Antonio; Godlewski, Jakub] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA.
RP Krichevsky, AM (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Ann Romney Ctr Neurol Dis, Boston, MA USA.
EM akrichevsky@rics.bwh.harvard.edu
OI Cialic, Ron/0000-0002-1589-2262
FU NIH/NCI [RO1CA138734]; Sontag Foundation; National Brain Tumor Society;
Brain Science Foundation
FX This work was supported by grants from NIH/NCI (RO1CA138734), Sontag
Foundation Distinguished Scientist Award, and National Brain Tumor
Society (to AMK), and Brain Science Foundation (to NT, AMK, and EJU). We
thank Anant Jain, Deeptha Vasudevan, and Meenakshi Basu for technical
assistance, Dr. Oleg Butovsky for assistance with IPA analysis, and Dr.
Vivek Kaimal for assistance with microarray analysis. We thank Regulus
Therapeutics, Inc., for providing miRNA inhibitors and antibody
recognizing the ASO. We also thank Dr. Hiroaki Wakamoto for providing
human GBM stem cells, Dr. Bozena Kaminska for mouse GL261 cells, and Dr.
Glenn Morris for sharing the anti-MBNL2 antibody.
NR 68
TC 8
Z9 9
U1 7
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD MAR
PY 2016
VL 8
IS 3
BP 268
EP 287
PG 20
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DG5WT
UT WOS:000372151100007
PM 26881967
ER
PT J
AU Brown, HE
Roffman, JL
AF Brown, Hannah E.
Roffman, Joshua L.
TI Emerging Treatments in Schizophrenia: Highlights from Recent
Supplementation and Prevention Trials
SO HARVARD REVIEW OF PSYCHIATRY
LA English
DT Article
ID PLACEBO-CONTROLLED-TRIAL; ETHYL-EICOSAPENTAENOIC ACID; VITAMIN-D
DEFICIENCY; ADD-ON THERAPY; DOUBLE-BLIND; NEGATIVE SYMPTOMS; FATTY-ACID;
CELECOXIB AUGMENTATION; STABLE SCHIZOPHRENIA; ADJUNCTIVE THERAPY
C1 [Brown, Hannah E.] Harvard Univ, Sch Med, Boston, MA USA.
[Brown, Hannah E.] Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA.
[Roffman, Joshua L.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
RP Brown, HE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA.
EM hebrown@partners.org
FU Pamlab
FX Dr. Roffman has previously received a research grant from Pamlab.
NR 61
TC 1
Z9 1
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1067-3229
EI 1465-7309
J9 HARVARD REV PSYCHIAT
JI Harv. Rev. Psychiatr.
PD MAR-APR
PY 2016
VL 24
IS 2
BP e1
EP e7
PG 7
WC Psychiatry
SC Psychiatry
GA DG5CQ
UT WOS:000372090900001
PM 26954600
ER
PT J
AU Hsu, J
Price, M
Spirt, J
Vogeli, C
Brand, R
Chernew, ME
Chaguturu, SK
Mohta, N
Weil, E
Ferris, T
AF Hsu, John
Price, Mary
Spirt, Jenna
Vogeli, Christine
Brand, Richard
Chernew, Michael E.
Chaguturu, Sreekanth K.
Mohta, Namita
Weil, Eric
Ferris, Timothy
TI Patient Population Loss At A Large Pioneer Accountable Care Organization
And Implications For Refining The Program
SO HEALTH AFFAIRS
LA English
DT Article
ID SHARED SAVINGS PROGRAM; HEALTH-CARE; MEDICARE; PERFORMANCE; PATTERNS;
RULES; ACOS
AB There is an ongoing move toward payment models that hold providers increasingly accountable for the care of their patients. The success of these new models depends in part on the stability of patient populations. We investigated the amount of population turnover in a large Medicare Pioneer accountable care organization (ACO) in the period 2012-14. We found that substantial numbers of beneficiaries became part of or left the ACO population during that period. For example, nearly one-third of beneficiaries who entered in 2012 left before 2014. Some of this turnover reflected that of ACO physicians-that is, beneficiaries whose physicians left the ACO were more likely to leave than those whose physicians remained. Some of the turnover also reflected changes in care delivery. For example, beneficiaries who were active in a care management program were less likely to leave the ACO than similar beneficiaries who had not yet started such a program. We recommend policy changes to increase the stability of ACO beneficiary populations, such as permitting lower cost sharing for care received within an ACO and requiring all beneficiaries to identify their primary care physician before being linked to an ACO.
C1 [Hsu, John] Massachusetts Gen Hosp, Mongan Inst, Clin Econ & Policy Anal Program, Boston, MA 02114 USA.
[Hsu, John] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Hsu, John; Chernew, Michael E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Price, Mary; Spirt, Jenna; Vogeli, Christine] Massachusetts Gen Hosp, Mongan Inst, Boston, MA 02114 USA.
[Brand, Richard] Univ Calif San Francisco, Biostat, San Francisco, CA 94143 USA.
[Chaguturu, Sreekanth K.; Weil, Eric; Ferris, Timothy] Partners HealthCare, Populat Hlth, Boston, MA USA.
[Chaguturu, Sreekanth K.; Ferris, Timothy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chaguturu, Sreekanth K.] Harvard Univ, Sch Med, Med, Boston, MA USA.
[Mohta, Namita] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Weil, Eric] Massachusetts Gen Phys Org, Boston, MA USA.
[Weil, Eric] Massachusetts Gen Hosp, Div Gen Internal Med, Clin Affairs, Boston, MA 02114 USA.
[Ferris, Timothy] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA.
[Ferris, Timothy] Harvard Univ, Sch Med, Boston, MA USA.
RP Hsu, J (reprint author), Massachusetts Gen Hosp, Mongan Inst, Clin Econ & Policy Anal Program, Boston, MA 02114 USA.; Hsu, J (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA USA.; Hsu, J (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
EM jhsu2000@gmail.com
FU National Institute on Aging [P01AG032952]
FX An earlier version of this article was presented at the biennial
conference of the International Health Economics Association, Milan,
Italy, July 2015. Funding was provided by the National Institute on
Aging (Grant No. P01AG032952).
NR 34
TC 1
Z9 1
U1 2
U2 4
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD MAR
PY 2016
VL 35
IS 3
BP 422
EP 430
DI 10.1377/hlthaff.2015.0805
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DG1KA
UT WOS:000371825000009
PM 26953296
ER
PT J
AU Hogarth, MW
Garton, FC
Houweling, PJ
Tukiainen, T
Lek, M
Macarthur, DG
Seto, JT
Quinlan, KGR
Yang, N
Head, SI
North, KN
AF Hogarth, Marshall W.
Garton, Fleur C.
Houweling, Peter J.
Tukiainen, Taru
Lek, Monkol
Macarthur, Daniel G.
Seto, Jane T.
Quinlan, Kate G. R.
Yang, Nan
Head, Stewart I.
North, Kathryn N.
TI Analysis of the ACTN3 heterozygous genotype suggests that
alpha-actinin-3 controls sarcomeric composition and muscle function in a
dose-dependent fashion
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SKELETAL-MUSCLE; ATHLETIC PERFORMANCE; R577X POLYMORPHISM; GENE
DUPLICATION; KNOCKOUT MOUSE; FIBER TYPES; DEFICIENCY; EXPRESSION; WOMEN;
PROTEINS
AB A common null polymorphism (R577X) in ACTN3 causes alpha-actinin-3 deficiency in similar to 18% of the global population. There is no associated disease phenotype, but alpha-actinin-3 deficiency is detrimental to sprint and power performance in both elite athletes and the general population. However, despite considerable investigation to date, the functional consequences of heterozygosity for ACTN3 are unclear. A subset of studies have shown an intermediate phenotype in 577RX individuals, suggesting dose-dependency of alpha-actinin-3, while others have shown no difference between 577RR and RX genotypes. Here, we investigate the effects of alpha-actinin-3 expression level by comparing the muscle phenotypes of Actn(3+/-) (HET) mice to Actn(3+/+) [wild-type (WT)] and Actn3(-/-) [knockout (KO)] littermates. We show reduction in alpha-actinin-3 mRNA and protein in HET muscle compared with WT, which is associated with dose-dependent up-regulation of alpha-actinin-2, z-band alternatively spliced PDZ-motif and myotilin at the Z-line, and an incremental shift towards oxidative metabolism. While there is no difference in force generation, HET mice have an intermediate endurance capacity compared with WT and KO. The R577X polymorphism is associated with changes in ACTN3 expression consistent with an additive model in the human genotype-tissue expression cohort, but does not influence any other muscle transcripts, including ACTN2. Overall, ACTN3 influences sarcomeric composition in a dose-dependent fashion in mouse skeletal muscle, which translates directly to function. Variance in fibre type between biopsies likely masks this phenomenon in human skeletal muscle, but we suggest that an additive model is the most appropriate for use in testing ACTN3 genotype associations.
C1 [Hogarth, Marshall W.; Garton, Fleur C.; Houweling, Peter J.; Quinlan, Kate G. R.; Yang, Nan; North, Kathryn N.] Childrens Hosp Westmead, Inst Neurosci & Muscle Res, Sydney, NSW 2145, Australia.
[Hogarth, Marshall W.; Garton, Fleur C.; Houweling, Peter J.; Quinlan, Kate G. R.; North, Kathryn N.] Univ Sydney, Discipline Paediat & Child Hlth, Fac Med, Sydney, NSW 2006, Australia.
[Garton, Fleur C.; Houweling, Peter J.; Seto, Jane T.; North, Kathryn N.] Murdoch Childrens Res Inst, Melbourne, Vic 3052, Australia.
[Garton, Fleur C.; Houweling, Peter J.; Seto, Jane T.; North, Kathryn N.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
[Tukiainen, Taru; Lek, Monkol; Macarthur, Daniel G.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Tukiainen, Taru; Lek, Monkol; Macarthur, Daniel G.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Head, Stewart I.] Univ New S Wales, Sch Med Sci, Sydney, NSW 2052, Australia.
RP North, KN (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.
EM kathryn.north@mcri.edu.au
RI Garton, Fleur/H-7713-2016; North, Kathryn/K-6476-2012; Houweling,
Peter/B-4157-2016
OI Garton, Fleur/0000-0002-1490-5930; North, Kathryn/0000-0003-0841-8009;
Houweling, Peter/0000-0001-6132-2554
FU National Health and Medical Research Council of Australia [1002033,
1062500]; Common Fund of the Office of the Director of the National
Institutes of Health; GTEx Laboratory, Data Analysis, and Coordinating
Center (LDACC) [HHSN268201000029C]; National Institute of General
Medical Sciences (NIGMS) of the National Institutes of Health
[R01GM104371]
FX This project was funded by grants from the National Health and Medical
Research Council of Australia (1002033 and 1062500). The Genotype-Tissue
Expression (GTEx) Project was supported by the Common Fund of the Office
of the Director of the National Institutes of Health. The work by TT and
DGM was partially funded by the GTEx Laboratory, Data Analysis, and
Coordinating Center (LDACC) contract (HHSN268201000029C) to The Broad
Institute, Inc. The work by M.L. and D.G.M. was partially funded by the
National Institute of General Medical Sciences (NIGMS) of the National
Institutes of Health, under award R01GM104371. The funders had no role
in study design, data collection and analysis, decision to publish or
preparation of the manuscript.
NR 39
TC 2
Z9 2
U1 6
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAR 1
PY 2016
VL 25
IS 5
BP 866
EP 877
DI 10.1093/hmg/ddv613
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DG5XA
UT WOS:000372152400003
PM 26681802
ER
PT J
AU Richards, AL
Leonenko, G
Walters, JT
Kavanagh, DH
Rees, EG
Evans, A
Chambert, KD
Moran, JL
Goldstein, J
Neale, BM
McCarroll, SA
Pocklington, AJ
Holmans, PA
Owen, MJ
O'Donovan, MC
AF Richards, A. L.
Leonenko, G.
Walters, J. T.
Kavanagh, D. H.
Rees, E. G.
Evans, A.
Chambert, K. D.
Moran, J. L.
Goldstein, J.
Neale, B. M.
McCarroll, S. A.
Pocklington, A. J.
Holmans, P. A.
Owen, M. J.
O'Donovan, M. C.
TI Exome arrays capture polygenic rare variant contributions to
schizophrenia
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; DE-NOVO MUTATIONS; GENE ONTOLOGY; LOCI;
HERITABILITY; DATABASE; DISEASE; BIOLOGY; LINKAGE; PANTHER
AB Schizophrenia is a highly heritable disorder. Genome-wide association studies based largely on commonalleles have identified over 100 schizophrenia risk loci, but it is also evident from studies of copy number variants (CNVs) and from exome-sequencing studies that rare alleles are also involved. Full characterization of the contribution of rare alleles to the disorder awaits the deployment of sequencing technology in very large sample sizes, meanwhile, as an interim measure, exome arrays allow rare non-synonymous variants to be sampled at a fraction of the cost. In an analysis of exome array data from 13 688 individuals (5585 cases and 8103 controls) from the UK, we found that rare (minor allele frequency <0.1%) variant association signal was enriched among genes that map to autosomal loci that are genome-wide significant (GWS) in common variant studies of schizophrenia genome-wide association study (P-GWAS = 0.01) as well as gene sets known to be enriched for rare variants in sequencing studies (P-RARE = 0.026). We also identified the gene-wise equivalent of GWS support for WDR88 (WD repeat-containing protein 88), a gene of unknown function (P = 6.5 x 10(-7)). Rare alleles represented on exome chip arrays contribute to the genetic architecture of schizophrenia, but as is the case for GWAS, very large studies are required to reveal additional susceptibility alleles for the disorder.
C1 [Richards, A. L.; Leonenko, G.; Walters, J. T.; Kavanagh, D. H.; Rees, E. G.; Evans, A.; Pocklington, A. J.; Holmans, P. A.; Owen, M. J.; O'Donovan, M. C.] Cardiff Univ, Sch Med, Inst Psychol Med & Clin Neurosci, MRC,Ctr Neuropsychiat Genet & Genom, Hadyn Ellis Bldg, Cardiff CF24 4HQ, S Glam, Wales.
[Kavanagh, D. H.] Icahn Sch Med Mt Sinai, 1468 Madison Ave, New York, NY 10029 USA.
[Chambert, K. D.; Moran, J. L.; Goldstein, J.; Neale, B. M.; McCarroll, S. A.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Neale, B. M.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
RP O'Donovan, MC (reprint author), Cardiff Univ, Sch Med, Inst Psychol Med & Clin Neurosci, MRC,Ctr Neuropsychiat Genet & Genom, Hadyn Ellis Bldg, Cardiff CF24 4HQ, S Glam, Wales.
EM odonovanmc@cardiff.ac.uk
OI Moran, Jennifer/0000-0002-5664-4716; Walters, James/0000-0002-6980-4053;
Holmans, Peter/0000-0003-0870-9412
FU Medical Research Council (MRC) [G0800509, G0801418]; European Community
[HEALTH-F2-2010-241909]; philanthropic gift; Cardiff University for RCUK
FX The work at Cardiff University was funded by Medical Research Council
(MRC) Centre (G0800509) and Program Grants (G0801418), the European
Community's Seventh Framework Programme [HEALTH-F2-2010-241909 (Project
EU-GEI)]. Genotyping at the Broad Institute was funded by a
philanthropic gift to the Stanley Center for Psychiatric Research.
Funding to pay the Open Access publication charges for this article was
provided by funds held within Cardiff University for RCUK funded
projects.
NR 44
TC 3
Z9 3
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAR 1
PY 2016
VL 25
IS 5
BP 1001
EP 1007
DI 10.1093/hmg/ddv620
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DG5XA
UT WOS:000372152400014
PM 26740555
ER
PT J
AU Nyholm, AM
Palm, H
Malchau, H
Troelsen, A
Gromov, K
AF Nyholm, Anne Marie
Palm, Henrik
Malchau, Henrik
Troelsen, Anders
Gromov, Kirill
TI Lacking evidence for performance of implants used for proximal femoral
fractures - A systematic review
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Review
DE Hip fracture; Proximal femoral fracture; Trochanteric fracture; Implant
survival; Implant failure; Reoperation
ID DYNAMIC HIP SCREW; UNSTABLE INTERTROCHANTERIC FRACTURES;
QUALITY-OF-LIFE; PERCUTANEOUS COMPRESSION PLATE; GAMMA LOCKING NAIL;
TROCHANTERIC FRACTURES; INTRAMEDULLARY NAIL; INTERNAL-FIXATION; NECK
FRACTURES; PERTROCHANTERIC FRACTURES
AB Introduction: Evaluation of the long-term performance of implants used in trauma surgery relies on post-marked clinical studies since no registry based implant assessment exists. The purpose of this study was to evaluate the evidence of performance of implants currently used for treating proximal femoral fractures (PFF) in Denmark.
Method: PubMed was searched for clinical studies on primary PFF with follow-up >= 12 months, reporting implant-related failure and evaluating one of following: DHS, CHS, HipLoc, Gamma3, IMHS, InterTan, PFN, PFNA or PTN. Limits: English language and publication date after 1st of January 1990.
Results: All studies were evidence level II or III. 30 publications for SHS were found: 13 of CHS, 15 of DHS and 2 of HipLoc. In total CHS was evaluated in 1110 patients (900 prospectively), DHS in 2486 (567 prospectively) and HipLoc in 251 (all prospectively). Fifty-four publications for nails were found: 13 of Gamma3, 7 of IMHS, 5 of InterTan, 10 of PFN, 24 of PFNA and 0 of PTN. In total Gamma3 was evaluated in 1088 patients (829 prospectively), IMHS in 1543 (210 prospectively), InterTan in 595 (585 prospectively), PFN in 716 (557 prospectively), PFNA in 1762 (1018 prospectively) and PTN in 0.
Conclusions: The clinical evidence behind the current implants used for proximal femoral fractures is weak considering the number of implants used worldwide. Sporadic evaluation is not sufficient to identify long term problems. A systematic post market surveillance of implants used for fracture treatment, preferable by a national register, is necessary in the future. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Nyholm, Anne Marie; Palm, Henrik; Troelsen, Anders; Gromov, Kirill] Univ Copenhagen, Hvidovre Hosp, Dept Orthopaed, Clin Orthopaed Res Hvidovre, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.
[Malchau, Henrik] Massachusetts Gen Hosp, Dept Orthoped, 55 Fruit St,GRJ 1126, Boston, MA 02114 USA.
RP Nyholm, AM (reprint author), Univ Copenhagen, Hvidovre Hosp, Dept Orthopaed, Clin Orthopaed Res Hvidovre, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.
EM rienyholm@gmail.com
NR 96
TC 0
Z9 0
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
EI 1879-0267
J9 INJURY
JI Injury-Int. J. Care Inj.
PD MAR
PY 2016
VL 47
IS 3
BP 586
EP 594
DI 10.1016/j.injury.2016.01.001
PG 9
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA DG3RV
UT WOS:000371988400011
PM 26803696
ER
PT J
AU Gill, A
Mellema, JJ
Menendez, ME
Ring, D
AF Gill, Aditya
Mellema, Jos J.
Menendez, Mariano E.
Ring, David
TI Articular osteotomy of the distal humerus and excision of extensive
heterotopic ossification
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Distal humeral fracture; Elbow; Intra-articular malunion; Heterotopic
ossification; Ankylosis; Osteotomy
ID RISK-FACTORS; ELBOW; RELEASE; FRACTURES; ANKYLOSIS
AB Prior case series of corrective osteotomy of substantial intra-articular malunion after a fracture of the distal humerus described concomitant heterotopic ossification in a subset of patient, but only in mild forms. We present our experience in treating two patients with malunited articular fractures of the distal humerus with extensive heterotopic ossification and near ankylosis where the lateral articular fragments were encased in heterotopic bone. Although osteotomy of articular malunion after distal humeral fracture along with excision of extensive HO is challenging and risky due to potential devitalization of the fragments, articular deterioration during the delay to osteotomy, and recurrence of heterotopic bone among other concerns, restoring articular congruity in these patients using articular fracture fragments extracted from heterotopic ossification can lead to improved function of the elbow. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Gill, Aditya; Mellema, Jos J.; Menendez, Mariano E.] Harvard Univ, Sch Med, Hand & Upper Extrem Serv, Dept Orthopaed Surg,Massachusetts Gen Hosp,Yawkey, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
[Ring, David] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Chief Hand Surg,Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
RP Ring, D (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Chief Hand Surg,Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM agill2@mgh.harvard.edu; jmellema@mgh.harvard.edu;
memenendez@partners.org; dring@mgh.harvard.edu
OI Ring, David/0000-0002-6506-4879
NR 14
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
EI 1879-0267
J9 INJURY
JI Injury-Int. J. Care Inj.
PD MAR
PY 2016
VL 47
IS 3
BP 776
EP 779
DI 10.1016/j.injury.2015.12.030
PG 4
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA DG3RV
UT WOS:000371988400044
PM 26854073
ER
PT J
AU Liu, XD
Li, JS
Hosseini, A
Gill, TJ
Li, GA
AF Liu, Xudong
Li, Jing-Sheng
Hosseini, Ali
Gill, Thomas J.
Li, Guoan
TI Anteromedial and posterolateral graft kinematics of a double-bundle ACL
reconstruction: a 3D computer simulation
SO INTERNATIONAL JOURNAL OF MEDICAL ROBOTICS AND COMPUTER ASSISTED SURGERY
LA English
DT Article
DE ACL; double-bundle ACL reconstruction; anatomical ACL reconstruction
ID ANTERIOR CRUCIATE LIGAMENT; ARTHROSCOPIC EVALUATION; SINGLE-BUNDLE;
JOINT; LENGTH; TUNNEL
AB BackgroundThe posterolateral graft has been reported to fail more frequently than the anteromedial graft in double-bundle ACL reconstructions. This study investigated the graft kinematics using a 3D modelling technique.
MethodsTwenty subjects performed a stair-ascending activity under dual fluoroscopy surveillance. A double-bundle ACL reconstruction was simulated on those healthy knees using an anteromedial portal technique. The graft-tunnel interaction was described using the graft-tunnel angle and the range of the graft-tunnel edge contact (GTEC).
ResultsThe femoral graft-tunnel angle of the anteromedial/posterolateral graft was 97.6 7.5/100.7 +/- 7.7 degrees and the tibial graft-tunnel angle was 158.8 +/- 6.5/146.5 +/- 8.9 degrees at knee extension. The femoral GTEC ranges were 23.2 +/- 5.3-28.1 +/- 7.6 degrees for both grafts and the tibial GTEC ranges were 27.3 +/- 2.2-34.5 +/- 2.1 degrees during stair-ascending.
ConclusionThe femoral graft-tunnel angle was larger than on the tibial side and the GTEC angles influenced the PL graft more, implying that grafts may experience a less optimal biomechanical environment at the femoral tunnels. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Liu, Xudong; Li, Jing-Sheng; Hosseini, Ali; Gill, Thomas J.; Li, Guoan] Harvard Univ, Sch Med, Dept Orthopaed Surg, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
[Liu, Xudong] Shanghai Jiao Tong Univ, Dept Orthopaed, Shanghai Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.
RP Li, GA (reprint author), Harvard Univ, Sch Med, Bioengn Lab, Dept Orthopaed Surg,Massachusetts Gen Hosp, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM gli1@mgh.harvard.edu
FU National Institutes of Health (NIH) [R01 AR0055612]
FX The authors gratefully acknowledge financial support from the National
Institutes of Health (NIH; Grant No. R01 AR0055612).
NR 25
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-5951
EI 1478-596X
J9 INT J MED ROBOT COMP
JI Int. J. Med. Robot. Comput. Assist. Surg.
PD MAR
PY 2016
VL 12
IS 1
BP 96
EP 101
DI 10.1002/rcs.1645
PG 6
WC Surgery
SC Surgery
GA DG8KW
UT WOS:000372333700009
PM 25644175
ER
PT J
AU McGinley, KF
Sun, XZ
Howard, LE
Aronson, WJ
Terris, MK
Kane, CJ
Amling, CL
Cooperberg, MR
Freedland, SJ
AF McGinley, Kathleen F.
Sun, Xizi
Howard, Lauren E.
Aronson, William J.
Terris, Martha K.
Kane, Christopher J.
Amling, Christopher L.
Cooperberg, Matthew R.
Freedland, Stephen J.
TI Utilization and impact of surgical technique on the performance of
pelvic lymph node dissection at radical prostatectomy: Results from the
Shared Equal Access Regional Cancer Hospital database
SO INTERNATIONAL JOURNAL OF UROLOGY
LA English
DT Article
DE lymph node excision; prostatectomy; prostatic neoplasms; quality of
health care; robotic surgical procedures
ID MEN; UPDATE
AB ObjectiveTo evaluate performance of pelvic lymph node dissection during radical prostatectomy within an equal access care setting over a period of time, and stratified by prostate cancer risk group and surgical technique.
MethodsWe identified men in the Shared Equal Access Regional Cancer Hospital database who had open or robotic-assisted radical prostatectomy from 2006 to 2013. Univariable logistic regression was used to test the association between age, race, body mass index, total biopsy cores, number of positive biopsy cores, risk group, year, center, surgical volume and surgical technique on pelvic lymph node dissection use. Multivariable logistic analysis was used to examine surgical technique and pelvic lymph node dissection performance. Spearman's correlation examined temporal changes in pelvic lymph node dissection utilization stratified by risk group and surgical technique.
ResultsA total of 1425 men met inclusion criteria; 67% of them underwent pelvic lymph node dissection. On multivariable analysis, robotic-assisted radical prostatectomy was associated with an 92% decreased use of pelvic lymph node dissection in low-risk, 84% decreased in intermediate-risk and 91% decreased in high-risk men (all P < 0.001). In robotic-assisted radical prostatectomy, there was a trend for increased pelvic lymph node dissection utilization over time in high-risk men (Spearman; P = 0.077) reaching similar to 85% in 2012-2013, which was accompanied by increased use in low-risk men (P = 0.016). For open radical prostatectomy, fewer pelvic lymph node dissections were carried out in low-risk men over time, decreasing to similar to 35% (P = 0.047) in 2012-2013, whereas rates remained high for high-risk men throughout (similar to 95%; P = 0.621).
ConclusionRegardless of risk group, pelvic lymph node dissection is carried out significantly less during robotic-assisted radical prostatectomy. For robotic-assisted radical prostatectomy, pelvic lymph node dissection utilization increased over time for high-risk men, but rates also increased for low-risk men. Further attention to the discrepancy between provided and guideline recommended pelvic lymph node dissection performance is required to improve prostate cancer care.
C1 [McGinley, Kathleen F.] Duke Univ, Dept Surg, Div Urol, Durham, NC USA.
[McGinley, Kathleen F.; Sun, Xizi; Howard, Lauren E.; Freedland, Stephen J.] Vet Affairs Med Ctr, Dept Surg, Div Urol, Durham, NC USA.
[Sun, Xizi; Howard, Lauren E.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA.
[Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Georgia Regents Univ, Dept Urol, Augusta, GA USA.
[Kane, Christopher J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR 97201 USA.
[Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA.
[Freedland, Stephen J.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA.
RP Freedland, SJ (reprint author), Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA.
EM stephen.freedland@cshs.org
NR 21
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-8172
EI 1442-2042
J9 INT J UROL
JI Int. J. Urol.
PD MAR
PY 2016
VL 23
IS 3
BP 241
EP 246
DI 10.1111/iju.13027
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA DG5YH
UT WOS:000372157100011
PM 26667212
ER
PT J
AU Hadlock, T
AF Hadlock, Tessa
TI Standard Outcome Measures in Facial Paralysis Getting on the Same Page
SO JAMA FACIAL PLASTIC SURGERY
LA English
DT Editorial Material
ID MANAGEMENT
C1 [Hadlock, Tessa] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Div Facial Plast & Reconstruct Surg, 243 Charles St, Boston, MA 02114 USA.
RP Hadlock, T (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Div Facial Plast & Reconstruct Surg, 243 Charles St, Boston, MA 02114 USA.
EM tessa_hadlock@meei.harvard.edu
NR 7
TC 2
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6076
EI 2168-6092
J9 JAMA FACIAL PLAST SU
JI JAMA Facial Plast. Surg.
PD MAR-APR
PY 2016
VL 18
IS 2
BP 85
EP 86
DI 10.1001/jamafacial.2015.2095
PG 2
WC Surgery
SC Surgery
GA DG5XF
UT WOS:000372153100001
PM 26746124
ER
PT J
AU Tjoa, T
Manuel, CT
Leary, RP
Harb, R
Protsenko, DE
Wong, BJF
AF Tjoa, Tjoson
Manuel, Cyrus T.
Leary, Ryan P.
Harb, Rani
Protsenko, Dmitriy E.
Wong, Brian J. F.
TI A Finite Element Model to Simulate Formation of the Inverted-V Deformity
SO JAMA FACIAL PLASTIC SURGERY
LA English
DT Article
ID COMPUTATIONAL FLUID-DYNAMICS; NASAL TIP SUPPORT; REVISION RHINOPLASTY;
CARTILAGE; EAR; BIOMECHANICS; MANAGEMENT; REDUCTION; SURGERY; SEPTUM
AB IMPORTANCE Computational modeling can be used to mimic the forces acting on the nasal framework that lead to the inverted-V deformity (IVD) after surgery and potentially determine long-range outcomes.
OBJECTIVE To demonstrate the use of the finite element method (FEM) to predict the formation of the IVD after separation of the upper lateral cartilages (ULCs) from the nasal septum.
DESIGN, SETTING, AND PARTICIPANTS A computer model of a nose was derived from human computed tomographic data. The septum and upper and lower lateral cartilages were designed to fit within the soft-tissue envelope using computer-aided design software. Mechanical properties were obtained from the literature. The 3 simulations created included (1) partial fusion of the ULCs to the septum, (2) separation of the ULCs from the septum, and (3) a fully connected model to serve as a control. Forces caused by wound healing were prescribed at the junction of the disarticulated ULCs and septum. Using FEM software, equilibrium stress and strain were calculated. Displacement of the soft tissue along the nasal dorsum was measured and evaluated for evidence of morphologic change consistent with the IVD.
MAIN OUTCOME AND MEASURES Morphologic changes on the computer models in response to each simulation.
RESULTS When a posteroinferior force vector was applied along the nasal dorsum, the areas of highest stress were along the medial edge of the ULCs and at the junction of the ULCs and the nasal bones. With full detachment of ULCs and the dorsal septum, the characteristic IVD was observed. Both separation FEMs produced a peak depression of 0.3mm along the nasal dorsum.
CONCLUSIONS AND RELEVANCE The FEM can be used to simulate the long-term structural complications of a surgical maneuver in rhinoplasty, such as the IVD. When applied to other rhinoplasty maneuvers, the use of FEMs may be useful to simulate the long-term outcomes, particularly when long-term clinical results are not available. In the future, use of FEMs may simulate rhinoplasty results beyond simply morphing the outer contours of the nose and allow estimation of potentially long-term clinical outcomes that may not be readily apparent.
C1 [Tjoa, Tjoson] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
[Manuel, Cyrus T.; Leary, Ryan P.; Harb, Rani; Protsenko, Dmitriy E.; Wong, Brian J. F.] Univ Calif Irvine, Beckman Laser Inst, 101 City Dr S,Bldg 56, Orange, CA 92868 USA.
[Wong, Brian J. F.] Univ Calif Irvine, Dept Otolaryngol, Orange, CA 92868 USA.
RP Wong, BJF (reprint author), Univ Calif Irvine, Beckman Laser Inst, 101 City Dr S,Bldg 56, Orange, CA 92868 USA.
EM bjwong@uci.edu
FU National Institutes of Health [R21DE019026-01A2]; US Department of
Defense [DR090349]; National Center for Advancing Translational Sciences
[UL1 TR000153]
FX This study was supported by grant R21DE019026-01A2 from the National
Institutes of Health; by grant DR090349 from the US Department of
Defense; and by grant UL1 TR000153 from the National Center for
Advancing Translational Sciences.
NR 34
TC 1
Z9 1
U1 10
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6076
EI 2168-6092
J9 JAMA FACIAL PLAST SU
JI JAMA Facial Plast. Surg.
PD MAR-APR
PY 2016
VL 18
IS 2
BP 136
EP 143
DI 10.1001/jamafacial.2015.1954
PG 8
WC Surgery
SC Surgery
GA DG5XF
UT WOS:000372153100013
PM 26720757
ER
PT J
AU Yee, CS
Massaad, MJ
Bainter, W
Ohsumi, TK
Foger, N
Chan, AC
Akarsu, NA
Aytekin, C
Ayvaz, DC
Tezcan, I
Sanal, O
Geha, RS
Chou, J
AF Yee, Christina S.
Massaad, Michel J.
Bainter, Wayne
Ohsumi, Toshiro K.
Foeger, Niko
Chan, Andrew C.
Akarsu, Nurten A.
Aytekin, Caner
Ayvaz, Deniz Cagdas
Tezcan, Ilhan
Sanal, Ozden
Geha, Raif S.
Chou, Janet
TI Recurrent viral infections associated with a homozygous CORO1A mutation
that disrupts oligomerization and cytoskeletal association
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Coronin-1A; immunodeficiency; T-cell lymphopenia
ID SEVERE COMBINED IMMUNODEFICIENCY; HEALTHY-CHILDREN; CORONIN 1A; ACTIN;
PROTEIN; DEFICIENCY; ACTIVATION; SURVIVAL; SERUM; MYCOBACTERIA
AB Background: Coronin-1A (CORO1A) is a regulator of actin dynamics important for T-cell homeostasis. CORO1A deficiency causes T-B+ natural killer-positive severe combined immunodeficiency or T-cell lymphopenia with severe viral infections. However, because all known human mutations in CORO1A abrogate protein expression, the role of the protein's functional domains in host immunity is unknown.
Objective: We sought to identify the cause of the primary immunodeficiency in 2 young adult siblings with a history of disseminated varicella, cutaneous warts, and CD4(+) T-cell lymphopenia.
Methods: We performed immunologic, genetic, and biochemical studies in the patients, family members, and healthy control subjects.
Results: Both patients had CD4(+) T-cell lymphopenia and decreased lymphocyte proliferation to mitogens. IgG, IgM, IgA, and specific antibody responses were normal. Whole-genome sequencing identified a homozygous frameshift mutation in CORO1A disrupting the last 2 C-terminal domains by replacing 61 amino acids with a novel 91-amino-acid sequence. The CORO1A(S401fs) mutant was expressed in the patients' lymphocytes at a level comparable with that of wild-type CORO1A in normal lymphocytes but did not oligomerize and had impaired cytoskeletal association. CORO1A(S401fs) was associated with increased filamentous actin accumulation in T cells, severely defective thymic output, and impaired T-cell survival but normal calcium flux and cytotoxicity, demonstrating the importance of CORO1A oligomerization and subcellular localization in T-cell homeostasis.
Conclusions: We describe a truncating mutation in CORO1A that permits protein expression and survival into young adulthood. Our studies demonstrate the importance of intact CORO1A C-terminal domains in thymic egress and T-cell survival, as well as in defense against viral pathogens.
C1 [Yee, Christina S.; Massaad, Michel J.; Bainter, Wayne; Geha, Raif S.; Chou, Janet] Boston Childrens Hosp, Div Immunol, Boston, MA USA.
[Yee, Christina S.; Massaad, Michel J.; Bainter, Wayne; Geha, Raif S.; Chou, Janet] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Ohsumi, Toshiro K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Ohsumi, Toshiro K.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Chan, Andrew C.] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.
[Akarsu, Nurten A.] Hacettepe Univ, Fac Med, Dept Med Genet, TR-06100 Ankara, Turkey.
[Aytekin, Caner] Dr Sami Ulus Childrens Hlth & Dis Training & Res, Ankara, Turkey.
[Ayvaz, Deniz Cagdas; Tezcan, Ilhan; Sanal, Ozden] Hacettepe Univ, Ankara, Turkey.
[Ayvaz, Deniz Cagdas; Tezcan, Ilhan; Sanal, Ozden] Ihsan Dogramaci Childrens Hosp, Ankara, Turkey.
RP Geha, RS (reprint author), Boston Childrens Hosp, Div Immunol, Boston, MA USA.; Geha, RS (reprint author), Childrens Hosp, Div Immunol, Karp Bldg,10th Floor,1 Blackfan Circle, Boston, MA 02115 USA.
EM Raif.Geha@childrens.harvard.edu
RI Bayram, Cem/D-7403-2013
OI Bayram, Cem/0000-0001-8717-4668
FU National Institutes of Health [P01AI-076210, AI-094017, T32
AI-007512-26]; Dubai-Harvard Foundation for Medical Research; Perkins
Fund; Jeffrey Modell Foundation; Hacettepe Scientific Research Projects
Unit (BAP) [010-01-101-010]
FX Supported by National Institutes of Health grants P01AI-076210 (to
R.S.G.), AI-094017 (to R.S.G.), and T32 AI-007512-26 (to C.S.Y.); the
Dubai-Harvard Foundation for Medical Research (to R.S.G.); the Perkins
Fund (to R.S.G); a Jeffrey Modell Foundation Translational Research
Program Grant Award (to J.C.); and the Hacettepe Scientific Research
Projects Unit (BAP) Project 010-01-101-010 (to N.A.A., D.C.A., I.T., and
O.S.).
NR 35
TC 1
Z9 1
U1 1
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD MAR
PY 2016
VL 137
IS 3
BP 879
EP +
DI 10.1016/j.jaci.2015.08.020
PG 12
WC Allergy; Immunology
SC Allergy; Immunology
GA DG2LB
UT WOS:000371897500032
PM 26476480
ER
PT J
AU Tahhan, AS
Vaduganathan, M
Kelkar, A
Georgiopoulou, VV
Kalogeropoulos, AP
Greene, SJ
Fonarow, GC
Gheorghiade, M
Butler, J
AF Tahhan, Ayman Samman
Vaduganathan, Muthiah
Kelkar, Anita
Georgiopoulou, Vasiliki V.
Kalogeropoulos, Andreas P.
Greene, Stephen J.
Fonarow, Gregg C.
Gheorghiade, Mihai
Butler, Javed
TI Trends in Heart Failure Clinical Trials From 2001-2012
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Clinical trials; heart failure; outcomes; temporal trends
ID DRUG TRIALS; RECRUITMENT; OUTCOMES; CLINICALTRIALS.GOV; GLOBALIZATION;
RETENTION; INSIGHTS
AB Background: A systematic assessment of the temporal trends in heart failure (HF) clinical trials is lacking.
Methods and Results: A total of 154 phase II-IV HF trials including 162,725 patients published from 2001 to 2012 in 8 high-impact-factor journals were reviewed. The median number of participants and sites per trial were 367 (interquartile range [IQR] 133-1450) and 38 (5-101), respectively. Median enrollment duration was 2.2 (1.5-3.3) years. The majority of studies investigated treatment for chronic HF (82.5%) and investigated HF with reduced ejection fraction (EF) (71.4%), whereas 27 trials (17.5%) enrolled patients with mixed EF and 9 (5.8%) enrolled HF with preserved EF patients alone. Enrollment rates did not significantly change over time (median 0.49 patients site(-1) month(-1), IQR 0.34-0.98; P = .53). Trials meeting their primary end point decreased over time from 73.5% in 2001-2003 to 52.5% in 2010-2012 (P = .08) and were more often smaller and used nonmortality end points. Industry trials were larger with shorter enrollment duration, more concentrated in North America, and more likely to be positive. Trials conducted exclusively outside North America and Western Europe had the highest enrollment rates (median 1.95 patients site(-1) month(-1), IQR 1.34-4.11).
Conclusions: Contemporary HF clinical trials display slow enrollment rates and decreased rates of positive outcomes over time. Positive trials tended to be smaller size with a higher proportion of surrogate end points.
C1 [Tahhan, Ayman Samman; Kelkar, Anita; Georgiopoulou, Vasiliki V.; Kalogeropoulos, Andreas P.] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA.
[Vaduganathan, Muthiah] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
[Greene, Stephen J.; Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
[Butler, Javed] SUNY Stony Brook, Div Cardiol, Stony Brook, NY 11794 USA.
RP Butler, J (reprint author), SUNY Stony Brook, Hlth Sci Ctr, Div Cardiol, T-16,Room 080, Stony Brook, NY 11794 USA.
EM javed.butler@stonybrookmedicine.edu
FU National Heart, Lung, and Blood Institute; National Institutes of
Health; European Union; Agency for Healthcare Research and Quality
FX Dr Fonarow reports significant research grants from the National Heart,
Lung, and Blood Institute and Agency for Healthcare Research and
Quality, significant consultancy support from Novartis and Takeda, and
modest consultancy support from Bayer, Gambro, Janssen, The Medicines
Company, and Medtronic. Dr Gheorghiade reports relationships with
Abbott, Astellas, Astrazeneca, Bayer, Cardiorentis, Corthera,
Cytokinetics, Cytopherx, Debiopharm, Errekappa Terapeutici,
Glaxosmithkline, Ikaria, Intersection Medical, Johnson and Johnson,
Medtronic, Merck, Novartis, Ono Pharma, Otsuka, Palatin Technologies,
Pericor Therapeutics, Protein Design, Sanofi-Aventis, Sigma Tau, Solvay,
Sticares Interact, Takeda, and Trevena. Dr Butler reports research
support from the National Institutes of Health and European Union and is
a consultant to Amgen, Bayer, BG Medicine, Celladon, Gambro, GE
Healthcare, Harvest, Medtronic, Ono Pharma, Stemedica, and Trevena. The
other authors report no relevant conflicts of interest.
NR 27
TC 2
Z9 2
U1 0
U2 1
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
EI 1532-8414
J9 J CARD FAIL
JI J. Card. Fail.
PD MAR
PY 2016
VL 22
IS 3
BP 171
EP 179
DI 10.1016/j.cardfail.2015.06.014
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG6QN
UT WOS:000372211300002
ER
PT J
AU Talab, SS
Elmi, A
Sarma, J
Barrisford, GW
Tabatabaei, S
AF Talab, Saman S.
Elmi, Azadeh
Sarma, Jaydev
Barrisford, Glen W.
Tabatabaei, Shahin
TI Safety and Effectiveness of SAF-R, a Novel Patient Positioning Device
for Robot-Assisted Pelvic Surgery in Trendelenburg Position
SO JOURNAL OF ENDOUROLOGY
LA English
DT Article
ID INJURIES
C1 [Talab, Saman S.; Elmi, Azadeh; Barrisford, Glen W.; Tabatabaei, Shahin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Urol, GRB 1102,15 Parkman St, Boston, MA 02114 USA.
[Sarma, Jaydev] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesiol, Boston, MA 02115 USA.
RP Tabatabaei, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Urol, GRB 1102,15 Parkman St, Boston, MA 02114 USA.
EM stabatabaei@mgh.harvard.edu
NR 13
TC 0
Z9 0
U1 1
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0892-7790
EI 1557-900X
J9 J ENDOUROL
JI J. Endourol.
PD MAR 1
PY 2016
VL 30
IS 3
BP 286
EP 292
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA DG2AZ
UT WOS:000371869900010
PM 26531773
ER
PT J
AU Rivlin, M
Fernandez, DL
Nagy, L
Grana, GL
Jupiter, J
AF Rivlin, Michael
Fernandez, Diego L.
Nagy, Ladislav
Lopez Grana, Gabriel
Jupiter, Jesse
TI Extensor Pollicis Longus Ruptures Following Distal Radius Osteotomy
Through a Volar Approach
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Malunion; reconstruction of the wrist; surgical risks; tendon rupture;
wrist deformity
ID FRACTURES; TENDON; FIXATION
AB Purpose To investigate the cause and pathological process of extensor pollicis longus (EPL) ruptures after correction of distal radius malunion through a volar approach.
Methods We included patients with EPL ruptures who underwent distal radius osteotomies performed through a volar approach. Data were pooled from members of the International Wrist Investigators Workshop. Patient demographics, initial injury parameters, imaging studies, preoperative and postoperative examination, intraoperative findings, surgical technique, and outcomes were compared and analyzed. Preoperative and postoperative radiographic images were evaluated and compared.
Results We evaluated 6 cases from 5 surgeons in 4 institutions. Length of follow-up ranged from 1 to 5 years. On initial radiographic evaluation all malunions were healed with dorsal angulation (20 degrees to 60 degrees) and with positive ulnar variance. Deformity correction in the sagittal plane was 25 degrees to 55 degrees. Osteotomies were fixed with volar locking plates with autologous bone graft except for one patient who received calcium phosphate-based bone void filler. Postoperative x-rays suggested prominent osteotomy resection edges, osteophytes, or dorsal bony prominence resulting from healed callus. Average time from osteotomy to EPL rupture was 10 weeks (range, 2-17 weeks). Two patients initially refused to undergo tendon transfers. One was pleased with the outcome despite the ruptured EPL. The other patient ruptured 2 more tendons and chose to have tendon transfers. One patient also ruptured the transferred tendon after 2 months and underwent successful tendon grafting.
Conclusions In the absence of screw prominence and technical flaws, it is likely that dorsal callus, prominent osteotomy resection edges, and osteophytes may contribute to attritional rupture of the EPL tendon after a corrective osteotomy through a volar approach. Exposure and debridement of excessive callus, dorsal ridge, or a prominent Lister tubercle performed during the osteotomy may reduce subsequent EPL rupture. (Copyright (C) 2016 by the American Society for Surgery of the Hand. All rights reserved.)
C1 [Rivlin, Michael] Thomas Jefferson Univ, Rothman Inst, Dept Hand & Orthopaed Surg, 925 Chestnut St,5th Floor, Philadelphia, PA 19107 USA.
[Fernandez, Diego L.] Lindenhof Hosp, Dept Orthopaed Surg, Bern, Switzerland.
[Nagy, Ladislav] Balgrist Univ Clin, Dept Hand Surg, Zurich, Switzerland.
[Lopez Grana, Gabriel] Ibermutuamur Clin, Madrid, Spain.
[Jupiter, Jesse] Harvard Univ, Massachusetts Gen Hosp, Dept Hand & Upper Extrem Surg, Boston, MA USA.
RP Rivlin, M (reprint author), Thomas Jefferson Univ, Rothman Inst, Dept Hand & Orthopaed Surg, 925 Chestnut St,5th Floor, Philadelphia, PA 19107 USA.
EM Michael.Rivlin@rothmaninstitute.com
OI Rivlin, Michael/0000-0003-1290-3410
NR 13
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD MAR
PY 2016
VL 41
IS 3
BP 395
EP 398
DI 10.1016/j.jhsa.2015.10.029
PG 4
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DG4CS
UT WOS:000372018800011
PM 26794125
ER
PT J
AU Wilkens, SC
Claessen, FMAP
Ogink, PT
Moradi, A
Ring, D
AF Wilkens, Suzanne C.
Claessen, Femke M. A. P.
Ogink, Paul T.
Moradi, Ali
Ring, David
TI Reoperation After Combined Injury of the Index Finger: Repair Versus
Immediate Amputation
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Amputation; combined injury; index finger; reoperation; repair
ID DIGITAL REPLANTATION; REVASCULARIZATION; HAND; RAY; FIXATION; SURGERY
AB Purpose To identify factors associated with unplanned reoperation of severely injured index fingers and to address the number of amputations after initial repair.
Methods In this retrospective study, we included all patients older than 18 years of age who had repair or immediate amputation for combined index finger injury at 2 level I trauma centers and 1 community hospital tied to a level I trauma center between January 2004 and February 2014. Twelve patients were excluded because of inadequate follow-up. Bivariate and multivariable analyses sought factors associated with unplanned reoperation after repair and immediate amputation.
Results Among 114 patients with combined injury, 75 were treated with repair and 39 with immediate amputation. A total of 41 patients had an unplanned reoperation, 33 after repair (44%) and 8 after immediate amputation (21%). In multivariable analysis, patients who had a reoperation for fingers other than the index finger were at risk for unplanned reoperation after repair. Women were more likely to have an unplanned reoperation than men, and patients who had a ray amputation were at risk for unplanned reoperation after immediate amputation. Six patients (18%) had amputation after initial repair.
Conclusions Surgeons may counsel patients that they are twice as likely to have an unplanned reoperation after a repair for combined injury of the index finger compared with an immediate amputation. Unplanned reoperations were more common among patients with injuries involving multiple fingers. Effective shared decision making is particularly important in this setting given that 1 in 5 repaired index fingers were eventually amputated. (Copyright (C) 2016 by the American Society for Surgery of the Hand. All rights reserved.)
C1 [Wilkens, Suzanne C.; Claessen, Femke M. A. P.; Ogink, Paul T.; Moradi, Ali; Ring, David] Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA USA.
RP Ring, D (reprint author), Harvard Univ, Sch Med, Dept Hand Surg,Massachusetts Gen Hosp, Dept Orthopaed Surg,Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@mgh.harvard.edu
OI Ring, David/0000-0002-6506-4879
NR 38
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD MAR
PY 2016
VL 41
IS 3
BP 436
EP +
DI 10.1016/j.jhsa.2015.12.013
PG 9
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DG4CS
UT WOS:000372018800018
PM 26794123
ER
PT J
AU Deng, W
Wickham, T
McMullin, D
Feeney, K
Buonanno, FS
Lo, EH
Ning, M
AF Deng, W.
Wickham, T.
McMullin, D.
Feeney, K.
Buonanno, F. S.
Lo, E. H.
Ning, M.
TI IMPORTANT ROLE OF PROTHROMBIN TIME (PT) AND PARTIAL THROMBOPLASTIN TIME
(PTT) IN PREDICTING TPA-RELATED HEMORRHAGIC TRANSFORMATION
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Eastern Regional Meeting of the American-Federation-for-Medical-Research
(AFMR)
CY APR 13, 2016
CL Washington, DC
SP Amer Federat Med Res
C1 [Deng, W.; Wickham, T.; McMullin, D.; Feeney, K.; Buonanno, F. S.; Lo, E. H.; Ning, M.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081-5589
EI 1708-8267
J9 J INVEST MED
JI J. Invest. Med.
PD MAR
PY 2016
VL 64
IS 3
MA MP13
BP 810
EP 810
DI 10.1136/jim-2016-000080.25
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA DG6GE
UT WOS:000372180700032
ER
PT J
AU Deng, W
McMullin, D
Wickham, T
Feeney, K
Inglessis, I
Palacios, I
Buonanno, FS
Lo, EH
Ning, M
AF Deng, W.
McMullin, D.
Wickham, T.
Feeney, K.
Inglessis, I.
Palacios, I.
Buonanno, F. S.
Lo, E. H.
Ning, M.
TI PFO CLOSURE REDUCES PLASMA LEVELS OF SEROTONIN IN A LONG TERM FOLLOWUP
OF STROKE PATIENTS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Eastern Regional Meeting of the American-Federation-for-Medical-Research
(AFMR)
CY APR 13, 2016
CL Washington, DC
SP Amer Federat Med Res
C1 [Deng, W.; McMullin, D.; Wickham, T.; Feeney, K.; Inglessis, I.; Palacios, I.; Buonanno, F. S.; Lo, E. H.; Ning, M.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081-5589
EI 1708-8267
J9 J INVEST MED
JI J. Invest. Med.
PD MAR
PY 2016
VL 64
IS 3
MA 15
BP 812
EP U105
DI 10.1136/jim-2016-000080.31
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA DG6GE
UT WOS:000372180700036
ER
PT J
AU Deng, W
Wickham, T
McMullin, D
Feeney, K
Silverman, S
Inglessis, I
Palacios, I
Lo, EH
Buonanno, FS
Ning, M
AF Deng, W.
Wickham, T.
McMullin, D.
Feeney, K.
Silverman, S.
Inglessis, I.
Palacios, I.
Lo, E. H.
Buonanno, F. S.
Ning, M.
TI HOMOCYSTEINE LEVEL IN PFO RELATED STROKE PATIENTS WITH RESPECT TO
MEDICAL THERAPY VS PFO CLOSURE
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Eastern Regional Meeting of the American-Federation-for-Medical-Research
(AFMR)
CY APR 13, 2016
CL Washington, DC
SP Amer Federat Med Res
C1 [Deng, W.; Wickham, T.; McMullin, D.; Feeney, K.; Silverman, S.; Inglessis, I.; Palacios, I.; Lo, E. H.; Buonanno, F. S.; Ning, M.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081-5589
EI 1708-8267
J9 J INVEST MED
JI J. Invest. Med.
PD MAR
PY 2016
VL 64
IS 3
MA MP6
DI 10.1136/jim-2016-000080.18
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA DG6GE
UT WOS:000372180700024
ER
PT J
AU Harwood, NMK
Golden-Mason, L
Cheng, LL
Rosen, HR
Mengshol, JA
AF Harwood, Noah M. K.
Golden-Mason, Lucy
Cheng, Linling
Rosen, Hugo R.
Mengshol, John A.
TI HCV-infected cells and differentiation increase monocyte
immunoregulatory galectin-9 production
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE JFH-1; non-classical monocyte; exosome
ID HEPATITIS-C VIRUS; NATURAL-KILLER-CELLS; IN-VITRO;
HEPATOCELLULAR-CARCINOMA; GLYCAN INTERACTIONS; SIGNALING PATHWAY; TIM-3
EXPRESSION; STRANDED-RNA; IMMUNITY; REPLICATION
AB The lectin galectin-9 may help establish and maintain chronic hepatitis C virus infection. Galectin-9 is elevated in the liver and sera of hepatitis C virus patients, induces apoptosis of hepatitis C virus-specific T cells, and increases inhibitory regulatory T cells. Kupffer cells stain strongly for galectin-9 protein in hepatitis C virus patients. In the current study, we determined stimuli that induce galectin-9 production by monocytes and macrophages in hepatitis C virus infection. With the use of real-time PCR and flow cytometry, we analyzed galectin-9 mRNA and protein from human monocytes cocultured with hepatitis C virus-infected cells or noninfectious hepatitis C virus subgenomic replicon cells. We focused on finding the stimuli for galectin-9 production. Additionally, we measured galectin-9 during monocyte-to-macrophage maturation. Finally, we examined galectin-9 in peripheral monocytes from hepatitis C virus patients using flow cytometry. Galectin-9 mRNA increased 8-fold when primary monocytes were exposed to hepatitis C virus-infected cells. Maximum induction required proximity or contact and did not require IFN-gamma or hepatitis C virus virions. Coculture of monocytes with subgenomic replicon cells increased galectin-9 5-fold, and purified exosomes from infected cells stimulated galectin-9 production. Stimulation of monocyte TLR3, -7, and -8 increased galectin-9 production. Differentiation of monocytes to macrophages increased galectin-9, and nonclassic monocytes from hepatitis C virus patients had the highest levels of galectin-9. Hepatitis C virus-infected cells stimulated monocytes to produce galectin-9 in close proximity, possibly, in part, as a result of exosomes and endosomal TLRs. Differentiation of monocytes to macrophages increased galectin-9. Nonclassic monocytes from hepatitis C virus patients express the highest galectin-9 levels, suggesting they may contribute to elevated galectin-9 and adaptive immune inhibition in hepatitis C virus infection.
C1 [Harwood, Noah M. K.; Golden-Mason, Lucy; Cheng, Linling; Rosen, Hugo R.; Mengshol, John A.] Univ Colorado, Sch Med, Denver VA Med Ctr, Div Gastroenterol & Hepatol, Denver, CO 80220 USA.
RP Mengshol, JA (reprint author), Univ Colorado, Sch Med, Div Gastroenterol & Hepatol, 1055 Clermont St,Box 111E, Denver, CO 80220 USA.
EM andy.mengshol@ucdenver.edu
FU Denver Research Institute; Liver Scholar Award from American Association
for the Study of Liver Disease; U.S. National Institutes of Health
National Institute of Allergy and Infectious Diseases [R21-AI103361];
American Liver Foundation; VA Merit Review Grant
FX J.A.M. is supported by the Denver Research Institute and a Liver Scholar
Award from the American Association for the Study of Liver Disease and
the American Liver Foundation. H.R.R. is funded by U.S. National
Institutes of Health National Institute of Allergy and Infectious
Diseases Grant R21-AI103361 and a VA Merit Review Grant. The authors
thank our leukocyte donors for their generous contribution and Diana Ir
and Katelyn Leahy for tissue-culture work. Additionally, the authors
thank Harsh Pratap for flow cytometry assistance and Ron Bouchard for
immunofluorescence guidance. Amy Stone provided valuable advice
regarding TLR stimulation.
NR 52
TC 1
Z9 1
U1 1
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD MAR
PY 2016
VL 99
IS 3
BP 495
EP 503
DI 10.1189/jlb.5A1214-582R
PG 9
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA DG2IO
UT WOS:000371890800012
PM 26475932
ER
PT J
AU Bernier, UR
Clark, GG
Gurman, P
Elman, NM
AF Bernier, Ulrich R.
Clark, Gary G.
Gurman, Pablo
Elman, Noel M.
TI The Use of Microdispensers with Spatial Repellents for Personal
Protection Against Mosquito Biting
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE vector-borne disease; drug delivery; human landing collection; spatial
repellent
ID MUCOSAL CELLS; DEET; TRANSFLUTHRIN; FORMULATION; SAFETY
AB Mosquito-borne pathogens affect millions of people worldwide. This work describes a new method to deliver spatial repellents. Functional microdispensers (FMDs) were designed to deliver spatial repellents against mosquitoes. In vivo trials showed that FMDs protect human subjects against mosquitoes by reducing 70-90% of bites received, with a protection that lasted up to 4 weeks. FMDs can be cost-effectively implemented as wearable or field-dispensed devices for local area protection, defined as a confined geographical region.
C1 [Bernier, Ulrich R.; Clark, Gary G.] USDA ARS, Ctr Med Agr & Vet Entomol, 1600 SW 23rd Dr, Gainesville, FL 32608 USA.
[Gurman, Pablo] Univ Texas Dallas, Dept Mat Sci & Engn, 800W Campbell Rd, Richardson, TX 75080 USA.
[Elman, Noel M.] MIT, Inst Soldier Nanotechnol, 500 Technol Sq,NE47-525, Cambridge, MA 02139 USA.
[Elman, Noel M.] Charles Stark Draper Labs, Div Mat, Bio Grp, 555 Technol Sq, Cambridge, MA 02139 USA.
[Elman, Noel M.] Massachusetts Gen Hosp, Ctr Innovat Care Delivery, 275 Cambridge St, Boston, MA 02114 USA.
RP Elman, NM (reprint author), MIT, Inst Soldier Nanotechnol, 500 Technol Sq,NE47-525, Cambridge, MA 02139 USA.; Elman, NM (reprint author), Charles Stark Draper Labs, Div Mat, Bio Grp, 555 Technol Sq, Cambridge, MA 02139 USA.; Elman, NM (reprint author), Massachusetts Gen Hosp, Ctr Innovat Care Delivery, 275 Cambridge St, Boston, MA 02114 USA.
EM uli.bernier@ars.usda.gov; roofus209@yahoo.com; pablogurman@gmail.com;
noel.elman@gmail.com
FU Department of Defense Deployed Warfighter Protection Program
[W911QY-12-1-0005]
FX We acknowledge Gregory M. Allen of United States Department of
Agriculture-Agriculture Research Service-Center for Medical,
Agricultural and Veterinary Entomology (USDA-ARS-CMAVE) for conducting
the study with the FMDs against laboratory mosquitoes. This research
work was partially supported by the Department of Defense Deployed
Warfighter Protection Program (contract: W911QY-12-1-0005).
NR 11
TC 0
Z9 0
U1 1
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD MAR
PY 2016
VL 53
IS 2
BP 470
EP 472
DI 10.1093/jme/tjv190
PG 3
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA DG2PA
UT WOS:000371908500027
PM 26637385
ER
PT J
AU Tang, Y
Chang, CCH
Lave, JR
Gellad, WF
Huskamp, HA
Donohue, JM
AF Tang, Yan
Chang, Chung-Chou H.
Lave, Judith R.
Gellad, Walid F.
Huskamp, Haiden A.
Donohue, Julie M.
TI Patient, Physician and Organizational Influences on Variation in
Antipsychotic Prescribing Behavior
SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS
LA English
DT Article
ID CARE; RECOMMENDATIONS; ANTIDEPRESSANT; SCHIZOPHRENIA; INFORMATION;
PERFORMANCE; MORTALITY; DIFFUSION; OUTCOMES; IMPACT
AB Background: Physicians face the choice of multiple ingredients when prescribing drugs in many therapeutic categories. For conditions with considerable patient heterogeneity in treatment response, customizing treatment to individual patient needs and preferences may improve outcomes.
Aims of the Study: To assess variation. in the diversity of antipsychotic prescribing for mental health conditions, a necessary although not sufficient condition for personalizing treatment. To identify patient caseload, physician, and organizational factors associated with the diversity of antipsychotic prescribing.
Methods: Using 2011 data from Pennsylvania's Medicaid program, IMS Health's HCOS (TM) database, and the AMA Masterfile, we identified 764 psychiatrists who prescribed antipsychotics to >= 10 patients. We constructed three physician level measures of diversity/concentration of antipsychotic prescribing: number of ingredients prescribed, share of prescriptions for most preferred ingredient, and Herfindahl-Hirschman index (HHI). We used multiple membership linear mixed models to examine patient caseload, physician, and healthcare organizational predictors of physician concentration of antipsychotic prescribing.
Results: There was substantial variability in antipsychotic prescribing concentration among psychiatrists, with number of ingredients ranging from 2-17, share for most preferred ingredient from 16%-85%, and HHI from 1,088-7,270. On average, psychiatrist prescribing behavior was relatively diversified; however, 11% of psychiatrists wrote an average of 55% of their prescriptions for their most preferred ingredient. Female prescribers and those with smaller shares of disabled or serious mental illness patients had more concentrated prescribing behavior on average.
Discussion: Antipsychotic prescribing by individual psychiatrists in a large state Medicaid program varied substantially across psychiatrists. Our findings illustrate the importance of understanding physicians' prescribing behavior and indicate that even among specialties regularly prescribing a therapeutic category, some physicians rely heavily on a small number of agents.
Implications for Health Policies, Health Care Provision and Use: Health systems may need to offer educational interventions to clinicians in order to improve their ability to tailor treatment decisions to the needs of individual patients.
Implications for Future Research: Future studies should examine the impact of the diversity of antipsychotic prescribing to determine whether more diversified prescribing improves patient adherence and outcomes.
C1 [Tang, Yan; Gellad, Walid F.; Donohue, Julie M.] Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing CP3, Pittsburgh, PA 15261 USA.
[Tang, Yan; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A645, Pittsburgh, PA 15261 USA.
[Chang, Chung-Chou H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Lave, Judith R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Gellad, Walid F.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA 15261 USA.
[Huskamp, Haiden A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Cambridge, MA 02138 USA.
RP Tang, Y (reprint author), Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing CP3, Pittsburgh, PA 15261 USA.; Tang, Y (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A645, Pittsburgh, PA 15261 USA.
EM yan.tang@pitt.edu
FU National Institute of Mental Health [R01MH093359]; Pennsylvania
Department of Human Services; University of Pittsburgh
FX This work was supported in part by grant R01MH093359 from the National
Institute of Mental Health (Drs. Donohue and Huskamp), and by an inter
-governmental agreement between the Pennsylvania Department of Human
Services and the University of Pittsburgh. Dr. Huskamp serves on the
Academic Advisory Committee for the Health Services Research Network at
IMS Health Inc. (uncompensated). The other authors report no conflict of
interest. Some of the findings were presented at the International
Society of Pharmacoeconomics and Outcomes Research 20th Annual
International Meeting, May 16-20, 2015, Philadelphia, PA, USA.
NR 40
TC 0
Z9 0
U1 0
U2 0
PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE
PI MILANO
PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY
SN 1091-4358
J9 J MENT HEALTH POLICY
JI J. Ment. Health Policy Econ.
PD MAR
PY 2016
VL 19
IS 1
BP 45
EP 59
PG 15
WC Health Policy & Services; Psychiatry
SC Health Care Sciences & Services; Psychiatry
GA DG6QP
UT WOS:000372211500005
PM 27084793
ER
PT J
AU Bunpin, JJD
Chapman, S
Blegen, M
Spetz, J
AF Bunpin, Jose J. Dy, III
Chapman, Susan
Blegen, Mary
Spetz, Joanne
TI Differences in Innovative Behavior Among Hospital-Based Registered
Nurses
SO JOURNAL OF NURSING ADMINISTRATION
LA English
DT Article
ID CARE; EMPOWERMENT; AUTONOMY
AB BACKGROUND: The 2010 Institute of Medicine report, 'The Future of Nursing: Leading Change, Advancing Health', advocated for nurses to innovate in their practice, research, and education. However, little is known about the innovative behavior of registered nurses or whether there are differences in innovative behavior among registered nurses. OBJECTIVE: The purpose of this article is to describe the innovative behavior of hospital-based registered nurses and understand the differences in innovative behavior when registered nurses are categorized into various demographic groups. METHODS: A survey of 251 hospital-based registered nurses from 9 hospitals in California was administered to assess demographic characteristics and innovative behavior, measured through Scott and Bruce's Individual Innovative Behavior Scale. RESULTS: Hospital-based registered nurses, on average, reported moderate levels of innovative behavior. There were statistically significant differences in innovative behavior when registered nurses were categorized according to specialty certification, role, level of education, hospital size, and hospital innovativeness. CONCLUSIONS: To support innovative behavior, organizations should provide opportunities for specialty certification and increasing levels of education.
C1 [Bunpin, Jose J. Dy, III] San Francisco VA Med Ctr, Surg & Procedural Care, San Francisco, CA 94121 USA.
[Chapman, Susan] Univ Calif San Francisco, Sch Nursing, Dept Social & Behav Sci, San Francisco, CA 94143 USA.
[Blegen, Mary] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Spetz, Joanne] Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
RP Bunpin, JJD (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM jose.dybunpin@va.gov
NR 33
TC 0
Z9 0
U1 5
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-0443
EI 1539-0721
J9 J NURS ADMIN
JI J. Nurs. Adm.
PD MAR
PY 2016
VL 46
IS 3
BP 122
EP 127
DI 10.1097/NNA.0000000000000310
PG 6
WC Nursing
SC Nursing
GA DF8BZ
UT WOS:000371583200006
ER
PT J
AU Ikizler, HO
Zelnick, L
Ruzinski, J
Curtin, L
Utzschneider, KM
Kestenbaum, B
Himmelfarb, J
de Boer, IH
AF Ikizler, Halil O.
Zelnick, Leila
Ruzinski, John
Curtin, Laura
Utzschneider, Kristina M.
Kestenbaum, Bryan
Himmelfarb, Jonathan
de Boer, Ian H.
TI Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin
Sensitivity in Chronic Kidney Disease
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; METABOLIC-ACIDOSIS; AFRICAN-AMERICANS;
HYPERTENSIVE NEPHROPATHY; UNITED-STATES; OLDER-ADULTS; RESISTANCE; RISK;
PROGRESSION; HUMANS
AB Objective: In chronic kidney disease (CKD), dietary acid may promote metabolic acidosis and insulin resistance, which in turn may contribute to adverse clinical health outcomes. We examined associations between dietary acid load, serum bicarbonate, and insulin sensitivity in CKD.
Design: In a cross-sectional study, we collected 3-day prospective food diaries to quantify dietary acid load as net endogenous acid production (NEAP, the nonvolatile acid load produced by the diet's acid balance) and potential renal acid load (PRAL). We measured urine net acid excretion (NAE) in 24-hour urine samples. Insulin sensitivity was measured by hyperinsulinemic euglycemic clamp.
Subjects: Forty-two patients with CKD Stages 3 to 5 attending nephrology clinics in the Pacific Northwest and 21 control subjects (estimated glomerular filtration rate [eGFR] >= 60 mL/minute/1.73 m(2)).
Main Outcome Measures: Serum bicarbonate and insulin sensitivity (SIclamp).
Results: Mean age was 60.8 +/- 13.6 years, and 54% of participants were men. Mean eGFR and serum bicarbonate concentrations were 34.4 +/- 13.1 mL/minute/1.73 m(2) and 24.1 +/- 2.9 mEq/L for participants with CKD and 88.6 +/- 14.5 mL/minute/1.73 m(2) and 26.3 +/- 1.8 mEq/L for control subjects, respectively. Mean NEAP, PRAL, and NAE were 58.2 +/- 24.3, 9.7 +/- 18.4, and 32.1 +/- 19.8 mEq/day, respectively. Considering all participants, dietary acid load was significantly, inversely associated with serum bicarbonate, adjusting for age, gender, race, eGFR, body mass index, and diuretic use: -1.2 mEq/L per standard deviation (SD) NEAP (95% confidence interval [CI] -1.8 to -0.6, P<.0001); -0.9 mEq/L bicarbonate per SD PRAL (95% CI -1.5 to -0.4, P=.0005); -0.7 mEq/L bicarbonate per SD NAE (95% CI -1.2 to -0.1, P=.01). These associations were similar in participants with and without CKD. However, neither NEAP and PRAL nor NAE was significantly associated with SIclamp. Serum bicarbonate was also not significantly associated with SIclamp.
Conclusions: In CKD, dietary acid load is associated with serum bicarbonate, suggesting that acidosis may be improved by dietary changes, but not with insulin sensitivity. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
C1 [Ikizler, Halil O.] Univ Vermont, Coll Med, Burlington, VT USA.
[Ikizler, Halil O.; Zelnick, Leila; Ruzinski, John; Curtin, Laura; Kestenbaum, Bryan; Himmelfarb, Jonathan; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA.
[Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Utzschneider, Kristina M.] Univ Washington, Seattle, WA 98195 USA.
[Kestenbaum, Bryan; Himmelfarb, Jonathan; de Boer, Ian H.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
[Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP de Boer, IH (reprint author), Univ Washington, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA.
EM deboer@u.washington.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[T32DK007247]; NIDDK [DK087726, DK007247, DK017047]; University of
Washington Diabetes Research Center [P30 DK01704]; University of
Washington Institute of Translational Health Sciences [UL1TR000423];
Department of Veterans Affairs
FX H.O.I. was supported by grant T32DK007247 from the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK). The SUGAR study was
supported by NIDDK grants DK087726, DK007247, and DK017047. Support was
also provided by the University of Washington Diabetes Research Center
(P30 DK01704), the University of Washington Institute of Translational
Health Sciences (UL1TR000423), and the Department of Veterans Affairs.
The funding sources had no role in study design, analysis or
interpretation of data, writing of the report, or the decision to submit
this article for publication.
NR 44
TC 4
Z9 4
U1 3
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
EI 1532-8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD MAR
PY 2016
VL 26
IS 2
BP 93
EP 102
DI 10.1053/j.jrn.2015.08.008
PG 10
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA DG4AA
UT WOS:000372011100007
PM 26508542
ER
PT J
AU Molfino, A
Kaysen, GA
Chertow, GM
Doyle, J
Delgado, C
Dwyer, T
Laviano, A
Fanelli, FR
Johansen, KL
AF Molfino, Alessio
Kaysen, George A.
Chertow, Glenn M.
Doyle, Julie
Delgado, Cynthia
Dwyer, Tjien
Laviano, Alessandro
Fanelli, Filippo Rossi
Johansen, Kirsten L.
TI Validating Appetite Assessment Tools Among Patients Receiving
Hemodialysis
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; HOSPITALIZED-PATIENTS; NUTRITIONAL-STATUS;
ANOREXIA; LEPTIN; INFLAMMATION; ADIPONECTIN; MORTALITY; CACHEXIA; DEATH
AB Objective: To test the performance of appetite assessment tools among patients receiving hemodialysis (HD).
Design: Cross-sectional.
Subjects: Two hundred twenty-one patients receiving HD enrolled in seven dialysis facilities in Northern California.
Intervention: We assessed 5 appetite assessment tools (self-assessment of appetite, subjective assessment of appetite, visual analog scale [VAS], Functional Assessment of Anorexia/Cachexia Therapy [FAACT] score, and the Anorexia Questionnaire [AQ]).
Main Outcome Measures: Reported food intake, normalized protein catabolic rate, and change in body weight were used as criterion measures, and we assessed associations among the appetite tools and biomarkers associated with nutrition and inflammation. Patients were asked to report their appetite and the percentage of food eaten (from 0% to 100%) during the last meal compared to usual intake.
Results: Fifty-eight (26%) patients reported food intake <= 50% (defined as poor appetite). The prevalence of anorexia was 12% by self-assessment of appetite, 6% by subjective assessment of appetite, 24% by VAS, 17% by FAACT score, and 12% by AQ. All the tools were significantly associated with food intake <= 50% (P<.001), except self-assessment of appetite. The FAACT score and the VAS had the strongest association with food intake <= 50% (C-statistic 0.80 and 0.76). Patients with food intake <= 50% reported weight loss more frequently than patients without low intake (36% vs 22%) and weight gain less frequently (19% vs 35%; P = .03). Normalized protein catabolic rate was lower among anorexic patients based on the VAS (1.1 +/- 0.3 vs 1.2 +/- 0.3, P=.03). Ln interleukin-6 correlated inversely with food intake (P = .03), but neither interleukin-6 nor C-reactive protein correlated with any of the appetite tools. Furthermore, only the self-assessment of appetite was significantly associated with serum albumin (P = .02), prealbumin (P = .02) and adiponectin concentrations (P = .03).
Conclusions: Alternative appetite assessment tools yielded widely different estimates of the prevalence of anorexia in HD. When considering self-reported food intake as the criterion standard for anorexia, the FAACT score and VAS discriminated patients reasonably well. (C) 2016 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Molfino, Alessio; Kaysen, George A.; Dwyer, Tjien] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA.
[Molfino, Alessio; Laviano, Alessandro; Fanelli, Filippo Rossi] Univ Roma La Sapienza, Dept Clin Med, Viale Univ 37, I-00185 Rome, Italy.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA.
[Doyle, Julie; Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Doyle, Julie; Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
RP Molfino, A (reprint author), Univ Roma La Sapienza, Dept Clin Med, Viale Univ 37, I-00185 Rome, Italy.
EM alessio.molfino@uniroma1.it
FU National Institute of Diabetes and Digestive and Kidney Diseases
[N01-DK-7-005, N01-DK-7-5004]; NIDDK [K24DK085153]; Department of
Veterans Affairs, Clinical Science Research and Development Program
[1IK2CX000527-01A2]; National Center for Research Resources; National
Center for Advancing Translational Sciences, National Institutes of
Health, through UCSF-CTSI Grant [UL1 RR024131]
FX This work was supported by contracts N01-DK-7-005 and N01-DK-7-5004 from
the National Institute of Diabetes and Digestive and Kidney Diseases.
K.L.J.'s effort was supported in part by K24DK085153 from NIDDK. C.D.'s
work was supported by the Department of Veterans Affairs, Clinical
Science Research and Development Program under Career Development Award
1IK2CX000527-01A2. Her contribution is the result of work supported with
the resources and the use of facilities at the San Francisco VA Medical
Center. This publication was also supported by the National Center for
Research Resources and the National Center for Advancing Translational
Sciences, National Institutes of Health, through UCSF-CTSI Grant number
UL1 RR024131.
NR 28
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
EI 1532-8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD MAR
PY 2016
VL 26
IS 2
BP 103
EP 110
DI 10.1053/j.jrn.2015.09.002
PG 8
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA DG4AA
UT WOS:000372011100008
PM 26522141
ER
PT J
AU Howard, J
Etz, RS
Crocker, JB
Skinner, D
Kelleher, KJ
Hahn, KA
Miller, WL
Crabtree, BF
AF Howard, Jenna
Etz, Rebecca S.
Crocker, J. Benjamin
Skinner, Daniel
Kelleher, Kelly J.
Hahn, Karissa A.
Miller, William L.
Crabtree, Benjamin F.
TI Maximizing the Patient-Centered Medical Home (PCMH) by Choosing Words
Wisely
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
DE Health Care Systems; Patient-Centered Care; Primary Health Care;
Qualitative Research
ID PRIMARY-CARE PRACTICES; MENTAL MODELS; TRANSFORMATION; QUALITY; PROJECT
AB Background: Culture is transmitted through language and reflects a group's values, yet much of the current language used to describe the new patient-centered medical home (PCMH) is a carryover from the traditional, physician-centric model of care. This language creates a subtle yet powerful force that can perpetuate the status quo, despite transformation efforts. This article describes new terminology that some innovative primary care practices are using to support the transformational culture of the PCMH.
Methods: Data come from the Agency for Healthcare Research and Quality-funded Working Conference for PCMH Innovation 2013, which convened 10 innovative practices and interdisciplinary content experts to discuss innovative practice redesign. Session and interview transcripts were analyzed using a grounded theory approach to identify patterns and explore their significance.
Results: Language innovations are used by 5 practices. Carefully selected terms facilitate creative reimagining of traditional roles and spaces through connotations that highlight practice goals. Participants felt that the language used was important for reinforcing substantive changes.
Conclusions: Reworking well-established vernacular requires openness to change. True transformation does not, however, occur through a simple relabeling of old concepts. New terminology must represent values to which practices genuinely aspire, although caution is advised when using language to support cultural and clinical change.
C1 [Howard, Jenna; Crabtree, Benjamin F.] Rutgers Robert Wood Johnson Med Sch, Dept Family Med & Community Hlth, 1 Worlds Fair Dr, Somerset, NJ 08873 USA.
[Etz, Rebecca S.] Virginia Commonwealth Univ, Dept Family Med & Populat Hlth, Richmond, VA 23284 USA.
[Crocker, J. Benjamin] Massachusetts Gen Hosp, Dept Gen Med, Ambulatory Practice Future, Boston, MA 02114 USA.
[Skinner, Daniel] Ohio Univ, Heritage Coll Osteopath Med, Dept Social Med, Dublin, Ireland.
[Kelleher, Kelly J.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA.
[Miller, William L.] Lehigh Valley Hlth Network, Dept Family Med, Allentown, PA USA.
RP Howard, J (reprint author), Rutgers Robert Wood Johnson Med Sch, Dept Family Med & Community Hlth, 1 Worlds Fair Dr, Somerset, NJ 08873 USA.
EM jenna.howard@rutgers.edu
FU Agency for Healthcare Research and Quality [R13HS021287]
FX This project was supported by grant no. R13HS021287 from the Agency for
Healthcare Research and Quality.
NR 30
TC 1
Z9 1
U1 3
U2 7
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
EI 1558-7118
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD MAR-APR
PY 2016
VL 29
IS 2
BP 248
EP 253
DI 10.3122/jabfm.2016.02.150199
PG 6
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA DG3WJ
UT WOS:000372000900011
PM 26957382
ER
PT J
AU Shah, PV
Kozin, ED
Kaplan, AB
Lee, DJ
AF Shah, Parth V.
Kozin, Elliott D.
Kaplan, Alyson B.
Lee, Daniel J.
TI Pediatric Auditory Brainstem Implant Surgery: A New Option for Auditory
Habilitation in Congenital Deafness?
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
DE Auditory Brain Stem Implants; Deafness; Cochlear Implants; Cochlear
Nucleus; Hearing Loss; Pediatrics
ID OUTCOMES
AB Introduction: The auditory brainstem implant (ABI) is a neuroprosthetic device that provides sound sensations to individuals with profound hearing loss who are not candidates for a cochlear implant (CI) because of anatomic constraints. Herein we describe the ABI for family physicians.
Methods: PubMed was searched to identify articles relevant to the ABI, as well as articles that contain outcomes data for pediatric patients (age <18 years) who have undergone ABI surgery.
Results: The ABI was originally developed for patients with neurofibromatosis type 2 (NF2) who become deaf from bilateral vestibular schwannomas. Over the past decade, indications for an ABI have expanded to adult patients without tumors (without NF2) who cannot receive a CI and children with no cochlea or cochlear nerve. Outcomes among NF2 ABI users are modest compared to cochlear implant patients, but recent studies from Europe suggest that some non-tumor adult and pediatric ABI users achieve speech perception.
Conclusion: The ABI is a reasonable surgical option for children with profound hearing loss due to severe cochlear or cochlear nerve deformities. Continued prospective data collection from several clinical trials in the U.S. will provide greater understanding on long term outcomes that focus on speech intelligibility.
C1 [Shah, Parth V.; Kozin, Elliott D.; Kaplan, Alyson B.; Lee, Daniel J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
RP Kozin, ED (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM elliott_kozin@meei.harvard.edu
NR 5
TC 1
Z9 1
U1 1
U2 2
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
EI 1558-7118
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD MAR-APR
PY 2016
VL 29
IS 2
BP 286
EP 288
DI 10.3122/jabfm.2016.02.150258
PG 3
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA DG3WJ
UT WOS:000372000900017
PM 26957388
ER
PT J
AU Klauschen, F
Blaker, H
Stenzinger, A
AF Klauschen, Frederick
Blaeker, Hendrik
Stenzinger, Albrecht
TI Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer
Rediagnosis That Guides an Effective Therapeutic Course"
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Letter
C1 [Klauschen, Frederick; Blaeker, Hendrik] Charite, Inst Pathol, D-13353 Berlin, Germany.
[Stenzinger, Albrecht] Heidelberg Univ, Sch Med, Inst Pathol, Heidelberg, Germany.
[Stenzinger, Albrecht] Harvard Univ, Sch Med, Dept Pathol, Ctr Integrated Diagnost,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Klauschen, F (reprint author), Charite, Inst Pathol, D-13353 Berlin, Germany.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAR
PY 2016
VL 14
IS 3
BP LXVI
EP LXVIII
PG 2
WC Oncology
SC Oncology
GA DG3VF
UT WOS:000371997900001
PM 26957621
ER
PT J
AU Kulke, MH
AF Kulke, Matthew H.
TI Somatostatin Analogues in Neuroendocrine Tumors
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Editorial Material
ID MALIGNANT CARCINOID-SYNDROME; FORMULATION; LANREOTIDE
C1 [Kulke, Matthew H.] Dana Farber Canc Inst, Program Neuroendocrine & Carcinoid Tumors, Boston, MA 02115 USA.
[Kulke, Matthew H.] Harvard Univ, Sch Med, Med, Cambridge, MA 02138 USA.
RP Kulke, MH (reprint author), Dana Farber Canc Inst, Program Neuroendocrine & Carcinoid Tumors, Boston, MA 02115 USA.; Kulke, MH (reprint author), Harvard Univ, Sch Med, Med, Cambridge, MA 02138 USA.
NR 7
TC 1
Z9 1
U1 0
U2 0
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAR
PY 2016
VL 14
IS 3
BP 241
EP 242
PG 2
WC Oncology
SC Oncology
GA DG3VF
UT WOS:000371997900004
PM 26957610
ER
PT J
AU Ettinger, DS
Wood, DE
Akerley, W
Bazhenova, LA
Borghaei, H
Camidge, DR
Cheney, RT
Chirieac, LR
D'Amico, TA
Dilling, TJ
Dobelbower, MC
Govindan, R
Hennon, M
Horn, L
Jahan, TM
Komaki, R
Lackner, RP
Lanuti, M
Lilenbaum, R
Lin, J
Loo, BW
Martins, R
Otterson, GA
Patel, JD
Pisters, KM
Reckamp, K
Riely, GJ
Schild, SE
Shapiro, TA
Sharma, N
Stevenson, J
Swanson, SJ
Tauer, K
Yang, SC
Gregory, K
Hughes, M
AF Ettinger, David S.
Wood, Douglas E.
Akerley, Wallace
Bazhenova, Lyudmila A.
Borghaei, Hossein
Camidge, David Ross
Cheney, Richard T.
Chirieac, Lucian R.
D'Amico, Thomas A.
Dilling, Thomas J.
Dobelbower, M. Chris
Govindan, Ramaswamy
Hennon, Mark
Horn, Leora
Jahan, Thierry M.
Komaki, Ritsuko
Lackner, Rudy P.
Lanuti, Michael
Lilenbaum, Rogerio
Lin, Jules
Loo, Billy W., Jr.
Martins, Renato
Otterson, Gregory A.
Patel, Jyoti D.
Pisters, Katherine M.
Reckamp, Karen
Riely, Gregory J.
Schild, Steven E.
Shapiro, Theresa A.
Sharma, Neelesh
Stevenson, James
Swanson, Scott J.
Tauer, Kurt
Yang, Stephen C.
Gregory, Kristina
Hughes, Miranda
TI NCCN Guidelines (R) Insights: Non-Small Cell Lung Cancer, Version 4.2016
Featured Updates to the NCCN Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID NIVOLUMAB; IMMUNOTHERAPY; PEMBROLIZUMAB; DOCETAXEL; SAFETY
AB These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
C1 [Ettinger, David S.; Shapiro, Theresa A.; Yang, Stephen C.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.
[Wood, Douglas E.; Martins, Renato] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Akerley, Wallace] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Bazhenova, Lyudmila A.] UC San Diego Moores Canc Ctr, San Diego, CA USA.
[Borghaei, Hossein] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Camidge, David Ross] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Cheney, Richard T.; Hennon, Mark] Roswell Pk Canc Inst, Buffalo, NY USA.
[Chirieac, Lucian R.; Swanson, Scott J.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[D'Amico, Thomas A.] Duke Canc Inst, Durham, NC USA.
[Dilling, Thomas J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Dobelbower, M. Chris] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Govindan, Ramaswamy] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Govindan, Ramaswamy] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Jahan, Thierry M.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Komaki, Ritsuko; Pisters, Katherine M.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Lackner, Rudy P.] Fred & Pamela Buffett Canc Ctr, Durham, NC USA.
[Lanuti, Michael] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Lilenbaum, Rogerio] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA.
[Lin, Jules] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Loo, Billy W., Jr.] Stanford Canc Inst, Palo Alto, CA USA.
[Otterson, Gregory A.] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Otterson, Gregory A.] Solove Res Inst, Columbus, OH USA.
[Patel, Jyoti D.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Reckamp, Karen] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Riely, Gregory J.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Schild, Steven E.] Mayo Clin, Ctr Canc, Rochester, MN USA.
[Sharma, Neelesh; Stevenson, James] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA.
[Sharma, Neelesh; Stevenson, James] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA.
[Tauer, Kurt] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Gregory, Kristina; Hughes, Miranda] Natl Comprehens Canc Network, Ft Washington, PA USA.
RP Ettinger, DS (reprint author), Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.
FU AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Bristol-Myers
Squibb; Clovis Oncology; Genentech; Novartis Oncology; Otsuka America
Pharmaceutical, Inc.; Seattle Genetics, Inc.; Takeda Oncology; Actelion
Pharmaceuticals US, Inc.; Astellas and Medivation, Inc.
FX This activity is supported by educational grants from AstraZeneca, Bayer
Healthcare Pharmaceuticals Inc., Bristol-Myers Squibb, Clovis Oncology,
Genentech, Novartis Oncology, Otsuka America Pharmaceutical, Inc.,
Seattle Genetics, Inc., and Takeda Oncology; support provided by
Actelion Pharmaceuticals US, Inc.; and by an independent educational
grant from Astellas and Medivation, Inc.
NR 23
TC 30
Z9 31
U1 4
U2 7
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAR
PY 2016
VL 14
IS 3
BP 255
EP 264
PG 10
WC Oncology
SC Oncology
GA DG3VF
UT WOS:000371997900006
PM 26957612
ER
PT J
AU Gradishar, WJ
Anderson, BO
Balassanian, R
Blair, SL
Burstein, HJ
Cyr, A
Elias, AD
Farrar, WB
Forero, A
Giordano, SH
Goetz, M
Goldstein, LJ
Hudis, CA
Isakoff, SJ
Marcom, PK
Mayer, IA
McCormick, B
Moran, M
Patel, SA
Pierce, LJ
Reed, EC
Salerno, KE
Schwartzberg, LS
Smith, KL
Smith, ML
Soliman, H
Somlo, G
Telli, M
Ward, JH
Shead, DA
Kumar, R
AF Gradishar, William J.
Anderson, Benjamin O.
Balassanian, Ron
Blair, Sarah L.
Burstein, Harold J.
Cyr, Amy
Elias, Anthony D.
Farrar, William B.
Forero, Andres
Giordano, Sharon Hermes
Goetz, Matthew
Goldstein, Lori J.
Hudis, Clifford A.
Isakoff, Steven J.
Marcom, P. Kelly
Mayer, Ingrid A.
McCormick, Beryl
Moran, Meena
Patel, Sameer A.
Pierce, Lori J.
Reed, Elizabeth C.
Salerno, Kilian E.
Schwartzberg, Lee S.
Smith, Karen Lisa
Smith, Mary Lou
Soliman, Hatem
Somlo, George
Telli, Melinda
Ward, John H.
Shead, Dorothy A.
Kumar, Rashmi
TI Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in
Oncology
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID SKIN-SPARING MASTECTOMY; CONTRALATERAL PROPHYLACTIC MASTECTOMY;
RANDOMIZED CONTROLLED-TRIAL; SENTINEL-NODE BIOPSY; 20-YEAR FOLLOW-UP;
POSTMASTECTOMY RADIATION IMPROVES; LUMPECTOMY PLUS TAMOXIFEN; CARCINOMA
IN-SITU; FERTILITY PRESERVATION; CONSERVING THERAPY
AB Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This article outlines the NCCN Guidelines specific to breast cancer that is locoregional (restricted to one region of the body), and discusses the management of clinical stage I, II, and IIIA (T3N1M0) tumors. For NCCN Guidelines on systemic adjuvant therapy after locoregional management of clinical stage I, II and IIIA (T3N1M0) and for management for other clinical stages of breast cancer, see the complete version of these guidelines at NCCN.org.
C1 [Gradishar, William J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Anderson, Benjamin O.] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Balassanian, Ron] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Blair, Sarah L.] UC San Diego Moores Canc Ctr, San Diego, CA USA.
[Burstein, Harold J.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Cyr, Amy] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Cyr, Amy] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Elias, Anthony D.] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Farrar, William B.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Farrar, William B.] Solove Res Inst, Columbus, OH USA.
[Forero, Andres] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Giordano, Sharon Hermes] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Goetz, Matthew] Mayo Clin, Ctr Canc, Rochester, MN USA.
[Goldstein, Lori J.; Patel, Sameer A.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Hudis, Clifford A.; McCormick, Beryl] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Isakoff, Steven J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Marcom, P. Kelly] Duke Canc Inst, Durham, NC USA.
[Mayer, Ingrid A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Moran, Meena] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA.
[Pierce, Lori J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Reed, Elizabeth C.] Fred & Pamela Buffett Canc Ctr, Durham, NC USA.
[Salerno, Kilian E.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Schwartzberg, Lee S.] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Smith, Karen Lisa] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Smith, Mary Lou] Res Advocacy Network, New York, NY USA.
[Soliman, Hatem] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Somlo, George] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Telli, Melinda] Stanford Canc Inst, Palo Alto, CA USA.
[Ward, John H.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
RP Gradishar, WJ (reprint author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
NR 178
TC 26
Z9 30
U1 6
U2 10
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAR
PY 2016
VL 14
IS 3
BP 324
EP 354
PG 31
WC Oncology
SC Oncology
GA DG3VF
UT WOS:000371997900012
PM 26957618
ER
PT J
AU Waks, AG
Partridge, AH
AF Waks, Adrienne G.
Partridge, Ann H.
TI Fertility Preservation in Patients With Breast Cancer: Necessity,
Methods, and Safety
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID OVARIAN-FUNCTION; ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL WOMEN; EMBRYO
CRYOPRESERVATION; ANTIMULLERIAN HORMONE; PROGNOSTIC IMPACT;
AMERICAN-SOCIETY; PREGNANCY; STIMULATION; TAMOXIFEN
AB As treatment paradigms improve and young women live longer after a breast cancer diagnosis, there is an increasing need to define the fertility-related problems that premenopausal women with breast cancer face, and, more importantly, to find solutions. This article discusses what is known regarding fertility risks associated with standard breast cancer treatment regimens and limitations of that information. We outline established and emerging techniques for fertility preservation, including recent developments surrounding the controversial utility of gonadotropin-releasing hormone agonists through chemotherapy, and review available data on the safety of pregnancy in breast cancer survivors. We highlight opportunities for further investigation, and contextualize fertility-related concerns in the modern treatment landscape. Above all, we stress the importance of this topic in a patient-centered approach to breast cancer care for young women.
C1 [Waks, Adrienne G.; Partridge, Ann H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Waks, Adrienne G.; Partridge, Ann H.] Harvard Univ, Sch Med, Boston, MA USA.
RP Partridge, AH (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM ann_partridge@dfci.harvard.edu
NR 50
TC 3
Z9 3
U1 1
U2 2
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAR
PY 2016
VL 14
IS 3
BP 355
EP 363
PG 9
WC Oncology
SC Oncology
GA DG3VF
UT WOS:000371997900013
PM 26957619
ER
PT J
AU Auchincloss, HG
Wright, CD
AF Auchincloss, Hugh G.
Wright, Cameron D.
TI Complications after tracheal resection and reconstruction: prevention
and treatment
SO JOURNAL OF THORACIC DISEASE
LA English
DT Review
DE Airway obstruction; laryngeal edema; tracheal stenosis;
tracheoesophageal fistula (TEF); tracheostomy
ID HYPERBARIC-OXYGEN THERAPY; ANASTOMOTIC COMPLICATIONS; STENOSIS; SURGERY
AB Tracheal resection and reconstruction (TRR) and laryngotracheal resection and reconstruction (LTRR) is commonly performed for post-intubation tracheal stenosis, tracheal tumor, idiopathic laryngotracheal stenosis (ILTS), and tracheoesophageal fistula (TEF). Ninety-five percent of patients have a good result from surgery. Complications occur in similar to 20% of patients, of which half are anastomotic complications. Complications include granulation tissue formation, restenosis of the trachea, anastomotic separation, TEF and tracheoinnominate fistula (TIF), wound infection, laryngeal edema, and glottic dysfunction. Risk factors for anastomotic complication include diabetes, reoperation, previous tracheal appliance, and long-segment tracheal resection. Bronchoscopy should be part of the diagnostic workup when a complication is suspected. Anastomotic separation-the most feared complication of tracheal surgery-may present subtly with stridor and wound infection, or with respiratory distress and extremis. Prompt management is required to prevent devastating consequences. The airway should be secured, bronchoscopy should be performed to address the degree of separation, and the anastomosis should be revised if needed, usually with the addition of t-tube or tracheostomy. Anastomotic complications that are managed aggressively typically yield good results. More than half of such patients will eventually have a satisfactory airway. However, an anastomotic complication is associated with a thirteen-fold increase in the risk of death following tracheal resection.
C1 [Auchincloss, Hugh G.] Massachusetts Gen Hosp, Div Cardiothorac Surg, Boston, MA 02114 USA.
[Wright, Cameron D.] Massachusetts Gen Hosp, Div Thorac Surg, Blake 1570, Boston, MA 02114 USA.
RP Wright, CD (reprint author), Massachusetts Gen Hosp, Div Thorac Surg, Blake 1570, Boston, MA 02114 USA.
EM Wright.Cameron@mgh.harvard.edu
NR 17
TC 3
Z9 3
U1 2
U2 5
PU PIONEER BIOSCIENCE PUBL CO
PI HONG KONG
PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG,
00000, PEOPLES R CHINA
SN 2072-1439
EI 2077-6624
J9 J THORAC DIS
JI J. Thorac. Dis.
PD MAR
PY 2016
VL 8
SU 2
BP S160
EP S167
DI 10.3978/j.issn.2072-1439.2016.01.86
PG 8
WC Respiratory System
SC Respiratory System
GA DG5EZ
UT WOS:000372099900008
PM 26981267
ER
PT J
AU Costantino, CL
Mathisen, DJ
AF Costantino, Christina L.
Mathisen, Douglas J.
TI Idiopathic laryngotracheal stenosis
SO JOURNAL OF THORACIC DISEASE
LA English
DT Article
DE Trachea; larynx; stenosis; idiopathic
AB Idiopathic laryngotracheal stenosis (ILTS) is a rare inflammatory disease of unknown etiology. Infectious, traumatic and immunologic processes must first be excluded. The majority of patients affected are female who present with progressive symptoms of upper airway obstruction, which can extend over a number of years. ILTS is characterized by short segment, circumferential stenotic lesions, located particularly at the level of the cricoid. Bronchoscopic evaluation is essential for establishing the diagnosis and operative planning. Various temporizing interventions have historically been utilized, including dilation and laser ablation, for symptomatic management. However these interventions have demonstrated diminishing returns and poor long-term outcomes. Patients with ILTS should be considered early for definitive surgical intervention to minimize complications and optimize outcomes. Laryngotracheal resection and reconstruction is a viable intervention, which has demonstrated good long-term results and low recurrence rates for this patient population.
C1 [Costantino, Christina L.; Mathisen, Douglas J.] Massachusetts Gen Hosp, 55 Fruit St,Blake 1570, Boston, MA 02114 USA.
RP Mathisen, DJ (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Blake 1570, Boston, MA 02114 USA.
EM dmathisen@partners.org
NR 10
TC 0
Z9 0
U1 1
U2 2
PU PIONEER BIOSCIENCE PUBL CO
PI HONG KONG
PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG,
00000, PEOPLES R CHINA
SN 2072-1439
EI 2077-6624
J9 J THORAC DIS
JI J. Thorac. Dis.
PD MAR
PY 2016
VL 8
SU 2
BP S204
EP S209
DI 10.3978/j.issn.2072-1439.2016.01.71
PG 6
WC Respiratory System
SC Respiratory System
GA DG5EZ
UT WOS:000372099900013
PM 26981272
ER
PT J
AU Madariaga, ML
Gaissert, HA
AF Madariaga, Maria Lucia
Gaissert, Henning A.
TI Reresection for recurrent stenosis after primary tracheal repair
SO JOURNAL OF THORACIC DISEASE
LA English
DT Review
DE Trachea; restenosis; reoperation
ID RESECTION; RECONSTRUCTION; COMPLICATIONS; ANASTOMOSIS; AIRWAY
AB Failure of the anastomosis after primary tracheal reconstruction for benign disease is uncommon. Here we review the available evidence on tracheal restenosis and the results of second reconstructions. Factors associated with failed primary anastomosis are examined. Temporizing immediate and alternative long-term management with T-tube or tracheostomy is described, emphasizing the role of tracheal stenting in abating the urgency for reoperation. From available evidence, elective reoperative treatment of failed tracheal reconstruction should be considered in selected patients after careful review and reversal of patient-and operation-specific factors that initiated failure. Referral to a high-volume center with a deep bench of nursing, anesthesiologic and surgical expertise is recommended for reoperation.
C1 [Madariaga, Maria Lucia; Gaissert, Henning A.] Massachusetts Gen Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02114 USA.
RP Gaissert, HA (reprint author), Massachusetts Gen Hosp, Blake 1570,55 Fruit St, Boston, MA 02114 USA.
EM hgaissert@partners.org
NR 16
TC 1
Z9 1
U1 1
U2 1
PU PIONEER BIOSCIENCE PUBL CO
PI HONG KONG
PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG,
00000, PEOPLES R CHINA
SN 2072-1439
EI 2077-6624
J9 J THORAC DIS
JI J. Thorac. Dis.
PD MAR
PY 2016
VL 8
SU 2
BP S153
EP S159
DI 10.3978/j.issn.2072-1439.2016.01.66
PG 7
WC Respiratory System
SC Respiratory System
GA DG5EZ
UT WOS:000372099900007
PM 26981266
ER
PT J
AU Mysore, VS
Szablowski, J
Dervan, PB
Frost, PJ
AF Mysore, Veena S.
Szablowski, Jerzy
Dervan, Peter B.
Frost, Patrick J.
TI A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in
Multiple Myeloma Has Potent Antitumor Activity
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID BONE-MARROW ANGIOGENESIS; IN-VIVO; ACTIVATED PRODRUG; INDUCIBLE FACTOR;
CELLS; CANCER; TUMOR; EXPRESSION; TRANSLATION; INHIBITION
AB Multiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although the mechanisms remain unclear, hypoxic conditions in the bone marrow have been implicated in contributing to multiple myeloma progression, angiogenesis, and resistance to chemotherapy. These effects occur via adaptive cellular responses mediated by hypoxia-inducible transcription factors (HIF), and targeting HIFs can have anticancer effects in both solid and hematologic malignancies. Here, it was found that in most myeloma cell lines tested, HIF1 alpha, but not HIF2 alpha expression was oxygen dependent, and this could be explained by the differential expression of the regulatory prolyl hydroxylase isoforms. The anti-multiple myeloma effects of a sequence-specific DNA-binding pyrrole-imidazole (Py-Im) polyamide (HIF-PA), which disrupts the HIF heterodimer from binding to its cognate DNA sequences, were also investigated. HIF-PA is cell permeable, localizes to the nuclei, and binds specific regions of DNA with an affinity comparable with that of HIFs. Most of the multiple myeloma cells were resistant to hypoxia-mediated apoptosis, and HIF-PA treatment could overcome this resistance in vitro. Using xenograft models, it was determined that HIF-PA significantly decreased tumor volume and increased hypoxic and apoptotic regions within solid tumor nodules and the growth of myeloma cells engrafted in the bone marrow. This provides a rationale for targeting the adaptive cellular hypoxic response of the O-2-dependent activation of HIF alpha using polyamides.
C1 [Mysore, Veena S.; Frost, Patrick J.] Greater Los Angeles Vet Adm Healthcare Syst, 11301Wilshire Blvd,Bldg 114,Room 113, Los Angeles, CA 90073 USA.
[Mysore, Veena S.; Frost, Patrick J.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Szablowski, Jerzy; Dervan, Peter B.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
RP Frost, PJ (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, 11301Wilshire Blvd,Bldg 114,Room 113, Los Angeles, CA 90073 USA.
EM pfrost@ucla.edu
FU MERIT from the United States Department of Veterans Affairs Biomedical
Laboratory Research and Development Service [1I01BX001532]; NIH
[GM051747]
FX This work was supported by a MERIT grant 1I01BX001532 (to P.J. Frost)
from the United States Department of Veterans Affairs Biomedical
Laboratory Research and Development Service and a NIH GM051747 grant (to
P.B. Dervan).
NR 50
TC 0
Z9 0
U1 4
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2016
VL 14
IS 3
BP 253
EP 266
DI 10.1158/1541-7786.MCR-15-0361
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DG3XM
UT WOS:000372004400002
PM 26801054
ER
PT J
AU Li, H
Wheeler, S
Park, Y
Ju, ZL
Thomas, SM
Fichera, M
Egloff, AM
Lui, VW
Duvvuri, U
Bauman, JE
Mills, GB
Grandis, JR
AF Li, Hua
Wheeler, Sarah
Park, Yongseok
Ju, Zhenlin
Thomas, Sufi M.
Fichera, Michele
Egloff, Ann M.
Lui, Vivian W.
Duvvuri, Umamaheswar
Bauman, Julie E.
Mills, Gordon B.
Grandis, Jennifer R.
TI Proteomic Characterization of Head and Neck Cancer Patient-Derived
Xenografts
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; PHASE PROTEIN ARRAY; DRUG DEVELOPMENT;
PANCREATIC-CANCER; GENOMIC CHARACTERIZATION; PREDICTIVE BIOMARKERS;
TUMOR XENOGRAFTS; IN-VITRO; MODELS; MOUSE
AB Despite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC), survival rates have remained stagnant due to the paucity of preclinical models that accurately reflect the human tumor. Patient-derived xeno-grafts (PDX) are an emerging model system where patient tumors are implanted directly into mice. Increased understanding of the application and limitations of PDXs will facilitate their rational use. Studies to date have not reported protein profiles of PDXs. Therefore, we developed a large cohort of HNSCC PDXs and found that tumor take rate was not influenced by the clinical, pathologic, or processing features. Protein expression profiles, from a subset of the PDXs, were characterized by reverse-phase protein array and the data was compared with The Cancer Genome Atlas HNSCC data. Cluster analysis revealed that HNSCC PDXs were more similar to primary HNSCC than to any other tumor type. Interestingly, while a significant fraction of proteins were expressed similarly in both primary HNSCC and PDXs, a subset of proteins/phosphoproteins were expressed at higher (or lower) levels in PDXs compared with primary HNSCC. These findings indicate that the proteome is generally conserved in PDXs, but mechanisms for both positive and negative model selection and/or differences in the stromal components exist.
C1 [Li, Hua; Egloff, Ann M.; Duvvuri, Umamaheswar; Grandis, Jennifer R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA.
[Wheeler, Sarah; Fichera, Michele; Grandis, Jennifer R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
[Park, Yongseok] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
[Ju, Zhenlin; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
[Thomas, Sufi M.] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA.
[Thomas, Sufi M.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA.
[Lui, Vivian W.] Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China.
[Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Healthcare Syst, Univ Dr Campus, Pittsburgh, PA USA.
[Bauman, Julie E.] Univ Pittsburgh, Dept Internal Med Hematol Oncol, Pittsburgh, PA USA.
[Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
[Grandis, Jennifer R.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94158 USA.
RP Grandis, JR (reprint author), Univ Calif San Francisco, 1450 3rd St,Room HD200, San Francisco, CA 94158 USA.
EM jennifer.grandis@ucsf.edu
RI Lui, Vivian/I-5458-2016
FU NIH [P50CA097190, K07 CA137140]; American Cancer Society; Department of
Veterans Affairs BLRD; NCI [CA16672]
FX This work was supported by grants NIH P50CA097190 and the American
Cancer Society (to J.R. Grandis), NIH K07 CA137140 (to A.M. Egloff),
Department of Veterans Affairs BLR&D (to U. Duvvuri). RPPA work was
performed in the MDACC CCSG supported core NCI CA16672.
NR 40
TC 4
Z9 5
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2016
VL 14
IS 3
BP 278
EP 286
DI 10.1158/1541-7786.MCR-15-0354
PG 9
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DG3XM
UT WOS:000372004400004
PM 26685214
ER
PT J
AU Videnovic, A
Willis, GL
AF Videnovic, Aleksandar
Willis, Gregory L.
TI Circadian system A novel diagnostic and therapeutic target in
Parkinson's disease?
SO MOVEMENT DISORDERS
LA English
DT Review
DE Parkinson's; circadian; sleep; clock genes; chronobiology
ID EXCESSIVE DAYTIME SLEEPINESS; AUTONOMIC NERVOUS-SYSTEM; SUPRACHIASMATIC
NUCLEUS; SECRETION PATTERN; BRIGHT LIGHT; MOUSE MODEL; DE-NOVO;
MELATONIN SECRETION; METABOLIC RHYTHMS; WAKE REGULATION
AB The circadian system regulates biological rhythmicity in the human body. The role of the circadian system in neurological disorders is a theme that is attracting an increasing amount of interest from the scientific community. This has arisen, in part, from emerging evidence that disorders such as Parkinson's disease (PD) are multifactorial with many features exhibiting diurnal fluctuations, thereby suggestive of circadian involvement. Although the importance of fluctuating motor and nonmotor manifestations in PD have been well acknowledged, the role of the circadian system has received little attention until recently. It is proposed that intervening with circadian function provides a novel research avenue down which new strategies for improving symptomatic treatment and slowing of the progressive degenerative process can be approached to lessen the burden of PD. In this article we review the literature describing existing circadian research in PD and its experimental models. (c) 2016 International Parkinson and Movement Disorder Society
C1 [Videnovic, Aleksandar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Movement Disorders Unit,Div Sleep Med, Boston, MA 02114 USA.
[Willis, Gregory L.] Bronowski Inst Behav Neurosci, Kyneton, Vic, Australia.
RP Videnovic, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, 165 Cambridge St,Suite 600, Boston, MA 02114 USA.
EM avidenovic@mgh.harvard.edu
FU NIH/NINDS [K23 NS072283]; Bronowski Institute of Behavioural
Neuroscience
FX Dr. Videnovic - NIH/NINDS, K23 NS072283; Dr. Willis - The Bronowski
Institute of Behavioural Neuroscience.
NR 83
TC 4
Z9 4
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR
PY 2016
VL 31
IS 3
BP 260
EP 269
DI 10.1002/mds.26509
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA DG7SR
UT WOS:000372284500002
PM 26826022
ER
PT J
AU Martinez-Martin, P
Leentjens, AFG
de Pedro-Cuesta, J
Chaudhuri, KR
Schrag, AE
Weintraub, D
AF Martinez-Martin, Pablo
Leentjens, Albert F. G.
de Pedro-Cuesta, Jesus
Chaudhuri, Kallol Ray
Schrag, Anette E.
Weintraub, Daniel
TI Accuracy of screening instruments for detection of neuropsychiatric
syndromes in Parkinson's disease
SO MOVEMENT DISORDERS
LA English
DT Review
DE Parkinson's disease; neuropsychiatric symptoms; screening; instruments;
accuracy
ID GERIATRIC DEPRESSION SCALE; IMPULSIVE-COMPULSIVE DISORDERS; DRUG-INDUCED
PSYCHOSIS; ANXIETY RATING-SCALES; QUALITY-OF-LIFE; NONMOTOR SYMPTOMS;
HOSPITAL ANXIETY; RECOGNIZING DEPRESSION; COGNITIVE IMPAIRMENT;
REPETITIVE BEHAVIORS
AB Parkinson's disease includes neuropsychiatric manifestations, such as depression, anxiety, apathy, psychosis, and impulse control disorders, which often are unreported by patients and caregivers or undetected by doctors. Given their substantial impact on patients and caregivers as well as the existence of effective therapies for some of these disorders, screening for neuropsychiatric symptoms is important. Instruments for screening have a particular methodology for validation, and their performance is expressed in terms of accuracy compared with formal diagnostic criteria. The present study reviews the attributes of the screening instruments applied for detection of the aforementioned major neuropsychiatric symptoms in Parkinson's disease. A quasi-systematic review (including predefined selection criteria, but not evaluating the quality of the reviewed studies) was carried out on the basis of previous systematic reviews (commissioned by the American Academy of Neurology and the Movement Disorder Society) and made current by conducting a literature search (2005-2014). For depression, 11 scales and questionnaires were shown to be valid for Parkinson's disease screening. The recently developed Parkinson Anxiety Scale and the Geriatric Anxiety Inventory demonstrate satisfactory properties as screening instruments for anxiety, and the Lille Apathy Rating Scale for detection of apathy. No scale adequately screens for psychosis, so a specific psychosis instrument should be developed. The Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (Questionnaire and Rating Scale) are valid for comprehensive screening of impulse control disorders, and the Parkinson's Disease-Sexual Addiction Screening Test for hypersexuality specifically. (c) 2015 International Parkinson and Movement Disorder Society
C1 [Martinez-Martin, Pablo; de Pedro-Cuesta, Jesus] Carlos III Inst Hlth, Natl Ctr Epidemiol, Avda Monforte de Lemos 5, Madrid 28029, Spain.
[Martinez-Martin, Pablo; de Pedro-Cuesta, Jesus] Carlos III Inst Hlth, CIBERNED, Madrid 28029, Spain.
[Leentjens, Albert F. G.] Maastricht Univ, Med Ctr, Dept Psychiat, NL-6200 MD Maastricht, Netherlands.
[Chaudhuri, Kallol Ray] Kings Coll London, Natl Parkinson Fdn Int Ctr Excellence, London WC2R 2LS, England.
[Chaudhuri, Kallol Ray] South London & Maudsley NHS Fdn Trust, Natl Inst Hlth Res, Mental Hlth Biomed Res Ctr, London, England.
[Chaudhuri, Kallol Ray] South London & Maudsley NHS Fdn Trust, Dementia Unit, London, England.
[Chaudhuri, Kallol Ray] Kings Coll London, London WC2R 2LS, England.
[Schrag, Anette E.] UCL, Inst Neurol, Royal Free Campus, London, England.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Martinez-Martin, P (reprint author), Carlos III Inst Hlth, Natl Ctr Epidemiol, Avda Monforte de Lemos 5, Madrid 28029, Spain.
EM pmartinez@isciii.es
NR 97
TC 6
Z9 6
U1 5
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR
PY 2016
VL 31
IS 3
BP 270
EP 279
DI 10.1002/mds.26522
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA DG7SR
UT WOS:000372284500003
PM 26695691
ER
PT J
AU Moelter, ST
Weintraub, D
Mace, L
Cary, M
Sullo, E
Xie, SX
Karlawish, J
AF Moelter, Stephen T.
Weintraub, Daniel
Mace, Lauren
Cary, Mark
Sullo, Elizabeth
Xie, Sharon X.
Karlawish, Jason
TI Research consent capacity varies with executive function and memory in
Parkinson's disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; decision making; capacity; cognitive impairment;
informed consent
ID MILD COGNITIVE IMPAIRMENT; DEMENTIA; TRIAL
AB BackgroundWe examined the association between cognitive domains and research consent capacity in PD. Our hypothesis was that research consent capacity is best predicted by executive function.
MethodsA cohort of 90 PD patients and 30 healthy older adults were administered the MacArthur Competence Assessment Tool for Clinical Research, Dementia Rating Scale-2, and the MoCA. Experts classified patients as either capable or not capable of providing informed consent to participate in two clinical trials.
ResultsMacArthur Competence Assessment Tool for Clinical Research Reasoning scores for both clinical trial types were most associated with executive functions and delayed recall. As scores on these domains improved, the odds of an expert rating of capable of consent increased.
ConclusionsThese results extend our previous findings by demonstrating that memory and executive abilities appear closely associated with capacity when evaluated using either a structured interview or expert judgment of that interview. (c) 2016 International Parkinson and Movement Disorder Society
C1 [Moelter, Stephen T.; Mace, Lauren] Univ Sci, Dept Behav & Social Sci, 600 South 43rd St, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Geriatr Psychiat Sect, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Cary, Mark; Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Sullo, Elizabeth; Karlawish, Jason] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Alzheimers Dis Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Moelter, ST (reprint author), Univ Sci, Dept Behav & Social Sci, 600 South 43rd St, Philadelphia, PA 19104 USA.
EM s.moelte@usciences.edu
FU National Institute of Neurological Disorders and Stroke [R01NS65087];
Morris K. Udall Center for Parkinson's Disease Research [P50 NS053488,
NS062684]; National Institute on Aging [AG10124]
FX This work was supported by the National Institute of Neurological
Disorders and Stroke (R01NS65087), Morris K. Udall Center for
Parkinson's Disease Research (P50 NS053488 and NS062684), and the
National Institute on Aging (AG10124).
NR 15
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR
PY 2016
VL 31
IS 3
BP 414
EP 417
DI 10.1002/mds.26469
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA DG7SR
UT WOS:000372284500026
PM 26861463
ER
PT J
AU Bhattacharyya, S
Bakshi, R
Logan, R
Ascherio, A
Macklin, EA
Schwarzschild, MA
AF Bhattacharyya, Shamik
Bakshi, Rachit
Logan, Robert
Ascherio, Alberto
Macklin, Eric A.
Schwarzschild, Michael A.
TI Oral Inosine Persistently Elevates Plasma antioxidant capacity in
Parkinson's disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; antioxidant; uric acid; urate; inosine
ID OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; CEREBROSPINAL-FLUID;
MEDITERRANEAN DIET; URIC-ACID; URATE; RISK; PROGRESSION; SERUM;
SUPPLEMENTATION
AB IntroductionHigher serum urate predicts slower progression in PD. The aim of this work was to assess whether oral inosine alters antioxidant capacity of plasma or CSF or urinary markers of oxidative injury in early PD.
MethodsWe assayed plasma and CSF antioxidant capacity by ferric-reducing antioxidant power and measured DNA oxidation adduct 8-hydroxydeoxyguanosine from urine in Safety of URate Elevation in PD, a randomized, placebo-controlled trial of oral inosine assessing safety of elevating serum urate from <6 mg/dL to 6.1-7.0 or 7.1-8.0 mg/dL in patients with early PD.
ResultsAt 6 months, antioxidant capacity was 29% higher among mild and 43% higher among moderate group participants compared to placebo and correlated with change in serum urate (r = 0.86) and inversely with rate of clinical decline (r=-0.26). CSF antioxidant capacity and urine 8-hydroxydeoxyguanosine did not differ.
ConclusionsThe findings demonstrate a dose-dependent, persistent elevation of plasma antioxidant capacity from oral inosine of potential therapeutic relevance. (c) 2016 International Parkinson and Movement Disorder Society
C1 [Bhattacharyya, Shamik; Bakshi, Rachit; Logan, Robert; Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, Mol Neurobiol Lab, Boston, MA 02114 USA.
[Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Macklin, Eric A.] Massachusetts Gen Hosp, Dept Med, Ctr Biostat, Boston, MA 02114 USA.
[Bhattacharyya, Shamik] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.
[Bhattacharyya, Shamik; Bakshi, Rachit; Ascherio, Alberto; Macklin, Eric A.; Schwarzschild, Michael A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Bhattacharyya, S (reprint author), MassGeneral Inst Neurodegenerat Dis, Bldg 114,Charlestown Navy Yard,16th St, Charlestown, MA 02129 USA.
EM sbhattacharyya3@partners.org
OI Bhattacharyya, Shamik/0000-0001-8047-3622; Macklin,
Eric/0000-0003-1618-3502
FU Michael J. Fox Foundation for Parkinson's Research; Department of
Defense [W81XWH-11-1-0150]; Granite State Development; Harvard
NeuroDiscovery Center
FX The authors were supported by a grant from the Michael J. Fox Foundation
for Parkinson's Research, Department of Defense W81XWH-11-1-0150 and
Granite State Development, and the Harvard NeuroDiscovery Center.
NR 28
TC 4
Z9 4
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR
PY 2016
VL 31
IS 3
BP 417
EP 421
DI 10.1002/mds.26483
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA DG7SR
UT WOS:000372284500027
PM 26805433
ER
PT J
AU Adamala, KP
Engelhart, AE
Szostak, JW
AF Adamala, Katarzyna P.
Engelhart, Aaron E.
Szostak, Jack W.
TI Collaboration between primitive cell membranes and soluble catalysts
SO NATURE COMMUNICATIONS
LA English
DT Article
ID VITRO SELECTED RIBOZYMES; RNA WORLD; MODEL PROTOCELLS; BOND FORMATION;
METAL-IONS; LIFE; CHEMISTRY; LIPOSOMES; RIBOSOME; ORIGINS
AB One widely held model of early life suggests primitive cells consisted of simple RNA-based catalysts within lipid compartments. One possible selective advantage conferred by an encapsulated catalyst is stabilization of the compartment, resulting from catalyst-promoted synthesis of key membrane components. Here we show model protocell vesicles containing an encapsulated enzyme that promotes the synthesis of simple fatty acid derivatives become stabilized to Mg2+, which is required for ribozyme activity and RNA synthesis. Thus, protocells capable of such catalytic transformations would have enjoyed a selective advantage over other protocells in high Mg2+ environments. The synthetic transformation requires both the catalyst and vesicles that solubilize the water-insoluble precursor lipid. We suggest that similar modified lipids could have played a key role in early life, and that primitive lipid membranes and encapsulated catalysts, such as ribozymes, may have acted in conjunction with each other, enabling otherwise-impossible chemical transformations within primordial cells.
C1 [Adamala, Katarzyna P.; Engelhart, Aaron E.; Szostak, Jack W.] Massachusetts Gen Hosp, Howard Hughes Med Inst, 185 Cambridge St, Boston, MA 02114 USA.
[Adamala, Katarzyna P.; Engelhart, Aaron E.; Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol, 185 Cambridge St, Boston, MA 02114 USA.
[Adamala, Katarzyna P.; Engelhart, Aaron E.; Szostak, Jack W.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, 185 Cambridge St, Boston, MA 02114 USA.
RP Szostak, JW (reprint author), Massachusetts Gen Hosp, Howard Hughes Med Inst, 185 Cambridge St, Boston, MA 02114 USA.; Szostak, JW (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, 185 Cambridge St, Boston, MA 02114 USA.; Szostak, JW (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM szostak@molbio.mgh.harvard.edu
OI Adamala, Kate/0000-0003-1066-7207
FU NASA Exobiology grant [NNX07AJ09G]; Simons Foundation [290363]; NASA;
Massachusetts General Hospital Executive Committee on Research
FX We thank Mr Tony Jia, Dr Neha Kamat, Ms Lin Jin, and Dr Christian
Hentrich for helpful discussions. This work was supported in part by
NASA Exobiology grant NNX07AJ09G to J.W.S. and a grant (290363) from the
Simons Foundation to J.W.S. A.E.E. was supported by an appointment to
the NASA Postdoctoral Program, administered by Oak Ridge Associated
Universities through a contract with NASA and a Tosteson Fellowship from
the Massachusetts General Hospital Executive Committee on Research.
J.W.S. is an investigator of the Howard Hughes Medical Institute.
NR 33
TC 2
Z9 3
U1 15
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 11041
DI 10.1038/ncomms11041
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH0UK
UT WOS:000372499400001
PM 26996603
ER
PT J
AU Du, Z
Sun, T
Hacisuleyman, E
Fei, T
Wang, XD
Brown, M
Rinn, JL
Lee, MGS
Chen, YW
Kantoff, PW
Liu, XS
AF Du, Zhou
Sun, Tong
Hacisuleyman, Ezgi
Fei, Teng
Wang, Xiaodong
Brown, Myles
Rinn, John L.
Lee, Mary Gwo-Shu
Chen, Yiwen
Kantoff, Philip W.
Liu, X. Shirley
TI Integrative analyses reveal a long noncoding RNA-mediated sponge
regulatory network in prostate cancer
SO NATURE COMMUNICATIONS
LA English
DT Article
ID TUMOR-SUPPRESSOR PTEN; IN-SITU HYBRIDIZATION; INTRAEPITHELIAL NEOPLASIA;
MICRORNA SPONGES; DOWN-REGULATION; MESSENGER-RNAS; CELL-SURVIVAL; GENE;
EXPRESSION; BIOLOGY
AB Mounting evidence suggests that long noncoding RNAs (lncRNAs) can function as microRNA sponges and compete for microRNA binding to protein-coding transcripts. However, the prevalence, functional significance and targets of lncRNA-mediated sponge regulation of cancer are mostly unknown. Here we identify a lncRNA-mediated sponge regulatory network that affects the expression of many protein-coding prostate cancer driver genes, by integrating analysis of sequence features and gene expression profiles of both lncRNAs and protein-coding genes in tumours. We confirm the tumour-suppressive function of two lncRNAs (TUG1 and CTB-89H12.4) and their regulation of PTEN expression in prostate cancer. Surprisingly, one of the two lncRNAs, TUG1, was previously known for its function in polycomb repressive complex 2 (PRC2)-mediated transcriptional regulation, suggesting its sub-cellular localization-dependent function. Our findings not only suggest an important role of lncRNA-mediated sponge regulation in cancer, but also underscore the critical influence of cytoplasmic localization on the efficacy of a sponge lncRNA.
C1 [Du, Zhou] Shanghai Pulm Hosp, Shanghai Key Lab TB, Shanghai 200433, Peoples R China.
[Du, Zhou] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China.
[Sun, Tong; Fei, Teng; Wang, Xiaodong; Brown, Myles; Lee, Mary Gwo-Shu; Kantoff, Philip W.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Sun, Tong; Fei, Teng; Wang, Xiaodong; Brown, Myles; Lee, Mary Gwo-Shu; Kantoff, Philip W.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Sun, Tong] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA.
[Hacisuleyman, Ezgi] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Hacisuleyman, Ezgi; Rinn, John L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Hacisuleyman, Ezgi; Rinn, John L.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA.
[Fei, Teng; Brown, Myles; Liu, X. Shirley] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
[Rinn, John L.] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.
[Chen, Yiwen] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Div Quantitat Sci, Houston, TX 77030 USA.
[Kantoff, Philip W.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.
[Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
RP Kantoff, PW (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Kantoff, PW (reprint author), Harvard Univ, Sch Med, Boston, MA 02215 USA.; Liu, XS (reprint author), Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.; Chen, YW (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Div Quantitat Sci, Houston, TX 77030 USA.; Kantoff, PW (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.; Liu, XS (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.; Liu, XS (reprint author), Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
EM ychen26@mdanderson.org; kantoff@mskcc.org; xsliu@jimmy.harvard.edu
FU National Natural Science Foundation of China [31329003, 2012M520923];
University of Texas Rising STARs award; University of Texas at MD
Anderson Cancer Center start-up fund; Texas CPRIT grant [RR140071]; US
National Cancer Institute (NCI; MD Anderson TCGA Genome Data Analysis
Center) [CA143883]; Cancer Prevention Research Institute of Texas
(CPRIT) [RP130397]; Mary K. Chapman Foundation; Michael and Susan Dell
Foundation; MD Anderson Cancer Center Support Grant [P30 CA016672];
NIH/NIEHS [R01ES020260]; NIH/NCI [U01CA180980, R00CA175290]
FX We thank Dr Bert Vogelstein for sharing the wild-type HCT116 and HCT116
Dicerex5 cells, Dr Marc Beal for his help with RNA-FISH
probe-design and, Dr Xuerui Yang and Dr Andrea Califano for sharing the
luciferase-PTEN-3'UTR reporter construct. This work was partially funded
by National Natural Science Foundation of China 31329003 to X.S.L.,
2012M520923 to D.Z., NIH/NCI U01CA180980 to X.S.L., NIH/NCI R00CA175290,
University of Texas Rising STARs award, University of Texas at MD
Anderson Cancer Center start-up fund and Texas CPRIT grant RR140071 to
Y.C. This work was also supported in part by US National Cancer
Institute (NCI; MD Anderson TCGA Genome Data Analysis Center) grant
number CA143883, the Cancer Prevention Research Institute of Texas
(CPRIT) grant number RP130397, the Mary K. Chapman Foundation, the
Michael and Susan Dell Foundation (honoring Lorraine Dell) and MD
Anderson Cancer Center Support Grant P30 CA016672 (the Bioinformatics
Shared Resource). J.L.R. is the Alvin and Esta Star Associate Professor
and is supported by NIH/NIEHS R01ES020260.
NR 45
TC 15
Z9 15
U1 7
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10982
DI 10.1038/ncomms10982
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG6IW
UT WOS:000372188800001
PM 26975529
ER
PT J
AU Ke, YG
Meyer, T
Shih, WM
Bellot, G
AF Ke, Yonggang
Meyer, Travis
Shih, William M.
Bellot, Gaetan
TI Regulation at a distance of biomolecular interactions using a DNA
origami nanoactuator
SO NATURE COMMUNICATIONS
LA English
DT Article
ID NANOSCALE SHAPES; FOLDING DNA; NANOSTRUCTURES; PATTERNS; BINDING;
ARRAYS; BOX
AB The creation of nanometre-sized structures that exhibit controllable motions and functions is a critical step towards building nanomachines. Recent developments in the field of DNA nanotechnology have begun to address these goals, demonstrating complex static or dynamic nanostructures made of DNA. Here we have designed and constructed a rhombus-shaped DNA origami 'nanoactuator' that uses mechanical linkages to copy distance changes induced on one half ('the driver') to be propagated to the other half ('the mirror'). By combining this nanoactuator with split enhanced green fluorescent protein (eGFP), we have constructed a DNA-protein hybrid nanostructure that demonstrates tunable fluorescent behaviours via long-range allosteric regulation. In addition, the nanoactuator can be used as a sensor that responds to specific stimuli, including changes in buffer composition and the presence of restriction enzymes or specific nucleic acids.
C1 [Ke, Yonggang; Meyer, Travis] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA.
[Ke, Yonggang; Meyer, Travis] Emory Univ, Atlanta, GA 30322 USA.
[Shih, William M.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
[Shih, William M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.
[Shih, William M.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Bellot, Gaetan] CNRS, CNRS Unite Mixte Rech UMR 5203, Inst Natl Sante & Rech Med, Dept Neurosci,Inst Genom Fonct,INSERM U1191, 141 Rue Cardonille, F-34000 Montpellier, France.
[Bellot, Gaetan] Univ Montpellier, F-34000 Montpellier, France.
RP Ke, YG (reprint author), Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA.; Ke, YG (reprint author), Emory Univ, Atlanta, GA 30322 USA.; Bellot, G (reprint author), CNRS, CNRS Unite Mixte Rech UMR 5203, Inst Natl Sante & Rech Med, Dept Neurosci,Inst Genom Fonct,INSERM U1191, 141 Rue Cardonille, F-34000 Montpellier, France.; Bellot, G (reprint author), Univ Montpellier, F-34000 Montpellier, France.
EM yonggang.ke@emory.edu; gaetan.bellot@inserm.fr
OI Meyer, Travis/0000-0002-8047-4649
FU Emory Department of Biomedical Engineering startup fund; Emory Billi and
Bernie Marcus Research Award; Wyss Institute Faculty Grant; ARO MURI
grant [W911NF1210420]; ONR Grants [N000014091118, N000141010241]; NIH
[1DP2OD004641]; National Science Foundation [DGE-1148903]
FX This work is supported by an Emory Department of Biomedical Engineering
startup fund and an Emory 2014 Billi and Bernie Marcus Research Award to
Y.K., a Wyss Institute Faculty Grant, ARO MURI grant W911NF1210420, ONR
Grants N000014091118 and N000141010241, and an NIH Director New
Innovator Award 1DP2OD004641 to W.M.S. T.M. is supported by a National
Science Foundation Graduate Research Fellowship under grant number
DGE-1148903.
NR 42
TC 4
Z9 4
U1 18
U2 63
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10935
DI 10.1038/ncomms10935
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG9MW
UT WOS:000372408100001
PM 26988942
ER
PT J
AU Kantor, ED
Rehm, CD
Haas, JS
Chan, AT
Giovannucci, EL
AF Kantor, Elizabeth D.
Rehm, Colin D.
Haas, Jennifer S.
Chan, Andrew T.
Giovannucci, Edward L.
TI Trends in Prescription Drug Use Among Adults in the United States From
1999-2012
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
AB Obstet Gynecol Surv 2016;71(3):131-133 Prescription drug usage is a major expenditure in the United States, and evidence indicates that this usage is increasing. Because practice patterns are continually evolving, an updated comprehensive assessment of prescription drug use is important to reflect the changing health needs, advances in treatment, new clinical guidelines, the entrance or exit of drugs from the market, and shifts in policies regarding drug marketing and promotion.
C1 [Kantor, Elizabeth D.; Giovannucci, Edward L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Kantor, Elizabeth D.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
[Rehm, Colin D.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
[Rehm, Colin D.] Montefiore Med Ctr, Off Community & Populat Hlth, 111 E 210th St, Bronx, NY 10467 USA.
[Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.
[Haas, Jennifer S.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
[Chan, Andrew T.; Giovannucci, Edward L.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA.
[Giovannucci, Edward L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
RP Kantor, ED (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.; Kantor, ED (reprint author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
NR 2
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD MAR
PY 2016
VL 71
IS 3
BP 131
EP 133
DI 10.1097/OGX.0000000000000306
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DG4JN
UT WOS:000372038600001
ER
PT J
AU Jena, AB
Schoemaker, L
Bhattacharya, J
Seabury, SA
AF Jena, Anupam B.
Schoemaker, Lena
Bhattacharya, Jay
Seabury, Seth A.
TI Physician Spending and Subsequent Risk of Malpractice Claims:
Observational Study
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
ID CESAREAN DELIVERY
AB Obstet Gynecol Surv 2016;71(3):139-141 This study explores whether greater resource use (defensively motivated or not) is associated with reduced malpractice claims. Data were obtained from Florida Agency for Health Care Administration on all hospital discharges (from all nonstate, nonfederal Florida acute care hospitals) during 2000-2009, from the Florida Office of Insurance Regulation on all closed malpractice claims against Florida physicians with active medical licenses reported during the study period and on physician specialty from publicly available practitioner profiles maintained by the Florida Agency for Health Care Administration.
C1 [Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jena, Anupam B.; Bhattacharya, Jay; Seabury, Seth A.] Natl Bur Econ Res, Cambridge, MA 02138 USA.
[Schoemaker, Lena; Bhattacharya, Jay] Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA.
[Seabury, Seth A.] Univ So Calif, Dept Emergency Med, Los Angeles, CA USA.
[Seabury, Seth A.] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA.
RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.; Jena, AB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.; Jena, AB (reprint author), Natl Bur Econ Res, Cambridge, MA 02138 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD MAR
PY 2016
VL 71
IS 3
BP 139
EP 141
DI 10.1097/01.ogx.0000481018.20322.1f
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DG4JN
UT WOS:000372038600005
ER
PT J
AU Oeffinger, KC
Fontham, ETH
Etzioni, R
Herzig, A
Michaelson, JS
Shih, YCT
Walter, LC
Church, TR
Flowers, CR
LaMonte, SJ
Wolf, AMD
DeSantis, C
Lortet-Tieulent, J
Andrews, K
Manassaram-Baptiste, D
Saslow, D
Smith, RA
Brawley, OW
Wender, R
AF Oeffinger, Kevin C.
Fontham, Elizabeth T. H.
Etzioni, Ruth
Herzig, Abbe
Michaelson, James S.
Shih, Ya-Chen Tina
Walter, Louise C.
Church, Timothy R.
Flowers, Christopher R.
LaMonte, Samuel J.
Wolf, Andrew M. D.
DeSantis, Carol
Lortet-Tieulent, Joannie
Andrews, Kimberly
Manassaram-Baptiste, Deana
Saslow, Debbie
Smith, Robert A.
Brawley, Otis W.
Wender, Richard
TI Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update
From the American Cancer Society
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
AB Obstet Gynecol Surv 2016;71(3):153-155 The aim of this updated American Cancer Society (ACS) guideline was to provide guidance and flexibility for women at average risk for breast cancer about when to start and stop screening mammography and how frequently screening should be performed. Since the last ACS update on breast cancer screening in 2003, new evidence has accumulated showing the need for greater emphasis on harms associated with screening and for balance of benefits and harms.
C1 [Oeffinger, Kevin C.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Fontham, Elizabeth T. H.] Louisiana State Univ, Sch Publ Hlth, New Orleans, LA USA.
[Etzioni, Ruth] Univ Washington, Seattle, WA 98195 USA.
[Etzioni, Ruth] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Michaelson, James S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Michaelson, James S.] Harvard Univ, Sch Med, Boston, MA USA.
[Shih, Ya-Chen Tina] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Church, Timothy R.] Masonic Canc Ctr, Minneapolis, MN USA.
[Church, Timothy R.] Univ Minnesota, Minneapolis, MN USA.
[Flowers, Christopher R.] Emory Univ, Sch Med, Atlanta, GA USA.
[Flowers, Christopher R.] Winship Canc Inst, Atlanta, GA USA.
[Wolf, Andrew M. D.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
[DeSantis, Carol; Lortet-Tieulent, Joannie; Andrews, Kimberly; Manassaram-Baptiste, Deana; Saslow, Debbie; Smith, Robert A.; Brawley, Otis W.; Wender, Richard] Amer Canc Soc, Atlanta, GA 30329 USA.
RP Oeffinger, KC (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
RI Flowers, Christopher/F-1953-2010
OI Flowers, Christopher/0000-0002-9524-3990
NR 3
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD MAR
PY 2016
VL 71
IS 3
BP 153
EP 155
DI 10.1097/01.ogx.0000480954.49941.b5
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DG4JN
UT WOS:000372038600012
ER
PT J
AU Scalia-Wilbur, J
Colins, BL
Penson, RT
Dizon, DS
AF Scalia-Wilbur, Jennifer
Colins, Bradley L.
Penson, Richard T.
Dizon, Don S.
TI Breast Cancer Risk Assessment: Moving Beyond BRCA1 and 2
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
AB Obstet Gynecol Surv 2016;71(3):156-157 Women carrying germ line mutations of the BRCA gene are at high risk of developing breast and ovarian cancer. Since the discovery of the BRCA1 gene in 1994 and the BRCA2 gene 1 year later, efforts have been made to develop effective screening methods for detection of breast cancer.
C1 [Scalia-Wilbur, Jennifer] Brown Univ, Women & Infants Hosp, Program Womens Oncol, Canc Risk & Prevent Program, Providence, RI USA.
[Colins, Bradley L.] Harvard Univ, Sch Med, Boston, MA USA.
[Penson, Richard T.; Dizon, Don S.] Massachusetts Gen Hosp, Ctr Canc, Gynecol Oncol Program, Boston, MA USA.
[Penson, Richard T.; Dizon, Don S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Scalia-Wilbur, J (reprint author), Brown Univ, Women & Infants Hosp, Program Womens Oncol, Canc Risk & Prevent Program, Providence, RI USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD MAR
PY 2016
VL 71
IS 3
BP 156
EP 157
DI 10.1097/OGX.0000000000000297
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DG4JN
UT WOS:000372038600013
ER
PT J
AU Jakobiec, FA
Stagner, AM
Freitag, SK
Yoon, MK
AF Jakobiec, Frederick A.
Stagner, Anna M.
Freitag, Suzanne K.
Yoon, Michael K.
TI Unusual Eyelid Dermal Keratinous Cysts of Pilosebaceous Origin
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID VELLUS HAIR CYSTS; STEATOCYSTOMA MULTIPLEX; PALPEBRAL CONJUNCTIVA;
HYBRID CYSTS; DACRYOPS; SIMPLEX
AB Purpose: To describe 2 types of previously unrecognized dermal keratinous cysts of the eyelids2 single sebaceous duct cysts derived from the glands of Zeis and 2 cases of multiple eruptive vellus hair cysts, both types associated with the pilosebaceous apparatus.
Methods: Clinical records and paraffin sections subjected to hematoxylin and eosin and acid-fast staining were critically reviewed from each case, and additional sections were immunoreacted for cytokeratins (CKs) 7, 14, and 17.
Results: Two patients had a slowly enlarging solitary sebaceous duct keratinous cyst at the eyelid margin where the glands of Zeis are located. The squamous cell lining displayed a corrugated squamous membrane manifesting an eosinophilic, refractile, surface cuticle. Either a sebaceous gland or a hair was proximate to the cyst. The squamous lining was CK7(-), CK14(+), and CK17(+). Two other patients developed over 2 and 10 years a different condition consisting of unilateral or bilateral clusters, respectively, of small papules of the upper eyelids. These were lined by keratinizing squamous epithelium without a cuticular membrane. Numerous small vellus hairs along with keratin in the lumens were discovered with acid-fast staining. The epithelium was also CK7(-), CK14(+), and CK17(+).
Conclusions: Histopathologic and immunohistochemical studies can separate these 2 disparate new eyelid entities from the more common keratinous epidermoid cyst of the surface epidermis or the upper hair follicle (CK7(-), CK14(+), and CK17(-)). Simple local excision of the anterior lamella of the eyelid is appropriate for the sebaceous duct keratinous cysts of Zeis, but the multiple vellus hair cysts are comparatively refractory to treatment. Both superficial types of cysts are totally unrelated to the deeper Meibomian keratinous cyst, which is not associated with a hair structure and is situated in the tarsus rather than the dermis of the eyelids.
C1 [Jakobiec, Frederick A.; Stagner, Anna M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, David G Cogan Ophthalm Pathol Lab, Boston, MA USA.
[Freitag, Suzanne K.; Yoon, Michael K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalm Plast Surg Serv, Boston, MA USA.
RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, David G Cogan Lab Ophthalm Pathol, 243 Charles St,Suite 328, Boston, MA 02114 USA.
EM fred_jakobiec@meei.harvard.edu
NR 26
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0740-9303
EI 1537-2677
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD MAR-APR
PY 2016
VL 32
IS 2
BP 93
EP 97
DI 10.1097/IOP.0000000000000423
PG 5
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA DG4RN
UT WOS:000372060200003
PM 25719379
ER
PT J
AU Jakobiec, FA
Rashid, A
Massoud, V
Fay, A
AF Jakobiec, Frederick A.
Rashid, Alia
Massoud, Vicky
Fay, Aaron
TI Pseudoadenomatous Hyperplasia of the Inferior Forniceal Conjunctiva Due
To Prosthetic Irritation in an Anophthalmic Socket
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID CARCINOMA
AB Secondary complications in an anophthalmic socket can include late appearing shrinkage due to scarring and squamous cell carcinoma. This article reports a 51-year-old man who 27 years after an enucleation developed an inability to retain his ocular prosthesis due to an acquired multilobular fleshy mass in his inferior fornix. The patient had worn his prosthesis without removal for years at a time. Microscopic evaluation of the excised lesion disclosed a pseudoadenomatous (pseudoglandular) hyperplasia of the conjunctival epithelium with myriad goblet cells and accompanying chronic inflammation. In cross section, these structures microscopically resembled an adenoma but were found to display multifocal origins from the surface epithelium resembling exaggerated pseudoglands of Henle. Simple excision without recurrence 6 months later has permitted a new prosthesis to be comfortably worn with stability.
C1 [Jakobiec, Frederick A.; Rashid, Alia] David G Cogan Lab Ophthalm Pathol, Boston, MA USA.
[Jakobiec, Frederick A.; Rashid, Alia; Massoud, Vicky; Fay, Aaron] Harvard Univ, Sch Med, Boston, MA USA.
[Massoud, Vicky; Fay, Aaron] Massachusetts Eye & Ear Infirm, Ophthalm Plast Surg Serv, Boston, MA 02114 USA.
RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Ophthalm Pathol Lab, 243 Charles St,Suite 328, Boston, MA 02114 USA.
EM Fred_Jakobiec@meei.harvard.edu
NR 12
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0740-9303
EI 1537-2677
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD MAR-APR
PY 2016
VL 32
IS 2
BP E32
EP E34
DI 10.1097/IOP.0000000000000208
PG 3
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA DG4RT
UT WOS:000372060900004
PM 24911539
ER
PT J
AU Brawner, BM
Alexander, KA
Fannin, EF
Baker, JL
Davis, ZM
AF Brawner, Bridgette M.
Alexander, Kamila A.
Fannin, Ehriel F.
Baker, Jillian L.
Davis, Zupenda M.
TI The Role of Sexual Health Professionals in Developing a Shared Concept
of Risky Sexual Behavior as it Relates to HIV Transmission
SO PUBLIC HEALTH NURSING
LA English
DT Article
DE disease prevention; diversity; health promotion; HIV; AIDS; patient
education; prevention; programme planning; public health systems; sexual
behavior
ID INTIMATE PARTNER VIOLENCE; YOUNG-ADULTS; RELATIONSHIP POWER; DOMESTIC
VIOLENCE; ADOLESCENT GIRLS; UNITED-STATES; SELF-EFFICACY; SOUTH-AFRICA;
CONDOM USE; PREVENTION
AB Risky sexual behavior accounts for the majority of new HIV infections regardless of gender, age, geographic location, or ethnicity. The phrase, however, refers to a relatively nebulous concept that hampers development of effective sexual health communication strategies. The purpose of this paper was to propose development of a shared conceptual understanding of risky sexual behavior. We reviewed multidisciplinary HIV/AIDS literature to identify definitions of risky sexual behavior. Both the linguistic components and the social mechanisms that contribute to the concept of risky sexual behaviors were noted. Risky sexual behavior was often defined in a subjective manner in the literature, even in the scientific research. We urge a paradigm shift to focus on explicit behaviors and the social context of those behaviors in determining HIV risk. We also propose a new definition that reduces individual biases and promotes a broader discussion of the degree of sexual risk across a diversity of behavioral contexts. Sexual health professionals can strengthen practice and research initiatives by operating from a concise working definition of risky sexual behavior that is broadly transferable and expands beyond a traditional focus on identity-based groups.
C1 [Brawner, Bridgette M.] Univ Penn, Sch Nursing, Dept Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
[Brawner, Bridgette M.; Fannin, Ehriel F.] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.
[Alexander, Kamila A.] Johns Hopkins Sch Nursing, Dept Community Publ Hlth, Baltimore, MD USA.
[Fannin, Ehriel F.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.
[Baker, Jillian L.; Davis, Zupenda M.] La Salle Univ, Sch Nursing & Hlth Sci, Dept Urban Publ Hlth & Nutr, Philadelphia, PA 19141 USA.
RP Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Global Womens Hlth, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.; Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.
EM brawnerb@nursing.upenn.edu
FU Centers for Disease Control and Prevention [CDC U01PS003304]; National
Institute of Mental Health [NIH/NIMH R25MH087217]; Substance Abuse and
Mental Health Services Administration at American Nurses Association
Minority Fellowship Program [5SM058566-02]; Hampton-Penn Center for
Health Disparities Research [NINR P20NR008361]; Distinguished
Postdoctoral Fellowship; Fontaine Society Fellowship at University of
Pennsylvania; Individual Ruth L. Kirschstein NRSA Predoctoral Fellowship
[F31NR013121]; Ruth L. Kirschstein NRSA Postdoctoral Fellowship; Ruth L.
Kirschstein NRSA Predoctoral Fellowship [5T32NR007100-13]; National
Institute of Child Health & Human Development Diversity Research
Supplement Award [5R01HD061061-03]
FX This article was supported by funding to Dr. Brawner from the Centers
for Disease Control and Prevention (CDC U01PS003304), the National
Institute of Mental Health (NIH/NIMH R25MH087217; PI: B. Guthrie, J.),
the Substance Abuse and Mental Health Services Administration at the
American Nurses Association Minority Fellowship Program (5SM058566-02),
the Hampton-Penn Center for Health Disparities Research (NINR
P20NR008361), and the Distinguished Postdoctoral Fellowship and the
Fontaine Society Fellowship at the University of Pennsylvania. The
article was also supported by the Individual Ruth L. Kirschstein NRSA
Predoctoral Fellowship (F31NR013121) and the Ruth L. Kirschstein NRSA
Postdoctoral Fellowship (T32HDO64428; PI: Campbell) awarded to Dr.
Alexander; the Ruth L. Kirschstein NRSA Predoctoral Fellowship
(5T32NR007100-13; PI: Sommers) awarded to Ms. Ehriel Fannin; and funding
from a National Institute of Child Health & Human Development Diversity
Research Supplement Award (5R01HD061061-03; PI: Jemmott) to Dr. Baker.
NR 74
TC 0
Z9 0
U1 5
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0737-1209
EI 1525-1446
J9 PUBLIC HEALTH NURS
JI Public Health Nurs.
PD MAR-APR
PY 2016
VL 33
IS 2
BP 139
EP 150
DI 10.1111/phn.12216
PG 12
WC Public, Environmental & Occupational Health; Nursing
SC Public, Environmental & Occupational Health; Nursing
GA DG2PW
UT WOS:000371910700007
PM 26184496
ER
PT J
AU Pang, CE
Sarraf, D
Freund, KB
AF Pang, Claudine E.
Sarraf, David
Freund, K. Bailey
TI An Atypical Presentation of Bartonella Neuroretinitis Reply
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Letter
ID MYOPIA
C1 [Pang, Claudine E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
[Pang, Claudine E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
[Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
[Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
RP Pang, CE (reprint author), Vitreous Retina Macula Consultants New York, New York, NY USA.; Pang, CE (reprint author), Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2016
VL 36
IS 3
BP e24
EP e24
DI 10.1097/IAE.0000000000000990
PG 1
WC Ophthalmology
SC Ophthalmology
GA DG1MX
UT WOS:000371833300008
PM 26849457
ER
PT J
AU Chen, SS
Unruh, M
Williams, M
AF Chen, Shan Shan
Unruh, Mark
Williams, Mark
TI In Quality We Trust; but Quality of Life or Quality of Care?
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS;
SERUM-ALBUMIN; HEALTH-CARE; MAINTENANCE HEMODIALYSIS;
PERFORMANCE-MEASUREMENT; PRACTICE PATTERNS; VASCULAR ACCESS; MEMBRANE
FLUX
AB The ESRD program provides medical care to a diverse and medically complex patient population. The care for the ESRD patient population has become increasingly benchmarked with process of care measures. These measures include dialysis adequacy, anemia, nutrition, and vascular access outcomes. These process-related dialysis measures may not improve the care of the individual patient as care relates to the individual's goals and values. There is also evidence that these process measures may not be causally related to quality of life, hospitalization, and survival. The adoption of patient-reported outcomes may shift the balance toward more patient-centered care. However, the extent to which mandated measures of health-related quality of life and patient satisfaction result in improved outcomes remains unclear.
C1 [Chen, Shan Shan; Unruh, Mark] Univ New Mexico, Dept Internal Med, Sch Med, Div Nephrol, Albuquerque, NM 87131 USA.
[Unruh, Mark] Univ New Mexico, Raymond G Murphy VA Med Ctr, Sch Med, Renal Sect,Med Serv,Dept Med, Albuquerque, NM 87131 USA.
[Williams, Mark] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA.
RP Williams, M (reprint author), Harvard Univ, Sch Med, Med, One Joslin Pl, Boston, MA 02215 USA.; Williams, M (reprint author), Beth Israel Deaconess Med Ctr, Dialysis Operat, One Joslin Pl, Boston, MA 02215 USA.; Williams, M (reprint author), Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
EM mark.williams@joslin.harvard.edu
NR 57
TC 0
Z9 0
U1 3
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR
PY 2016
VL 29
IS 2
BP 103
EP 110
DI 10.1111/sdi.12470
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA DG7SC
UT WOS:000372283000003
PM 26860436
ER
PT J
AU Weisbord, SD
AF Weisbord, Steven D.
TI Patient-Centered Dialysis Care: Depression, Pain, and Quality of Life
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID STAGE RENAL-DISEASE; RECEIVING CHRONIC-HEMODIALYSIS; MAINTENANCE
HEMODIALYSIS; PSYCHOSOCIAL FACTORS; TRANSPLANT PATIENTS; MORTALITY RISK;
SYMPTOMS; PREVALENCE; ADHERENCE; HOSPITALIZATION
AB Remarkable advancements have been made in the provision of chronic dialysis therapy since its inception decades ago. A series of studies inform current dialysis dosing recommendations, while advancements in strategies to treat mineral and bone disease, acid-base and electrolyte disturbances, and anemia have facilitated the management of these well-recognized complications of ESRD. The collective result has been a model of chronic dialysis care focused principally on the achievement of metabolic and dialysis-related targets. In fact, guidelines such as the Kidney Disease Outcomes Quality Initiative put forth by the National Kidney Foundation recommend metrics that characterize successful dialysis care, including the attainment of specific solute clearance targets; maintenance of hemoglobin, calcium, phosphorous, and parathyroid hormone levels within target ranges; and the preferred use of primary arteriovenous fistulae for vascular access. This focus on serologic and dialysis-specific outcomes has helped renal providers manage the biochemical effects related to the loss of kidney function and has reduced ESRD-related morbidity and mortality. Yet, absent from this model of care is an emphasis on the treatment of bothersome symptoms and the impact of such treatment on quality of life (QOL). Among the many symptoms that affect patients on chronic dialysis, depression and pain are particularly common, strongly associated with decrements in QOL, and potentially treatable. This review discusses key research findings and unanswered questions pertaining to the prevalence, significance, and treatment of depression and pain and the effect of such treatment on QOL in patients dependent on chronic dialysis, with the broad goal of incorporating symptom management strategies into a paradigm of patient-centered dialysis care.
C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Med Serv Line, Renal Sect, Pittsburgh, PA USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, 7E Room 120,111F U, Pittsburgh, PA 15240 USA.
EM weisbordsd@upmc.edu
NR 47
TC 2
Z9 2
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR
PY 2016
VL 29
IS 2
BP 158
EP 164
DI 10.1111/sdi.12464
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA DG7SC
UT WOS:000372283000010
PM 26748494
ER
PT J
AU Saby, A
Miller, LS
AF Saby, Adam
Miller, Lawrence S.
TI Functional Assessment in End-Stage Renal Disease: Enhancing Quality of
Life
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID DIALYSIS PATIENTS; HEMODIALYSIS; MORTALITY; HEALTH; FACILITIES;
DISABILITY; CAPACITY; OUTCOMES; FALLS; RISK
AB Why do functional assessments in patients with end-stage renal disease (ESRD) matter? Multiple studies show that new dialysis patients undergo a substantial decline among activities of daily living. Moreover, poor functional status in ESRD patients is associated with early morality. That is why CMS has developed new criteria to assess ESRD patients in regards to their functional, psychologic, and cognitive capabilities. Functional assessments by health providers have been used in field of Rehabilitation Medicine for over 50 years; rehabilitation physicians have found them effective in establishing goals and monitoring improvement. Assessments can provide guidance by identifying the needs and types of intervention most suited for patients. Impairments can be addressed with referrals to physical therapy for gross motor issues, occupational therapy for self-care problems, psychiatry for mental disorders, and neurology for cognitive deficits. The more accurate the assessments over time, the more targeted and effective the therapies become. We believe that the new CMS goals to assess functionality will improve ESRD patient's quality of life, longevity, and long-term healthcare costs.
C1 [Saby, Adam] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Adm Hlth Care Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90095 USA.
[Miller, Lawrence S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Saby, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Adm Hlth Care Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90095 USA.; Saby, A (reprint author), Dept Phys Med & Rehabil 117, 11301 Wilshire blvd, Los Angeles, CA 90073 USA.
EM asaby@ucla.edu
NR 21
TC 0
Z9 0
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR
PY 2016
VL 29
IS 2
BP 170
EP 172
DI 10.1111/sdi.12466
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA DG7SC
UT WOS:000372283000012
PM 26756940
ER
PT J
AU Sarmiento, K
Rossettie, J
Stepnowsky, C
Atwood, C
Calvitti, A
AF Sarmiento, Kathleen
Rossettie, John
Stepnowsky, Carl
Atwood, Charles
Calvitti, Alan
CA VA Sleep Network
TI The state of Veterans Affairs sleep medicine programs: 2012 inventory
results
SO SLEEP AND BREATHING
LA English
DT Article
DE Access to health care; Health services; Sleep disorders; Veterans
AB The Veterans Health Administration (VHA) represents one of the largest integrated health-care systems in the country. In 2012, the Veterans Affairs Sleep Network (VASN) sought to identify available sleep resources at VA medical centers (VAMCs) across the country through a national sleep inventory.
The sleep inventory was administered at the annual 2012 VA Sleep Practitioners meeting and by email to sleep contacts at each VAMC. National prosthetics contacts were used to identify personnel at VAMCs without established sleep programs. Follow-up emails and telephone calls were made through March 2013.
One hundred eleven VA medical centers were included for analysis. Thirty-nine programs did not respond, and 10 were considered "satellites," referring all sleep services to a larger neighboring VAMC. Sleep programs were stratified based on extent of services offered (i.e., in-lab and home testing, sleep specialty clinics, cognitive behavioral therapy for insomnia (CBT-i)): 28 % were complex sleep programs (CSPs), 46 % were intermediate (ISPs), 9 % were standard (SSPs), and 17 % offered no formal sleep services. Overall, 138,175 clinic visits and 90,904 sleep testing encounters were provided in fiscal year 2011 by 112.1 physicians and clinical psychologists, 100.4 sleep technologists, and 115.3 respiratory therapists. More than half of all programs had home testing and CBT-i programs, and 26 % utilized sleep telehealth.
The 2012 VA sleep inventory suggests considerable variability in sleep services within the VA. Demand for sleep services is high, with programs using home testing, sleep telehealth, and a growing number of mid-level providers to improve access to care.
C1 [Sarmiento, Kathleen; Rossettie, John; Stepnowsky, Carl; Calvitti, Alan] VA San Diego Healthcare Syst, 3350 Jolla Village Dr,111J, San Diego, CA 92161 USA.
[Sarmiento, Kathleen] Univ Calif San Diego, Dept Pulm & Crit Care Med, La Jolla, CA 92093 USA.
[Rossettie, John; Stepnowsky, Carl] Univ Calif San Diego, Dept Med, La Jolla, CA 92103 USA.
[Atwood, Charles] VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA.
[Atwood, Charles] UPMC Montefiore, PACCM, Pittsburgh, PA 15213 USA.
RP Sarmiento, K (reprint author), VA San Diego Healthcare Syst, 3350 Jolla Village Dr,111J, San Diego, CA 92161 USA.; Sarmiento, K (reprint author), Univ Calif San Diego, Dept Pulm & Crit Care Med, La Jolla, CA 92093 USA.
EM kfsarmiento@ucsd.edu
NR 1
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1520-9512
EI 1522-1709
J9 SLEEP BREATH
JI Sleep Breath.
PD MAR
PY 2016
VL 20
IS 1
BP 379
EP 382
DI 10.1007/s11325-015-1184-0
PG 4
WC Clinical Neurology; Respiratory System
SC Neurosciences & Neurology; Respiratory System
GA DG5ZJ
UT WOS:000372160800058
PM 25924933
ER
PT J
AU Dzik, WS
Ziman, A
Cohen, C
Pai, M
Lozano, M
Kaufman, RM
Delaney, M
Selleng, K
Murphy, MF
Hervig, T
Yazer, M
AF Dzik, Walter Sunny
Ziman, Alyssa
Cohen, Claudia
Pai, Menaka
Lozano, Miguel
Kaufman, Richard M.
Delaney, Meghan
Selleng, Kathleen
Murphy, Michael F.
Hervig, Tor
Yazer, Mark
CA Biomed Excellence Safer Transfusio
TI Survival after ultramassive transfusion: a review of 1360 cases
SO TRANSFUSION
LA English
DT Review
ID MASSIVE BLOOD-TRANSFUSION; TRAUMA; STATE
AB BACKGROUNDInformation about patient survival after transfusion of multiple blood volumes is limited, and most reports have focused on trauma patients.
STUDY DESIGN AND METHODSRetrospective study of blood use and survival at 11 hospitals in six nations between 2009 and 2013. Ultramassive transfusion (UMT) was defined as transfusion of 20 or more red blood cell (RBC) units over the course of any 2 consecutive calendar days.
RESULTSA total of 1975 patients received UMT and a representative sample of 1360 patients was studied in detail. Patients were grouped into seven diagnostic categories: solid organ transplantation (n=411), cardiac or major vascular surgery (n=317), general surgery (n=228), trauma (n=221), general medicine (n=124), obstetrics (n=23), and other (n=36). During the 7 days after initiation of UMT, these patients used more than 120,000 blood components. The median (interquartile range) blood use was 35 (26-50) RBC units, 30 (20-47) plasma units, and 7 (4-13) platelet doses. Five- and 30-day survival significantly declined with increasing RBC use. Overall survivals of patients receiving UMT were 71% (5 day) and 60% (30 day), and in the subset of 165 patients receiving 60 or more RBC units over 2 consecutive days, 5-day survival was 54% ranging from 17% (trauma) to 75% (solid organ transplant). The decline in survival with increasing RBC transfusions was minimal for patients undergoing solid organ transplantation and was most pronounced for trauma and nonsurgical bleeding patients.
CONCLUSIONTrauma was not the leading cause of UMT. Increasing RBC requirements were significantly associated with decreasing survival. However, survival was more strongly associated with diagnostic category than total RBCs transfused, with highest survival rates in solid organ transplant surgery.
C1 [Dzik, Walter Sunny] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ziman, Alyssa] Univ Calif Los Angeles, Med Ctr, Dept Pathol & Lab Med, Div Transfus Med, Los Angeles, CA 90024 USA.
[Cohen, Claudia] Univ Minnesota, Med Ctr, Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Pai, Menaka] McMaster Univ, Med, Hamilton, ON, Canada.
[Pai, Menaka] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
[Lozano, Miguel] Univ Clin Hosp, Hemotherapy & Hemostasis, Barcelona, Spain.
[Kaufman, Richard M.] Brigham & Womens Hosp, Pathol, 75 Francis St, Boston, MA 02115 USA.
[Delaney, Meghan] Univ Washington, Lab Med, Seattle, WA 98195 USA.
[Delaney, Meghan] Puget Sound Blood Ctr, Seattle, WA 98104 USA.
[Selleng, Kathleen] Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, Greifswald, Germany.
[Murphy, Michael F.] John Radcliffe Hosp, NHS Blood & Transplant, Oxford OX3 9DU, England.
[Hervig, Tor] Haukeland Hosp, Transfus Med, N-5021 Bergen, Norway.
[Yazer, Mark] Inst Transfus Med, Pittsburgh, PA USA.
RP Dzik, WS (reprint author), Massachusetts Gen Hosp, Blood Transfus Serv, J-224, Boston, MA 02114 USA.
EM sdzik@mgh.harvard.edu
NR 16
TC 4
Z9 4
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD MAR
PY 2016
VL 56
IS 3
BP 558
EP 563
DI 10.1111/trf.13370
PG 6
WC Hematology
SC Hematology
GA DG7SH
UT WOS:000372283500005
PM 26450364
ER
PT J
AU Becker, WC
Gordon, K
Edelman, EJ
Kerns, RD
Crystal, S
Dziura, JD
Fiellin, LE
Gordon, AJ
Goulet, JL
Justice, AC
Fiellin, DA
AF Becker, William C.
Gordon, Kirsha
Edelman, E. Jennifer
Kerns, Robert D.
Crystal, Stephen
Dziura, James D.
Fiellin, Lynn E.
Gordon, Adam J.
Goulet, Joseph L.
Justice, Amy C.
Fiellin, David A.
TI Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging
Patients With and Without HIV
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Analgesics; Opioids; Aging; Pain; Chronic; Human immunodeficiency virus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-HEART-DISEASE; CHRONIC NONCANCER
PAIN; HEALTH-CARE-SYSTEM; UNINFECTED PATIENTS; INFECTED ADULTS;
DRUG-DEPENDENCE; UNITED-STATES; RISK-FACTORS; BACK-PAIN
AB Harms of opioid analgesics, especially high-dose therapy among individuals with comorbidities and older age, are increasingly recognized. However, trends in opioid receipt among HIV-infected patients are not well characterized. We examined trends, from 1999 to 2010, in any and high-dose (a parts per thousand yen120 mg/day) opioid receipt among patients with and without HIV, by age strata, controlling for demographic and clinical correlates. Of 127,216 patients, 64 % received at least one opioid prescription. Opioid receipt increased substantially among HIV-infected and uninfected patients over the study; high-dose therapy was more prevalent among HIV-infected patients. Trends in high-dose receipt stratified by three age groups revealed an increasing trend in each age strata, higher among HIV-infected patients. Correlates of any opioid receipt included HIV, PTSD and major depression. Correlates of high-dose receipt included HIV, PTSD, major depression and drug use disorders. These findings suggest a need for appropriate balance of risks and benefits, especially as these populations age.
C1 [Becker, William C.; Gordon, Kirsha; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven VA Med Ctr, Internal Med, Mail Stop 151B,950 Campbell Ave, West Haven, CT 06516 USA.
[Kerns, Robert D.; Goulet, Joseph L.] VA Connecticut Healthcare Syst, Psychol, West Haven, CT 06516 USA.
[Becker, William C.; Edelman, E. Jennifer; Dziura, James D.; Fiellin, Lynn E.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Internal Med, New Haven, CT USA.
[Kerns, Robert D.; Goulet, Joseph L.] Yale Univ, Sch Med, Psychol, New Haven, CT USA.
[Crystal, Stephen] Rutgers State Univ, Ctr Hlth Serv Res, New Brunswick, NJ 08903 USA.
[Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA.
[Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Becker, WC (reprint author), VA Connecticut Healthcare Syst, West Haven VA Med Ctr, Internal Med, Mail Stop 151B,950 Campbell Ave, West Haven, CT 06516 USA.; Becker, WC (reprint author), Yale Univ, Sch Med, Internal Med, New Haven, CT USA.
EM william.becker@yale.edu
OI Edelman, E. Jennifer/0000-0002-9375-0489; Fiellin,
David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502; Goulet,
Joseph/0000-0002-0842-804X
FU Veterans Health Administration Health Services Research & Development
Career Development Award [08-276]; VA Health Services Research and
Development Center of Innovation [CIN 13-047]; Society of General
Internal Medicine's Lawrence Linn Award; Robert Wood Johnson Foundation
Clinical Scholars Program; Veterans Aging Cohort study; National
Institute on Alcohol Abuse and Alcoholism [U10 AA 13566]
FX This work was supported by a Veterans Health Administration Health
Services Research & Development Career Development Award (08-276); other
VA support came from VA Health Services Research and Development Center
of Innovation (CIN 13-047). This work was also supported by the Society
of General Internal Medicine's Lawrence Linn Award, the Robert Wood
Johnson Foundation Clinical Scholars Program, and the Veterans Aging
Cohort study, funded by the National Institute on Alcohol Abuse and
Alcoholism (U10 AA 13566). This work was presented at the Northeast
Regional Society of General Internal Medicine Meeting, New Haven, CT,
March 8, 2013 and the Society of General Internal Medicine National
Meeting, Denver, CO, April 25, 2013. The authors would like to thank Dr.
Eugenia Buta for input on statistical analyses.
NR 60
TC 2
Z9 2
U1 2
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD MAR
PY 2016
VL 20
IS 3
BP 679
EP 686
DI 10.1007/s10461-015-1197-5
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DF8JA
UT WOS:000371602700020
PM 26384973
ER
PT J
AU Merlin, JS
Tamhane, A
Starrels, JL
Kertesz, S
Saag, M
Cropsey, K
AF Merlin, Jessica S.
Tamhane, Ashutosh
Starrels, Joanna L.
Kertesz, Stefan
Saag, Michael
Cropsey, Karen
TI Factors Associated with Prescription of Opioids and Co-prescription of
Sedating Medications in Individuals with HIV
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV; Chronic pain; Opioid; Benzodiazepine; Muscle relaxant
ID QUALITY-OF-LIFE; OVERDOSE DEATHS; UNITED-STATES; PRESCRIBING PRACTICES;
NONMALIGNANT PAIN; INFECTED PATIENTS; SCREENING-TEST; MENTAL-HEALTH;
BENZODIAZEPINES; DISORDERS
AB Opioids are often prescribed for chronic pain, and opioid risks such as overdose and death are heightened when opioids are co-prescribed with other sedating medications. We investigated factors associated with chronic opioid prescription, alone and in combination with benzodiazepines and muscle relaxants, in a clinical cohort of individuals with HIV. We used multivariable logistic regression models to determine participant clinical and demographic characteristics that are associated with chronic prescription of opioids or chronic co-prescription of opioids with sedating medications. Among 1474 participants, chronic prescription of opioids occurred in 253 individuals (17.2 %), and chronic co-prescription occurred in 90 individuals (6.1 %). Age > 50, public insurance as compared to private insurance, and symptoms of depression and anxiety were significantly associated with chronic opioid prescription and chronic co-prescription. Our findings raise concern that opioid prescription and co-prescription of sedating medications occurs disproportionately in patients for whom use is riskier.
C1 [Merlin, Jessica S.; Tamhane, Ashutosh; Saag, Michael] Univ Alabama Birmingham, Dept Med, Div Infect Dis, BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA.
[Merlin, Jessica S.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA.
[Starrels, Joanna L.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
[Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA.
[Kertesz, Stefan] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
[Cropsey, Karen] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL 35294 USA.
RP Merlin, JS (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA.; Merlin, JS (reprint author), Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA.
EM jmerlin@uab.edu
OI Tamhane, Ashutosh/0000-0002-4475-2760; Kertesz,
Stefan/0000-0001-6101-8421
FU University of Alabama at Birmingham (UAB) Center for AIDS Research, an
NIH [P30 A1027767]; NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; FIC; OAR;
AHRQ [1K12HS02169401]; NIDA [K23DA027719]; Mary Fisher CARE Fund at UAB
FX This research was supported by the University of Alabama at Birmingham
(UAB) Center for AIDS Research, an NIH funded program (P30 A1027767)
that was made possible by the following institutes: NIAID, NCI, NICHD,
NHLBI, NIDA, NIMH, NIA, FIC, and OAR. JSM was supported by
1K12HS02169401 (AHRQ). JLS was supported by K23DA027719 (NIDA). Funding
was also provided by the Mary Fisher CARE Fund at UAB.
NR 52
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD MAR
PY 2016
VL 20
IS 3
BP 687
EP 698
DI 10.1007/s10461-015-1178-8
PG 12
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DF8JA
UT WOS:000371602700021
PM 26487298
ER
PT J
AU Hou, JB
Xing, L
Jia, HB
Vergallo, R
Soeda, T
Minami, Y
Hu, SN
Yang, S
Zhang, SS
Lee, H
Yu, B
Jang, IK
AF Hou, Jingbo
Xing, Lei
Jia, Haibo
Vergallo, Rocco
Soeda, Tsunerari
Minami, Yoshiyasu
Hu, Sining
Yang, Shuang
Zhang, Shaosong
Lee, Hang
Yu, Bo
Jang, Ik-Kyung
TI Comparison of Intensive Versus Moderate Lipid-Lowering Therapy on
Fibrous Cap and Atheroma Volume of Coronary Lipid-Rich Plaque Using
Serial Optical Coherence Tomography and Intravascular Ultrasound Imaging
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; STATIN THERAPY; ATHEROSCLEROTIC PLAQUE;
ARTERY-DISEASE; RUPTURE; PROGRESSION; THICKNESS; EVENTS; ATORVASTATIN;
SIMVASTATIN
AB Despite marked clinical benefit, reduction in atheroma volume with statin therapy is minimal. Changes in plaque composition may explain this discrepancy. We aimed in the present study to assess the effect of statin therapy on coronary plaque composition and plaque volume using serial multimodality imaging. From an open-label, single-blinded study, patients with angiographically mild-to-moderate lesion were randomized to receive atorvastatin 60 (AT 60) mg or atorvastatin 20 (AT 20) mg for 12 months. Optical coherence tomography was used to assess fibrous cap thickness (FCT) and intravascular ultrasound to assess atheroma burden at 3 time points: baseline, at 6 months, and at 12 months. Thirty-six lipid-rich plaques in 27 patients with AT 60 mg and 30 lipid-rich plaques in 19 patients with AT 20 mg were enrolled in this study. Low-density lipoprotein cholesterol level was significantly decreased at 6 months without further reduction at 12 months. AT 60 mg induced greater reduction in low-density lipoprotein cholesterol compared with AT 20 mg. Optical coherence tomography revealed continuous increase in FCT from baseline to 6 months and to 12 months in both groups. AT 60 mg induced greater increase in FCT compared with AT 20 mg at both follow-up points. The prevalence of thin-cap fibroatheroma and the presence of macrophage at 6 months were significantly lower in AT 60 mg compared with AT 20 mg. Plaque burden did not change significantly in both groups. In conclusion, both intensive and moderate statin therapy stabilizes coronary plaques, with a greater benefit in the intensive statin group. However, no significant changes in plaque volume were observed over time regardless of the intensity of statin therapy. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Hou, Jingbo; Xing, Lei; Jia, Haibo; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Key Lab Myocardial Ischemia, Dept Cardiol,Chinese Minist Educ, Harbin, Peoples R China.
[Xing, Lei; Vergallo, Rocco; Soeda, Tsunerari; Minami, Yoshiyasu; Hu, Sining; Yang, Shuang; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Zhang, Shaosong] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China.
[Lee, Hang] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Lee, Hang] Harvard Univ, Sch Med, Boston, MA USA.
[Jang, Ik-Kyung] Kyung Hee Univ, Sch Med, Div Cardiol, Seoul, South Korea.
RP Yu, B (reprint author), Harbin Med Univ, Affiliated Hosp 2, Key Lab Myocardial Ischemia, Dept Cardiol,Chinese Minist Educ, Harbin, Peoples R China.
EM yubodr@163.com
OI minami, yoshiyasu/0000-0003-2745-9682
FU National Natural Science Foundation, China [81330033]; St. Jude Medical
FX Dr. Yu has received research grants from National Natural Science
Foundation, China, grant 81330033. Dr. Ik-Kyung Jang has received grants
and consulting fees from St. Jude Medical. And Dr. Ik-Kyung Jang's
research was supported by "Mr. and Mrs. Michael and Kathryn Park" and by
"Mrs. and Mr. Gill and Allan Gray." The other authors have no conflicts
of interest to disclose.
NR 30
TC 11
Z9 11
U1 2
U2 8
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAR 1
PY 2016
VL 117
IS 5
BP 800
EP 806
DI 10.1016/j.amjcard.2015.11.062
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG0JA
UT WOS:000371749900016
PM 26778524
ER
PT J
AU Graff, RE
Pettersson, A
Lis, RT
Ahearn, TU
Markt, SC
Wilson, KM
Rider, JR
Fiorentino, M
Finn, S
Kenfield, SA
Loda, M
Giovannucci, EL
Rosner, B
Mucci, LA
AF Graff, Rebecca E.
Pettersson, Andreas
Lis, Rosina T.
Ahearn, Thomas U.
Markt, Sarah C.
Wilson, Kathryn M.
Rider, Jennifer R.
Fiorentino, Michelangelo
Finn, Stephen
Kenfield, Stacey A.
Loda, Massimo
Giovannucci, Edward L.
Rosner, Bernard
Mucci, Lorelei A.
TI Dietary lycopene intake and risk of prostate cancer defined by ERG
protein expression
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE ERG protein expression; TMPRSS2:ERG; lycopene; prostate cancer; tomato
sauce
ID DOUBLE-STRAND BREAKS; FOOD FREQUENCY QUESTIONNAIRE;
CORONARY-HEART-DISEASE; OXIDATIVE STRESS; CHROMOSOMAL TRANSLOCATIONS;
GENE REARRANGEMENTS; CAROTENOID DATABASE; FRUIT CONSUMPTION;
EPITHELIAL-CELLS; COMPETING RISKS
AB Background: There is limited evidence that supports etiologically distinct molecular subtypes of prostate cancer, the identification of which may improve prevention. Given their antioxidant properties, we hypothesized that lycopene and tomato sauce may be especially protective against diseases harboring the common gene fusion trans membrane protease, serine 2 (TMPRSS2):v-ets avian erythroblastosis virus E26 oncogene homolog (ERG).
Objective: We aimed to examine associations between estimated lycopene and tomato sauce intake and the risk of prostate cancer defined by ERG protein expression subtype.
Design: Our study population consisted of a prospective cohort of 46,719 men from the Health Professionals Follow-Up Study. TMPRSS2:ERG was assessed by ERG immunohistochemistry on tumor tissue microarrays constructed from radical prostatectomy specimens. We used multivariable competing risk models to calculate HRs and 95% CIs for the risk of ERG-positive and, separately, ERG negative disease. We implemented inverse probability weighting to account for evaluating ERG status only in surgically treated cases.
Results: During 23 y of follow-up, 5543 men were diagnosed with prostate cancer, among whom 884 were assayed for ERG (426 ERG-positive). With inclusion of only the latter cases, increasing cumulative average tomato sauce intake was associated with a decreased risk of prostate cancer overall (>= 2 servings/wk compared with <1 serving/mo; multivariable HR: 0.70; 95% CI: 0.52, 0.95; P-trend = 0.002). With respect to molecular subtypes, cumulative average tomato sauce intake was associated with a decreased risk of ERG-positive disease (HR: 0.54; 95% CI: 0.37, 0.81; P-trend = 0.004) but not with ERG-negative disease (HR: 0.96; 95% CI: 0.62, 1.50; P-trend = 0.10) (P-heterogeneity = 0.04). Increasing quintiles of lycopene intake were associated with a decreased risk of both subtypes (P-heterogeneity = 0.79). Inverse probability weighting did not materially change the results.
Conclusions: Our results lend some support to the hypothesis that prostate cancers that harbor TMPRSS2:ERG may be etiologically distinct from fusion-negative cancers. In particular, tomato sauce consumption may play a role in reducing TMPRSS2:ERG-positive disease.
C1 [Graff, Rebecca E.; Pettersson, Andreas; Ahearn, Thomas U.; Markt, Sarah C.; Wilson, Kathryn M.; Rider, Jennifer R.; Fiorentino, Michelangelo; Kenfield, Stacey A.; Giovannucci, Edward L.; Mucci, Lorelei A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Rosner, Bernard] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Graff, Rebecca E.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Kenfield, Stacey A.] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA.
[Pettersson, Andreas] Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, Stockholm, Sweden.
[Lis, Rosina T.; Loda, Massimo] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Wilson, Kathryn M.; Rider, Jennifer R.; Kenfield, Stacey A.; Giovannucci, Edward L.; Rosner, Bernard; Mucci, Lorelei A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div,Network Med, Boston, MA 02115 USA.
[Lis, Rosina T.; Fiorentino, Michelangelo; Finn, Stephen; Loda, Massimo] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Fiorentino, Michelangelo] St Orsola Marcello Malpighi Hosp, Addarii Inst, Pathol Unit, Bologna, Italy.
[Finn, Stephen] Univ Dublin Trinity Coll, Dept Histopathol, Dublin 2, Ireland.
RP Graff, RE (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.; Graff, RE (reprint author), Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
EM rebecca.graff@ucsf.edu
OI Finn, Stephen/0000-0002-8628-5814
FU Dana-Farber/Harvard Cancer Center Specialized Programs of Research
Excellence (SPORE) in Prostate Cancer [5P50CA090381]; National Cancer
Institute at the NIH [R25 CA098566, R25 CA112355, T32 CA09001, R25
CA136578, CA141298, CA40360, CA097193, PO1 CA055075, UM1CA167552,
U01CA098233]; American Cancer Society Ellison Foundation Postdoctoral
Fellowship [PF-14-140-01-CCE]; Swedish Research Council [2009-7309];
Royal Physiographic Society in Lund
FX Supported by the Dana-Farber/Harvard Cancer Center Specialized Programs
of Research Excellence (SPORE) in Prostate Cancer (5P50CA090381); the
National Cancer Institute at the NIH (R25 CA098566 to REG and SCM, R25
CA112355 to REG, T32 CA09001 to TUA and SCM, R25 CA136578, CA141298,
CA40360, CA097193, PO1 CA055075, UM1CA167552, U01CA098233); the American
Cancer Society Ellison Foundation Postdoctoral Fellowship
(PF-14-140-01-CCE to TUA); the Swedish Research Council (registration
number 2009-7309 to AP); and the Royal Physiographic Society in Lund (to
AP). LAM and JRR are Prostate Cancer Foundation Young Investigators.
NR 84
TC 4
Z9 4
U1 7
U2 15
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAR
PY 2016
VL 103
IS 3
BP 851
EP 860
DI 10.3945/ajcn.115.118703
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DF8ZO
UT WOS:000371650200022
PM 26817504
ER
PT J
AU Korom-Djakovic, D
Canamucio, A
Lempa, M
Yano, EM
Long, JA
AF Korom-Djakovic, Danijela
Canamucio, Anne
Lempa, Michele
Yano, Elizabeth M.
Long, Judith A.
TI Organization Complexity and Primary Care Providers' Perceptions of
Quality Improvement Culture Within the Veterans Health Administration
SO AMERICAN JOURNAL OF MEDICAL QUALITY
LA English
DT Article
DE quality improvement; culture; organizational complexity; primary care;
Veterans Affairs
ID MEDICAL GROUP PRACTICES; IMPLEMENTATION; DELIVERY; STAFF; HOME
AB This study examined how aspects of quality improvement (QI) culture changed during the introduction of the Veterans Health Administration (VHA) patient-centered medical home initiative and how they were influenced by existing organizational factors, including VHA facility complexity and practice location. A voluntary survey, measuring primary care providers' (PCPs') perspectives on QI culture at their primary care clinics, was administered in 2010 and 2012. Participants were 320 PCPs from hospital- and community-based primary care practices in Pennsylvania, West Virginia, Delaware, New Jersey, New York, and Ohio. PCPs in community-based outpatient clinics reported an improvement in established processes for QI, and communication and cooperation from 2010 to 2012. However, their peers in hospital-based clinics did not report any significant improvements in QI culture. In both years, compared with high-complexity facilities, medium- and low-complexity facilities had better scores on the scales assessing established processes for QI, and communication and cooperation.
C1 [Korom-Djakovic, Danijela; Canamucio, Anne; Lempa, Michele; Long, Judith A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Korom-Djakovic, Danijela; Long, Judith A.] Univ Penn, Philadelphia, PA 19104 USA.
[Yano, Elizabeth M.] VA Greater Angeles Healthcare Syst, Sepulveda, CA USA.
[Yano, Elizabeth M.] UCLA Fielding Sch Publ Hlth, Los Angeles, CA USA.
RP Long, JA (reprint author), Univ Penn, Perelman Sch Med, 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM jalong@mail.med.upenn.edu
FU VA Office of Patient Care Services
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
undertaken as part of the Veterans Affairs (VA) Patient Aligned Care
Team (PACT) Demonstration Laboratory initiative, supporting and
evaluating VA's transition to a patient-centered medical home. Funding
for the PACT Demonstration Laboratory initiative is provided by the VA
Office of Patient Care Services.
NR 25
TC 2
Z9 2
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1062-8606
EI 1555-824X
J9 AM J MED QUAL
JI Am. J. Med. Qual.
PD MAR-APR
PY 2016
VL 31
IS 2
BP 139
EP 146
DI 10.1177/1062860614559743
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DF8VL
UT WOS:000371638300007
PM 25414376
ER
PT J
AU Chen, Q
Shin, MH
Chan, JA
Sullivan, JL
Borzecki, AM
Shwartz, M
Rivard, PE
Hatoun, J
Rosen, AK
AF Chen, Qi
Shin, Marlena H.
Chan, Jeffrey A.
Sullivan, Jennifer L.
Borzecki, Ann M.
Shwartz, Michael
Rivard, Peter E.
Hatoun, Jonathan
Rosen, Amy K.
TI Partnering With VA Stakeholders to Develop a Comprehensive Patient
Safety Data Display: Lessons Learned From the Field
SO AMERICAN JOURNAL OF MEDICAL QUALITY
LA English
DT Article
DE engage frontline stakeholders; patient safety; quality improvement; tool
development
ID DETECTING ADVERSE EVENTS; IMPLEMENTATION; INNOVATIONS
AB Health care systems are increasingly burdened by the large numbers of safety measures currently being reported. Within the Veterans Administration (VA), most safety reporting occurs within organizational silos, with little involvement by the frontline users of these measures. To provide a more integrated picture of patient safety, the study team partnered with multiple VA stakeholders and engaged potential frontline users at 2 hospitals to develop a Guiding Patient Safety (GPS) tool. The GPS is currently in its fourth generation; once approval is obtained from senior leadership, implementation will begin. Stakeholders were enthusiastic about the GPS's user-friendly format, comprehensive content, and potential utility for improving safety. These findings suggest that stakeholder engagement is a critical first step in the development of tools that will more likely be used by frontline users. Policy makers and researchers may consider adopting this innovative partnered-research model in developing future national initiatives to deliver meaningful programs to frontline users.
C1 [Chen, Qi; Shin, Marlena H.; Chan, Jeffrey A.; Sullivan, Jennifer L.; Shwartz, Michael; Rivard, Peter E.; Rosen, Amy K.] VA Boston Healthcare Syst, Boston, MA USA.
[Borzecki, Ann M.] Bedford VAMC, Bedford, MA USA.
[Borzecki, Ann M.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Borzecki, Ann M.; Rosen, Amy K.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Shwartz, Michael] Boston Univ, Sch Management, Boston, MA 02215 USA.
[Rivard, Peter E.] Suffolk Univ, Sawyer Business Sch, Boston, MA 02114 USA.
[Hatoun, Jonathan] Boston Med Ctr, Boston, MA USA.
RP Chen, Q (reprint author), CHOIR, VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA.
EM qc2112@bu.edu
FU Department of Veterans Affairs, Veterans Health Administration, National
Center for Patient Safety, the Patient Safety Center of Inquiry on
Measurement to Advance Patient Safety [XVA 68-023]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: Department of
Veterans Affairs, Veterans Health Administration, National Center for
Patient Safety, the Patient Safety Center of Inquiry on Measurement to
Advance Patient Safety, #XVA 68-023.
NR 13
TC 0
Z9 0
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1062-8606
EI 1555-824X
J9 AM J MED QUAL
JI Am. J. Med. Qual.
PD MAR-APR
PY 2016
VL 31
IS 2
BP 178
EP 186
DI 10.1177/1062860614560214
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DF8VL
UT WOS:000371638300012
PM 25500716
ER
PT J
AU Castillo, ER
Hsu, C
Mair, RW
Lieberman, DE
AF Castillo, Eric R.
Hsu, Connie
Mair, Ross W.
Lieberman, Daniel E.
TI Testing biomechanical models for lumbar lordosis variation in hominins
SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY
LA English
DT Meeting Abstract
CT 85th Annual Meeting of the
American-Association-of-Physical-Anthropologists
CY APR 13-16, 2016
CL Atlanta, GA
SP Amer Assoc Phys Anthropologists
C1 [Castillo, Eric R.; Hsu, Connie; Lieberman, Daniel E.] Harvard Univ, Dept Human Evolutionary Biol, Cambridge, MA 02138 USA.
[Mair, Ross W.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Mair, Ross W.] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-9483
EI 1096-8644
J9 AM J PHYS ANTHROPOL
JI Am. J. Phys. Anthropol.
PD MAR
PY 2016
VL 159
SU 62
BP 111
EP 111
PG 1
WC Anthropology; Evolutionary Biology
SC Anthropology; Evolutionary Biology
GA DF3OW
UT WOS:000371255201011
ER
PT J
AU Green, DR
Colman, AS
Green, GM
Bidlack, FB
Tafforeau, P
Smith, TM
AF Green, Daniel R.
Colman, Albert S.
Green, Gregory M.
Bidlack, Felicitas B.
Tafforeau, Paul
Smith, Tanya M.
TI Experimental water switch in sheep improves models for seasonal climate
reconstruction
SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY
LA English
DT Meeting Abstract
CT 85th Annual Meeting of the
American-Association-of-Physical-Anthropologists
CY APR 13-16, 2016
CL Atlanta, GA
SP Amer Assoc Phys Anthropologists
C1 [Green, Daniel R.; Smith, Tanya M.] Harvard Univ, Human Evolutionary Biol, Cambridge, MA 02138 USA.
[Colman, Albert S.] Univ Chicago, Geophys Sci, Chicago, IL 60637 USA.
[Green, Gregory M.] Harvard Univ, Ctr Astrophys, Cambridge, MA 02138 USA.
[Bidlack, Felicitas B.] Forsyth Inst, Mineralized Tissue Biol, Cambridge, MA USA.
[Tafforeau, Paul] European Synchrotron Radiat Facil, Paleontol, Grenoble, France.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-9483
EI 1096-8644
J9 AM J PHYS ANTHROPOL
JI Am. J. Phys. Anthropol.
PD MAR
PY 2016
VL 159
SU 62
BP 160
EP 160
PG 1
WC Anthropology; Evolutionary Biology
SC Anthropology; Evolutionary Biology
GA DF3OW
UT WOS:000371255201208
ER
PT J
AU Tanner, NT
Kanodra, NM
Gebregziabher, M
Payne, E
Halbert, CH
Warren, GW
Egede, LE
Silvestri, GA
AF Tanner, Nichole T.
Kanodra, Neeti M.
Gebregziabher, Mulugeta
Payne, Elizabeth
Halbert, Chanita Hughes
Warren, Graham W.
Egede, Leonard E.
Silvestri, Gerard A.
TI The Association between Smoking Abstinence and Mortality in the National
Lung Screening Trial
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE smoking cessation; lung neoplasms; early detection of cancer; tobacco
ID UNITED-STATES; COST-EFFECTIVENESS; CLINICAL-PRACTICE; CANCER-PATIENTS;
PUBLIC-HEALTH; TOBACCO USE; CESSATION; PARTICIPANTS; GUIDELINE;
DIAGNOSIS
AB Rationale: Smoking is the largest contributor to lung cancer risk, and those who continue to smoke after diagnosis have a worse survival. Screening for lung cancer with low-dose computed tomography (LDCT) reduces mortality in high-risk individuals. Smoking cessation is an essential component of a high-quality screening program.
Objectives: To quantify the effects of smoking history and abstinence on mortality in high-risk individuals who participated in the NLST (National Lung Screening Trial).
Methods: This is a secondary analysis of a randomized controlled trial (NLST).
Measurements and Main Results: Measurements included self-reported demographics, medical and smoking history, and lung cancer-specific and all-cause mortality. Cox regression was used to study the association of mortality with smoking status and pack-years. Kaplan-Meier survival curves were examined for differences in survival based on trial arm and smoking status. Current smokers had an increased lung cancer-specific (hazard ratio [HR], 2.14-2.29) and all-cause mortality (HR, 1.79-1.85) compared with former smokers irrespective of screening arm. Former smokers in the control arm abstinent for 7 years had a 20% mortality reduction comparable with the benefit reported with LDCT screening in the NLST. The maximum benefit was seen with the combination of smoking abstinence at 15 years and LDCT screening, which resulted in a 38% reduction in lung cancer-specific mortality (HR, 0.62; 95% confidence interval, 0.51-0.76).
Conclusions: Seven years of smoking abstinence reduced lung cancer-specific mortality at a magnitude comparable with LDCT screening. This reduction was greater when abstinence was combined with screening, highlighting the importance of smoking cessation efforts-in screening programs.
C1 [Tanner, Nichole T.; Kanodra, Neeti M.; Silvestri, Gerard A.] Med Univ S Carolina, Div Pulm Crit Care & Sleep Med, Charleston, SC 29425 USA.
[Tanner, Nichole T.; Gebregziabher, Mulugeta; Halbert, Chanita Hughes; Egede, Leonard E.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta; Payne, Elizabeth] Med Univ S Carolina, Dept Psychiat & Behav Sci, Hollings Canc Ctr, 171 Ashley Ave, Charleston, SC 29425 USA.
[Halbert, Chanita Hughes] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
[Warren, Graham W.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA.
[Warren, Graham W.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson Vet Affairs Hosp, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA.
RP Tanner, NT (reprint author), 96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM tripici@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU OneBreath Foundation
FX Supported by OneBreath Foundation.
NR 33
TC 12
Z9 12
U1 2
U2 6
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAR 1
PY 2016
VL 193
IS 5
BP 534
EP 541
DI 10.1164/rccm.201507-1420OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DG0KI
UT WOS:000371753300014
PM 26502000
ER
PT J
AU Ramalingam, SS
O'Byrne, K
Boyer, M
Mok, T
Janne, PA
Zhang, H
Liang, J
Taylor, I
Sbar, EI
Paz-Ares, L
AF Ramalingam, S. S.
O'Byrne, K.
Boyer, M.
Mok, T.
Jaenne, P. A.
Zhang, H.
Liang, J.
Taylor, I.
Sbar, E. I.
Paz-Ares, L.
TI Dacomitinib versus erlotinib in patients with EGFR-mutated advanced
nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two
randomized trials
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE dacomitinib; erlotinib; EGFR mutation; NSCLC; tyrosine kinase inhibitor
ID CLINICAL-RESPONSE; OPEN-LABEL; MUTATIONS; INHIBITOR; GEFITINIB;
ADENOCARCINOMA; PF-00299804; MULTICENTER; RESISTANT; AFATINIB
AB The irreversible epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown if they are superior to the reversible inhibitors. Dacomitinib is an oral, small-molecule irreversible inhibitor of all enzymatically active HER family tyrosine kinases.
The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067) studies randomized patients with locally advanced/metastatic NSCLC following progression with one or two prior chemotherapy regimens to dacomitinib or erlotinib. EGFR mutation testing was performed centrally on archived tumor samples. We pooled patients with exon 19 deletion and L858R EGFR mutations from both studies to compare the efficacy of dacomitinib to erlotinib.
One hundred twenty-one patients with any EGFR mutation were enrolled; 101 had activating mutations in exon 19 or 21. For patients with exon19/21 mutations, the median progression-free survival was 14.6 months [95% confidence interval (CI) 9.0-18.2] with dacomitinib and 9.6 months (95% CI 7.4-12.7) with erlotinib [unstratified hazard ratio (HR) 0.717 (95% CI 0.458-1.124), two-sided log-rank, P = 0.146]. The median survival was 26.6 months (95% CI 21.6-41.5) with dacomitinib versus 23.2 months (95% CI 16.0-31.8) with erlotinib [unstratified HR 0.737 (95% CI 0.431-1.259), two-sided log-rank, P = 0.265]. Dacomitinib was associated with a higher incidence of diarrhea and mucositis in both studies compared with erlotinib.
Dacomitinib is an active agent with comparable efficacy to erlotinib in the EGFR mutated patients. The subgroup with exon 19 deletion had favorable outcomes with dacomitinib. An ongoing phase III study will compare dacomitinib to gefitinib in first-line therapy of patients with NSCLC harboring common activating EGFR mutations (ARCHER 1050; NCT01774721).
ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067).
C1 [Ramalingam, S. S.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, 1365 Clifton Rd NE,Suite C-3090, Atlanta, GA 30322 USA.
[O'Byrne, K.] Princess Alexandra Hosp, Dept Oncol, Brisbane, Qld 4102, Australia.
[Boyer, M.] Chris Brien Lifehouse, Dept Oncol, Sydney, NSW, Australia.
[Mok, T.] Chinese Univ Hong Kong, Clin Oncol, Shatin, Hong Kong, Peoples R China.
[Jaenne, P. A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zhang, H.; Liang, J.; Taylor, I.; Sbar, E. I.] Pfizer Oncol, New York, NY USA.
[Paz-Ares, L.] Doce Octubre Univ Hosp, Dept Oncol, Madrid, Spain.
[Paz-Ares, L.] CNIO, Madrid, Spain.
RP Ramalingam, SS (reprint author), Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, 1365 Clifton Rd NE,Suite C-3090, Atlanta, GA 30322 USA.
EM suresh.ramalingam@emory.edu
FU Pfizer, Inc.
FX This study was sponsored by Pfizer, Inc. No grant numbers apply.
NR 16
TC 8
Z9 8
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD MAR
PY 2016
VL 27
IS 3
BP 423
EP 429
DI 10.1093/annonc/mdv593
PG 7
WC Oncology
SC Oncology
GA DF9OU
UT WOS:000371691600010
PM 26768165
ER
PT J
AU De Santis, M
Wiechno, PJ
Bellmunt, J
Lucas, C
Su, WC
Albiges, L
Lin, CC
Senkus-Konefka, E
Flechon, A
Mourey, L
Necchi, A
Loidl, WC
Retz, MM
Vaissiere, N
Culine, S
AF De Santis, M.
Wiechno, P. J.
Bellmunt, J.
Lucas, C.
Su, W. -C.
Albiges, L.
Lin, C. -C.
Senkus-Konefka, E.
Flechon, A.
Mourey, L.
Necchi, A.
Loidl, W. C.
Retz, M. M.
Vaissiere, N.
Culine, S.
TI Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line
chemotherapy in cisplatin-unfit patients with advanced urothelial
carcinoma: results of an international randomized phase II trial
(JASINT1)
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE vinflunine; urothelial carcinoma; bladder cancer; cisplatin-ineligible;
renal impairment
ID TRANSITIONAL-CELL CARCINOMA; CHEMONAIVE PATIENTS; IV VINFLUNINE;
LUNG-CANCER; COMBINATION; PACLITAXEL; THERAPY; PLUS; GUIDELINES; DESIGN
AB There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and tolerability profile of two vinflunine-based cytotoxic regimens in this setting.
Patients with aUC a creatinine clearance (CrCl) of < 60 but a parts per thousand yen30 ml/min, performance status 0 or 1 and no prior chemotherapy for advanced disease were randomized (1 : 1). They received vinflunine 250 or 280 mg/m(2) (based on baseline CrCl) on day 1, plus either gemcitabine [750 mg/m(2) escalated to 1000 mg/m(2) in cycle 2 if no toxicity grade (G) a parts per thousand yen2 on days 1 and 8 (VG) or plus carboplatin area under the curve 4.5 day 1 (VC) every 21 days]. To detect a 22% improvement in each arm compared with H0 (41%) in the primary end point, disease control rate (DCR = complete response + partial response + stable disease), 31 assessable patients per arm were required (alpha = 5%, beta = 20%).
Sixty-nine patients were enrolled (34 VG, 35 VC). Less G3/4 haematological adverse events (AEs) were reported with VG: neutropaenia was seen in 38% (versus 68% with VC) and febrile neutropaenia in 3% (versus 14% with VC) of patients. No major differences were observed for non-haematological AEs. DCR was 77% in both groups; overall response rate (ORR) was 44.1% versus 28.6%, with a median progression-free survival of 5.9 versus 6.1 months and median OS of 14.0 versus 12.8 months with VG and VC, respectively.
Both vinflunine-based doublets offer a similar DCR, ORR and OS. The better haematological tolerance favours the VG combination, which warrants further study.
NCT 01599013.
C1 [De Santis, M.] KFJ Spital, ACR VIEnna LB CTO ACR ITR VIEnna, Ludwig Boltzmann Inst, Vienna, Austria.
[De Santis, M.] Univ Warwick, Canc Res Ctr, Gibbet Hill Campus,Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.
[Wiechno, P. J.] Inst Sklodowskiej Curie, Inst Oncol, Warsaw, Poland.
[Bellmunt, J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[Lucas, C.; Vaissiere, N.] Inst Rech Pierre Fabre, Boulogne, France.
[Su, W. -C.] Natl Cheng Kung Univ Hosp, Dept Internal Med, Taipei, Taiwan.
[Albiges, L.] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France.
[Lin, C. -C.] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan.
[Senkus-Konefka, E.] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland.
[Flechon, A.] Ctr Leon Berard, Dept Med, F-69373 Lyon, France.
[Mourey, L.] Inst Claudius Regaud, Dept Oncol, Toulouse, France.
[Necchi, A.] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy.
[Loidl, W. C.] KH Barmherzige Schwestern Linz, Dept Urol, Linz, Austria.
[Retz, M. M.] Univ Hosp Rechts Isar, Dept Urol, Munich, Germany.
[Culine, S.] Paris Diderot Univ, Hop St Louis, AP HP, Dept Med Oncol, Paris, France.
RP De Santis, M (reprint author), Univ Warwick, Canc Res Ctr, Gibbet Hill Campus,Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.
EM maria@desantis.cc
OI Necchi, Andrea/0000-0002-3007-2756
FU Pierre Fabre Research Institute, France
FX This study was supported by Pierre Fabre Research Institute, France. No
grant number is applicable.
NR 23
TC 7
Z9 7
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD MAR
PY 2016
VL 27
IS 3
BP 449
EP 454
DI 10.1093/annonc/mdv609
PG 6
WC Oncology
SC Oncology
GA DF9OU
UT WOS:000371691600014
PM 26673352
ER
PT J
AU Chi, KN
Kheoh, T
Ryan, CJ
Molina, A
Bellmunt, J
Vogelzang, NJ
Rathkopf, DE
Fizazi, K
Kantoff, PW
Li, J
Azad, AA
Eigl, BJ
Heng, DYC
Joshua, AM
de Bono, JS
Scher, HI
AF Chi, K. N.
Kheoh, T.
Ryan, C. J.
Molina, A.
Bellmunt, J.
Vogelzang, N. J.
Rathkopf, D. E.
Fizazi, K.
Kantoff, P. W.
Li, J.
Azad, A. A.
Eigl, B. J.
Heng, D. Y. C.
Joshua, A. M.
de Bono, J. S.
Scher, H. I.
TI A prognostic index model for predicting overall survival in patients
with metastatic castration-resistant prostate cancer treated with
abiraterone acetate after docetaxel
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE castration-resistant prostate cancer; abiraterone acetate; prognostic;
risk; survival
ID PLACEBO-CONTROLLED PHASE-3; 1ST-LINE CHEMOTHERAPY; PLUS PREDNISONE;
DOUBLE-BLIND; MEN; ENZALUTAMIDE; MITOXANTRONE; MANAGEMENT; CARCINOMA;
LYMPHOMA
AB Few prognostic models for overall survival (OS) are available for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with recently approved agents. We developed a prognostic index model using readily available clinical and laboratory factors from a phase III trial of abiraterone acetate (hereafter abiraterone) in combination with prednisone in post-docetaxel mCRPC.
Baseline data were available from 762 patients treated with abiraterone-prednisone. Factors were assessed for association with OS through a univariate Cox model and used in a multivariate Cox model with a stepwise procedure to identify those of significance. Data were validated using an independent, external, population-based cohort.
Six risk factors individually associated with poor prognosis were included in the final model: lactate dehydrogenase > upper limit of normal (ULN) [hazard ratio (HR) = 2.31], Eastern Cooperative Oncology Group performance status of 2 (HR = 2.19), presence of liver metastases (HR = 2.00), albumin a parts per thousand currency sign4 g/dl (HR = 1.54), alkaline phosphatase > ULN (HR = 1.38) and time from start of initial androgen-deprivation therapy to start of treatment a parts per thousand currency sign36 months (HR = 1.30). Patients were categorized into good (n = 369, 46%), intermediate (n = 321, 40%) and poor (n = 107, 13%) prognosis groups based on the number of risk factors and relative HRs. The C-index was 0.70 +/- 0.014. The model was validated by the external dataset (n = 286).
This analysis identified six factors used to model survival in mCRPC and categorized patients into three distinct risk groups. Prognostic stratification with this model could assist clinical practice decisions for follow-up and monitoring, and may aid in clinical trial design.
NCT00638690.
C1 [Chi, K. N.; Azad, A. A.; Eigl, B. J.] BC Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada.
[Kheoh, T.] Janssen Res & Dev, San Diego, CA USA.
[Ryan, C. J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Molina, A.] Janssen Res & Dev, Menlo Pk, CA USA.
[Bellmunt, J.; Kantoff, P. W.] Dana Farber Canc Inst, Dept Solid Tumor Oncol, Boston, MA 02115 USA.
[Bellmunt, J.; Kantoff, P. W.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Vogelzang, N. J.] Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
[Rathkopf, D. E.] Mem Sloan Kettering Canc Ctr, Dept Oncol & Internal Med, 1275 York Ave, New York, NY 10021 USA.
[Rathkopf, D. E.; Scher, H. I.] Weill Cornell Med Coll, New York, NY USA.
[Fizazi, K.] Univ Paris Sud, Inst Gustave Roussy, Grp Urogenitol, Villejuif, France.
[Li, J.] Johnson & Johnson Med China, Shanghai, Peoples R China.
[Heng, D. Y. C.] Tom Baker Canc Clin, Calgary, AB, Canada.
[Heng, D. Y. C.] Univ Calgary, Calgary, AB, Canada.
[Joshua, A. M.] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada.
[Joshua, A. M.] Univ Toronto, Toronto, ON, Canada.
[de Bono, J. S.] Inst Canc Res, Div Canc Therapeut Clin Studies, Drug Dev Unit, Sutton, Surrey, England.
[de Bono, J. S.] Royal Marsden Hosp, Sutton, Surrey, England.
[Scher, H. I.] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA.
RP Chi, KN (reprint author), BC Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada.
EM kchi@bccancer.bc.ca
FU Janssen Research Development
FX This work was supported by Ortho Biotech Oncology Research &
Development, unit of Cougar Biotechnology (now Janssen Research &
Development). No grant number is applicable.
NR 34
TC 6
Z9 7
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD MAR
PY 2016
VL 27
IS 3
BP 454
EP 460
DI 10.1093/annonc/mdv594
PG 7
WC Oncology
SC Oncology
GA DF9OU
UT WOS:000371691600015
PM 26685010
ER
PT J
AU Clark, DJ
Neptune, RR
Behrman, AL
Kautz, SA
AF Clark, David J.
Neptune, Richard R.
Behrman, Andrea L.
Kautz, Steven A.
TI Locomotor Adaptability Task Promotes Intense and Task-Appropriate Output
From the Paretic Leg During Walking
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Electromyography; Rehabilitation; Stroke; Walking
ID COORDINATION; HEMIPARESIS; PERFORMANCE; POSTSTROKE; LENGTH; STROKE
AB Objective: To test the hypothesis that participants with stroke will exhibit appropriate increase in muscle activation of the paretic leg when taking a long step with the nonparetic leg compared to during steady-state walking, with a consequent increase in biomechanical output and symmetry during the stance phase of the modified gait cycle.
Design: Single-session observational study.
Setting: Clinical research center in an outpatient hospital setting.
Participants: Adults with chronic poststroke hemiparesis (N=15).
Interventions: Participants walked on an instrumented treadmill while kinetic, kinematic, and electromyogram data were recorded. Participants performed steady-state walking and a separate trial of the long-step adaptability task in which they were instructed to intermittently take a longer step with the nonparetic leg.
Main Outcome Measures: Forward progression, propulsive force, and neuromuscular activation during walking.
Results: Participants performed the adaptability task successfully and demonstrated greater neuromuscular activation in appropriate paretic leg muscles, particularly increased activity in paretic plantarflexor muscles. Propulsion and forward progression by the paretic leg were also increased.
Conclusions: These findings support the assertion that the nonparetic long-step task may be effective for use in poststroke locomotor rehabilitation to engage the paretic leg and promote recovery of walking. (C) 2016 by the American Congress of Rehabilitation Medicine
C1 [Clark, David J.] Malcom Randall Vet Affairs Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA.
[Clark, David J.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA.
[Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
[Behrman, Andrea L.] Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA.
[Kautz, Steven A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA.
RP Clark, DJ (reprint author), Malcom Randall Vet Affairs Med Ctr, Brain Rehabil Res Ctr 151A, 1601 SW Archer Rd, Gainesville, FL 32608 USA.
EM davidclark@ufl.edu
FU National Institutes of Health [HD-46820, GM-109040]; U.S. Department of
Veterans Affairs Rehabilitation Research and Development Service
[B3983R, B4888M, B7176W]
FX Supported by the National Institutes of Health (grant nos. HD-46820 and
GM-109040) and the U.S. Department of Veterans Affairs Rehabilitation
Research and Development Service (Merit Review B3983R and Career
Development Awards B4888M and B7176W). The contents do not represent the
views of the U.S Department of Veterans Affairs or the U.S. government.
NR 10
TC 2
Z9 2
U1 5
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAR
PY 2016
VL 97
IS 3
BP 493
EP 496
DI 10.1016/j.apmr.2015.10.081
PG 4
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA DG1TJ
UT WOS:000371850100018
PM 26525528
ER
PT J
AU Vopat, BG
Lee, BJ
DeStefano, S
Waryasz, GR
Kane, PM
Gallacher, SE
Fava, J
Green, AG
AF Vopat, Bryan G.
Lee, Bea J.
DeStefano, Sherilyn
Waryasz, Gregory R.
Kane, Patrick M.
Gallacher, Stacey E.
Fava, Joseph
Green, Andrew G.
TI Risk Factors for Infection After Rotator Cuff Repair
SO ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
LA English
DT Article
ID 2-YEAR FOLLOW-UP; MINI-OPEN; PROPIONIBACTERIUM-ACNES; DEEP INFECTION;
CLINICAL-OUTCOMES; SHOULDER SURGERY; TEARS; MANAGEMENT; TRIAL
AB Purpose: To identify risk factors for infection after rotator cuff repair. We hypothesized that patient characteristics and surgical technique would affect the rate of infection. Methods: The records of 1,824 rotator cuff repairs performed by a single surgeon from 1995 to 2010 were reviewed retrospectively. Fourteen patients had an early deep postoperative wound infection that was treated with surgical irrigation and debridement. One hundred eighty-five control patients who were treated with rotator cuff repair and did not develop an infection were selected randomly for comparison and statistical analysis. Data regarding preoperative and intraoperative risk factors for infection were recorded, and a multiple logistic regression was conducted to investigate predictors of infection. Results: The infection rate was 0.77% (14/1,822). On average 2.1 (range 1 to 4) surgical debridements were performed in addition to treatment with intravenous antibiotics. Patients who had open or miniopen rotator cuff repair had a significantly greater risk of acute postoperative infection (odds ratio [OR] = 8.63, P = .002). Seventy-nine percent of the patients in the infection group had an open or miniopen repair, whereas only 28% of the control group had an open or miniopen repair. Male patients also had a significantly greater risk of acute postoperative infection (OR = 9.52, P = .042). A total of 92% of the infection patients were male compared with 58% of the control group. In addition, as body mass index increased there was a reduction in the odds of infection (OR = 0.81, P = .023). Conclusions: The results of this case control study demonstrate that open or miniopen surgical technique and male sex are significant risk factors for infection after rotator cuff repair. In our study, arthroscopic rotator cuff repair reduced the risk of infection compared with open techniques.
C1 [Vopat, Bryan G.] Massachusetts Gen Hosp Harvard, 175 Cambridge St,Suite 400, Boston, MA 02114 USA.
[Waryasz, Gregory R.; Kane, Patrick M.; Fava, Joseph; Green, Andrew G.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Providence, RI 02903 USA.
[Lee, Bea J.] Irving Orthoped & Sports Med, Irving, TX USA.
[DeStefano, Sherilyn] Univ Vermont, Sch Med, Burlington, VT 05405 USA.
[Kane, Patrick M.] Philadelphia Hand Ctr South Jersey, Cherry Hill, NJ USA.
[Gallacher, Stacey E.] St Lukes Univ Hlth Network, Bethlehem, PA USA.
RP Vopat, BG (reprint author), Massachusetts Gen Hosp Harvard, 175 Cambridge St,Suite 400, Boston, MA 02114 USA.
EM bvopat@gmail.com
FU Tornier; Orthopaedics; IlluminOss Medical; Pfizer
FX The authors report the following potential conflict of interest or
source of funding: A.G.G. receives support from Tornier, Orthopaedics,
IlluminOss Medical, and Pfizer.
NR 40
TC 1
Z9 1
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-8063
EI 1526-3231
J9 ARTHROSCOPY
JI Arthroscopy
PD MAR
PY 2016
VL 32
IS 3
BP 428
EP 434
DI 10.1016/j.arthro.2015.08.021
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DG1MY
UT WOS:000371833400008
PM 26483170
ER
PT J
AU Trahanas, JM
Kolobow, MA
Hardy, MA
Berra, L
Zapol, WM
Bartlett, RH
AF Trahanas, John M.
Kolobow, Mary Anne
Hardy, Mark A.
Berra, Lorenzo
Zapol, Warren M.
Bartlett, Robert H.
TI "Treating Lungs": The Scientific Contributions of Dr. Theodor Kolobow
SO ASAIO JOURNAL
LA English
DT Article
DE Kolobow; ECMO; Barotrauma; Extracorporeal life support; ECLS; ECC02R
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; POSITIVE-PRESSURE VENTILATION;
RESPIRATORY-DISTRESS SYNDROME; ARTIFICIAL LUNG; CO2 REMOVAL; SUPPORT;
FAILURE
AB We are fortunate to live in an age in which biomedical technology has provided us with unprecedented ability to supplant the functions of organs and support the physiologic processes of the human body. Ingenious doctors, physiologists, and engineers helped create these advances with new and innovative ideas. One of these pioneers was Dr. Theodor Kolobow. He is best known for one of his earliest inventions, the spiral coil membrane lung. His contributions to medical innovation, however, are diverse, as he also contributed to advances in hemodialysis, improvements in extracorporeal life support technology/circuit components, and through his laboratory experiments helped shape our current understanding of cardiopulmonary pathophysiology. In retrospect, much of Kolobow's work was unified by the theme of preventing iatrogenic lung injury caused by mechanical ventilation. This tenet became more obvious as his later studies progressed to developing techniques and devices intended to limit ventilator pressures, and prevent bacterial colonization of the lungs. Although he formally retired from his research endeavors in 2009, the impact of his contributions remains prominent in our everyday use of techniques and equipment that he either originated or helped to develop.
C1 [Trahanas, John M.; Bartlett, Robert H.] Univ Michigan, Dept Surg, Extracorporeal Life Support Lab, 1150 W Med Ctr Dr,B560 MSRBII SPC 5686, Ann Arbor, MI 48109 USA.
[Trahanas, John M.; Hardy, Mark A.] Columbia Univ, Med Ctr, Dept Surg, New York, NY USA.
[Berra, Lorenzo; Zapol, Warren M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Trahanas, JM (reprint author), Univ Michigan, Dept Surg, Extracorporeal Life Support Lab, 1150 W Med Ctr Dr,B560 MSRBII SPC 5686, Ann Arbor, MI 48109 USA.
EM jtrahana@med.umich.edu
FU NIH [T32HL007854-20, 2R01 HD015434-29]
FX This study was in part supported by NIH Grant T32HL007854-20 (MAH); and
NIH Grant 2R01 HD015434-29 (RHB).
NR 28
TC 1
Z9 1
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1058-2916
EI 1538-943X
J9 ASAIO J
JI Asaio J.
PD MAR-APR
PY 2016
VL 62
IS 2
BP 203
EP 210
DI 10.1097/MAT.0000000000000323
PG 8
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA DG0IA
UT WOS:000371747300016
PM 26720733
ER
PT J
AU Thorgeirsson, T
Jordahl, KM
Flavin, R
Epstein, MM
Fiorentino, M
Andersson, SO
Andren, O
Rider, JR
Mosquera, JM
Ingoldsby, H
Fall, K
Tryggvadottir, L
Mucci, LA
AF Thorgeirsson, Tryggvi
Jordahl, Kristina M.
Flavin, Richard
Epstein, Mara Meyer
Fiorentino, Michelangelo
Andersson, Swen-Olof
Andren, Ove
Rider, Jennifer R.
Mosquera, Juan Miguel
Ingoldsby, Helen
Fall, Katja
Tryggvadottir, Laufey
Mucci, Lorelei A.
CA Transdisciplinary Prostate Canc Pa
TI Intracellular location of BRCA2 protein expression and prostate cancer
progression in the Swedish Watchful Waiting Cohort
SO CARCINOGENESIS
LA English
DT Article
ID MUTATION CARRIERS; LOCALIZATION
AB We found association between prognosis of prostate cancer patients and positive staining for the BRCA2 protein in diagnostic cancer tissue. Positive staining at the cell membrane was associated with improved survival whereas staining in the cytoplasm predicted adverse outcome.Prostate cancer patients with inherited BRCA2 mutations have a survival disadvantage. However, it is unknown whether progression is associated with BRCA2 protein expression in diagnostic prostate cancer tissue, among men without inherited mutations. We conducted a nested case-control study within the Swedish Watchful Waiting cohort. The case group included all 71 patients who died from prostate cancer within 5 years from diagnosis and controls were all patients (n = 165) who lived at least 7 years after diagnosis. Tissue microarrays were stained using antibodies for C- and N-terminal domains of the BRCA2 protein. Location (nuclear, cytoplasmic and membranous) and magnitude (intensity and percentage) of expression were assessed. Logistic regression models produced odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, year of diagnosis and Gleason score. Positive BRCA2 staining at the cell membrane was associated with reduced risk of death within 5 years (N-terminal: OR = 0.47, 95% CI = 0.21-1.04, P = 0.06; C-terminal: OR = 0.41, 95% CI = 0.18-0.91, P = 0.03) and low Gleason scores (P = 0.006). Positive cytoplasmic C-terminal staining was associated with higher Gleason scores and increased lethality (OR = 3.61, 95% CI = 1.61-8.07, P = 0.002). BRCA2 protein expression at the cell membrane and lack of C-terminal expression in the cytoplasm were associated with a reduced risk of rapidly fatal prostate cancer. BRCA2 protein expression in prostate cancer tissue may have independent prognostic value. The potential biological significance of BRCA2 expression at the cell membrane warrants further investigation.
C1 [Thorgeirsson, Tryggvi; Jordahl, Kristina M.; Fiorentino, Michelangelo; Rider, Jennifer R.; Mucci, Lorelei A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Thorgeirsson, Tryggvi; Mucci, Lorelei A.] Univ Iceland, Publ Hlth Sci, IS-101 Reykjavik, Iceland.
[Flavin, Richard] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02215 USA.
[Flavin, Richard] St James Hosp, Dept Histopathol, Dublin 8, Ireland.
[Flavin, Richard] Trinity Coll Dublin, Dublin, Ireland.
[Epstein, Mara Meyer] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA.
[Epstein, Mara Meyer] Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Worcester, MA 01605 USA.
[Fiorentino, Michelangelo] Univ Bologna, S Orsola Malpighi Hosp, F Addarii Inst Oncol & Transplantat Pathol, I-40126 Bologna, Italy.
[Andersson, Swen-Olof; Andren, Ove] Univ Orebro, Fac Med & Hlth, Dept Urol, SE-70182 Orebro, Sweden.
[Mosquera, Juan Miguel] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
[Mosquera, Juan Miguel] Weill Cornell Med Coll, Inst Precis Med, New York, NY 10065 USA.
[Mosquera, Juan Miguel] New York Presbyterian, New York, NY 10065 USA.
[Ingoldsby, Helen] Nat Univ Ireland, Shantalla Rd, Galway, Ireland.
[Fall, Katja] Univ Orebro, Fac Med & Hlth, Clin Epidemiol & Biostat, SE-70182 Orebro, Sweden.
[Tryggvadottir, Laufey] Iceland Canc Registry, IS-105 Reykjavik, Iceland.
[Tryggvadottir, Laufey] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
RP Tryggvadottir, L (reprint author), Iceland Canc Registry, IS-105 Reykjavik, Iceland.; Tryggvadottir, L (reprint author), Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
EM laufeyt@krabb.is
OI Fall, Katja/0000-0002-3649-2639
FU Icelandic Prostate Cancer Group Framfor; Icelandic Cancer Society;
Swedish Cancer Society, CAN; Dana Farber/Harvard Cancer Center SPORE in
Prostate Cancer [P50 CA090381]
FX Icelandic Prostate Cancer Group Framfor, the Dana Farber/Harvard Cancer
Center SPORE in Prostate Cancer (P50 CA090381 to L.M.); Icelandic Cancer
Society and the Swedish Cancer Society, CAN 2006.
NR 21
TC 0
Z9 0
U1 3
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2016
VL 37
IS 3
BP 262
EP 268
DI 10.1093/carcin/bgw001
PG 7
WC Oncology
SC Oncology
GA DF9QP
UT WOS:000371696400004
PM 26775038
ER
PT J
AU Kang, XZ
Liu, HL
Onaitis, MW
Liu, ZS
Owzar, K
Han, YH
Su, L
Wei, YY
Hung, RJ
Brhane, Y
McLaughlin, J
Brennan, P
Bickeboller, H
Rosenberger, A
Houlston, RS
Caporaso, N
Landi, MT
Heinrich, J
Risch, A
Wu, XF
Ye, YQ
Christiani, DC
Amos, CI
Wei, QY
AF Kang, Xiaozheng
Liu, Hongliang
Onaitis, Mark W.
Liu, Zhensheng
Owzar, Kouros
Han, Younghun
Su, Li
Wei, Yongyue
Hung, Rayjean J.
Brhane, Yonathan
McLaughlin, John
Brennan, Paul
Bickeboeller, Heike
Rosenberger, Albert
Houlston, Richard S.
Caporaso, Neil
Landi, Maria Teresa
Heinrich, Joachim
Risch, Angela
Wu, Xifeng
Ye, Yuanqing
Christiani, David C.
Amos, Christopher I.
Wei, Qingyi
CA Transdisciplinary Res Canc Lung
TI Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a
meta-analysis of 14 463 cases and 44 188 controls
SO CARCINOGENESIS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCUS; DISEASE; AMPLIFICATION;
ABNORMALITIES; VITILIGO; VARIANTS; CELLS; VISUALIZATION; INSTABILITY
AB After combining the summary results of SNPs in 106 centrosomal genes from eight published lung cancer GWASs, we found that two potential functional SNPs (rs151606 and rs12212247) in FGFR1OP were significantly associated with lung cancer risk.Centrosome abnormalities are often observed in premalignant lesions and in situ tumors and have been associated with aneuploidy and tumor development. We investigated the associations of 9354 single-nucleotide polymorphisms (SNPs) in 106 centrosomal genes with lung cancer risk by first using the summary data from six published genome-wide association studies (GWASs) of the Transdisciplinary Research in Cancer of the Lung (TRICL) (12 160 cases and 16 838 controls) and then conducted in silico replication in two additional independent lung cancer GWASs of Harvard University (984 cases and 970 controls) and deCODE (1319 cases and 26 380 controls). A total of 44 significant SNPs with false discovery rate (FDR) a parts per thousand currency sign 0.05 were mapped to one novel gene FGFR1OP and two previously reported genes (TUBB and BRCA2). After combined the results from TRICL with those from Harvard and deCODE, the most significant association (P (combined) = 8.032x10(-6)) was with rs151606 within FGFR1OP. The rs151606 T > G was associated with an increased risk of lung cancer [odds ratio (OR) = 1.10, 95% confidence interval (95% CI) = 1.05-1.14]. Another significant tagSNP rs12212247 T > C (P (combined) = 9.589x10(-6)) was associated with a decreased risk of lung cancer (OR = 0.93, 95% CI = 0.90-0.96). Further in silico functional analyzes revealed that rs151606 might affect transcriptional regulation and result in decreased FGFR1OP expression (P (trend) = 0.022). The findings shed some new light on the role of centrosome abnormalities in the susceptibility to lung carcinogenesis.
C1 [Kang, Xiaozheng; Liu, Hongliang; Onaitis, Mark W.; Liu, Zhensheng; Owzar, Kouros; Wei, Qingyi] Duke Univ, Med Ctr, Duke Canc Inst, 905 S LaSalle St, Durham, NC 27710 USA.
[Kang, Xiaozheng; Onaitis, Mark W.] Duke Univ, Med Ctr, Div Cardiovasc & Thorac Surg, Dept Surg, 905 S LaSalle St, Durham, NC 27710 USA.
[Kang, Xiaozheng] Peking Univ, Canc Hosp & Inst, Minist Educ,Dept Thorac Surg 1, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China.
[Liu, Hongliang; Liu, Zhensheng; Wei, Qingyi] Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA.
[Owzar, Kouros] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
[Han, Younghun; Amos, Christopher I.] Dartmouth Coll, Geisel Sch Med, Community & Family Med, Hanover, NH 03755 USA.
[Su, Li; Wei, Yongyue; Christiani, David C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Su, Li; Wei, Yongyue; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
[Hung, Rayjean J.; Brhane, Yonathan] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
[McLaughlin, John] Publ Hlth Ontario, Toronto, ON M5T 3L9, Canada.
[Brennan, Paul] Int Agcy Res Canc, Genet Epidemiol Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.
[Bickeboeller, Heike; Rosenberger, Albert] Univ Gottingen, Univ Med Ctr, Dept Genet Epidemiol, D-37073 Gottingen, Germany.
[Houlston, Richard S.] Inst Canc Res, Div Genet & Epidemiol, London SW7 3RP, England.
[Caporaso, Neil; Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Epidemiol 1, D-85764 Neuherberg, Germany.
[Risch, Angela] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria.
[Wu, Xifeng; Ye, Yuanqing] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
RP Wei, QY (reprint author), Duke Univ, Med Ctr, Duke Canc Inst, 905 S LaSalle St, Durham, NC 27710 USA.; Wei, QY (reprint author), Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA.
EM qingyi.wei@duke.edu
RI Hung, Rayjean/A-7439-2013; Risch, Angela/H-2669-2013;
OI Risch, Angela/0000-0002-8026-5505; Houlston, Richard/0000-0002-5268-0242
FU Duke Cancer Institute as part of the P30 Cancer Center Support Grant
[NIH CA014236]; Duke Cancer Institute, Duke University Medical Center
FX As Duke Cancer Institute members, Q.W., M.W.O., and K.O. acknowledge
support from the Duke Cancer Institute as part of the P30 Cancer Center
Support Grant (NIH CA014236). Q.W. was also supported by a start-up fund
from Duke Cancer Institute, Duke University Medical Center.
NR 61
TC 1
Z9 1
U1 3
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2016
VL 37
IS 3
BP 280
EP 289
DI 10.1093/carcin/bgw014
PG 10
WC Oncology
SC Oncology
GA DF9QP
UT WOS:000371696400006
PM 26905588
ER
PT J
AU Ma, JF
Yang, F
Mahida, SN
Zhao, L
Chen, XM
Zhang, ML
Sun, ZJ
Yao, Y
Zhang, YX
Zheng, GY
Dong, J
Feng, MJ
Zhang, R
Sun, J
Li, S
Wang, QS
Cao, HQ
Benjamin, EJ
Ellinor, PT
Li, YG
Tian, XL
AF Ma, Ji-Fang
Yang, Fan
Mahida, Saagar N.
Zhao, Ling
Chen, Xiaomin
Zhang, Micheal L.
Sun, Zhijun
Yao, Yan
Zhang, Yi-Xin
Zheng, Gu-Yan
Dong, Jie
Feng, Ming-Jun
Zhang, Rui
Sun, Jian
Li, Shuo
Wang, Qun-Shan
Cao, Huiqing
Benjamin, Emelia J.
Ellinor, Patrick T.
Li, Yi-Gang
Tian, Xiao-Li
TI TBX5 mutations contribute to early-onset atrial fibrillation in Chinese
and Caucasians
SO CARDIOVASCULAR RESEARCH
LA English
DT Article
DE Atrial fibrillation; TBX5; ANP; Connexin; Mutation
ID HOLT-ORAM-SYNDROME; CARDIAC CONDUCTION SYSTEM; TRANSCRIPTION FACTOR
TBX5; NATRIURETIC-PEPTIDE; COMMON VARIANTS; RISK-FACTORS; PR INTERVAL;
CONNEXIN40; GENE; POLYMORPHISMS
AB Atrial fibrillation (AF) is a common arrhythmia with an important heritable aspect. The genetic factors underlying AF have not been fully elucidated.
We screened six candidate genes (CAV1, KCNJ2, KCNQ1, NKX2.5, PITX2, and TBX5) for novel mutations in 139 patients of Chinese descent with early-onset AF and 576 controls. Four missense TBX5 mutations, p.R355C, p.Q376R, p.A428S, and p.S372L, were identified in evolutionarily conserved regions. We did not find any mutations in CAV1, KCNJ2, KCNQ1, NKX2.5, and PITX2. These mutations increased the expression of atrial natriuretic peptide (ANP) and connexin-40 (CX40) in the primarily cultured rat atrial myocytes but did not alter the expression of cardiac structural genes, atrial myosin heavy chain-alpha (MHC-alpha) and myosin light chain-2 alpha (MLC-2 alpha). Overexpression of p.R355C developed an atrial arrhythmia suggestive of paroxysmal AF in the zebrafish model. To replicate our findings, we screened TBX5 in 527 early-onset AF cases from the Massachusetts General Hospital AF study. A novel TBX5 deletion (Delta Asp118, p.D118del) was identified, while no TBX5 mutations were identified in 1176 control subjects.
Our results provide both genetic and functional evidence to support the contribution of TBX5 gene in the pathogenesis of AF. The potential mechanism of arrhythmia may be due in part to the disturbed expression of ANP and CX40.
C1 [Ma, Ji-Fang; Zhang, Rui; Sun, Jian; Li, Shuo; Wang, Qun-Shan; Li, Yi-Gang] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Cardiol, Shanghai 200092, Peoples R China.
[Yang, Fan; Zhao, Ling; Zhang, Yi-Xin; Zheng, Gu-Yan; Dong, Jie; Cao, Huiqing; Tian, Xiao-Li] Peking Univ, Dept Human Populat Genet, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.
[Yang, Fan; Zhao, Ling; Zhang, Yi-Xin; Zheng, Gu-Yan; Dong, Jie; Cao, Huiqing; Tian, Xiao-Li] Peking Univ, Beijing Key Lab Cardiometabol Mol Med, IMM, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.
[Mahida, Saagar N.; Zhang, Micheal L.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
[Chen, Xiaomin; Feng, Ming-Jun] Ningbo Univ, Ningbo Hosp 1, Key Lab, 59 Liuting St, Ningbo 315010, Peoples R China.
[Chen, Xiaomin; Feng, Ming-Jun] Ningbo Univ, Ningbo Hosp 1, Ctr Cardiovasc, 59 Liuting St, Ningbo 315010, Peoples R China.
[Sun, Zhijun] Peoples Liberat Army Gen Hosp, Cardiovasc Dept, 28 Fuxing Rd, Beijing 100853, Peoples R China.
[Yao, Yan] Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
[Benjamin, Emelia J.] NHLBI, Framingham, MA USA.
[Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Med, Prevent Med Sect, Boston, MA 02215 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Med, Cardiol Sect, Boston, MA 02215 USA.
[Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
RP Li, YG (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Cardiol, Shanghai 200092, Peoples R China.; Tian, XL (reprint author), Peking Univ, Dept Human Populat Genet, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.; Tian, XL (reprint author), Peking Univ, Beijing Key Lab Cardiometabol Mol Med, IMM, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.
EM drliyigang@outlook.com; tianxiaoli@pku.edu.cn
FU National Basic Research Program of China (973 program) [2013CB530700,
2007CB512100]; National Science Foundation of China [31221002, 81070154,
81270258]; Shanghai Excellent Academic Leaders Project [10xd1402800];
National Institutes of Health [1RO1HL104156, 1K24HL105780,
1RO1HL092577]; American Heart Association [13EIA14220013]
FX This study was supported by grants from the National Basic Research
Program of China (973 program) (2013CB530700 and 2007CB512100 to
X.L.T.), the National Science Foundation of China (31221002 to X.L.T.,
no. 81070154 and No. 81270258 to Y.G.L.), the Shanghai Excellent
Academic Leaders Project (grant number 10xd1402800 to Y.G.L.), the
National Institutes of Health to P.T.E. (1RO1HL104156 and 1K24HL105780
to P.T.E., 1RO1HL092577 to P.T.E. and E.J.B.), and the American Heart
Association (13EIA14220013 to P.T.E.).
NR 50
TC 4
Z9 4
U1 2
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
EI 1755-3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD MAR 1
PY 2016
VL 109
IS 3
BP 442
EP 450
DI 10.1093/cvr/cvw003
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DF7ER
UT WOS:000371521100013
PM 26762269
ER
PT J
AU Fjell, AM
Sneve, MH
Storsve, AB
Grydeland, H
Yendiki, A
Walhovd, KB
AF Fjell, Anders M.
Sneve, Markus H.
Storsve, Andreas B.
Grydeland, Hakon
Yendiki, Anastasia
Walhovd, Kristine B.
TI Brain Events Underlying Episodic Memory Changes in Aging: A Longitudinal
Investigation of Structural and Functional Connectivity
SO CEREBRAL CORTEX
LA English
DT Article
DE aging; longitudinal; memory; resting-state functional connectivity;
structural connectivity
ID RESTING-STATE FMRI; HUMAN CEREBRAL-CORTEX; DEFAULT-MODE NETWORK;
MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; ALZHEIMERS-DISEASE;
BASAL GANGLIA; HEALTHY-ADULTS; WHITE-MATTER; HYPOTHETICAL MODEL
AB Episodic memories are established and maintained by close interplay between hippocampus and other cortical regions, but degradation of a fronto-striatal network has been suggested to be a driving force of memory decline in aging. We wanted to directly address how changes in hippocampal-cortical versus striatal-cortical networks over time impact episodic memory with age. We followed 119 healthy participants (20-83 years) for 3.5 years with repeated tests of episodic verbal memory and magnetic resonance imaging for quantification of functional and structural connectivity and regional brain atrophy. While hippocampal-cortical functional connectivity predicted memory change in young, changes in cortico-striatal functional connectivity were related to change in recall in older adults. Within each age group, effects of functional and structural connectivity were anatomically closely aligned. Interestingly, the relationship between functional connectivity and memory was strongest in the age ranges where the rate of reduction of the relevant brain structure was lowest, implying selective impacts of the different brain events on memory. Together, these findings suggest a partly sequential and partly simultaneous model of brain events underlying cognitive changes in aging, where different functional and structural events are more or less important in various time windows, dismissing a simple uni-factorial view on neurocognitive aging.
C1 [Fjell, Anders M.; Sneve, Markus H.; Storsve, Andreas B.; Grydeland, Hakon; Walhovd, Kristine B.] Univ Oslo, Dept Psychol, Res Grp Lifespan Changes Brain & Cognit, N-0373 Oslo, Norway.
[Fjell, Anders M.; Walhovd, Kristine B.] Oslo Univ Hosp, Unit Neuropsychol, Dept Phys Med & Rehabil, N-0424 Oslo, Norway.
[Yendiki, Anastasia] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Boston, MA USA.
RP Fjell, AM (reprint author), Dept Psychol, Pb 1094 Blindern, N-0317 Oslo, Norway.
EM andersmf@psykologi.uio.no
OI Storsve, Andreas B/0000-0001-6807-8638
FU Department of Psychology, University of Oslo; Norwegian Research
Council; European Research Council's Starting Grant scheme (ERC)
[313440, 283634]; US-Norway Fulbright Foundation; National Institute for
Biomedical Imaging and Bioengineering [R00-EB008129, R01-EB006758];
National Institutes of Health Blueprint for Neuroscience Research
[5U01-MH093765]; National Institute of Biomedical Imaging and
Bioengineering, National Institutes of Health; NIH [S10RR023401,
S10RR019307, S10RR019254, S10RR023043]
FX This work was supported by the Department of Psychology, University of
Oslo (A.B.S., K.B.W. and A.M.F.), the Norwegian Research Council (to
K.B.W. and A.M.F.), the European Research Council's Starting Grant
scheme (ERC grant agreement 313440 to K.B.W. and 283634 to A.M.F.), the
US-Norway Fulbright Foundation (to A.B.S.), the National Institute for
Biomedical Imaging and Bioengineering (R00-EB008129, R01-EB006758) (to
A.Y.), and the National Institutes of Health Blueprint for Neuroscience
Research (5U01-MH093765) (to A.Y.), part of the multi-institutional
Human Connectome Project. Additional resources were provided by the
Center for Functional Neuroimaging Technologies, P41EB015896, a P41
Biotechnology Resource Grant supported by the National Institute of
Biomedical Imaging and Bioengineering, National Institutes of Health (to
A.Y.). This work also involved the use of instrumentation supported by
the NIH Shared Instrumentation Grants S10RR023401, S10RR019307,
S10RR019254, S10RR023043.
NR 94
TC 8
Z9 8
U1 3
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
EI 1460-2199
J9 CEREB CORTEX
JI Cereb. Cortex
PD MAR
PY 2016
VL 26
IS 3
BP 1272
EP 1286
DI 10.1093/cercor/bhv102
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA DF7FP
UT WOS:000371523600033
PM 25994960
ER
PT J
AU Kheirkhah, A
Saboo, US
Marmalidou, A
Dana, R
AF Kheirkhah, Ahmad
Saboo, Ujwala S.
Marmalidou, Anna
Dana, Reza
TI Overestimation of Corneal Endothelial Cell Density in Smaller Frame
Sizes in In Vivo Confocal Microscopy
SO CORNEA
LA English
DT Article
DE in vivo confocal microscopy; cornea; endothelial cells
ID NONCONTACT SPECULAR MICROSCOPE; IMAGES; TRANSPLANTATION; RELIABILITY;
DYSTROPHY; NERVES
AB Purpose:
To evaluate the effect of frame size on the calculated corneal endothelial cell density (CECD) in images of laser scanning in vivo confocal microscopy (IVCM).
Methods:
Forty-nine corneal endothelial images acquired by laser scanning IVCM (Heidelberg Retina Tomograph 3 with Rostock Corneal Module) with different endothelial cell densities were analyzed. In each image (160,000 mu m(2)), the CECD was calculated using the fixed-frame method by counting cells in the following frame sizes: 80,000 mu m(2), 40,000 mu m(2), 20,000 mu m(2), 10,000 mu m(2), 5000 mu m(2), and 2500 mu m(2). The calculated CECD was then compared with that of the variable-frame method as the reference value.
Results:
There was no significant difference in the calculated CECD between the variable-frame method (2004 +/- 832 cells/mm(2)), and the fixed-frame method using a 40,000-mu m(2) frame (2023 +/- 810 cells/mm(2)). On the other hand, the calculated CECD showed significant overestimations in frame sizes of 20,000 mu m(2) (2066 +/- 820 cells/mm(2)), 10,000 mu m(2) (2156 +/- 785 cells/mm(2)), 5000 mu m(2) (2352 +/- 783 cells/mm(2)), and 2500 mu m(2) (2715 +/- 754 cells/mm(2)), with P < 0.001 in all. This resulted in overestimations of 4.8 +/- 9.8%, 11.9 +/- 16.2%, 24.9 +/- 23.1%, and 49.1 +/- 38.8% for these frame sizes, respectively. Images with lower CECD demonstrated higher overestimations of cell density in smaller frame sizes.
Conclusions:
In laser scanning IVCM images, there is significant overestimation of CECD if the cells are counted in frames smaller than 25% of the image. Similar frame sizes should be used when monitoring CECD over time.
C1 [Kheirkhah, Ahmad; Saboo, Ujwala S.; Marmalidou, Anna; Dana, Reza] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Cornea & Refract Surg Serv,Dept Ophthalmol, Boston, MA USA.
RP Dana, R (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM reza_dana@meei.harvard.edu
NR 30
TC 1
Z9 1
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3740
EI 1536-4798
J9 CORNEA
JI Cornea
PD MAR
PY 2016
VL 35
IS 3
BP 363
EP 369
DI 10.1097/ICO.0000000000000698
PG 7
WC Ophthalmology
SC Ophthalmology
GA DF5IY
UT WOS:000371386400014
PM 26606299
ER
PT J
AU Smith, HAB
Gangopadhyay, M
Goben, CM
Jacobowski, NL
Chestnut, MH
Savage, S
Rutherford, MT
Denton, D
Thompson, JL
Chandrasekhar, R
Acton, M
Newman, J
Noori, HP
Terrell, MK
Williams, SR
Griffith, K
Cooper, TJ
Ely, EW
Fuchs, DC
Pandharipande, PP
AF Smith, Heidi A. B.
Gangopadhyay, Maalobeeka
Goben, Christina M.
Jacobowski, Natalie L.
Chestnut, Mary Hamilton
Savage, Shane
Rutherford, Michael T.
Denton, Danica
Thompson, Jennifer L.
Chandrasekhar, Rameela
Acton, Michelle
Newman, Jessica
Noori, Hannah P.
Terrell, Michelle K.
Williams, Stacey R.
Griffith, Katherine
Cooper, Timothy J.
Ely, E. Wesley
Fuchs, D. Catherine
Pandharipande, Pratik P.
TI The Preschool Confusion Assessment Method for the ICU: Valid and
Reliable Delirium Monitoring for Critically Ill Infants and Children*
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE encephalopathy; agitation; sedation; pediatric; critical care
ID INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; PEDIATRIC
DELIRIUM; CRITICAL ILLNESS; COGNITIVE IMPAIRMENT; CAM-ICU; SEDATION;
SCALE; TOOL; RELIABILITY
AB Objectives:
Delirium assessments in critically ill infants and young children pose unique challenges due to evolution of cognitive and language skills. The objectives of this study were to determine the validity and reliability of a fundamentally objective and developmentally appropriate delirium assessment tool for critically ill infants and preschool-aged children and to determine delirium prevalence.
Design and Setting:
Prospective, observational cohort validation study of the PreSchool Confusion Assessment Method for the ICU in a tertiary medical center PICU.
Patients:
Participants aged 6 months to 5 years and admitted to the PICU regardless of admission diagnosis were enrolled.
Measurements and Main Results:
An interdisciplinary team created the PreSchool Confusion Assessment Method for the ICU for pediatric delirium monitoring. To assess validity, patients were independently assessed for delirium daily by the research team using the PreSchool Confusion Assessment Method for the ICU and by a child psychiatrist using the Diagnostic and Statistical Manual of Mental Disorders criteria. Reliability was assessed using blinded, concurrent PreSchool Confusion Assessment Method for the ICU evaluations by research staff. A total of 530-paired delirium assessments were completed among 300 patients, with a median age of 20 months (interquartile range, 11-37) and 43% requiring mechanical ventilation. The PreSchool Confusion Assessment Method for the ICU demonstrated a specificity of 91% (95% CI, 90-93), sensitivity of 75% (95% CI, 72-78), negative predictive value of 86% (95% CI, 84-88), positive predictive value of 84% (95% CI, 81-87), and a reliability kappa-statistic of 0.79 (0.76-0.83). Delirium prevalence was 44% using the PreSchool Confusion Assessment Method for the ICU and 47% by the reference rater. The rates of delirium were 53% versus 56% in patients younger than 2 years old and 33% versus 35% in patients 2-5 years old using the PreSchool Confusion Assessment Method for the ICU and reference rater, respectively. The short-form PreSchool Confusion Assessment Method for the ICU maintained a high specificity (87%) and sensitivity (78%) in post hoc analysis.
Conclusions:
The PreSchool Confusion Assessment Method for the ICU is a highly valid and reliable delirium instrument for critically ill infants and preschool-aged children, in whom delirium is extremely prevalent.
C1 [Smith, Heidi A. B.; Chestnut, Mary Hamilton; Pandharipande, Pratik P.] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA.
[Smith, Heidi A. B.; Goben, Christina M.; Acton, Michelle; Newman, Jessica; Noori, Hannah P.; Terrell, Michelle K.; Williams, Stacey R.; Griffith, Katherine] Monroe Carell Jr Childrens Hosp Vanderbilt, Dept Pediat, Nashville, TN USA.
[Gangopadhyay, Maalobeeka] New York Presbyterian Morgan Stanley Childrens Ho, Dept Psychiat, New York, NY USA.
[Jacobowski, Natalie L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Savage, Shane] Georgia Regents Univ, Dept Psychiat, Augusta, GA USA.
[Rutherford, Michael T.] Kalispell Reg Healthcare, Dept Psychiat, Kalispell, MT USA.
[Denton, Danica; Fuchs, D. Catherine] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN USA.
[Thompson, Jennifer L.; Chandrasekhar, Rameela] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
[Cooper, Timothy J.] Monroe Carell Jr Childrens Hosp Vanderbilt, Dept Dev Med, Nashville, TN USA.
[Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Dept Internal Med, Nashville, TN USA.
[Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Div Pulm & Crit Care Med, Nashville, TN USA.
[Ely, E. Wesley] Tennessee Valley VA GRECC, Nashville, TN USA.
RP Smith, HAB (reprint author), Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA.; Smith, HAB (reprint author), Monroe Carell Jr Childrens Hosp Vanderbilt, Dept Pediat, Nashville, TN USA.
EM heidi.smith@vanderbilt.edu
FU Foundation for Anesthesia Education and Research; Vanderbilt Clinical
and Translational Science Awards (CTSA) grant from National Center for
Research Resources (NCRR)/National Institutes of Health (NIH) [UL1
TR000445]; Vanderbilt CTSA grant from NCRR/NIH [UL1 TR000445]; NIH
[HL111111, AG027472, AG035117]; Hospira Inc.; Veterans Affairs Tennessee
Valley Geriatric Research, Education and Clinical Center; VA Clinical
Science Research and Development Service; Abbott Laboratories; Orion;
Hospira
FX Dr. Smith is supported by the Foundation for Anesthesia Education and
Research and supported in part by the Vanderbilt Clinical and
Translational Science Awards (CTSA) grant UL1 TR000445 from the National
Center for Research Resources (NCRR)/National Institutes of Health
(NIH). Dr. Gangopadhyay and Dr. Fuchs are supported in part by the
Vanderbilt CTSA grant UL1 TR000445 from NCRR/NIH. Dr. Pandharipande is
supported by the NIH (HL111111, AG027472, and AG035117); and his
institute receives research funding from Hospira Inc. Dr. Ely is
supported by the Veterans Affairs Tennessee Valley Geriatric Research,
Education and Clinical Center, the VA Clinical Science Research and
Development Service, and the NIH (AG027472, AG035117, and HL111111). He
has received funding from Abbott Laboratories, Orion, and Hospira. The
remaining authors have disclosed that they do not have any potential
conflicts of interest.
NR 30
TC 10
Z9 10
U1 6
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAR
PY 2016
VL 44
IS 3
BP 592
EP 600
DI 10.1097/CCM.0000000000001428
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA DF7HM
UT WOS:000371528700017
PM 26565631
ER
PT J
AU Muralidhar, V
Nipp, RD
Ryan, DP
Hong, TS
Nguyen, PL
Wo, JY
AF Muralidhar, Vinayak
Nipp, Ryan D.
Ryan, David P.
Hong, Theodore S.
Nguyen, Paul L.
Wo, Jennifer Y.
TI Association Between Very Small Tumor Size and Increased Cancer-Specific
Mortality in Node-Positive Colon Cancer
SO DISEASES OF THE COLON & RECTUM
LA English
DT Article
DE Lymph node metastasis; Personalized medicine; Colon cancer; Tumor size
ID COLORECTAL-CANCER; HEPATIC METASTASES; SURVIVAL; DISSECTION; EXPRESSION;
INVASION; INSIGHTS; BREAST; CELLS
AB BACKGROUND:
Larger tumor size and lymph node involvement are traditionally associated with increased colon cancer-specific mortality.
OBJECTIVE:
We sought to determine whether patients with very small tumors associated with lymph node involvement are at paradoxically increased risk of colon cancer-specific mortality in comparison with those who have larger tumors and lymph node involvement.
DESIGN:
This is a retrospective cohort study using the Surveillance, Epidemiology, and End Results database.
SETTING:
Geographic areas included in one of the 18 Surveillance, Epidemiology, and End Results registries were used.
PATIENTS:
We identified 99,594 patients with nonmetastatic colon adenocarcinoma treated with surgery between 1988 and 2001.
MAIN OUTCOME MEASURES:
The primary predictor variables were regional lymph node involvement and primary tumor size by longest dimension, grouped into the following predetermined strata: < 5 mm, 5 to 19 mm, 20 to 39 mm, 40 to 59 mm, >= 60 mm. We used competing risks regression to determine differences in the risk of colon cancer-specific mortality between strata after controlling for T stage, tumor grade, age, year of diagnosis, race, and number of dissected lymph nodes.
RESULTS:
Median follow-up among censored patients was 12.9 years. We found a significant interaction between lymph node involvement and tumor size (p < 0.05). Among those with node-negative disease, colon cancer-specific mortality increased monotonically with tumor size. In contrast, among those with node-positive disease, patients with the smallest tumors (< 5 mm) were at increased risk of 10-year colon cancer-specific mortality compared with those with tumors sized 5 to 19 mm, 20 to 39 mm, 40 to 59 mm, and >= 60 mm (53.3% vs 30.1%, 37.5%, 39.2%, and 39.7%; adjusted hazard ratios, 1.63-2.24; p < 0.05 in all cases).
LIMITATIONS:
The main limitations are the retrospective design and information available in the study database.
CONCLUSION:
In the setting of lymph node involvement, very small tumor size may predict for increased colon cancer-specific mortality compared with larger tumors. Smaller tumors associated with lymph node involvement may represent more aggressive malignancies with a distinct biology that merits further investigation.
C1 [Muralidhar, Vinayak] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol, Boston, MA USA.
[Nipp, Ryan D.; Ryan, David P.] Massachusetts Gen Hosp, Div Hematol & Med Oncol, Boston, MA 02114 USA.
[Hong, Theodore S.; Wo, Jennifer Y.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Nguyen, Paul L.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Nguyen, Paul L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
RP Wo, JY (reprint author), 55 Fruit St, Boston, MA 02114 USA.
EM jwo@mgh.harvard.edu
NR 29
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0012-3706
EI 1530-0358
J9 DIS COLON RECTUM
JI Dis. Colon Rectum
PD MAR
PY 2016
VL 59
IS 3
BP 187
EP 193
DI 10.1097/DCR.0000000000000532
PG 7
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA DF5GW
UT WOS:000371380800005
PM 26855392
ER
PT J
AU Yoder, KK
Albrecht, DS
Dzemidzic, M
Normandin, MD
Federici, LM
Graves, T
Herring, CM
Hile, KL
Walters, JW
Liang, TB
Plawecki, MH
O'Connor, S
Kareken, DA
AF Yoder, Karmen K.
Albrecht, Daniel S.
Dzemidzic, Mario
Normandin, Marc D.
Federici, Lauren M.
Graves, Tammy
Herring, Christine M.
Hile, Karen L.
Walters, James W.
Liang, Tiebing
Plawecki, Martin H.
O'Connor, Sean
Kareken, David A.
TI Differences in IV alcohol-induced dopamine release in the ventral
striatum of social drinkers and nontreatment-seeking alcoholics
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Dopamine; Raclopride; Alcohol; Positron emission tomography; Ventral
striatum
ID POSITRON-EMISSION-TOMOGRAPHY; NUCLEUS-ACCUMBENS DOPAMINE; RECEPTOR
AVAILABILITY; SUBJECTIVE RESPONSES; FAMILY-HISTORY; ORAL ALCOHOL;
DEPENDENCE; ETHANOL; REWARD; RELIABILITY
AB Background: Striatal dopamine (DA) has been implicated in alcohol use disorders, but it is still unclear whether or not alcohol can induce dopamine release in social drinkers. Furthermore, no data exist on dopamine responses to alcohol in dependent drinkers. We sought to characterize the DA responses to alcohol intoxication in moderately large samples of social drinkers (SD) and nontreatment-seeking alcoholics (NTS).
Methods: Twenty-four SD and twenty-one NTS received two [C-11]raclopride (RAC) PET scans; one at rest, and one during an intravenous alcohol infusion, with a prescribed ascent to a target breath alcohol concentration (BrAC), at which it was then "clamped." The alcohol clamp was started 5 min after scan start, with a linear increase in BrAC over 15 min to the target of 80 mg%, the legal threshold for intoxication. Target BrAC was maintained for 30 min. Voxel-wise binding potential (BPND) was estimated with MRTM2.
Results: IV EtOH induced significant increases in DA in the right ventral striatum in NTS, but not SD. No decreases in DA were observed in either group.
Conclusions: Alcohol intoxication results in distinct anatomic profiles of DA responses in SD and NTS, suggesting that in NTS, the striatal DA system may process effects of alcohol intoxication differently than in SD. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Yoder, Karmen K.; Albrecht, Daniel S.; Dzemidzic, Mario; Normandin, Marc D.; Federici, Lauren M.; Graves, Tammy; Herring, Christine M.; Hile, Karen L.; Walters, James W.; Kareken, David A.] IUSM, Dept Radiol & Imaging Sci, R2-E124,950 W Walnut St, Indianapolis, IN 46202 USA.
[Yoder, Karmen K.; Albrecht, Daniel S.; Dzemidzic, Mario; Federici, Lauren M.; Herring, Christine M.; Hile, Karen L.; Walters, James W.; Kareken, David A.] IUSM, Ctr Neuroimaging, GH Ste 4100,355 W 16th St, Indianapolis, IN 46202 USA.
[Yoder, Karmen K.; Albrecht, Daniel S.] IUSM, Stark Neurosci Res Inst, NB Ste 414,320 W 16th St, Indianapolis, IN 46202 USA.
[Yoder, Karmen K.] Indiana Univ Purdue Univ, Dept Psychol, 402 N Blackford St, Indianapolis, IN 46202 USA.
[Dzemidzic, Mario; Kareken, David A.] IUSM, Dept Neurol, GH Ste 4700,355 W 16th St, Indianapolis, IN 46202 USA.
[Graves, Tammy; Liang, Tiebing] IUSM, Dept Med, 340 W 10th St,Ste 6200, Indianapolis, IN 46202 USA.
[Plawecki, Martin H.; O'Connor, Sean; Kareken, David A.] IUSM, Dept Psychiat, GH Ste 4800,355 W 16th St, Indianapolis, IN 46202 USA.
[O'Connor, Sean] Richard L Roudebush Vet Adm Med Ctr, 1481 W 10th St, Indianapolis, IN 46202 USA.
[Albrecht, Daniel S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, 149 Thirteenth St,Room 2301, Charlestown, MA 02129 USA.
[Normandin, Marc D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gordon Ctr Med Imaging,Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
RP Yoder, KK (reprint author), Indiana Univ Sch Med, Radiol & Imaging Sci, Ctr Neuroimaging, Goodman Hall Ste 4100,355 W 16th St, Indianapolis, IN 46202 USA.
EM kkyoder@iupui.edu
FU National Institute on Alcoholism and Alcohol Abuse [R01AA018354];
ABMRF/The Foundation for Alcohol Research; NIAAA [P60 AA007611];
Genomics and Bioinformatics Core; Indiana Clinical and Translational
Sciences Institute (from the National Institutes of Health, National
Center for Research Resources, Clinical and Translational Sciences
Award) [UL RR025761]
FX National Institute on Alcoholism and Alcohol Abuse R01AA018354 (KKY),
ABMRF/The Foundation for Alcohol Research (KKY), NIAAA (SOC, MP; Pilot
50 to KKY) and Genomics and Bioinformatics Core (TL), and the Indiana
Clinical and Translational Sciences Institute (from the National
Institutes of Health, National Center for Research Resources, Clinical
and Translational Sciences Award, grant #UL RR025761).
NR 50
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD MAR 1
PY 2016
VL 160
BP 163
EP 169
DI 10.1016/j.drugalcdep.2016.01.001
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DG1OK
UT WOS:000371837200021
PM 26832934
ER
PT J
AU West, JS
Low, JCM
Stankovic, KM
AF West, Jessica S.
Low, Jacob C. M.
Stankovic, Konstantina M.
TI Revealing Hearing Loss: A Survey of How People Verbally Disclose Their
Hearing Loss
SO EAR AND HEARING
LA English
DT Article
DE Hearing loss; Public health; Self-disclosure
ID QUALITATIVE CONTENT-ANALYSIS; NORMAL AUDIOGRAM; BEAVER DAM; HIV STATUS;
PREVALENCE; STIGMA; TINNITUS; NOISE; IMPAIRMENT; STRATEGIES
AB Objective:
Hearing loss is the most common sensory deficit and congenital anomaly, yet the decision-making processes involved in disclosing hearing loss have been little studied. To address this issue, we have explored the phrases that adults with hearing loss use to disclose their hearing loss.
Design:
Since self-disclosure research has not focused on hearing loss-specific issues, we created a 15-question survey about verbally disclosing hearing loss. English speaking adults (> 18 years old) with hearing loss of any etiology were recruited from otology clinics in a major referral hospital. Three hundred and thirty-seven participants completed the survey instrument. Participants' phrase(s) used to tell people they have hearing loss were compared across objective characteristics (age; sex; type, degree, and laterality of hearing loss; word recognition scores) and self-reported characteristics (degree of hearing loss; age of onset and years lived with hearing loss; use of technology; hearing handicap score).
Results:
Participants' responses revealed three strategies to address hearing loss: Multipurpose disclosure (phrases that disclose hearing loss and provide information to facilitate communication), Basic disclosure (phrases that disclose hearing loss through the term, a label, or details about the condition), or nondisclosure (phrases that do not disclose hearing loss). Variables were compared between patients who used and who did not use each disclosure strategy using chi(2) or Wilcoxon rank sum tests. Multipurpose disclosers were mostly female (p = 0.002); had experienced reactions of help, support, and accommodation after disclosing (p = 0.008); and had experienced reactions of being overly helpful after disclosing (p=0.039). Basic disclosers were predominantly male (p = 0.004); reported feeling somewhat more comfortable disclosing their hearing loss over time (p = 0.009); had not experienced reactions of being treated unfairly or discriminated against (p = 0.021); and were diagnosed with mixed hearing loss (p = 0.004). Nondisclosers tended not to disclose in a group setting (p = 0.002) and were diagnosed with bilateral hearing loss (p = 0.005). In addition, all of the variables were examined to build logistic regression models to predict the use of each disclosure strategy.
Conclusions:
Our results reveal three simple strategies for verbally addressing hearing loss that can be used in a variety of contexts. We recommend educating people with hearing loss about these strategies-this could improve the experience of disclosing hearing loss, and could educate society at large about how to interact with those who have a hearing loss.
C1 [West, Jessica S.; Low, Jacob C. M.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
[West, Jessica S.; Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[West, Jessica S.] Duke Univ, Dept Sociol, 276 Sociol Psychol Bldg,417 Chapel Dr, Durham, NC 27708 USA.
RP Stankovic, KM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.; West, JS (reprint author), Duke Univ, Dept Sociol, 276 Sociol Psychol Bldg,417 Chapel Dr, Durham, NC 27708 USA.
EM jessie.west@duke.edu; Konstantina_Stankovic@meei.harvard.edu
FU National Institute on Deafness and Other Communication Disorders
NIH-NIDCD [K08 DC010419]; Bertarelli Foundation; Nancy Sayles Day
Foundation
FX Dr. Stankovic is a board member of the American Auditory Society. No
other conflicts of interest were declared. Dr. Stankovic's research is
supported by the National Institute on Deafness and Other Communication
Disorders NIH-NIDCD K08 DC010419, the Bertarelli Foundation, and the
Nancy Sayles Day Foundation.
NR 99
TC 1
Z9 1
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-0202
EI 1538-4667
J9 EAR HEARING
JI Ear Hear.
PD MAR-APR
PY 2016
VL 37
IS 2
BP 194
EP 205
DI 10.1097/AUD.0000000000000238
PG 12
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA DG0IK
UT WOS:000371748300008
PM 26513208
ER
PT J
AU Farahmand, RB
Merchant, GR
Lookabaugh, SA
Roosli, C
Ulku, CH
McKenna, MJ
de Venecia, RK
Halpin, CF
Rosowski, JJ
Nakajima, HH
AF Farahmand, Rosemary B.
Merchant, Gabrielle R.
Lookabaugh, Sarah A.
Roeoesli, Christof
Ulku, Cagatay H.
McKenna, Michael J.
de Venecia, Ronald K.
Halpin, Christopher F.
Rosowski, John J.
Nakajima, Hideko H.
TI The Audiometric and Mechanical Effects of Partial Ossicular
Discontinuity
SO EAR AND HEARING
LA English
DT Article
DE Audiogram; Air-bone gap; Ossicular interruption; Wideband immittance;
Ossicular discontinuity; Laser Doppler vibrometry; Ossicular disruption
ID CONDUCTIVE HEARING-LOSS; EAR-CANAL REFLECTANCE; AIR-BONE GAPS; UMBO
VELOCITY; ADULTS; CHAIN
AB Objectives:
Ossicular discontinuity may be complete, with no contact between the disconnected ends, or partial, where normal contact at an ossicular joint or along a continuous bony segment of an ossicle is replaced by soft tissue or simply by contact of opposing bones. Complete ossicular discontinuity typically results in an audiometric pattern of a large, flat conductive hearing loss. In contrast, in cases where otomicroscopy reveals a normal external ear canal and tympanic membrane, high-frequency conductive hearing loss has been proposed as an indicator of partial ossicular discontinuity. Nevertheless, the diagnostic utility of high-frequency conductive hearing loss has been limited due to gaps in previous research on the subject, and clinicians often assume that an audiogram showing high-frequency conductive hearing loss is flawed. This study aims to improve the diagnostic utility of high-frequency conductive hearing loss in cases of partial ossicular discontinuity by (1) making use of a control population against which to compare the audiometry of partial ossicular discontinuity patients and (2) examining the correlation between high-frequency conductive hearing loss and partial ossicular discontinuity under controlled experimental conditions on fresh cadaveric temporal bones. Furthermore, ear-canal measurements of umbo velocity and wideband acoustic immittance measurements were investigated to determine the usefulness regarding diagnosis of ossicular discontinuity.
Design:
The authors analyzed audiograms from 66 patients with either form of surgically confirmed ossicular discontinuity and no confounding pathologies. The authors also analyzed umbo velocity (n = 29) and power reflectance (n = 12) measurements from a subset of these patients. Finally, the authors performed experiments on six fresh temporal bone specimens to study the differing mechanical effects of complete and partial discontinuity. The mechanical effects of these lesions were assessed via laser Doppler measurements of stapes velocity. In a subset of the specimen (n = 4), wideband acoustic immittance measurements were also collected.
Results:
(1) Calculations comparing the air-bone gap (ABG) at high and low frequencies show that when high-frequency ABGs are larger than low-frequency ABGs, the surgeon usually reported soft-tissue bands at the point of discontinuity. However, in cases with larger low-frequency ABGs and flat ABGs across frequencies, some partial discontinuities as well as complete discontinuities were reported. (2) Analysis of umbo velocity and power reflectance (calculated from wideband acoustic immittance) in patients reveal no significant difference across frequencies between the two types of ossicular discontinuities. (3) Temporal bone experiments reveal that partial discontinuity results in a greater loss in stapes velocity at high frequencies when compared with low frequencies, whereas with complete discontinuity, large losses in stapes velocity occur at all frequencies.
Conclusion:
The clinical and experimental findings suggest that when encountering larger ABGs at high frequencies when compared with low frequencies, partial ossicular discontinuity should be considered in the differential diagnosis.
C1 [Farahmand, Rosemary B.; Merchant, Gabrielle R.; Lookabaugh, Sarah A.; Rosowski, John J.; Nakajima, Hideko H.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Merchant, Gabrielle R.; Rosowski, John J.; Nakajima, Hideko H.] Harvard MIT, Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol, Cambridge, MA USA.
[Roeoesli, Christof] Univ Zurich, Univ Zurich Hosp, Dept Otorhinolaryngol Head & Neck Surg, Zurich, Switzerland.
[Ulku, Cagatay H.] Necmettin Erbakan Univ, Meram Med Fac, Dept Otolaryngol, Konya, Turkey.
[McKenna, Michael J.; de Venecia, Ronald K.; Halpin, Christopher F.; Rosowski, John J.; Nakajima, Hideko H.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[McKenna, Michael J.; de Venecia, Ronald K.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Halpin, Christopher F.] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA.
RP Nakajima, HH (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, 243 Charles St, Boston, MA 02114 USA.
EM heidi_nakajima@meei.harvard.edu
OI Merchant, Gabrielle/0000-0001-7251-1879
FU Nachwuchsforderungskredit of the University of Zurich; TUBITAK
[2011-1059B191100156]; National Institutes of Health/National Institute
on Deafness and Other Communication [R01DC004798, R03DC011158]
FX This research is supported by the Nachwuchsforderungskredit of the
University of Zurich (C.R.), TUBITAK (2011-1059B191100156; C.H.U.), and
the National Institutes of Health/National Institute on Deafness and
Other Communication-R01DC004798 (J.J.R.) and R03DC011158 (H.H.N.).
NR 15
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-0202
EI 1538-4667
J9 EAR HEARING
JI Ear Hear.
PD MAR-APR
PY 2016
VL 37
IS 2
BP 206
EP 215
DI 10.1097/AUD.0000000000000239
PG 10
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA DG0IK
UT WOS:000371748300009
PM 26510125
ER
PT J
AU Placzek, AN
Molfese, DL
Khatiwada, S
Di Prisco, GV
Huang, W
Sidrauski, C
Krnjevic, K
Amos, CL
Ray, R
Dani, JA
Walter, P
Salas, R
Costa-Mattioli, M
AF Placzek, Andon N.
Molfese, David L.
Khatiwada, Sanjeev
Di Prisco, Gonzalo Viana
Huang, Wei
Sidrauski, Carmela
Krnjevic, Kresimir
Amos, Christopher L.
Ray, Russell
Dani, John A.
Walter, Peter
Salas, Ramiro
Costa-Mattioli, Mauro
TI Translational control of nicotine -evoked synaptic potentiation in mice
and neuronal responses in human smokers by elF2 alpha
SO ELIFE
LA English
DT Article
ID LONG-TERM POTENTIATION; DOPAMINE NEURONS; BINDING-PROTEIN; IN-VIVO;
HOMEOSTASIS; EXPOSURE; SMOKING; REWARD; DEPRESSION; WITHDRAWAL
AB Adolescents are particularly vulnerable to nicotine, the principal addictive component driving tobacco smoking. In a companion study, we found that reduced activity of the translation initiation factor eIF2 alpha underlies the hypersensitivity of adolescent mice to the effects of cocaine. Here we report that nicotine potentiates excitatory synaptic transmission in ventral tegmental area dopaminergic neurons more readily in adolescent mice compared to adults. Adult mice with genetic or pharmacological reduction in p-eIF2 alpha-mediated translation are more susceptible to nicotine's synaptic effects, like adolescents. When we investigated the influence of allelic variability of the Eif2s1 gene (encoding eIF2 alpha) on reward -related neuronal responses in human smokers, we found that a single nucleotide polymorphism in the Eif2s1 gene modulates mesolimbic neuronal reward responses in human smokers. These findings suggest that p-eIF2 alpha regulates synaptic actions of nicotine in both mice and humans, and that reduced p-eIF2 alpha may enhance susceptibility to nicotine (and other drugs of abuse) during adolescence.
C1 [Placzek, Andon N.; Khatiwada, Sanjeev; Di Prisco, Gonzalo Viana; Huang, Wei; Ray, Russell; Salas, Ramiro; Costa-Mattioli, Mauro] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.
[Placzek, Andon N.; Khatiwada, Sanjeev; Di Prisco, Gonzalo Viana; Huang, Wei; Ray, Russell; Costa-Mattioli, Mauro] Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA.
[Molfese, David L.; Salas, Ramiro] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Molfese, David L.; Salas, Ramiro] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA.
[Khatiwada, Sanjeev] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.
[Sidrauski, Carmela; Walter, Peter] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA USA.
[Krnjevic, Kresimir] McGill Univ, Dept Physiol, Montreal, PQ, Canada.
[Amos, Christopher L.] Dartmouth Coll, Geisel Sch Med, Dept Community & Family Med, Ctr Genom Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
[Dani, John A.] Perelman Sch Med, Mahoney Inst Neurosci, Dept Neurosci, Philadelphia, PA USA.
[Placzek, Andon N.] Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA.
[Sidrauski, Carmela] Calico LLC, San Francisco, CA USA.
RP Costa-Mattioli, M (reprint author), Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.; Costa-Mattioli, M (reprint author), Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA.
EM costamat@bcm.edu
FU National Institute of Mental Health [MH096816]; National Institute of
Neurological Disorders and Stroke [NS076708, NS21229]; National
Institute on Drug Abuse [DA09411, DA026539, DA09167]; Howard Hughes
Medical Institute; U.S. Department of Veterans Affairs [VHA5101CX000994]
FX National Institute of Mental Health MH096816 Mauro Costa-Mattioli;
National Institute of Neurological Disorders and Stroke NS076708,
NS21229 John A Dani Mauro Costa-Mattioli; National Institute on Drug
Abuse DA09411, DA026539, DA09167 John A Dani Ramiro Salas; Howard Hughes
Medical Institute PW Peter Walter; U.S. Department of Veterans Affairs
VHA5101CX000994 Ramiro Salas
NR 32
TC 3
Z9 3
U1 1
U2 2
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAR 1
PY 2016
VL 5
AR e12056
DI 10.7554/eLife.12056
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DG2IA
UT WOS:000371889400001
ER
PT J
AU Braunwald, E
AF Braunwald, Eugene
TI Academic-industrial collaboration in the development of the first
angiotensin receptor blocker: neprilysin inhibitor in the treatment of
heart failure
SO EUROPEAN HEART JOURNAL
LA English
DT Article
ID CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE; HYPERTENSION; DESIGN
C1 [Braunwald, Eugene] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc,TIMI Study Grp,Dept Med, 350 Longwood Ave,1st Off Floor, Boston, MA 02115 USA.
RP Braunwald, E (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc,TIMI Study Grp,Dept Med, 350 Longwood Ave,1st Off Floor, Boston, MA 02115 USA.
EM ebraunwald@partners.org
FU AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Duke University;
Johnson Johnson; Merck; Sanofi Aventis
FX Research grant to institution: AstraZeneca, Bristol-Myers Squibb,
Daiichi Sankyo, Duke University, Johnson & Johnson, Merck, and Sanofi
Aventis; honoraria: Bayer, Daiichi-Sankyo, Medscape, and Menarini
International; consultancy: Sanofi Aventis, and The Medicines Company.
NR 19
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD MAR 1
PY 2016
VL 37
IS 9
BP 745
EP 746
DI 10.1093/eurheartj/ehw055
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG1IO
UT WOS:000371820200010
PM 26933120
ER
PT J
AU Strasser-Weippl, K
Horick, N
Smith, IE
O'Shaughnessy, J
Ejlertsen, B
Boyle, F
Buzdar, AU
Fumoleau, P
Gradishar, W
Martin, M
Moy, B
Piccart-Gebhart, M
Pritchard, KI
Lindquist, D
Rappold, E
Finkelstein, DM
Goss, PE
AF Strasser-Weippl, Kathrin
Horick, Nora
Smith, Ian E.
O'Shaughnessy, Joyce
Ejlertsen, Bent
Boyle, Frances
Buzdar, Aman U.
Fumoleau, Pierre
Gradishar, William
Martin, Miguel
Moy, Beverly
Piccart-Gebhart, Martine
Pritchard, Kathleen I.
Lindquist, Deborah
Rappold, Erica
Finkelstein, Dianne M.
Goss, Paul E.
TI Identification of early breast cancer patient cohorts who may benefit
from lapatinib therapy
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Lapatinib; Early breast cancer; Adjuvant; Hormone receptor
ID PLUS ADJUVANT CHEMOTHERAPY; HORMONE-RECEPTOR STATUS; NEOADJUVANT
CHEMOTHERAPY; ESTROGEN-RECEPTOR; OVARIAN-CANCER; PHASE-3 TRIAL;
TRASTUZUMAB; EXPRESSION; HER-2/NEU; HER2
AB In resource-constrained environments many patients with human epidermal growth factor receptor 2 (HER2)+ early breast cancer are currently not offered adjuvant anti-HER2 therapy. For patients who might be able to receive the tyrosine kinase inhibitor (TKI) lapatinib (e.g. after patent expiration), it is important to identify subgroups of patients for whom anti-HER2 TKI therapy could be beneficial.
To do this, we used data from 2489 patients with centrally confirmed HER2+ disease enrolled in the adjuvant Tykerb Evaluation After Chemotherapy (TEACH) trial, investigating the effect of lapatinib in patients with HER2+ early breast cancer not treated with trastuzumab. We performed subgroup analyses and number-needed-to-treat (NNT) calculations using patient and tumour associated predictors.
Hormone receptor negative (HR-) patients on lapatinib had a significantly prolonged disease-free survival (DFS) compared to HR- patients on placebo (hazard ratio 0.64, P=0.003). For patients with HR- disease, starting treatment with lapatinib <1 year from diagnosis improved DFS by 12.1% [2.1-22.1] at 2 years and 15.7% [4.1-27.2] at 5 years. Depending on lymph node status and time since diagnosis the NNT for recurrence (at 5 years) was between 5.9 (node positive patients <1 year from diagnosis) and 15.9. These numbers are in range with numbers reported for up-front adjuvant trastuzumab for HR unselected patients (e.g. 15.6 for DFS at 4 years in HERA).
In a subgroup analysis of the adjuvant TEACH trial, we show that anti-HER2 monotherapy with a TKI is beneficial as adjuvant therapy in a subgroup of patients. NNT in HER2+ HR- patients are in range with those reported from up-front adjuvant trastuzumab trials. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Strasser-Weippl, Kathrin] Wilhelminen Hosp, Ctr Oncol & Hematol, Vienna, Austria.
[Horick, Nora; Finkelstein, Dianne M.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Smith, Ian E.] Royal Marsden Hosp, London SW3 6JJ, England.
[O'Shaughnessy, Joyce] US Oncol, Texas Oncol, Baylor Sammons Canc Ctr, Dallas, TX USA.
[Ejlertsen, Bent] DBCG Secretariat, Rigshosp, Copenhagen, Denmark.
[Boyle, Frances] Mater Hosp, Sydney, NSW, Australia.
[Buzdar, Aman U.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Fumoleau, Pierre] Ctr GF Leclerc, Dijon, France.
[Gradishar, William] Northwestern Univ, Chicago, IL 60611 USA.
[Martin, Miguel] Univ Complutense, Hosp Univ Gregorio Maranon, E-28040 Madrid, Spain.
[Moy, Beverly; Goss, Paul E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Piccart-Gebhart, Martine] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium.
[Pritchard, Kathleen I.] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
[Lindquist, Deborah] US Oncol, Arizona Oncol, Sedona, AZ USA.
[Rappold, Erica] GlaxoSmithKline, Collegeville, PA USA.
RP Goss, PE (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Lawrence House,LRH-302, Boston, MA 02114 USA.
EM kathrin.strasserweippl@gmail.com; nhorick@partners.org;
ian.smith@rmh.nhs.uk; Joyce.OShaughnessy@usoncology.com;
ejlertsen@dadlnet.dk; franb@bigpond.net.au; abuzdar@mdanderson.org;
pfumoleau@cgfl.fr; WGradishar@nmff.org; mmartin@geicam.org;
bmoy@partners.org; martine.piccart@bordet.be;
kathy.pritchard@sunnybrook.ca; deborah.lindquist@usoncology.com;
mprcer@gmail.com; dfinkelstein@partners.org; pgoss@partners.org
FU GlaxoSmithKline [EGF105485]; Avon Foundation, NY [02-2010-083]
FX The sponsor, GlaxoSmithKline (EGF105485) provided funding for the study.
Part of the academic effort and time for this analysis was funded by a
grant from the Avon Foundation, NY (02-2010-083). The corresponding
author had full access to all the data and had final responsibility for
the decision to submit the results for publication.
NR 31
TC 1
Z9 1
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAR
PY 2016
VL 56
BP 85
EP 92
DI 10.1016/j.ejca.2015.12.024
PG 8
WC Oncology
SC Oncology
GA DG0TK
UT WOS:000371778400011
PM 26829011
ER
PT J
AU Yang, M
Hu, FB
Giovannucci, EL
Stampfer, MJ
Willett, WC
Fuchs, CS
Wu, K
Bao, Y
AF Yang, M.
Hu, F. B.
Giovannucci, E. L.
Stampfer, M. J.
Willett, W. C.
Fuchs, C. S.
Wu, K.
Bao, Y.
TI Nut consumption and risk of colorectal cancer in women
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID COLON-CANCER; INFLAMMATORY MARKERS; METABOLIC SYNDROME; DIET;
QUESTIONNAIRE; WALNUTS; OBESITY; FAT
AB BACKGROUND/OBJECTIVES: Increasing nut consumption has been associated with reduced risk of obesity and type II diabetes, the risk factors for colorectal cancer. However, the association between nut consumption and colorectal cancer risk is unclear. We aimed to examine the association of long-term nut consumption with risk of colorectal cancer.
SUBJECTS/METHODS: We prospectively followed 75 680 women who were free of cancer at baseline in the Nurses' Health Study, and examined the association between nut consumption and colorectal cancer risk. Nut consumption was assessed at baseline and updated every 2-4 years. Relative risks (RRs) and 95% confidence intervals (95% CIs) were estimated using Cox proportional hazards models.
RESULTS: During 2 103 037 person-years of follow-up, we identified 1503 colorectal cancer cases. After adjustment for other known or suspected risk factors, women who consumed nuts 2 or more times per week (that is, >= 56 g per week) had a 13% lower risk of colorectal cancer compared with those who rarely consumed nuts, but the association was not statistically significant (RR: 0.87; 95% CI: 0.72-1.05; P-trend: 0.06). No association was observed for peanut butter.
CONCLUSIONS: In this large prospective cohort of women, frequent nut consumption was not significantly associated with colorectal cancer risk after adjusting for other risk factors.
C1 [Yang, M.; Hu, F. B.; Giovannucci, E. L.; Stampfer, M. J.; Willett, W. C.; Fuchs, C. S.; Wu, K.; Bao, Y.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
[Yang, M.; Hu, F. B.; Giovannucci, E. L.; Stampfer, M. J.; Willett, W. C.; Wu, K.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
[Hu, F. B.; Giovannucci, E. L.; Stampfer, M. J.; Willett, W. C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Fuchs, C. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Bao, Y (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM ying.bao@channing.harvard.ed
FU National Institutes of Health [P01 CA87969, P50 CA127003, 1U54CA155626];
International Tree Nut Council Nutrition Research & Education Foundation
FX This study is supported by the Grants P01 CA87969, P50 CA127003 and
1U54CA155626 from the National Institutes of Health, and by the grant
from the International Tree Nut Council Nutrition Research & Education
Foundation. We thank the participants and staff of the Nurses' Health
Study for their valuable contributions as well as the following state
cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA,
ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK,
OR, PA, RI, SC, TN, TX, VA, WA and WY. In addition, this study was
approved by the Connecticut Department of Public Health (DPH) Human
Investigations Committee. Certain data used in this publication were
obtained from the DPH. The authors assume full responsibility for
analyses and interpretation of these data.
NR 29
TC 1
Z9 1
U1 6
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD MAR
PY 2016
VL 70
IS 3
BP 333
EP 337
DI 10.1038/ejcn.2015.66
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DF9FZ
UT WOS:000371667700008
PM 25944181
ER
PT J
AU Liu, M
Blanco-Centurion, C
Konadhode, RR
Luan, LJ
Shiromani, PJ
AF Liu, Meng
Blanco-Centurion, Carlos
Konadhode, Roda Rani
Luan, Liju
Shiromani, Priyattam J.
TI Orexin gene transfer into the amygdala suppresses both spontaneous and
emotion-induced cataplexy in orexin-knockout mice
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE amygdala; emotion; narcolepsy; orexin; predator odour; sleep
ID HUMAN NARCOLEPSY; NEURONS; SLEEP; RAT; MUTATION; BEHAVIOR; RECEPTOR;
MODELS; BRAIN; ONSET
AB Narcolepsy is a chronic sleep disorder linked to the loss of orexin-producing neurons in the hypothalamus. Cataplexy, a sudden loss of muscle tone during waking, is an important distinguishing symptom of narcolepsy and it is often triggered by strong emotions. The neural circuit underlying cataplexy attacks is not known, but is likely to involve the amygdala, a region implicated in regulating emotions. In mice models of narcolepsy, transfer of the orexin gene into surrogate neurons has been successful in ameliorating narcoleptic symptoms. However, it is not known whether this method also blocks cataplexy triggered by strong emotions. To examine this possibility, the gene encoding mouse prepro-orexin was transferred into amygdala neurons of orexin-knockout (KO) mice (rAAV-orexin; n=8). Orexin-KO mice that did not receive gene transfer (no-rAAV; n=7) or received only the reporter gene (rAAV-GFP; n=7) served as controls. Three weeks later, the animal's sleep and behaviour were recorded at night (no-odour control night), followed by another recording at night in the presence of predator odour (odour night). Orexin-KO mice given the orexin gene transfer into surrogate amygdala neurons had significantly less spontaneous bouts of cataplexy, and predator odour did not induce cataplexy compared with control mice. Moreover, the mice with orexin gene transfer were awake more during the odour night. These results demonstrate that orexin gene transfer into amygdala neurons can suppress both spontaneous and emotion-induced cataplexy attacks in narcoleptic mice. It suggests that manipulating amygdala pathways is a potential strategy for treating cataplexy in narcolepsy.
C1 [Liu, Meng; Blanco-Centurion, Carlos; Konadhode, Roda Rani; Luan, Liju; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
[Shiromani, Priyattam J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Liu, M (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA.; Shiromani, PJ (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.
EM liumen@musc.edu; shiroman@musc.edu
FU Medical Research Service of the Department of Veterans Affairs [I01
BX000798]; NIH [1K01AG041520, NS052287, NS084477, NS079940, HL091363]
FX This study was supported by Medical Research Service of the Department
of Veterans Affairs (I01 BX000798) and NIH grants 1K01AG041520,
NS052287, NS084477, NS079940 and HL091363. We thank Dr Patrick K.
Randall for support with the SPSS statistical analysis program.
NR 34
TC 0
Z9 0
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD MAR
PY 2016
VL 43
IS 5
BP 681
EP 688
DI 10.1111/ejn.13158
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA DG2PN
UT WOS:000371909800009
PM 26741960
ER
PT J
AU Modestino, EJ
AF Modestino, Edward J.
TI NEUROPHENOMENOLOGY OF AN ALTERED STATE OF CONSCIOUSNESS: AN FMRI CASE
STUDY
SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
LA English
DT Article
DE Neurophenomenology; Kundalini; meditation; fMRI; physio-Kundalini
syndrome
ID KUNDALINI-YOGA MEDITATION; MINDFULNESS MEDITATION; BRAIN; ACTIVATION;
DISORDERS; ATTENTION; MOTION
AB A research participant came to our lab with self-proclaimed, ecstatic, Kundalini meditative experiences. Using neurophenomenology and functional magnetic resonance imaging (fMRI), we were able to identify brain activation in the left prefrontal cortex [primarily in left Brodmann's areas (BAs) 46 and 10, but also extending into BAs 11, 47, and 45] associated with this experience. The Phenomenology of Consciousness Inventory provided evidence that this was a perceived altered state of consciousness. Additionally, the Physio-Kundalini Syndrome Index strongly suggested that what he was experiencing was indeed Kundalini. The feelings of joy, happiness and the left prefrontal brain region found in this study are consistent with many published neuroimaging and electrophysiological studies of meditation. This case study suggests that using first-person subjective experience within a phenomenological reduction process can be combined with neuroimaging to divulge objective brain regions associated with such experiences. Furthermore, this provides evidence that at least in this participant, the Kundalini experience is associated with brain activation in the left prefrontal cortex. Future research is needed to confirm these results in a large group study, perhaps contrasting brain activation of those who experience spontaneously emerging Kundalini with trained Kundalini practitioners.
C1 [Modestino, Edward J.] Boston Univ, Sch Med, Dept Neurol, VA Boston Healthcare Syst, Boston, MA 02118 USA.
RP Modestino, EJ (reprint author), Boston Univ, Sch Med, Dept Neurol, VA Boston Healthcare Syst, Boston, MA 02118 USA.
EM edward.modestino@gmail.com
NR 46
TC 0
Z9 0
U1 7
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1550-8307
EI 1878-7541
J9 EXPLORE-NY
JI Explore-J Sci. Heal.
PD MAR-APR
PY 2016
VL 12
IS 2
BP 128
EP 135
DI 10.1016/j.explore.2015.12.004
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA DG0KS
UT WOS:000371754300010
PM 26775225
ER
PT J
AU Greiner, JV
AF Greiner, Jack V.
TI Long-Term (3 Year) Effects of a Single Thermal Pulsation System
Treatment on Meibomian Gland Function and Dry Eye Symptoms
SO EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
LA English
DT Article
DE Dry eye disease; Meibomian gland dysfunction; Thermal pulsation system
treatment; Long-term treatment
ID LIPID LAYER THICKNESS; INTERNATIONAL WORKSHOP; TEAR FILM; THERMODYNAMIC
TREATMENT; DYSFUNCTION; SUBCOMMITTEE; FLUORESCEIN; IMPROVEMENT
AB Purpose:
The present study examined the long-term (3 years) effects of a single (12 min) thermal pulsation system (TPS) treatment on symptomatic patients with evaporative dry eye disease (DED) secondary to meibomian gland dysfunction (MGD).
Methods:
In this prospective, cohort, observational, single-center study design, signs (meibomian gland secretion [MGS] scores and tear film breakup time [TBUT]) and symptoms (Ocular Surface Disease Index [OSDI] and Standard Patient Evaluation of Eye Dryness [SPEED] questionnaires) were determined in 20 patients (40 eyes) with MGD and dry eye symptoms at baseline (BL), 1 month, and 3 years post-TPS treatment using LipiFlow.
Results:
Meibomian gland secretion scores increased from BL (4.5 +/- 0.8) to 1 month (12.0 +/- 1.1, P <= 0.001). Improvement persisted at 3 years (18.4 +/- 1.4) relative to BL (P <= 0.001). Meibomian gland secretion scores in all regions of the lower eyelid were improved over BL at 1 month (nasal [P <= 0.001], central [P <= 0.001], temporal [P <= 0.01]) and 3 years (nasal [P <= 0.001], central [P <= 0.001], temporal [P <= 0.001]). TBUT increased from BL (4.1 +/- 0.4) to 1 month (7.9 +/- 1.4, P <= 0.05) but was not significantly different than BL at 3 years (4.5 +/- 0.6, P>0.05). The OSDI scores decreased from BL (26.0 +/- 4.6) to 1 month (14.7 +/- 4.3, P <= 0.001) but returned to BL levels at 3 years (22.5 +/- 5.4, P>0.05). The SPEED scores decreased from BL (13.4 +/- 1.0) to 1 month (6.5 +/- 1.3, P <= 0.001), and this improvement persisted at 3 years (9.5 +/- 1.6, P <= 0.001).
Conclusions:
Thermal pulsation may be a uniquely efficacious treatment option for DED secondary to MGD in that a single 12-min procedure is associated with significant improvement in MGS and SPEED scores for up to 3 years.
C1 [Greiner, Jack V.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
[Greiner, Jack V.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Greiner, Jack V.] Boston Ocular Surface Ctr, Boston, MA USA.
[Greiner, Jack V.] Boston Ocular Surface Ctr, Winchester, MA USA.
RP Greiner, JV (reprint author), Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM jack_greiner@meei.harvard.edu
FU Valerie and Walter Winchester Grant; Schepens Eye Research Institute,
Boston, MA; Boston Ocular Surface Center, Boston and Winchester, MA;
TearScience, Inc., Morrisville, NC
FX Supported by Valerie and Walter Winchester Grant, Schepens Eye Research
Institute, Boston, MA, Boston Ocular Surface Center, Boston and
Winchester, MA, and TearScience, Inc., Morrisville, NC.
NR 34
TC 3
Z9 3
U1 4
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1542-2321
EI 1542-233X
J9 EYE CONTACT LENS
JI Eye Contact Lens-Sci. Clin. Pra.
PD MAR
PY 2016
VL 42
IS 2
BP 99
EP 107
DI 10.1097/ICL.0000000000000166
PG 9
WC Ophthalmology
SC Ophthalmology
GA DG0IG
UT WOS:000371747900003
PM 26222095
ER
PT J
AU Cheesman, HK
Feinbaum, RL
Thekkiniath, J
Dowen, RH
Conery, AL
Pukkila-Worley, R
AF Cheesman, Hilary K.
Feinbaum, Rhonda L.
Thekkiniath, Jose
Dowen, Robert H.
Conery, Annie L.
Pukkila-Worley, Read
TI Aberrant Activation of p38 MAP Kinase-Dependent Innate Immune Responses
Is Toxic to Caenorhabditis elegans
SO G3-GENES GENOMES GENETICS
LA English
DT Article
DE innate immunity; immune regulation; C. elegans genetics; host-pathogen
interactions; genetics of immunity
ID INFLAMMATORY-BOWEL-DISEASE; PROTEIN-KINASE; HOST-DEFENSE; C. ELEGANS;
PATHOGENESIS; RESISTANCE; TOLERANCE; PATHWAYS; STRESS; PHOSPHATASE
AB Inappropriate activation of innate immune responses in intestinal epithelial cells underlies the pathophysiology of inflammatory disorders of the intestine. Here we examine the physiological effects of immune hyperactivation in the intestine of the nematode Caenorhabditis elegans. We previously identified an immunostimulatory xenobiotic that protects C. elegans from bacterial infection by inducing immune effector expression via the conserved p38 MAP kinase pathway, but was toxic to nematodes developing in the absence of pathogen. To investigate a possible connection between the toxicity and immunostimulatory properties of this xenobiotic, we conducted a forward genetic screen for C. elegans mutants that are resistant to the deleterious effects of the compound, and identified five toxicity suppressors. These strains contained hypomorphic mutations in each of the known components of the p38 MAP kinase cassette (tir-1, nsy-1, sek-1, and pmk-1), demonstrating that hyperstimulation of the p38 MAPK pathway is toxic to animals. To explore mechanisms of immune pathway regulation in C. elegans, we conducted another genetic screen for dominant activators of the p38 MAPK pathway, and identified a single allele that had a gain-of-function (gf) mutation in nsy-1, the MAP kinase kinase kinase that acts upstream of p38 MAPK pmk-1. The nsy-1(gf) allele caused hyperinduction of p38 MAPK PMK-1-dependent immune effectors, had greater levels of phosphorylated p38 MAPK, and was more resistant to killing by the bacterial pathogen Pseudomonas aeruginosa compared to wild-type controls. In addition, the nsy-1(gf) mutation was toxic to developing animals. Together, these data suggest that the activity of the MAPKKK NSY-1 is tightly regulated as part of a physiological mechanism to control p38 MAPK-mediated innate immune hyperactivation, and ensure cellular homeostasis in C. elegans.
C1 [Cheesman, Hilary K.; Feinbaum, Rhonda L.; Thekkiniath, Jose; Pukkila-Worley, Read] Univ Massachusetts, Div Infect Dis & Immunol, Program Innate Immun, Sch Med, Worcester, MA 01605 USA.
[Dowen, Robert H.; Conery, Annie L.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
RP Pukkila-Worley, R (reprint author), Univ Massachusetts, Sch Med, 364 Plantat St,Lazare Res Bldg 325, Worcester, MA 01605 USA.
EM Pukkila-Worley@umassmed.edu
FU National Institute of Allergy and Infectious Diseases [K08 AI081747, R01
AI085581, P01 AI083214]
FX We thank Neal Silverman and Amy Walker for helpful discussions and Richa
Chhaya for technical assistance. This study was supported by National
Institute of Allergy and Infectious Diseases Award K08 AI081747 (to
R.P.W.). R.L.F. and A.L.C. were supported by National Institute of
Allergy and Infectious Diseases Awards R01 AI085581 and P01 AI083214.
NR 37
TC 8
Z9 8
U1 3
U2 7
PU GENETICS SOCIETY AMERICA
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 2160-1836
J9 G3-GENES GENOM GENET
JI G3-Genes Genomes Genet.
PD MAR 1
PY 2016
VL 6
IS 3
BP 541
EP 549
DI 10.1534/g3.115.025650
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA DG1MA
UT WOS:000371831000005
PM 26818074
ER
PT J
AU Zhang, DF
Schumacher, C
Harris, MB
Bono, CM
AF Zhang, Dafang
Schumacher, Charles
Harris, Mitchel B.
Bono, Christopher M.
TI The Quality and Readability of Information Available on the Internet
Regarding Lumbar Fusion
SO GLOBAL SPINE JOURNAL
LA English
DT Article
DE lumbar fusion; Internet; patient education; quality; readability
ID PATIENT EDUCATION MATERIALS; DISC HERNIATION; SURGERY; DEVICE; SITES
AB Study DesignAn Internet-based evaluation of Web sites regarding lumbar fusion.
ObjectiveThe Internet has become a major resource for patients; however, the quality and readability of Internet information regarding lumbar fusion is unclear. The objective of this study is to evaluate the quality and readability of Internet information regarding lumbar fusion and to determine whether these measures changed with Web site modality, complexity of the search term, or Health on the Net Code of Conduct certification.
MethodsUsing five search engines and three different search terms of varying complexity (low back fusion, lumbar fusion, and lumbar arthrodesis), we identified and reviewed 153 unique Web site hits for information quality and readability. Web sites were specifically analyzed by search term and Web site modality. Information quality was evaluated on a 5-point scale. Information readability was assessed using the Flesch-Kincaid score for reading grade level.
ResultsThe average quality score was low. The average reading grade level was nearly six grade levels above that recommended by National Work Group on Literacy and Health. The quality and readability of Internet information was significantly dependent on Web site modality. The use of more complex search terms yielded information of higher reading grade level but not higher quality.
ConclusionsHigher-quality information about lumbar fusion conveyed using language that is more readable by the general public is needed on the Internet. It is important for health care providers to be aware of the information accessible to patients, as it likely influences their decision making regarding care.
C1 [Zhang, Dafang; Schumacher, Charles] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Zhang, Dafang; Schumacher, Charles; Harris, Mitchel B.; Bono, Christopher M.] Harvard Univ, Dept Orthopaed Surg, Sch Med, Boston, MA USA.
[Harris, Mitchel B.; Bono, Christopher M.] Brigham & Womens Hosp, Dept Orthopaed Surg, 75 Francis St, Boston, MA 02115 USA.
RP Bono, CM (reprint author), Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.
EM cmbono@partners.org
NR 26
TC 0
Z9 0
U1 4
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 2192-5682
EI 2192-5690
J9 GLOB SPINE J
JI Glob. Spine J.
PD MAR
PY 2016
VL 6
IS 2
BP 133
EP 138
DI 10.1055/s-0035-1557145
PG 6
WC Orthopedics
SC Orthopedics
GA DF8JE
UT WOS:000371603100006
PM 26933614
ER
PT J
AU Burke, RE
Johnson-Koenke, R
Nowels, C
Silveira, MJ
Jones, J
Bekelman, DB
AF Burke, Robert E.
Johnson-Koenke, Rachel
Nowels, Carolyn
Silveira, Maria J.
Jones, Jacqueline
Bekelman, David B.
TI Can we engage caregiver spouses of patients with heart failure with a
low-intensity, symptom-guided intervention?
SO HEART & LUNG
LA English
DT Article
DE Symptom management; Heart failure; Caregiver; Palliative care; Quality
of life
ID QUALITY-OF-LIFE; INFORMAL CAREGIVERS; PALLIATIVE CARE; TRANSITIONAL
CARE; FAMILY CAREGIVERS; SELF-MANAGEMENT; OLDER-ADULTS; TRIAL; SUPPORT;
METAANALYSIS
AB Objective: Evaluate a pilot intervention to engage caregivers in management of heart failure (HF) patient symptoms.
Background: HF impairs quality of life; caregivers provide an important role in HF management.
Methods: We developed modules to help patients report and caregivers alleviate symptoms of depression, pain, dyspnea, and fatigue. Semi-structured interviews followed by a mixed inductive and deductive, team based analysis were used to evaluate acceptability and feasibility in patients with HF and their caregivers.
Results: Participants (n = 22) expressed significant interest but few used the modules in follow-up. We identified three barriers to acceptability and feasibility: the quality of dyadic relationship, the timing and structure of the intervention, and the patient's perceived control over their illness.
Conclusions: Future interventions should evaluate dyadic relationship dynamics, match the timing and content of the intervention to the patient population, and enroll patients with perceived control over their illness to maximize intervention acceptability and feasibility. Published by Elsevier Inc.
C1 [Burke, Robert E.; Johnson-Koenke, Rachel; Bekelman, David B.] Denver VA Med Ctr, Dept Med, Denver, CO USA.
[Burke, Robert E.; Nowels, Carolyn; Bekelman, David B.] Univ Colorado, Denver Sch Med, Dept Med, Div Gen Internal Med, Anschutz Med Campus, Aurora, CO USA.
[Silveira, Maria J.] Ann Arbor Vet Affairs Med Ctr, Ctr Clin Management Res, Ann Arbor, MI USA.
[Silveira, Maria J.] Univ Michigan, Dept Internal Med, Div Gen Med, Ann Arbor, MI 48109 USA.
[Jones, Jacqueline] Univ Colorado, Coll Nursing, Aurora, CO USA.
RP Burke, RE (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA.
EM Robert.Burke5@va.gov
FU VA Chronic Heart Failure Quality Enhancement Research Initiative (QUERI)
Locally Initiated Project award; VA [IIR 08-0309]; VA Career Development
Award [08-022]
FX The study was supported by a VA Chronic Heart Failure Quality
Enhancement Research Initiative (QUERI) Locally Initiated Project award
to Drs. Burke and Bekelman. Dr. Silveira was supported by VA IIR
08-0309. Dr. Bekelman was supported by a VA Career Development Award
(08-022). These funding sources had no role in the design,
interpretation, or presentation of results. This report represents the
views of the authors and not necessarily those of the U.S. Department of
Veterans Affairs.
NR 57
TC 0
Z9 0
U1 6
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0147-9563
EI 1527-3288
J9 HEART LUNG
JI Heart Lung
PD MAR-APR
PY 2016
VL 45
IS 2
BP 114
EP 120
DI 10.1016/j.hrtlng.2015.12.006
PG 7
WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System
SC Cardiovascular System & Cardiology; Nursing; Respiratory System
GA DG1SL
UT WOS:000371847700006
PM 26831372
ER
PT J
AU Choi, J
Tate, JA
Rogers, MA
Donahoe, MP
Hoffman, LA
AF Choi, JiYeon
Tate, Judith A.
Rogers, Mary Alana
Donahoe, Michael P.
Hoffman, Leslie A.
TI Depressive symptoms and anxiety in intensive care unit (ICU) survivors
after ICU discharge
SO HEART & LUNG
LA English
DT Article
DE Post intensive care unit; Intensive care unit survivors; Depressive
symptoms; Anxiety; Recovery
ID QUALITY-OF-LIFE; PROLONGED MECHANICAL VENTILATION;
RESPIRATORY-DISTRESS-SYNDROME; LONG-TERM OUTCOMES; RANDOMIZED
CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; ACUTE LUNG INJURY; CRITICAL
ILLNESS; POSTTRAUMATIC-STRESS; HEALTH
AB Background: The association between intensive care unit (ICU) survivors' psychological sequelae, individual care needs, and discharge disposition has not been evaluated.
Objective: To describe depressive symptoms and anxiety in ICU survivors and explore these symptoms based on individual care needs and discharge disposition for 4 months post-ICU discharge.
Methods: We analyzed data from 39 ICU survivors who self-reported measures of depressive symptoms (Center for Epidemiologic Studies-Depression 10 items [CESD-10]) and anxiety (Shortened Profile of Mood States-Anxiety subscale [POMS-A]).
Results: A majority of patients reported CESD-10 scores above the cut off (>= 8) indicating risk for clinical depression. POMS-A scores were highest within 2 weeks post-ICU discharge and decreased subsequently. Data trends suggest worse depressive symptoms and anxiety when patients had moderate to high care needs and/or were unable to return home.
Conclusion: ICU survivors who need caregiver assistance and extended institutional care reported trends of worse depressive symptoms and anxiety. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Choi, JiYeon; Hoffman, Leslie A.] Univ Pittsburgh, Sch Nursing, Dept Acute & Tertiary Care, Pittsburgh, PA 15261 USA.
[Donahoe, Michael P.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA.
[Tate, Judith A.] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA.
[Rogers, Mary Alana] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hoffman, Leslie A.] Clin & Translat Sci Inst, San Francisco, CA USA.
RP Choi, J (reprint author), Univ Pittsburgh, Sch Nursing, 336 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.
EM jic11@pitt.edu
FU NIH, National Institute of Nursing Research, U.S. Public Health Service
[F32 NR 011271, T32 NR 008857]; Rehabilitation Nursing Foundation
[FEL-0905]; Undergraduate Research Mentorship Program, University of
Pittsburgh School of Nursing
FX Funding was provided by the NIH, National Institute of Nursing Research,
U.S. Public Health Service (F32 NR 011271 and T32 NR 008857) and
Rehabilitation Nursing Foundation, Fellow Research Award (FEL-0905).
Work from Ms. Mary Alana Rogers was supported by the Undergraduate
Research Mentorship Program, University of Pittsburgh School of Nursing.
The authors declare no conflicts of interest.
NR 54
TC 1
Z9 1
U1 3
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0147-9563
EI 1527-3288
J9 HEART LUNG
JI Heart Lung
PD MAR-APR
PY 2016
VL 45
IS 2
BP 140
EP 146
DI 10.1016/j.hrtlng.2015.12.002
PG 7
WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System
SC Cardiovascular System & Cardiology; Nursing; Respiratory System
GA DG1SL
UT WOS:000371847700010
PM 26791248
ER
PT J
AU Nasioudis, D
Tsilimigras, D
Economopoulos, KP
AF Nasioudis, Dimitrios
Tsilimigras, Diamantis
Economopoulos, Konstantinos P.
TI Laparoscopic cholecystectomy during pregnancy: A systematic review of
590 patients
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Review
DE Pregnancy; Laparoscopy; Cholecystectomy
ID BILIARY-TRACT DISEASE; SURGICAL-MANAGEMENT; GALLSTONE DISEASE; INCREASES
MORBIDITY; ACUTE-PANCREATITIS; CENTER EXPERIENCE; ABDOMINAL-WALL; 3RD
TRIMESTER; SURGERY; COMPLICATIONS
AB Background: The incidence of symptomatic biliary disease during pregnancy ranges from 0.05 to 8%. Cholecystectomy is one of the common operations performed during pregnancy and laparoscopic approach has gained popularity as an attractive alternative to open surgery.
Methods: In order to evaluate the safety, feasibility, outcomes and technical aspects of laparoscopic cholecystectomy during pregnancy a comprehensive search of Medline and Cohrane Library databases was conducted.
Results: Fifty-one studies were deemed eligible, in which laparoscopic cholecystectomy was attempted in 590 patients. The majority of the procedures (70.7%) were performed during the second trimester. Intraoperative and postoperative complications were observed in 3.5% and 4% of the study population. Conversion rate to open surgery was 2.2%. Fetal loss rate and preterm delivery rate were 0.4% and 5.7% respectively.
Conclusion: Laparoscopic cholecystectomy seems to be a safe alternative to open surgery during pregnancy. (C) 2016 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.
C1 [Nasioudis, Dimitrios; Tsilimigras, Diamantis; Economopoulos, Konstantinos P.] Soc Jr Doctors, Athens, Greece.
[Nasioudis, Dimitrios] Weill Cornell Med, Dept Obstet & Gynecol, New York, NY USA.
[Economopoulos, Konstantinos P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, 101 Merrimac St, Boston, MA 02114 USA.
RP Economopoulos, KP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, 101 Merrimac St, Boston, MA 02114 USA.
NR 85
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1743-9191
EI 1743-9159
J9 INT J SURG
JI Int. J. Surg.
PD MAR
PY 2016
VL 27
BP 165
EP 175
DI 10.1016/j.ijsu.2016.01.070
PG 11
WC Surgery
SC Surgery
GA DG0VI
UT WOS:000371783400029
PM 26826612
ER
PT J
AU Gandhi, RT
Kwon, DS
Macklin, EA
Shopis, JR
McLean, AP
McBrine, N
Flynn, T
Peter, L
Sbrolla, A
Kaufmann, DE
Porichis, F
Walker, BD
Bhardwaj, N
Barouch, DH
Kavanagh, DG
AF Gandhi, Rajesh T.
Kwon, Douglas S.
Macklin, Eric A.
Shopis, Janet R.
McLean, Anna P.
McBrine, Nicole
Flynn, Theresa
Peter, Lauren
Sbrolla, Amy
Kaufmann, Daniel E.
Porichis, Filippos
Walker, Bruce D.
Bhardwaj, Nina
Barouch, Dan H.
Kavanagh, Daniel G.
TI Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells
Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a
Randomized, Placebo-Controlled Clinical Trial
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE randomized controlled trial; immunization; mRNA-transfected dendritic
cell; HIV-1; therapeutic vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; ANTIRETROVIRAL THERAPY; II
COMPARTMENT; IN-VITRO; INFECTION; RESPONSES; CD8(+); ANTIGEN;
IMMUNOTHERAPY
AB Background:
HIV-1 eradication may require reactivation of latent virus along with stimulation of HIV-1-specific immune responses to clear infected cells. Immunization with autologous dendritic cells (DCs) transfected with viral mRNA is a promising strategy for eliciting HIV-1-specific immune responses. We performed a randomized controlled clinical trial to evaluate the immunogenicity of this approach in HIV-1-infected persons on antiretroviral therapy.
Methods:
Fifteen participants were randomized 2:1 to receive intradermal immunization with HIV-1 Gag- and Nef-transfected DCs (vaccine) or mock-transfected DCs (placebo) at weeks 0, 2, 6, and 10. All participants also received DCs pulsed with keyhole limpet hemocyanin (KLH) to assess whether responses to a neo-antigen could be induced.
Results:
After immunization, there were no differences in interferon-gamma enzyme-linked immunospot responses to HIV-1 Gag or Nef in the vaccine or placebo group. CD4 proliferative responses to KLH increased 2.4-fold (P = 0.026) and CD8 proliferative responses to KLH increased 2.5-fold (P = 0.053) after vaccination. There were increases in CD4 proliferative responses to HIV-1 Gag (2.5-fold vs. baseline, 3.4-fold vs. placebo, P = 0.054) and HIV-1 Nef (2.3-fold vs. baseline, 6.3-fold vs. placebo, P = 0.009) among vaccine recipients, but these responses were short-lived.
Conclusion:
Immunization with DCs transfected with mRNA encoding HIV-1 Gag and Nef did not induce significant interferon-gamma enzyme-linked immunospot responses. There were increases in proliferative responses to HIV-1 antigens and to a neo-antigen, KLH, but the effects were transient. Dendritic cell vaccination should be optimized to elicit stronger and long-lasting immune responses for this strategy to be effective as an HIV-1 therapeutic vaccine.
C1 [Gandhi, Rajesh T.; Kwon, Douglas S.; Shopis, Janet R.; Flynn, Theresa; Sbrolla, Amy; Walker, Bruce D.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Gandhi, Rajesh T.; Kwon, Douglas S.; McLean, Anna P.; McBrine, Nicole; Kaufmann, Daniel E.; Porichis, Filippos; Walker, Bruce D.; Barouch, Dan H.; Kavanagh, Daniel G.] Massachusetts Gen Hosp, MIT, Ragon Inst, Cambridge, MA USA.
[Gandhi, Rajesh T.; Kwon, Douglas S.; McLean, Anna P.; McBrine, Nicole; Kaufmann, Daniel E.; Porichis, Filippos; Walker, Bruce D.; Barouch, Dan H.; Kavanagh, Daniel G.] Harvard, Cambridge, MA USA.
[Macklin, Eric A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Macklin, Eric A.] Harvard Univ, Sch Med, Boston, MA USA.
[Kaufmann, Daniel E.] Ctr Hosp Univ Montreal CRCHUM, Ctr Rech, Montreal, PQ, Canada.
[Kaufmann, Daniel E.] Univ Montreal, Montreal, PQ, Canada.
[Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Bhardwaj, Nina] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA.
[Barouch, Dan H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
RP Gandhi, RT (reprint author), Massachusetts Gen Hosp, GRJ 504,55 Fruit St, Boston, MA 02114 USA.
EM rgandhi@mgh.harvard.edu
OI Macklin, Eric/0000-0003-1618-3502
FU National Institutes of Health [R01 AI066992-01A1, AI078526, AI096040,
HL092565]; Center of AIDS Research [NIAID 5P30AI060354-08]; Ragon
Institute of MGH, MIT, and Harvard; Harvard Catalyst \ The Harvard
Clinical and Translational Science Center (National Center for Research
Resources); Harvard Catalyst \ The Harvard Clinical and Translational
Science Center (National Center for Advancing Translational Sciences,
National Institutes of Health) [UL1 TR001102]; Harvard University
FX Supported by National Institutes of Health (R01 AI066992-01A1, AI078526,
AI096040, HL092565), by the Center of AIDS Research (NIAID
5P30AI060354-08), and by the Ragon Institute of MGH, MIT, and Harvard.
This work was conducted with support from Harvard Catalyst vertical bar
The Harvard Clinical and Translational Science Center (National Center
for Research Resources and the National Center for Advancing
Translational Sciences, National Institutes of Health Award UL1
TR001102) and financial contributions from Harvard University and its
affiliated academic healthcare centers. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of Harvard Catalyst, Harvard University and its
affiliated academic healthcare centers, or the National Institutes of
Health.
NR 33
TC 3
Z9 3
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAR 1
PY 2016
VL 71
IS 3
BP 246
EP 253
DI 10.1097/QAI.0000000000000852
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DF7FB
UT WOS:000371522100002
PM 26379068
ER
PT J
AU Blosnich, JR
Bossarte, RM
AF Blosnich, John R.
Bossarte, Robert M.
TI Childhood Abuse and Military Experience-Important Information to Better
Serve Those Who Have Served
SO JAMA PSYCHIATRY
LA English
DT Editorial Material
C1 [Blosnich, John R.] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Blosnich, John R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA.
[Bossarte, Robert M.] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA.
[Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA.
[Bossarte, Robert M.] Univ Rochester, Dept Publ Hlth Sci, Rochester, NY USA.
RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA.
EM john.blosnich@va.gov
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAR
PY 2016
VL 73
IS 3
BP 195
EP 196
DI 10.1001/jamapsychiatry.2015.2736
PG 2
WC Psychiatry
SC Psychiatry
GA DF8NC
UT WOS:000371613500005
PM 26817448
ER
PT J
AU Volkow, ND
Swanson, JM
Evins, AE
DeLisi, LE
Meier, MH
Gonzalez, R
Bloomfield, MAP
Curran, HV
Baler, R
AF Volkow, Nora D.
Swanson, James M.
Evins, A. Eden
DeLisi, Lynn E.
Meier, Madeline H.
Gonzalez, Raul
Bloomfield, Michael A. P.
Curran, H. Valerie
Baler, Ruben
TI Effects of Cannabis Use on Human Behavior, Including Cognition,
Motivation, and Psychosis: A Review
SO JAMA PSYCHIATRY
LA English
DT Review
ID HIGH-POTENCY CANNABIS; SWEDISH CONSCRIPTS; MEMORY IMPAIRMENT;
GENETIC-VARIATION; ADULT PSYCHOSIS; SEX-DIFFERENCES; SCHIZOPHRENIA;
RISK; ADOLESCENT; MARIJUANA
AB With a political debate about the potential risks and benefits of cannabis use as a backdrop, the wave of legalization and liberalization initiatives continues to spread. Four states (Colorado, Washington, Oregon, and Alaska) and the District of Columbia have passed laws that legalized cannabis for recreational use by adults, and 23 others plus the District of Columbia now regulate cannabis use for medical purposes. These policy changes could trigger a broad range of unintended consequences, with profound and lasting implications for the health and social systems in our country. Cannabis use is emerging as one among many interacting factors that can affect brain development and mental function. To inform the political discourse with scientific evidence, the literature was reviewed to identify what is known and not known about the effects of cannabis use on human behavior, including cognition, motivation, and psychosis.
C1 [Volkow, Nora D.; Baler, Ruben] NIDA, NIH, 6001 Execut Blvd, Bethesda, MD 20892 USA.
[Swanson, James M.] Univ Calif Irvine, Child Dev Ctr, Irvine, CA USA.
[Evins, A. Eden] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA.
[Evins, A. Eden] Harvard Univ, Sch Med, Boston, MA USA.
[DeLisi, Lynn E.] Harvard Univ, Sch Med, Vet Affairs Boston Healthcare Syst, Boston, MA USA.
[Meier, Madeline H.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA.
[Gonzalez, Raul] Florida Int Univ, Dept Psychol, Ctr Children & Families, Miami, FL 33199 USA.
[Bloomfield, Michael A. P.] UCL, Div Psychiat, London, England.
[Bloomfield, Michael A. P.] Hammersmith Hosp, MRC, Ctr Clin Sci, Psychiat Imaging Grp, London, England.
[Curran, H. Valerie] UCL, Clin Psychopharmacol Unit, Clin Hlth Psychol, London, England.
RP Volkow, ND (reprint author), NIDA, NIH, 6001 Execut Blvd, Bethesda, MD 20892 USA.
EM nvolkow@nida.nih.gov
FU Forum Pharmaceuticals from the National Institute of Drug Abuse [R01
DA030992]; Pfizer from the National Institute of Drug Abuse [R01
DA021245]; National Institutes of Health Intramural Research Program
(National Institute on Alcohol Abuse and Alcoholism)
[DE-AC02-98CH10886]; National Institute of Drug Abuse [R01 DA021576];
United Kingdom Medical Research Council; National Institute of Health
Research; British Medical Association; United Kingdom National Institute
of Health Research Biomedical Research Council; United Kingdom Medical
Research Council grant
FX This work was financed in part by support from the following: Forum
Pharmaceuticals to support grant R01 DA030992 from the National
Institute of Drug Abuse and Pfizer to support grant R01 DA021245 from
the National Institute of Drug Abuse (Dr Evins); National Institutes of
Health Intramural Research Program (National Institute on Alcohol Abuse
and Alcoholism) using the infrastructure of the Brookhaven National
Laboratory under contract DE-AC02-98CH10886 (Dr Volkow); grant R01
DA021576 from the National Institute of Drug Abuse (Dr DeLisi); United
Kingdom Medical Research Council, National Institute of Health Research,
and British Medical Association (Dr Bloomfield); and a grant from the
United Kingdom National Institute of Health Research Biomedical Research
Council to King's College London and a United Kingdom Medical Research
Council grant (Dr Curran).
NR 84
TC 32
Z9 32
U1 54
U2 119
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAR
PY 2016
VL 73
IS 3
BP 292
EP 297
DI 10.1001/jamapsychiatry.2015.3278
PG 6
WC Psychiatry
SC Psychiatry
GA DF8NC
UT WOS:000371613500017
PM 26842658
ER
PT J
AU Carter, SP
DiMauro, J
Renshaw, KD
Curby, TW
Babson, KA
Bonn-Miller, MO
AF Carter, Sarah P.
DiMauro, Jennifer
Renshaw, Keith D.
Curby, Timothy W.
Babson, Kimberly A.
Bonn-Miller, Marcel O.
TI Longitudinal associations of friend-based social support and PTSD
symptomatology during a cannabis cessation attempt
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE PTSD; Social support; Substance use; Longitudinal study; Military
ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; PSYCHOLOGICAL
DISTRESS; CAREGIVER BURDEN; MENTAL-ILLNESS; VETERANS; SYMPTOMS;
PARTNERS; ABUSE; METAANALYSIS
AB Research supports bidirectional associations between social support and posttraumatic stress disorder (PTSD), whereby social support may buffer against PTSD, and individuals with PTSD may experience decreasing support over time. Research examining contexts that may affect these relations is needed. This study examined the longitudinal associations between PTSD and social support from friends over a 6-month period in 116 veterans with cannabis dependence who had recently initiated an attempt to quit cannabis use. A cross-lagged autoregressive model revealed a significant, negative relation between earlier PTSD symptoms and later support. An exploratory multigroup analysis comparing those with and without a relapse in the first month after their quit attempt revealed that the significant negative association between PTSD and future support was present only in those who relapsed. Although this analysis was limited by a small sample size, results suggest that substance use may be an influential contextual variable that impacts the longitudinal associations between PTSD and support. (c) 2016 Elsevier Ltd. All rights reserved.
C1 [Carter, Sarah P.; DiMauro, Jennifer; Renshaw, Keith D.; Curby, Timothy W.] George Mason Univ, Dept Psychol, 4400 Univ Dr,3F5, Fairfax, VA 22030 USA.
[Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA.
[Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA.
[Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
[Bonn-Miller, Marcel O.] Univ Penn, Perelman Sch Med, Dept Psychiat, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA.
RP Carter, SP (reprint author), George Mason Univ, Dept Psychol, 4400 Univ Dr,3F5, Fairfax, VA 22030 USA.
EM scarte18@gmu.edu
FU VA Clinical Science Research and Development (CSR&D) Career Development
Award [CDA-2, 1IK2CX1023-01A1]
FX This work was supported, in part, by a VA Clinical Science Research and
Development (CSR&D) Career Development Award (CDA-2; 1IK2CX1023-01A1)
awarded to Dr. Babson. Data for the parent study were collected as part
of VA CSR&D CDA-2 awarded to Dr. Bonn-Miller.
NR 43
TC 0
Z9 0
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD MAR
PY 2016
VL 38
BP 62
EP 67
DI 10.1016/j.janxdis.2016.01.008
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DF6EQ
UT WOS:000371449100008
PM 26836369
ER
PT J
AU Korte, KJ
Allan, NP
Gros, DF
Acierno, R
AF Korte, Kristina J.
Allan, Nicholas P.
Gros, Daniel F.
Acierno, Ron
TI Differential treatment response trajectories in individuals with
subclinical and clinical PTSD
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE PTSD; Posttraumatic stress disorder; Subclinical; Subthreshold;
Military; Veterans; Growth curve modeling
ID POSTTRAUMATIC-STRESS-DISORDER; COVARIANCE STRUCTURE-ANALYSIS; COGNITIVE
PROCESSING THERAPY; CONFIRMATORY FACTOR-ANALYSIS; RANDOMIZED
CONTROLLED-TRIAL; SUBTHRESHOLD PTSD; PRIMARY-CARE; BEHAVIORAL
ACTIVATION; PROLONGED EXPOSURE; MILITARY VETERANS
AB Subclinical presentations of posttraumatic stress disorder (PTSD), wherein patients are one or two symptom criteria short of the full disorder, are prevalent and associated with levels of distress and impaired functioning approximating that of full PTSD. Nonetheless, research examining treatment efficacy for this group is in the nascent stage. The purpose of the present study was to examine whether the sub clinical PTSD group would: (1) show a greater reduction in PTSD symptoms at pre and post treatment in response to an exposure based treatment and (2) show a greater rate of change over the course of treatment, when compared to the full criteria PTSD group. We also examined whether differences would emerge when examining PTSD symptom clusters. Consistent with predictions, the subclinical PTSD group demonstrated a greater reduction in PTSD symptoms at post-treatment (29%) than those with a PTSD diagnosis (14%). Further, the groups had different treatment trajectories, with the subclinical PTSD group showing a marginally greater rate of change during the course of treatment. Findings also varied by symptom cluster with the subclinical group showing a greater rate of change in the intrusions, hyper vigilance, and avoidance symptom clusters. There was not a significant between group difference in the numbing symptom cluster. This study provides preliminary evidence that treating PTSD symptoms at the subclinical level may result in a larger, and more rapid symptom reduction, and thus has implications supporting treatment earlier in the developmental trajectory of the disorder. Published by Elsevier Ltd.
C1 [Korte, Kristina J.; Allan, Nicholas P.; Gros, Daniel F.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Korte, Kristina J.; Allan, Nicholas P.; Gros, Daniel F.; Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM kortek@musc.edu; grosd@musc.edu
FU CSRD VA [IK2 CX000845]; NIAAA NIH HHS [T32 AA007474]
NR 49
TC 0
Z9 0
U1 4
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD MAR
PY 2016
VL 38
BP 95
EP 101
DI 10.1016/j.janxdis.2016.01.006
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DF6EQ
UT WOS:000371449100012
PM 26874291
ER
PT J
AU Pellino, G
Nicolai, E
Catalano, OA
Campione, S
D'Armiento, FP
Salvatore, M
Cuocolo, A
Selvaggi, F
AF Pellino, Gianluca
Nicolai, Emanuele
Catalano, Onofrio A.
Campione, Severo
D'Armiento, Francesco P.
Salvatore, Marco
Cuocolo, Alberto
Selvaggi, Francesco
TI PET/MR Versus PET/CT Imaging: Impact on the Clinical Management of
Small-Bowel Crohn's Disease
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Article
DE Crohn's disease; diagnosis; surgery; magnetic resonance imaging;
fibrosis; inflammation; pathology
ID COMPUTED-TOMOGRAPHY ENTEROGRAPHY; 4TH SCIENTIFIC WORKSHOP; INTESTINAL
FIBROSIS; NONINVASIVE ASSESSMENT; ULCERATIVE-COLITIS; MR ENTEROGRAPHY;
F-18-FDG PET/CT; INFLAMMATION; STRICTURES; ECCO
AB Background and Aims: The aim of this study was to compare the accuracy and clinical impact of hybrid positron emission tomography [PET]/magnetic resonance-enterography [MR-E] and PET/computed tomography-enterography [CT-E] in patients with Crohn's disease [CD].
Methods: A total of 35 patients with symptomatic small-bowel CD who were scheduled to undergo operation were evaluated before operation by same-day PET/CT-E and PET/MR-E. PET/MR-E was also compared with MR-E alone. Imaging accuracy for detecting pathological sites and discriminating between fibrotic and inflammatory strictures was assessed. Treatment was adjusted according to imaging findings and change in medical/surgical strategy was also evaluated.
Results: PET/CT-E, PET/MR-E, and MR-E were equally accurate in detecting CD sites. PET/MR-E was more accurate in assessing extra-luminal disease [p = 0.002], which was associated with higher need for stoma [p = 0.022] and distant localisation [p = 0.002]. When the latter was observed, laparoscopy was started with hand-assisted device, reducing operative time [p = 0.022]. PET/MR-E was also more accurate in detecting a fibrotic component compared with PET/CT-E [p = 0.043] and with MR-E [p = 0.024]. Fibrosis was more frequently classified as inflammation with MR-E compared with PET/MR-E [p = 0.019]. Out of 8 patients with predominantly inflammatory CD who received medical treatment, 6 [75%] remained surgery free. Overall, 29 patients received surgery. At median follow-up of 9 [6-22] months, no recurrences occurred in either the medical or the surgical group. Conclusions: Preoperative PET/MR-E imaging is highly accurate for assessing CD lesions before operation and contributed to clinical management of patients with small-bowel CD more often than PET/CT-E.
C1 [Pellino, Gianluca; Selvaggi, Francesco] Univ Naples 2, Dept Med Surg Neurol Metab & Geriatr Sci, Unit Colorectal Surg, Piazza Miraglia 2, I-80138 Naples, Italy.
[Nicolai, Emanuele; Salvatore, Marco] IRCCS SDN, Naples, Italy.
[Catalano, Onofrio A.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Campione, Severo; D'Armiento, Francesco P.; Cuocolo, Alberto] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy.
RP Selvaggi, F (reprint author), Univ Naples 2, Dept Med Surg Neurol Metab & Geriatr Sci, Unit Colorectal Surg, Piazza Miraglia 2, I-80138 Naples, Italy.
EM fselvaggi@hotmail.com
RI Nicolai, Emanuele/K-6678-2016;
OI Nicolai, Emanuele/0000-0003-3171-368X; Cuocolo,
Alberto/0000-0003-3431-7658; Pellino, Gianluca/0000-0002-8322-6421
NR 44
TC 3
Z9 3
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1873-9946
EI 1876-4479
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD MAR
PY 2016
VL 10
IS 3
BP 277
EP 285
DI 10.1093/ecco-jcc/jjv207
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DG1HS
UT WOS:000371817600006
PM 26574490
ER
PT J
AU Sedaghat, G
Ghafoori, E
Waks, JW
Kabir, MM
Shvilkin, A
Josephson, ME
Tereshchenko, LG
AF Sedaghat, Golriz
Ghafoori, Elyar
Waks, Jonathan W.
Kabir, Muammar M.
Shvilkin, Alexei
Josephson, Mark E.
Tereshchenko, Larisa G.
TI Quantitative Assessment of Vectorcardiographic Loop Morphology
SO JOURNAL OF ELECTROCARDIOLOGY
LA English
DT Article
DE Vectorcardiography; Planarity; Ventricular tachycardia
ID MYOCARDIAL-INFARCTION; HEART-RATE; QRS LOOP; SYSTEM; ELECTROCARDIOGRAM;
MORTALITY
AB Vectorcardiography (VCG), developed 100 years ago, characterizes clinically important electrophysiological properties of the heart. In this study, VCG QRS loop roundness, planarity, thickness, rotational angle, and dihedral angle were measured in 81 healthy control subjects (39.0 +/- 14.2y; 51.8% male; 94% white), and 8 patients with infarct-cardiomyopathy and sustained monomorphic ventricular tachycardia (VT) (68.0 +/- 7.8y, 37.5% male). The angle between two consecutive QRS vectors was defined as the rotational angle, while dihedral angle quantified planar alteration over the QRS loop. In VT subjects, planarity index decreased (0.63 +/- 0.22 vs. 0.88 +/- 0.10; P = 0.014), and dihedral angle was significantly more variable (variance of dihedral angle, median (IQR): 897(575-1450) vs. 542(343-773); P = 0.029; rMSSD: 47.7 +/- 12.7 vs. 35.1 +/- 13.1; P = 0.027). Abnormal electrophysiological substrate in VT patients is characterized by the appearance of QRS loop folding, likely due to local conduction block. The presence of fragmented QRS complexes on the 12-lead ECG had low sensitivity (31%) for detecting QRS loop folding on the VCG. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Sedaghat, Golriz; Ghafoori, Elyar; Kabir, Muammar M.; Tereshchenko, Larisa G.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA.
[Waks, Jonathan W.; Shvilkin, Alexei; Josephson, Mark E.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA USA.
[Sedaghat, Golriz] Portland State Univ, Portland, OR 97207 USA.
[Ghafoori, Elyar] Univ Utah, Salt Lake City, UT USA.
RP Tereshchenko, LG (reprint author), Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA.
EM tereshch@ohsu.edu
OI Shvilkin, Alexei/0000-0003-3662-9938; Tereshchenko,
Larisa/0000-0002-6976-1313
FU National Institute of Health [1R01HL118277]
FX The authors would like to thank the National Institute of Health
#1R01HL118277 (LGT and MEJ) for its support.
NR 17
TC 1
Z9 1
U1 0
U2 2
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0022-0736
EI 1532-8430
J9 J ELECTROCARDIOL
JI J. Electrocardiol.
PD MAR-APR
PY 2016
VL 49
IS 2
BP 154
EP 163
DI 10.1016/j.jelectrocard.2015.12.014
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG1TH
UT WOS:000371849900008
PM 26826894
ER
PT J
AU Karadeli, HH
Giurgiutiu, DV
Cloonan, L
Fitzpatrick, K
Kanakis, A
Ozcan, ME
Schwamm, LH
Rost, NS
AF Karadeli, Hasan H.
Giurgiutiu, Dan-Victor
Cloonan, Lisa
Fitzpatrick, Kaitlin
Kanakis, Allison
Ozcan, Muhammed E.
Schwamm, Lee H.
Rost, Natalia S.
TI FLAIR Vascular Hyperintensity is a Surrogate of Collateral Flow and
Leukoaraiosis in Patients With Acute Stroke Due to Proximal Artery
Occlusion
SO JOURNAL OF NEUROIMAGING
LA English
DT Article
DE Fluid attenuated inversion recovery (FLAIR) vascular hyperintensity
(FVH); acute ischemic stroke (AIS); white matter disease; leukoaraiosis;
collateral
ID ACUTE ISCHEMIC-STROKE; WHITE-MATTER LESIONS; CEREBRAL AMYLOID
ANGIOPATHY; MR-ANGIOGRAPHY; INFARCTION; SEVERITY; PROGRESSION; VESSELS;
DISEASE
AB BACKGROUNDFluid attenuated inversion recovery (FLAIR) vascular hyperintensity (FVH) is a novel radiographic marker detected in acute ischemic stroke (AIS) patients, which is linked to slow blood flow and potentially salvageable brain tissue. Poor leptomeningeal collateral status in AIS patients with proximal artery occlusion (PAO) is associated with larger final infarct and worse clinical outcomes, which are also affected by severity of white matter hyperintensity (WMH). We sought to evaluate FVH utility as a marker of acute collateral vessel status and its association with WMH burden in AIS patients.
METHODSConsecutive AIS patients with PAO on baseline CT angiography (CTA) were retrospectively selected from a prospectively derived database. FVH was graded by its location, degree, and score on admission MRI obtained immediately after intravenous tissue plasminogen activator administration. Leptomeningeal collateral flow grade was ranked on admission CTA. WMH volume (WMHV) was assessed using a validated volumetric protocol. Relationship between FVH, collateral flow grade, and WMHV were analyzed.
RESULTSAmong 39 patients (mean age 70.5 12.7 years; 56% women, mean National Institutes of Health Stroke Scale score 17.2 (+/- 4.4)), median WMHV was 6.0cm(3). FVH score and collateral flow grade were significantly correlated (Spearman's = .41, P = .009). In a univariate regression model, FVH degree was inversely associated with WMHV ( = -.33, P = .04).
CONCLUSIONSFVH score detected on acute MRI can be used as a surrogate of collateral flow grade in AIS patients. FVH degree is inversely associated with WMHV, possibly signifying diffuse disease of cerebral vasculature in patients with severe leukoaraiosis.
C1 [Karadeli, Hasan H.; Giurgiutiu, Dan-Victor; Cloonan, Lisa; Fitzpatrick, Kaitlin; Kanakis, Allison; Schwamm, Lee H.; Rost, Natalia S.] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Dept Neurol, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
[Karadeli, Hasan H.; Ozcan, Muhammed E.] BezmialemVakif Univ, Dept Neurol, Istanbul, Turkey.
[Giurgiutiu, Dan-Victor; Kanakis, Allison] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
RP Rost, NS (reprint author), Massachusetts Gen Hosp, Philip Kistler Stroke Res Ctr, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
EM nrost@partners.org
FU NIH-NINDS [K23NS064052, R01NS082285-01A1]; TUBITAK [1059B191400176]
FX This work is supported by the NIH-NINDS (K23NS064052 and
R01NS082285-01A1, N. S. R) and the TUBITAK (1059B191400176, H. H. K.)
awards.
NR 26
TC 1
Z9 1
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1051-2284
EI 1552-6569
J9 J NEUROIMAGING
JI J. Neuroimaging
PD MAR-APR
PY 2016
VL 26
IS 2
BP 219
EP 223
DI 10.1111/jon.12274
PG 5
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DG0DW
UT WOS:000371734400011
PM 26250448
ER
PT J
AU Krigbaum, H
Takemoto, S
Kim, HT
Kuo, AC
AF Krigbaum, Henry
Takemoto, Steven
Kim, Hubert T.
Kuo, Alfred C.
TI Costs and Complications of Short Versus Long Cephalomedullary Nailing of
OTA 31-A2 Proximal Femur Fractures in U.S. Veterans
SO JOURNAL OF ORTHOPAEDIC TRAUMA
LA English
DT Article
DE cephalomedullary nail; intertrochanteric femur fracture
ID INTERTROCHANTERIC HIP-FRACTURES; INTRAMEDULLARY NAILS; GAMMA-NAIL; A2
AB Objectives:
In fractures without subtrochanteric extension, the indications for the use of short versus long cephalomedullary nails (CMNs) for intertrochanteric femur fractures are unclear. We hypothesized that long nails would be associated with higher costs and similar complication rates.
Design:
Retrospective comparative study.
Setting:
United States Department of Veterans Affairs Medical Centers.
Participants:
Patients receiving CMNs for OTA 31-A2 pertrochanteric fractures from 2001 to 2010.
Interventions:
Short versus long cephalomedullary nailing.
Main Outcome Measurements:
Costs, perioperative complications, readmissions, surgical failures, and mortality.
Results:
We identified 262 patients with OTA 31-A2 pertrochanteric fractures (125 treated with short CMNs and 137 treated with long CMNs). The 2 cohorts had similar demographic and medical characteristics. There were no significant differences in perioperative complications, readmissions within 30 days, surgical failures within one year, or death within 30 days or one year. The average cost of hospitalization was significantly higher for the cohort treated with long nails (greater than $7000 in actual costs, and greater than $3000 when statistically adjusted for differences in postoperative lengths of stay). Multivariable analyses showed no significant differences in the rates of development of at least one complication, readmission, or death.
Conclusions:
In a cohort of patients with similar characteristics and fracture patterns, the use of long CMNs was associated with similar rates of complications, readmission, and reoperations, but significantly higher costs than with the use of short nails.
Level of Evidence:
Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
C1 [Kuo, Alfred C.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Kuo, AC (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM kuoac@orthosurg.ucsf.edu
FU James O. Johnston resident research grant
FX Supported by the James O. Johnston resident research grant to H.
Krigbaum.
NR 14
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0890-5339
EI 1531-2291
J9 J ORTHOP TRAUMA
JI J. Orthop. Trauma
PD MAR
PY 2016
VL 30
IS 3
BP 125
EP 129
DI 10.1097/BOT.0000000000000521
PG 5
WC Orthopedics; Sport Sciences
SC Orthopedics; Sport Sciences
GA DF5IK
UT WOS:000371384900005
PM 26894639
ER
PT J
AU Sidhu, MS
Lumish, H
Uthamalingam, S
Engel, LC
Abbara, S
Brady, TJ
Hoffmann, U
Ghoshhajra, BB
AF Sidhu, Manavjot S.
Lumish, Heidi
Uthamalingam, Shanmugam
Engel, Leif-Christopher
Abbara, Suhny
Brady, Thomas J.
Hoffmann, Udo
Ghoshhajra, Brian B.
TI Adherence to the 2010 American College of Cardiology Foundation
Appropriate Use Criteria for Cardiac Computed Tomography: Quality
Analysis at a Tertiary Referral Center
SO JOURNAL OF PATIENT SAFETY
LA English
DT Article
DE appropriate use criteria; cardiac computed tomography; quality
improvement
ID ECHOCARDIOGRAPHY; ASSOCIATION; PROGRESS; DISEASE
AB Background In November 2010, the American College of Cardiology Foundation published revised appropriateness criteria (AC) for cardiac computed tomography (CT). We evaluated adherence to these criteria by providers of different subspecialties at a tertiary referral center. Methods Reports of 383 consecutive patients who underwent clinically indicated cardiac CT from December 1, 2010, to July 31, 2011, were reviewed by physicians with appropriate training in cardiac CT. Scans were classified as appropriate, inappropriate, or uncertain based on the revised 2010 AC. Studies that did not fall under any of the specified indications were labeled as unclassified. Adherence to the AC was also analyzed as a function of provider type. Research scans were excluded from this analysis. Results Three hundred eight exams (80%) were classified as appropriate; 26 (7%), as inappropriate; 30 (8%), as uncertain; and 19 (5%), as unclassified. Of the 19 (5%) unclassified cardiac CT exams, the most common indication was for evaluation of suspected aortic dissection. Three hundred five exams (80%) were referred by cardiologists; 73 (19%), by internists; and 5 (1%), by neurologists. Of the 305 cardiology-referred studies, 221 (73%) were ordered by general cardiologists; 28 (9%), by interventional cardiologists; and 56 (19%), by electrophysiologists. There was no significant difference in adherence to the criteria between provider specialties or between cardiology subspecialties (P > 0.05). Conclusions high across provider specialties.
C1 [Sidhu, Manavjot S.] Massachusetts Gen Hosp, Dept Radiol, Dept Cardiovasc Imaging, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
[Sidhu, Manavjot S.] Massachusetts Gen Hosp, Div Cardiol, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
[Sidhu, Manavjot S.] Harvard Univ, Sch Med, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
RP Sidhu, MS (reprint author), Massachusetts Gen Hosp, Dept Radiol, Dept Cardiovasc Imaging, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.; Sidhu, MS (reprint author), Massachusetts Gen Hosp, Div Cardiol, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.; Sidhu, MS (reprint author), Harvard Univ, Sch Med, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
EM manavsidhu83@gmail.com
NR 16
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1549-8417
J9 J PATIENT SAF
JI J. Patient Saf.
PD MAR
PY 2016
VL 12
IS 1
BP 40
EP 43
DI 10.1097/PTS.0000000000000124
PG 4
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DF8AJ
UT WOS:000371578700006
PM 25136850
ER
PT J
AU Norton, EK
Singer, SJ
Sparks, W
Ozonoff, A
Baxter, J
Rangel, S
AF Norton, Elizabeth K.
Singer, Sara J.
Sparks, William
Ozonoff, Al
Baxter, Jessica
Rangel, Shawn
TI Operating Room Clinicians' Attitudes and Perceptions of a Pediatric
Surgical Safety Checklist at 1 Institution
SO JOURNAL OF PATIENT SAFETY
LA English
DT Article
DE pediatric surgical safety checklist; attitudes; survey; teamwork;
operating room; communication; perceptions
ID IMPLEMENTATION; MORTALITY
AB Background Despite mounting evidence that use of surgical checklists improves patient morbidity and mortality, compliance among surgical teams in executing required elements of checklists has been low. Recognizing that clinicians' receptivity is a major determinant of checklist use, we conducted a survey to investigate how mandated use of a surgical checklist impacts its operating room clinicians' attitudes about and perceptions of operating room safety, efficiency, teamwork, and prevention of medical errors. Methods Operating room clinicians at 1 pediatric hospital were surveyed on their attitudes and perception of the novel Pediatric Surgical Safety Checklist and the impact the checklist had on efficiency, teamwork, and prevention of medical errors 1 year after its implementation. The survey responses were compared and classified by multidisciplinary perioperative clinical staff. Results Most responses reflected positive attitudes toward checklist use. The respondents felt that the checklist reduced complications and errors and improved patient safety, communication among team members, teamwork in complex procedures, and efficiency in the operating room. Many operating room staff also reported that checklist use had prevented or averted an error or a complication. Perceptions varied according to perioperative clinical discipline, reflecting differences in perspectives. For example, the nurses perceived a higher rate of consent-related errors and site marking errors than did the physicians; the surgeons reported more antibiotic timing and equipment errors than did others. Conclusions The surgical staff at 1 pediatric hospital who responded viewed the novel Pediatric Surgical Safety Checklist as potentially beneficial to operative patient safety by improving teamwork and communication, reducing errors, and improving efficiency. Responses varied by discipline, indicating that team members view the checklist from different perspectives.
C1 [Norton, Elizabeth K.; Baxter, Jessica] Boston Childrens Hosp, Dept Nursing, Boston, MA 02115 USA.
[Rangel, Shawn] Boston Childrens Hosp, Dept Gen Surg, Boston, MA 02115 USA.
[Singer, Sara J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Singer, Sara J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Mongan Inst Hlth Policy, Boston, MA USA.
[Sparks, William] Boston Childrens Hosp, Dept Anesthesiol & Perioperat Pain Management, Clin Res Ctr, Boston, MA 02115 USA.
[Ozonoff, Al] Boston Childrens Hosp, Dept Design & Anal Core, Clin Res Ctr, Boston, MA 02115 USA.
[Ozonoff, Al] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Norton, EK (reprint author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
EM elizabeth.norton@childrens.harvard.edu
NR 11
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1549-8417
J9 J PATIENT SAF
JI J. Patient Saf.
PD MAR
PY 2016
VL 12
IS 1
BP 44
EP 50
DI 10.1097/PTS.0000000000000120
PG 7
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DF8AJ
UT WOS:000371578700007
PM 25010191
ER
PT J
AU Schuler, M
Wu, YL
Hirsh, V
O'Byrne, K
Yamamoto, N
Mok, T
Popat, S
Sequist, LV
Massey, D
Zazulina, V
Yang, JCH
AF Schuler, Martin
Wu, Yi-Long
Hirsh, Vera
O'Byrne, Kenneth
Yamamoto, Nobuyuki
Mok, Tony
Popat, Sanjay
Sequist, Lecia V.
Massey, Dan
Zazulina, Victoria
Yang, James C. -H.
TI First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell
Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations
and Brain Metastases
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Afatinib; NSCLC; Brain metastases; Epidermal growth factor receptor
ID TYROSINE KINASE INHIBITORS; ERBB FAMILY BLOCKER; HIGH-DOSE ERLOTINIB;
EGFR MUTATIONS; PHASE-III; ADENOCARCINOMA; MANAGEMENT; SURVIVAL;
RADIOTHERAPY; GEFITINIB
AB Introduction: Metastatic spread to the brain is common in patients with non-small cell lung cancer (NSCLC), but these patients are generally excluded from prospective clinical trials. The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article.
Methods: For both LUX-Lung 3 and LUX-Lung 6, prespecified subgroup analyses of progression-free survival (PFS), overall survival, and objective response rate were undertaken in patients with asymptomatic brain metastases at baseline (n = 35 and n = 46, respectively). Post hoc analyses of clinical outcomes was undertaken in the combined data set (n = 81).
Results: In both studies, there was a trend toward improved PFS with afatinib versus chemotherapy in patients with brain metastases (LUX-Lung 3:11.1 versus 5.4 months, hazard ratio [HR] = 0.54, p = 0.1378; LUX-Lung 6:8.2 versus 4.7 months, HR = 0.47, p = 0.1060). The magnitude of PFS improvement with afatinib was similar to that observed in patients without brain metastases. In combined analysis, PFS was significantly improved with afatinib versus with chemotherapy in patients with brain metastases (8.2 versus 5.4 months; HR, 0.50; p = 0.0297). Afatinib significantly improved the objective response rate versus chemotherapy in patients with brain metastases. Safety findings were consistent with previous reports.
Conclusions: These findings lend support to the clinical activity of afatinib in EGFR mutation-positive patients with NSCLC and asymptomatic brain metastases. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc.
C1 [Schuler, Martin] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany.
[Schuler, Martin] German Canc Consortium DKTK, Heidelberg, Germany.
[Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China.
[Wu, Yi-Long] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China.
[Hirsh, Vera] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada.
[O'Byrne, Kenneth] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
[O'Byrne, Kenneth] Queensland Univ Technol, Brisbane, Qld 4001, Australia.
[Yamamoto, Nobuyuki] Wakayama Med Univ, Wakayama, Japan.
[Mok, Tony] Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Hong Kong, Peoples R China.
[Popat, Sanjay] Royal Marsden Hosp, London SW3 6JJ, England.
[Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sequist, Lecia V.] Harvard Univ, Sch Med, Boston, MA USA.
[Massey, Dan; Zazulina, Victoria] Boehringer Ingelheim Ltd, Bracknell, Berks, England.
[Yang, James C. -H.] Natl Taiwan Univ Hosp, Taipei, Taiwan.
[Yang, James C. -H.] Natl Taiwan Univ, Taipei 10764, Taiwan.
RP Schuler, M (reprint author), Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Hufelandstr 55, D-45147 Essen, Germany.
EM Martin.Schuler@uk-essen.de
NR 33
TC 24
Z9 25
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD MAR
PY 2016
VL 11
IS 3
BP 380
EP 390
DI 10.1016/j.jtho.2015.11.014
PG 11
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA DF6DP
UT WOS:000371446400011
PM 26823294
ER
PT J
AU Suhasini, AN
Wang, L
Holder, KN
Lin, AP
Bhatnagar, H
Kim, SW
Moritz, AW
Aguiar, RCT
AF Suhasini, A. N.
Wang, L.
Holder, K. N.
Lin, A-P
Bhatnagar, H.
Kim, S-W
Moritz, A. W.
Aguiar, R. C. T.
TI A phosphodiesterase 4B-dependent interplay between tumor cells and the
microenvironment regulates angiogenesis in B-cell lymphoma
SO LEUKEMIA
LA English
DT Article
ID NON-HODGKIN-LYMPHOMA; MICROVESSEL DENSITY; GENE-EXPRESSION; CYCLIC-AMP;
MURINE LYMPHOMAS; PDE4 INHIBITORS; PROLIFERATION; CANCER; VEGF;
CHEMOTHERAPY
AB Angiogenesis associates with poor outcome in diffuse large B-cell lymphoma (DLBCL), but the contribution of the lymphoma cells to this process remains unclear. Addressing this knowledge gap may uncover unsuspecting proangiogenic signaling nodes and highlight alternative antiangiogenic therapies. Here, we identify the second messenger cyclic-AMP (cAMP) and the enzyme that terminates its activity, phosphodiesterase 4B (PDE4B), as regulators of B-cell lymphoma angiogenesis. We first show that cAMP, in a PDE4B-dependent manner, suppresses PI3K/AKT signals to downmodulate vascular endothelial growth factor (VEGF) secretion and vessel formation in vitro. Next, we create a novel mouse model that combines the lymphomagenic Myc transgene with germline deletion of Pde4b. We show that lymphomas developing in a Pde4b-null background display significantly lower microvessel density (MVD) in association with lower VEGF levels and PI3K/AKT activity. We recapitulate these observations by treating lymphoma-bearing mice with the FDA-approved PDE4 inhibitor, Roflumilast. Lastly, we show that primary human DLBCLs with high PDE4B expression display significantly higher MVD. Here, we defined an unsuspected signaling circuitry in which the cAMP generated in lymphoma cells downmodulates PI3K/AKT and VEGF secretion to negatively influence vessel development in the microenvironment. These data identify PDE4 as an actionable antiangiogenic target in DLBCL.
C1 [Suhasini, A. N.; Wang, L.; Lin, A-P; Bhatnagar, H.; Kim, S-W; Aguiar, R. C. T.] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
[Holder, K. N.; Moritz, A. W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Aguiar, R. C. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
[Aguiar, R. C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Aguiar, RCT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM aguiarr@uthscsa.edu
FU CPRIT [RP110200, RP150277]; William and Ella Owens Medical Research
Foundation; Cancer Center support grant [P30 CA054174]
FX We thank the Cancer Therapy and Research Center at UTHSCSA Core
Pathology Tissue Bank for procurement of the primary DLBCL samples. We
acknowledge Patricia Dahia for insightful suggestions during the
execution of this project. This work was supported by CPRIT awards
RP110200 and RP150277 (to RCTA), a grant from the William and Ella Owens
Medical Research Foundation (to RCTA), and a Cancer Center support grant
P30 CA054174.
NR 48
TC 3
Z9 3
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD MAR
PY 2016
VL 30
IS 3
BP 617
EP 626
DI 10.1038/leu.2015.302
PG 10
WC Oncology; Hematology
SC Oncology; Hematology
GA DF9NR
UT WOS:000371688500011
PM 26503641
ER
PT J
AU Zeidan, AM
Sekeres, MA
Garcia-Manero, G
Steensma, D
Zell, K
Barnard, J
Ali, NA
Zimmerman, C
Roboz, G
DeZern, A
Nazha, A
Jabbour, E
Kantarjian, H
Gore, SD
Maciejewski, JP
List, A
Komrokji, R
AF Zeidan, A. M.
Sekeres, M. A.
Garcia-Manero, G.
Steensma, D. P.
Zell, K.
Barnard, J.
Ali, N. A.
Zimmerman, C.
Roboz, G.
DeZern, A.
Nazha, A.
Jabbour, E.
Kantarjian, H.
Gore, S. D.
Maciejewski, J. P.
List, A.
Komrokji, R.
CA MDS Clinical Res Consortium
TI Comparison of risk stratification tools in predicting outcomes of
patients with higher-risk myelodysplastic syndromes treated with
azanucleosides
SO LEUKEMIA
LA English
DT Article
ID PROGNOSTIC SCORING SYSTEM; LEUKEMIA GROUP-B; CONVENTIONAL CARE REGIMENS;
ACUTE MYELOID-LEUKEMIA; RANDOMIZED PHASE-III; HYPOMETHYLATING AGENTS;
MOLECULAR MUTATIONS; ELDERLY-PATIENTS; GENETIC-BASIS; AZACITIDINE
AB Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely derived from untreated patient cohorts. Although azanucleosides are standard therapies for higher-risk (HR)-MDS, the relative prognostic performance of existing prognostic tools among patients with HR-MDS receiving azanucleoside therapy is unknown. In the MDS Clinical Research Consortium database, we compared the prognostic utility of the International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R), MD Anderson Prognostic Scoring System (MDAPSS), World Health Organization-based Prognostic Scoring System (WPSS) and the French Prognostic Scoring System (FPSS) among 632 patients who presented with HR-MDS and were treated with azanucleosides as the first-line therapy. Median follow-up from diagnosis was 15.7 months. No prognostic tool predicted the probability of achieving an objective response. Nonetheless, all five tools were associated with overall survival (OS, P = 0.025 for the IPSS, P = 0.011 for WPSS and P<0.001 for the other three tools). The corrected Akaike Information Criteria, which were used to compare OS with the different prognostic scoring systems as covariates (lower is better) were 4138 (MDAPSS), 4156 (FPSS), 4196 (IPSS-R), 4186 (WPSS) and 4196 (IPSS). Patients in the highest-risk groups of the prognostic tools had a median OS from diagnosis of 11 - 16 months and should be considered for up-front transplantation or experimental approaches.
C1 [Zeidan, A. M.; Gore, S. D.] Yale Univ, Sect Hematol, Dept Internal Med, Yale Comprehens Canc Ctr, 333 Cedar St,POB 208028, New Haven, CT 06520 USA.
[Sekeres, M. A.; Zell, K.; Barnard, J.; Zimmerman, C.; Nazha, A.; Maciejewski, J. P.] Cleveland Clin, Dept Translat Hematol & Oncol Res, Leukemia Program, Cleveland, OH 44106 USA.
[Garcia-Manero, G.; Jabbour, E.; Kantarjian, H.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
[Steensma, D. P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[List, A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA.
[Roboz, G.] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA.
[DeZern, A.] Johns Hopkins Univ, Dept Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
RP Zeidan, AM (reprint author), Yale Univ, Sect Hematol, Dept Internal Med, Yale Comprehens Canc Ctr, 333 Cedar St,POB 208028, New Haven, CT 06520 USA.
EM amer.zeidan@yale.edu
FU Evans Foundation; Aplastic Anemia and Myelodysplastic Syndromes
Foundation; MDS Clinical Research Consortium; American Society of
Oncology Young Investigator Award
FX We would like to thank the patients who contributed to this large
database and their families, as well the research coordinators in the
six sites who worked to construct the database. The authors would also
like to thank the Evans Foundation and the Aplastic Anemia and
Myelodysplastic Syndromes Foundation for supporting the research
activities of the MDS Clinical Research Consortium. This research was
presented in part at the American Society of Hematology 56th Annual
meeting in San Francisco, CA, USA in December 2014. AMZ received funding
through MDS Clinical Research Consortium and the American Society of
Oncology Young Investigator Award.
NR 45
TC 6
Z9 6
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD MAR
PY 2016
VL 30
IS 3
BP 649
EP 657
DI 10.1038/leu.2015.283
PG 9
WC Oncology; Hematology
SC Oncology; Hematology
GA DF9NR
UT WOS:000371688500015
PM 26464171
ER
PT J
AU Wu, H
Hu, C
Wang, A
Weisberg, EL
Wang, W
Chen, C
Zhao, Z
Yu, K
Liu, J
Wu, J
Nonami, A
Wang, L
Wang, B
Stone, RM
Liu, S
Griffin, JD
Liu, J
Liu, Q
AF Wu, H.
Hu, C.
Wang, A.
Weisberg, E. L.
Wang, W.
Chen, C.
Zhao, Z.
Yu, K.
Liu, J.
Wu, J.
Nonami, A.
Wang, L.
Wang, B.
Stone, R. M.
Liu, S.
Griffin, J. D.
Liu, J.
Liu, Q.
TI Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
SO LEUKEMIA
LA English
DT Letter
ID BRUTON TYROSINE KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE
MYELOID-LEUKEMIA; B-CELL MALIGNANCIES; BTK; INHIBITION; PCI-32765;
ARTHRITIS
C1 [Wu, H.; Hu, C.; Wang, A.; Wang, W.; Chen, C.; Zhao, Z.; Yu, K.; Liu, J.; Wu, J.; Wang, L.; Wang, B.; Liu, J.; Liu, Q.] Chinese Acad Sci, High Field Magnet Lab, Hefei, Anhui, Peoples R China.
[Wu, H.; Wang, A.; Wu, J.; Liu, Q.] Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China.
[Weisberg, E. L.; Nonami, A.; Stone, R. M.; Liu, S.; Griffin, J. D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
RP Liu, J; Liu, Q (reprint author), Chinese Acad Sci, High Field Magnet Lab, Hefei, Anhui, Peoples R China.; Liu, Q (reprint author), Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China.
EM jingliu@hmfl.ac.cn; qsliu97@hmfl.ac.cn
OI liu, jing/0000-0001-9513-3591
FU NCI NIH HHS [P01 CA066996]
NR 18
TC 3
Z9 3
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD MAR
PY 2016
VL 30
IS 3
BP 754
EP 757
DI 10.1038/leu.2015.175
PG 4
WC Oncology; Hematology
SC Oncology; Hematology
GA DF9NR
UT WOS:000371688500029
PM 26139428
ER
PT J
AU Touzeau, C
Ryan, J
Guerriero, J
Moreau, P
Chonghaile, TN
Le Gouill, S
Richardson, P
Anderson, K
Amiot, M
Letai, A
AF Touzeau, C.
Ryan, J.
Guerriero, J.
Moreau, P.
Chonghaile, T. N.
Le Gouill, S.
Richardson, P.
Anderson, K.
Amiot, M.
Letai, A.
TI BH3 profiling identifies heterogeneous dependency on Bcl-2 family
members in multiple myeloma and predicts sensitivity to BH3 mimetics
SO LEUKEMIA
LA English
DT Letter
ID ABT-199; LEUKEMIA; CELLS; MCL-1; INHIBITION; ADDICTION; DEATH
C1 [Touzeau, C.; Ryan, J.; Guerriero, J.; Richardson, P.; Anderson, K.; Letai, A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Touzeau, C.; Moreau, P.; Le Gouill, S.] Univ Hosp, Dept Hematol, Nantes, France.
[Touzeau, C.; Moreau, P.; Le Gouill, S.; Amiot, M.] Univ Nantes, CNRS UMR6299, INSERM UMR892, Nantes, France.
[Chonghaile, T. N.] Conway Inst Biomol & Biomed Res, Dublin, Ireland.
RP Letai, A (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM anthony_letai@dfci.harvard.edu
RI richard, chrystelle/K-8595-2015
FU NCI NIH HHS [R01 CA129974, R01CA129974]
NR 17
TC 12
Z9 12
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD MAR
PY 2016
VL 30
IS 3
BP 761
EP 764
DI 10.1038/leu.2015.184
PG 4
WC Oncology; Hematology
SC Oncology; Hematology
GA DF9NR
UT WOS:000371688500031
PM 26174630
ER
PT J
AU Brown, RB
Razzaque, MS
AF Brown, Ronald B.
Razzaque, Mohammed S.
TI Phosphate toxicity: a stealth biochemical stress factor?
SO MEDICAL MOLECULAR MORPHOLOGY
LA English
DT Editorial Material
ID INORGANIC-PHOSPHATE; FGF23-KLOTHO AXIS; VITAMIN-D; HOMEOSTASIS;
APOPTOSIS; CELLS; FGF23; RECEPTOR; KLOTHO; CKD
C1 [Brown, Ronald B.] Kansas State Univ, Coll Human Ecol, Manhattan, KS 66506 USA.
[Razzaque, Mohammed S.] Forsyth Inst, Dept Appl Oral Sci, 245 First St, Cambridge, MA 02142 USA.
[Razzaque, Mohammed S.] VPS Hlth Care, Div Res & Dev, Abu Dhabi, U Arab Emirates.
[Razzaque, Mohammed S.] Saba Univ, Dept Pathol, Devens, MA USA.
RP Razzaque, MS (reprint author), Forsyth Inst, Dept Appl Oral Sci, 245 First St, Cambridge, MA 02142 USA.; Razzaque, MS (reprint author), VPS Hlth Care, Div Res & Dev, Abu Dhabi, U Arab Emirates.; Razzaque, MS (reprint author), Saba Univ, Dept Pathol, Devens, MA USA.
EM mrazzaque@forsyth.org
NR 33
TC 1
Z9 1
U1 2
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
JAPAN
SN 1860-1480
EI 1860-1499
J9 MED MOL MORPHOL
JI Med. Mol. Morphol.
PD MAR
PY 2016
VL 49
IS 1
BP 1
EP 4
DI 10.1007/s00795-015-0122-3
PG 4
WC Biology; Microscopy; Pathology
SC Life Sciences & Biomedicine - Other Topics; Microscopy; Pathology
GA DF7IC
UT WOS:000371530300001
PM 26582553
ER
PT J
AU Logan, SM
Tessier, SN
Tye, J
Storey, KB
AF Logan, Samantha M.
Tessier, Shannon N.
Tye, Joann
Storey, Kenneth B.
TI Response of the JAK-STAT pathway to mammalian hibernation in 13-lined
ground squirrel striated muscle
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE JAK-STAT signal transduction; Anti-apoptosis; Heart; Muscle; Ictidomys
tridecemlineatus; Mammalian hibernation
ID SKELETAL-MUSCLE; GENE-EXPRESSION; SERINE PHOSPHORYLATION; SIGNALING
PATHWAY; GROWTH-HORMONE; REAL-TIME; TRANSCRIPTION; ACTIVATION; SURVIVAL;
TORPOR
AB Over the course of the torpor-arousal cycle, hibernators must make behavioral, physiological, and molecular rearrangements in order to keep a very low metabolic rate and retain organ viability. 13-lined ground squirrels (Ictidomys tridecemlineatus) remain immobile during hibernation, and although the mechanisms of skeletal muscle survival are largely unknown, studies have shown minimal muscle loss in hibernating organisms. Additionally, the ground squirrel heart undergoes cold-stress, reversible cardiac hypertrophy, and ischemia-reperfusion without experiencing fatal impairment. This study examines the role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway in the regulation of cell stress in cardiac and skeletal muscles, comparing euthermic and hibernating ground squirrels. Immunoblots showed a fivefold decrease in JAK3 expression during torpor in skeletal muscle, along with increases in STAT3 and 5 phosphorylation and suppressors of cytokine signaling-1 (SOCS1) protein levels. Immunoblots also showed coordinated increases in STAT1, 3 and 5 phosphorylation and STAT1 inhibitor protein expression in cardiac muscle during torpor. PCR analysis revealed that the activation of these pro-survival signaling cascades did not result in coordinate changes in downstream genes such as anti-apoptotic B-cell lymphoma-2 (Bcl-2) family gene expression. Overall, these results indicate activation of the JAK-STAT pathway in both cardiac and skeletal muscles, suggesting a response to cellular stress during hibernation.
C1 [Logan, Samantha M.; Tessier, Shannon N.; Tye, Joann; Storey, Kenneth B.] Carleton Univ, Inst Biochem, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.
[Logan, Samantha M.; Tessier, Shannon N.; Tye, Joann; Storey, Kenneth B.] Carleton Univ, Dept Biol, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.
[Tessier, Shannon N.] Massachusetts Gen Hosp, Dept Surg, Bldg 114,16th St, Charlestown, MA 02129 USA.
[Tessier, Shannon N.] Massachusetts Gen Hosp, Ctr Engn Med, Bldg 114,16th St, Charlestown, MA 02129 USA.
[Tessier, Shannon N.] Harvard Univ, Sch Med, Bldg 114,16th St, Charlestown, MA 02129 USA.
[Tye, Joann] New Beginnings Ob Gyn, 193 Mt Ave, Springfield, NJ 07081 USA.
RP Storey, KB (reprint author), Carleton Univ, Inst Biochem, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.; Storey, KB (reprint author), Carleton Univ, Dept Biol, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.
EM kenneth_storey@carleton.ca
FU Natural Sciences and Engineering Research Council of Canada [6793];
Heart and Stroke Foundation of Canada [G-14-0005874]; NSERC
FX We thank Dr. J. M. Hallenbeck at the NIH for providing ground squirrel
tissues, Bryan E. Luu for advice and assistance with polymerase chain
reaction and Luminex (R) assay preparation, and Jan Storey for editorial
review of this manuscript. This work was supported by a Discovery Grant
(#6793) from the Natural Sciences and Engineering Research Council of
Canada and a grant from the Heart and Stroke Foundation of Canada
(#G-14-0005874). KBS holds the Canada Research Chair in Molecular
Physiology, SNT holds a NSERC Postdoctoral Fellowship, and SML held an
NSERC Undergraduate Student Research Award.
NR 55
TC 2
Z9 3
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD MAR
PY 2016
VL 414
IS 1-2
BP 115
EP 127
DI 10.1007/s11010-016-2665-6
PG 13
WC Cell Biology
SC Cell Biology
GA DF8TU
UT WOS:000371633300012
PM 26885984
ER
PT J
AU Kvedar, JC
Fogel, AL
Elenko, E
Zohar, D
AF Kvedar, Joseph C.
Fogel, Alexander L.
Elenko, Eric
Zohar, Daphne
TI Digital medicine's march on chronic disease
SO NATURE BIOTECHNOLOGY
LA English
DT Editorial Material
ID UNITED-STATES; ADHERENCE; THERAPY; MEDICATION; TRIAL
C1 [Kvedar, Joseph C.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Kvedar, Joseph C.] Harvard Univ, Sch Med, Boston, MA USA.
[Kvedar, Joseph C.] Partners Healthcare, Partners Connected Hlth, Boston, MA USA.
[Fogel, Alexander L.] Stanford Univ, Grad Sch Business, Stanford, CA 94305 USA.
[Fogel, Alexander L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Elenko, Eric; Zohar, Daphne] PureTech Hlth, Boston, MA USA.
RP Zohar, D (reprint author), PureTech Hlth, Boston, MA USA.
EM DaphneNB@puretechhealth.com
NR 41
TC 2
Z9 2
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD MAR
PY 2016
VL 34
IS 3
BP 239
EP 246
DI 10.1038/nbt.3495
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA DG1CJ
UT WOS:000371802600014
PM 26963544
ER
PT J
AU Amit, I
Baker, D
Barker, R
Berger, B
Bertozzi, C
Bhatia, S
Biffi, A
Demichelis, F
Doudna, J
Dowdy, SF
Endy, D
Helmstaedter, M
Junca, H
June, C
Kamb, S
Khvorova, A
Kim, DH
Kim, JS
Krishnan, Y
Lakadamyali, M
Lappalainen, T
Lewin, S
Liao, J
Loman, N
Lundberg, E
Lynd, L
Martin, C
Mellman, I
Miyawaki, A
Mummery, C
Nelson, K
Paz, J
Peralta-Yahya, P
Picotti, P
Polyak, K
Prather, K
Qin, J
Quake, S
Regev, A
Rogers, JA
Shetty, R
Sommer, M
Stevens, M
Stolovitzky, G
Takahashi, M
Tang, F
Teichmann, S
Torres-Padilla, ME
Tripathi, L
Vemula, P
Verdine, G
Vollmer, F
Wang, J
Ying, JY
Zhang, F
Zhang, T
AF Amit, Ido
Baker, David
Barker, Roger
Berger, Bonnie
Bertozzi, Carolyn
Bhatia, Sangeeta
Biffi, Alessandra
Demichelis, Francesca
Doudna, Jennifer
Dowdy, Steven F.
Endy, Drew
Helmstaedter, Moritz
Junca, Howard
June, Carl
Kamb, Sasha
Khvorova, Anastasia
Kim, Dae-Hyeong
Kim, Jin-Soo
Krishnan, Yamuna
Lakadamyali, Melike
Lappalainen, Tuuli
Lewin, Sharon
Liao, James
Loman, Nick
Lundberg, Emma
Lynd, Lee
Martin, Cathie
Mellman, Ira
Miyawaki, Atsushi
Mummery, Christine
Nelson, Karen
Paz, Jeanne
Peralta-Yahya, Pamela
Picotti, Paola
Polyak, Kornelia
Prather, Kristala
Qin, Jun
Quake, Stephen
Regev, Aviv
Rogers, John A.
Shetty, Reshma
Sommer, Morten
Stevens, Molly
Stolovitzky, Gustavo
Takahashi, Masayo
Tang, Fuchou
Teichmann, Sarah
Torres-Padilla, Maria-Elena
Tripathi, Leena
Vemula, Praveen
Verdine, Greg
Vollmer, Frank
Wang, Jun
Ying, Jackie Y.
Zhang, Feng
Zhang, Tian
TI Voices of biotech
SO NATURE BIOTECHNOLOGY
LA English
DT Article
C1 [Amit, Ido] Weizmann Inst Sci, IL-76100 Rehovot, Israel.
[Baker, David] Univ Washington, Seattle, WA 98195 USA.
[Barker, Roger] Univ Cambridge, Cambridge, England.
MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Bertozzi, Carolyn; Endy, Drew; Quake, Stephen] Stanford Univ, Stanford, CA 94305 USA.
[Biffi, Alessandra; Polyak, Kornelia] Dana Farber Canc Inst, Cambridge, MA USA.
[Biffi, Alessandra; Polyak, Kornelia; Regev, Aviv; Verdine, Greg] Harvard Univ, Cambridge, MA 02138 USA.
[Demichelis, Francesca] Univ Trento, Trento, Italy.
[Doudna, Jennifer] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Dowdy, Steven F.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Helmstaedter, Moritz] Max Planck Inst Brain Res, Frankfurt, Germany.
[Junca, Howard] Microbiomas Fdn, Chia, Colombia.
[June, Carl] Univ Penn, Philadelphia, PA 19104 USA.
[Kamb, Sasha] Amgen Inc, Thousand Oaks, CA USA.
[Khvorova, Anastasia] Univ Massachusetts, Worcester, MA 01605 USA.
[Kim, Dae-Hyeong; Kim, Jin-Soo] Seoul Natl Univ, Seoul, South Korea.
[Krishnan, Yamuna] Univ Chicago, Chicago, IL 60637 USA.
[Lakadamyali, Melike] Inst Photon Sci, Barcelona, Spain.
[Lappalainen, Tuuli] New York Genome Ctr New York, New York, NY USA.
[Lappalainen, Tuuli] Columbia Univ, New York, NY USA.
[Lewin, Sharon] Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.
[Liao, James] Univ Calif Los Angeles, Los Angeles, CA USA.
[Loman, Nick] Univ Birmingham, Birmingham, W Midlands, England.
[Lundberg, Emma] KTH Royal Inst Technol, Stockholm, Sweden.
[Lynd, Lee] Dartmouth Coll, Hanover, NH 03755 USA.
[Martin, Cathie] John Innes Ctr, Norwich, Norfolk, England.
[Mellman, Ira] Genentech Inc, San Francisco, CA 94080 USA.
[Miyawaki, Atsushi] RIKEN, Brain Sci Inst, Wako, Saitama, Japan.
[Mummery, Christine] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Nelson, Karen] J Craig Venter Inst, La Jolla, CA USA.
[Nelson, Karen] Human Longev, San Diego, CA USA.
[Paz, Jeanne] Univ Calif San Francisco, Gladstone Inst, San Francisco, CA 94143 USA.
[Peralta-Yahya, Pamela] Georgia Inst Technol, Atlanta, GA 30332 USA.
[Picotti, Paola] Swiss Fed Inst Technol, Zurich, Switzerland.
[Qin, Jun] Beijing Proteome Res Ctr, Beijing, Peoples R China.
[Qin, Jun] Baylor Coll Med, Houston, TX 77030 USA.
[Rogers, John A.] Univ Illinois, Champaign, IL USA.
[Shetty, Reshma] Ginkgo Bioworks, Boston, MA USA.
[Sommer, Morten; Zhang, Tian] Tech Univ Denmark, Horsholm, Denmark.
[Stevens, Molly] Univ London Imperial Coll Sci Technol & Med, London, England.
[Stolovitzky, Gustavo] IBM Res Corp, Yorktown Hts, NY USA.
[Stolovitzky, Gustavo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Takahashi, Masayo] RIKEN, Ctr Dev Biol, Kobe, Hyogo, Japan.
[Tang, Fuchou] Peking Univ, Biodynam Opt Imaging Ctr, Beijing 100871, Peoples R China.
[Teichmann, Sarah] Wellcome Trust Sanger Inst, Cambridge, England.
[Torres-Padilla, Maria-Elena] Inst Genet & Biol Mol & Cellulaire, Strasbourg, France.
[Torres-Padilla, Maria-Elena] Helmholtz Ctr, Inst Epigenet & Stem Cells, Munich, Germany.
[Tripathi, Leena] Int Inst Trop Agr, Ibadan, Kenya.
[Vemula, Praveen] Inst Stem Cell Biol & Regenerat Med, Bangalore, Karnataka, India.
[Verdine, Greg] Warp Drive Bio, Cambridge, MA USA.
[Verdine, Greg] FogPharma, Gloucester, MA USA.
[Vollmer, Frank] Max Planck Inst Sci Light, Erlangen, Germany.
[Wang, Jun] ICarbonX, Shenzhen, Peoples R China.
[Ying, Jackie Y.] Inst Bioengn & Nanotechnol, Singapore, Singapore.
RP Amit, I (reprint author), Weizmann Inst Sci, IL-76100 Rehovot, Israel.
RI Rogers, John /L-2798-2016; Junca, Howard/K-5525-2014; Miyawaki,
Atsushi/K-3569-2014; Zhang, Tian/N-4696-2015
OI Junca, Howard/0000-0003-4546-6229; Miyawaki,
Atsushi/0000-0002-2329-3235; Lappalainen, Tuuli/0000-0002-7746-8109;
Vollmer, Frank/0000-0003-0565-4671; Zhang, Tian/0000-0003-3840-4839
FU Biotechnology and Biological Sciences Research Council
[BBS/E/J/00000153]; Medical Research Council [MR/M501621/1]; NIGMS NIH
HHS [R01 GM108803]
NR 0
TC 0
Z9 0
U1 15
U2 55
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD MAR
PY 2016
VL 34
IS 3
BP 270
EP 275
DI 10.1038/nbt.3502
PG 6
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA DG1CJ
UT WOS:000371802600019
PM 26963549
ER
PT J
AU Vegas, AJ
Veiseh, O
Doloff, JC
Ma, ML
Tam, HH
Bratlie, K
Li, J
Bader, AR
Langan, E
Olejnik, K
Fenton, P
Kang, JW
Hollister-Locke, J
Bochenek, MA
Chiu, A
Siebert, S
Tang, K
Jhunjhunwala, S
Aresta-Dasilva, S
Dholakia, N
Thakrar, R
Vietti, T
Chen, M
Cohen, J
Siniakowicz, K
Qi, MRG
McGarrigle, J
Lyle, S
Harlan, DM
Greiner, DL
Oberholzer, J
Weir, GC
Langer, R
Anderson, DG
AF Vegas, Arturo J.
Veiseh, Omid
Doloff, Joshua C.
Ma, Minglin
Tam, Hok Hei
Bratlie, Kaitlin
Li, Jie
Bader, Andrew R.
Langan, Erin
Olejnik, Karsten
Fenton, Patrick
Kang, Jeon Woong
Hollister-Locke, Jennifer
Bochenek, Matthew A.
Chiu, Alan
Siebert, Sean
Tang, Katherine
Jhunjhunwala, Siddharth
Aresta-Dasilva, Stephanie
Dholakia, Nimit
Thakrar, Raj
Vietti, Thema
Chen, Michael
Cohen, Josh
Siniakowicz, Karolina
Qi, Meirigeng
McGarrigle, James
Lyle, Stephen
Harlan, David M.
Greiner, Dale L.
Oberholzer, Jose
Weir, Gordon C.
Langer, Robert
Anderson, Daniel G.
TI Combinatorial hydrogel library enables identification of materials that
mitigate the foreign body response in primates
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID ALGINATE-BASED MICROCAPSULES; L-LYSINE MICROCAPSULES; INFLAMMATORY
RESPONSES; MECHANICAL-PROPERTIES; CONFOCAL RAMAN; ISLETS; BIOMATERIALS;
MEMBRANE; BIOCOMPATIBILITY; ENCAPSULATION
AB The foreign body response is an immune-mediated reaction that can lead to the failure of implanted medical devices and discomfort for the recipient(1-6). There is a critical need for biomaterials that overcome this key challenge in the development of medical devices. Here we use a combinatorial approach for covalent chemical modification to generate a large library of variants of one of the most widely used hydrogel biomaterials, alginate. We evaluated the materials in vivo and identified three triazole-containing analogs that substantially reduce foreign body reactions in both rodents and, for at least 6 months, in non-human primates. The distribution of the triazole modification creates a unique hydrogel surface that inhibits recognition by macrophages and fibrous deposition. In addition to the utility of the compounds reported here, our approach may enable the discovery of other materials that mitigate the foreign body response.
C1 [Vegas, Arturo J.; Veiseh, Omid; Doloff, Joshua C.; Ma, Minglin; Tam, Hok Hei; Bratlie, Kaitlin; Li, Jie; Bader, Andrew R.; Langan, Erin; Olejnik, Karsten; Fenton, Patrick; Chiu, Alan; Siebert, Sean; Tang, Katherine; Jhunjhunwala, Siddharth; Aresta-Dasilva, Stephanie; Dholakia, Nimit; Thakrar, Raj; Vietti, Thema; Chen, Michael; Langer, Robert; Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Vegas, Arturo J.; Doloff, Joshua C.; Ma, Minglin; Li, Jie; Bader, Andrew R.; Langan, Erin; Olejnik, Karsten; Fenton, Patrick; Chiu, Alan; Siebert, Sean; Tang, Katherine; Jhunjhunwala, Siddharth; Aresta-Dasilva, Stephanie; Dholakia, Nimit; Thakrar, Raj; Vietti, Thema; Chen, Michael; Langer, Robert; Anderson, Daniel G.] Boston Childrens Hosp, Dept Anesthesiol, Boston, MA USA.
[Veiseh, Omid; Tam, Hok Hei; Bratlie, Kaitlin; Langer, Robert; Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Kang, Jeon Woong] MIT, Spect Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Hollister-Locke, Jennifer; Cohen, Josh; Siniakowicz, Karolina; Weir, Gordon C.] Joslin Diabet Ctr, Div Res, Sect Islet Cell & Regenerat Biol, 1 Joslin Pl, Boston, MA 02215 USA.
[Bochenek, Matthew A.; Qi, Meirigeng; McGarrigle, James; Oberholzer, Jose] Univ Illinois, Dept Surg, Div Transplantat, Chicago, IL 60680 USA.
[Lyle, Stephen] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA USA.
[Harlan, David M.; Greiner, Dale L.] Univ Massachusetts, Sch Med, Diabet Ctr Excellence, Worcester, MA USA.
[Langer, Robert; Anderson, Daniel G.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Langer, Robert; Anderson, Daniel G.] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Vegas, Arturo J.] Boston Univ, Dept Chem, 590 Commonwealth Ave, Boston, MA 02215 USA.
[Ma, Minglin] Cornell Univ, Dept Biol & Environm Engn, Ithaca, NY USA.
[Bratlie, Kaitlin] Iowa State Univ, Dept Mat Sci & Engn, Ames, IA USA.
[Bratlie, Kaitlin] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA USA.
[Bader, Andrew R.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
RP Anderson, DG (reprint author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Anderson, DG (reprint author), Boston Childrens Hosp, Dept Anesthesiol, Boston, MA USA.; Anderson, DG (reprint author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.; Anderson, DG (reprint author), MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Anderson, DG (reprint author), MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
EM dgander@mit.edu
OI Bratlie, Kaitlin/0000-0002-5197-0176; Chen, Michael/0000-0002-1590-768X
FU JDRF [3-SRA-2014-285-M-R]; Leona M. and the Harry B. Helmsley Charitable
Trust [3-SRA-2014-285-M-R]; National Institutes of Health (NIH)
[EB000244, EB000351, DE013023, CA151884, R01DK093909, P30DK036836]; NIH
NIBIB [P41EB015871-27]; MIT SkolTech initiative; JDRF; Department of
Defense/Congressionally Directed Medical Research Programs (DOD/CDMRP)
[3-2013-178, W81XWH-13-1-0215]; National Institutes of Health (NIH,
Joslin Diabetes Research Center and its Advanced Microscopy Core);
Diabetes Research and Wellness Foundation; National Institutes of Health
(NIH/NIDDK) [R01DK091526]; Chicago Diabetes Project; Koch Institute from
the National Cancer Institute [P30-CA14051]
FX This work was supported jointly by the JDRF and Leona M. and the Harry
B. Helmsley Charitable Trust (grant 3-SRA-2014-285-M-R), National
Institutes of Health (NIH grants EB000244, EB000351, DE013023 and
CA151884), NIH NIBIB (P41EB015871-27), MIT SkolTech initiative (J.W.K.),
JDRF and the Department of Defense/Congressionally Directed Medical
Research Programs (DOD/CDMRP postdoctoral fellowships 3-2013-178 and
W81XWH-13-1-0215 for O.V.) and through a generous gift from the Tayebati
Family Foundation. G.C.W. is supported by National Institutes of Health
(NIH grants R01DK093909 and P30DK036836, the Joslin Diabetes Research
Center and its Advanced Microscopy Core), as well as the Diabetes
Research and Wellness Foundation. J.O. is supported by the National
Institutes of Health (NIH/NIDDK) R01DK091526 and the Chicago Diabetes
Project. This work was also supported in part by the Koch Institute
Support (core) grant P30-CA14051 from the National Cancer Institute. We
also thank the Koch Institute Swanson Biotechnology Center for technical
support, specifically Tang Histology Facility, Microscopy, Flow
Cytometry, Nanotechnology Materials, and Applied Therapeutics and Whole
Animal Imaging. The authors would like to acknowledge the use of
resources at W.M. Keck Biological Imaging Facility (Whitehead
Institute).
NR 56
TC 24
Z9 24
U1 34
U2 67
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD MAR
PY 2016
VL 34
IS 3
BP 345
EP +
DI 10.1038/nbt.3462
PG 14
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA DG1CJ
UT WOS:000371802600033
PM 26807527
ER
PT J
AU Cote, AJ
McLeod, CM
Farrell, MJ
McClanahan, PD
Dunagin, MC
Raj, A
Mauck, RL
AF Cote, Allison J.
McLeod, Claire M.
Farrell, Megan J.
McClanahan, Patrick D.
Dunagin, Margaret C.
Raj, Arjun
Mauck, Robert L.
TI Single-cell differences in matrix gene expression do not predict matrix
deposition
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; HUMAN ARTICULAR
CHONDROCYTES; BONE-MARROW; IN-VITRO; CHONDROGENIC DIFFERENTIATION;
ADIPOGENIC DIFFERENTIATION; LINEAGE COMMITMENT; HETEROGENEITY; CARTILAGE
AB Mesenchymal stem cells (MSCs) display substantial cell-to-cell heterogeneity, complicating their use in regenerative medicine. However, conventional bulk assays mask this variability. Here we show that both chondrocytes and chondrogenically induced MSCs exhibit substantial mRNA expression heterogeneity. Single-molecule RNA FISH to measure mRNA expression of differentiation markers in single cells reveals that sister cell pairs have high levels of mRNA variability, suggesting that marker expression is not heritable. Surprisingly, this variability does not correlate with cell-to-cell differences in cartilage-like matrix production. Transcriptome-wide analysis suggests that no combination of markers can predict functional potential. De-differentiating chondrocytes also show a disconnect between mRNA expression of the cartilage marker aggrecan and cartilage-like matrix accumulation. Altogether, these quantitative analyses suggest that sorting subpopulations based on these markers would only marginally enrich the progenitor population for ' superior' MSCs. Our results suggest that instantaneous mRNA abundance of canonical markers is tenuously linked to the chondrogenic phenotype at the single-cell level.
C1 [Cote, Allison J.; McLeod, Claire M.; Farrell, Megan J.; McClanahan, Patrick D.; Dunagin, Margaret C.; Raj, Arjun; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
[McLeod, Claire M.; Farrell, Megan J.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
[McLeod, Claire M.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA.
RP Raj, A; Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA.
EM arjunrajlab@gmail.com; lemauck@mail.med.upenn.edu
OI Raj, Arjun/0000-0002-2915-6960
FU NSF CAREER award [1350601]; NIH New Innovator [1DP2OD008514]; Penn
Center for Musculoskeletal Disorders [P30 AR050950]; NIH [R01 EB008722,
R01 EB02425]; NIH training grant [T32 GM-07229, T32 HL007954]; NSF
Graduate Research Fellowship [DGE-0822]
FX A.R. acknowledges support from an NSF CAREER award (Grant Number
1350601), NIH New Innovator 1DP2OD008514, and a pilot grant from the
Penn Center for Musculoskeletal Disorders P30 AR050950. R.L.M.
acknowledges support from NIH grants R01 EB008722 and R01 EB02425.
A.J.C. was supported by NIH training grant T32 GM-07229. C.M.M. was
supported by NSF Graduate Research Fellowship DGE-0822 and by NIH
training grant T32 HL007954.
NR 70
TC 5
Z9 5
U1 5
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10865
DI 10.1038/ncomms10865
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF9WG
UT WOS:000371712300001
PM 26936319
ER
PT J
AU Lane, JM
Vlasac, I
Anderson, SG
Kyle, SD
Dixon, WG
Bechtold, DA
Gill, S
Little, MA
Luik, A
Loudon, A
Emsley, R
Scheer, FAJL
Lawlor, DA
Redline, S
Ray, DW
Rutter, MK
Saxena, R
AF Lane, Jacqueline M.
Vlasac, Irma
Anderson, Simon G.
Kyle, Simon D.
Dixon, William G.
Bechtold, David A.
Gill, Shubhroz
Little, Max A.
Luik, Annemarie
Loudon, Andrew
Emsley, Richard
Scheer, Frank A. J. L.
Lawlor, Deborah A.
Redline, Susan
Ray, David W.
Rutter, Martin K.
Saxena, Richa
TI Genome-wide association analysis identifies novel loci for chronotype in
100,420 individuals from the UK Biobank
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CIRCADIAN-RHYTHM DISRUPTION; SLEEP-PHASE SYNDROME; BODY-MASS INDEX;
MORNINGNESS-EVENINGNESS; MENDELIAN RANDOMIZATION; GENETIC EPIDEMIOLOGY;
CLOCK; INSIGHTS; SCHIZOPHRENIA; IMPUTATION
AB Our sleep timing preference, or chronotype, is a manifestation of our internal biological clock. Variation in chronotype has been linked to sleep disorders, cognitive and physical performance, and chronic disease. Here we perform a genome-wide association study of self-reported chronotype within the UK Biobank cohort (n = 100,420). We identify 12 new genetic loci that implicate known components of the circadian clock machinery and point to previously unstudied genetic variants and candidate genes that might modulate core circadian rhythms or light-sensing pathways. Pathway analyses highlight central nervous and ocular systems and fear-response-related processes. Genetic correlation analysis suggests chronotype shares underlying genetic pathways with schizophrenia, educational attainment and possibly BMI. Further, Mendelian randomization suggests that evening chronotype relates to higher educational attainment. These results not only expand our knowledge of the circadian system in humans but also expose the influence of circadian characteristics over human health and life-history variables such as educational attainment.
C1 [Lane, Jacqueline M.; Vlasac, Irma; Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Lane, Jacqueline M.; Saxena, Richa] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Lane, Jacqueline M.; Saxena, Richa] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Lane, Jacqueline M.; Vlasac, Irma; Saxena, Richa] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Anderson, Simon G.] Univ Manchester, Inst Cardiovasc Sci, Cardiovasc Res Grp, Manchester M13 9PL, Lancs, England.
[Kyle, Simon D.; Luik, Annemarie] Univ Oxford, Nuffield Dept Clin Neurosci, Sleep & Circadian Neurosci Inst, S Parks Rd, Oxford OX1 2JD, England.
[Dixon, William G.] Univ Manchester, Ctr Musculoskeletal Res, Inst Inflammat & Repair, Manchester M13 9PL, Lancs, England.
[Bechtold, David A.; Loudon, Andrew] Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England.
[Gill, Shubhroz] Broad Inst, Chem Biol Program, Cambridge, MA 02142 USA.
[Little, Max A.] Aston Univ, Dept Math Engn & Appl Sci, Birmingham B4 7ET, W Midlands, England.
[Emsley, Richard] Univ Manchester, Inst Populat Hlth, Manchester M13 9PL, Lancs, England.
[Scheer, Frank A. J. L.; Redline, Susan; Saxena, Richa] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
[Scheer, Frank A. J. L.; Redline, Susan] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02115 USA.
[Lawlor, Deborah A.] Univ Bristol, MRC, Integrat Epidemiol Unit, Bristol BS8 1TH, Avon, England.
[Lawlor, Deborah A.] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England.
[Ray, David W.; Rutter, Martin K.] Univ Manchester, Inst Human Dev, Ctr Endocrinol & Diabet, Manchester M13 9PL, Lancs, England.
[Rutter, Martin K.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Diabet Ctr, Manchester M13 9PL, Lancs, England.
RP Saxena, R (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.; Saxena, R (reprint author), Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.; Saxena, R (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.; Saxena, R (reprint author), Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.; Saxena, R (reprint author), Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
EM rsaxena@partners.org
RI Emsley, Richard/N-1342-2016;
OI Emsley, Richard/0000-0002-1218-675X; Kyle, Simon/0000-0002-9581-5311;
Ray, David/0000-0002-4739-6773; Anderson, Simon/0000-0002-8896-073X;
Lawlor, Debbie A/0000-0002-6793-2262; Luik, Annemarie
I/0000-0001-7517-197X; Dixon, William/0000-0001-5881-4857
FU NIH [R21HL121728-02, F32DK102323-01A1, R01HL113338-04]; University of
Manchester (Research Infrastructure Fund); Wellcome Trust; UK Medical
Research Council [MC_UU_12013/5]
FX This work was supported by NIH grants R21HL121728-02 (R.S.),
F32DK102323-01A1 (J.M.L.), R01HL113338-04 (J.M.L., S.R. and R.S.), the
University of Manchester (Research Infrastructure Fund), the Wellcome
Trust (salary support D.W.R. and A.L.) and UK Medical Research Council
MC_UU_12013/5 (D.A.L.). Data on glycemic traits have been contributed by
MAGIC investigators and have been downloaded from
www.magicinvestigators.org. Data on coronary artery disease/myocardial
infarction have been contributed by CARDIo-GRAMplusC4D investigators and
have been downloaded from www.CARDIOGRAMPLUSC4D.ORG. We thank the
International Genomics of Alzheimer's Project (IGAP) for providing
summary results data for these analyses.
NR 70
TC 11
Z9 11
U1 3
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10889
DI 10.1038/ncomms10889
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG0BZ
UT WOS:000371728300001
PM 26955885
ER
PT J
AU Meyer, PA
Socias, S
Key, J
Ransey, E
Tjon, EC
Buschiazzo, A
Lei, M
Botka, C
Withrow, J
Neau, D
Rajashankar, K
Anderson, KS
Baxter, RH
Blacklow, SC
Boggon, TJ
Bonvin, AMJJ
Borek, D
Brett, TJ
Caflisch, A
Chang, CI
Chazin, WJ
Corbett, KD
Cosgrove, MS
Crosson, S
Dhe-Paganon, S
Di Cera, E
Drennan, CL
Eck, MJ
Eichman, BF
Fan, QR
Ferre-D'Amare, AR
Fromme, JC
Garcia, KC
Gaudet, R
Gong, P
Harrison, SC
Heldwein, EE
Jia, ZC
Keenan, RJ
Kruse, AC
Kvansakul, M
McLellan, JS
Modis, Y
Nam, Y
Otwinowski, Z
Pai, EF
Pereira, PJB
Petosa, C
Raman, S
Rapoport, TA
Roll-Mecak, A
Rosen, MK
Rudenko, G
Schlessinger, J
Schwartz, TU
Shamoo, Y
Sondermann, H
Tao, YZJ
Tolia, NH
Tsodikov, OV
Westover, KD
Wu, H
Foster, I
Fraser, JS
Maia, FRNC
Gonen, T
Kirchhausen, T
Diederichs, K
Crosas, M
Sliz, P
AF Meyer, Peter A.
Socias, Stephanie
Key, Jason
Ransey, Elizabeth
Tjon, Emily C.
Buschiazzo, Alejandro
Lei, Ming
Botka, Chris
Withrow, James
Neau, David
Rajashankar, Kanagalaghatta
Anderson, Karen S.
Baxter, Richard H.
Blacklow, Stephen C.
Boggon, Titus J.
Bonvin, Alexandre M. J. J.
Borek, Dominika
Brett, Tom J.
Caflisch, Amedeo
Chang, Chung-I
Chazin, Walter J.
Corbett, Kevin D.
Cosgrove, Michael S.
Crosson, Sean
Dhe-Paganon, Sirano
Di Cera, Enrico
Drennan, Catherine L.
Eck, Michael J.
Eichman, Brandt F.
Fan, Qing R.
Ferre-D'Amare, Adrian R.
Fromme, J. Christopher
Garcia, K. Christopher
Gaudet, Rachelle
Gong, Peng
Harrison, Stephen C.
Heldwein, Ekaterina E.
Jia, Zongchao
Keenan, Robert J.
Kruse, Andrew C.
Kvansakul, Marc
McLellan, Jason S.
Modis, Yorgo
Nam, Yunsun
Otwinowski, Zbyszek
Pai, Emil F.
Barbosa Pereira, Pedro Jose
Petosa, Carlo
Raman, S.
Rapoport, Tom A.
Roll-Mecak, Antonina
Rosen, Michael K.
Rudenko, Gabby
Schlessinger, Joseph
Schwartz, Thomas U.
Shamoo, Yousif
Sondermann, Holger
Tao, Yizhi J.
Tolia, Niraj H.
Tsodikov, Oleg V.
Westover, Kenneth D.
Wu, Hao
Foster, Ian
Fraser, James S.
Maia, Filipe R. N. C.
Gonen, Tamir
Kirchhausen, Tom
Diederichs, Kay
Crosas, Merce
Sliz, Piotr
TI Data publication with the structural biology data grid supports live
analysis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID X-RAY SCATTERING; PROTEIN DATA-BANK; MACROMOLECULAR CRYSTALLOGRAPHY;
STRUCTURE MODELS; DATA QUALITY; SYNCHROTRON; SOFTWARE; SCIENCE;
EXPERIENCES; RESOLUTION
AB Access to experimental X-ray diffraction image data is fundamental for validation and reproduction of macromolecular models and indispensable for development of structural biology processing methods. Here, we established a diffraction data publication and dissemination system, Structural Biology Data Grid (SBDG; data. sbgrid. org), to preserve primary experimental data sets that support scientific publications. Data sets are accessible to researchers through a community driven data grid, which facilitates global data access. Our analysis of a pilot collection of crystallographic data sets demonstrates that the information archived by SBDG is sufficient to reprocess data to statistics that meet or exceed the quality of the original published structures. SBDG has extended its services to the entire community and is used to develop support for other types of biomedical data sets. It is anticipated that access to the experimental data sets will enhance the paradigm shift in the community towards a much more dynamic body of continuously improving data analysis.
C1 [Meyer, Peter A.; Socias, Stephanie; Key, Jason; Ransey, Elizabeth; Tjon, Emily C.; Blacklow, Stephen C.; Eck, Michael J.; Harrison, Stephen C.; Kruse, Andrew C.; Wu, Hao; Sliz, Piotr] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Buschiazzo, Alejandro] Inst Pasteur Montevideo, Lab Mol & Struct Microbiol, Montevideo 11400, Uruguay.
[Buschiazzo, Alejandro] Inst Pasteur, Dept Biol Struct & Chem, F-75015 Paris, France.
[Lei, Ming] Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.
[Botka, Chris] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Withrow, James; Neau, David; Rajashankar, Kanagalaghatta] Cornell Univ, Argonne Natl Lab, NE CAT, Bldg 436E,9700S Cass Ave, Argonne, IL 60439 USA.
[Withrow, James; Neau, David; Rajashankar, Kanagalaghatta] Cornell Univ, Argonne Natl Lab, Dept Chem & Chem Biol, Bldg 436E,9700S Cass Ave, Argonne, IL 60439 USA.
[Anderson, Karen S.; Boggon, Titus J.] Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.
[Anderson, Karen S.; Baxter, Richard H.; Boggon, Titus J.] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.
[Baxter, Richard H.] Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.
[Bonvin, Alexandre M. J. J.] Univ Utrecht, Bijvoet Ctr, Fac Sci, NL-3584 CH Utrecht, Netherlands.
[Borek, Dominika; Otwinowski, Zbyszek] Univ Texas SW Med Ctr Dallas, Dept Biophys & Biochem, Dallas, TX 75390 USA.
[Brett, Tom J.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
[Caflisch, Amedeo] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland.
[Chang, Chung-I] Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.
[Chazin, Walter J.] Vanderbilt Univ, Dept Biochem, Struct Biol Ctr, Nashville, TN 37232 USA.
[Chazin, Walter J.] Vanderbilt Univ, Dept Chem, Struct Biol Ctr, Nashville, TN 37232 USA.
[Corbett, Kevin D.] Ludwig Inst Canc Res, San Diego Branch, La Jolla, CA 92093 USA.
[Corbett, Kevin D.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
[Cosgrove, Michael S.] SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.
[Crosson, Sean; Keenan, Robert J.] Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA.
[Dhe-Paganon, Sirano; Eck, Michael J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Di Cera, Enrico] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
[Drennan, Catherine L.] MIT, Dept Chem, Cambridge, MA 02139 USA.
[Drennan, Catherine L.] MIT, Dept Biol, Cambridge, MA 02139 USA.
MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
[Eichman, Brandt F.] Vanderbilt Univ, Dept Biol, Nashville, TN 37235 USA.
[Eichman, Brandt F.] Vanderbilt Univ, Struct Biol Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Fan, Qing R.] Columbia Univ, Dept Pharmacol, New York, NY 10032 USA.
[Fan, Qing R.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
[Ferre-D'Amare, Adrian R.] NHLBI, Lab RNA Biophys, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Fromme, J. Christopher] Cornell Univ, Dept Mol Biol & Genet, Weill Inst Cell & Mol Biol, Ithaca, NY 14853 USA.
[Garcia, K. Christopher] Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA.
[Garcia, K. Christopher] Stanford Univ, Dept Mol & Cellular Physiol, Sch Med, Stanford, CA 94305 USA.
[Garcia, K. Christopher] Stanford Univ, Dept Biol Struct, Sch Med, Stanford, CA 94305 USA.
[Gaudet, Rachelle] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Gong, Peng] Chinese Acad Sci, Key Lab Special Pathogens & Biosafety, Wuhan Inst Virol, Wuhan 430071, Peoples R China.
[Harrison, Stephen C.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Harrison, Stephen C.] Harvard Univ, Mol Med Lab, Boston Childrens Hosp, Sch Med, Boston, MA 02115 USA.
[Heldwein, Ekaterina E.] Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.
[Jia, Zongchao] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON K7M 3G5, Canada.
[Kvansakul, Marc] La Trobe Univ, Dept Biochem & Genet, Melbourne, Vic, Australia.
[McLellan, Jason S.] Geisel Sch Med Dartmouth, Dept Biochem, Hanover, NH 03755 USA.
[Modis, Yorgo] Univ Cambridge, Dept Med, MRC Lab Mol Biol, Francis Crick Ave, Cambridge CB2 0QH, England.
[Nam, Yunsun] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Pai, Emil F.] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.
[Pai, Emil F.] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada.
[Pai, Emil F.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada.
[Pai, Emil F.] Univ Hlth Network, Ontario Canc Inst, Campbell Family Inst Canc Res, Toronto, ON M5G 2M9, Canada.
[Barbosa Pereira, Pedro Jose] Univ Porto, Inst Biol Mol & Celular, P-4150 Oporto, Portugal.
[Barbosa Pereira, Pedro Jose] Univ Porto, Inst Invest & Inovacao Saude, P-4150 Oporto, Portugal.
[Petosa, Carlo] Univ Grenoble Alpes, CNRS, CFA, Inst Biol Struct, F-38027 Grenoble, France.
[Raman, S.] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
[Rapoport, Tom A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Rapoport, Tom A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Roll-Mecak, Antonina] Natl Inst Neurol Disorders & Stroke, Cell Biol & Biophys Unit, Porter Neurosci Res Ctr, Bethesda, MD 20892 USA.
[Roll-Mecak, Antonina] NHLBI, Bethesda, MD 20892 USA.
[Rosen, Michael K.] Univ Texas SW Med Ctr Dallas, Dept Biophys, Dallas, TX 75390 USA.
[Rosen, Michael K.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.
[Rudenko, Gabby] Univ Texas Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.
[Schlessinger, Joseph] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
[Schwartz, Thomas U.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Shamoo, Yousif; Tao, Yizhi J.] Rice Univ, Dept Biosci, Houston, TX 77005 USA.
[Sondermann, Holger] Cornell Univ, Dept Mol Med, Coll Vet Med, Ithaca, NY 14853 USA.
[Tolia, Niraj H.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
[Tsodikov, Oleg V.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
[Westover, Kenneth D.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.
[Westover, Kenneth D.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.
[Wu, Hao; Kirchhausen, Tom] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Foster, Ian] Argonne Natl Lab, Math & Comp Sci Div, 9700 S Cass Ave, Argonne, IL 60439 USA.
[Foster, Ian] Univ Chicago, Dept Comp Sci, Chicago, IL 60637 USA.
[Fraser, James S.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94158 USA.
[Maia, Filipe R. N. C.] Uppsala Univ, Lab Mol Biophys, Dept Cell & Mol Biol, Husargatan 3,Box 596, SE-75124 Uppsala, Sweden.
[Maia, Filipe R. N. C.] Lawrence Berkeley Natl Lab, NERSC, Berkeley, CA 94720 USA.
[Gonen, Tamir] Howard Hughes Med Inst, Janelia Res Campus, Ashburn, VA 20147 USA.
[Kirchhausen, Tom] Boston Childrens Hosp, Dept Pediat, Boston, MA 02115 USA.
[Kirchhausen, Tom] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Kirchhausen, Tom] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Diederichs, Kay] Univ Konstanz, Dept Biol, D-78457 Constance, Germany.
[Crosas, Merce] Harvard Univ, Inst Quantitat Social Sci, Cambridge, MA 02138 USA.
RP Sliz, P (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM sliz@hkl.hms.harvard.edu
RI Bonvin, Alexandre/A-5420-2009; Borek, Dominika/D-2943-2011; Pereira,
Pedro/F-8972-2011;
OI Bonvin, Alexandre/0000-0001-7369-1322; Gaudet,
Rachelle/0000-0002-9177-054X; Borek, Dominika/0000-0002-4321-6253;
Pereira, Pedro/0000-0003-0969-5438; Corbett, Kevin/0000-0001-5854-2388;
Modis, Yorgo/0000-0002-6084-0429; Fraser, James/0000-0002-5080-2859;
Pai, Emil/0000-0002-1162-7242; Kvansakul, Marc/0000-0003-2639-2498
FU Leona M. and Harry B. Helmsley Charitable Trust [2016PG-BRI002]; NSF
[1448069]; NIH [P41 GM103403, 1S10RR028832, 1U54EB020406-01]; DOE
[DE-AC02-06CH11357]; NIST [60NANB15D077]
FX Development of the Structural Biology Data Grid is funded by The Leona
M. and Harry B. Helmsley Charitable Trust 2016PG-BRI002 to PS and MC.
Development of citation workflows is supported NSF 1448069 (to PS). DAA
is being developed as a pilot project of the National Data Service, with
additional funds to support storage and technology development,
including NIH P41 GM103403 (NE-CAT) and 1S10RR028832 (HMS) and DOE
DE-AC02-06CH11357; NIH 1U54EB020406-01, Big Data for Discovery Science
Center; and NIST 60NANB15D077 (Globus Project). AB acknowledges Ariel
Chaparro for assistance with the DAA setup (Inst Pasteur Montevideo).
Collections of pilot data sets were supported by various grants (see
Supplementary Table 1).
NR 52
TC 12
Z9 12
U1 3
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10882
DI 10.1038/ncomms10882
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF9YS
UT WOS:000371719200001
PM 26947396
ER
PT J
AU Soh, BS
Ng, SY
Wu, H
Buac, K
Park, JHC
Lian, XJ
Xu, JJ
Foo, KS
Felldin, U
He, XB
Nichane, M
Yang, H
Bu, L
Li, RA
Lim, B
Chien, KR
AF Soh, Boon-Seng
Ng, Shi-Yan
Wu, Hao
Buac, Kristina
Park, Joo-Hye C.
Lian, Xiaojun
Xu, Jiejia
Foo, Kylie S.
Felldin, Ulrika
He, Xiaobing
Nichane, Massimo
Yang, Henry
Bu, Lei
Li, Ronald A.
Lim, Bing
Chien, Kenneth R.
TI Endothelin-1 supports clonal derivation and expansion of cardiovascular
progenitors derived from human embryonic stem cells
SO NATURE COMMUNICATIONS
LA English
DT Article
ID IN-VITRO EXPANSION; SMOOTH-MUSCLE; SELF-RENEWAL; HEART; DIFFERENTIATION;
PERICYTES; MICE; REGENERATION; MAINTENANCE; POPULATION
AB Coronary arteriogenesis is a central step in cardiogenesis, requiring coordinated generation and integration of endothelial cell and vascular smooth muscle cells. At present, it is unclear whether the cell fate programme of cardiac progenitors to generate complex muscular or vascular structures is entirely cell autonomous. Here we demonstrate the intrinsic ability of vascular progenitors to develop and self-organize into cardiac tissues by clonally isolating and expanding second heart field cardiovascular progenitors using WNT3A and endothelin-1 (EDN1) human recombinant proteins. Progenitor clones undergo long-term expansion and differentiate primarily into endothelial and smooth muscle cell lineages in vitro, and contribute extensively to coronary-like vessels in vivo, forming a functional human-mouse chimeric circulatory system. Our study identifies EDN1 as a key factor towards the generation and clonal derivation of ISL1(+) vascular intermediates, and demonstrates the intrinsic cell-autonomous nature of these progenitors to differentiate and self-organize into functional vasculatures in vivo.
C1 [Soh, Boon-Seng; Wu, Hao; Buac, Kristina; Park, Joo-Hye C.; Bu, Lei] Massachusetts Gen Hosp, Cardiovasc Res Ctr, 185 Cambridge St, Boston, MA 02114 USA.
[Soh, Boon-Seng; Ng, Shi-Yan; Wu, Hao; Buac, Kristina; Park, Joo-Hye C.; Bu, Lei; Chien, Kenneth R.] Harvard Univ, Dept Stem Cell & Regenerat Biol, 7 Divin Ave, Cambridge, MA 02138 USA.
[Soh, Boon-Seng; Bu, Lei; Li, Ronald A.] Univ Hong Kong, Li Dak Sum Res Ctr, HKU, Karolinska Inst Collaborat Regenerat Med, Hong Kong, Hong Kong, Peoples R China.
[Soh, Boon-Seng; Bu, Lei; Li, Ronald A.] Karolinska Inst, Lau Ming Wai Ctr Regenerat Med, Hong Kong, Hong Kong, Peoples R China.
[Soh, Boon-Seng; Lian, Xiaojun; Xu, Jiejia; Foo, Kylie S.; Felldin, Ulrika; He, Xiaobing; Chien, Kenneth R.] Karolinska Inst, Dept Cell & Mol Biol & Med, S-17177 Stockholm, Sweden.
[Buac, Kristina] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.
[Nichane, Massimo; Lim, Bing] Genome Inst Singapore, Stem Cell & Dev Biol, Genome, 60 Biopolis St 02-01, Singapore 138672, Singapore.
[Yang, Henry] Natl Univ Singapore, Canc Inst Singapore, 28 Med Dr, Singapore 117456, Singapore.
[Soh, Boon-Seng] Proteos, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.
RP Chien, KR (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, 7 Divin Ave, Cambridge, MA 02138 USA.; Chien, KR (reprint author), Karolinska Inst, Dept Cell & Mol Biol & Med, S-17177 Stockholm, Sweden.
EM kenneth.chien@ki.se
OI Lian, Xiaojun/0000-0002-9161-1004
FU Research Grant Council of HKSAR [T13-706/11]
FX This work was supported in part by the Research Grant Council of HKSAR
(T13-706/11).
NR 50
TC 3
Z9 3
U1 9
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10774
DI 10.1038/ncomms10774
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG0AB
UT WOS:000371722900001
PM 26952167
ER
PT J
AU Ingelfinger, JR
Kalantar-Zadeh, K
Schaefer, F
AF Ingelfinger, Julie R.
Kalantar-Zadeh, Kamyar
Schaefer, Franz
CA World Kidney Day Steering Comm
TI Averting the legacy of kidney disease: focus on childhood
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
ID NEPHROLOGY ASSOCIATION IPNA; RENAL REPLACEMENT THERAPY;
LOW-BIRTH-WEIGHT; NONCOMMUNICABLE DISEASES; INTERNATIONAL SOCIETY;
CONSENSUS STATEMENT; PROSPECTIVE COHORT; GLOBAL HEALTH; CHILDREN;
EPIDEMIOLOGY
AB Until recently, the WHO consensus statement on non-communicable diseases (NCD) included cardiovascular disease, cancer, diabetes and chronic respiratory disease, but not kidney disease. Fortunately, the Political Declaration on NCDs from the United Nations Summit in 2011 mentioned kidney disease under Item 19.35.
C1 [Ingelfinger, Julie R.] Harvard Univ, Sch Med, Boston, MA USA.
[Ingelfinger, Julie R.] Massachusetts Gen Hosp, Massachusetts Gen Hosp Children, Boston, MA 02114 USA.
[Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Sch Med, Pediat & Publ Hlth, Irvine, CA 92717 USA.
[Kalantar-Zadeh, Kamyar] VA Long Beach Healthcare Syst, Long Beach, CA USA.
[Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA.
[Schaefer, Franz] Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Heidelberg, Germany.
RP Ingelfinger, JR (reprint author), Int Federat Kidney Fdn, Int Soc Nephrol, World Kidney Day, Rues Fabriques 1B, B-1000 Brussels, Belgium.
OI Kalantar-Zadeh, Kamyar/0000-0002-8666-0725
NR 33
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAR
PY 2016
VL 31
IS 3
BP 327
EP 331
DI 10.1093/ndt/gfw003
PG 5
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA DF7EU
UT WOS:000371521400001
PM 26908830
ER
PT J
AU O'Hare, AM
Rodriguez, RA
Bowling, CB
AF O'Hare, Ann M.
Rodriguez, Rudolph A.
Bowling, Christopher Barrett
TI Caring for patients with kidney disease: shifting the paradigm from
evidence-based medicine to patient-centered care
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Review
DE evidence-based medicine; patient-centered care; kidney disease; older
adults; paradigm
ID MULTIPLE CHRONIC CONDITIONS; SHARED DECISION-MAKING; QUALITY-OF-CARE;
CLINICAL-PRACTICE GUIDELINES; STAGE RENAL-DISEASE; OLDER-ADULTS;
UNITED-STATES; HEALTH-CARE; BLOOD-PRESSURE; TRIALS
AB The last several decades have witnessed the emergence of evidence-based medicine as the dominant paradigm for medical teaching, research and practice. Under an evidence-based approach, populations rather than individuals become the primary focus of investigation. Treatment priorities are largely shaped by the availability, relevance and quality of evidence and study outcomes and results are assumed to have more or less universal significance based on their implications at the population level. However, population-level treatment goals do not always align with what matters the most to individual patients-who may weigh the risks, benefits and harms of recommended treatments quite differently. In this article we describe the rise of evidence-based medicine in historical context. We discuss limitations of this approach for supporting real-world treatment decisions-especially in older adults with confluent comorbidity, functional impairment and/or limited life expectancy-and we describe the emergence of more patient-centered paradigms to address these limitations. We explain how the principles of evidence-based medicine have helped to shape contemporary approaches to defining, classifying and managing patients with chronic kidney disease. We discuss the limitations of this approach and the potential value of a more patient-centered paradigm, with a particular focus on the care of older adults with this condition. We conclude by outlining ways in which the evidence-base might be reconfigured to better support real-world treatment decisions in individual patients and summarize relevant ongoing initiatives.
C1 [O'Hare, Ann M.; Rodriguez, Rudolph A.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA.
[O'Hare, Ann M.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA.
[O'Hare, Ann M.; Rodriguez, Rudolph A.] Univ Washington, Dept Med, Seattle, WA USA.
[Bowling, Christopher Barrett] Atlanta VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA USA.
[Bowling, Christopher Barrett] Emory Univ, Dept Med, Atlanta, GA 30322 USA.
RP O'Hare, AM (reprint author), VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA.; O'Hare, AM (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA.; O'Hare, AM (reprint author), Univ Washington, Dept Med, Seattle, WA USA.
EM ann.ohare@va.gov
FU NIH [1U01DK102150-01]; US Department of Veterans Affairs
[1I01HX000961-01, 1IK2CX000856-01A1]; CDC [IAA 14FED1405094-0001];
National Institute on Aging [R03AG042336-01]; T. Franklin Williams
Scholarship Award (Atlantic Philanthropies, Inc.); T. Franklin Williams
Scholarship Award (John A. Hartford Foundation); T. Franklin Williams
Scholarship Award (Association of Specialty Professors); T. Franklin
Williams Scholarship Award (American Society of Nephrology); T. Franklin
Williams Scholarship Award (American Geriatrics Society)
FX A.M.O. receives research funding from the NIH (1U01DK102150-01), the US
Department of Veterans Affairs (1I01HX000961-01) and the CDC (IAA
14FED1405094-0001). She receives an honorarium from UpToDate. C.B.B.
receives funding from the National Institute on Aging (R03AG042336-01)
and the T. Franklin Williams Scholarship Award (funding provided by
Atlantic Philanthropies, Inc., the John A. Hartford Foundation, the
Association of Specialty Professors, the American Society of Nephrology
and the American Geriatrics Society) and the US Department of Veterans
Affairs (1IK2CX000856-01A1).
NR 89
TC 3
Z9 3
U1 5
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAR
PY 2016
VL 31
IS 3
BP 368
EP 375
DI 10.1093/ndt/gfv003
PG 8
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA DF7EU
UT WOS:000371521400007
PM 25637639
ER
PT J
AU Bedlack, RS
Vaughan, T
Wicks, P
Heywood, J
Sinani, E
Selsov, R
Macklin, EA
Schoenfeld, D
Cudkowicz, M
Sherman, A
AF Bedlack, Richard S.
Vaughan, Timothy
Wicks, Paul
Heywood, Jamie
Sinani, Ervin
Selsov, Roger
Macklin, Eric A.
Schoenfeld, David
Cudkowicz, Merit
Sherman, Alex
TI How common are ALS plateaus and reversals?
SO NEUROLOGY
LA English
DT Article
ID FUNCTIONAL RATING-SCALE; CLINICAL-TRIALS
AB Objective:
To determine the frequency of amyotrophic lateral sclerosis (ALS) plateaus and reversals in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.
Methods:
We analyzed Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) and ALSFRS-revised (ALSFRS-R) data from PRO-ACT participants. The frequencies of participants experiencing plateaus (periods where scores did not change) were calculated over 6-, 12-, and 18-month epochs. The percentage of participants ever experiencing reversals (periods where scores improved) of different lengths were also calculated and plotted.
Results:
Over 6 months, 25% of 3,132 participants did not decline. Over 12 months, 16% of 2,105 participants did not decline. Over 18 months, 7% of 1,218 participants did not decline. Small ALS reversals were also common, especially over shorter follow-up intervals; 14% of 1,343 participants had a 180-day interval where their ALSFRS-R slope was greater than zero. Fewer than 1% of participants ever experienced improvements of 4 or more ALSFRS-R points lasting at least 12 months.
Conclusion:
ALS plateaus and small reversals are common, especially over brief intervals. In light of these data, stable disease, especially for a short period of time, should not be interpreted as an ALS treatment effect. Large sustained ALS reversals, on the other hand, are rare, potentially important, and warrant further study.
C1 [Bedlack, Richard S.] Duke Univ, Dept Neurol, Durham, NC USA.
[Bedlack, Richard S.] Durham VA Med Ctr, Durham, NC USA.
[Vaughan, Timothy; Wicks, Paul; Heywood, Jamie] PatientsLikeMe, Cambridge, MA USA.
[Sinani, Ervin; Selsov, Roger; Macklin, Eric A.; Schoenfeld, David; Cudkowicz, Merit; Sherman, Alex] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Macklin, Eric A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Bedlack, RS (reprint author), Duke Univ, Dept Neurol, Durham, NC USA.; Bedlack, RS (reprint author), Durham VA Med Ctr, Durham, NC USA.
EM Bedla001@mc.duke.edu
OI Macklin, Eric/0000-0003-1618-3502
FU LVH ALS Foundation; Abbvie; Accorda; Actelion; Amgen; AstraZeneca;
Avanir; Biogen; Boehringer Ingelheim; Genentech; Genzyme; Janssen;
Johnson Johnson; Merck; Novartis; Sanofi; UCB; Kaiser Permanente; Robert
Wood Johnson Foundation; Sage Bionetworks; AKU Society; University of
Maryland
FX Supported by the LVH ALS Foundation. The PatientsLikeMe Research Team
has received research funding (including conference support and
consulting fees) from Abbvie, Accorda, Actelion, Amgen, AstraZeneca,
Avanir, Biogen, Boehringer Ingelheim, Genentech, Genzyme, Janssen,
Johnson & Johnson, Merck, Novartis, Sanofi, and UCB. The PatientsLikeMe
R&D team has received research grant funding from Kaiser Permanente, the
Robert Wood Johnson Foundation, Sage Bionetworks, The AKU Society, and
the University of Maryland.
NR 8
TC 10
Z9 10
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 1
PY 2016
VL 86
IS 9
BP 808
EP 812
DI 10.1212/WNL.0000000000002251
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA DF4TA
UT WOS:000371342400004
PM 26658909
ER
PT J
AU Barnett, PG
Jeffers, A
Smith, MW
Chow, BK
McFall, M
Saxon, AJ
AF Barnett, Paul G.
Jeffers, Abra
Smith, Mark W.
Chow, Bruce K.
McFall, Miles
Saxon, Andrew J.
TI Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic
Stress Disorder Treatment
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID QUALITY-OF-LIFE; SMOKING-CESSATION; VIETNAM VETERANS; ECONOMIC
EVALUATIONS; CIGARETTE-SMOKING; MENTAL-ILLNESS; FORMER SMOKERS;
HEALTH-CARE; MORTALITY; POPULATION
AB We examined the cost-effectiveness of smoking cessation integrated with treatment for post-traumatic stress disorder (PTSD).
Smoking veterans receiving care for PTSD (N = 943) were randomized to care integrated with smoking cessation versus referral to a smoking cessation clinic. Smoking cessation services, health care cost and utilization, quality of life, and biochemically-verified abstinence from cigarettes were assessed over 18-months of follow-up. Clinical outcomes were combined with literature on changes in smoking status and the effect of smoking on health care cost, mortality, and quality of life in a Markov model of cost-effectiveness over a lifetime horizon. We discounted cost and outcomes at 3% per year and report costs in 2010 US dollars.
The mean of smoking cessation services cost was $1286 in those randomized to integrated care and $551 in those receiving standard care (P < .001). There were no significant differences in the cost of mental health services or other care. After 12 months, prolonged biochemically verified abstinence was observed in 8.9% of those randomized to integrated care and 4.5% of those randomized to standard care (P = .004). The model projected that Integrated Care added $836 in lifetime cost and generated 0.0259 quality adjusted life years (QALYs), an incremental cost-effectiveness ratio of $32 257 per QALY. It was 86.0% likely to be cost-effective compared to a threshold of $100 000/QALY.
Smoking cessation integrated with treatment for PTSD was cost-effective, within a broad confidence region, but less cost-effective than most other smoking cessation programs reported in the literature.
C1 [Barnett, Paul G.] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA.
[Barnett, Paul G.] Univ Calif San Francisco, Dept Psychiat, Treatment Res Ctr, San Francisco, CA 94143 USA.
[Jeffers, Abra] Stanford Univ, Dept Management Sci & Engn, Stanford, CA 94305 USA.
[Smith, Mark W.] Truven Hlth Analyt, Bethesda, MD USA.
[Chow, Bruce K.] Vet Affairs Cooperat Studies Program Coordinating, Palo Alto, CA USA.
[McFall, Miles; Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Barnett, PG (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA.
EM paul.barnett@va.gov
FU Cooperative Studies Program; National Institute on Drug Abuse [P50
DA09253]
FX This research was supported by the Cooperative Studies Program and grant
P50 DA09253 from the National Institute on Drug Abuse. Trial
registration: http://ClinicalTrials.gov identifier: NCT00118534.
NR 49
TC 0
Z9 0
U1 3
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
EI 1469-994X
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD MAR
PY 2016
VL 18
IS 3
BP 267
EP 274
DI 10.1093/ntr/ntv094
PG 8
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA DF8HP
UT WOS:000371598600006
PM 25943761
ER
PT J
AU Kaufman, AR
Koblitz, AR
Persoskie, A
Ferrer, RA
Klein, WMP
Dwyer, LA
Park, ER
AF Kaufman, Annette R.
Koblitz, Amber R.
Persoskie, Alexander
Ferrer, Rebecca A.
Klein, William M. P.
Dwyer, Laura A.
Park, Elyse R.
TI Factor Structure and Stability of Smoking-Related Health Beliefs in the
National Lung Screening Trial
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID CANCER-RISK PERCEPTIONS; QUIT SMOKING; SMOKERS; SUSCEPTIBILITY;
INTENTIONS; BEHAVIOR; WOMEN; WORRY; PARTICIPANTS; ASSOCIATION
AB Absolute and comparative risk perceptions, worry, perceived severity, perceived benefits, and self-efficacy are important theoretical determinants of tobacco use, but no measures have been validated to ensure the discriminant validity as well as test-retest reliability of these measures in the tobacco context. The purpose of the current study is to examine the reliability and factor structure of a measure assessing smoking-related health cognitions and emotions in a national sample of current and former heavy smokers in the National Lung Screening Trial.
A sub-study of the National Lung Screening Trial assessed current and former smokers' (age 55-74; N = 4379) self-reported health cognitions and emotions at trial enrollment and at 12-month follow-up. Items were derived from the Health Belief Model and Self-Regulation Model.
An exploratory factor analysis of baseline responses revealed a five-factor structure for former smokers (risk perceptions, worry, perceived severity, perceived benefits, and self-efficacy) and a six-factor structure for current smokers, such that absolute risk and comparative risk perceptions emerged as separate factors. A confirmatory factor analysis of 12-month follow-up responses revealed a good fit for the five latent constructs for former smokers and six latent constructs for current smokers. Longitudinal stability of these constructs was also demonstrated.
This is the first study to examine tobacco-related health cognition and emotional constructs over time in current and former heavy smokers undergoing lung screening. This study found that the theoretical constructs were stable across time and that the factor structure differed based on smoking status (current vs. former).
C1 [Kaufman, Annette R.] NCI, Tobacco Control Res Branch, Behav Res Program, Div Canc Control & Populat Sci, Rockville, MD USA.
[Koblitz, Amber R.; Persoskie, Alexander; Klein, William M. P.] NCI, Behav Res Program, Div Canc Control & Populat Sci, Rockville, MD USA.
[Ferrer, Rebecca A.] NCI, Basic Biobehav & Psychol Sci Branch, Behav Res Program, Div Canc Control & Populat Sci, Rockville, MD USA.
[Dwyer, Laura A.] NCI, Hlth Behav Res Branch, Behav Res Program, Div Canc Control & Populat Sci, Rockville, MD USA.
[Park, Elyse R.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Park, Elyse R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Kaufman, AR (reprint author), Natl Canc Inst, Tobacco Control Res Branch, Behav Res Program, Div Canc Control & Populat Sci,NIH, 9609 Med Ctr Dr,3-E-546, Rockville, MD 20850 USA.
EM kaufmana@mail.nih.gov
FU American Cancer Society Mentored Research Scholar Award
[MRSG-005-05-CPPB]; National Cancer Institute [U01 CA079778, U01
CA080098]
FX This work was funded by an American Cancer Society Mentored Research
Scholar Award (MRSG-005-05-CPPB) to ERP, and the American College of
Radiology Imaging Network (ACRIN) received funding from the National
Cancer Institute through the grants U01 CA079778 and U01 CA080098.
NR 50
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
EI 1469-994X
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD MAR
PY 2016
VL 18
IS 3
BP 321
EP 329
DI 10.1093/ntr/ntv091
PG 9
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA DF8HP
UT WOS:000371598600013
PM 25964503
ER
PT J
AU Hartman, ML
Goodson, JM
Barake, R
Alsmadi, O
Al-Mutawa, S
Ariga, J
Soparkar, P
Behbehani, J
Behbehani, K
AF Hartman, Mor-Li
Goodson, J. Max
Barake, Roula
Alsmadi, Osama
Al-Mutawa, Sabiha
Ariga, Jitendra
Soparkar, Pramod
Behbehani, Jawad
Behbehani, Kazem
TI Salivary Biomarkers in Pediatric Metabolic Disease Research
SO PEDIATRIC ENDOCRINOLOGY REVIEWS PER
LA English
DT Article
DE Saliva; Biomarkers; Obesity; Type 2 Diabetes; Adolescence; Children;
Metabolic disease; Hormones; Cytokines; Antioxidants
ID C-REACTIVE PROTEIN; CARDIOVASCULAR RISK-FACTORS; INSULIN-RESISTANCE;
ADIPONECTIN LEVELS; OXIDATIVE STRESS; CORTISOL; CHILDREN; OBESITY;
INFLAMMATION; DIAGNOSTICS
AB The increasing prevalence of childhood obesity and obesity-related metabolic disorders is now considered a global pandemic. The main goal of the pediatric obesity research community is to identify children who are at risk of becoming obese before their body mass index rises above age norms. To do so, we must identify biomarkers of metabolic health and immunometabolism that can be used for large-scale; Screening and diagnosis initiatives among at-risk children. Because blood sampling is often unacceptable to both parents and children when there is no direct benefit to the child, as in a community-based research study, there is a clear need for a low-risk, non-invasive sampling strategy. Salivary analysis is now well recognized as a likely candidate for this purpose. In this review, we discuss the physiologic role of saliva and its strengths and limitations as a fluid for biomarker discovery, obesity screening, metabolic disease diagnosis, and response monitoring after interventions. We also describe the current state of the salivary biomarker field as it pertains to metabolic research, With a special emphasis on studies conducted in children and adolescents. Finally, we took forward to technological developments, such as salivary "omics" and point:of service diagnostic devices, which have the potential to accelerate the pace of research and discovery in this vitally important field.
C1 [Hartman, Mor-Li; Goodson, J. Max; Soparkar, Pramod] Forsyth Inst, Dept Appl Oral Sci, 245 First St, Cambridge, MA 02142 USA.
[Barake, Roula; Alsmadi, Osama; Behbehani, Kazem] Dasman Diabet Inst, Dasman, Kuwait.
[Al-Mutawa, Sabiha; Ariga, Jitendra] Minist Hlth, Kuwait, Kuwait.
[Behbehani, Jawad] Kuwait Univ, Fac Dent, Kuwait, Kuwait.
RP Hartman, ML (reprint author), Forsyth Inst, 245 First St, Cambridge, MA 02142 USA.
EM mhartman@forsyth.org
FU Dasman Diabetes Institute, Kuwait
FX The authors were supported in part by a grant from the Dasman Diabetes
Institute, Kuwait. The authors confirm independence from the funding
source.
NR 74
TC 1
Z9 1
U1 1
U2 12
PU MEDICAL MEDIA
PI NETANYA
PA PO BOX 8214, NETANYA, 4250543, ISRAEL
SN 1565-4753
J9 PEDIATR ENDOCR REV P
JI Pediatr. Endocrinol. Rev. PER
PD MAR
PY 2016
VL 13
IS 3
BP 602
EP 611
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DF8ZQ
UT WOS:000371650400005
PM 27116847
ER
PT J
AU Farvid, MS
Eliassen, AH
Cho, E
Liao, XM
Chen, WY
Willett, WC
AF Farvid, Maryam S.
Eliassen, A. Heather
Cho, Eunyoung
Liao, Xiaomei
Chen, Wendy Y.
Willett, Walter C.
TI Dietary Fiber Intake in Young Adults and Breast Cancer Risk
SO PEDIATRICS
LA English
DT Article
ID PROSPECTIVE COHORT; GLYCEMIC INDEX; PREMENOPAUSAL WOMEN;
PHYSICAL-ACTIVITY; POSTMENOPAUSAL WOMEN; MEASUREMENT-ERROR; ADOLESCENT
DIET; LIFE-STYLE; FAT; ESTROGEN
AB OBJECTIVE: We evaluated fiber intake during adolescence and early adulthood in relation to breast cancer (BC) risk in the Nurses' Health Study II.
METHODS: Among 90 534 premenopausal women who completed a dietary questionnaire in 1991, we documented 2833 invasive BC cases during 20 years of follow-up. In 1998, 44 263 of these women also completed a questionnaire about their diet during high school; among these women, we documented 1118 cases of BC by end of follow-up. Multivariable-adjusted Cox proportional hazards regression was used to model relative risks (RRs) and 95% confidence intervals (CIs) for BC across categories of dietary fiber.
RESULTS: Among all women, early adulthood total dietary fiber intake was associated with significantly lower BC risk (RR for highest versus lowest quintile 0.81; 95% CI 0.72-0.91; P-trend = .002). Higher intakes of soluble fiber (RR for highest versus lowest quintile 0.86; 95% CI 0.77-0.97; P-trend = .02) and insoluble fiber (RR for highest versus lowest quintile 0.80; 95% CI 0.71-0.90; P-trend <. 001) were each associated with lower BC risk. Total dietary fiber intake in adolescence was also associated with lower BC risk (RR for highest versus lowest quintile 0.84; 95% CI 0.70-1.01; P-trend = .04). For the average of fiber intake during adolescence and early adult life, the RR comparing highest with lowest quintiles was 0.75 (95% CI 0.62-0.91, P(tren)d =.004).
CONCLUSIONS: Our findings support the hypothesis that higher fiber intakes reduce BC risk and suggest that intake during adolescence and early adulthood may be particularly important.
C1 [Farvid, Maryam S.; Willett, Walter C.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Eliassen, A. Heather; Liao, Xiaomei; Willett, Walter C.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Liao, Xiaomei] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Eliassen, A. Heather; Cho, Eunyoung; Liao, Xiaomei; Chen, Wendy Y.; Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Eliassen, A. Heather; Cho, Eunyoung; Liao, Xiaomei; Chen, Wendy Y.; Willett, Walter C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Cho, Eunyoung] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA.
[Chen, Wendy Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Farvid, MS (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM mfarvid@hsph.harvard.edu
FU NIH [R01 CA050385, UM1 CA176726]; Breast Cancer Research Foundation;
Japan Pharmaceutical Manufacturers Association; National Institutes of
Health (NIH)
FX The study was supported by NIH grants (R01 CA050385, UM1 CA176726) and a
grant from the Breast Cancer Research Foundation. Dr Farvid was
supported by the Japan Pharmaceutical Manufacturers Association. Funded
by the National Institutes of Health (NIH).
NR 56
TC 7
Z9 7
U1 8
U2 12
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2016
VL 137
IS 3
AR e20151226
DI 10.1542/peds.2015-1226
PG 11
WC Pediatrics
SC Pediatrics
GA DF5MK
UT WOS:000371395800011
PM 26908709
ER
PT J
AU Hillis, S
Mercy, J
Amobi, A
Kress, H
AF Hillis, Susan
Mercy, James
Amobi, Adaugo
Kress, Howard
TI Global Prevalence of Past-year Violence Against Children: A Systematic
Review and Minimum Estimates
SO PEDIATRICS
LA English
DT Review
ID ADVERSE CHILDHOOD EXPERIENCES; SECONDARY-SCHOOL STUDENTS; INTIMATE
PARTNER VIOLENCE; SEXUAL VIOLENCE; BULLYING VICTIMIZATION; CORPORAL
PUNISHMENT; INCOME COUNTRIES; CONTROLLED-TRIAL; NATIONAL SAMPLE;
UNITED-STATES
AB CONTEXT: Evidence confirms associations between childhood violence and major causes of mortality in adulthood. A synthesis of data on past-year prevalence of violence against children will help advance the United Nations' call to end all violence against children.
OBJECTIVES: Investigators systematically reviewed population-based surveys on the prevalence of past-year violence against children and synthesized the best available evidence to generate minimum regional and global estimates.
DATA SOURCES: We searched Medline, PubMed, Global Health, NBASE, CINAHL, and the World Wide Web for reports of representative surveys estimating prevalences of violence against children.
STUDY SELECTION: Two investigators independently assessed surveys against inclusion criteria and rated those included on indicators of quality.
DATA EXTRACTION: Investigators extracted data on past-year prevalences of violent victimization by country, age group, and type (physical, sexual, emotional, or multiple types). We used a triangulation approach which synthesized data to generate minimum regional prevalences, derived from population-weighted averages of the country-specific prevalences.
RESULTS: Thirty-eight reports provided quality data for 96 countries on past-year prevalences of violence against children. Base case estimates showed a minimum of 50% or more of children in Asia, Africa, and Northern America experienced past-year violence, and that globally over half of all children-1 billion children, ages 2-17 years-experienced such violence.
LIMITATIONS: Due to variations in timing and types of violence reported, triangulation could only be used to generate minimum prevalence estimates.
CONCLUSIONS: Expanded population-based surveillance of violence against children is essential to target prevention and drive the urgent investment in action endorsed in the United Nations 2030 Sustainable Development Agenda.
C1 [Hillis, Susan] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA.
[Mercy, James; Kress, Howard] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Amobi, Adaugo] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
RP Hillis, S (reprint author), Ctr Dis Control & Prevent, US Publ Hlth Serv, Natl Ctr Injury Prevent & Control, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM shillis@cdc.gov
RI Figueroa Ossa, Ulda Omar/N-5821-2016
NR 92
TC 10
Z9 11
U1 6
U2 14
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2016
VL 137
IS 3
AR e20154079
DI 10.1542/peds.2015-4079
PG 13
WC Pediatrics
SC Pediatrics
GA DF5MK
UT WOS:000371395800062
PM 26810785
ER
PT J
AU Raffetto, JD
AF Raffetto, Joseph D.
TI Pathophysiology of wound healing and alterations in venous leg
ulcers-review
SO PHLEBOLOGY
LA English
DT Review
DE Venous leg ulcer; wound; wound healing; fibroblasts; inflammation;
endothelial cells; glycocalyx; leukocytes; macrophages; chemokines;
cytokines; growth factors; collagen; extracellular matrix; matrix
metalloproteinases; iron; free radical; oxidative stress
ID MATRIX-METALLOPROTEINASE ACTIVITY; INFLAMMATORY PATHWAYS; COMPRESSION
THERAPY; DISEASE; TISSUE; INSUFFICIENCY; ULCERATION; GLYCOSAMINOGLYCANS;
GELATINASE; REPAIR
AB Venous leg ulcer (VLU) is one of the most common lower extremity ulcerated wound, and is a significant healthcare problem with implications that affect social, economic, and the well-being of a patient. VLU can have debilitating related problems which require weekly medical care and may take months to years to heal. The pathophysiology of VLU is complex, and healing is delayed in many patients due to a persistent inflammatory condition. Patient genetic and environmental factors predispose individuals to chronic venous diseases including VLU. Changes in shear stress affecting the glycocalyx are likely initiating events, leading to activation of adhesion molecules on endothelial cells, and leukocyte activation with attachment and migration into vein wall, microcirculation, and in the interstitial space. Multiple chemokines, cytokines, growth factors, proteases and matrix metalloproteinases are produced. The pathology of VLU involves an imbalance of inflammation, inflammatory modulators, oxidative stress, and proteinase activity. Understanding the cellular and biochemical events that lead to the progression of VLU is critical. With further understanding of inflammatory pathways and potential mechanisms, certain biomarkers could be revealed and studied as both involvement in the pathophysiology of VLU but also as therapeutic targets for VLU healing.
C1 [Raffetto, Joseph D.] Boston VA Hlth Care Syst, Vasc Surg, Boston, MA USA.
[Raffetto, Joseph D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Raffetto, Joseph D.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Raffetto, JD (reprint author), VA Boston Hlth Care Syst, Surg 112,1400 VFW Pkwy, Boston, MA 02132 USA.
EM joseph.raffetto@med.va.gov
NR 24
TC 0
Z9 0
U1 7
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0268-3555
EI 1758-1125
J9 PHLEBOLOGY
JI Phlebology
PD MAR
PY 2016
VL 31
SU 1
BP 56
EP 62
DI 10.1177/0268355516632998
PG 7
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA DF8HY
UT WOS:000371599600010
PM 26916770
ER
PT J
AU Katzman, WB
Vittinghoff, E
Kado, DM
Schafer, AL
Wong, SS
Gladin, A
Lane, NE
AF Katzman, Wendy B.
Vittinghoff, Eric
Kado, Deborah M.
Schafer, Anne L.
Wong, Shirley S.
Gladin, Amy
Lane, Nancy E.
TI Study of Hyperkyphosis, Exercise and Function (SHEAF) Protocol of a
Randomized Controlled Trial of Multimodal Spine-Strengthening Exercise
in Older Adults With Hyperkyphosis
SO PHYSICAL THERAPY
LA English
DT Article
ID COMMUNITY-DWELLING MEN; OSTEOPOROTIC FRACTURES; PHYSICAL PERFORMANCE;
RANCHO-BERNARDO; THORACIC KYPHOSIS; WOMEN; POSTURE; TRUNK; VALIDATION;
GUIDELINES
AB Background. Hyperkyphosis negatively affects health status, physical mobility, and quality of life, but there is no standard protocol for treating people with hyperkyphosis. Treatment options include targeted exercise.
Objectives. This single-site randomized controlled trial (RCT) will determine the efficacy of a targeted multimodal spine-strengthening exercise program, compared with no exercise intervention, among community-dwelling men and women aged >= 60 years, with thoracic kyphosis >= 40
Design. The RCT is a parallel-group design, with 1:1 randomization to exercise and attentional control groups.
Setting. The study will be conducted at one primary site (one academic medical center partnered with one local community medical center).
Participants. One hundred men and women, aged years, with thoracic kyphosis degrees will be randomized.
Intervention. The targeted multimodal spine-strengthening exercise intervention includes exercise and postural training delivered by a physical therapist in a group of 10 participants, 3 times a week for 6 months. Controls receive monthly health education meetings in a group of 10 participants and monthly calls from the study. coordinator to monitor physical activity and any adverse events.
Measurements. The primary outcome is change in Cobb angle of kyphosis measured from lateral spine radiographs at baseline and 6 months. Secondary outcomes include change in physical function (assessed with the modified Physical Performance Test, Timed "Up & Go" Test, timed loaded standing, 4-m walk, and Six-Minute Walk Test) and health-related quality of life (assessed with the modified Scoliosis Research Society instrument [SRS-30] self-image domain and Patient Reported Outcomes Measurement Information System [PROMIS] global health and physical function indexes). Additional secondary outcomes include pain, physical activity level, spinal flexion and extension muscle strength, paraspinal extensor muscle density, and adverse events.
Limitations. Blinding of the participants and instructors providing the intervention is not possible.
Conclusions. The efficacy of a high-quality, adequately powered exercise intervention in men and women with kyphosis degrees will be evaluated to determine whether targeted multimodal spine-strengthening exercise reduces hyperkyphosis in older adults and improves important secondary outcomes of physical function and health-related quality of life.
C1 [Katzman, Wendy B.; Wong, Shirley S.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, UCSF Box 0625, San Francisco, CA 94143 USA.
[Vittinghoff, Eric; Schafer, Anne L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kado, Deborah M.] Univ Calif San Diego, Dept Family Med, San Diego, CA 92103 USA.
[Kado, Deborah M.] Univ Calif San Diego, Dept Publ Hlth, San Diego, CA 92103 USA.
[Kado, Deborah M.] Univ Calif San Diego, Dept Internal Med, San Diego, CA 92103 USA.
[Schafer, Anne L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Schafer, Anne L.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
[Gladin, Amy] Kaiser Permanente No Calif, San Francisco Med Ctr, San Francisco, CA USA.
[Lane, Nancy E.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA.
RP Katzman, WB (reprint author), Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, UCSF Box 0625, San Francisco, CA 94143 USA.
EM wendy.katzman@ucsf.edu
FU National Institute of Aging [R01-AG028]; US Department of Veterans
Affairs, Veterans Health Administration, Office of Clinical Science
Research and Development [5 IK2 CX000549]
FX The study was funded by National Institute of Aging grant R01-AG028.
Additional support was provided by the US Department of Veterans
Affairs, Veterans Health Administration, Office of Clinical Science
Research and Development, under grant 5 IK2 CX000549 (to Dr Schafer).
NR 36
TC 1
Z9 1
U1 4
U2 5
PU AMER PHYSICAL THERAPY ASSOC
PI ALEXANDRIA
PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD MAR
PY 2016
VL 96
IS 3
BP 371
EP 381
DI 10.2522/ptj.20150171
PG 11
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA DF6FV
UT WOS:000371452200013
PM 26251480
ER
PT J
AU Brune, KA
Ferreira, F
Mandke, P
Chau, E
Aggarwal, NR
D'Alessio, FR
Lambert, AA
Kirk, G
Blankson, J
Drummond, MB
Tsibris, AM
Sidhaye, VK
AF Brune, Kieran A.
Ferreira, Fernanda
Mandke, Pooja
Chau, Eric
Aggarwal, Neil R.
D'Alessio, Franco R.
Lambert, Allison A.
Kirk, Gregory
Blankson, Joel
Drummond, M. Bradley
Tsibris, Athe M.
Sidhaye, Venkataramana K.
TI HIV Impairs Lung Epithelial Integrity and Enters the Epithelium to
Promote Chronic Lung Inflammation
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BARRIER FUNCTION; E-CADHERIN; SUBTYPE-B;
IN-VIVO; INFECTION; CELLS; ICAM-1; ACTIVATION; TROPISM
AB Several clinical studies show that individuals with HIV are at an increased risk for worsened lung function and for the development of COPD, although the mechanism underlying this increased susceptibility is poorly understood. The airway epithelium, situated at the interface between the external environment and the lung parenchyma, acts as a physical and immunological barrier that secretes mucins and cytokines in response to noxious stimuli which can contribute to the pathobiology of chronic obstructive pulmonary disease (COPD). We sought to determine the effects of HIV on the lung epithelium. We grew primary normal human bronchial epithelial (NHBE) cells and primary lung epithelial cells isolated from bronchial brushings of patients to confluence and allowed them to differentiate at an air-liquid interface (ALI) to assess the effects of HIV on the lung epithelium. We assessed changes in monolayer permeability as well as the expression of E-cadherin and inflammatory modulators to determine the effect of HIV on the lung epithelium. We measured E-cadherin protein abundance in patients with HIV compared to normal controls. Cell associated HIV RNA and DNA were quantified and the p24 viral antigen was measured in culture supernatant. Surprisingly, X4, not R5, tropic virus decreased expression of E-cadherin and increased monolayer permeability. While there was some transcriptional regulation of E-cadherin, there was significant increase in lysosome-mediated protein degradation in cells exposed to X4 tropic HIV. Interaction with CXCR4 and viral fusion with the epithelial cell were required to induce the epithelial changes. X4 tropic virus was able to enter the airway epithelial cells but not replicate in these cells, while R5 tropic viruses did not enter the epithelial cells. Significantly, X4 tropic HIV induced the expression of intercellular adhesion molecule-1 (ICAM-1) and activated extracellular signal-regulated kinase (ERK). We demonstrate that HIV can enter airway epithelial cells and alter their function by impairing cell-cell adhesion and increasing the expression of inflammatory mediators. These observed changes may contribute local inflammation, which can lead to lung function decline and increased susceptibility to COPD in HIV patients.
C1 [Brune, Kieran A.; Mandke, Pooja; Chau, Eric; Aggarwal, Neil R.; D'Alessio, Franco R.; Lambert, Allison A.; Drummond, M. Bradley; Sidhaye, Venkataramana K.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
[Ferreira, Fernanda; Tsibris, Athe M.] Mass Gen Hosp, Div Infect Dis, Boston, MA USA.
[Kirk, Gregory] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Kirk, Gregory; Blankson, Joel] Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA.
RP Sidhaye, VK (reprint author), Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
EM vsidhay1@jhmi.edu
FU Johns Hopkins University Center for AIDS Research (JHU CFAR), a center
created through the NIH [P30AI094189]
FX This work was funded by Johns Hopkins University Center for AIDS
Research (JHU CFAR), a center created through the NIH P30AI094189. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 50
TC 2
Z9 2
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2016
VL 11
IS 3
AR e0149679
DI 10.1371/journal.pone.0149679
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF5ZW
UT WOS:000371434500041
PM 26930653
ER
PT J
AU Ho, CMK
Donovan-Banfield, IZ
Tan, L
Zhang, TH
Gray, NS
Strang, BL
AF Ho, Catherine M. K.
Donovan-Banfield, I'ah Z.
Tan, Li
Zhang, Tinghu
Gray, Nathanael S.
Strang, Blair L.
TI Inhibition of IKK alpha by BAY61-3606 Reveals IKK alpha-Dependent
Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; PROTEIN-KINASE UL97; EPSTEIN-BARR-VIRUS; GENE-EXPRESSION;
BINDING-SITES; UL84 PROTEIN; IE2 86; REPLICATION; ACTIVATION;
TRANSCRIPTION
AB Protein kinase inhibitors can be used as tools to identify proteins and pathways required for virus replication. Using virus replication assays and western blotting we found that the widely used protein kinase inhibitor BAY61-3606 inhibits replication of human cytomegalovirus (HCMV) strain AD169 and the accumulation of HCMV immediate-early proteins in AD169 infected cells, but has no effect on replication of HCMV strain Merlin. Using in vitro kinase assays we found that BAY61-3606 is a potent inhibitor of the cellular kinase IKK alpha. Infection of cells treated with siRNA targeting IKK alpha indicated IKK alpha was required for efficient AD169 replication and immediate-early protein production. We hypothesized that IKK alpha was required for AD169 immediate-early protein production as part of the canonical NF-kappa B signaling pathway. However, although BAY61-3606 inhibited phosphorylation of the IKK alpha substrate I kappa B alpha, we found no canonical or non-canonical NF-kappa B signaling in AD169 infected cells. Rather, we observed that treatment of cells with BAY61-3606 or siRNA targeting IKK alpha decreased phosphorylation of histone H3 at serine 10 (H3S10p) in western blotting assays. Furthermore, we found treatment of cells with BAY61-3606, but not siRNA targeting IKK alpha, inhibited the accumulation of histone H3 acetylation (H3K9ac, H3K18ac and H3K27ac) and tri-methylation (H3K27me3 and H3K36me3) modifications. Therefore, the requirement for IKK alpha in HCMV replication was strain-dependent and during replication of an HCMV strain requiring IKK alpha, IKK alpha-dependent H3S10 phosphorylation was associated with efficient HCMV replication and immediate-early protein production. Plus, inhibition of HCMV replication by BAY61-3606 is associated with acetylation and tri-methylation modifications of histone H3 that do not involve IKK alpha.
C1 [Ho, Catherine M. K.; Donovan-Banfield, I'ah Z.; Strang, Blair L.] Univ London, Inst Infect & Immun, Cranmer Terrace, London SW17 0RE, England.
[Tan, Li; Zhang, Tinghu; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Tan, Li; Zhang, Tinghu; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Longwood Ave, Boston, MA 02115 USA.
RP Strang, BL (reprint author), Univ London, Inst Infect & Immun, Cranmer Terrace, London SW17 0RE, England.
EM bstrang@sgul.ac.uk
FU St George's, University of London; St George's Impact & Innovation
Award; PARK/WestFocus Award
FX New Investigator funds from St George's, University of London, a St
George's Impact & Innovation Award and a PARK/WestFocus Award. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 52
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2016
VL 11
IS 3
AR e0150339
DI 10.1371/journal.pone.0150339
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF5ZW
UT WOS:000371434500128
PM 26930276
ER
PT J
AU Lewis, NA
Newell, J
Burden, R
Howatson, G
Pedlar, CR
AF Lewis, Nathan A.
Newell, John
Burden, Richard
Howatson, Glyn
Pedlar, Charles R.
TI Critical Difference and Biological Variation in Biomarkers of Oxidative
Stress and Nutritional Status in Athletes
SO PLOS ONE
LA English
DT Article
ID FREE OXYGEN RADICALS; C-REACTIVE PROTEIN; ALPHA-TOCOPHEROL;
BETA-CAROTENE; VITAMIN-C; EXERCISE; MUSCLE; SUPPLEMENTATION;
VARIABILITY; PERFORMANCE
AB The longitudinal monitoring of oxidative stress (OS) in athletes may enable the identification of fatigued states and underperformance. The application of OS biomarker monitoring programs in sport are hindered by reliability and repeatability of in-the-field testing tools, the turnaround of results, and the understanding of biological variation (BV). Knowledge of BV and critical difference values (CDV) may assist with data interpretation in the individual athlete. Methods: We aimed firstly to assess the repeatability of the clinical point of care redox test, Free Oxygen Radical Test (FORT) and the Free Oxygen Radical Defence (FORD) in trained participants and elite athletes and secondly to calculate the analytical, BV, CDV and index of individuality (II) for FORT, FORD, red blood cell glutathione, lutein, alpha and gamma-tocopherol. Part 1: Fifteen elite athletes were sampled in duplicate for calculation of the repeatability of the FORT and FORD tests. Part 2: Twelve well-trained athletes had venous samples drawn every 2 hours from 0800 to 1800 for calculation of BV, CDV, II for FORT, FORD, RBC GSH, lutein, alpha-tocopherol and gamma-tocopherol. Results: Repeatability of the FORT and FORD assay was 3.9% and 3.7% respectively. Biomarker CDV ranged from 12.8% to 37%, with a circadian effect for FORT, alpha-tocopherol and gamma-tocopherol (p<0.01), with all biomarker indices of individuality < 0.8 arbitrary units. Conclusion: We report that the use of the novel redox test in athletes is practical, and the generation of BV and CDV for biomarkers of OS enhances the interpretation of physiologically meaningful changes in individuals above the use of clinical reference ranges alone.
C1 [Lewis, Nathan A.; Burden, Richard] Univ Bath, English Inst Sport, Athletes Training Village, Bath BA2 7AY, Avon, England.
[Lewis, Nathan A.; Burden, Richard; Pedlar, Charles R.] St Marys Univ, Sch Sport Hlth & Appl Sci, London, England.
[Lewis, Nathan A.; Newell, John; Burden, Richard; Pedlar, Charles R.] Inst Technol, ORRECO, Sligo, Ireland.
[Newell, John] Natl Univ Ireland, Sch Math Appl Stat & Math, Galway, Ireland.
[Howatson, Glyn] Northumbria Univ, Dept Sport Exercise & Rehabil, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.
[Howatson, Glyn] Northwest Univ, Sch Environm Sci & Dev, Water Res Grp, Potchefstroom, South Africa.
[Pedlar, Charles R.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA.
RP Lewis, NA (reprint author), Univ Bath, English Inst Sport, Athletes Training Village, Bath BA2 7AY, Avon, England.; Lewis, NA (reprint author), St Marys Univ, Sch Sport Hlth & Appl Sci, London, England.; Lewis, NA (reprint author), Inst Technol, ORRECO, Sligo, Ireland.
EM nathan.lewis@eis2win.co.uk
OI Newell, John/0000-0001-7685-6655
FU School of Sport, Health and Applied Science at St Mary's University,
Twickenham; ORRECO Ltd.
FX This study was financially supported by the research support fund in the
School of Sport, Health and Applied Science at St Mary's University,
Twickenham. The company ORRECO Ltd. had no role in funding the study,
provided support in the form of salaries for authors N.A.L., C.A.P., and
R.B., and did not have any additional role in the study design, data
collection and analysis, decision to publish, or preparation of the
manuscript. J.N. is a scientific advisor to ORRECO Ltd. only. ORRECO
Ltd. makes no contribution to his salary.
NR 38
TC 3
Z9 3
U1 4
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2016
VL 11
IS 3
AR e0149927
DI 10.1371/journal.pone.0149927
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF5ZW
UT WOS:000371434500074
PM 26930475
ER
PT J
AU Geng, CR
Tang, XB
Guan, FD
Johns, J
Vasudevan, L
Gong, CH
Shu, DY
Chen, D
AF Geng, Changran
Tang, Xiaobin
Guan, Fada
Johns, Jesse
Vasudevan, Latha
Gong, Chunhui
Shu, Diyun
Chen, Da
TI GEANT4 calculations of neutron dose in radiation protection using a
homogeneous phantom and a Chinese hybrid male phantom
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
ID MONTE-CARLO; CONVERSION COEFFICIENTS; DOSIMETRY; THERAPY; MCNP
AB The purpose of this study is to verify the feasibility of applying GEANT4 (version 10.01) in neutron dose calculations in radiation protection by comparing the calculation results with MCNP5. The depth dose distributions are investigated in a homogeneous phantom, and the fluence-to-dose conversion coefficients are calculated for different organs in the Chinese hybrid male phantom for neutrons with energy ranging from 1 x 10(-9) to 10 MeV. By comparing the simulation results between GEANT4 and MCNP5, it is shown that using the high-precision (HP) neutron physics list, GEANT4 produces the closest simulation results to MCNP5. However, differences could be observed when the neutron energy is lower than 1 x 10(-6) MeV. Activating the thermal scattering with an S matrix correction in GEANT4 with HP and MCNP5 in thermal energy range can reduce the difference between these two codes.
C1 [Geng, Changran; Tang, Xiaobin; Gong, Chunhui; Shu, Diyun; Chen, Da] Nanjing Univ Aeronaut & Astronaut, Dept Nucl Sci & Engn, Nanjing 210016, Jiangsu, Peoples R China.
[Geng, Changran; Tang, Xiaobin; Gong, Chunhui; Shu, Diyun; Chen, Da] Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou, Peoples R China.
[Geng, Changran] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Geng, Changran] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Guan, Fada] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA.
[Johns, Jesse] Nimbus Innovat LLC, Temple, TX 76501 USA.
[Vasudevan, Latha] Texas A&M Univ, Environm Hlth & Safety, College Stn, TX 77843 USA.
RP Tang, XB (reprint author), Nanjing Univ Aeronaut & Astronaut, Dept Nucl Sci & Engn, Nanjing 210016, Jiangsu, Peoples R China.; Tang, XB (reprint author), Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou, Peoples R China.
EM tangxiaobin@nuaa.edu.cn
RI Tang, Xiaobin/I-7601-2014;
OI Tang, Xiaobin/0000-0003-3308-0468; GUAN, FADA/0000-0001-8477-7391
FU National Natural Science Foundation of China [11475087]; Jiangsu
Innovation Program for Graduate Education [KYLX_0265]; Fundamental
Research Funds for the Central Universities [NS2014060]; Priority
Academic Program Development of Jiangsu Higher Education Institutions
FX This work was supported by National Natural Science Foundation of China
(11475087), funding of Jiangsu Innovation Program for Graduate Education
(KYLX_0265), the Fundamental Research Funds for the Central Universities
(NS2014060) and a project funded by the Priority Academic Program
Development of Jiangsu Higher Education Institutions.
NR 21
TC 1
Z9 1
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD MAR
PY 2016
VL 168
IS 4
BP 433
EP 440
DI 10.1093/rpd/ncv364
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA DF8LE
UT WOS:000371608500001
PM 26156875
ER
PT J
AU Lewis, RC
Hauser, R
Wang, L
Kavet, R
Meeker, JD
AF Lewis, Ryan C.
Hauser, Russ
Wang, Lu
Kavet, Robert
Meeker, John D.
TI Personal power-frequency magnetic field exposure in women recruited at
an infertility clinic: association with physical activity and temporal
variability
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
ID PREGNANCY; RISK; MISCARRIAGE; MEN
AB Current epidemiologic approaches for studying exposure to power-frequency magnetic fields and the risk of miscarriage are potentially biased due to lack of attention to the relationship of exposure with physical activity and within-individual variability in exposures over time. This analysis examines these two issues using data from a longitudinal pilot study of 40 women recruited from an infertility clinic that contributed data for up to three 24-h periods separated by a median of 3.6 weeks. Physical activity was positively associated with peak exposure metrics. Higher physical activity within environments did not necessarily lead to higher peak exposures, suggesting that movement between and not within environments increases one's probability of encountering a high field source. Peak compared with central tendency metrics were more variable over time. Future epidemiology studies associated with peak exposure metrics should adjust for physical activity and collect more than 1 d of exposure measurement to reduce bias.
C1 [Lewis, Ryan C.; Meeker, John D.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, 1835 SPH 1,1415Washington Hts, Ann Arbor, MI 48109 USA.
[Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Bldg 1,14th Floor,665 Huntington Ave, Boston, MA 02115 USA.
[Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, 55 Fruit St, Boston, MA 02114 USA.
[Wang, Lu] Univ Michigan, Sch Publ Hlth, Dept Biostat, M4132 SPH 2,1415Washington Hts, Ann Arbor, MI 48109 USA.
[Kavet, Robert] Elect Power Res Inst, 3420 Hillview Ave, Palo Alto, CA 94304 USA.
RP Meeker, JD (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, 1835 SPH 1,1415Washington Hts, Ann Arbor, MI 48109 USA.
EM meekerj@umich.edu
OI Meeker, John/0000-0001-8357-5085
FU Electric Power Research Institute; National Institute of Environmental
Health Sciences of the National Institutes of Health [R01 ES009718, R01
ES016099]
FX Work was supported by the Electric Power Research Institute and grants
R01 ES009718 and R01 ES016099 from the National Institute of
Environmental Health Sciences of the National Institutes of Health.
NR 22
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD MAR
PY 2016
VL 168
IS 4
BP 478
EP 488
DI 10.1093/rpd/ncv365
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA DF8LE
UT WOS:000371608500007
PM 26152565
ER
PT J
AU Rai, SK
Choi, HK
Sayre, EC
Avina-Zubieta, JA
AF Rai, Sharan K.
Choi, Hyon K.
Sayre, Eric C.
Avina-Zubieta, J. Antonio
TI Risk of myocardial infarction and ischaemic stroke in adults with
polymyositis and dermatomyositis: a general population-based study
SO RHEUMATOLOGY
LA English
DT Article
DE dermatomyositis; polymyositis; inflammatory myopathies; myocardial
infarction; ischaemic stroke; cardiovascular disease
ID BODY-MASS INDEX; RHEUMATOID-ARTHRITIS; CARDIOVASCULAR-DISEASE;
ADMINISTRATIVE DATA; CARDIAC INVOLVEMENT; AUTOPSIED PATIENTS; 52
COUNTRIES; MORTALITY; METAANALYSIS; ACCURACY
AB Objective. Limited data are available on the risk of cardiovascular disease in DM and PM. The purpose of this study was to estimate the risk of incident myocardial infarction (MI) and ischaemic stroke in adults with incident PM/DM at the general population level.
Methods. We assembled a retrospective cohort of all adults with incident PM/DM in British Columbia, and we matched up to 10 adults randomly selected from the general population. We estimated the incidence rates (IRs) per 1000 person-years for MI and stroke. We calculated hazard ratios (HRs), adjusting for potential confounders.
Results. Among 774 new cases of inflammatory myopathies, 424 had PM (59% female, mean age 60 years) and 350 had DM (65% female, mean age 56 years). IRs for MI and stroke in PM were 22.52 and 10.15 events per 1000 person-years, respectively, vs 5.50 and 5.58 events in the comparison cohort, respectively. Fully adjusted HRs (95% CI) were 3.89 (95% CI: 2.28, 6.65) for MI and 1.76 (95% CI: 0.91, 3.40) for stroke. The age-, sex- and entry time-matched HRs for MI and stroke were highest in the first year after PM diagnosis (6.51, [95% CI: 3.15, 13.47] and 3.48 [95% CI: 1.26, 9.62], respectively). Similar trends were seen for DM.
Conclusion. Our study demonstrates that PM and DM are both associated with an increased risk of MI but not ischaemic stroke. Our findings support increased vigilance in cardiovascular prevention, surveillance and risk modification in adults with PM and DM.
C1 [Rai, Sharan K.; Choi, Hyon K.; Sayre, Eric C.; Avina-Zubieta, J. Antonio] Arthrit Res Canada, Richmond, BC, Canada.
[Rai, Sharan K.; Avina-Zubieta, J. Antonio] Univ British Columbia, Fac Med, Dept Expt Med, Vancouver, BC V5Z 1M9, Canada.
[Choi, Hyon K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA.
[Avina-Zubieta, J. Antonio] Univ British Columbia, Dept Med, Div Rheumatol, Vancouver, BC V5Z 1M9, Canada.
RP Avina-Zubieta, JA (reprint author), Univ British Columbia, Dept Med, Arthrit Res Canada, Div Rheumatol, 5591 3 Rd, Richmond, BC V6X 2C7, Canada.
EM azubieta@arthritisresearch.ca
FU Canadian Arthritis Network; Arthritis Society of Canada; British
Columbia Lupus Society [10-SRP-IJD-01]; Canadian Institutes for Health
Research [THC 135235]
FX The work was supported by the Canadian Arthritis Network, The Arthritis
Society of Canada, the British Columbia Lupus Society (Grant
10-SRP-IJD-01) and the Canadian Institutes for Health Research (THC
135235).
NR 53
TC 2
Z9 2
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
EI 1462-0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD MAR
PY 2016
VL 55
IS 3
BP 461
EP 469
DI 10.1093/rheumatology/kev336
PG 9
WC Rheumatology
SC Rheumatology
GA DF7SL
UT WOS:000371557800011
PM 26424835
ER
PT J
AU Cassa, CA
Smith, SE
Docken, W
Hoffman, E
McLaughlin, H
Chun, S
Leshchiner, I
Miraoui, H
Raychaudhuri, S
Frank, NY
Wilson, BJ
Sunyaev, SR
Maas, RL
Vuzman, D
AF Cassa, Christopher A.
Smith, Stacy E.
Docken, William
Hoffman, Erin
McLaughlin, Heather
Chun, Sung
Leshchiner, Ignaty
Miraoui, Hichem
Raychaudhuri, Soumya
Frank, Natasha Y.
Wilson, Brian J.
Sunyaev, Shamil R.
Maas, Richard L.
Vuzman, Dana
CA Brigham Genomic Med
TI An argument for early genomic sequencing in atypical cases: a WISP3
variant leads to diagnosis of progressive pseudorheumatoid arthropathy
of childhood
SO RHEUMATOLOGY
LA English
DT Letter
ID DYSPLASIA; MUTATIONS; GENE
C1 [Cassa, Christopher A.; Hoffman, Erin; Chun, Sung; Leshchiner, Ignaty; Miraoui, Hichem; Raychaudhuri, Soumya; Frank, Natasha Y.; Sunyaev, Shamil R.; Maas, Richard L.; Vuzman, Dana] Brigham & Womens Hosp, Div Genet, Harvard New Res Bldg,Room 0168B, Boston, MA 02115 USA.
[Cassa, Christopher A.; Docken, William; Chun, Sung; Leshchiner, Ignaty; Miraoui, Hichem; Raychaudhuri, Soumya; Frank, Natasha Y.; Sunyaev, Shamil R.; Maas, Richard L.; Vuzman, Dana] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Smith, Stacy E.] Brigham & Womens Hosp, Div Musculoskeletal Imaging & Intervent, 75 Francis St, Boston, MA 02115 USA.
[Smith, Stacy E.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Docken, William] Brigham & Womens Hosp, Div Rheumatol, 75 Francis St, Boston, MA 02115 USA.
[McLaughlin, Heather] Partners Healthcare Ctr Personalized Med, Cambridge, MA USA.
[McLaughlin, Heather] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Frank, Natasha Y.; Wilson, Brian J.] Boston Childrens Hosp, Dept Med, Boston, MA USA.
[Frank, Natasha Y.] VA Boston Healthcare Syst, Dept Med, Boston, MA USA.
RP Vuzman, D (reprint author), Brigham & Womens Hosp, Div Genet, Harvard New Res Bldg,Room 0168B, Boston, MA 02115 USA.
EM dvuzman@broadinstitute.org
OI Chun, Sung/0000-0003-3440-1913
FU NHGRI NIH HHS [K99 HG007229, K99-HG007229, U01 HG007690, U01-HG007690]
NR 4
TC 0
Z9 0
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
EI 1462-0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD MAR
PY 2016
VL 55
IS 3
BP 586
EP 589
DI 10.1093/rheumatology/kev367
PG 4
WC Rheumatology
SC Rheumatology
GA DF7SL
UT WOS:000371557800026
PM 26493744
ER
PT J
AU Martin, CJ
Carey, AF
Fortune, SM
AF Martin, Constance J.
Carey, Allison F.
Fortune, Sarah M.
TI A bug's life in the granuloma
SO SEMINARS IN IMMUNOPATHOLOGY
LA English
DT Review
DE Tuberculosis; Granuloma; Phenotypic heterogeneity; Macrophage
ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; NITRIC-OXIDE SYNTHASE; CELL-WALL
LIPIDS; IN-VITRO; STRINGENT RESPONSE; HUMAN MACROPHAGES; ISOCITRATE
LYASE; FATTY-ACIDS; BOVIS BCG; EXPRESSION
AB The granuloma is the defining feature of the host response to infection with Mycobacterium tuberculosis (Mtb). Despite knowing of its existence for centuries, much remains unclear regarding the host and bacterial factors that contribute to granuloma formation, heterogeneity of presentation, and the forces at play within. Mtb is highly adapted to life within the granuloma and employs many unique strategies to both create a niche within the host as well as survive the stresses imposed upon it. Adding to the complexity of the granuloma is the vast range of pathology observed, often within the same individual. Here, we explore some of the many ways in which Mtb crafts the immune response to its liking and builds a variety of granuloma features that contribute to its survival. We also consider the multitude of ways that Mtb is adapted to life in the granuloma and how variability in the deployment of these strategies may result in different fates for both the bacterium and the host. It is through better understanding of these complex interactions that we may begin to strategize novel approaches for tuberculosis treatments.
C1 [Martin, Constance J.; Carey, Allison F.; Fortune, Sarah M.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Martin, Constance J.; Fortune, Sarah M.] Ragon Inst Massachusetts Gen Hosp Harvard & Massa, Cambridge, MA USA.
[Carey, Allison F.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Fortune, SM (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.; Fortune, SM (reprint author), Ragon Inst Massachusetts Gen Hosp Harvard & Massa, Cambridge, MA USA.
EM sfortune@hsph.harvard.edu
FU NIAID NIH HHS [P30 AI060354, R01 AI114674, R01 AI123286, T32 AI007061]
NR 66
TC 6
Z9 6
U1 1
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2297
EI 1863-2300
J9 SEMIN IMMUNOPATHOL
JI Semin. Immunopathol.
PD MAR
PY 2016
VL 38
IS 2
BP 213
EP 220
DI 10.1007/s00281-015-0533-1
PG 8
WC Immunology; Pathology
SC Immunology; Pathology
GA DF8UI
UT WOS:000371634900007
PM 26577238
ER
PT J
AU Rutten-Jacobs, LCA
Traylor, M
Adib-Samii, P
Thijs, V
Sudlow, C
Rothwell, PM
Boncoraglio, G
Dichgans, M
Meschia, J
Maguire, J
Levi, C
Rost, NS
Rosand, J
Hassan, A
Bevan, S
Markus, HS
AF Rutten-Jacobs, Loes C. A.
Traylor, Matthew
Adib-Samii, Poneh
Thijs, Vincent
Sudlow, Cathie
Rothwell, Peter M.
Boncoraglio, Giorgio
Dichgans, Martin
Meschia, James
Maguire, Jane
Levi, Christopher
Rost, Natalia S.
Rosand, Jonathan
Hassan, Ahamad
Bevan, Steve
Markus, Hugh S.
TI Association of MTHFR C677T Genotype With Ischemic Stroke Is Confined to
Cerebral Small Vessel Disease Subtype
SO STROKE
LA English
DT Article
DE lacunar stroke; homocysteine; hypertension; genetic association; MTHFR;
cerebral small vessel disease
ID SOUTH LONDON ETHNICITY; B-VITAMINS; FOLIC-ACID; HOMOCYSTEINE
CONCENTRATIONS; MYOCARDIAL-INFARCTION; CONTROLLED-TRIAL; CLINICAL-TRIAL;
RISK; POPULATION; CLASSIFICATION
AB Background and Purpose-
Elevated plasma homocysteine levels are associated with stroke. However, this might be a reflection of bias or confounding because trials have failed to demonstrate an effect from homocysteine lowering in stroke patients, although a possible benefit has been suggested in lacunar stroke. Genetic studies could potentially overcome these issues because genetic variants are inherited randomly and are fixed at conception. Therefore, we tested the homocysteine levels-associated genetic variant MTHFR C677T for association with magnetic resonance imaging-confirmed lacunar stroke and compared this with associations with large artery and cardioembolic stroke subtypes.
Methods-
We included 1359 magnetic resonance imaging-confirmed lacunar stroke cases, 1824 large artery stroke cases, 1970 cardioembolic stroke cases, and 14 448 controls, all of European ancestry. Furthermore, we studied 3670 ischemic stroke patients in whom white matter hyperintensities volume was measured. We tested MTHFR C677T for association with stroke subtypes and white matter hyperintensities volume. Because of the established association of homocysteine with hypertension, we additionally stratified for hypertension status.
Results-
MTHFR C677T was associated with lacunar stroke (P=0.0003) and white matter hyperintensity volume (P=0.04), but not with the other stroke subtypes. Stratifying the lacunar stroke cases for hypertension status confirmed this association in hypertensive individuals (P=0.0002), but not in normotensive individuals (P=0.30).
Conclusions-
MTHFR C677T was associated with magnetic resonance imaging-confirmed lacunar stroke, but not large artery or cardioembolic stroke. The association may act through increased susceptibility to, or interaction with, high blood pressure. This heterogeneity of association might explain the lack of effect of lowering homocysteine in secondary prevention trials which included all strokes.
C1 [Rutten-Jacobs, Loes C. A.; Traylor, Matthew; Markus, Hugh S.] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0QQ, England.
[Traylor, Matthew] Kings Coll London, Dept Med & Mol Genet, London WC2R 2LS, England.
[Adib-Samii, Poneh] St Georges Univ London, Stroke & Dementia Res Ctr, Dept Clin Neurosci, London, England.
[Thijs, Vincent] KULeuven, Dept Expt Neurol, Leuven, Belgium.
[Thijs, Vincent] Univ Leuven, Leuven Res Inst Neurosci & Dis, Leuven, Belgium.
[Thijs, Vincent] VIB, Neurobiol Lab, Vesalius Res Ctr, Leuven, Belgium.
[Thijs, Vincent] Austin Hlth & Florey Inst Neurosci & Mental Hlth, Dept Neurol, Heidelberg, Vic, Australia.
[Sudlow, Cathie] Univ Edinburgh, Neuroimaging Sci & Inst Genet & Mol Med, Div Clin Neurosci, Edinburgh, Midlothian, Scotland.
[Rothwell, Peter M.] Univ Oxford, Stroke Prevent Res Unit, Nuffield Dept Neurosci, Oxford OX1 2JD, England.
[Boncoraglio, Giorgio] Fdn IRCCS Ist Neurol Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy.
[Dichgans, Martin] Univ Munich, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany.
[Dichgans, Martin] SyNergy, Munich Cluster Syst Neurol, Munich, Germany.
[Meschia, James] Mayo Clin, Dept Neurol, Jacksonville, FL USA.
[Meschia, James] Univ Newcastle, Sch Nursing & Midwifery, Callaghan, NSW 2308, Australia.
[Meschia, James; Levi, Christopher] Univ Newcastle, Hunter Med Res Inst, Callaghan, NSW 2308, Australia.
[Rost, Natalia S.; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Rost, Natalia S.; Rosand, Jonathan] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Hassan, Ahamad] Leeds Teaching Hosp NHS Trust, Leeds Gen Infirm, Dept Neurol, Leeds, W Yorkshire, England.
[Bevan, Steve] Lincoln Univ, Sch Life Sci, Lincoln, England.
RP Rutten-Jacobs, LCA (reprint author), Univ Cambridge, Stroke Res Grp, Dept Neurosci, Cambridge CB2 0QQ, England.
EM LR406@medschl.cam.ac.uk
RI Boncoraglio, Giorgio/B-8647-2011; Thijs, Vincent/C-3647-2009;
OI Thijs, Vincent/0000-0002-6614-8417; Traylor,
Matthew/0000-0001-6624-8621; Bevan, Steve/0000-0003-0490-6830;
Rutten-Jacobs, Loes/0000-0003-3223-885X
FU Wellcome Trust [WT072952]; Stroke Association [TSA 2010/01, FSA
2013/00]; Wolfson Foundation; UK Stroke Association; British Heart
Foundation; Dunhill Medical Trust; National Institute of Health Research
(NIHR); Medical Research Council; NIHR Oxford Biomedical Research
Centre; Massachusetts General Hospital-Deane Institute for the
Integrative Study of Atrial Fibrillation and Stroke; National Institute
of Neurological Disorders and Stroke [U01 NS069208]; Stroke
Association/British Heart Foundation programme grant [TSA BHF 2010/01];
Medical Research Council (United Kingdom); National Institute for Health
Research Cambridge University Hospitals Comprehensive Biomedical
Research Centre; National Institute for Health Research Senior
Investigator award; scientific research fund, Fonds Wetenschappelijk
Onderzoek Flanders; National Health and Medical Research Council (NHMRC
Australia) Practitioner Fellowship; NHMRC [1010287]; National Institute
of Neurological Disorders and Stroke grant [R01 NS082285-01]
FX Collection of the UK Young Lacunar Stroke DNA Study (DNA Lacunar) was
primarily supported by the Wellcome Trust (WT072952) with additional
support from the Stroke Association (TSA 2010/01). Genotyping of the DNA
Lacunar samples and Dr Traylor were supported by a Stroke Association
Grant (FSA 2013/00). Genotyping of WTCCC2 ischemic stroke study was
funded by the Wellcome Trust. The Oxford Vascular Study has been funded
by Wellcome Trust, Wolfson Foundation, UK Stroke Association, British
Heart Foundation, Dunhill Medical Trust, National Institute of Health
Research (NIHR), Medical Research Council, and the NIHR Oxford
Biomedical Research Centre. Funding for the genotyping at Massachusetts
General Hospital was provided by the Massachusetts General
Hospital-Deane Institute for the Integrative Study of Atrial
Fibrillation and Stroke and the National Institute of Neurological
Disorders and Stroke (U01 NS069208). Dr Rutten-Jacobs was supported by a
Stroke Association/British Heart Foundation programme grant (TSA BHF
2010/01). Dr Adib-Samii was supported by a Medical Research Council
(United Kingdom) training fellowship. Drs Markus and Bevan are supported
by the National Institute for Health Research Cambridge University
Hospitals Comprehensive Biomedical Research Centre. Dr Markus is
supported by a National Institute for Health Research Senior
Investigator award. Dr Thijs is supported by a Clinical Investigator
Grant from the scientific research fund, Fonds Wetenschappelijk
Onderzoek Flanders. Dr Levi is supported by a National Health and
Medical Research Council (NHMRC Australia) Practitioner Fellowship and
the Australian Stroke Genetics Collaboration has received Project Grant
support from the NHMRC (App 1010287). Dr Rost was supported by a
National Institute of Neurological Disorders and Stroke grant (R01
NS082285-01). Professor Rothwell is in receipt of an NIHR Senior
Investigator Award and a Wellcome Trust Senior Investigator Award. We.
also acknowledge the use of the facilities of the Acute Vascular Imaging
Centre, Oxford, and the Cardiovascular Clinical Research Facility,
Oxford. The sponsors of the study had no role in the study design, data
collection, data analysis, interpretation, writing of the article, or
the decision to submit the article for publication.
NR 26
TC 2
Z9 3
U1 5
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD MAR
PY 2016
VL 47
IS 3
BP 646
EP 651
DI 10.1161/STROKEAHA.115.011545
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DF6VT
UT WOS:000371496200002
PM 26839351
ER
PT J
AU Dowlatshahi, D
Brouwers, HB
Demchuk, AM
Hill, MD
Aviv, RI
Ufholz, LA
Reaume, M
Wintermark, M
Hemphill, JC
Murai, Y
Wang, YJ
Zhao, XQ
Wang, YL
Li, N
Sorimachi, T
Matsumae, M
Steiner, T
Rizos, T
Greenberg, SM
Romero, JM
Rosand, J
Goldstein, JN
Sharma, M
AF Dowlatshahi, Dar
Brouwers, H. Bart
Demchuk, Andrew M.
Hill, Michael D.
Aviv, Richard I.
Ufholz, Lee-Anne
Reaume, Michael
Wintermark, Max
Hemphill, J. Claude, III
Murai, Yasuo
Wang, Yongjun
Zhao, Xingquan
Wang, Yilong
Li, Na
Sorimachi, Takatoshi
Matsumae, Mitsunori
Steiner, Thorsten
Rizos, Timolaos
Greenberg, Steven M.
Romero, Javier M.
Rosand, Jonathan
Goldstein, Joshua N.
Sharma, Mukul
TI Predicting Intracerebral Hemorrhage Growth With the Spot Sign The Effect
of Onset-to-Scan Time
SO STROKE
LA English
DT Article
DE cerebral hemorrhage; hematoma expansion; CT angiography; spot sign;
intracerebral hemorrhage
ID COMPUTED-TOMOGRAPHY ANGIOGRAPHY; BLOOD-PRESSURE REDUCTION; ACTIVATED
FACTOR-VII; HEMATOMA EXPANSION; CONTRAST EXTRAVASATION; CT ANGIOGRAPHY;
CEREBRAL-HEMORRHAGE; MORTALITY; RISK; VOLUME
AB Background and Purpose- Hematoma expansion after acute intracerebral hemorrhage is common and is associated with early deterioration and poor clinical outcome. The computed tomographic angiography (CTA) spot sign is a promising predictor of expansion; however, frequency and predictive values are variable across studies, possibly because of differences in onset-to-CTA time. We performed a patient-level meta-analysis to define the relationship between onset-to-CTA time and frequency and predictive ability of the spot sign. Methods- We completed a systematic review for studies of CTA spot sign and hematoma expansion. We subsequently pooled patient-level data on the frequency and predictive values for significant hematoma expansion according to 5 predefined categorized onset-to-CTA times. We calculated spot-sign frequency both as raw and frequency-adjusted rates. Results- Among 2051 studies identified, 12 met our inclusion criteria. Baseline hematoma volume, spot-sign status, and time-to-CTA were available for 1176 patients, and 1039 patients had follow-up computed tomographies for hematoma expansion analysis. The overall spot sign frequency was 26%, decreasing from 39% within 2 hours of onset to 13% beyond 8 hours (P < 0.001). There was a significant decrease in hematoma expansion in spot-positive patients as onset-to-CTA time increased (P=0.004), with positive predictive values decreasing from 53% to 33%. Conclusions- The frequency of the CTA spot sign is inversely related to intracerebral hemorrhage onset-to-CTA time. Furthermore, the positive predictive value of the spot sign for significant hematoma expansion decreases as time-to-CTA increases. Our results offer more precise risk stratification for patients with acute intracerebral hemorrhage and will help refine clinical prediction rules for intracerebral hemorrhage expansion.
C1 [Dowlatshahi, Dar; Reaume, Michael] Univ Ottawa, Dept Med, Ottawa, ON K1Y 4E9, Canada.
[Dowlatshahi, Dar; Reaume, Michael] Ottawa Hosp Res Inst, Ottawa, ON K1Y 4E9, Canada.
[Brouwers, H. Bart; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Romero, Javier M.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.
[Goldstein, Joshua N.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Goldstein, Joshua N.] Harvard Univ, Sch Med, Boston, MA USA.
[Brouwers, H. Bart] Univ Utrecht, Univ Med Ctr Utrecht, Dept Neurosurg, Utrecht, Netherlands.
[Demchuk, Andrew M.; Hill, Michael D.] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB, Canada.
[Demchuk, Andrew M.; Hill, Michael D.] Univ Calgary, Calgary Stroke Program, Calgary, AB, Canada.
[Aviv, Richard I.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Imaging, Toronto, ON, Canada.
[Ufholz, Lee-Anne] Univ Ottawa, Hlth Sci Lib, Ottawa, ON, Canada.
[Wintermark, Max] Stanford Univ, Neuroradiol Div, Dept Radiol, Stanford, CA 94305 USA.
[Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Murai, Yasuo] Nippon Med Sch, Dept Neurol Surg, 1-1-5 Sendagi, Tokyo 113, Japan.
[Wang, Yongjun; Zhao, Xingquan; Wang, Yilong; Li, Na] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.
[Sorimachi, Takatoshi; Matsumae, Mitsunori] Tokai Univ, Dept Neurosurg, Hiratsuka, Kanagawa 25912, Japan.
[Steiner, Thorsten; Rizos, Timolaos] Heidelberg Univ, Dept Neurol, Bergheimer Str 58, D-69115 Heidelberg, Germany.
[Steiner, Thorsten] Klinikum Frankfurt Hochst, Frankfurt, Germany.
[Sharma, Mukul] McMaster Univ, Dept Med, Populat Hlth Res Inst, Hamilton, ON, Canada.
RP Dowlatshahi, D (reprint author), Univ Ottawa, Ottawa Hosp Civ Campus Room C2102, Ottawa, ON K1Y 4E9, Canada.; Dowlatshahi, D (reprint author), Ottawa Hosp Res Inst, Ottawa Hosp Civ Campus Room C2102, Ottawa, ON K1Y 4E9, Canada.
EM ddowlat@toh.on.ca
RI Goldstein, Joshua/H-8953-2016
FU Heart & Stroke Foundation of Canada; University of Ottawa Department of
Medicine; Heart & Stroke Foundation of Alberta/NWT/NU; Hotchkiss Brain
Institute; Alberta Innovates Health Solutions; National Institutes of
Health-National Institute of Neurological Disorders and Stroke
FX Heart & Stroke Foundation of Canada (Dr Dowlatshahi), University of
Ottawa Department of Medicine (Dr Dowlatshahi), Heart & Stroke
Foundation of Alberta/NWT/NU (Dr Demchuk and Dr Hill), the Hotchkiss
Brain Institute (Dr Demchuk and Dr Hill), Alberta Innovates Health
Solutions (Dr Demchuk and Dr Hill), and National Institutes of
Health-National Institute of Neurological Disorders and Stroke (Dr
Brouwers, Dr Goldstein, and Dr Rosand).
NR 41
TC 4
Z9 4
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD MAR
PY 2016
VL 47
IS 3
BP 695
EP 700
DI 10.1161/STROKEAHA.115.012012
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DF6VT
UT WOS:000371496200009
PM 26846857
ER
PT J
AU Chua, MH
Griessenauer, CJ
Stapleton, CJ
He, L
Thomas, AJ
Ogilvy, CS
AF Chua, Michelle H.
Griessenauer, Christoph J.
Stapleton, Christopher J.
He, Lucy
Thomas, Ajith J.
Ogilvy, Christopher S.
TI Documentation of Improved Outcomes for Intracranial Aneurysm Management
Over a 15-Year Interval
SO STROKE
LA English
DT Article
DE outcomes research; Glasgow Outcome Scale; surgical instruments;
intracranial aneurysms; endovascular techniques
ID UNRUPTURED CEREBRAL ANEURYSMS; SUBARACHNOID HEMORRHAGE; ENDOVASCULAR
TREATMENT; COIL EMBOLIZATION; MORTALITY; DATABASE; SYSTEM; TRENDS;
TRIAL; AGE
AB Background and Purpose-
Despite rapid advancements in intracranial aneurysm management, there is no evidence as of yet that this has translated into improvement in overall prognosis.
Methods-
We compared 2 periods of aneurysm management, 1998 to 2003 (n=1023 aneurysms) and 2007 to 2013 (n=1499 aneurysms), at a single, high-volume neurovascular center. Our outcome of interest was low or moderate disability (Glasgow Outcome Scale score of 4 or 5) at 6 months or more post treatment.
Results-
There were significant improvements in outcome for surgical, endovascular, and overall treatment of unruptured (adjusted odds ratio [OR], 2.33; P=0.0091; adjusted OR, 4.40; P=0.0271; and adjusted OR, 2.58; P=0.0008, respectively) and ruptured (adjusted OR, 3.18; P=0.0004; adjusted OR, 3.54; P=0.0001; and adjusted OR, 3.11; P < 0.0001, respectively) aneurysms from the first to the second time period. In 2007 to 2013, the proportion of cases with low or moderate disability at 6 months post subarachnoid hemorrhage was 75.6% for surgical clipping and 76.6% for endovascular therapy.
Conclusions-
We report significantly improved outcomes over time for overall aneurysm management and for multiple patient subgroups, associated with increased usage of endovascular therapy.
C1 [Chua, Michelle H.; Griessenauer, Christoph J.; He, Lucy; Thomas, Ajith J.; Ogilvy, Christopher S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Brain Aneurysm Inst, Neurosurg Serv,Med Sch, Boston, MA 02215 USA.
[Stapleton, Christopher J.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP Ogilvy, CS (reprint author), 110 Francis St,Suite 3B, Boston, MA 02215 USA.
EM cogilvy@bidmc.harvard.edu
NR 23
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD MAR
PY 2016
VL 47
IS 3
BP 708
EP 712
DI 10.1161/STROKEAHA.115.011959
PG 5
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DF6VT
UT WOS:000371496200011
PM 26839350
ER
PT J
AU Fonarow, GC
Liang, L
Thomas, L
Xian, Y
Saver, JL
Smith, EE
Schwamm, LH
Peterson, ED
Hernandez, AF
Duncan, PW
O'Brien, EC
Bushnell, C
Bettger, JP
AF Fonarow, Gregg C.
Liang, Li
Thomas, Laine
Xian, Ying
Saver, Jeffrey L.
Smith, Eric E.
Schwamm, Lee H.
Peterson, Eric D.
Hernandez, Adrian F.
Duncan, Pamela W.
O'Brien, Emily C.
Bushnell, Cheryl
Bettger, Janet Prvu
TI Assessment of Home-Time After Acute Ischemic Stroke in Medicare
Beneficiaries
SO STROKE
LA English
DT Article
DE skilled nursing facilities; stroke; survivors; modified Rankin Scale;
patient-centered outcomes research
ID GUIDELINES-STROKE; PATIENTS PERSPECTIVE; UNCERTAINTY LIFE;
CLINICAL-TRIALS; PATIENT; DISABILITY; OUTCOMES
AB Background and Purpose-
Stroke survivors have identified home-time as a meaningful outcome. We evaluated home-time as a patient-centered outcome in Medicare beneficiaries with ischemic stroke in comparison with modified Rankin Scale (mRS) score at 90 days and at 1 year post event.
Methods-
Patients enrolled in Get With The Guidelines-Stroke (GWTG-Stroke) and Adherence Evaluation After Ischemic Stroke-Longitudinal (AVAIL) registries were linked to Medicare claims to ascertain home-time, defined as time spent alive and out of a hospital, inpatient rehabilitation, or skilled nursing facilities, at 90 days and at 1 year after admission. The correlation of home-time with mRS at 90 days and at 1 year was evaluated by Pearson correlation coefficients, and the ability of home-time to discriminate mRS (0-2) was assessed by c-index.
Results-
There were 815 patients with ischemic stroke (age median, 76 years [interquartile range {IQR}, 70-82]; 46% women; National Institutes of Health Stroke Scale median, 4 [IQR, 2-7]) from 88 hospitals. The 90-day and 1-year median home-times were 79 (IQR, 52-86) days and 349 (IQR, 303-360) days and median mRS were 2 (IQR, 1-4) and 2 (IQR, 1-4). Greater home-time within 90 days was significantly correlated with lower 90-day mRS (Pearson correlation coefficient, -0.731; P < 0.0001) and showed strong ability to discriminate functional independence with mRS 0 to 2 (c-index, 0.837). Similar findings were observed at 1 year.
Conclusions-
In a population of older patients with ischemic stroke, home-time was readily available from administrative data and associated with mRS at 90 days and 1 year. Home-time represents a novel, easily measured, patient-centered, outcome measure for an episode of stroke care.
C1 [Fonarow, Gregg C.] Ronald Reagan UCLA Med Ctr, Dept Med, Los Angeles, CA 90095 USA.
[Saver, Jeffrey L.] Ronald Reagan UCLA Med Ctr, Dept Neurol, Los Angeles, CA 90095 USA.
[Liang, Li; Thomas, Laine; Xian, Ying; Peterson, Eric D.; Hernandez, Adrian F.; O'Brien, Emily C.; Bettger, Janet Prvu] Duke Clin Res Inst, Durham, NC USA.
[Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
[Schwamm, Lee H.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Duncan, Pamela W.; Bushnell, Cheryl] Wake Forest Baptist Med Ctr, Dept Neurol, Winston Salem, NC USA.
RP Fonarow, GC (reprint author), Ronald Reagan UCLA Med Ctr, 10833 Leconte Ave,Room 47-123 CHS, Los Angeles, CA 90095 USA.
EM gfonarow@mednet.ucla.edu
FU Agency for Healthcare Research and Quality [U18HS016964, K12HS019479];
Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; Patient
Centered Outcomes Research Institute [130]; Boeringher-Ingelheim; Merck;
Bristol-Myers Squib/Sanofi Pharmaceutical Partnership; Janssen
Pharmaceutical Companies of Johnson Johnson; AHA Pharmaceutical
Roundtable
FX Adherence Evaluation After Ischemic Stroke-Longitudinal (AVAIL) was
supported by the Agency for Healthcare Research and Quality
(U18HS016964) and unrestricted funds from Bristol-Myers Squibb/Sanofi
Pharmaceuticals Partnership. Medicare claims were obtained with funding
from the Agency for Healthcare Research and Quality (K12HS019479).
Analysis was funded by the Patient Centered Outcomes Research Institute
(Project #130; PI: P. Bettger). The Get With The Guidelines-Stroke
program is provided by the American Heart Association (AHA)/American
Stroke Association and has been funded in the past through support from
Boeringher-Ingelheim, Merck, Bristol-Myers Squib/Sanofi Pharmaceutical
Partnership, Janssen Pharmaceutical Companies of Johnson & Johnson, and
the AHA Pharmaceutical Roundtable, none of which participated in the
design, analysis, article preparation, or approval.
NR 15
TC 1
Z9 1
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD MAR
PY 2016
VL 47
IS 3
BP 836
EP 842
DI 10.1161/STROKEAHA.115.011599
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DF6VT
UT WOS:000371496200029
PM 26892279
ER
PT J
AU Diener, HC
Selim, MH
Molina, CA
Greenberg, SM
AF Diener, Hans-Christoph
Selim, Magdy H.
Molina, Carlos A.
Greenberg, Steven M.
TI Embolic Stroke, Atrial Fibrillation, and Microbleeds Is There a Role for
Anticoagulation?
SO STROKE
LA English
DT Article
DE carotid stenosis; amyloid; aspirin; anticoagulants; warfarin
ID TRANSIENT ISCHEMIC ATTACK; ANTAGONIST ORAL ANTICOAGULANTS; INTRACEREBRAL
HEMORRHAGE; CEREBRAL MICROBLEEDS; ANTITHROMBOTIC THERAPY; LOBAR
MICROBLEEDS; SUBGROUP ANALYSIS; WARFARIN; METAANALYSIS; RISK
C1 [Diener, Hans-Christoph] Univ Hosp Essen, Stroke Ctr, Dept Neurol, Essen, Germany.
[Greenberg, Steven M.] Harvard Univ, Massachusetts Gen Hosp, Hemorrhag Stroke Res Unit, Sch Med, Boston, MA USA.
[Selim, Magdy H.] Beth Israel Deaconess Med Ctr, Stroke Div, Boston, MA 02215 USA.
[Molina, Carlos A.] Hosp Vall dHebron Barcelona, Dept Neurol, Stroke Unit, Barcelona, Spain.
RP Diener, HC (reprint author), Univ Hosp Essen, Stroke Ctr, Dept Neurol, Essen, Germany.; Greenberg, SM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Hemorrhag Stroke Res Unit, Sch Med, Boston, MA USA.
EM h.diener@uni-essen.de; sgreenberg@mgh.harvard.edu
NR 22
TC 4
Z9 4
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD MAR
PY 2016
VL 47
IS 3
BP 904
EP 907
DI 10.1161/STROKEAHA.115.011150
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DF6VT
UT WOS:000371496200042
PM 26896435
ER
PT J
AU Harriott, A
Faye, EC
Abreu, N
Silverman, S
Rordorf, G
AF Harriott, Andrea
Faye, Erica Camargo
Abreu, Nicholas
Silverman, Scott
Rordorf, Guy
TI Aneurysmal Subarachnoid and Spinal Hemorrhage Associated With Systemic
Lupus Erythematosus
SO STROKE
LA English
DT Editorial Material
DE aneurysm; subarachnoid hemorrhage; vasculitis; lupus erythematosus,
systemic; stroke
ID COMPLICATION
C1 [Harriott, Andrea; Faye, Erica Camargo; Abreu, Nicholas; Silverman, Scott; Rordorf, Guy] Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA.
RP Harriott, A (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA.
EM aharriott@mgh.harvard.edu
NR 10
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD MAR
PY 2016
VL 47
IS 3
BP E42
EP E45
DI 10.1161/STROKEAHA.115.012373
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DF6VU
UT WOS:000371496400001
PM 26797667
ER
PT J
AU Tahvildari, M
Omoto, M
Chen, YH
Emami-Naeini, P
Inomata, T
Dohlman, TH
Kaye, AE
Chauhan, SK
Dana, R
AF Tahvildari, Maryam
Omoto, Masahiro
Chen, Yihe
Emami-Naeini, Parisa
Inomata, Takenori
Dohlman, Thomas H.
Kaye, Abigail E.
Chauhan, Sunil K.
Dana, Reza
TI In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2
Treatment Increases Allograft Survival in Corneal Transplantation
SO TRANSPLANTATION
LA English
DT Article
ID VERSUS-HOST-DISEASE; SKIN-GRAFT SURVIVAL; IMMUNE PRIVILEGE; IL-2;
TOLERANCE; REJECTION; RAPAMYCIN; DONOR; MICE; ALLORECOGNITION
AB Background. Corneal allograft survival dramatically decreases in hosts with inflamed or vascularized recipient beds. We have previously shown that in rejected corneal allografts regulatory Tcells (Treg) demonstrate diminished Foxp3 expression and immunoregulatory function. Treatment with low doses of IL-2 selectively expands Treg and has been proposed for the treatment of autoimmune diseases. In this study, we investigated the effect of low-dose IL-2 administration on Treg function and corneal allograft survival. Methods. Allogeneic corneal transplantation was performed on inflamed host beds. Low-dose systemic IL-2 was administered starting 3 days before grafting until 6 weeks after transplantation. Frequencies of Treg and their immunosuppressive function and antigen specificity were assessed using flow cytometry, in vitro proliferation assays, and adoptive transfer experiments. Frequencies of effector T cells (Teff) and graft infiltrating immune cells were measured at 2 weeks posttransplantation. Long-term allograft survival was evaluated for up to 9 weeks using Kaplan-Meier survival analysis. Results. Treatment with low-dose IL-2 significantly increased frequencies of CD4(+)CD25(+)Foxp3(+) Treg and their immunosuppressive function. It also suppressed alloimmune response as shown by the decreased CD4(+)IFN gamma(+) T cell frequencies and graft infiltration of CD45(+) and CD4(+) cells. Clinical evaluation of the grafts showed significant improvement in long-term corneal allograft survival in the IL-2 treated group compared with controls. Conclusions. Our study is the first to report that treatment with low-dose IL-2 increases survival of corneal allografts. We propose that IL-2-mediated Treg expansion can be an effective tool to prevent alloimmunity and to improve long-term allograft survival in transplantation.
C1 [Tahvildari, Maryam; Omoto, Masahiro; Chen, Yihe; Emami-Naeini, Parisa; Inomata, Takenori; Dohlman, Thomas H.; Kaye, Abigail E.; Chauhan, Sunil K.; Dana, Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
[Tahvildari, Maryam; Omoto, Masahiro; Chen, Yihe; Emami-Naeini, Parisa; Inomata, Takenori; Dohlman, Thomas H.; Kaye, Abigail E.; Chauhan, Sunil K.; Dana, Reza] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA.
[Emami-Naeini, Parisa] Wayne State Univ, Kresge Eye Inst, Detroit, MI USA.
RP Dana, R (reprint author), Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM Reza_Dana@meei.harvard.edu
OI Inomata, Takenori/0000-0003-3435-1055
FU NIH [EY12963]
FX This study was funded by NIH Grant EY12963. The authors thank Dr.
Susanne Eiglmeier (Schepens Eye Research Institute) for editorial
assistance and helpful discussions regarding the project, and Dr. Jing
Hua (Schepens Eye Research Institute) for valuable input.
NR 41
TC 3
Z9 4
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD MAR
PY 2016
VL 100
IS 3
BP 525
EP 532
DI 10.1097/TP.0000000000001044
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DF8BR
UT WOS:000371582400023
PM 26881788
ER
PT J
AU Jain, S
Keys, D
Martin, S
Edelstein, CL
Jani, A
AF Jain, Swati
Keys, Daniel
Martin, Sandra
Edelstein, Charles L.
Jani, Alkesh
TI Protection From Apoptotic Cell Death During Cold Storage Followed by
Rewarming in 13-Lined Ground Squirrel Tubular Cells: The Role of
Prosurvival Factors X-Linked Inhibitor of Apoptosis and PhosphoAkt
SO TRANSPLANTATION
LA English
DT Article
ID POLYCYSTIC KIDNEY-DISEASE; AKT PHOSPHORYLATION; EPITHELIAL-CELLS;
HIBERNATION; INJURY; ISCHEMIA; MITOCHONDRIA; REPERFUSION; PROGRESSION;
METABOLISM
AB Background. Hibernators, such as the 13-lined ground squirrel, endure severe hypothermia during torpor followed by periodic rewarming (REW) during interbout arousal (IBA), proapoptotic conditions that are lethal to nonhibernatingmammals. We have previously shown that 13-lined ground squirrel tubular cells are protected from apoptotic cell death during IBA. To understand the mechanism of protection, we developed an in vitro model of prolonged cold storage (CS) followed by REW, which is akin to the in vivo changes of hypothermia followed by REW observed during IBA. We hypothesized that renal tubular epithelial cells (RTECs) isolated from hibernating ground squirrels would be protected against apoptosis during CS/REW versus nonhibernating mouse RTECs. Methods. Isolated hibernating ground squirrel and mouse RTECs were subjected to CS at 4 degrees C for 24 hours followed by REW to 37 degrees C for 24 hours (CS/REW). Results. Ground squirrel RTECs had significantly less apoptosis compared to mouse RTECs when subjected to CS/REW. Next, we hypothesized that the mechanism of protection was related to the antiapoptotic proteins X-linked inhibitor of apoptosis (XIAP), phospho-Akt (pAkt), and phospho-BAD. There was a significantly increased pAkt and pBAD expression in ground squirrel versus mouse RTECs subjected to CS/REW. The XIAP expression was maintained in ground squirrel RTECs but was significantly decreased in mouse RTECs after CS/REW. Ground squirrel RTECs in which gene expression of Akt1 and XIAP was silenced lost their protection and demonstrated increased apoptosis and cleaved caspase-3 expression after CS/REW. Conclusions. Our findings suggest that ground squirrel RTECs are protected against apoptosis during prolonged CS/REW by the "prosurvival" factors XIAP and pAkt.
C1 [Jain, Swati; Keys, Daniel; Martin, Sandra; Edelstein, Charles L.; Jani, Alkesh] Univ Colorado, Denver, CO 80202 USA.
[Edelstein, Charles L.; Jani, Alkesh] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Jani, A (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, 12700 East 19th Ave,C281, Aurora, CO 80045 USA.
EM Alkesh.jani@ucdenver.edu
FU NIH [1 R03 DK96151-01]; VA Merit Award [1I01BX001737]
FX This work was supported by NIH 1 R03 DK96151-01 and a VA Merit Award
1I01BX001737.
NR 33
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD MAR
PY 2016
VL 100
IS 3
BP 538
EP 545
DI 10.1097/TP.0000000000000937
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DF8BR
UT WOS:000371582400025
PM 26457601
ER
PT J
AU Adler, JT
Yeh, H
Markmann, JF
Nguyen, LL
AF Adler, Joel T.
Yeh, Heidi
Markmann, James F.
Nguyen, Louis L.
TI Temporal Analysis of Market Competition and Density in Renal
Transplantation Volume and Outcome
SO TRANSPLANTATION
LA English
DT Article
ID KIDNEY-TRANSPLANTATION; UNITED-STATES; ACCESS; RISK
AB Background. Kidney transplant centers are distributed unevenly throughout 58 donor service areas (DSAs) in the United States. Market competition and transplant center density may affect transplantation access and outcomes. We evaluated the role of spatial organization of transplant centers in conjunction with market competition in the conduct of kidney transplantation. Methods. The Scientific Registry of Transplant Recipients was queried for market characteristics associated with kidney transplantation between 2003 and 2012. Market competition was calculated using the Herfindahl Hirschman Index. Kidney transplant centers were geocoded to measure spatial organization by the average nearest neighbor (ANN) method. Kidney quality was assessed by kidney donor risk index. A hierarchical negative binomialmixed effects model tested the relationship between market characteristics and annual kidney transplants by DSA. Results. About 152,071 kidney transplants were performed at 229 adult kidney transplant centers in 58 DSAs. Greater market competition was associated with kidney transplant center spatial clustering (P < 0.001). In multivariable analysis, more kidney transplant centers (incidence rate ratio [IRR], 1.04; P = 0.005), 100 more new listings (IRR, 1.02; P = 0.003), 100 more deceased donors (IRR, 1.23; P < 0.001), 100 more new dialysis registrants (IRR, 1.01; P < 0.001), and higher kidney donor risk index (IRR, 1.98; P < 0.001) were associated with increased kidney transplants. Conclusions. After controlling for market characteristics, larger numbers of kidney transplant centers were associated with more kidney transplants and increased utilization of deceased donor kidneys. This underlines the importance of understanding geography as well as competition in improving access to kidney transplantation.
C1 [Adler, Joel T.; Nguyen, Louis L.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, 75 Francis St, Boston, MA 02115 USA.
[Adler, Joel T.; Yeh, Heidi; Markmann, James F.] Massachusetts Gen Hosp, Dept Surg, Div Transplant Surg, Boston, MA 02114 USA.
[Nguyen, Louis L.] Brigham & Womens Hosp, Dept Surg, Div Vasc & Endovasc Surg, 75 Francis St, Boston, MA 02115 USA.
RP Nguyen, LL (reprint author), Brigham & Womens Hosp, Ctr Surg & Publ Hlth, 75 Francis St, Boston, MA 02115 USA.; Nguyen, LL (reprint author), Brigham & Womens Hosp, Div Vasc & Endovasc Surg, 75 Francis St, Boston, MA 02115 USA.
EM llnguyen@partners.org
OI Adler, Joel/0000-0001-8190-3444
NR 14
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD MAR
PY 2016
VL 100
IS 3
BP 670
EP 677
DI 10.1097/TP.0000000000000851
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DF8BR
UT WOS:000371582400042
PM 26574684
ER
PT J
AU Treuting, PM
Snyder, JM
Ikeno, Y
Schofield, PN
Ward, JM
Sundberg, JP
AF Treuting, P. M.
Snyder, J. M.
Ikeno, Y.
Schofield, P. N.
Ward, J. M.
Sundberg, J. P.
TI The Vital Role of Pathology in Improving Reproducibility and
Translational Relevance of Aging Studies in Rodents
SO VETERINARY PATHOLOGY
LA English
DT Article
DE aging; pathology; health span; life span; longevity; necropsy;
histopathology; rodent; mouse model; animal model; cause of death
ID GENETICALLY HETEROGENEOUS MICE; OF-DEATH ASSIGNMENT; EXTENDS LIFE-SPAN;
CHRONIC DISEASE; INTERIM-REPORT; ANIMAL-MODELS; MOUSE MODELS;
DATA-CAPTURE; RAPAMYCIN; LONGEVITY
AB Pathology is a discipline of medicine that adds great benefit to aging studies of rodents by integrating in vivo, biochemical, and molecular data. It is not possible to diagnose systemic illness, comorbidities, and proximate causes of death in aging studies without the morphologic context provided by histopathology. To date, many rodent aging studies do not utilize end points supported by systematic necropsy and histopathology, which leaves studies incomplete, contradictory, and difficult to interpret. As in traditional toxicity studies, if the effect of a drug, dietary treatment, or altered gene expression on aging is to be studied, systematic pathology analysis must be included to determine the causes of age-related illness, moribundity, and death. In this Commentary, the authors discuss the factors that should be considered in the design of aging studies in mice, with the inclusion of robust pathology practices modified after those developed by toxicologic and discovery research pathologists. Investigators in the field of aging must consider the use of histopathology in their rodent aging studies in this era of integrative and preclinical geriatric science (geroscience).
C1 [Treuting, P. M.; Snyder, J. M.] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA.
[Ikeno, Y.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78229 USA.
[Ikeno, Y.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Ikeno, Y.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.
[Ikeno, Y.] South Texas Vet Hlth Care Syst, Audie L Murphy VA Hosp, Geriatr Res & Educ Clin Ctr, San Antonio, TX USA.
[Schofield, P. N.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England.
[Schofield, P. N.; Sundberg, J. P.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
[Ward, J. M.] Global VetPathol, Montgomery Village, MD USA.
RP Treuting, PM (reprint author), Univ Washington, Comparat Pathol, Dept Comparat Med & Histol & Imaging Core, Sch Med, 1-458,Box 357340, Seattle, WA 98195 USA.
EM treuting@uw.edu
FU BLRD VA [I01 BX001023]; NCI NIH HHS [CA34196, P30 CA034196]; NIA NIH HHS
[P30 AG013280, AG13319, AG25707, P01 AG001751, P01AG01751, P30 AG013319,
P30 AG025707, P30AG013280]; NIH HHS [R25 OD010450, R25OD010450]
NR 81
TC 2
Z9 2
U1 4
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0300-9858
EI 1544-2217
J9 VET PATHOL
JI Vet. Pathol.
PD MAR
PY 2016
VL 53
IS 2
BP 244
EP 249
DI 10.1177/0300985815620629
PG 6
WC Pathology; Veterinary Sciences
SC Pathology; Veterinary Sciences
GA DF8PO
UT WOS:000371620500003
PM 26792843
ER
PT J
AU Chien, AT
Schiavoni, KH
Sprecher, E
Landon, BE
McNeil, BJ
Chernew, ME
Schuster, MA
AF Chien, Alyna T.
Schiavoni, Katherine H.
Sprecher, Eli
Landon, Bruce E.
McNeil, Barbara J.
Chernew, Michael E.
Schuster, Mark A.
TI How Accountable Care Organizations Responded to Pediatric Incentives in
the Alternative Quality Contract
SO ACADEMIC PEDIATRICS
LA English
DT Article
DE accountable care organizations; payment incentives; pediatrics
ID HEALTH-CARE; CHILDREN; PERFORMANCE; MASSACHUSETTS; DISABILITIES;
ALGORITHM; PAY
AB OBJECTIVE: From 2009 to 2010, 12 accountable care organizations (ACOs) entered into the alternative quality contract (AQC), BlueCross BlueShield of Massachusetts's global payment arrangement. The AQC included 6 outpatient pediatric quality measures among 64 total measures tied to pay-for-performance bonuses and incorporated pediatric populations in their global budgets. We characterized the pediatric infrastructure of these adult-oriented ACOs and obtained leaders' perspectives on their ACOs' response to pediatric incentives.
METHODS: We used Massachusetts Health Quality Partners and American Hospital Association Survey data to characterize ACOs' pediatric infrastructure as extremely limited, basic, and substantial on the basis of the extent of pediatric primary care, outpatient specialist, and inpatient services. After ACOs had 16 to 43 months of experience with the AQC, we interviewed 22 leaders to gain insight into how organizations made changes to improve pediatric care quality, tried to reduce pediatric spending, and addressed care for children with special health care needs.
RESULTS: ACOs' pediatric infrastructure ranged from extremely limited (eg, no general pediatricians in their primary care workforce) to substantial (eg, 42% of workforce was general pediatricians). Most leaders reported intensifying their pediatric quality improvement efforts and witnessing changes in quality metrics; most also investigated pediatric spending patterns but struggled to change patients' utilization patterns. All reported that the AQC did little to incentivize care for children with special health care needs and that future incentive programs should include this population.
CONCLUSIONS: Although ACOs involved in the AQC were adult-oriented, most augmented their pediatric quality improvement and spending reduction efforts when faced with pediatric incentives.
C1 [Chien, Alyna T.; Sprecher, Eli; Schuster, Mark A.] Boston Childrens Hosp, Dept Med, Div Gen Pediat, Boston, MA USA.
[Landon, Bruce E.; McNeil, Barbara J.; Chernew, Michael E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Chien, Alyna T.; Schiavoni, Katherine H.; Schuster, Mark A.] Harvard Univ, Sch Med, Boston, MA USA.
[Schiavoni, Katherine H.] Massachusetts Gen Hosp, Dept Med & Pediat, Boston, MA 02114 USA.
[Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[McNeil, Barbara J.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
RP Chien, AT (reprint author), Boston Childrens Hosp, Div Gen Pediat, 300 Longwood Ave, Boston, MA 02115 USA.
EM alyna.chien@childrens.harvard.edu
FU Charles H. Hood Foundation; Agency for Healthcare Research and Quality
[K08HS017146]
FX This work was financially supported by the Charles H. Hood Foundation.
ATC was also supported by the Agency for Healthcare Research and Quality
(K08HS017146). The funder had no role in study design, data collection,
analysis and interpretation of data, or manuscript preparation. The
authors would like to thank their collaborators at BlueCross BlueShield
Massachusetts, Dana G. Safran, ScD, and Tony Dodek, MD.
NR 26
TC 3
Z9 3
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1876-2859
EI 1876-2867
J9 ACAD PEDIATR
JI Acad. Pediatr.
PD MAR
PY 2016
VL 16
IS 2
BP 200
EP 207
PG 8
WC Pediatrics
SC Pediatrics
GA DF5AK
UT WOS:000371364000015
PM 26523636
ER
PT J
AU Jarlenski, M
Baller, J
Borrero, S
Bennett, WL
AF Jarlenski, Marian
Baller, Julia
Borrero, Sonya
Bennett, Wendy L.
TI Trends in Disparities in Low-Income Children's Health Insurance Coverage
and Access to Care by Family Immigration Status
SO ACADEMIC PEDIATRICS
LA English
DT Article
DE access to care; disparities; health insurance; immigrant
ID UNINSURED CHILDREN; UNITED-STATES; EXPANSIONS; MEDICAID; PARENTS; IMPACT
AB OBJECTIVE: To examine time trends in disparities in low-income children's health insurance coverage and access to care by family immigration status.
METHODS: We used data from the National Survey of Children's Health in 2003 to 2011-2012, including 83,612 children aged 0 to 17 years with family incomes <200% of the federal poverty level. We examined 3 immigration status categories: citizen children with nonimmigrant parents; citizen children with immigrant parents; and immigrant children. We used multivariable regression analyses to obtain adjusted trends in health insurance coverage and access to care..
RESULTS: All low-income children experienced gains in health insurance coverage and access to care from 2003 to 2011-2012, regardless of family immigration status. Relative to citizen children with nonimmigrant parents, citizen children with immigrant parents had a 5 percentage point greater increase in health insurance coverage (P = .06), a 9 percentage point greater increase in having a personal doctor or nurse (P < .01), and an 11 percentage point greater increase in having no unmet medical need (P < .01). Immigrant children had significantly lower health insurance coverage than other groups. However, the group had a 14 percentage point greater increase in having a personal doctor or nurse (P < .01) and a 26 percentage point greater increase in having no unmet medical need (P < .01) relative to citizen children with nonimmigrant parents.
CONCLUSIONS: Some disparities in access to care related to family immigration status have lessened over time among children in low-income families, although large disparities still exist. Policy efforts are needed to ensure that children of immigrant parents and immigrant children are able to access health insurance and health care.
C1 [Jarlenski, Marian] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 DeSoto St,A647, Pittsburgh, PA 15261 USA.
[Jarlenski, Marian; Borrero, Sonya] Univ Pittsburgh, Ctr Womens Hlth Res & Innovat, Pittsburgh, PA USA.
[Baller, Julia] Math Policy Res, Washington, DC USA.
[Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Bennett, Wendy L.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA.
[Bennett, Wendy L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA.
RP Jarlenski, M (reprint author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 DeSoto St,A647, Pittsburgh, PA 15261 USA.
EM marian.jarlenski@pitt.edu
OI Jarlenski, Marian/0000-0001-6907-5447
NR 37
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1876-2859
EI 1876-2867
J9 ACAD PEDIATR
JI Acad. Pediatr.
PD MAR
PY 2016
VL 16
IS 2
BP 208
EP 215
PG 8
WC Pediatrics
SC Pediatrics
GA DF5AK
UT WOS:000371364000016
PM 26329016
ER
PT J
AU Kranzler, HR
Armeli, S
Wetherill, R
Feinn, R
Tennen, H
Gelernter, J
Covault, J
Pond, T
AF Kranzler, Henry R.
Armeli, Stephen
Wetherill, Reagan
Feinn, Richard
Tennen, Howard
Gelernter, Joel
Covault, Jonathan
Pond, Timothy
TI Self-efficacy mediates the effects of topiramate and GRIK1 genotype on
drinking
SO ADDICTION BIOLOGY
LA English
DT Article
DE GRIK1; mediated moderation; personalized treatment; pharmacogenetics;
self-efficacy; topiramate
ID ALCOHOL DEPENDENCE; 12-STEP; EXPECTATIONS; MODERATION; DRINKERS;
PROGRAMS; OUTCOMES
AB Previous studies indicate that topiramate reduces alcohol use among problem drinkers, with one study showing that the effect was moderated by a polymorphism (rs2832407) in GRIK1, the gene encoding the GluK1 kainate subunit. We examined whether the interactive effect of medication and genotype (1) altered the association between daily self-efficacy and later-day drinking; and (2) had an indirect effect on drinking via self-efficacy. In a 12-week, placebo-controlled trial of topiramate, we used daily interactive voice response technology to measure self-efficacy (i.e. confidence in avoiding heavy drinking later in the day) and drinking behavior in 122 European-American heavy drinkers. Topiramate's effects on both self-efficacy and drinking level were moderated by rs2832407. C-allele homozygotes treated with topiramate showed higher levels of self-efficacy and lower levels of nighttime drinking across the 12-week trial. Further, the interactive effect of topiramate and genotype on mean nighttime drinking levels was mediated by mean levels of self-efficacy. By modeling topiramate's effects on nighttime drinking across multiple levels of analysis, we found that self-efficacy, a key psychologic construct, mediated the effect of topiramate, which was moderated by rs2832407 genotype. Thus, it may be possible to use an individualized assessment (i.e. genotype) to select treatment to optimize the reduction in heavy drinking and thereby provide a personalized treatment approach.
C1 [Kranzler, Henry R.; Wetherill, Reagan; Pond, Timothy] Univ Penn, Dept Psychiat, Ctr Studies Addict, Perelman Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA.
[Armeli, Stephen] Fairleigh Dickinson Univ, Dept Psychol, Teaneck, NJ USA.
[Feinn, Richard] Quinnipiac Univ, Frank Netter Sch Med, Dept Med Sci, Hamden, CT USA.
[Tennen, Howard] Univ Connecticut, Sch Med, Dept Community Med & Healthcare, Farmington, CT USA.
[Covault, Jonathan] Univ Connecticut, Dept Psychiat, Sch Med, Alcohol Res Ctr, Farmington, CT 06107 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Gelernter, Joel] Vet Affairs Connecticut Healthcare Ctr, West Haven, CT USA.
RP Kranzler, HR (reprint author), Univ Penn, Dept Psychiat, Ctr Studies Addict, Perelman Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM kranzler@mail.med.upenn.edu
FU National Institutes of Health [P60 AA03510, K24 AA13736]
FX Supported by National Institutes of Health grants P60 AA03510 and K24
AA13736. Staff members of the Clinical Research and Evaluation Unit of
the University of Connecticut Alcohol Research Center and the Center for
Studies of Addiction of the University of Pennsylvania Perelman School
of Medicine were instrumental in the conduct of the study.
NR 31
TC 7
Z9 9
U1 4
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1355-6215
EI 1369-1600
J9 ADDICT BIOL
JI Addict. Biol.
PD MAR
PY 2016
VL 21
IS 2
BP 450
EP 459
DI 10.1111/adb.12207
PG 10
WC Biochemistry & Molecular Biology; Substance Abuse
SC Biochemistry & Molecular Biology; Substance Abuse
GA DF2CW
UT WOS:000371148700020
PM 25496338
ER
PT J
AU Clarke, TK
Smith, AH
Gelernter, J
Kranzler, HR
Farrer, LA
Hall, LS
Fernandez-Pujals, AM
MacIntyre, DJ
Smith, BH
Hocking, LJ
Padmanabhan, S
Hayward, C
Thomson, PA
Porteous, DJ
Deary, IJ
McIntosh, AM
AF Clarke, Toni-Kim
Smith, Andrew H.
Gelernter, Joel
Kranzler, Henry R.
Farrer, Lindsay A.
Hall, Lynsey S.
Fernandez-Pujals, Ana M.
MacIntyre, Donald J.
Smith, Blair H.
Hocking, Lynne J.
Padmanabhan, Sandosh
Hayward, Caroline
Thomson, Pippa A.
Porteous, David J.
Deary, Ian J.
McIntosh, Andrew M.
TI Polygenic risk for alcohol dependence associates with alcohol
consumption, cognitive function and social deprivation in a
population-based cohort
SO ADDICTION BIOLOGY
LA English
DT Article
DE Alcohol dependence; cognition; environment; genetics; polygenic; social
deprivation
ID EXECUTIVE FUNCTIONS; FAMILY HEALTH; OLD-AGE; CHILDREN; INTELLIGENCE;
ADOLESCENCE; CHILDHOOD; EDUCATION; CORTEX; ABUSE
AB Alcohol dependence is frequently co-morbid with cognitive impairment. The relationship between these traits is complex as cognitive dysfunction may arise as a consequence of heavy drinking or exist prior to the onset of dependence. In the present study, we tested the genetic overlap between cognitive abilities and alcohol dependence using polygenic risk scores (PGRS). We created two independent PGRS derived from two recent genome-wide association studies (GWAS) of alcohol dependence (SAGE GWAS: n=2750; Yale-Penn GWAS: n=2377) in a population-based cohort, Generation Scotland: Scottish Family Health Study (GS:SFHS) (n=9863). Data on alcohol consumption and four tests of cognitive function [Mill Hill Vocabulary (MHV), digit symbol coding, phonemic verbal fluency (VF) and logical memory] were available. PGRS for alcohol dependence were negatively associated with two measures of cognitive function: MHV (SAGE: P=0.009, =-0.027; Yale-Penn: P=0.001, =-0.034) and VF (SAGE: P=0.0008, =-0.036; Yale-Penn: P=0.00005, =-0.044). VF remained robustly associated after adjustment for education and social deprivation; however, the association with MHV was substantially attenuated. Shared genetic variants may account for some of the phenotypic association between cognitive ability and alcohol dependence. A significant negative association between PGRS and social deprivation was found (SAGE: P=5.2x10(-7), =-0.054; Yale-Penn: P=0.000012, =-0.047). Individuals living in socially deprived regions were found to carry more alcohol dependence risk alleles which may contribute to the increased prevalence of problem drinking in regions of deprivation. Future work to identify genes which affect both cognitive impairment and alcohol dependence will help elucidate biological processes common to both disorders.
C1 [Clarke, Toni-Kim; Hall, Lynsey S.; Fernandez-Pujals, Ana M.; MacIntyre, Donald J.; McIntosh, Andrew M.] Univ Edinburgh, Div Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland.
[Hayward, Caroline; Thomson, Pippa A.] Univ Edinburgh, Western Gen Hosp, Ctr Genom & Expt Med, Inst Genet & Mol Med, Edinburgh EH10 5HF, Midlothian, Scotland.
[Hayward, Caroline; Porteous, David J.] Univ Edinburgh, MRC Human Genet, MRC IGMM, Edinburgh EH10 5HF, Midlothian, Scotland.
[Thomson, Pippa A.; Porteous, David J.; Deary, Ian J.; McIntosh, Andrew M.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh EH10 5HF, Midlothian, Scotland.
[Deary, Ian J.] Univ Edinburgh, Dept Psychol, Edinburgh EH10 5HF, Midlothian, Scotland.
[Smith, Andrew H.; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, West Haven, CT 06516 USA.
[Smith, Andrew H.; Gelernter, Joel] VA CT Healthcare Ctr, West Haven, CT USA.
[Smith, Andrew H.] Yale Univ, Sch Med, Med Scientist Training Program, West Haven, CT 06516 USA.
[Smith, Andrew H.] Yale Univ, Sch Med, Interdept Neurosci Program, West Haven, CT 06516 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Genet & Neurobiol, West Haven, CT 06516 USA.
[Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med & Publ Hlth, Dept Med, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Neurol, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Ophthalmol, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Biomed Genet, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Epidemiol, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Biostat, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Smith, Blair H.] Univ Dundee, Populat Hlth Sci, Dundee DD1 4HN, Scotland.
[Hocking, Lynne J.] Univ Aberdeen, Div Appl Hlth Sci, Aberdeen AB9 1FX, Scotland.
[Padmanabhan, Sandosh] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland.
RP Clarke, TK (reprint author), Univ Edinburgh, Royal Edinburgh Hosp, Div Psychiat, Kennedy Tower, Edinburgh EH10 5HF, Midlothian, Scotland.
EM toni.clarke@ed.ac.uk
RI Padmanabhan, Sandosh/S-3963-2016;
OI Clarke, Toni-Kim/0000-0002-7745-6351; Farrer,
Lindsay/0000-0001-5533-4225; MacIntyre, Donald J/0000-0001-6963-1335;
Hocking, Lynne J/0000-0002-2414-2826; Padmanabhan,
Sandosh/0000-0003-3869-5808; Smith, Blair/0000-0002-5362-9430; McIntosh,
Andrew/0000-0002-0198-4588
FU Chief Scientist Office of the Scottish Government; Scottish Funding
Council; Scottish Government Health Department, Chief Scientist Office
[CZD/16/6]; National Institutes of Health [N01-HG-65403, RC2 DA028909,
R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, P50
AA12870, MSTP T32GM07205, CTSA 8UL1TR000142]; Study of Addiction:
Genetics and Environment (SAGE) was provided through the NIH Genes,
Environment and Health Initiative [GEI] [U01 HG004422]; GENEVA
Coordinating [U01 HG004446]; Collaborative Study on the Genetics of
Alcoholism (COGA) [U10 AA008401]; Collaborative Genetic Study of
Nicotine Dependence (COGEND) [P01 CA089392]; Family Study of Cocaine
Dependence (FSCD) [R01 DA013423]; Johns Hopkins University Center for
Inherited Disease Research; NIH GEI [U01HG004438]; National Institute on
Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; NIH
[HHSN268200782096C]; Dr Mortimer and Theresa Sackler Foundation;
Biotechnology and Biological Sciences Research Council (BBSRC); Medical
Research Council (MRC); Wellcome Trust [104036/Z/14/Z]
FX The Chief Scientist Office of the Scottish Government and the Scottish
Funding Council provided core support for Generation Scotland. GS:SFHS
was funded by a grant from the Scottish Government Health Department,
Chief Scientist Office (No. CZD/16/6). Genotyping services for a part of
the Yale GWAS study were provided by the Center for Inherited Disease
Research (CIDR) and Yale University (Center for Genome Analysis). CIDR
is fully funded through a federal contract from the National Institutes
of Health to The Johns Hopkins University (Contract No. N01-HG-65403).
The publicly available datasets used for the analyses described in this
manuscript were obtained from dbGaP at
http://www.ncbi.nlmnih.gov/projects/gap/cgi-bin/studycgi?study_id=phs000
092.vl.p1 through dbGaP accession number phs000092.vl.p. Funding support
for the Study of Addiction: Genetics and Environment (SAGE) was provided
through the NIH Genes, Environment and Health Initiative [GEI] (U01
HG004422). SAGE is one of the genome-wide association studies funded as
part of the Gene Environment Association Studies (GENEVA) under GEL
Assistance with phenotype harmonization and genotype cleaning, as well
as with general study coordination, was provided by the GENEVA
Coordinating Center (U01 HG004446). Assistance with data cleaning was
provided by the National Center for Biotechnology Information. Support
for collection of datasets and samples was provided by the Collaborative
Study on the Genetics of Alcoholism (COGA; U10 AA008401), the
Collaborative Genetic Study of Nicotine Dependence (COGEND; P01
CA089392) and the Family Study of Cocaine Dependence (FSCD: R01
DA013423). Funding support for genotyping, which was performed at the
Johns Hopkins University Center for Inherited Disease Research, was
provided by the NIH GEI (U01HG004438), the National Institute on Alcohol
Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH
contract 'High throughput genotyping for studying the genetic
contributions to human disease' (HHSN268200782096C). The authors TKC and
AN NI acknowledge with gratitude the financial support received for this
work from the Dr Mortimer and Theresa Sackler Foundation. PAT, DTP, IJD
and AMM are members of Hie University of Edinburgh Centre for Cognitive
Ageing and Cognitive Epidemiology, part of the cross council Lifelong
Health and Wellbeing Initiative (MR/K026992/1). Funding from the
Biotechnology and Biological Sciences Research Council (BBSRC) and
Medical Research Council (MRC) is gratefully acknowledged, supported in
part by National Institutes of Health grants RC2 DA028909, R01 DA12690,
R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, P50 AA12870, MSTP
T32GM07205 and CTSA 8UL1TR000142. This work is supported by the Wellcome
Trust through a Strategic Award, reference 104036/Z/14/Z.
NR 47
TC 3
Z9 5
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1355-6215
EI 1369-1600
J9 ADDICT BIOL
JI Addict. Biol.
PD MAR
PY 2016
VL 21
IS 2
BP 469
EP 480
DI 10.1111/adb.12245
PG 12
WC Biochemistry & Molecular Biology; Substance Abuse
SC Biochemistry & Molecular Biology; Substance Abuse
GA DF2CW
UT WOS:000371148700022
PM 25865819
ER
PT J
AU Delnomdedieu, M
Duvvuri, S
Li, DJ
Atassi, N
Lu, M
Brashear, HR
Liu, E
Ness, S
Kupiec, JW
AF Delnomdedieu, Marielle
Duvvuri, Sridhar
Li, David Jianjun
Atassi, Nazem
Lu, Ming
Brashear, H. Robert
Liu, Enchi
Ness, Seth
Kupiec, James W.
TI First-In-Human safety and long-term exposure data for AAB-003
(PF-05236812) and biomarkers after intravenous infusions of escalating
doses in patients with mild to moderate Alzheimer's disease
SO ALZHEIMERS RESEARCH & THERAPY
LA English
DT Article
DE Alzheimer's disease; Pharmacokinetics; Monoclonal antibody; Humans;
Safety; Immunotherapy; ARIA
ID IMAGING ABNORMALITIES; PHASE-3 TRIALS; IMMUNOTHERAPY; BAPINEUZUMAB;
SOLANEZUMAB
AB Background: In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer's disease (AD) after infusion of a humanized monoclonal antibody to amyloid beta, AAB-003 (NCT01193608; registered 19 August 2010). AAB-003 was developed by modifying bapineuzumab to reduce Fc-receptor-mediated effector function as a strategy to reduce the removal of amyloid from vessel walls associated with amyloid-related imaging abnormalities with edema/effusions (ARIA-E) without diminishing overall amyloid clearance.
Methods: Eighty-eight patients with AD received up to three infusions of AAB-003 (or placebo) 13 weeks apart at doses of 0.5, 1, 2, 4 or 8 mg/kg in the FIH trial. Dose escalation was based on safety data reviews using a Bayesian escalation algorithm. Subjects who completed the FIH study were permitted to enter a 1-year open-label extension trial with four additional intravenous infusions of AAB-003 (NCT01369225; registered 10 May 2011).
Results: Dose-dependent increases in plasma amyloid beta and AAB-003 were observed. No significant changes in cerebral spinal fluid biomarkers were observed. Pharmacokinetics elimination half-life (21-28 days) clearance and volume of distribution values were consistent across dose groups indicating linearity. ARIA-E was the most notable safety finding detected by magnetic resonance imaging (MRI) at 8 mg/kg in two patients. Three cases of microhemorrhage were observed. No new safety findings or MRI abnormalities were observed for the 52 subjects who received AAB-003 in the extension trial.
Conclusion: Based on integrated review of laboratory, electrocardiogram, adverse events, and MRI, AAB-003 was safe and well tolerated up to 8 mg/kg for up to 91 weeks (FIH and extension trials) in patients with mild to moderate AD. Asymptomatic and resolvable ARIA-E was observed after the first or second infusion of AAB-003, similar to bapineuzumab. The AAB-003 dose at which ARIA-E was observed was higher compared to bapineuzumab, supporting the hypothesis that reducing Fc-receptor effector function may reduce the ARIA associated with monoclonal antibodies targeting cerebral amyloid.
C1 [Delnomdedieu, Marielle; Duvvuri, Sridhar; Li, David Jianjun; Kupiec, James W.] Pfizer Neurosci Res Unit, Cambridge, MA USA.
[Atassi, Nazem] Mass Gen Hosp, Boston, MA USA.
[Lu, Ming] Janssen R&D, Spring House, PA USA.
[Brashear, H. Robert; Liu, Enchi; Ness, Seth] Janssen R&D, Fremont, CA USA.
RP Delnomdedieu, M (reprint author), Pfizer Neurosci Res Unit, Cambridge, MA USA.
EM marielle.delnomdedieu@pfizer.com
FU Pfizer Inc.; Janssen Research & Development, LLC.
FX The studies were sponsored by Pfizer Inc. and Janssen Research &
Development, LLC. NA was a paid contractor to Pfizer Inc. during the
conduct of the studies and the development of the manuscript. EL (former
Janssen employee) was an employee of Janssen R&D during the conduct of
the studies and initiation of the manuscript. Eve Pickering provided
statistical leadership. Vladimir Dragalin and Michael Krams provided
critical input on trial design and originated the adaptive components.
Wendy Luca and Maria Graziewicz provided operational and clinical trial
support. Jeffrey Miceli provided clinical guidance during the design and
execution of the trial. No editorial service was provided.
NR 17
TC 1
Z9 1
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-9193
J9 ALZHEIMERS RES THER
JI Alzheimers Res. Ther.
PD MAR 1
PY 2016
VL 8
AR 12
DI 10.1186/s13195-016-0177-y
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DF3AN
UT WOS:000371216200001
PM 26925577
ER
PT J
AU Zent, CS
Wang, XV
Ketterling, RP
Hanson, CA
Libby, EN
Barrientos, JC
Call, TG
Chang, JE
Liu, JJ
Calvo, AR
Lazarus, HM
Rowe, JM
Luger, SM
Litzow, MR
Tallman, MS
AF Zent, Clive S.
Wang, Xin Victoria
Ketterling, Rhett P.
Hanson, Curtis A.
Libby, Edward N.
Barrientos, Jacqueline C.
Call, Timothy G.
Chang, Julie E.
Liu, Jane J.
Calvo, Alejandro R.
Lazarus, Hillard M.
Rowe, Jacob M.
Luger, Selina M.
Litzow, Mark R.
Tallman, Martin S.
TI A phase II randomized trial comparing standard and low dose rituximab
combined with alemtuzumab as initial treatment of progressive chronic
lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer
research group (E1908)
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID OPEN-LABEL; CD20 LOSS; CYCLOPHOSPHAMIDE; FLUDARABINE; CLL; CHLORAMBUCIL;
COMBINATION; MECHANISMS; OFATUMUMAB; GUIDELINES
AB Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients requiring initial therapy are often older and frailer and unsuitable candidates for standard chemoimmunotherapy regimens. Shorter duration combination monoclonal antibody (mAb) therapy using alemtuzumab and rituximab has been shown to be effective and tolerable treatment for CLL. Standard dose anti-CD20 mAb therapy causes loss of CD20 expression by surviving CLL cells, which can be minimized by decreasing the mAb dose. We report a randomized phase II clinical trial enrolling older ( 65 years) patients (median age 76 years, n=31) with treatment naive progressive CLL. Patients received 8-12 weeks of standard subcutaneous alemtuzumab with either intravenous standard (375 mg/m(2) weekly)(n=16) or low dose (20 mg/m(2) 3x week)(n=15) rituximab. This study was closed before full accrual because the manufacturer withdrew alemtuzumab for treatment of CLL. The overall response rate was 90% with an 45% complete response rate, median progression-free survival of 17.9 months and no significant differences in outcome between the low and standard dose rituximab arms. The major toxicities were cytopenia and infection with one treatment fatality caused by progressive multifocal leukoencephalopathy but no other opportunistic infections. Combination mAb therapy was effective and tolerable treatment for older and frailer patients with progressive CLL, achieving a high rate of complete remissions. These data support the role of mAb in therapy for less fit CLL patients and the further study of low dose higher frequency anti-CD20 mAb therapy as a potentially more effective use of anti-CD20 mAb in the treatment of CLL. Am. J. Hematol. 91:308-312, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Zent, Clive S.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Zent, Clive S.; Ketterling, Rhett P.; Hanson, Curtis A.; Call, Timothy G.; Litzow, Mark R.] Mayo Clin, Rochester, MN USA.
[Wang, Xin Victoria] Dana Farber Canc Inst, ECOG ACRIN Biostat Ctr, Boston, MA 02115 USA.
[Libby, Edward N.] Seattle Canc Care Alliance, Seattle, WA USA.
[Libby, Edward N.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
[Barrientos, Jacqueline C.] North Shore LIJ Hlth Syst NCORP, Manhasset, NY USA.
[Chang, Julie E.] Univ Wisconsin, Madison, WI USA.
[Liu, Jane J.] Illinois CancerCare, Peoria, IL USA.
[Calvo, Alejandro R.] Kettering Hlth Network, Kettering, OH USA.
[Lazarus, Hillard M.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Rowe, Jacob M.] Rambam Med Ctr, Haifa, Israel.
[Luger, Selina M.] Univ Penn, Philadelphia, PA 19104 USA.
[Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Tallman, Martin S.] Northwestern Univ, Sch Med, Chicago, IL USA.
RP Zent, CS (reprint author), Univ Rochester, Med Ctr, Wilmot Canc Inst, 601 Elmswood Ave Box 704, Rochester, NY 14642 USA.
EM clive_zent@urmc.rochester.edu
FU NCI NIH HHS [UG1 CA189957, CA180790, CA180791, CA180794, CA180799,
CA180820, CA180821, CA180853, CA180888, CA189830, CA189953, CA189957,
P30 CA008748, U01 CA079778, U10 CA021115, U10 CA023318, U10 CA066636,
U10 CA180790, U10 CA180791, U10 CA180794, U10 CA180799, U10 CA180820,
U10 CA180821, U10 CA180853, U10 CA180888, UG1 CA189830, UG1 CA189850,
UG1 CA189953]
NR 34
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAR
PY 2016
VL 91
IS 3
BP 308
EP 312
DI 10.1002/ajh.24265
PG 5
WC Hematology
SC Hematology
GA DF2HI
UT WOS:000371162800255
PM 26662208
ER
PT J
AU Seftel, MD
Neuberg, D
Zhang, MJ
Wang, HL
Ballen, KK
Bergeron, J
Couban, S
Freytes, CO
Hamadani, M
Kharfan-Dabaja, MA
Lazarus, HM
Nishihori, T
Paulson, K
Saber, W
Sallan, SE
Soiffer, R
Tallman, MS
Woolfrey, AE
DeAngelo, DJ
Weisdorf, DJ
AF Seftel, Matthew D.
Neuberg, Donna
Zhang, Mei-Jie
Wang, Hai-Lin
Ballen, Karen Kuhn
Bergeron, Julie
Couban, Stephen
Freytes, Cesar O.
Hamadani, Mehdi
Kharfan-Dabaja, Mohamed A.
Lazarus, Hillard M.
Nishihori, Taiga
Paulson, Kristjan
Saber, Wael
Sallan, Stephen E.
Soiffer, Robert
Tallman, Martin S.
Woolfrey, Ann E.
DeAngelo, Daniel J.
Weisdorf, Daniel J.
CA CIBMTR
Dana Farber ALL Consortium
TI Pediatric-inspired therapy compared to allografting for Philadelphia
chromosome-negative adult ALL in first complete remission
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC-CELL TRANSPLANTATION;
CONVENTIONAL CONSOLIDATION/MAINTENANCE CHEMOTHERAPY; MINIMAL RESIDUAL
DISEASE; 2ND COMPLETE REMISSION; REDUCED-INTENSITY; UNRELATED DONORS;
YOUNG-ADULTS; DOSE INTENSIFICATION; GROUP-B
AB For adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in first complete remission (CR1), allogeneic hematopoietic cell transplantation (HCT) is an established curative strategy. However, pediatric-inspired chemotherapy may also offer durable leukemia-free survival in the absence of HCT. We compared 422 HCT recipients aged 18-50 years with Ph-ALL in CR1 reported to the CIBMTR with an age-matched concurrent cohort of 108 Ph- ALL CR1 patients who received a Dana-Farber Consortium pediatric-inspired non-HCT regimen. At 4 years of follow-up, incidence of relapse after HCT was 24% (95% CI 19-28) versus 23% (95% CI 15-32) for the non-HCT (chemo) cohort (P=0.97). Treatment-related mortality (TRM) was higher in the HCT cohort [HCT 37% (95% CI 31-42) versus chemo 6% (95% CI 3-12), P<0.0001]. DFS in the HCT cohort was 40% (95% CI 35-45) versus 71% (95% CI 60-79) for chemo, P<0.0001. Similarly, OS favored chemo [HCT 45% (95% CI 40-50)] versus chemo 73% [(95% CI 63-81), P<0.0001]. In multivariable analysis, the sole factor predictive of shorter OS was the administration of HCT [hazard ratio 3.12 (1.99-4.90), P<0.0001]. For younger adults with Ph- ALL, pediatric-inspired chemotherapy had lower TRM, no increase in relapse, and superior overall survival compared to HCT. Am. J. Hematol. 91:322-329, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Seftel, Matthew D.; Paulson, Kristjan] CancerCare Manitoba, Dept Med Oncol & Haematol, ON2047, Winnipeg, MB R3E 0V9, Canada.
[Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Zhang, Mei-Jie; Wang, Hai-Lin; Hamadani, Mehdi; Saber, Wael] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Zhang, Mei-Jie] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
[Ballen, Karen Kuhn] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA.
[Bergeron, Julie] Hop Maison Neuve Rosemont, Dept Hematol, Montreal, PQ, Canada.
[Couban, Stephen] Dalhousie Univ, Queen Elizabeth Hlth Sci Ctr 2, Div Haematol, Halifax, NS, Canada.
[Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Kharfan-Dabaja, Mohamed A.; Nishihori, Taiga] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA.
[Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA.
[Sallan, Stephen E.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Soiffer, Robert; DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol Hematol Malignancies, Boston, MA 02115 USA.
[Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.
[Woolfrey, Ann E.] Fred Hutchinson Canc Res Ctr, Dept Pediat Hematopoiet Cell Transplant, 1124 Columbia St, Seattle, WA 98104 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA.
RP Seftel, MD (reprint author), CancerCare Manitoba, Dept Med Oncol & Haematol, ON2047, Winnipeg, MB R3E 0V9, Canada.
EM mseftel@cancercare.mb.ca
FU NCI NIH HHS [U24-CA076518, P01 CA068484, P30 CA008748, T32 CA009515, U24
CA076518]; NHLBI NIH HHS [5U10HL069294, U10 HL069294]; PHS HHS
[HHSH250201200016C]
NR 35
TC 5
Z9 5
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAR
PY 2016
VL 91
IS 3
BP 322
EP 329
DI 10.1002/ajh.24285
PG 8
WC Hematology
SC Hematology
GA DF2HI
UT WOS:000371162800258
PM 26701142
ER
PT J
AU Canali, S
Core, AB
Zumbrennen-Bullough, KB
Merkulova, M
Schneyer, A
Pietrangelo, A
Babitt, JL
AF Canali, Susanna
Core, Amanda B.
Zumbrennen-Bullough, Kimberly B.
Merkulova, Maria
Schneyer, Alan
Pietrangelo, Antonello
Babitt, Jodie L.
TI ACTIVIN B UTILIZES ACTIVIN TYPE II RECEPTORS, BMP TYPE I RECEPTORS,
HEMOJUVELIN AND SMAD1/5/8 SELECTIVELY IN HEPATOCYTES TO PROMOTE HEPCIDIN
INDUCTION BY INFLAMMATION IN MICE
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Canali, Susanna; Core, Amanda B.; Zumbrennen-Bullough, Kimberly B.; Merkulova, Maria; Babitt, Jodie L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Ctr Syst Biol, Program Anemia Signaling Res,Div Nephrol,Program, Cambridge, MA 02138 USA.
[Schneyer, Alan] UMass Amherst, Dept Vet & Anim Sci, Amherst, MA USA.
[Pietrangelo, Antonello] Univ Hosp Modena & Reggio Emilia, Ctr Hemochromatosis, Modena, Italy.
RI Pietrangelo, Antonello/K-1517-2016
OI Pietrangelo, Antonello/0000-0002-7411-935X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAR
PY 2016
VL 91
IS 3
MA 51
BP E251
EP E251
PG 1
WC Hematology
SC Hematology
GA DF2HI
UT WOS:000371162800232
ER
PT J
AU Kortman, G
Mulder, M
Richters, T
Shanmugam, N
Trebicka, E
Boekhorst, J
Timmerman, H
Roelofs, R
Wiegerinck, E
Laarakkers, C
Swinkels, D
Bolhuis, A
Cherayil, B
Tjalsma, H
AF Kortman, Guus
Mulder, Michelle
Richters, Thijs
Shanmugam, Nanda
Trebicka, Estela
Boekhorst, Jos
Timmerman, Harro
Roelofs, Rian
Wiegerinck, Erwin
Laarakkers, Coby
Swinkels, Dorine
Bolhuis, Albert
Cherayil, Bobby
Tjalsma, Harold
TI LOW DIETARY IRON INTAKE RESTRAINS THE INTESTINAL INFLAMMATORY RESPONSE
AND PATHOLOGY OF ENTERIC INFECTION BY FOOD-BORNE BACTERIAL PATHOGENS
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Kortman, Guus; Mulder, Michelle; Richters, Thijs; Roelofs, Rian; Wiegerinck, Erwin; Laarakkers, Coby; Swinkels, Dorine; Tjalsma, Harold] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.
[Shanmugam, Nanda; Trebicka, Estela; Cherayil, Bobby] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Boekhorst, Jos; Timmerman, Harro] NIZO Food Res BV, Nijmegen, Netherlands.
[Bolhuis, Albert] Univ Bath, Bath BA2 7AY, Avon, England.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAR
PY 2016
VL 91
IS 3
MA 16
BP E36
EP E36
PG 1
WC Hematology
SC Hematology
GA DF2HI
UT WOS:000371162800025
ER
PT J
AU Rubio, A
Gourbeyre, O
Lin, H
Coppin, H
Roth, MP
Meynard, D
AF Rubio, Aude
Gourbeyre, Ophelie
Lin, Herbert
Coppin, Helene
Roth, Marie-Paule
Meynard, Delphine
TI ROLE OF MATRIPTASE-2 ON HEPCIDIN SUPPRESSION IN RESPONSE TO
ERYTHROPOIESIS NEEDS
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Rubio, Aude; Gourbeyre, Ophelie; Coppin, Helene; Roth, Marie-Paule; Meynard, Delphine] Univ Toulouse 3, CPTP, Inserm U1043, F-31062 Toulouse, France.
[Lin, Herbert] Massachusetts Gen Hosp, Ctr Syst Biol, Program Membrane Biol, Program Anemia Signaling Res, Boston, MA 02114 USA.
RI coppin, helene/G-4326-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAR
PY 2016
VL 91
IS 3
MA 57
BP E257
EP E257
PG 1
WC Hematology
SC Hematology
GA DF2HI
UT WOS:000371162800238
ER
PT J
AU Williams, DA
Gavillet, M
AF Williams, David A.
Gavillet, Mathilde
TI Response to correspondence: Flow cytometric quantification of neutrophil
extracellular traps: Limitations of the methodological approach by
Ciepiela et al.
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Letter
ID NETOSIS; MICE
C1 [Williams, David A.; Gavillet, Mathilde] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Williams, David A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Williams, David A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Gavillet, Mathilde] Univ Lausanne Hosp, Serv & Cent Lab Hematol, Lausanne, Switzerland.
RP Williams, DA (reprint author), 300 Longwood Ave,Karp 08125-3, Boston, MA 02115 USA.
EM dawilliams@childrens.harvard.edu
NR 9
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAR
PY 2016
VL 91
IS 3
BP E10
EP E10
DI 10.1002/ajh.24292
PG 1
WC Hematology
SC Hematology
GA DF2HI
UT WOS:000371162800002
PM 26749259
ER
PT J
AU Heath, B
Bernhardt, J
Michalski, TJ
Crnich, CJ
Moehring, R
Schmader, KE
Olds, D
Higgins, PA
Jump, RLP
AF Heath, Barbara
Bernhardt, Jaime
Michalski, Thomas J.
Crnich, Christopher J.
Moehring, Rebekah
Schmader, Kenneth E.
Olds, Danielle
Higgins, Patricia A.
Jump, Robin L. P.
TI Results of a Veterans Affairs employee education program on
antimicrobial stewardship for older adults
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Antimicrobial stewardship; Professional education; Nursing home;
Registered nurses; Asymptomatic bacteriuria; Aged
ID CARE FACILITIES; NURSES
AB We describe a course in the Veterans Affairs (VA) Employee Education System designed to engage nursing staff working in VA long-term care facilities as partners in antimicrobial stewardship. We found that the course addressed an important knowledge gap. Our outcomes suggest opportunities to engage nursing staff in advancing antimicrobial stewardship, particularly in the long-term care setting. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc.
C1 [Heath, Barbara; Higgins, Patricia A.; Jump, Robin L. P.] Geriatr Res Educ & Clin Ctr, Cleveland, OH USA.
[Bernhardt, Jaime; Michalski, Thomas J.] Louis Stokes Cleveland Vet Affairs Med Ctr, Employee Educ Syst, Cleveland, OH USA.
[Crnich, Christopher J.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Crnich, Christopher J.] Univ Wisconsin, Madison, WI USA.
[Moehring, Rebekah; Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA.
[Moehring, Rebekah; Schmader, Kenneth E.] Duke Univ, Durham, NC USA.
[Olds, Danielle] Louis Stokes Cleveland Vet Affairs Med Ctr, Qual Scholars Program, Cleveland, OH USA.
[Higgins, Patricia A.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Jump, Robin L. P.] Case Western Reserve Univ, Dept Med, Div Infect Dis & HIV Med, Cleveland, OH 44106 USA.
[Jump, Robin L. P.] Louis Stokes Cleveland Vet Affairs Med Ctr, Div Med, Infect Dis Sect, Cleveland, OH USA.
RP Jump, RLP (reprint author), Louis Stokes Cleveland VA Med Ctr, GRECC 111C W,10701 East Blvd, Cleveland, OH 44106 USA.
EM robin.jump@va.gov
FU AHRQ HHS [K08 HS023866]
NR 10
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAR 1
PY 2016
VL 44
IS 3
BP 349
EP 351
DI 10.1016/j.ajic.2015.09.026
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DF4CS
UT WOS:000371295500024
PM 26553404
ER
PT J
AU Safdar, N
Codispoti, N
Purvis, S
Knobloch, MJ
AF Safdar, Nasia
Codispoti, Nicolette
Purvis, Suzanne
Knobloch, Mary Jo
TI Patient perspectives on indwelling urinary catheter use in the hospital
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Patient perspectives; Catheter-associated urinary tract infections
ID TRACT-INFECTIONS
AB Urinary tract infections are one of the most common hospital-acquired infections, with 70%-80% resulting from catheter-associated urinary tract infections (CAUTIs). We undertook a qualitative study to assess patient perspectives of indwelling urinary catheters using a semistructured interview. We found that patient awareness and patient engagement regarding indwelling urinary catheters and their consequences could be improved in the hospital setting. Implementing educational programs incorporating patient preferences for both health care workers and patients is likely to increase the involvement of patients in decision-making regarding urinary catheters and may lead to a decline in CAUTIs. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.
C1 [Safdar, Nasia; Knobloch, Mary Jo] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Infect Dis, Dept Med, Madison, WI USA.
[Codispoti, Nicolette] Univ Wisconsin, Madison, WI USA.
[Purvis, Suzanne] Univ Wisconsin Hosp & Clin, Geriatr, Madison, WI 53792 USA.
RP Safdar, N (reprint author), MFCB 5221,1685 Highland Ave, Madison, WI 53705 USA.
EM ns2@medicine.wisc.edu
OI Purvis, Suzanne/0000-0001-5977-5984
FU Agency for Healthcare Research and Quality [R03HS023791]
FX Supported by the Agency for Healthcare Research and Quality (grant no.
R03HS023791).
NR 11
TC 2
Z9 2
U1 1
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAR 1
PY 2016
VL 44
IS 3
BP E23
EP E24
DI 10.1016/j.ajic.2015.10.011
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DF4CS
UT WOS:000371295500003
PM 26698670
ER
PT J
AU Bigdeli, TB
Ripke, S
Bacanu, SA
Lee, SH
Wray, NR
Gejman, PV
Rietschel, M
Cichon, S
St Clair, D
Corvin, A
Kirov, G
McQuillin, A
Gurling, H
Rujescu, D
Andreassen, OA
Werge, T
Blackwood, DHR
Pato, CN
Pato, MT
Malhotra, AK
O'Donovan, MC
Kendler, KS
Fanous, AH
AF Bigdeli, Tim B.
Ripke, Stephan
Bacanu, Silviu-Alin
Lee, Sang Hong
Wray, Naomi R.
Gejman, Pablo V.
Rietschel, Marcella
Cichon, Sven
St Clair, David
Corvin, Aiden
Kirov, George
McQuillin, Andrew
Gurling, Hugh
Rujescu, Dan
Andreassen, Ole A.
Werge, Thomas
Blackwood, Douglas H. R.
Pato, Carlos N.
Pato, Michele T.
Malhotra, Anil K.
O'Donovan, Michael C.
Kendler, Kenneth S.
Fanous, Ayman H.
CA Schizophrenia Working Grp Psychiat
TI Genome-wide association study reveals greater polygenic loading for
schizophrenia in cases with a family history of illness
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE schizophrenia; polygenic; GWAS; family history
ID ETIOLOGIC HETEROGENEITY; CLASSIFICATION; RISK; SNPS
AB Genome-wide association studies (GWAS) of schizophrenia have yielded more than 100 common susceptibility variants, and strongly support a substantial polygenic contribution of a large number of small allelic effects. It has been hypothesized that familial schizophrenia is largely a consequence of inherited rather than environmental factors. We investigated the extent to which familiality of schizophrenia is associated with enrichment for common risk variants detectable in a large GWAS. We analyzed single nucleotide polymorphism (SNP) data for cases reporting a family history of psychotic illness (N=978), cases reporting no such family history (N=4,503), and unscreened controls (N=8,285) from the Psychiatric Genomics Consortium (PGC1) study of schizophrenia. We used a multinomial logistic regression approach with model-fitting to detect allelic effects specific to either family history subgroup. We also considered a polygenic model, in which we tested whether family history positive subjects carried more schizophrenia risk alleles than family history negative subjects, on average. Several individual SNPs attained suggestive but not genome-wide significant association with either family history subgroup. Comparison of genome-wide polygenic risk scores based on GWAS summary statistics indicated a significant enrichment for SNP effects among family history positive compared to family history negative cases (Nagelkerke's R-2=0.0021; P=0.00331; P-value threshold <0.4). Estimates of variability in disease liability attributable to the aggregate effect of genome-wide SNPs were significantly greater for family history positive compared to family history negative cases (0.32 and 0.22, respectively; P=0.031). We found suggestive evidence of allelic effects detectable in large GWAS of schizophrenia that might be specific to particular family history subgroups. However, consideration of a polygenic risk score indicated a significant enrichment among family history positive cases for common allelic effects. Familial illness might, therefore, represent a more heritable form of schizophrenia, as suggested by previous epidemiological studies. (c) 2015 Wiley Periodicals, Inc.
C1 [Bigdeli, Tim B.; Kendler, Kenneth S.; Fanous, Ayman H.] Virginia Commonwealth Univ, Dept Psychiat, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
[Ripke, Stephan] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Ripke, Stephan] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Lee, Sang Hong; Wray, Naomi R.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia.
[Gejman, Pablo V.] NorthShore Univ HealthSyst, Dept Psychiat & Behav Sci, Evanston, IL USA.
[Gejman, Pablo V.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
[Rietschel, Marcella] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Genet Epidemiol Psychiat, Heidelberg, Germany.
[Cichon, Sven] Univ Basel, Dept Biomed, Div Med Genet, Basel, Switzerland.
[Cichon, Sven] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Cichon, Sven] Life & Brain Ctr, Dept Genom, Bonn, Germany.
[Cichon, Sven] Res Ctr Juelich, Inst Neurosci & Med INM 1, Julich, Germany.
[St Clair, David] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland.
[Corvin, Aiden] Univ Dublin Trinity Coll, Dept Psychiat, Neuropsychiat Genet Res Grp, Dublin 2, Ireland.
[Kirov, George; O'Donovan, Michael C.] Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Inst Psychol Med & Clin Neurosci, Sch Med, Cardiff CF10 3AX, S Glam, Wales.
[McQuillin, Andrew; Gurling, Hugh] UCL, Div Psychiat, Mol Psychiat Lab, London WC1E 6BT, England.
[Rujescu, Dan] Univ Halle, Dept Psychiat, Halle, Germany.
[Rujescu, Dan] Univ Munich, Dept Psychiat, D-80539 Munich, Germany.
[Andreassen, Ole A.] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Psychosis Res, NORMENT, Oslo, Norway.
[Andreassen, Ole A.] Oslo Univ Hosp, Div Mental Hlth & Addict, Oslo, Norway.
[Werge, Thomas] MHC Sct Hans, Mental Hlth Serv Copenhagen, Inst Biol Psychiat, Copenhagen, Denmark.
[Werge, Thomas] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
[Werge, Thomas] Lundbeck Fdn Initiat Integrat Psychiat Res, iPSYCH, Copenhagen, Denmark.
[Blackwood, Douglas H. R.] Univ Edinburgh, Div Psychiat, Edinburgh, Midlothian, Scotland.
[Pato, Carlos N.; Pato, Michele T.; Fanous, Ayman H.] Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA.
[Pato, Carlos N.; Pato, Michele T.] Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA.
[Malhotra, Anil K.] Zucker Hillside Hosp, Glen Oaks, NY USA.
[Malhotra, Anil K.] Feinstein Inst Med Res, Manhasset, NY USA.
[Malhotra, Anil K.] Hofstra NS LIJ Sch Med, Hempstead, NY USA.
[O'Donovan, Michael C.] Cardiff Univ, Natl Ctr Mental Hlth, Cardiff CF10 3AX, S Glam, Wales.
[Kendler, Kenneth S.] Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, Richmond, VA USA.
[Fanous, Ayman H.] Washington VA Med Ctr, Mental Hlth Serv Line, Washington, DC USA.
[Fanous, Ayman H.] Georgetown Univ, Sch Med, Dept Psychiat, Washington, DC USA.
RP Fanous, AH (reprint author), VA Med Ctr, Psychiat Genet Res Program, 50 Irving St NW, Washington, DC 20422 USA.
EM ayman.fanous@va.gov
RI Melle, Ingrid /B-4858-2011; Ruderfer, Douglas/M-5795-2016; Lee, Sang
Hong/A-2569-2011; Webb, Bradley/B-1459-2009; Domenici,
Enrico/K-8194-2016; McQuillin, Andrew/C-1623-2008; Pantelis,
Christos/H-7722-2014;
OI Melle, Ingrid /0000-0002-9783-548X; Bruggeman,
Richard/0000-0002-3238-8471; Ruderfer, Douglas/0000-0002-2365-386X; Lee,
Sang Hong/0000-0001-9701-2718; O'Neill, Francis
Anthony/0000-0002-7531-7657; Webb, Bradley/0000-0002-0576-5366;
Domenici, Enrico/0000-0001-7436-6919; McQuillin,
Andrew/0000-0003-1567-2240; Pantelis, Christos/0000-0002-9565-0238;
Corvin, Aiden/0000-0001-6717-4089; Holmans, Peter/0000-0003-0870-9412;
Adolfsson, Rolf/0000-0001-9785-8473; Nothen, Markus/0000-0002-8770-2464
FU United States Department of Veterans Affairs Merit Review Program
[5I01CX000278]; Netherlands Scientific Organization [NWO480-05-003];
Dutch Brain Foundation; VU University Amsterdam
FX Grant sponsor: United States Department of Veterans Affairs Merit Review
Program; Grant number: 5I01CX000278; Grant sponsor: Netherlands
Scientific Organization; Grant number: NWO480-05-003; Grant sponsor:
Dutch Brain Foundation and the VU University Amsterdam.
NR 40
TC 1
Z9 1
U1 4
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD MAR
PY 2016
VL 171
IS 2
BP 276
EP 289
DI 10.1002/ajmg.b.32402
PG 14
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA DF3LM
UT WOS:000371245700015
PM 26663532
ER
PT J
AU Bukhari, OM
Sohrabi, K
Tavares, M
AF Bukhari, Omair M.
Sohrabi, Keyvan
Tavares, Mary
TI Factors affecting patients' adherence to orthodontic appointments
SO AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS
LA English
DT Article
ID FAILED APPOINTMENTS; DURATION; MEDICAID; ATTENDANCE; CHILDREN
AB Introduction: Studies show that attendance at orthodontic appointments affects treatment outcomes, treatment duration, and the probability of side effects. The aim of this study was to predict factors that influence patients' attendance at orthodontic appointments. Methods: We conducted a face-to-face guided interview survey of 153 participants from orthodontic clinics in the Greater Boston area. Attendance at scheduled orthodontic appointments was self-reported as always, sometimes, or rarely. Participants' characteristics, including demographics, dental insurance, and oral hygiene practices, were self-reported. Moreover, from dental records, we collected the time that the participants spent undergoing active orthodontic treatment. Multivariable ordered logistic regression was used to report proportional odds ratios and attendance probabilities. A likelihood ratio test was performed to ensure that the proportional odds assumption held. Results: For overall appointment attendance, 76% of the participants reported always attending, 16% reported sometimes attending, and 8% reported rarely attending. Based on multivariable logistic regression (adjusted for age, race, and sex), the participants with optimal oral hygiene practices were almost 6 times (5.9) more likely to attend appointments than those who did not (P = 0.002). The odds of attending appointments decreased significantly (by 23%) for every 6-month increase in treatment duration (P = 0.008). Participants covered by non-Medicaid insurance were 4 times (P = 0.018) more likely to attend appointments than were those with Medicaid insurance. Conclusion: Our findings indicate that adherence to orthodontic treatment follow-up visits was strongly correlated to insurance type, treatment duration, and oral hygiene practices. Unlike previous studies, sex was not a significant predictor of adherence.
C1 [Bukhari, Omair M.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Bukhari, Omair M.] Umm Al Qura Univ, Fac Dent, Mecca, Saudi Arabia.
[Sohrabi, Keyvan] Univ Washington, Sch Dent, Seattle, WA 98195 USA.
[Tavares, Mary] Forsyth Inst, Cambridge, MA USA.
[Tavares, Mary] Harvard Univ, Sch Dent Med, Oral Hlth Policy & Epidemiol, Dent Publ Hlth Residency, Boston, MA 02115 USA.
RP Bukhari, OM (reprint author), Harvard Univ, Sch Dent Med, Oral Hlth Policy & Epidemiol, REB 204,188 Longwood Ave, Boston, MA 02115 USA.
EM omair_bukhari@hsdm.harvard.edu
NR 19
TC 1
Z9 1
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0889-5406
EI 1097-6752
J9 AM J ORTHOD DENTOFAC
JI Am. J. Orthod. Dentofac. Orthop.
PD MAR
PY 2016
VL 149
IS 3
BP 319
EP 324
DI 10.1016/j.ajodo.2015.07.040
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DF0HZ
UT WOS:000371021100007
PM 26926018
ER
PT J
AU Madariaga, MLL
Spencer, PJ
Michel, SG
La Muraglia, GM
O'Neil, MJ
Mannon, EC
Leblang, C
Rosales, IA
Colvin, RB
Sachs, DH
Allan, JS
Madsen, JC
AF Madariaga, M. L. L.
Spencer, P. J.
Michel, S. G.
La Muraglia, G. M., II
O'Neil, M. J.
Mannon, E. C.
Leblang, C.
Rosales, I. A.
Colvin, R. B.
Sachs, D. H.
Allan, J. S.
Madsen, J. C.
TI Effects of Lung Cotransplantation on Cardiac Allograft Tolerance Across
a Full Major Histocompatibility Complex Barrier in Miniature Swine
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
ID REGULATORY T-CELLS; CLINICAL OPERATIONAL TOLERANCE; RENAL-ALLOGRAFTS;
TRANSPLANTATION TOLERANCE; HEART-TRANSPLANTATION; WORKING FORMULATION;
IMMUNE-MECHANISMS; CUTTING EDGE; LONG-TERM; CLASS-I
AB A 12-day course of high-dose tacrolimus induces tolerance of major histocompatibility complex-mismatched lung allografts in miniature swine but does not induce tolerance of heart allografts unless a kidney is cotransplanted. To determine whether lungs share with kidneys the ability to induce cardiac allograft tolerance, we investigated heart-lung cotransplantation using the same induction protocol. Hearts (n=3), heart-kidneys (n=3), lungs (n=6), and hearts-lungs (n=3) were transplanted into fully major histocompatibility complex-mismatched recipients treated with high-dose tacrolimus for 12 days. Serial biopsy samples were used to evaluate rejection, and in vitro assays were used to detect donor responsiveness. All heart-kidney recipients and five of six lung recipients demonstrated long-term graft survival for longer than 272 days, while all heart recipients rejected their allografts within 35 days. Tolerant recipients remained free of alloantibody and showed persistent donor-specific unresponsiveness by cell-mediated lympholysis/mixed-lymphocyte reaction. In contrast, heart-lung recipients demonstrated rejection of both allografts (days 47, 55, and 202) and antidonor responsiveness in vitro. In contrast to kidneys, lung cotransplantation leads to rejection of both heart and lung allografts, indicating that lungs do not have the same tolerogenic capacity as kidneys. We conclude that cells or cell products present in kidney, but not heart or lung allografts, have a unique capacity to confer unresponsiveness on cotransplanted organs, most likely by amplifying host regulatory mechanisms.
C1 [Madariaga, M. L. L.; Spencer, P. J.; Michel, S. G.; La Muraglia, G. M., II; O'Neil, M. J.; Mannon, E. C.; Leblang, C.; Rosales, I. A.; Colvin, R. B.; Sachs, D. H.; Allan, J. S.; Madsen, J. C.] Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02114 USA.
RP Madsen, JC (reprint author), Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02114 USA.
EM jcmadsen@partners.org
FU International Society for Heart and Lung Transplantation and a National
Research Service Award; National Heart, Lung, and Blood Institute of the
National Institutes of Health [F32HL117540]; Fellowship Grant in
Transplantation Biology [T32AI07529]; ASTS-Novartis Scientist
Scholarship Grant [C06RR020135-01]
FX Dr. Madariaga is an Edward D. Churchill Surgical Research Fellow,
Massachusetts General Hospital and a recipient of a fellowship from the
International Society for Heart and Lung Transplantation and a National
Research Service Award from the National Heart, Lung, and Blood
Institute of the National Institutes of Health (F32HL117540). Dr.
Spencer is an Edward D. Churchill Surgical Research Fellow,
Massachusetts General Hospital, and recipient of a Training Fellowship
Grant in Transplantation Biology (T32AI07529). Dr. Michel is a recipient
of the 2013 ASTS-Novartis Scientist Scholarship Grant. We acknowledge
C06RR020135-01 for construction of the facility utilized for production
and maintenance of miniature swine. We are indebted to Mr. J. Scott Arn
for herd management and quality control typing. We thank Nicole
Brousaides for preparing biopsy samples for histological analysis.
NR 37
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD MAR
PY 2016
VL 16
IS 3
BP 979
EP 986
DI 10.1111/ajt.13489
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA DF3JQ
UT WOS:000371240500030
PM 26469344
ER
PT J
AU Kuo, AS
Vijjeswarapu, MA
Philip, JH
AF Kuo, Alexander S.
Vijjeswarapu, Mary A.
Philip, James H.
TI Incomplete Spontaneous Recovery from Airway Obstruction During Inhaled
Anesthesia Induction: A Computational Simulation
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID DIFFICULT TRACHEAL INTUBATION; GASMAN(R) SIMULATION; SEVOFLURANE;
HALOTHANE; PROPOFOL; MODEL
AB BACKGROUND:
Inhaled induction with spontaneous respiration is a technique used for difficult airways. One of the proposed advantages is if airway patency is lost, the anesthetic agent will spontaneously redistribute until anesthetic depth is reduced and airway patency can be recovered. There are little and conflicting clinical or experimental data regarding the kinetics of this anesthetic technique. We used computer simulation to investigate this situation.
METHODS:
We used GasMan (R), a computer simulation of inhaled anesthetic kinetics. For each simulation, alveolar ventilation was initiated with a set anesthetic induction concentration. When the vessel-rich group level reached the simulation specified airway obstruction threshold, alveolar ventilation was set at 0 to simulate complete airway obstruction. The time until the vessel-rich group anesthetic level decreased below the airway obstruction threshold was designated time to spontaneous recovery. We varied the parameters for each simulation, exploring the use of sevoflurane and halothane, airway obstruction threshold from 0.5 to 2 minimum alveolar concentration (MAC), anesthetic induction concentration 2 to 4 MAC sevoflurane and 4 to 6 MAC halothane, cardiac output 2.5 to 10 L/min, functional residual capacity 1.5 to 3.5 L, and relative vessel-rich group perfusion 67% to 85%.
RESULTS:
In each simulation, there were 3 general phases: anesthetic wash-in, obstruction and overshoot, and then slow redistribution. During the first 2 phases, there was a large gradient between the alveolar and vessel-rich group. Alveolar do not reflect vessel-rich group anesthetic levels until the late third phase. Time to spontaneous recovery varied between 35 and 749 seconds for sevoflurane and 13 and 222 seconds for halothane depending on the simulation parameters. Halothane had a faster time to spontaneous recovery because of the lower alveolar gradient and less overshoot of the vessel-rich group, not faster redistribution. Higher airway obstruction thresholds, decreased anesthetic induction, and higher cardiac output reduced time to spontaneous recovery. To a lesser effect, decreased functional residual capacity and the decreased relative vessel-rich groups' perfusion also reduced the time to spontaneous recovery.
CONCLUSIONS:
Spontaneous recovery after complete airway obstruction during inhaled induction is plausible, but the recovery time is highly variable and depends on the clinical and physiologic situation. These results emphasize that induction is a non-steady-state situation, thus effect-site anesthetic levels should be modeled in future research, not alveolar concentration. Finally, this study provides an example of using computer simulation to explore situations that are difficult to investigate clinically.
C1 [Kuo, Alexander S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, 75 Francis St, Boston, MA 02115 USA.
[Vijjeswarapu, Mary A.; Philip, James H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
RP Vijjeswarapu, MA (reprint author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.
EM mvijjeswarapu@partners.org
NR 19
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAR
PY 2016
VL 122
IS 3
BP 698
EP 705
DI 10.1213/ANE.0000000000001101
PG 8
WC Anesthesiology
SC Anesthesiology
GA DE2EZ
UT WOS:000370440700002
PM 26745755
ER
PT J
AU Nair, BG
Horibe, M
Neradilek, MB
Newman, SF
Peterson, GN
AF Nair, Bala G.
Horibe, Mayumi
Neradilek, Moni B.
Newman, Shu-Fang
Peterson, Gene N.
TI The Effect of Intraoperative Blood Glucose Management on Postoperative
Blood Glucose Levels in Noncardiac Surgery Patients
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID INDEPENDENT RISK-FACTOR; VASCULAR-SURGERY; PERIOPERATIVE PERIOD;
COLORECTAL SURGERY; INSULIN INFUSION; GLYCEMIC CONTROL; CARDIAC-SURGERY;
SITE INFECTION; HYPERGLYCEMIA; OUTCOMES
AB BACKGROUND:
Postoperative hyperglycemia has been associated with poor surgical outcome. The effect of intraoperative glucose management on postoperative glucose levels and the optimal glycemic threshold for initiating insulin are currently unknown.
METHODS:
We performed a retrospective cohort study of surgery patients who required intraoperative glucose management with data extracted from electronic medical records. In patients who required glucose management, intraoperative glucose levels and insulin therapy were compared against postoperative glucose levels during 3 periods: first postoperative level within 1 hour, within the first 12 hours, and 24 hours of the postoperative period. Logistic regression models that adjusted for patient and surgical factors were used to determine the association between intraoperative glucose management and postoperative glucose levels.
RESULTS:
In 2440 patients who required intraoperative glucose management, an increase in mean intraoperative glucose level by 10 mg/dL was associated with an increase in postoperative glucose levels by 4.7 mg/dL (confidence interval [CI], 4.1-5.3; P < 0.001) for the first postoperative glucose measurement, 2.6 mg/dL (CI, 2.1-3.1; P < 0.001) for the mean first 12-hour postoperative glucose, and 2.4 mg/dL (CI, 2.0-2.9; P < 0.001) for the mean first 24-hour postoperative glucose levels (univariate analysis). Multivariate analysis showed that these effects depended on (interacted with) body mass index and diabetes status of the patient. Both diabetes status (regression coefficient = 12.2; P < 0.001) and intraoperative steroid use (regression coefficient = 10.2; P < 0.001) had a positive effect on elevated postoperative glucose levels. Intraoperative hyperglycemia (> 180 mg/dL) was associated with postoperative hyperglycemia during the first 12 hours and the first 24 hours. However, interaction with procedure duration meant that this association was stronger for shorter surgeries. When compared with starting insulin for an intraoperative glucose threshold of 140 mg/dL thus avoiding hyperglycemia, initiation of insulin for a hyperglycemia threshold of 180 mg/dL was associated with an increase in postoperative glucose level (7 mg/dL; P < 0.001) and postoperative hyperglycemia incidence (odds ratio = 1.53; P = 0.01).
CONCLUSIONS:
A higher intraoperative glucose level is associated with a higher postoperative glucose level. Intraoperative hyperglycemia increases the odds for postoperative hyperglycemia. Adequate intraoperative glucose management by initiating insulin infusion when glucose level exceeds 140 mg/dL to prevent hyperglycemia is associated with lower postoperative glucose levels and fewer incidences of postoperative hyperglycemia. However, patient- and procedure-specific variable interactions make the relationship between intraoperative and postoperative glucose levels complicated.
C1 [Nair, Bala G.; Newman, Shu-Fang; Peterson, Gene N.] Univ Washington, Dept Anesthesiol & Pain Med, BB 1469 Hlth Sci Bldg,Mail Box 356540, Seattle, WA 98195 USA.
[Horibe, Mayumi] VA Puget Sound Hlth Care Syst, Dept Anesthesiol, Seattle, WA USA.
[Neradilek, Moni B.] Mt Whisper Light Stat LLC, Seattle, WA USA.
[Peterson, Gene N.] Virginia Commonwealth Univ, Dept Anesthesiol, Richmond, VA USA.
RP Nair, BG (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, BB 1469 Hlth Sci Bldg,Mail Box 356540, Seattle, WA 98195 USA.
EM nairbg@uw.edu
FU Patient Safety Innovation Program Grant by the University of Washington
FX This research was partly supported by a Patient Safety Innovation
Program Grant provided by the University of Washington.
NR 25
TC 1
Z9 1
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAR
PY 2016
VL 122
IS 3
BP 893
EP 902
DI 10.1213/ANE.0000000000001100
PG 10
WC Anesthesiology
SC Anesthesiology
GA DE2FL
UT WOS:000370441900010
PM 26599793
ER
PT J
AU Pejo, E
Santer, P
Wang, L
Dershwitz, P
Husain, SS
Raines, DE
AF Pejo, Ervin
Santer, Peter
Wang, Lei
Dershwitz, Philip
Husain, S. Shaukat
Raines, Douglas E.
TI gamma-Aminobutyric Acid Type A Receptor Modulation by Etomidate Analogs
SO ANESTHESIOLOGY
LA English
DT Article
ID GENERAL ANESTHETIC ETOMIDATE; GABA(A) RECEPTOR; IN-VITRO; BINDING-SITE;
METHOXYCARBONYL-ETOMIDATE; OPTICAL ISOMERS; VIVO; CARBOETOMIDATE;
PHARMACOLOGY; MECHANISMS
AB Background:
Etomidate is a highly potent anesthetic agent that is believed to produce hypnosis by enhancing gamma-aminobutyric acid type A (GABA(A)) receptor function. The authors characterized the GABA(A) receptor and hypnotic potencies of etomidate analogs. The authors then used computational techniques to build statistical and graphical models that relate the potencies of these etomidate analogs to their structures to identify the specific molecular determinants of potency.
Methods:
GABA(A) receptor potencies were defined with voltage clamp electrophysiology using alpha(1)beta(3)gamma(2) receptors harboring a channel mutation (alpha(1)[L264T]) that enhances anesthetic sensitivity (n = 36 to 60 measurements per concentration-response curve). The hypnotic potencies of etomidate analogs were defined using a loss of righting reflexes assay in Sprague Dawley rats (n = 9 to 21 measurements per dose-response curve). Three-dimensional quantitative structure-activity relationships were determined in silico using comparative molecular field analysis.
Results:
The GABA(A) receptor and hypnotic potencies of etomidate and the etomidate analogs ranged by 91- and 53-fold, respectively. These potency measurements were significantly correlated (r(2) = 0.72), but neither measurement correlated with drug hydrophobicity (r(2) = 0.019 and 0.005, respectively). Statistically significant and predictive comparative molecular field analysis models were generated, and a pharmacophore model was built that revealed both the structural elements in etomidate analogs associated with high potency and the interactions that these elements make with the etomidate-binding site.
Conclusions:
There are multiple specific structural elements in etomidate and etomidate analogs that mediate GABA(A) receptor modulation. Modifying any one element can alter receptor potency by an order of magnitude or more.
C1 [Pejo, Ervin; Santer, Peter; Dershwitz, Philip; Husain, S. Shaukat; Raines, Douglas E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB444, Boston, MA 02114 USA.
[Wang, Lei] Certara L P, St Louis, MO USA.
RP Raines, DE (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB444, Boston, MA 02114 USA.
EM draines@partners.org
FU National Institutes of Health, Bethesda, Maryland [R01-GM087316];
Department of Anesthesia, Critical Care, and Pain Medicine,
Massachusetts General Hospital, Boston, Massachusetts
FX This study was funded by grant R01-GM087316 from the National Institutes
of Health, Bethesda, Maryland, and the Department of Anesthesia,
Critical Care, and Pain Medicine, Massachusetts General Hospital,
Boston, Massachusetts.
NR 39
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD MAR
PY 2016
VL 124
IS 3
BP 651
EP 663
DI 10.1097/ALN.0000000000000992
PG 13
WC Anesthesiology
SC Anesthesiology
GA DE5US
UT WOS:000370698900019
PM 26691905
ER
PT J
AU King, MR
Ladha, KS
Gelineau, AM
Anderson, TA
AF King, Michael R.
Ladha, Karim S.
Gelineau, Amanda M.
Anderson, T. Anthony
TI Perioperative Dextromethorphan as an Adjunct for Postoperative Pain A
Meta-analysis of Randomized Controlled Trials
SO ANESTHESIOLOGY
LA English
DT Article
ID ASPARTATE RECEPTOR ANTAGONISTS; PATIENT-CONTROLLED ANALGESIA; DOSE ORAL
DEXTROMETHORPHAN; DOUBLE-BLIND; MORPHINE CONSUMPTION; LAPAROSCOPIC
CHOLECYSTECTOMY; CENTRAL SENSITIZATION; PREEMPTIVE ANALGESIA;
GENERAL-ANESTHESIA; OPIOID REQUIREMENT
AB Background:
N-methyl-d-aspartate receptor antagonists have been shown to reduce perioperative pain and opioid use. The authors performed a meta-analysis to determine whether the use of perioperative dextromethorphan lowers opioid consumption or pain scores.
Methods:
PubMed, Web of Science, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Pubget, and EMBASE were searched. Studies were included if they were randomized, double-blinded, placebo-controlled trials written in English, and performed on patients 12 yr or older. For comparison of opioid use, included studies tracked total consumption of IV or intramuscular opioids over 24 to 48 h. Pain score comparisons were performed at 1, 4 to 6, and 24 h postoperatively. Difference in means (MD) was used for effect size.
Results:
Forty studies were identified and 21 were eligible for one or more comparisons. In 848 patients from 14 trials, opioid consumption favored dextromethorphan (MD, -10.51 mg IV morphine equivalents; 95% CI, -16.48 to -4.53 mg; P = 0.0006). In 884 patients from 13 trials, pain at 1 h favored dextromethorphan (MD, -1.60; 95% CI, -1.89 to -1.31; P < 0.00001). In 950 patients from 13 trials, pain at 4 to 6 h favored dextromethorphan (MD, -0.89; 95% CI, -1.11 to -0.66; P < 0.00001). In 797 patients from 12 trials, pain at 24 h favored dextromethorphan (MD, -0.92; 95% CI, -1.24 to -0.60; P < 0.00001).
Conclusion:
This meta-analysis suggests that dextromethorphan use perioperatively reduces the postoperative opioid consumption at 24 to 48 h and pain scores at 1, 4 to 6, and 24 h.
C1 [King, Michael R.; Ladha, Karim S.; Gelineau, Amanda M.; Anderson, T. Anthony] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St GRJ 409, Boston, MA 02114 USA.
[King, Michael R.; Ladha, Karim S.; Gelineau, Amanda M.; Anderson, T. Anthony] Harvard Univ, Sch Med, 55 Fruit St GRJ 409, Boston, MA USA.
[Ladha, Karim S.] Toronto Gen Hosp, Dept Anesthesia, Toronto, ON, Canada.
[Ladha, Karim S.] Univ Toronto, Toronto, ON, Canada.
RP Anderson, TA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St GRJ 409, Boston, MA 02114 USA.; Anderson, TA (reprint author), Harvard Univ, Sch Med, 55 Fruit St GRJ 409, Boston, MA USA.
EM tanderson9@mgh.harvard.edu
FU Harvard Catalyst/The Harvard Clinical and Translational Science Center
(National Center for Research Resources); Harvard Catalyst/The Harvard
Clinical and Translational Science Center (National Center for Advancing
Translational Sciences, National Institutes of Health [Bethesda,
Maryland] Award) [UL1 TR001102]; Harvard University (Cambridge,
Massachusetts)
FX This work was conducted with support from Harvard Catalyst/The Harvard
Clinical and Translational Science Center (National Center for Research
Resources and National Center for Advancing Translational Sciences,
National Institutes of Health [Bethesda, Maryland] Award UL1 TR001102)
and financial contributions from Harvard University (Cambridge,
Massachusetts) and its affiliated academic healthcare centers.
NR 61
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD MAR
PY 2016
VL 124
IS 3
BP 696
EP 705
DI 10.1097/ALN.0000000000000950
PG 10
WC Anesthesiology
SC Anesthesiology
GA DE5US
UT WOS:000370698900023
PM 26587683
ER
PT J
AU Nemcova, L
Jansova, D
Vodickova-Kepkova, K
Vodicka, P
Jeseta, M
Machatkova, M
Kanka, J
AF Nemcova, Lucie
Jansova, Denisa
Vodickova-Kepkova, Katerina
Vodicka, Petr
Jeseta, Michal
Machatkova, Marie
Kanka, Jiri
TI Detection of genes associated with developmental competence of bovine
oocytes
SO ANIMAL REPRODUCTION SCIENCE
LA English
DT Article
DE Oocyte; Embryo; Bovine; Developmental competence; Transcription
ID IN-VITRO MATURATION; DIFFERENT MEIOTIC COMPETENCE; MITOCHONDRIAL-DNA
CONTENT; TERMINATION CODONS UAA; HUMAN MPS1 KINASE; FOLLICLE SIZE;
MLF1-INTERACTING PROTEIN; TRANSCRIPTIONAL ACTIVITY; PREIMPLANTATION
EMBRYOS; ANTRAL FOLLICLES
AB The developmental competence of oocytes is acquired progressively during folliculogenesis and is linked to follicular size. It has been documented that oocytes originating from larger follicles exhibit a greater ability to develop to the blastocyst stage. The differences in cytoplasmic factors such as mRNA transcripts could explain the differences in oocyte developmental potential. We used bovine oligonucleotide microarrays to characterize differences between the gene expression profiles of germinal vesicle stage (GV) oocytes with greater developmental competence from medium follicles (MF) and those with less developmental competence from small follicles (SF). After normalizing the microarray data, our analysis found differences in the level of 60 transcripts (>= 1.4 fold), corresponding to 49 upregulated and 11 downregulated transcripts in MF oocytes compared to SF oocytes. The gene expression data were classified according to gene ontology, the majority of the genes were associated with the regulation of transcription, translation, the cell cycle, and mitochondria) activity. A subset of 16 selected genes was validated for GV oocytes by quantitative real-time RT-PCR; significant differences (P<0.01) were found in the level of TAF1A,MTRF1L, ATP5C1, UBL5 and MAP3K13 between the MF and SF oocytes. After maturation the transcript level remained stable for ATP5F1, BRD7, and UBL5 in both oocyte categories. The transcript level of another 13 genes substantially dropped in the MF and/or SF oocytes. It can be concluded that the developmental competence of bovine oocytes and embryos may be a quantitative trait dependent on small changes in the transcription profiles of many genes. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Nemcova, Lucie; Jansova, Denisa; Vodickova-Kepkova, Katerina; Vodicka, Petr; Kanka, Jiri] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Dev Biol Lab, Libechov, Czech Republic.
[Vodicka, Petr] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA.
[Vodicka, Petr] Harvard Univ, Sch Med, Charlestown, MA USA.
[Jeseta, Michal; Machatkova, Marie] Vet Res Inst, Dept Genet & Reprod, CS-62132 Brno, Czech Republic.
RP Nemcova, L (reprint author), Acad Sci Czech Republic, Inst Anim Physiol & Genet, Dev Biol Lab, Libechov, Czech Republic.
EM nemcova@iapg.cas.cz
RI Jeseta, Michal/A-3159-2013; Vodicka, Petr/C-3845-2009
OI Jeseta, Michal/0000-0003-1778-3454; Vodicka, Petr/0000-0002-6605-9158
FU Ministry of Education, Youth and Sport of the Czech Republic [LD 14104];
IAPG, AS CR v.v.i. [RVO: 67985904]
FX This study was supported by grant LD 14104 from the Ministry of
Education, Youth and Sport of the Czech Republic. Additional support was
provided by institutional research concept RVO: 67985904 (IAPG, AS CR
v.v.i.).
NR 67
TC 2
Z9 2
U1 6
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4320
EI 1873-2232
J9 ANIM REPROD SCI
JI Anim. Reprod. Sci.
PD MAR
PY 2016
VL 166
BP 58
EP 71
DI 10.1016/j.anireprosci.2016.01.004
PG 14
WC Agriculture, Dairy & Animal Science; Reproductive Biology
SC Agriculture; Reproductive Biology
GA DF2QR
UT WOS:000371189400008
PM 26811294
ER
PT J
AU Nakhlis, F
Gilmore, L
Gelman, R
Bedrosian, I
Ludwig, K
Hwang, ES
Willey, S
Hudis, C
Iglehart, JD
Lawler, E
Ryabin, NY
Golshan, M
Schnitt, SJ
King, TA
AF Nakhlis, Faina
Gilmore, Lauren
Gelman, Rebecca
Bedrosian, Isabelle
Ludwig, Kandice
Hwang, E. Shelley
Willey, Shawna
Hudis, Clifford
Iglehart, J. Dirk
Lawler, Elizabeth
Ryabin, Nicole Y.
Golshan, Mehra
Schnitt, Stuart J.
King, Tari A.
TI Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal
Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy:
Results from a Prospective Multi-Institutional Registry (TBCRC 020)
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID UP SURGICAL EXCISION; TERM-FOLLOW-UP; NEEDLE-BIOPSY;
CLINICAL-SIGNIFICANCE; PATHOLOGICAL FINDINGS; BREAST-CANCER;
HYPERPLASIA; LESIONS; RISK; MALIGNANCY
AB Background. Lobular neoplasia (LN) represents a spectrum of atypical proliferative lesions, including atypical lobular hyperplasia and lobular carcinoma-in-situ. The need for excision for LN found on core biopsy (CB) is controversial. We conducted a prospective multi-institutional trial (TBCRC 20) to determine the rate of upgrade to cancer after excision for pure LN on CB.
Methods. Patients with a CB diagnosis of pure LN were prospectively identified and consented to excision. Cases with discordant imaging and those with additional lesions requiring excision were excluded. Upgrade rates to cancer were quantified on the basis of local and central pathology review. Confidence intervals and sample size were based on exact binomial calculations.
Results. A total of 77 of 79 registered patients underwent excision (median age 51 years, range 27-82 years). Two cases (3 %; 95 % confidence interval 0.3-9) were upgraded to cancer (one tubular carcinoma, one ductal carcinoma-in-situ) at excision per local pathology. Central pathology review of 76 cases confirmed pure LN in the CB in all but two cases. In one case, the tubular carcinoma identified at excision was also found in the CB specimen, and in the other, LN was not identified, yielding an upgrade rate of one case (1 %; 95 % CI 0.01-7) by central pathology review.
Conclusions. In this prospective study of 77 patients with pure LN on CB, the upgrade rate was 3 % by local pathology and 1 % by central pathology review, demonstrating that routine excision is not indicated for patients with pure LN on CB and concordant imaging findings.
C1 [Nakhlis, Faina; Gelman, Rebecca; Iglehart, J. Dirk; Lawler, Elizabeth; Ryabin, Nicole Y.; Golshan, Mehra] Dana Farber Harvard Canc Ctr, Boston, MA USA.
[Gilmore, Lauren] Mt Auburn Hosp, Cambridge, MA USA.
[Hudis, Clifford] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Med Serv, 1275 York Ave, New York, NY 10021 USA.
[Bedrosian, Isabelle] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Ludwig, Kandice] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA.
[Hwang, E. Shelley] Duke Univ, Med Ctr, Durham, NC USA.
[Willey, Shawna] Georgetown Univ, Ctr Canc, Washington, DC USA.
[Iglehart, J. Dirk; Golshan, Mehra] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Schnitt, Stuart J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[King, Tari A.] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA.
RP King, TA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA.
EM tking7@partners.org
FU NCI NIH HHS [P30 CA008748]
NR 35
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAR
PY 2016
VL 23
IS 3
BP 722
EP 728
DI 10.1245/s10434-015-4922-4
PG 7
WC Oncology; Surgery
SC Oncology; Surgery
GA DF4QL
UT WOS:000371334600005
PM 26542585
ER
PT J
AU Merrill, AL
Coopey, SB
Tang, R
McEvoy, MP
Specht, MC
Hughes, KS
Gadd, MA
Smith, BL
AF Merrill, Andrea L.
Coopey, Suzanne B.
Tang, Rong
McEvoy, Maureen P.
Specht, Michele C.
Hughes, Kevin S.
Gadd, Michelle A.
Smith, Barbara L.
TI Implications of New Lumpectomy Margin Guidelines for Breast-Conserving
Surgery: Changes in Reexcision Rates and Predicted Rates of Residual
Tumor
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID CARCINOMA IN-SITU; 20-YEAR FOLLOW-UP; ONCOLOGY CONSENSUS GUIDELINE;
RANDOMIZED-TRIAL; CONSERVATIVE TREATMENT; AMERICAN SOCIETY; LOCAL
RECURRENCE; RE-EXCISION; CANCER; THERAPY
AB Background. The 2014 guidelines endorsed by Society of Surgical Oncology, the American Society of Breast Surgeons, and the American Society for Radiation Oncology advocate "no ink on tumor'' as the new margin requirement for breast-conserving therapy (BCT). We used our lumpectomy margins database from 2004 to 2006 to predict the effect of these new guidelines on BCT.
Methods. Patients with neoadjuvant therapy, pure ductal carcinoma-in situ, or incomplete margin data were excluded. We applied new ("no ink on tumor'') and old (>= 2 mm) margin guidelines and compared rates of positive margins, reexcision, and rates of residual disease found at reexcision.
Results. A total of 437 lumpectomy surgeries met the eligibility criteria. Eighty-six percent had invasive ductal carcinoma, 12 % invasive lobular carcinoma, and 2 % invasive ductal carcinoma and invasive lobular carcinoma. Using a >= 2 mm margin standard, 36 % of lumpectomies had positive margins compared to 18 % using new guidelines (p < 0.0001). Seventy-seven percent of patients with "ink on tumor'' had residual disease found at reexcision. Fifty percent of subjects with margins <2 mm had residual disease (p = 0.0013) but would not have undergone reexcision under the new guidelines. With margins of >= 2 mm, residual tumor was seen in the shaved margins of 14 % of lumpectomies. Residual tumor was more common in reexcisions for ductal carcinoma-in situ <2 mm from a margin than for invasive cancer (53 vs. 40 %), although this was not statistically significant.
Conclusions. Use of new lumpectomy margin guidelines would have reduced reoperation for BCT by half in our patient cohort. However, residual disease was present in many patients who would not have been reexcised with the new guidelines. Long-term follow-up of local recurrence rates is needed to determine if this increase in residual disease is clinically significant.
C1 [Merrill, Andrea L.; Coopey, Suzanne B.; Tang, Rong; McEvoy, Maureen P.; Specht, Michele C.; Hughes, Kevin S.; Gadd, Michelle A.; Smith, Barbara L.] Massachusetts Gen Hosp, Div Surg Oncol, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
[Tang, Rong] Cent S Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Div Breast Surg,Hunan Canc Hosp, Changsha, Hunan, Peoples R China.
RP Smith, BL (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
EM blsmith1@mgh.harvard.edu
NR 26
TC 6
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAR
PY 2016
VL 23
IS 3
BP 729
EP 734
DI 10.1245/s10434-015-4916-2
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA DF4QL
UT WOS:000371334600006
PM 26467458
ER
PT J
AU Mattos, D
Gfrerer, L
Ling, ITC
Reish, RG
Hughes, KS
Halpern, EF
Cetrulo, C
Colwell, AS
Winograd, JM
Yaremchuk, MJ
Austen, WG
Liao, EC
AF Mattos, David
Gfrerer, Lisa
Ling, Irving T. C.
Reish, Richard G.
Hughes, Kevin S.
Halpern, Elkan F.
Cetrulo, Curtis
Colwell, Amy S.
Winograd, Jonathan M.
Yaremchuk, Michael J.
Austen, William G., Jr.
Liao, Eric C.
TI Occult Histopathology and Its Predictors in Contralateral and Bilateral
Prophylactic Mastectomies
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID REDUCTION MAMMAPLASTY SPECIMENS; BRCA2 MUTATION CARRIERS; LYMPH-NODE
BIOPSY; IMMEDIATE BREAST RECONSTRUCTION; CANCER RISK; WOMEN; EXPERIENCE;
CARCINOMA; TRENDS
AB Background. The last decade has seen an increasing prevalence of prophylactic mastectomies with decreasing age of patients treated for breast cancer. Data are limited on the prevalence of histopathologic abnormalities in this population. This study aimed to measure the prevalence of histopathologic findings in contralateral prophylactic mastectomy (CPM) and bilateral prophylactic mastectomy (BPM) patients and identify predictors of findings.
Methods. Our institution's prophylactic mastectomies from 2004 to 2011 were reviewed. Breast specimens with prior malignancies were excluded. Patient factors and pathology reports were collected. Independent predictive factors were identified with univariate and multivariate logistic analysis.
Results. A total of 524 specimens in 454 patients were identified. Malignancy was found in 7.0 % of CPM and 5.7 % of BPM specimens. In CPM patients, ipsilateral lobular carcinoma-in situ [odds ratio (OR) 4.0] and mammogram risk group (OR 2.0) were predictive of malignancy. Age group (OR 1.5), ipsilateral lobular carcinoma-in situ (OR 2.3), and prior bilateral salpingo-oophorectomy (OR 0.3) were predictive of moderate-to high-risk histopathology. Only increasing age group was predictive of increased moderate-to high-risk histopathology in BPM patients (OR 2.3). There were no independent predictors of malignancy in BPM. BRCA status was not predictive in either CPM or BPM.
Conclusions. Patients with lobular carcinoma-in situ in the index breast or high-risk mammograms have a higher prevalence of malignancies. Although BRCA patients may benefit from prophylactic mastectomy, the genetic diagnosis does not increase the prevalence of detecting occult pathology. BPM patients can be counseled about relative risk, where occult pathology increases with age.
C1 [Mattos, David; Gfrerer, Lisa; Ling, Irving T. C.; Reish, Richard G.; Cetrulo, Curtis; Colwell, Amy S.; Winograd, Jonathan M.; Yaremchuk, Michael J.; Austen, William G., Jr.; Liao, Eric C.] Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02114 USA.
[Hughes, Kevin S.] Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr, Boston, MA 02114 USA.
[Halpern, Elkan F.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
RP Liao, EC (reprint author), Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02114 USA.
EM cliao@partners.org
NR 31
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAR
PY 2016
VL 23
IS 3
BP 767
EP 775
DI 10.1245/s10434-015-4896-2
PG 9
WC Oncology; Surgery
SC Oncology; Surgery
GA DF4QL
UT WOS:000371334600011
PM 26577123
ER
PT J
AU Hanyuda, A
Kim, SA
Martinez-Fernandez, A
Qian, ZR
Yamauchi, M
Nishihara, R
Morikawa, T
Liao, XY
Inamura, K
Mima, K
Cao, Y
Zhang, XH
Wu, KN
Chan, AT
Giovannucci, EL
Meyerhardt, JA
Fuchs, CS
Shivdasani, RA
Ogino, S
AF Hanyuda, Akiko
Kim, Sun A.
Martinez-Fernandez, Alejandro
Qian, Zhi Rong
Yamauchi, Mai
Nishihara, Reiko
Morikawa, Teppei
Liao, Xiaoyun
Inamura, Kentaro
Mima, Kosuke
Cao, Yin
Zhang, Xuehong
Wu, Kana
Chan, Andrew T.
Giovannucci, Edward L.
Meyerhardt, Jeffrey A.
Fuchs, Charles S.
Shivdasani, Ramesh A.
Ogino, Shuji
TI Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in
Colorectal Cancer
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY;
BODY-MASS INDEX; INSULIN-RECEPTOR SUBSTRATE-1; LIFE-STYLE FACTORS;
PHYSICAL-ACTIVITY; COLON-CANCER; MICROSATELLITE INSTABILITY;
RISK-FACTORS; PIK3CA MUTATION
AB Background. High-level physical activity is associated with lower colorectal cancer (CRC) mortality, likely through insulin sensitization. Insulin receptor substrate 1 (IRS1) is a mediator of insulin and insulin-like growth factor (IGF) signaling pathways, and its down-regulation is associated with insulin resistance. Therefore, we hypothesized that tumor IRS1 expression status might modify cellular sensitivity to insulin and IGF, and the prognostic association of physical activity.
Methods. We assessed IRS1 expression level in 371 stage I-III rectal and colon cancers in the Nurses' Health Study and the Health Professionals Follow-up Study by immunohistochemistry. In survival analysis, Cox proportional hazards model was used to assess an interaction between post-diagnosis physical activity (ordinal scale of sex-specific quartiles Q1 to Q4) and IRS1 expression (ordinal scale of negative, low, and high), controlling for potential confounders, including microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 (LINE-1) methylation level, and KRAS, BRAF, and PIK3CA mutation status.
Results. There was a statistically significant interaction between post-diagnosis physical activity and tumor IRS1 expression in CRC-specific mortality analysis (P-interaction = 0.005). Multivariable hazard ratio (95 % confidence interval) for higher post-diagnosis physical activity (Q3-Q4 vs. Q1-Q2) was 0.15 (0.02-1.38) in the IRS1-negative group, 0.45 (0.19-1.03) in the IRS1-low group, and 1.32 (0.50-3.53) in the IRS1-high group.
Conclusions. The association of post-diagnosis physical activity with colorectal carcinoma patient survival may differ by tumor IRS1 expression level. If validated, tumor IRS1 expression status may serve as a predictive marker to identify subgroups of patients who might gain greater survival benefit from an increased level of exercise.
C1 [Hanyuda, Akiko; Nishihara, Reiko; Cao, Yin; Wu, Kana; Giovannucci, Edward L.] Harvard Univ, Dept Nutr, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Kim, Sun A.; Martinez-Fernandez, Alejandro; Qian, Zhi Rong; Yamauchi, Mai; Nishihara, Reiko; Morikawa, Teppei; Liao, Xiaoyun; Inamura, Kentaro; Mima, Kosuke; Zhang, Xuehong; Chan, Andrew T.; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Shivdasani, Ramesh A.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Kim, Sun A.; Martinez-Fernandez, Alejandro; Qian, Zhi Rong; Yamauchi, Mai; Nishihara, Reiko; Morikawa, Teppei; Liao, Xiaoyun; Inamura, Kentaro; Mima, Kosuke; Zhang, Xuehong; Chan, Andrew T.; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Shivdasani, Ramesh A.; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA USA.
[Nishihara, Reiko] Harvard Univ, Dept Biostat, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Nishihara, Reiko; Giovannucci, Edward L.; Ogino, Shuji] Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Morikawa, Teppei] Tokyo Univ Hosp, Dept Pathol, Tokyo 113, Japan.
[Inamura, Kentaro] JFCR, Inst Canc, Div Pathol, Tokyo, Japan.
[Cao, Yin; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Cao, Yin; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA.
[Zhang, Xuehong; Chan, Andrew T.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
RP Ogino, S (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Ogino, S (reprint author), Harvard Univ, Sch Med, Boston, MA USA.; Ogino, S (reprint author), Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.; Ogino, S (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM shuji_ogino@dfci.harvard.edu
FU NCI NIH HHS [UM1 CA167552, K07 CA190673, P01 CA055075, P01 CA087969, P01
CA55075, P01 CA87969, P50 CA127003, R01 CA118553, R01 CA137178, R01
CA151993, R01 CA169141, R35 CA197735, UM1 CA186107]; NIDDK NIH HHS [K24
DK098311]
NR 75
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAR
PY 2016
VL 23
IS 3
BP 908
EP 917
DI 10.1245/s10434-015-4967-4
PG 10
WC Oncology; Surgery
SC Oncology; Surgery
GA DF4QL
UT WOS:000371334600030
PM 26577117
ER
PT J
AU Lu, N
Dubreuil, M
Zhang, YQ
Neogi, T
Rai, SK
Ascherio, A
Hernan, MA
Choi, HK
AF Lu, Na
Dubreuil, Maureen
Zhang, Yuqing
Neogi, Tuhina
Rai, Sharan K.
Ascherio, Alberto
Hernan, Miguel A.
Choi, Hyon K.
TI Gout and the risk of Alzheimer's disease: a population-based,
BMI-matched cohort study
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID CORONARY-HEART-DISEASE; URIC-ACID; PARKINSON-DISEASE; INCIDENT GOUT;
URATE; DEMENTIA; DRUGS; SERUM; ANTIOXIDANTS; INHIBITION
AB Objective While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, the antioxidant effects of uric acid may have neuroprotective benefits. We evaluated the potential impact of incident gout on the risk of developing Alzheimer's disease (AD) in a general population context.
Methods We conducted an age-matched, sex-matched, entry-time-matched and body mass index (BMI)-matched cohort study using data from The Health Improvement Network, an electronic medical record database representative of the UK general population, from 1 January 1995 to 31 December 2013. Up to five non-gout individuals were matched to each case of incident gout by age, sex, year of enrolment and BMI. We compared incidence rates of AD between the gout and comparison cohorts, excluding individuals with prevalent gout or dementia at baseline. Multivariate hazard ratios (HRs) were calculated, while adjusting for smoking, alcohol use, physician visits, social deprivation index, comorbidities and medication use. We repeated the same analysis among patients with incident osteoarthritis (OA) as a negative control exposure.
Results We identified 309 new cases of AD among 59 224 patients with gout (29% female, mean age 65 years) and 1942 cases among 238 805 in the comparison cohort over a 5-year median follow up (1.0 vs 1.5 per 1000 person-years, respectively). Univariate (age-matched, sex-matched, entry-time-matched and BMI-matched) and multivariate HRs for AD among patients with gout were 0.71 (95% CI 0.62 to 0.80) and 0.76 (95% CI 0.66 to 0.87), respectively. The inverse association persisted among subgroups stratified by sex, age group (<75 and >= 75 years), social deprivation index and history of CV disease. The association between incident OA and the risk of incident AD was null.
Conclusions These findings provide the first general population-based evidence that gout is inversely associated with the risk of developing AD, supporting the purported potential neuroprotective role of uric acid.
C1 [Lu, Na; Choi, Hyon K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA.
[Lu, Na; Dubreuil, Maureen; Zhang, Yuqing; Neogi, Tuhina] Boston Univ, Sch Med, Clin Epidemiol Unit, Boston, MA 02118 USA.
[Dubreuil, Maureen] Boston Univ, Sch Med, Dept Med, Sect Rheumatol, Boston, MA 02118 USA.
[Rai, Sharan K.] Univ British Columbia, Arthritis Res Ctr Canada, Vancouver, BC V5Z 1M9, Canada.
[Ascherio, Alberto; Hernan, Miguel A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Choi, HK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA.
EM choi.hyon@mgh.harvard.edu
OI Neogi, Tuhina/0000-0002-9515-1711
FU NIAMS [P60AR047785, R01AR056291, R01AR065944]
FX This work was supported in part by grants from NIAMS (P60AR047785,
R01AR056291 and R01AR065944).
NR 40
TC 8
Z9 8
U1 1
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD MAR
PY 2016
VL 75
IS 3
BP 547
EP 551
DI 10.1136/annrheumdis-2014-206917
PG 5
WC Rheumatology
SC Rheumatology
GA DF1DD
UT WOS:000371077700010
PM 25739830
ER
PT J
AU Grubaugh, AL
Clapp, JD
Frueh, BC
Tuerk, PW
Knapp, RG
Egede, LE
AF Grubaugh, Anouk L.
Clapp, Joshua D.
Frueh, B. Christopher
Tuerk, Peter W.
Knapp, Rebecca G.
Egede, Leonard E.
TI Open trial of exposure therapy for PTSD among patients with severe and
persistent mental illness
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Severe mental illness (SMI); Posttraumatic stress disorder (PTSD);
Trauma; Exposure therapy; Prolonged exposure
ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL TREATMENT;
QUALITY-OF-LIFE; SCHIZOAFFECTIVE DISORDER; PSYCHOMETRIC PROPERTIES;
DSM-IV; SCHIZOPHRENIA; TRAUMA; VETERANS; ADULTS
AB Objective: There are few empirical data regarding effective treatment of trauma-related symptoms among individuals with severe mental illness (SMI; e.g., bipolar disorder, schizophrenia). This under examined clinical issue is significant because rates of trauma and PTSD are higher among individuals with SMI relative to the general population, and there are sufficient data to suggest that PTSD symptoms exacerbate the overall course and prognosis of SMI.
Method: 34 veterans with SMI received prolonged exposure (PE) for PTSD using an open trial study design.
Results: Data suggest that PE is feasible to implement, well-tolerated, and results in clinically significant decreases in PTSD severity in patients with SMI. Mean CAPS scores improved 27.2 points from baseline to immediate post [95% CI for mean change: -44.3, - 10.1; p = 0.002, paired t-test, and treatment gains were maintained at 6 months [mean change from baseline to 6-months, W-16.1; 95% CI: -31.0, -1.2; p = 0.034, paired t-test].
Conclusions: The current data support the use of exposure-based interventions for PTSD among individuals with SMI and highlight the need for rigorous randomized efficacy trials investigating frontline PTSD interventions in this patient population. (C) 2015 Published by Elsevier Ltd.
C1 [Grubaugh, Anouk L.; Tuerk, Peter W.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
[Grubaugh, Anouk L.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 109 Bee St, Charleston, SC 29401 USA.
[Clapp, Joshua D.] Univ Wyoming, Dept Psychol, 1000 E Univ Ave, Laramie, WY 82071 USA.
[Frueh, B. Christopher] Menninger Clin, Houston, TX USA.
[Frueh, B. Christopher] Univ Hawaii, Dept Psychol, 200 W Kawili St, Hilo, HI 96720 USA.
[Knapp, Rebecca G.] Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St, Charleston, SC 29403 USA.
[Egede, Leonard E.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA.
RP Grubaugh, AL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, POB 250861, Charleston, SC 29425 USA.
EM grubaugh@musc.edu
NR 58
TC 1
Z9 1
U1 4
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
EI 1873-622X
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD MAR
PY 2016
VL 78
BP 1
EP 12
DI 10.1016/j.brat.2015.12.006
PG 12
WC Psychology, Clinical
SC Psychology
GA DF5DX
UT WOS:000371373100001
PM 26797658
ER
PT J
AU Erpelding, N
Simons, L
Lebel, A
Serrano, P
Pielech, M
Prabhu, S
Becerra, L
Borsook, D
AF Erpelding, Nathalie
Simons, Laura
Lebel, Alyssa
Serrano, Paul
Pielech, Melissa
Prabhu, Sanjay
Becerra, Lino
Borsook, David
TI Rapid treatment-induced brain changes in pediatric CRPS
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Article
DE Cortical thickness; Voxel-based morphometry; Functional connectivity;
Chronic pain; Neuropathic pain; Children; Hippocampus; Prefrontal
cortex; Periaqueductal gray
ID REGIONAL PAIN SYNDROME; CHRONIC BACK-PAIN; TRANSCRANIAL MAGNETIC
STIMULATION; DORSOLATERAL PREFRONTAL CORTEX; REFLEX SYMPATHETIC
DYSTROPHY; TRIGEMINAL NEUROPATHIC PAIN; WHITE-MATTER ABNORMALITIES;
MEDIATED CHRONIC PAIN; GRAY-MATTER; FUNCTIONAL CONNECTIVITY
AB To date, brain structure and function changes in children with complex regional pain syndrome (CRPS) as a result of disease and treatment remain unknown. Here, we investigated (a) gray matter (GM) differences between patients with CRPS and healthy controls and (b) GM and functional connectivity (FC) changes in patients following intensive interdisciplinary psychophysical pain treatment. Twenty-three patients (13 females, 9 males; average age +/- A SD = 13.3 +/- A 2.5 years) and 21 healthy sex- and age-matched controls underwent magnetic resonance imaging. Compared to controls, patients had reduced GM in the primary motor cortex, premotor cortex, supplementary motor area, midcingulate cortex, orbitofrontal cortex, dorsolateral prefrontal cortex (dlPFC), posterior cingulate cortex, precuneus, basal ganglia, thalamus, and hippocampus. Following treatment, patients had increased GM in the dlPFC, thalamus, basal ganglia, amygdala, and hippocampus, and enhanced FC between the dlPFC and the periaqueductal gray, two regions involved in descending pain modulation. Accordingly, our results provide novel evidence for GM abnormalities in sensory, motor, emotional, cognitive, and pain modulatory regions in children with CRPS. Furthermore, this is the first study to demonstrate rapid treatment-induced GM and FC changes in areas implicated in sensation, emotion, cognition, and pain modulation.
C1 [Erpelding, Nathalie; Simons, Laura; Lebel, Alyssa; Serrano, Paul; Pielech, Melissa; Becerra, Lino; Borsook, David] Boston Childrens Hosp, PAIN Grp, Ctr Pain & Brain, 9 Hope Ave, Waltham, MA 02453 USA.
[Erpelding, Nathalie; Simons, Laura; Lebel, Alyssa; Prabhu, Sanjay; Becerra, Lino; Borsook, David] Harvard Univ, Sch Med, Boston, MA USA.
[Prabhu, Sanjay] Boston Childrens Hosp, Dept Radiol, Boston, MA USA.
[Becerra, Lino; Borsook, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Becerra, Lino; Borsook, David] McLean Hosp, 115 Mill St, Belmont, MA 02178 USA.
RP Erpelding, N (reprint author), Boston Childrens Hosp, PAIN Grp, Ctr Pain & Brain, 9 Hope Ave, Waltham, MA 02453 USA.
EM nathalie.erpelding@gmail.com
FU National Institute of Neurological Disorders and Stroke [R01-NS-065051,
K24-NS-064050]; National Institute of Child Health and Human Development
[HD-067202]; Mayday Foundation, New York
FX This study was primarily supported by National Institute of Neurological
Disorders and Stroke Grants R01-NS-065051 and K24-NS-064050 (to D.
Borsook), by National Institute of Child Health and Human Development
K23 Career Development Award HD-067202 (to L. Simons), and by a Grant
from the Mayday Foundation, New York. We would like to thank Charles
Berde, MD Ph.D. for his support through the Sara Page Mayo Endowment for
Pediatric Pain Research. We would like to thank Simona Sava, Ph.D. for
contributing to the data collection.
NR 147
TC 7
Z9 7
U1 1
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
EI 1863-2661
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD MAR
PY 2016
VL 221
IS 2
BP 1095
EP 1111
DI 10.1007/s00429-014-0957-8
PG 17
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA DF5GP
UT WOS:000371380100022
PM 25515312
ER
PT J
AU Beker, S
Goldin, M
Menkes-Caspi, N
Kellner, V
Chechik, G
Stern, EA
AF Beker, Shlomit
Goldin, Miri
Menkes-Caspi, Noa
Kellner, Vered
Chechik, Gal
Stern, Edward A.
TI Amyloid-beta disrupts ongoing spontaneous activity in sensory cortex
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Article
DE Alzheimer's disease; Membrane potential; Synaptic summation; Plaques;
LFP; Firing patterns
ID NEURONS IN-VIVO; CAT VISUAL-CORTEX; MEMBRANE-POTENTIAL FLUCTUATIONS;
ALZHEIMERS-DISEASE; MOUSE MODEL; FUNCTIONAL CONNECTIVITY; SYNAPTIC
INTEGRATION; NETWORK ACTIVITY; FRONTAL-CORTEX; BARREL CORTEX
AB The effect of Alzheimer's disease pathology on activity of individual neocortical neurons in the intact neural network remains obscure. Ongoing spontaneous activity, which constitutes most of neocortical activity, is the background template on which further evoked-activity is superimposed. We compared in vivo intracellular recordings and local field potentials (LFP) of ongoing activity in the barrel cortex of APP/PS1 transgenic mice and age-matched littermate Controls, following significant amyloid-beta (A beta) accumulation and aggregation. We found that membrane potential dynamics of neurons in A beta-burdened cortex significantly differed from those of nontransgenic Controls: durations of the depolarized state were considerably shorter, and transitions to that state frequently failed. The spiking properties of APP/PS1 neurons showed alterations from those of Controls: both firing patterns and spike shape were changed in the APP/PS1 group. At the population level, LFP recordings indicated reduced coherence within neuronal assemblies of APP/PS1 mice. In addition to the physiological effects, we show that morphology of neurites within the barrel cortex of the APP/PS1 model is altered compared to Controls. These results are consistent with a process where the effect of A beta on spontaneous activity of individual neurons amplifies into a network effect, reducing network integrity and leading to a wide cortical dysfunction.
C1 [Beker, Shlomit; Goldin, Miri; Menkes-Caspi, Noa; Kellner, Vered; Chechik, Gal; Stern, Edward A.] Bar Ilan Univ, Gonda Brain Res Ctr, IL-52900 Ramat Gan, Israel.
[Stern, Edward A.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Dept Neurol, Charlestown, MA USA.
RP Stern, EA (reprint author), Bar Ilan Univ, Gonda Brain Res Ctr, IL-52900 Ramat Gan, Israel.
EM sterned@mail.biu.ac.il
FU National Institute on Aging at the National Institute on Health
[AG024238]; Legacy Heritage Bio-Medical Program of the Israel Science
Foundation [688/10]; Marie Curie European Reintegration Grant within the
7th European Community Framework Programme [PERG03-GA-2008-230981]
FX This work was supported by the National Institute on Aging at the
National Institute on Health (Grant Number AG024238); the Legacy
Heritage Bio-Medical Program of the Israel Science Foundation (Grant
Number 688/10); and Marie Curie European Reintegration Grant within the
7th European Community Framework Programme (Grant Number
PERG03-GA-2008-230981). We thank Profs. Israel Nelken and Moshe Abeles
for their helpful suggestions on this manuscript.
NR 46
TC 3
Z9 3
U1 1
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
EI 1863-2661
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD MAR
PY 2016
VL 221
IS 2
BP 1173
EP 1188
DI 10.1007/s00429-014-0963-x
PG 16
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA DF5GP
UT WOS:000371380100027
PM 25523106
ER
PT J
AU Luke, JJ
LoRusso, P
Shapiro, GI
Krivoshik, A
Schuster, R
Yamazaki, T
Arai, Y
Fakhoury, A
Dmuchowski, C
Infante, JR
AF Luke, Jason J.
LoRusso, Patricia
Shapiro, Geoffrey I.
Krivoshik, Andrew
Schuster, Robin
Yamazaki, Takao
Arai, Yukinori
Fakhoury, Allam
Dmuchowski, Carl
Infante, Jeffrey R.
TI ASP9853, an inhibitor of inducible nitric oxide synthase dimerization,
in combination with docetaxel: preclinical investigation and a Phase I
study in advanced solid tumors
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Phase I clinical trial; Tumor; ASP9853; Taxane; Nitric oxide synthase
dimerization; Docetaxel
ID SUPPRESSOR-CELLS; CANCER; NO; CHEMOTHERAPY; GROWTH; MODULATION;
EXPRESSION; MECHANISM; APOPTOSIS; SURVIVIN
AB ASP9853 is an inhibitor of inducible nitric oxide (NO) synthase (iNOS) dimerization, which results in decreased NO production. Here, we report preclinical pharmacology of ASP9853 and the impact of ASP9853 in combination with a taxane on tumor volume in vivo. In addition, a Phase I open-label study of ASP9853 plus docetaxel was conducted to assess this combination in patients with advanced solid tumors.
The preclinical efficacy of ASP9853 in combination with a taxane was studied in tumor-bearing mice. In the clinic, patients with solid tumors that had progressed or failed to respond to previous therapies were treated with once-daily ASP9853 in combination with docetaxel once every 3 weeks to assess safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D) of the combination.
ASP9853 in combination with docetaxel showed greater tumor growth inhibition than docetaxel alone against non-small lung cancer xenografts. Twenty patients were treated with ASP9853 and docetaxel. Five patients experienced neutropenic dose-limiting toxicities. Owing to overall toxicity that limited further dose escalation, the ASP9853 concentrations predicted for efficacy, based on the preclinical data, were not achieved. Due to toxicity and lack of clear efficacy, the study was terminated without determination of MTD or RP2D.
Inhibition of iNOS by ASP9853 in combination with docetaxel was not tolerable and resulted in the possible potentiation of neutropenia. Manipulation of the iNOS pathway, with or without chemotherapy, appears to be more complicated than initially expected.
C1 [Luke, Jason J.] Univ Chicago Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.
[LoRusso, Patricia] Yale Smilow Canc Ctr, New Haven, CT USA.
[Shapiro, Geoffrey I.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Shapiro, Geoffrey I.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
[Krivoshik, Andrew; Schuster, Robin; Yamazaki, Takao; Fakhoury, Allam; Dmuchowski, Carl] Astellas Pharma Global Dev Inc, 1 Astellas Way, Northbrook, IL USA.
[Arai, Yukinori] Astellas Pharma Inc, Drug Discovery Res, 21 Miyukigaoka, Tsukuba, Ibaraki, Japan.
[Infante, Jeffrey R.] PLLC, Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
RP Luke, JJ (reprint author), Univ Chicago Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.
EM jluke@medicine.bsd.uchicago.edu
FU Astellas Pharma Inc.
FX We would like to thank Michelle Utton-Mishra, Choice Healthcare
Solutions, for medical writing assistance, funded by Astellas Pharma
Inc.
NR 34
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
EI 1432-0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD MAR
PY 2016
VL 77
IS 3
BP 549
EP 558
DI 10.1007/s00280-016-2967-0
PG 10
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA DF3LQ
UT WOS:000371246100010
PM 26811179
ER
PT J
AU Peng, SW
Mattox, A
Best, SR
Barbu, AM
Burns, JA
Akpeng, B
Jeang, J
Yang, B
Ishida, E
Hung, CF
Wu, TC
Pai, SI
AF Peng, Shiwen
Mattox, Austin
Best, Simon R.
Barbu, Anca M.
Burns, James A.
Akpeng, Belinda
Jeang, Jessica
Yang, Benjamin
Ishida, Eiichi
Hung, Chien-Fu
Wu, Tzyy-Choou
Pai, Sara I.
TI Identification of the murine H-2D(b) and human HLA-A*0201 MHC class
I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE Human papillomavirus; Vaccine; T cell epitope; MHC class I; Recurrent
respiratory papillomatosis; Immunotherapy
ID RECURRENT RESPIRATORY PAPILLOMATOSIS; HUMAN-PAPILLOMAVIRUS TYPE-11; DNA
VACCINES; IMMUNE-RESPONSES; CALRETICULIN; ANTIGEN; PEPTIDES; MODEL; E6
AB Recurrent respiratory papillomatosis is caused by human papillomavirus (HPV) infection, most commonly types 6 (HPV-6) and 11 (HPV-11). Due to failed host immune responses, HPV is unable to be cleared from the host, resulting in recurrent growth of HPV-related lesions that can obstruct the lumen of the airway within the upper aerodigestive tract. In our murine model, the HPV-6b and HPV-11 E7 antigens are not innately immunogenic. In order to enhance the host immune responses against the HPV E7 antigen, we linked calreticulin (CRT) to HPV-6b E7 and found that vaccinating C57BL/6 mice with the HPV-6b CRT/E7 DNA vaccine is able to induce a CD8(+) T cell response that recognizes an H-2D(b)-restricted E7aa21-29 epitope. Additionally, vaccination of HLA-A*0201 transgenic mice with HPV-6b CRT/E7 DNA generated a CD8(+) T cell response against the E7aa82-90 epitope that was not observed in the wild-type C57BL/6 mice, indicating this T cell response is restricted to HLA-A*0201. In vivo cytotoxic T cell killing assays demonstrated that the vaccine-induced CD8(+) T cells are able to efficiently kill target cells. Interestingly, the H-2D(b)-restricted E7aa21-29 sequence and the HLA-A*0201-restricted E7aa82-90 sequence are conserved between HPV-6b and HPV-11 and may represent shared immunogenic epitopes. The identification of the HPV-6b/HPV-11 CD8(+) T cell epitopes facilitates the evaluation of various immunomodulatory strategies in preclinical models. More importantly, the identified HLA-A*0201-restricted T cell epitope may serve as a peptide vaccination strategy, as well as facilitate the monitoring of vaccine-induced HPV-specific immunologic responses in future human clinical trials.
C1 [Peng, Shiwen; Jeang, Jessica; Yang, Benjamin; Hung, Chien-Fu; Wu, Tzyy-Choou] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.
[Mattox, Austin; Hung, Chien-Fu; Wu, Tzyy-Choou] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA.
[Best, Simon R.] Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.
[Barbu, Anca M.; Burns, James A.; Akpeng, Belinda; Ishida, Eiichi; Pai, Sara I.] Massachusetts Gen Hosp, Dept Surg, 55 Fruit St, Boston, MA 02114 USA.
[Wu, Tzyy-Choou] Johns Hopkins Med Inst, Dept Obstet & Gynecol, Baltimore, MD 21205 USA.
[Wu, Tzyy-Choou] Johns Hopkins Med Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
RP Pai, SI (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St, Boston, MA 02114 USA.
EM sara.pai@mgh.harvard.edu
FU NCI NIH HHS [1R01CA181538-01A1]; NIDCR NIH HHS [R01 DE025340]
NR 22
TC 0
Z9 1
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
EI 1432-0851
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD MAR
PY 2016
VL 65
IS 3
BP 261
EP 271
DI 10.1007/s00262-016-1793-x
PG 11
WC Oncology; Immunology
SC Oncology; Immunology
GA DF8TD
UT WOS:000371631100002
PM 26759151
ER
PT J
AU Bommarito, D
Martin, A
Forcade, E
Nastke, MD
Ritz, J
Bellucci, R
AF Bommarito, Davide
Martin, Allison
Forcade, Edouard
Nastke, Maria-Dorothea
Ritz, Jerome
Bellucci, Roberto
TI Enhancement of tumor cell susceptibility to natural killer cell activity
through inhibition of the PI3K signaling pathway
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE NK cells; PI3K; Immunotherapy; shRNA; Tyrosine kinase inhibitors
ID LENTIVIRAL RNAI LIBRARY; KINASE INHIBITORS; CANCER-TREATMENT; SORAFENIB;
SUNITINIB; IMMUNITY; IMMUNOSURVEILLANCE; REACTIVITY; RECEPTORS;
CARCINOMA
AB Natural killer (NK) cells are the primary effectors of the innate immune response against virus-infected cells or cells that have undergone malignant transformation. NK cells recognize their targets through a complex array of activating and inhibitory receptors, which regulate the intensity of the effector response against individual target cells. However, many studies have shown that tumor cells can escape immune cell recognition through a variety of mechanisms, developing resistance to NK cell killing. Using a lentiviral shRNA library, we previously demonstrated that several common signaling pathways modulate susceptibility of tumor cells to NK cell activity. In this study, we focused on one of the genes (PI3KCB), identified in this genetic screen. The PI3KCB gene encodes an isoform of the catalytic subunit of PI3K called P110 beta. The PI3K pathway has been linked to diverse cellular functions, but has never been associated with susceptibility to NK cell activity. Gene silencing of PI3KCB resulted in increased susceptibility of several tumor cell lines to NK cell lytic activity and induced increased IFN-gamma secretion by NK cells. Treatment of primary tumor cells with two different PI3K inhibitors also increased target cell susceptibility to NK cell activity. These effects are due, at least in part, to modulation of several activating and inhibitory ligands and appear to be correlated with PI3K signaling pathway inhibition. These findings identify a new and important role of PI3KCB in modulating tumor cell susceptibility to NK cells and open the way to future combined target immunotherapies.
C1 [Bommarito, Davide; Martin, Allison; Forcade, Edouard; Nastke, Maria-Dorothea; Ritz, Jerome; Bellucci, Roberto] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,M526, Boston, MA 02215 USA.
[Ritz, Jerome] Dana Farber Canc Inst, Canc Vaccine Ctr, 450 Brookline Ave,M530, Boston, MA 02215 USA.
[Forcade, Edouard; Ritz, Jerome; Bellucci, Roberto] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
[Forcade, Edouard; Ritz, Jerome; Bellucci, Roberto] Harvard Univ, Sch Med, Boston, MA USA.
RP Ritz, J; Bellucci, R (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,M526, Boston, MA 02215 USA.; Ritz, J (reprint author), Dana Farber Canc Inst, Canc Vaccine Ctr, 450 Brookline Ave,M530, Boston, MA 02215 USA.; Ritz, J; Bellucci, R (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Ritz, J; Bellucci, R (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
EM Jerome_ritz@dfci.Harvard.edu; Roberto_Bellucci@dfci.harvard.edu
FU NIH [R21AI088521, P01CA078378, PO1CA142106, CA183560]; Multiple Myeloma
Research Foundation (MMRF); Claudia Adams Barr Research Program
FX R21AI088521 (NIH), Multiple Myeloma Research Foundation (MMRF) and
Claudia Adams Barr Research Program (Roberto Bellucci), P01CA078378
(NIH), PO1CA142106 (NIH), CA183560 (NIH) (Jerome Ritz).
NR 44
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
EI 1432-0851
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD MAR
PY 2016
VL 65
IS 3
BP 355
EP 366
DI 10.1007/s00262-016-1804-y
PG 12
WC Oncology; Immunology
SC Oncology; Immunology
GA DF8TD
UT WOS:000371631100010
PM 26883876
ER
PT J
AU Danis, E
Yamauchi, T
Echanique, K
Zhang, X
Haladyna, JN
Riedel, SS
Zhu, N
Xie, HF
Orkin, SH
Armstrong, SA
Bernt, KM
Neff, T
AF Danis, Etienne
Yamauchi, Taylor
Echanique, Kristen
Zhang, Xi
Haladyna, Jessica N.
Riedel, Simone S.
Zhu, Nan
Xie, Huafeng
Orkin, Stuart H.
Armstrong, Scott A.
Bernt, Kathrin M.
Neff, Tobias
TI Ezh2 Controls an Early Hematopoietic Program and Growth and Survival
Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia
SO CELL REPORTS
LA English
DT Article
ID REPRESSIVE COMPLEX 2; ACUTE MYELOID-LEUKEMIA; METHYLTRANSFERASE GENE
EZH2; MLL-REARRANGED LEUKEMIA; GROUP PROTEIN EZH2; SOMATIC MUTATIONS;
G-CSF; DIFFERENTIATION; INHIBITION; TRANSFORMATION
AB Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) is an aggressive subtype of ALL distinguished by stem-cell-associated and myeloid transcriptional programs. Inactivating alterations of Poly-comb repressive complex 2 components are frequent in human ETP-ALL, but their functional role is largely undefined. We have studied the involvement of Ezh2 in a murine model of NRASQ61K-driven leukemia that recapitulates phenotypic and transcriptional features of ETP-ALL. Homozygous inactivation of Ezh2 cooperated with oncogenic NRASQ61K to accelerate leukemia onset. Inactivation of Ezh2 accentuated expression of genes highly expressed in human ETP-ALL and in normal murine early thymic progenitors. Moreover, we found that Ezh2 contributes to the silencing of stem-cell-and early-progenitor-cell-associated genes. Loss of Ezh2 also resulted in increased activation of STAT3 by tyrosine 705 phosphorylation. Our data mechanistically link Ezh2 inactivation to stem-cell-associated transcriptional programs and increased growth/survival signaling, features that convey an adverse prognosis in patients.
C1 [Danis, Etienne; Yamauchi, Taylor; Echanique, Kristen; Zhang, Xi; Haladyna, Jessica N.; Riedel, Simone S.; Bernt, Kathrin M.; Neff, Tobias] Univ Colorado Denver, Dept Pediat, Sect Pediat Hematol Oncol Bone Marrow Transplanta, Aurora, CO 80045 USA.
[Zhu, Nan] Blood Ctr Wisconsin, Blood Res Inst, Stem Cell Biol & Hematopoiesis Program, Milwaukee, WI 53226 USA.
[Xie, Huafeng; Orkin, Stuart H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Xie, Huafeng; Orkin, Stuart H.] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA 02115 USA.
[Xie, Huafeng; Orkin, Stuart H.] HHMI, Boston, MA 02115 USA.
[Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Med, New York, NY 10065 USA.
[Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Pediat, New York, NY 10065 USA.
[Bernt, Kathrin M.; Neff, Tobias] Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO 80045 USA.
RP Bernt, KM; Neff, T (reprint author), Univ Colorado Denver, Dept Pediat, Sect Pediat Hematol Oncol Bone Marrow Transplanta, Aurora, CO 80045 USA.; Bernt, KM; Neff, T (reprint author), Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO 80045 USA.
EM kathrin.bernt@ucdenver.edu; tobias.neff@ucdenver.edu
RI Bernt, Kathrin/L-1826-2016;
OI Bernt, Kathrin/0000-0002-5400-0482; Neff, Tobias/0000-0002-0188-8393
FU National Cancer Institute (NCI) [K08CA154777]; University of Colorado
Denver, Section for Pediatric Hematology/Oncology; Cancer League
Colorado; Sidney Kimmel Foundation for Cancer Research; National Heart,
Lung, and Blood Institute [K08HL102264]; NCI (Shared Resource of the
University of Colorado Cancer Center) [P30CA046934]; Children's Hospital
Colorado Research Institute
FX We thank Karen Helm and the staff at the flow cytometry core for
assistance with FACS and cell sorting. We thank Katrina Diener and Ted
Shade at the Genomics core of the University of Colorado AMC. We thank
Ken Jones at the Bioinformatics core for help with Illumina data
analysis. We thank Tracy Haney and Holly Goold for animal Husbandry. We
thank Patricia Ernst and Craig Jordan for critically reading the
manuscript. This work was supported by National Cancer Institute (NCI)
grant K08CA154777 (T.N.); start-up funds from University of Colorado
Denver, Section for Pediatric Hematology/Oncology, and the Children's
Hospital Colorado Research Institute (T.N.); the Cancer League Colorado
(T.N.); the Sidney Kimmel Foundation for Cancer Research (T.N.);
National Heart, Lung, and Blood Institute grant K08HL102264 (K.M.B.);
and NCI grant P30CA046934 (Shared Resource of the University of Colorado
Cancer Center).
NR 72
TC 5
Z9 5
U1 2
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAR 1
PY 2016
VL 14
IS 8
BP 1953
EP 1965
DI 10.1016/j.celrep.2016.01.064
PG 13
WC Cell Biology
SC Cell Biology
GA DF3BC
UT WOS:000371217700015
PM 26904942
ER
PT J
AU Wu, JQ
Keng, VW
Patmore, DM
Kendall, JJ
Patel, AV
Jousma, E
Jessen, WJ
Choi, K
Tschida, BR
Silverstein, KAT
Fan, DH
Schwartz, EB
Fuchs, JR
Zou, YS
Kim, MO
Dombi, E
Levy, DE
Huang, G
Cancelas, JA
Stemmer-Rachamimov, AO
Spinner, RJ
Largaespada, DA
Ratner, N
AF Wu, Jianqiang
Keng, Vincent W.
Patmore, Deanna M.
Kendall, Jed J.
Patel, Ami V.
Jousma, Edwin
Jessen, Walter J.
Choi, Kwangmin
Tschida, Barbara R.
Silverstein, Kevin A. T.
Fan, Danhua
Schwartz, Eric B.
Fuchs, James R.
Zou, Yuanshu
Kim, Mi-Ok
Dombi, Eva
Levy, David E.
Huang, Gang
Cancelas, Jose A.
Stemmer-Rachamimov, Anat O.
Spinner, Robert J.
Largaespada, David A.
Ratner, Nancy
TI Insertional Mutagenesis Identifies a STAT3/Arid1b/beta-catenin Pathway
Driving Neurofibroma Initiation
SO CELL REPORTS
LA English
DT Article
ID NERVE SHEATH TUMORS; NATURAL ANTISENSE TRANSCRIPTS; PANCREATIC-CANCER;
BETA-CATENIN; CELLS; NF1; PROGRESSION; GENE; ACTIVATION; TYPE-1
AB To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/beta-catenin pathway that becomes active in the context of Nf1 loss. Genetic deletion of Stat3 in Schwann cell progenitors (SCPs) and Schwann cells (SCs) prevents neurofibroma formation, decreasing SCP self-renewal and beta-catenin activity. beta-catenin expression rescues effects of Stat3 loss in SCPs. Importantly, P-STAT3 and beta-catenin expression correlate in human neurofibromas. Mechanistically, P-Stat3 represses Gsk3 beta and the SWI/SNF gene Arid1b to increase beta-catenin. Knockdown of Arid1b or Gsk3 beta in Stat3(fl/fl); Nf1(fl/fl); DhhCre SCPs rescues neurofibroma formation after in vivo transplantation. Stat3 represses Arid1b through histone modification in a Brg1-dependent manner, indicating that epigenetic modification plays a role in early tumorigenesis. Our data map a neural tumorigenesis pathway and support testing JAK/STAT and Wnt/beta-catenin pathway inhibitors in neurofibroma therapeutic trials.
C1 [Wu, Jianqiang; Patmore, Deanna M.; Kendall, Jed J.; Patel, Ami V.; Jousma, Edwin; Jessen, Walter J.; Choi, Kwangmin; Huang, Gang; Cancelas, Jose A.; Ratner, Nancy] Univ Cincinnati, Cincinnati Childrens Hosp, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.
[Zou, Yuanshu; Kim, Mi-Ok] Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA.
[Keng, Vincent W.; Tschida, Barbara R.; Largaespada, David A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
[Keng, Vincent W.; Largaespada, David A.] Univ Minnesota, Dept Pediat Cell Biol & Dev, Minneapolis, MN 55455 USA.
[Keng, Vincent W.; Tschida, Barbara R.; Largaespada, David A.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA.
[Silverstein, Kevin A. T.; Fan, Danhua] Univ Minnesota, Biostat & Informat, Minneapolis, MN 55455 USA.
[Schwartz, Eric B.; Fuchs, James R.] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA.
[Dombi, Eva] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Levy, David E.] NYU, Sch Med, Dept Pathol, 550 First Ave, New York, NY 10016 USA.
[Levy, David E.] NYU, Sch Med, Inst Canc, 550 First Ave, New York, NY 10016 USA.
[Cancelas, Jose A.] Univ Cincinnati, Coll Med, Hoxworth Blood Ctr, Cincinnati, OH 45267 USA.
[Stemmer-Rachamimov, Anat O.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Stemmer-Rachamimov, Anat O.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Spinner, Robert J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
[Keng, Vincent W.] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
RP Ratner, N (reprint author), Univ Cincinnati, Cincinnati Childrens Hosp, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.
EM nancy.ratner@cchmc.org
OI Keng, Vincent/0000-0003-3473-0653; Levy, David/0000-0002-7320-7788
FU NIH [R01 NS28840, P50 NS057531]; DAMD New Investigator Award
[W81XWH-11-1-0259]; Ohio State University Comprehensive Cancer Center
Pelotonia Idea Grant; American Cancer Society [IRG-67-00344]
FX We thank the Minnesota Supercomputing Institute for computational
resources for sequence analysis, Dr. Ari Melnick (Weil Cornell Medical
School) for assistance in design of histone modification analysis, and
Ms. Huiqing Li for animal husbandry. This work was supported by NIH R01
NS28840 (N.R.), NIH P50 NS057531 (N.R. and D.A.L.), a DAMD New
Investigator Award (W81XWH-11-1-0259), an Ohio State University
Comprehensive Cancer Center Pelotonia Idea Grant (J.W.), and the
American Cancer Society (IRG-67-003-44) (J.R.F.). The CHTN provided some
benign neurofibromas used in this study.
NR 40
TC 4
Z9 4
U1 1
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAR 1
PY 2016
VL 14
IS 8
BP 1979
EP 1990
DI 10.1016/j.celrep.2016.01.074
PG 12
WC Cell Biology
SC Cell Biology
GA DF3BC
UT WOS:000371217700017
PM 26904939
ER
PT J
AU Antman, EM
Bierer, BE
AF Antman, Elliott M.
Bierer, Barbara E.
TI Standards for Clinical Research Keeping Pace With the Technology of the
Future
SO CIRCULATION
LA English
DT Editorial Material
DE Editorials; clinical trial; ethics; research ethics; research
methodology
ID TRIALS; HEALTH
C1 [Antman, Elliott M.; Bierer, Barbara E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Antman, EM (reprint author), Brigham & Womens Hosp, TIMI Study Grp, 350 Longwood Ave,Off Level One, Boston, MA 02115 USA.
EM eantman@rics.bwh.harvard.edu
FU NCATS NIH HHS [KL2 TR000168, KL2 TR001100]; NCRR NIH HHS [KL2 RR025757]
NR 12
TC 1
Z9 1
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAR 1
PY 2016
VL 133
IS 9
BP 823
EP 825
DI 10.1161/CIRCULATIONAHA.116.020976
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DF4VG
UT WOS:000371348900001
PM 26927004
ER
PT J
AU Kubiak, DW
Farmakiotis, D
Arons, V
Hollins, RM
Rostas, SE
Weiser, LM
Baden, LR
Marty, FM
Koo, S
AF Kubiak, David W.
Farmakiotis, Dimitrios
Arons, Viktoria
Hollins, Randy M.
Rostas, Sara E.
Weiser, Linda M.
Baden, Lindsey R.
Marty, Francisco M.
Koo, Sophia
TI Utility of in-house fluconazole disk diffusion susceptibility testing in
the treatment of candidemia
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Candidemia; Fluconazole; Disk diffusion susceptibility testing
ID GLOBAL ANTIFUNGAL SURVEILLANCE; INVASIVE CANDIDIASIS; CANCER-PATIENTS;
GLABRATA; RISK; VORICONAZOLE; OUTCOMES; FAILURE; PROGRAM
AB Among 302 first candidemia episodes, 210 (69.6%) were initially treated with an echinocandin or polyene (E/P) antifungal drug. In 137 (72.5%) patients with fluconazole-susceptible isolates, treatment was changed to fluconazole based on disk diffusion susceptibility testing. Clinical outcomes were not compromised in patients receiving E/P who were de-escalated to fluconazole for treatment of candidemia based on disk diffusion results. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Kubiak, David W.; Arons, Viktoria; Hollins, Randy M.; Rostas, Sara E.] Brigham & Womens Hosp, Dept Pharm, 75 Francis St, Boston, MA 02115 USA.
[Kubiak, David W.; Baden, Lindsey R.; Marty, Francisco M.; Koo, Sophia] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.
[Farmakiotis, Dimitrios] Brown Univ, Warren Alpert Med Sch, Div Infect Dis, Rhode Isl Hosp, 593 Eddy St, Providence, RI 02115 USA.
[Weiser, Linda M.] Brigham & Womens Hosp, Clin Microbiol Lab, 75 Francis St, Boston, MA 02115 USA.
[Baden, Lindsey R.; Marty, Francisco M.; Koo, Sophia] Dana Farber Canc Inst, Div Infect Dis, 450 Brookline Ave, Boston, MA 02215 USA.
[Baden, Lindsey R.; Marty, Francisco M.; Koo, Sophia] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Kubiak, DW (reprint author), Brigham & Womens Hosp, Dept Pharm, 75 Francis St, Boston, MA 02115 USA.; Kubiak, DW; Koo, S (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.; Koo, S (reprint author), Dana Farber Canc Inst, Div Infect Dis, 450 Brookline Ave, Boston, MA 02215 USA.; Koo, S (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM dwkubiak@partners.org; skoo@bwh.harvard.edu
OI Koo, Sophia/0000-0002-4973-7439
FU National Institutes of Health [K23 AI097225]
FX Funding: There was no financial support for this study. SK is supported
by a grant from the National Institutes of Health (K23 AI097225).
NR 16
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD MAR
PY 2016
VL 84
IS 3
BP 223
EP 226
DI 10.1016/j.diagmicrobio.2015.11.018
PG 4
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA DF2PP
UT WOS:000371186500012
PM 26763713
ER
PT J
AU Salihovic, S
Ganna, A
Fall, T
Broeckling, CD
Prenni, JE
van Bavel, B
Lind, PM
Ingelsson, E
Lind, L
AF Salihovic, Samira
Ganna, Andrea
Fall, Tove
Broeckling, Corey D.
Prenni, Jessica E.
van Bavel, Bert
Lind, P. Monica
Ingelsson, Erik
Lind, Lars
TI The metabolic fingerprint of p,p '-DDE and HCB exposure in humans
SO ENVIRONMENT INTERNATIONAL
LA English
DT Article
DE Organochlorine pesticides; Human exposure; Metabolomics; Metabolic
effects; DDT; HCB
AB Background: Dichlorodiphenyldichloroethylene (p,p'-DDE) and hexachlorobenzene (HCB) are organochlorine pesticides with well-known endocrine disrupting properties. Exposure to p,p'-DDE and HCB concerns human populations worldwide and has been linked to metabolic disorders such as obesity and type 2 diabetes, but details about these associations in humans from the general population are largely unknown. Objectives: We investigated the associations between p,p'-DDE and HCB exposure and global metabolomic profiles in serum samples from 1016 participants from the Swedish population-based Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study.
Methods: HCB and p,p'-DDE levels were determined using gas chromatography coupled to high-resolution mass spectrometry (GC-HRMS). Metabolite levels were determined by using a non-targeted metabolomics approach with ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry (UPLC-TOFMS). Association analyses were performed using multivariate linear regression.
Results: We found circulating levels of p,p-DDE and HCB to be significantly associated with circulating levels of 16 metabolites following adjustment for age, sex, education level, exercise habits, smoking, energy intake, and alcohol intake. The majority of the 16 metabolites belong to lipid metabolism pathways and include fatty acids, glycerophospholipids, sphingolipids, and glycerolipids. Overall, p,p'-DDE and HCB levels were found to be correlated to different metabolites, which suggests that different metabolic fingerprints may be related to circulating levels of these two pesticides.
Conclusions: Our findings establish a link between human exposure to organochlorine pesticides and metabolites of key metabolic processes mainly related to human lipid metabolism. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Salihovic, Samira; Fall, Tove; Ingelsson, Erik] Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, SE-75141 Uppsala, Sweden.
[Ganna, Andrea] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Ganna, Andrea] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Ganna, Andrea] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge Ctr 7, Cambridge, MA 02142 USA.
[Broeckling, Corey D.; Prenni, Jessica E.] Colorado State Univ, Prote & Metabol Facil, Ft Collins, CO 80523 USA.
[Salihovic, Samira; van Bavel, Bert] Univ Orebro, Sch Sci & Technol, MTM Res Ctr, SE-70182 Orebro, Sweden.
[Lind, P. Monica] Univ Uppsala Hosp, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden.
[Ingelsson, Erik] Stanford Univ, Dept Med, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA.
[Lind, Lars] Uppsala Univ, Dept Med Sci, Cardiovasc Epidemiol, SE-75141 Uppsala, Sweden.
RP Salihovic, S (reprint author), Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, SE-75141 Uppsala, Sweden.
EM samira.salihovic@medsci.uu.se
OI Prenni, Jessica/0000-0002-0337-8450; Ganna, Andrea/0000-0002-8147-240X
FU Swedish Research Council (VR); Swedish Research Council for Environment,
Agricultural Sciences and Spatial Planning (FORMAS)
FX This study was supported by the Swedish Research Council (VR) and the
Swedish Research Council for Environment, Agricultural Sciences and
Spatial Planning (FORMAS). We greatly acknowledge Erik Lampa and Stefan
Gustafsson for technical assistance.
NR 39
TC 1
Z9 2
U1 12
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0160-4120
EI 1873-6750
J9 ENVIRON INT
JI Environ. Int.
PD MAR
PY 2016
VL 88
BP 60
EP 66
DI 10.1016/j.envint.2015.12.015
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA DF4YU
UT WOS:000371359300009
PM 26720637
ER
PT J
AU Colicino, E
Giuliano, G
Power, MC
Lepeule, J
Wilker, EH
Vokonas, P
Brennan, KJM
Fossati, S
Hoxha, M
Spiro, A
Weisskopf, MG
Schwartz, J
Baccarelli, AA
AF Colicino, Elena
Giuliano, Giulia
Power, Melinda C.
Lepeule, Johanna
Wilker, Elissa H.
Vokonas, Pantel
Brennan, Kasey J. M.
Fossati, Serena
Hoxha, Mirjam
Spiro, Avron, III
Weisskopf, Marc G.
Schwartz, Joel
Baccarelli, Andrea A.
TI Long-term exposure to black carbon, cognition and single nucleotide
polymorphisms in microRNA processing genes in older men
SO ENVIRONMENT INTERNATIONAL
LA English
DT Article
DE Air pollution; Black carbon; Cognitive function; Single nucleotide
polymorphisms; MicroRNA
ID PARTICULATE AIR-POLLUTION; ELDERLY-MEN; NEURODEGENERATIVE DISORDERS;
DISEASE; EXPRESSION; CANCER; CELLS; RISK; RNAI; SMN
AB Introduction: Air pollution exposure has been linked to impaired cognitive aging, but little is known about biomarkers modifying this association. MicroRNAs (miRNAs) control gene expression and neuronal programming. miRNA levels vary due to single nucleotide polymorphisms (SNPs) in genes processing miRNAs from precursor molecules.
Objectives: To investigate whether SNPs in miRNA-processing genes are associated with cognition and modify the relationship between black carbon (BC), marker of traffic-related pollution, and cognitive functions.
Methods: 533 Normative Aging Study men (mean +/- SD 72 +/- 7 years) were tested times (mean = 1.7 times) using seven cognitive tests between 1995 and 2007. We tested interactions of 16 miRNA-related SNPs with 1-year average BC from a validated land-use-regression model. We used covariate-adjusted logistic regression for low (25) Mini-Mental tate Examination (MMSE) and mixed-effect regression for a global cognitive score combining six other tests.
Results: Global cognition was negatively associated with the homozygous minor variant of rs595961 AGO) (-0.42SD; 95%CI: (-0.71, -0.13)) relative to the major variant. BC-MMSE association was stronger in heterozygous carriers of rs11077 XPO5 (OR = 1.99; 95%CI: (1.39, 2.85)) and minor variant carriers of GEMIN4 rs2740348 (OR = 134; 95%CI: (1.05, 1.7)), compared to their major variant. The BC-global-cognition association was stronger in heterozygous carriers of GEMIN4 rs4968104 (-0.10SD; 95%CI: (-0.18, -0.02)), and GEMIN4 rs910924 (-0.09SD; 95%Cl: (-0.17, -0.02)) relative to the major variant. Blood miRNA expression analyses showed associations only of XPO5 rs11077 with miR-9 and miR-96.
Conclusions: Carriers of particular miRNA-processing SNPs had higher susceptibility to BC in BC-cognition associations, possibly due to influences on miRNA expression. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Colicino, Elena; Giuliano, Giulia; Power, Melinda C.; Lepeule, Johanna; Wilker, Elissa H.; Brennan, Kasey J. M.; Fossati, Serena; Weisskopf, Marc G.; Schwartz, Joel; Baccarelli, Andrea A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA.
[Power, Melinda C.; Weisskopf, Marc G.; Schwartz, Joel; Baccarelli, Andrea A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
[Wilker, Elissa H.] Beth Israel Deaconess Med Ctr, Cardiovasc Epidemiol Res Unit, 330 Brookline Ave, Boston, MA 02215 USA.
[Vokonas, Pantel; Spiro, Avron, III] VA Boston Healthcare Syst, 330 Brookline Ave, Boston, MA 02215 USA.
[Vokonas, Pantel; Spiro, Avron, III] Boston Univ, Sch Publ Hlth, 330 Brookline Ave, Boston, MA 02215 USA.
[Vokonas, Pantel; Spiro, Avron, III] Boston Univ, Sch Med, 330 Brookline Ave, Boston, MA 02215 USA.
[Fossati, Serena] Univ Milan, Dept Biomed & Clin Sci L Sacco, Via Festa Perdono 7, I-20122 Milan, Italy.
[Hoxha, Mirjam] Univ Milan, Dept Clin Sci & Community Hlth, Via Festa Perdono 7, I-20122 Milan, Italy.
[Hoxha, Mirjam] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Prevent Med, Epidemiol Unit, Via Francesco Sforza 33, I-20122 Milan, Italy.
RP Colicino, E (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA.
EM ecolicin@hsph.harvard.edu; g.giuliano6@campus.unimib.it;
melinda.c.power@gmail.com; jlepeule@hsph.harvard.edu;
ewilker@bidmc.harvard.edu; pantel.vokonas@va.gov;
kbrennan@hsph.harvard.edu; sfossati@hsph.harvard.edu;
mirjam.hoxha@unimi.it; aspiro3@bu.edu; mweissko@hsph.harvard.edu;
joel@hsph.harvard.edu; abaccare@hsph.harvard.edu
RI LEPEULE, Johanna/K-1085-2016; Colicino, Elena/Q-4973-2016;
OI Colicino, Elena/0000-0002-1875-8448; Fossati, Serena/0000-0002-7484-5837
FU NIEHS [R01ES021733, R01ES015172, R01ES014663, R21ES020010]; EPA
[RD832416]; CSR&D Research Career Scientist award; US Department of
Agriculture, Agricultural Research Service [53-K06-510]; Cooperative
Studies Program/ERIC; US Department of Veterans Affairs; Massachusetts
Veterans Epidemiology Research and Information Center (MAVERIC)
FX EC is supported by a grant from the NIEHS (R01ES021733). Other support
comes was provided by NIEHS grants R01ES015172, R01ES014663 and
R21ES020010, and EPA grant RD832416. Cognitive data collection at the VA
NAS was supported by a VA Merit Review and a CSR&D Research Career
Scientist award to AS. Additional support was provided by the US
Department of Agriculture, Agricultural Research Service (contract
53-K06-510).; The VA Normative Aging Study is supported by the
Cooperative Studies Program/ERIC, US Department of Veterans Affairs, and
is a research component of the Massachusetts Veterans Epidemiology
Research and Information Center (MAVERIC). The views expressed in this
paper are those of the authors and do not necessarily represent the
views of the US Department of Veterans Affairs.
NR 50
TC 0
Z9 0
U1 4
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0160-4120
EI 1873-6750
J9 ENVIRON INT
JI Environ. Int.
PD MAR
PY 2016
VL 88
BP 86
EP 93
DI 10.1016/j.envint.2015.12.014
PG 8
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA DF4YU
UT WOS:000371359300013
PM 26724585
ER
PT J
AU El-Hachem, N
Grossmann, P
Blanchet-Cohen, A
Bateman, AR
Bouchard, N
Archambault, J
Aerts, HJWL
Haibe-Kains, B
AF El-Hachem, Nehme
Grossmann, Patrick
Blanchet-Cohen, Alexis
Bateman, Alain R.
Bouchard, Nicolas
Archambault, Jacques
Aerts, Hugo J. W. L.
Haibe-Kains, Benjamin
TI Characterization of Conserved Toxicogenomic Responses in Chemically
Exposed Hepatocytes across Species and Platforms
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID INDUCED LIVER-INJURY; GENE-EXPRESSION DATA; IN-VITRO; TRANSCRIPTOMIC
RESPONSES; PROBE LEVEL; VIVO; HEPATOCARCINOGENS; CARCINOGENICITY;
MICROARRAYS; PREDICTION
AB BACKGROUND: Genome-wide expression profiling is increasingly being used to identify-transcriptional changes induced by drugs and environmental stressors. In this context, the Toxicogenomics Project-Genomics Assisted Toxicity Evaluation system (TG-GATEs) project generated transcriptional profiles from rat liver samples and human/rat cultured primary hepatocytes exposed to more than 100 different chemicals.
OBJECTIVES: To assess the capacity of the cell culture models to recapitulate pathways induced by chemicals in vivo, we leveraged the TG-GATEs data set to compare the early transcriptional responses observed in the liver of rats treated with a large set of chemicals with those of cultured rat and human primary hepatocytes challenged with the same compounds in vitro.
METHODS: We developed a new pathway-based computational pipeline that efficiently combines gene set enrichment analysis (GSEA) using pathways from the Reactome database with biclustering to identify common modules of pathways that are modulated by several chemicals in vivo and in vitro across species.
RESULTS: We found that some chemicals induced conserved patterns of early transcriptional responses in in vitro and in vivo settings, and across human and rat genomes. These responses involved pathways of cell survival, inflammation, xenobiotic metabolism, oxidative stress, and apoptosis. Moreover, our results support the transforming growth factor beta receptor (TGF-beta R) signaling pathway as a candidate biomarker associated with exposure to environmental toxicants in primary human hepatocytes.
CONCLUSIONS: Our integrative analysis of toxicogenomics data provides a comprehensive overview of biochemical perturbations affected by a large panel of chemicals. Furthermore, we show that the early toxicological response occurring in animals is recapitulated in human and rat primary hepatocyte cultures at the molecular level, indicating that these models reproduce key pathways in response to chemical stress. These findings expand our understanding and interpretation of -toxicogenomics data from human hepatocytes exposed to environmental toxicants.
C1 [El-Hachem, Nehme] Inst Rech Clin Montreal, Integrat Syst Biol, Montreal, PQ H2W 1R7, Canada.
[El-Hachem, Nehme] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
[Grossmann, Patrick; Aerts, Hugo J. W. L.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Grossmann, Patrick; Aerts, Hugo J. W. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiat Oncol, Boston, MA 02115 USA.
[Blanchet-Cohen, Alexis] Inst Rech Clin Montreal, Bioinformat, Montreal, PQ H2W 1R7, Canada.
[Bateman, Alain R.] McGill Univ, Dept Human Genet, Montreal, PQ, Canada.
[Bouchard, Nicolas] Inst Rech Clin Montreal, Mol Biol Neural Dev, Montreal, PQ H2W 1R7, Canada.
[Archambault, Jacques] Inst Rech Clin Montreal, Mol Virol Lab, Montreal, PQ H2W 1R7, Canada.
[Aerts, Hugo J. W. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiol, Boston, MA 02115 USA.
[Haibe-Kains, Benjamin] Princess Margaret Canc Ctr, Univ Hlth Network, 101 Coll St, Toronto, ON M5G 1L7, Canada.
[Haibe-Kains, Benjamin] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
RP Aerts, HJWL (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiol, Boston, MA 02115 USA.; Haibe-Kains, B (reprint author), Princess Margaret Canc Ctr, Univ Hlth Network, 101 Coll St, Toronto, ON M5G 1L7, Canada.
EM hugo@jimmy.harvard.edu; bhaibeka@uhnresearch.ca
RI Haibe-Kains, Benjamin/D-3702-2011; Aerts, Hugo/P-6350-2015;
OI Haibe-Kains, Benjamin/0000-0002-7684-0079; Aerts,
Hugo/0000-0002-2122-2003; Archambault, Jacques/0000-0001-8107-3428
FU Institut de Recherches Cliniques de Montreal (IRCM); Gattuso Slaight
Personalized Cancer Medicine Fund at Princess Margaret Cancer Centre;
diXa, a part of the European Union (EU) Seventh Framework Programme
[RI-283775]; National Institutes of Health (NIH-USA) [U01CA190234]
FX N.E.-H. was supported by an Institut de Recherches Cliniques de Montreal
(IRCM) doctoral fellowship. B.H.-K. was supported by the Gattuso Slaight
Personalized Cancer Medicine Fund at Princess Margaret Cancer Centre.
H.J.W.L.A. was supported by diXa, a part of the European Union (EU)
Seventh Framework Programme, under grant agreement number no. RI-283775.
We also acknowledge financial support from the National Institutes of
Health (NIH-USA U01CA190234).
NR 42
TC 2
Z9 2
U1 2
U2 6
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD MAR
PY 2016
VL 124
IS 3
BP 313
EP 320
DI 10.1289/ehp.1409157
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA DF6CJ
UT WOS:000371442500017
PM 26173225
ER
PT J
AU Wang, L
Manson, JE
Rautiainen, S
Gaziano, JM
Buring, JE
Tsai, MY
Sesso, HD
AF Wang, Lu
Manson, JoAnn E.
Rautiainen, Susanne
Gaziano, J. Michael
Buring, Julie E.
Tsai, Michael Y.
Sesso, Howard D.
TI A prospective study of erythrocyte polyunsaturated fatty acid, weight
gain, and risk of becoming overweight or obese in middle-aged and older
women
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Fatty acids; Prospective study; Women; Obesity; Weight gain
ID RANDOMIZED CONTROLLED-TRIAL; SELF-REPORTED WEIGHT;
CARDIOVASCULAR-DISEASE; DIETARY-FAT; LINOLEIC-ACID; PRIMARY PREVENTION;
CHOLESTERYL ESTER; PHYSICAL-ACTIVITY; GENE-EXPRESSION; NATIONAL-HEALTH
AB omega 3 and omega 6 fatty acids (FA) may have divergent effects on the development of obesity. We examined the association of baseline erythrocyte omega 3 and omega 6 FA composition with body weight change and the risk of becoming overweight or obese in the Women's Health Study (WHS) participants.
We identified 534 women who had baseline erythrocyte FA measured and a baseline body mass index (BMI) of 18.5-< 25 kg/m(2). Body weight was updated at a total of six time points during follow-up.
Weight gain during a mean of 10.4-year follow-up increased with increasing quartiles of baseline erythrocyte cis omega 6 FA, omega 6/omega 3 ratio, and trans FA while decreased with increasing cis omega 3 FA. After multivariable adjustment including total energy intake and physical activity, the weight gain (kg) in the highest versus the lowest quartile was 3.08 versus 2.32 for erythrocyte cis omega 6 FA (p (trend) 0.04), 2.07 versus 2.92 for cis omega 3 FA (p (trend) 0.08), 2.93 versus 2.05 for omega 6/omega 3 ratio (p (trend) 0.046), and 3.03 versus 2.27 for trans FA (p (trend) 0.06). Among individual FA, the associations were significant for 18:2 omega 6, 18:3 omega 6, and trans 18:1 and marginally significant for 20:3 omega 6 and trans 18:2. The risk of becoming overweight or obese (defined as BMI a parts per thousand yen25 kg/m(2) at any follow-up time point) increased across increasing omega 6/omega 3 ratio (multivariable model p (trend) 0.04).
In this prospective study, we found suggestive evidence that erythrocyte cis omega 6 FA may be positively associated, and cis omega 3 FA inversely associated with weight gain in initially normal-weight women.
C1 [Wang, Lu; Manson, JoAnn E.; Gaziano, J. Michael; Buring, Julie E.; Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave East, Boston, MA 02215 USA.
[Manson, JoAnn E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Rautiainen, Susanne] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.
[Gaziano, J. Michael; Buring, Julie E.; Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02215 USA.
[Gaziano, J. Michael] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
[Gaziano, J. Michael] VA Boston Healthcare Syst, Ctr Geriatr Res Educ & Clin, Boston, MA USA.
[Tsai, Michael Y.] Univ Minnesota, Dept Lab Med & Pathol, St Paul, MN USA.
RP Wang, L (reprint author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave East, Boston, MA 02215 USA.
EM lwang@research.bwh.harvard.edu
FU American Heart Association [0735390N]; National Institutes of Health,
Bethesda, MD [CA047988, HL043851, HL080467]; National Heart, Lung, and
Blood Institutes [HL095649]
FX We are indebted to the 39,876 participants in the Women's Health Study
for their dedicated and conscientious collaboration, and to the entire
staff of the Women's Health Study for their assistance in designing and
conducting the trial. This study was supported by a national scientist
development grant funded by American Heart Association (0735390N) and
research grants CA047988, HL043851, and HL080467 from the National
Institutes of Health, Bethesda, MD. Dr. Wang was supported by Grant
HL095649 from the National Heart, Lung, and Blood Institutes. These
grants provided funding for study conduction, data collection, data
analysis, and manuscript writing.
NR 60
TC 2
Z9 2
U1 3
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD MAR
PY 2016
VL 55
IS 2
BP 687
EP 697
DI 10.1007/s00394-015-0889-y
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DF3RD
UT WOS:000371262400024
PM 25820817
ER
PT J
AU Jordan, TH
Talarico, RH
Schuberth, JM
AF Jordan, Thomas H.
Talarico, Ross H.
Schuberth, John M.
TI Letter Regarding: The Fate of the Fixed Syndesmosis Over Time
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Letter
C1 [Jordan, Thomas H.] Kaiser Permanente Med Grp, Santa Rosa, CA USA.
[Talarico, Ross H.] Podiat Surg Sect, San Francisco, CA USA.
[Talarico, Ross H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Schuberth, John M.] Kaiser Fdn Hosp, Dept Orthoped Surg, Foot & Ankle Surg, San Francisco, CA USA.
RP Schuberth, JM (reprint author), Kaiser Fdn Hosp, Dept Orthoped Surg, Foot & Ankle Surg, San Francisco, CA USA.
EM jmfoot@aol.com
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1071-1007
EI 1944-7876
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD MAR
PY 2016
VL 37
IS 3
BP 344
EP 344
DI 10.1177/1071100715627352
PG 1
WC Orthopedics
SC Orthopedics
GA DF4JS
UT WOS:000371314500015
PM 26921312
ER
PT J
AU Klingaman, EA
Hoerster, KD
Aakre, JM
Viverito, KM
Medoff, DR
Goldberg, RW
AF Klingaman, Elizabeth A.
Hoerster, Katherine D.
Aakre, Jennifer M.
Viverito, Kristen M.
Medoff, Deborah R.
Goldberg, Richard W.
TI Veterans with PTSD report more weight loss barriers than Veterans with
no mental health disorders
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Veterans; Post-traumatic stress disorder; Weight management; MOVE
ID POSTTRAUMATIC-STRESS-DISORDER; PHYSICAL-ACTIVITY; SELF-EFFICACY;
BEHAVIORAL ACTIVATION; ANXIETY DISORDERS; MILITARY SERVICE;
HEART-DISEASE; RISK-FACTOR; DEPRESSION; MORTALITY
AB Objective: This study characterized and compared Veterans of the United States Armed Forces with posttraumatic stress disorder ( PTSD) to Veterans with no mental health disorders on self-reported measures of factors that influence success in weight management programs.
Method: We examined the relation of PTSD diagnosis with weight loss plan, reasons for overweight/obesity and barriers to dieting and physical exercise among 171,884 Veterans. Statistically significant variables in chi-square tests (P<.05) with at least a small effect size were then compared via multivariate logistic regression analyses.
Results: Both groups reported high ratings of importance and confidence regarding changing weight loss behaviors and were preparing or actively engaging in efforts to manage their weight. Compared to Veterans without mental health disorders, more Veterans with PTSD endorsed 27 of the 28 barriers to changing eating and physical habits.
Conclusions: The results of this study help to explain the lower rates of success of Veterans with PTSD in weight loss programs. Results suggest that a comprehensive, integrated approach to promoting weight loss in Veterans with PTSD is needed. Published by Elsevier Inc.
C1 [Klingaman, Elizabeth A.; Aakre, Jennifer M.; Medoff, Deborah R.; Goldberg, Richard W.] US Dept Vet Affairs, Capitol Healthcare Network, Mental Illness Res Educ & Clin Ctr, 10 North Greene St,Annex Suite 720, Baltimore, MD 21201 USA.
[Klingaman, Elizabeth A.; Aakre, Jennifer M.; Medoff, Deborah R.; Goldberg, Richard W.] Univ Maryland, Sch Med, Dept Psychiat, 737 West Lombard St, Baltimore, MD 21201 USA.
[Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Seattle Div, Mental Hlth Serv, 1660 South Columbian Way S-116, Seattle, WA 98108 USA.
[Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, 1959 Northeast Pacific St,Box 356560,Room BB1644, Seattle, WA 98195 USA.
[Viverito, Kristen M.] Cent Arkansas Vet Healthcare Syst, Hlth Serv Res & Dev Serv, Mental Healthcare & Outcomes Res, North Little Rock, AR 72114 USA.
[Viverito, Kristen M.] Univ Arkansas Med Sci, Inst Psychiat Res, Div Hlth Serv Res, 4301 West Markham,554, Little Rock, AR 72205 USA.
RP Klingaman, EA (reprint author), Baltimore VA Med Ctr, VA Maryland Healthcare Syst, 10 North Greene St,Annex Suite 720, Baltimore, MD 21201 USA.
EM elizabeth.klingaman@va.gov; Katherine.hoerster@va.gov;
jennifer.aakre@va.gov; Kristen.viverito@va.gov;
dmedoff@psych.umaryland.edu; richard.goldberg@va.gov
FU Department of Veterans Affairs (VA) Office of Academic Affiliations
Advanced Fellowship Program in Mental Illness Research and Treatment; VA
Health Services Research and Development Fellowship; VA Career
Development Award (HSRD) [CDA 12-263]; VA Capitol Healthcare Network
Mental Illness Research, Education and Clinical Center; Central Arkansas
Veterans Healthcare System Center for Mental Healthcare and Outcomes
Research
FX This research is supported by the Department of Veterans Affairs (VA)
Office of Academic Affiliations Advanced Fellowship Program in Mental
Illness Research and Treatment and the VA Health Services Research and
Development Fellowship. Dr. Hoerster is supported by VA Career
Development Award (HSR&D CDA 12-263). It is the result of work supported
with resources and the use of facilities at the VA Capitol Healthcare
Network Mental Illness Research, Education and Clinical Center and the
Central Arkansas Veterans Healthcare System Center for Mental Healthcare
and Outcomes Research. Special thanks to Susan Raffa, Ken Jones and Tony
Rogers for their contributions to this manuscript.
NR 51
TC 4
Z9 4
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAR-APR
PY 2016
VL 39
BP 1
EP 7
DI 10.1016/j.genhosppsych.2015.11.003
PG 7
WC Psychiatry
SC Psychiatry
GA DF3KY
UT WOS:000371244000001
PM 26719103
ER
PT J
AU Saint-Andre, V
Federation, AJ
Lin, CY
Abraham, BJ
Reddy, J
Lee, TI
Bradner, JE
Young, RA
AF Saint-Andre, Violaine
Federation, Alexander J.
Lin, Charles Y.
Abraham, Brian J.
Reddy, Jessica
Lee, Tong Ihn
Bradner, James E.
Young, Richard A.
TI Models of human core transcriptional regulatory circuitries
SO GENOME RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; PROTEIN-DNA INTERACTIONS; BINDING MICROARRAY DATA;
NANOG GENE-EXPRESSION; SUPER-ENHANCERS; SELF-RENEWAL; ES CELLS;
COLORECTAL-CANCER; IDENTITY GENES; CHROMATIN ARCHITECTURE
AB A small set of core transcription factors (TFs) dominates control of the gene expression program in embryonic stem cells and other well-studied cellular models. These core TFs collectively regulate their own gene expression, thus forming an interconnected auto-regulatory loop that can be considered the core transcriptional regulatory circuitry (CRC) for that cell type. There is limited knowledge of core TFs, and thus models of core regulatory circuitry, for most cell types. We recently discovered that genes encoding known core TFs forming CRCs are driven by super-enhancers, which provides an opportunity to systematically predict CRCs in poorly studied cell types through super-enhancer mapping. Here, we use super-enhancer maps to generate CRC models for 75 human cell and tissue types. These core circuitry models should prove valuable for further investigating cell-type specific transcriptional regulation in healthy and diseased cells.
C1 [Saint-Andre, Violaine; Abraham, Brian J.; Reddy, Jessica; Lee, Tong Ihn; Young, Richard A.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
[Federation, Alexander J.; Lin, Charles Y.; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Reddy, Jessica; Young, Richard A.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Bradner, James E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Saint-Andre, V; Young, RA (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.; Bradner, JE (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Young, RA (reprint author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Bradner, JE (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
EM violaine.saintandre@gmail.com; james_bradner@dfci.harvard.edu;
young@wi.mit.edu
RI Young, Richard/F-6495-2012
OI Young, Richard/0000-0001-8855-8647
FU Foundation for the National Institutes of Health [HG002668]; National
Science Foundation
FX We thank members of the Young lab, especially Ana D'Alessio, Zi Peng
Fan, and Jurian Schuijers for helpful discussions. This work was
supported by the Foundation for the National Institutes of Health grant
HG002668 (R.A.Y.). A.J.F. was funded by a National Science Foundation
graduate fellowship, and B.J.A. is the Hope Funds for Cancer Research
Grillo-Marxuach Family Fellow.
NR 133
TC 7
Z9 8
U1 1
U2 10
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD MAR
PY 2016
VL 26
IS 3
BP 385
EP 396
DI 10.1101/gr.197590.115
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
GA DF5EF
UT WOS:000371373900010
PM 26843070
ER
PT J
AU Quevrain, E
Maubert, MA
Michon, C
Chain, F
Marquant, R
Tailhades, J
Miquel, S
Carlier, L
Bermudez-Humaran, LG
Pigneur, B
Lequin, O
Kharrat, P
Thomas, G
Rainteau, D
Aubry, C
Breyner, N
Afonso, C
Lavielle, S
Grill, JP
Chassaing, G
Chatel, JM
Trugnan, G
Xavier, R
Langella, P
Sokol, H
Seksik, P
AF Quevrain, E.
Maubert, M. A.
Michon, C.
Chain, F.
Marquant, R.
Tailhades, J.
Miquel, S.
Carlier, L.
Bermudez-Humaran, L. G.
Pigneur, B.
Lequin, O.
Kharrat, P.
Thomas, G.
Rainteau, D.
Aubry, C.
Breyner, N.
Afonso, C.
Lavielle, S.
Grill, J-P
Chassaing, G.
Chatel, J. M.
Trugnan, G.
Xavier, R.
Langella, P.
Sokol, H.
Seksik, P.
TI Identification of an anti-inflammatory protein from Faecalibacterium
prausnitzii, a commensal bacterium deficient in Crohn's disease
SO GUT
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; SEGMENTED FILAMENTOUS BACTERIA; REGULATORY
T-CELLS; CAMPYLOBACTER-CONCISUS; EPITHELIAL BARRIER; FECAL MICROBIOTA;
TIGHT JUNCTION; IMMUNE-SYSTEM; GUT; COLITIS
AB Background Crohn's disease (CD)-associated dysbiosis is characterised by a loss of Faecalibacterium prausnitzii, whose culture supernatant exerts an anti-inflammatory effect both in vitro and in vivo. However, the chemical nature of the anti-inflammatory compounds has not yet been determined.
Methods Peptidomic analysis using mass spectrometry was applied to F. prausnitzii supernatant. Antiinflammatory effects of identified peptides were tested in vitro directly on intestinal epithelial cell lines and on cell lines transfected with a plasmid construction coding for the candidate protein encompassing these peptides. In vivo, the cDNA of the candidate protein was delivered to the gut by recombinant lactic acid bacteria to prevent dinitrobenzene sulfonic acid (DNBS)-colitis in mice.
Results The seven peptides, identified in the F. prausnitzii culture supernatants, derived from a single microbial anti-inflammatory molecule (MAM), a protein of 15 kDa, and comprising 53% of non-polar residues. This last feature prevented the direct characterisation of the putative anti-inflammatory activity of MAM-derived peptides. Transfection of MAM cDNA in epithelial cells led to a significant decrease in the activation of the nuclear factor (NF)-kappa B pathway with a dose-dependent effect. Finally, the use of a food-grade bacterium, Lactococcus lactis, delivering a plasmid encoding MAM was able to alleviate DNBS-induced colitis in mice.
Conclusions A 15 kDa protein with anti-inflammatory properties is produced by F. prausnitzii, a commensal bacterium involved in CD pathogenesis. This protein is able to inhibit the NF-kappa B pathway in intestinal epithelial cells and to prevent colitis in an animal model.
C1 [Quevrain, E.; Maubert, M. A.; Marquant, R.; Tailhades, J.; Carlier, L.; Pigneur, B.; Lequin, O.; Thomas, G.; Rainteau, D.; Lavielle, S.; Grill, J-P; Chassaing, G.; Trugnan, G.; Sokol, H.; Seksik, P.] Univ Paris 06, Sorbonne Univ, Paris, France.
[Quevrain, E.; Maubert, M. A.; Pigneur, B.; Thomas, G.; Rainteau, D.; Grill, J-P; Trugnan, G.; Sokol, H.; Seksik, P.] CHU St Antoine 27, INSERM, ERL 1157, Paris, France.
[Quevrain, E.; Maubert, M. A.; Pigneur, B.; Thomas, G.; Rainteau, D.; Grill, J-P; Trugnan, G.; Sokol, H.; Seksik, P.] CHU St Antoine 27, Inflammat Immunopathol Biotherapy Dept DHU i2B, Paris, France.
[Quevrain, E.; Maubert, M. A.; Marquant, R.; Tailhades, J.; Carlier, L.; Pigneur, B.; Lequin, O.; Thomas, G.; Rainteau, D.; Lavielle, S.; Grill, J-P; Chassaing, G.; Trugnan, G.; Sokol, H.; Seksik, P.] CNRS, UMR, Paris, France.
[Maubert, M. A.; Rainteau, D.; Trugnan, G.] Hop St Antoine, AP HP, Dept Plateforme Metabol PM2, Peptidom & Dosage Medicaments, Paris, France.
[Michon, C.; Chain, F.; Miquel, S.; Bermudez-Humaran, L. G.; Kharrat, P.; Aubry, C.; Breyner, N.; Chatel, J. M.; Langella, P.; Sokol, H.] INRA, Micalis UMR1319, Jouy En Josas, France.
[Michon, C.; Chain, F.; Miquel, S.; Bermudez-Humaran, L. G.; Kharrat, P.; Aubry, C.; Breyner, N.; Chatel, J. M.; Langella, P.] AgroParisTech, UMR Micalis, Jouy En Josas, France.
[Marquant, R.; Tailhades, J.; Carlier, L.; Lequin, O.; Lavielle, S.; Chassaing, G.] PSL Res Univ, Ecole Normale Super, Dept Chim, 24 Rue Lhomond, Paris, France.
[Afonso, C.] Univ Rouen, COBRA IRCOF, UMR 6014, Mont St Aignan, France.
[Xavier, R.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Sokol, H.; Seksik, P.] Hop St Antoine, AP HP, Serv Gastroenterol & Nutr, F-75571 Paris, France.
RP Seksik, P (reprint author), Hop St Antoine, Serv Gastroenterol & Nutr, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.
EM philippe.seksik@sat.aphp.fr
RI Afonso, Carlos/E-9736-2011;
OI Afonso, Carlos/0000-0002-2406-5664; PIGNEUR,
Benedicte/0000-0002-5324-9964; sokol, harry/0000-0002-2914-1822
FU Association Francois Aupetit; Agence Nationale de la Recherche [Mi2];
French FUI (Fond Unique Interministeriel; FUI) [F1010012D]; FEDER (Fonds
Europeen de Developpement Regional; Bourgogne) [34606]; Burgundy Region;
Conseil General [21]; Grand Dijon; Merck Medication Familiale (Dijon,
France); Biovitis (Saint Etienne de Chomeil, France)
FX We thank Association Francois Aupetit (2009) and Agence Nationale de la
Recherche (Mi2 2010) for funding this work. This last study was a part
of the FPARIS collaborative project selected and supported by the
Vitagora Competitive Cluster and funded by the French FUI (Fond Unique
Interministeriel; FUI no. F1010012D), the FEDER (Fonds Europeen de
Developpement Regional; Bourgogne no. 34606), the Burgundy Region, the
Conseil General 21, and the Grand Dijon. This work was also supported by
Merck Medication Familiale (Dijon, France) and Biovitis (Saint Etienne
de Chomeil, France).
NR 50
TC 39
Z9 40
U1 23
U2 45
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD MAR
PY 2016
VL 65
IS 3
BP 415
EP 425
DI 10.1136/gutjnl-2014-307649
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DF4ME
UT WOS:000371321700010
PM 26045134
ER
PT J
AU Hinchcliff, E
Rauh-Hain, JA
Clemmer, JT
Diver, E
Hall, T
Stall, J
Growdon, W
Clark, R
Schorge, J
AF Hinchcliff, Emily
Rauh-Hain, J. Alejandro
Clemmer, Joel T.
Diver, Elisabeth
Hall, Tracilyn
Stall, Jennifer
Growdon, Whitfield
Clark, Rachel
Schorge, John
TI Racial disparities in survival in malignant germ cell tumors of the
ovary
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Ovarian germ cell tumors; Rare tumors; Racial disparities; Ovarian
cancer
ID CANCER DATA-BASE; BLACK-AND-WHITE; UNITED-STATES; CERVICAL-CANCER;
WOMEN; CARE; CHEMOTHERAPY; QUALITY; TRENDS; RATES
AB Objective. To investigate racial disparities with respect to adjuvant treatment and survival inpatients presenting with malignant ovarian germ cell tumors (OGCT).
Methods. The National Cancer Database (NCDB) was used to identify women diagnosed with OGCT. Demographic data were abstracted, including stratification by race and histology. Standard univariate and multivariate analyses using logistic regression were performed to describe predictors of adjuvant treatment. Kaplan-Meier and Cox proportional hazards survival methods were used to evaluate racial differences in survival between African American (AA) and white (W) women.
Results. The study population included 2196 patients, with 1654 (753%) W and 328 (14.9%) AA women. Histologic distribution varied significantly by race (p < 0.0001), but neither age nor stage at presentation showed racial differences (p = 0.086 and p = 0209, respectively). AA received more chemotherapy than W (W: 54.6%, AA: 65.5%, p = 0.008), but in multivariate analysis there was no statistically significant difference in any adjuvant treatment modality. Despite similar treatment, and independent of histology, survival varied significantly by race with 91% (CI 0.89-0.93) five year survival in W patients compared to 84% five year survival in AA (CI 0.8-0.89) (p = 0.02). These disparities were most pronounced in advanced stage disease, with 5 year survival of 84% (CI 0.79-0.89) in W compared to 61% (CI 0.48-0.78) for AA in stage III (p = 0.0002), and 54% (CI 0.42-0.68) compared to 14% (CI 0.03-0.71) for stage IV (p = 0.05).
Conclusions. AA with OGCT have significantly worse 5 year survival when compared to W patients despite similar rates and modalities of adjuvant treatment. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Hinchcliff, Emily; Rauh-Hain, J. Alejandro; Clemmer, Joel T.; Diver, Elisabeth; Hall, Tracilyn; Growdon, Whitfield; Clark, Rachel; Schorge, John] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Hinchcliff, Emily] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA.
[Stall, Jennifer] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Hinchcliff, Emily; Rauh-Hain, J. Alejandro; Diver, Elisabeth; Hall, Tracilyn; Stall, Jennifer; Growdon, Whitfield; Clark, Rachel; Schorge, John] Harvard Univ, Sch Med, Boston, MA USA.
RP Hinchcliff, E (reprint author), Massachusetts Gen Hosp, Div Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA.
EM ehinchcliff@partners.org
NR 26
TC 2
Z9 2
U1 3
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD MAR
PY 2016
VL 140
IS 3
BP 463
EP 469
DI 10.1016/j.ygyno.2016.01.006
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA DF5DT
UT WOS:000371372700016
PM 26773470
ER
PT J
AU Gockley, AA
Melamed, A
Joseph, NT
Clapp, M
Sun, SY
Goldstein, DP
Horowitz, NS
Berkowitz, RS
AF Gockley, Allison A.
Melamed, Alexander
Joseph, Naima T.
Clapp, Mark
Sun, Sue Yazaki
Goldstein, Donald P.
Horowitz, Neil S.
Berkowitz, Ross S.
TI The effect of adolescence and advanced maternal age on the incidence of
complete and partial molar pregnancy
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Complete mole; Partial mole; Maternal age
ID PARTIAL HYDATIDIFORM MOLE; ORIGIN; RISK
AB Objective. To compare the age-specific incidence of complete (CM) and partial molar (PM) pregnancy in a large tertiary care center in the United States.
Methods. Incidence rates of CM and PM per 10,000 live births were calculated using databases from Brigham and Women's Hospital, between 2000 and 2013. Age-specific rates were calculated for women younger than 20 years old (adolescents), 20-39 years old (average age), and 40 years and older (advanced maternal age). Pearson chi(2) test was used to evaluate potential differences among groups. Rate ratios (RR) and 95% confidence intervals (CI) were used to compare risk of molar pregnancy among average age women with that of adolescents and women of advanced age. Holm-Bonferonni adjustment was used to correct for multiple comparisons.
Results. Between 2000 and 2013, there were 255 molar pregnancies (140 CM and 115 PM) and 105,942 live births, corresponding to a molar pregnancy rate of 24 per 10,000 live births (95% CI 21-27). Rates of CM and PM were 13 (95% CI 11-16) and 11 (95% CI 9-14) per 10,000 live births respectively. The incidence of CM differed significantly among maternal age groups (p < 0.001). Compared to average age women, adolescents were 7.0 times as likely to develop CM (95% CI 3.6-8.9, p < 0.001), and women with advanced maternal age were nearly twice as likely (1.9, 95% CI 1.8-4.7, p = 0.002). The rate of PM did not vary significantly among age groups (p = 026).
Conclusions. Adolescence and advanced maternal age were associated with increased risk of complete mole, but not partial mole. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Gockley, Allison A.; Melamed, Alexander; Joseph, Naima T.; Clapp, Mark; Goldstein, Donald P.; Horowitz, Neil S.; Berkowitz, Ross S.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.
[Gockley, Allison A.; Melamed, Alexander; Joseph, Naima T.; Clapp, Mark] Massachusetts Gen Hosp, Vincent Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA.
[Gockley, Allison A.; Melamed, Alexander; Joseph, Naima T.; Clapp, Mark] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
[Goldstein, Donald P.; Horowitz, Neil S.; Berkowitz, Ross S.] Harvard Canc Ctr, Dana Farber Canc Inst, Susan F Smith Ctr Womens Canc, Gynecol Oncol Program, Boston, MA USA.
[Sun, Sue Yazaki] Univ Fed Sao Paulo, UNIFESP, Paulista Sch Med, Dept Obstet, Sao Paulo, SP, Brazil.
[Sun, Sue Yazaki] Univ Fed Sao Paulo, UNIFESP, Paulista Sch Med, Trophoblast Dis,Ctr Sao Paulo Hosp, Sao Paulo, SP, Brazil.
[Sun, Sue Yazaki; Goldstein, Donald P.; Horowitz, Neil S.; Berkowitz, Ross S.] Donald P Goldstein MD Trophoblast Tumor Registry, New England Trophoblast Dis Ctr, Boston, MA USA.
RP Berkowitz, RS (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, ASBI, 75 Francis St, Boston, MA 02115 USA.
EM rberkowitz@partners.org
OI Melamed, Alexander/0000-0002-0654-0863
FU Donald P. Goldstein Trophoblastic Tumor Registry Endowment; Dyett Family
Trophoblastic Disease Research and Registry Endowment
FX This research was supported by the Donald P. Goldstein Trophoblastic
Tumor Registry Endowment and the Dyett Family Trophoblastic Disease
Research and Registry Endowment.
NR 19
TC 1
Z9 1
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD MAR
PY 2016
VL 140
IS 3
BP 470
EP 473
DI 10.1016/j.ygyno.2016.01.005
PG 4
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA DF5DT
UT WOS:000371372700017
PM 26777992
ER
PT J
AU Lozo, S
Eckardt, MJ
Altawil, Z
Nelson, BD
Ahn, R
Khisa, W
Burke, TF
AF Lozo, Svjetlana
Eckardt, Melody J.
Altawil, Zaid
Nelson, Brett D.
Ahn, Roy
Khisa, Weston
Burke, Thomas F.
TI Prevalence of unrepaired third- and fourth-degree tears among women
taken to the operating room for repair of presumed obstetric fistula
during two fistula camps in Kenya
SO INTERNATIONAL UROGYNECOLOGY JOURNAL
LA English
DT Article
DE Obstetric fistula; Third- and fourth-degree obstetric tears; Fistula
camp; Obstetric lacerations
ID MANAGEMENT
AB Introduction and hypothesis More than 2 million women on earth today are said to be suffering from obstetric fistula (OF), a communication between the vagina and either the urinary tract or rectum. Since unrepaired third- and fourth-degree perineal tears often manifest with symptoms identical to OF, we hypothesized that the global burden of OF is in part due to these unrepaired deep obstetric tears.
Methods Four consultant gynecologists retrospectively reviewed the medical and operative records of all obstetric fistula cases that underwent surgical repair during the July and August, 2014, Kenyatta National Hospital and Embu Provincial Hospital Fistula Camps in Kenya.
Results One hundred and eighty charts were reviewed. All 180 women had fecal incontinence (FI), urinary incontinence (UI), or both as their primary complaint. Sixty of the 180 (33 %) women had isolated FI as their presenting symptom, and at operation, 57 of these 60 (95 %) were found to have unrepaired third-and fourth-degree obstetric tears. Ninety-two of the 180 (51 %) women with OF symptoms ultimately had true OF confirmed at operation.
Conclusion These findings suggest that many women with OF symptoms in Kenya may harbor unrepaired third- and fourth-degree tears. Additionally, women with isolated FI may be more likely to suffer from third-and fourth-degree tears than from true OF. Immediate postpartum diagnosis and repair of third- and fourth-degree perineal tears could significantly reduce the overall burden of women with symptoms of OF.
C1 [Lozo, Svjetlana; Eckardt, Melody J.; Altawil, Zaid; Nelson, Brett D.; Ahn, Roy; Burke, Thomas F.] Massachusetts Gen Hosp, Dept Emergency Med, Div Global Hlth & Human Rights, 125 Nashua St,Suite 910, Boston, MA 02114 USA.
[Nelson, Brett D.; Ahn, Roy; Burke, Thomas F.] Harvard Univ, Sch Med, Boston, MA USA.
[Khisa, Weston] Kenyatta Natl Hosp, Sect Urogynecol, Dept Reprod Hlth, Nairobi, Kenya.
RP Burke, TF (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Div Global Hlth & Human Rights, 125 Nashua St,Suite 910, Boston, MA 02114 USA.; Burke, TF (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
EM tfburke@mgh.harvard.edu
OI Nelson, Brett/0000-0002-5049-1798
FU Massachusetts General Hospital; Ujenzi Charitable Trust
FX Support for this study came from the Massachusetts General Hospital and
the Ujenzi Charitable Trust.
NR 19
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-3462
EI 1433-3023
J9 INT UROGYNECOL J
JI Int. Urogynecol. J.
PD MAR
PY 2016
VL 27
IS 3
BP 463
EP 466
DI 10.1007/s00192-015-2850-2
PG 4
WC Obstetrics & Gynecology; Urology & Nephrology
SC Obstetrics & Gynecology; Urology & Nephrology
GA DF2OD
UT WOS:000371182300018
PM 26407562
ER
PT J
AU Longo, DL
Michelotti, F
Consolino, L
Bardini, P
Digilio, G
Xiao, G
Sun, PZ
Aime, S
AF Longo, Dario Livio
Michelotti, Filippo
Consolino, Lorena
Bardini, Paola
Digilio, Giuseppe
Xiao, Gang
Sun, Phillip Zhe
Aime, Silvio
TI In Vitro and In Vivo Assessment of Nonionic Iodinated Radiographic
Molecules as Chemical Exchange Saturation Transfer Magnetic Resonance
Imaging Tumor Perfusion Agents
SO INVESTIGATIVE RADIOLOGY
LA English
DT Article
DE iodixanol; iohexol; iomeprol; CT; MRI; x-ray; contrast agents; tumor;
ioversol; CEST
ID TRANSFER CEST MRI; CONTRAST AGENT; EXTRACELLULAR PH; ACIDOCEST MRI;
QUANTITATIVE DESCRIPTION; COMPUTED-TOMOGRAPHY; 7 T; IOPAMIDOL; BRAIN;
POWER
AB Objectives
The aim of this study was to evaluate 4 nonionic x-ray iodinated contrast agents (CAs), commonly used in radiographic procedures, as novel chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) agents by assessing their in vitro exchange properties and preliminary in vivo use as tumor enhancing agents.
Materials and Methods
The CEST properties, as function of pH (range, 5.5-7.9) and of radio frequency conditions (irradiation field strength range of 1-9 mu T and time of 1-9 seconds), have been determined at 7 T and 310 K for 4 x-ray CAs commonly used in clinical settings, namely, iomeprol, iohexol, ioversol, and iodixanol. Their in vivo properties have been investigated upon intravenous injection in a murine HER2+ breast tumor model (n = 4 mice for each CA) using both computed tomography (CT) and MRI modalities.
Results
The prototropic exchange rates measured for the 4 investigated iodinated molecules showed strong pH dependence with base catalyzed exchange rate that was faster for monomeric compounds (20-4000 Hz in the pH range of 5.5-7.9). Computed tomography quantification showed marked (up to 2 mg I/mL concentration) and prolonged accumulation (up to 30 minutes postinjection) inside tumor regions. Among the 4 agents we tested, iohexol and ioversol display good CEST contrast properties at 7 T, and in vivo results confirmed strong and prolonged contrast enhancement of the tumors, with elevated extravasation fractions (74%-91%). A strong and significant correlation was found between CT and CEST-MRI tumor-enhanced images (R-2 = 0.70, P < 0.01).
Conclusions
The obtained results demonstrate that iohexol and ioversol, 2 commonly used radiographic compounds, can be used as MRI perfusion agents, particularly useful when serial images acquisitions are needed to complement CT information.
C1 [Longo, Dario Livio] Univ Turin, CNR, Ist Biostrutture & Bioimmagini, Ctr Mol Biotechnol, Turin, Italy.
[Michelotti, Filippo; Consolino, Lorena; Bardini, Paola; Aime, Silvio] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Mol Imaging Ctr, Turin, Italy.
[Digilio, Giuseppe] Univ Piemonte Orientale, Dept Sci & Technol Innovat, Alessandria, Italy.
[Xiao, Gang] Hanshan Normal Univ, Dept Math & Stat, Hanshan, Guangdong, Peoples R China.
[Sun, Phillip Zhe] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Sun, Phillip Zhe] Harvard Univ, Sch Med, Boston, MA USA.
RP Longo, DL (reprint author), CNR, Ist Biostrutture & Bioimmagini, Mol Biotechonol Ctr, Via Nizza 52, I-10126 Turin, Italy.
EM dario.longo@unito.it
OI Digilio, Giuseppe/0000-0003-2397-2913; Longo, Dario/0000-0002-6906-9925
FU European Community's Seventh Framework Programme [602306]; MIUR project
PRIN [2010B5B2NL]
FX Conflicts of interest and sources of funding: Support by the European
Community's Seventh Framework Programme (mitigate project 602306) and by
MIUR project PRIN no 2010B5B2NL.
NR 53
TC 2
Z9 2
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0020-9996
EI 1536-0210
J9 INVEST RADIOL
JI Invest. Radiol.
PD MAR
PY 2016
VL 51
IS 3
BP 155
EP 162
DI 10.1097/RLI.0000000000000217
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DE2UF
UT WOS:000370482000002
PM 26460826
ER
PT J
AU Swenson, ER
AF Swenson, Erik R.
TI Reply to Drs. Teppema and Berendsen
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Letter
ID CARBONIC-ANHYDRASE INHIBITION; VENTILATORY RESPONSES; AMMONIUM-CHLORIDE;
ACETAZOLAMIDE; HYPOXIA; HUMANS; ACIDOSIS
C1 [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
EM erik.swenson@va.gov
NR 10
TC 0
Z9 0
U1 2
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD MAR 1
PY 2016
VL 120
IS 5
BP 565
EP 565
DI 10.1152/japplphysiol.00872.2015
PG 1
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA DF6CN
UT WOS:000371442900011
PM 26933003
ER
PT J
AU Urayama, A
Grubb, JH
Sly, WS
Banks, WA
AF Urayama, Akihiko
Grubb, Jeffrey H.
Sly, William S.
Banks, William A.
TI Pharmacologic manipulation of lysosomal enzyme transport across the
blood-brain barrier
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE Blood-brain barrier; beta-glucuronidase; enzyme replacement therapy;
brain uptake; mannose 6-phosphate receptor
ID MANNOSE 6-PHOSPHATE RECEPTOR; MUCOPOLYSACCHARIDOSIS TYPE-VII;
ALPHA-MANNOSIDOSIS MICE; REPLACEMENT-THERAPY; MEDIATED TRANSPORT;
BETA-GLUCURONIDASE; MOUSE MODEL; LIGAND INTERACTIONS; INSULIN TRANSPORT;
PERMEABILITY
AB The adult blood-brain barrier, unlike the neonatal blood-brain barrier, does not transport lysosomal enzymes into brain, making enzyme replacement therapy ineffective in treating the central nervous system symptoms of lysosomal storage diseases. However, enzyme transport can be re-induced with alpha-adrenergics. Here, we examined agents that are known to alter the blood-brain barrier transport of large molecules or to induce lysosomal enzyme transport across the blood-brain barrier ((+/-)epinephrine, insulin, retinoic acid, and lipopolysaccharide) in 2-week-old and adult mice. In 2-week-old adolescent mice, all these pharmacologic agents increased brain and heart uptake of phosphorylated human beta-glucuronidase. In 8-week-old adult mice, manipulations with (+/-)epinephrine, insulin, and retinoic acid were significantly effective on uptake by brain and heart. The increased uptake of phosphorylated human b-glucuronidase was inhibited by mannose 6-phosphate for the agents (+/-)epinephrine and retinoic acid and by L-NG-nitroarginine methyl ester for the agent lipopolysaccharide in neonatal and adult mice. An in situ brain perfusion study revealed that retinoic acid directly modulated the transport of phosphorylated human beta-glucuronidase across the blood-brain barrier. The present study indicates that there are multiple opportunities to at least transiently induce phosphorylated human beta-glucuronidase transport at the adult blood-brain barrier.
C1 [Urayama, Akihiko] Univ Texas Med Sch Houston, Dept Neurol, Houston, TX USA.
[Grubb, Jeffrey H.] Ultragenyx Pharmaceut Inc, Lysosomal Res, Novato, CA USA.
[Grubb, Jeffrey H.; Sly, William S.] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO USA.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Urayama, A (reprint author), Univ Texas Med Sch Houston, Dept Neurol, Houston, TX USA.
EM Akihiko.Urayama@uth.tmc.edu
FU Sanfilippo Syndrome Medical Research Foundation; Veterans Affairs Merit
Review; National Institutes of Health [NS050547, AG029839]; National
Institutes of Health Grant [GM34182]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This study
was supported by The Sanfilippo Syndrome Medical Research Foundation
(WAB and WSS), Veterans Affairs Merit Review (WAB), National Institutes
of Health Grants NS050547 and AG029839 (to WAB), and National Institutes
of Health Grant GM34182 (to WSS).
NR 40
TC 1
Z9 1
U1 1
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0271-678X
EI 1559-7016
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD MAR
PY 2016
VL 36
IS 3
BP 476
EP 486
DI 10.1177/0271678X15614589
PG 11
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA DF4ER
UT WOS:000371301100004
PM 26661222
ER
PT J
AU Khamaisi, M
Katagiri, S
Keenan, H
Park, K
Maeda, Y
Li, Q
Qi, WE
Thomou, T
Eschuk, D
Tellechea, A
Veves, A
Huang, CY
Orgill, DP
Wagers, A
King, GL
AF Khamaisi, Mogher
Katagiri, Sayaka
Keenan, Hillary
Park, Kyoungmin
Maeda, Yasutaka
Li, Qian
Qi, Weier
Thomou, Thomas
Eschuk, Danielle
Tellechea, Ana
Veves, Aris
Huang, Chenyu
Orgill, Dennis Paul
Wagers, Amy
King, George L.
TI PKC delta inhibition normalizes the wound-healing capacity of diabetic
human fibroblasts
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID PROTEIN-KINASE-C; INSULIN-RESISTANCE; FOOT ULCERS; CULTURED FIBROBLASTS;
ENDOTHELIAL-CELLS; EXTREME-DURATION; VEGF EXPRESSION; MOLECULAR-BASIS;
IN-VITRO; REPAIR
AB Abnormal fibroblast function underlies poor wound healing in patients with diabetes; however, the mechanisms that impair wound healing are poorly defined. Here, we evaluated fibroblasts from individuals who had type 1 diabetes (T1D) for 50 years or more (Medalists, n = 26) and from age-matched controls (n = 7). Compared with those from controls, Medalist fibroblasts demonstrated a reduced migration response to insulin, lower VEGF expression, and less phosphorylated (p-AKT), but not p-ERK, activation. Medalist fibroblasts were also functionally less effective at wound closure in nude mice. Activation of the delta isoform of protein kinase C (PKC delta) was increased in postmortem fibroblasts from Medalists, fibroblasts from living T1D subjects, biopsies of active wounds of living T1D subjects, and granulation tissues from mice with streptozotocin-induced diabetes. Diabetes-induced PKCD mRNA expression was related to a 2-fold increase in the mRNA half-life. Pharmacologic inhibition and siRNA-mediated knockdown of PKC delta or expression of a dominant-negative isoform restored insulin signaling of p-AKT and VEGF expression in vitro and improved wound healing in vivo. Additionally, increasing PKC delta expression in control fibroblasts produced the same abnormalities as those seen in Medalist fibroblasts. Our results indicate that persistent PKC delta elevation in fibroblasts from diabetic patients inhibits insulin signaling and function to impair wound healing and suggest PKC delta inhibition as a potential therapy to improve wound healing in diabetic patients.
C1 [Khamaisi, Mogher; Katagiri, Sayaka; Keenan, Hillary; Park, Kyoungmin; Maeda, Yasutaka; Li, Qian; Qi, Weier; King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Vasc Cell Biol, Boston, MA 02115 USA.
[Khamaisi, Mogher] Technion Israel Inst Technol, Rambam Med Ctr, Inst Endocrinol Diabet & Metab, Haifa, Israel.
[Khamaisi, Mogher] Technion Israel Inst Technol, RB Rappaport Fac Med, Haifa, Israel.
[Thomou, Thomas] Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA.
[Thomou, Thomas] Harvard Univ, Sch Med, Boston, MA USA.
[Eschuk, Danielle; Tellechea, Ana; Veves, Aris] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Huang, Chenyu] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Med Ctr, Dept Plast Reconstruct & Aesthet Surg, Beijing 100084, Peoples R China.
[Orgill, Dennis Paul] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Plast Surg,Dept Surg, Boston, MA 02115 USA.
[Wagers, Amy] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Wagers, Amy] Harvard Stem Cell Inst, Cambridge, MA USA.
[Wagers, Amy] Howard Hughes Med Inst, Cambridge, MA USA.
[Wagers, Amy] Harvard Univ, Sch Med, Dept Stem Cell & Regenerat Biol, Paul F Glenn Labs Biol Mech Aging, Cambridge, MA 02138 USA.
RP King, GL (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, One Joslin Pl, Boston, MA USA.
EM George.King@joslin.harvard.edu
FU NIH, National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) [1R24DK090961-01, DP3 DK094333-01]; Juvenile Diabetes Research
Foundation (JDRF) [17-2013-310]; Diabetic Research Center (DRC) Group
[P30DK036836]; Beatson Foundation Gift; Dianne Nunnally Hoppes Fund;
Hearst Foundation; Gillian Reny Stepping Strong Fund
FX This study was supported by grants from the NIH, National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) (1R24DK090961-01 and
DP3 DK094333-01, to G.L. King); the Juvenile Diabetes Research
Foundation (JDRF) (17-2013-310, to H. Keenan); the Diabetic Research
Center (DRC) Group (P30DK036836); the Beatson Foundation Gift; and the
Dianne Nunnally Hoppes Fund. This study was also supported by a William
Randolph Hearst Fellowship provided by the Hearst Foundation (to M.
Khamaisi) and by the Gillian Reny Stepping Strong Fund (to D.P. Orgill).
We thank the Medalists and their families, the people who donated skin
samples, the National Disease Research Interchange (NDRI) for
coordinating the donations, and the Medalist study staff (Liane Tinsley,
Stephanie D'Eon, Stephanie Hastings, and David M. Pober) at the Joslin
Diabetes Center. We also thank Patti Muehter for her excellent
assistance with manuscript preparation.
NR 64
TC 5
Z9 5
U1 4
U2 4
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 2016
VL 126
IS 3
BP 837
EP 853
DI 10.1172/JCI82788
PG 17
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DF2SI
UT WOS:000371193700007
PM 26808499
ER
PT J
AU Yu, HY
Artomov, M
Brahler, S
Stander, MC
Shamsan, G
Sampson, MG
White, JM
Kretzler, M
Miner, JH
Jain, S
Winkler, CA
Mitra, RD
Kopp, JB
Daly, MJ
Shaw, AS
AF Yu, Haiyang
Artomov, Mykyta
Braehler, Sebastian
Stander, M. Christine
Shamsan, Ghaidan
Sampson, Matthew G.
White, J. Michael
Kretzler, Matthias
Miner, Jeffrey H.
Jain, Sanjay
Winkler, Cheryl A.
Mitra, Robi D.
Kopp, Jeffrey B.
Daly, Mark J.
Shaw, Andrey S.
TI A role for genetic susceptibility in sporadic focal segmental
glomerulosclerosis (Retracted Article. See vol 126, pg 1603, 2016)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID RESISTANT NEPHROTIC SYNDROME; HIV-ASSOCIATED NEPHROPATHY; EMBRYONIC
STEM-CELLS; PODOCYTE INJURY; CD2-ASSOCIATED PROTEIN;
GLOMERULAR-DISEASES; AFRICAN-AMERICANS; RNA INTERFERENCE; RENAL-DISEASE;
MUTATIONS
AB Focal segmental glomerulosclerosis (FSGS) is a syndrome that involves kidney podocyte dysfunction and causes chronic kidney disease. Multiple factors including chemical toxicity, inflammation, and infection underlie FSGS; however, highly penetrant disease genes have been identified in a small fraction of patients with a family history of FSGS. Variants of apolipoprotein 1:1 (APOL1) have been linked to FSGS in African Americans with HIV or hypertension, supporting the proposal that genetic factors enhance FSGS susceptibility. Here, we used sequencing to investigate whether genetics plays a role in the majority of FSGS cases that are identified as primary or sporadic FSGS and have no known cause. Given the limited number of biopsy-proven cases with ethnically matched controls, we devised an analytic strategy to identify and rank potential candidate genes and used an animal model for validation. Nine candidate FSGS susceptibility genes were identified in our patient cohort, and three were validated using a high-throughput mouse method that we developed. Specifically, we introduced a podocyte-specific, doxycycline-inducible transactivator into a murine embryonic stem cell line with an FSGS-susceptible genetic background that allows shRNA-mediated targeting of candidate genes in the adult kidney. Our analysis supports a broader role for genetic susceptibility of both sporadic and familial cases of FSGS and provides a tool to rapidly evaluate candidate FSGS-associated genes.
C1 [Yu, Haiyang; Braehler, Sebastian; Stander, M. Christine; Shamsan, Ghaidan; White, J. Michael; Shaw, Andrey S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Artomov, Mykyta; Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Artomov, Mykyta; Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA USA.
[Artomov, Mykyta; Daly, Mark J.] Broad Inst, Cambridge, MA USA.
[Artomov, Mykyta] Harvard Univ, Dept Chem, 12 Oxford St, Cambridge, MA 02138 USA.
[Sampson, Matthew G.] Univ Michigan, Pediat Nephrol, Ann Arbor, MI 48109 USA.
[Kretzler, Matthias] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA.
[Miner, Jeffrey H.; Jain, Sanjay] Washington Univ, Sch Med, Dept Med, Div Renal, St Louis, MO 63110 USA.
[Winkler, Cheryl A.] NCI, Mol Genet Epidemiol Studies Sect, Frederick, MD 21701 USA.
[Mitra, Robi D.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
[Kopp, Jeffrey B.] NIDDKD, Kidney Dis Sect, Kidney Dis Branch, NIH, Bethesda, MD USA.
[Shaw, Andrey S.] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.
RP Shaw, AS (reprint author), Genentech Inc, One DNA Way,Mail Stop 93B, San Francisco, CA 94080 USA.; Daly, MJ (reprint author), Massachusetts Gen Hosp, Richard B Simches Res Ctr, Analyt & Translat Genet Unit, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA.
EM mjdaly@atgu.mgh.harvard.edu; shawa6@gene.com
FU NIDDK; HHMI; Intramural Research Programs of the NIDDK; NCI; Deutsche
Forschungsgemeinschaft (DFG)
FX This project was supported by grants from the NIDDK (to A.S. Shaw, J.H.
Miner, M. Kretzler, and M.G. Sampson); the HHMI (to A.S. Shaw); and the
Intramural Research Programs of the NIDDK (to J.B. Kopp), NCI (to C.A.
Winkler), and the Deutsche Forschungsgemeinschaft (DFG) (to S. Brahler).
We thank V. Vasioukhin for sharing Dlg5+/- mice,
overexpression and RNAi lentiviral plasmids, and histology stainings of
Dlg5-/- kidney. We also thank C. Der for sharing the Arhgefl7
cDNA construct. We also thank R. Kopan and members of the Shaw
laboratory for critical discussions.
NR 60
TC 4
Z9 4
U1 1
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 2016
VL 126
IS 3
BP 1067
EP 1078
DI 10.1172/JCI82592
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DF2SI
UT WOS:000371193700025
PM 26901816
ER
PT J
AU Finkelstein, JS
Lee, H
Leder, BZ
Burnett-Bowie, SAM
Goldstein, DW
Hahn, CW
Hirsch, SC
Linker, A
Perros, N
Servais, AB
Taylor, AP
Webb, ML
Youngner, JM
Yu, EW
AF Finkelstein, Joel S.
Lee, Hang
Leder, Benjamin Z.
Burnett-Bowie, Sherri-Ann M.
Goldstein, David W.
Hahn, Christopher W.
Hirsch, Sarah C.
Linker, Alex
Perros, Nicholas
Servais, Andrew B.
Taylor, Alexander P.
Webb, Matthew L.
Youngner, Jonathan M.
Yu, Elaine W.
TI Gonadal steroid-dependent effects on bone turnover and bone mineral
density in men
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ANDROGEN-DEPRIVATION THERAPY; ESTROGEN-RECEPTOR; AROMATASE DEFICIENCY;
CORTICAL BONE; OLDER MEN; TESTOSTERONE LEVELS; SERUM TESTOSTERONE;
ESTRADIOL LEVELS; MALE SKELETON; ELDERLY MEN
AB BACKGROUND. Severe gonadal steroid deficiency induces bone loss in adult men; however, the specific roles of androgen and estrogen deficiency in hypogonadal bone loss are unclear. Additionally, the threshold levels of testosterone and estradiol that initiate bone loss are uncertain.
METHODS. One hundred ninety-eight healthy men, ages 20-50, received goserelin acetate, which suppresses endogenous gonadal steroid production, and were randomized to treatment with 0, 1.25, 2.5, 5, or 10 grams of testosterone gel daily for 16 weeks. An additional cohort of 202 men was randomized to receive these treatments plus anastrozole, which suppresses conversion of androgens to estrogens. Thirty-seven men served as controls and received placebos for goserelin and testosterone. Changes in bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA), and BMD by quantitative computed tomography (QCT) were assessed in all men. Bone microarchitecture was assessed in 100 men.
RESULTS. As testosterone dosage decreased, the percent change in C-telopeptide increased. These increases were considerably greater when aromatization of testosterone to estradiol was also suppressed, suggesting effects of both testosterone and estradiol deficiency. Decreases in DXA BMD were observed when aromatization was suppressed but were modest in most groups. QCT spine BMD fell substantially in all testosterone-dose groups in which aromatization was also suppressed, and this decline was independent of testosterone dose. Estradiol deficiency disrupted cortical microarchitecture at peripheral sites. Estradiol levels above 10 pg/ml and testosterone levels above 200 ng/dI were generally sufficient to prevent increases in bone resorption and decreases in BMD in men.
CONCLUSIONS. Estrogens primarily regulate bone homeostasis in adult men, and testosterone and estradiol levels must decline substantially to impact the skeleton.
C1 [Finkelstein, Joel S.; Leder, Benjamin Z.; Burnett-Bowie, Sherri-Ann M.; Goldstein, David W.; Hahn, Christopher W.; Hirsch, Sarah C.; Linker, Alex; Perros, Nicholas; Servais, Andrew B.; Taylor, Alexander P.; Webb, Matthew L.; Youngner, Jonathan M.; Yu, Elaine W.] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA.
[Lee, Hang] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
RP Finkelstein, JS (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Thier 1051,50 Blossom St, Boston, MA 02114 USA.
EM jfinkelstein@partners.org
FU AbbVie Inc.; AstraZeneca Pharmaceuticals LP; NIH
FX AbbVie Inc., AstraZeneca Pharmaceuticals LP, NIH.
NR 46
TC 6
Z9 6
U1 0
U2 2
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 2016
VL 126
IS 3
BP 1114
EP 1125
DI 10.1172/JCI84137
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DF2SI
UT WOS:000371193700029
PM 26901812
ER
PT J
AU Farhat, MR
Jacobson, KR
Franke, MF
Kaur, D
Sloutsky, A
Mitnick, CD
Murray, M
AF Farhat, Maha R.
Jacobson, Karen R.
Franke, Molly F.
Kaur, Devinder
Sloutsky, Alex
Mitnick, Carole D.
Murray, Megan
TI Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone
Resistance in Mycobacterium tuberculosis
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID GENOTYPE MTBDRSL ASSAY; DRUG-RESISTANCE; PULMONARY TUBERCULOSIS;
ANTIBIOTIC-RESISTANCE; FUNCTIONAL-ANALYSIS; COMPLEX STRAINS;
SUSCEPTIBILITY; EPIDEMIOLOGY; POPULATION; MOXIFLOXACIN
AB Molecular diagnostics that rapidly and accurately predict resistance to fluoroquinolone drugs and especially later-generation agents promise to improve treatment outcomes for patients with multidrug-resistant tuberculosis and prevent the spread of disease. Mutations in the gyr genes are known to confer most fluoroquinolone resistance, but knowledge about the effects of gyr mutations on susceptibility to early-versus later-generation fluoroquinolones and about the role of mutation-mutation interactions is limited. Here, we sequenced the full gyrA and gyrB open reading frames in 240 multidrug-resistant and extensively drug-resistant tuberculosis strains and quantified their ofloxacin and moxifloxacin MIC by testing growth at six concentrations for each drug. We constructed a multivariate regression model to assess both the individual mutation effects and interactions on the drug MICs. We found that gyrB mutations contribute to fluoroquinolone resistance both individually and through interactions with gyrA mutations. These effects were statistically significant. In these clinical isolates, several gyrA and gyrB mutations conferred different levels of resistance to ofloxacin and moxifloxacin. Consideration of gyr mutation combinations during the interpretation of molecular test results may improve the accuracy of predicting the fluoroquinolone resistance phenotype. Further, the differential effects of gyr mutations on the activity of early-and later-generation fluoroquinolones requires further investigation and could inform the selection of a fluoroquinolone for treatment.
C1 [Farhat, Maha R.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
[Farhat, Maha R.; Franke, Molly F.; Mitnick, Carole D.; Murray, Megan] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Jacobson, Karen R.] Boston Univ, Sch Med, Infect Dis Sect, Boston, MA 02118 USA.
[Jacobson, Karen R.] Univ Stellenbosch, DST NRF Ctr Excellence Biomed TB Res, MRC Ctr Mol & Cellular Biol, Div Mol Biol & Human Genet,Fac Med & Hlth Sci, ZA-7505 Tygerberg, South Africa.
[Kaur, Devinder; Sloutsky, Alex] Univ Massachusetts, Sch Med, Massachusetts Supranat TB Reference Lab, Boston, MA 02125 USA.
[Mitnick, Carole D.] Brigham & Womens Hosp, Dept Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA.
[Murray, Megan] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Farhat, MR (reprint author), Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA.; Farhat, MR (reprint author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
EM mrfarhat@partners.org
OI Farhat, Maha/0000-0002-3871-5760; Jacobson, Karen/0000-0003-4239-3685
FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases
(NIAID) [U19-AI109755]; HHS \ NIH \ Fogarty International Center (FIC)
[K01 TW009213]; American Lung Association [RG-270912-N]; Harvard
University Center for AIDS Research (HU CFAR) [P30 AI060354]
FX Parker B Francis provided funding to Maha Farhat. HHS vertical bar NIH
vertical bar National Institute of Allergy and Infectious Diseases
(NIAID) provided funding to Megan Murray under grant number
U19-AI109755. HHS vertical bar NIH vertical bar Fogarty International
Center (FIC) provided funding to Karen Jacobson under grant number K01
TW009213. American Lung Association provided funding to Maha Farhat
under grant number RG-270912-N. Harvard University Center for AIDS
Research (HU CFAR) provided funding to Maha Farhat and Karen Jacobson
under grant number P30 AI060354.
NR 42
TC 1
Z9 1
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAR
PY 2016
VL 54
IS 3
BP 727
EP 733
DI 10.1128/JCM.02775-15
PG 7
WC Microbiology
SC Microbiology
GA DF2EC
UT WOS:000371152200032
PM 26763957
ER
PT J
AU Winchester, RJ
Williams, JS
Wolfman, TE
Egede, LE
AF Winchester, Rhonda J.
Williams, Joni S.
Wolfman, Tamara E.
Egede, Leonard E.
TI Depressive symptoms, serious psychological distress, diabetes distress
and cardiovascular risk factor control in patients with type 2 diabetes
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Diabetes; Diabetes distress; Depressive symptoms; Serious psychological
distress; Cardiovascular disease risk factor
ID CLINICAL DEPRESSION; GENERAL-POPULATION; GLYCEMIC CONTROL; SCREENING
SCALE; MENTAL-ILLNESS; MORTALITY; HEALTH; ADULTS; K6
AB Objective: This study examined the association between cardiovascular disease (CVD) risk factor control and elevated depressive symptoms (EDS), serious psychological distress (SPD), and diabetes distress (DD) in patients with type 2 diabetes (T2DM).
Methods: This was a cross-sectional study of adults seen at an academic medical center and Veterans Affairs Medical Center in the southeastern US. Linear regression models were computed using CVD risk factors as clinically meaningful outcomes (glycosylated hemoglobin A1c (HbA1c); systolic (SBP) and diastolic (DBP) blood pressure; and low-density lipoprotein cholesterol (LDL-C)); EDS, SPD, and DD were primary independent variables. Covariates included sociodemographics and comorbidities.
Results: The sample consisted of 361 adults. Correlation analyses showed significant relationships between DD and HbA1c, DBP, and LDL-C. Adjusted linear regression models showed DD to be significantly associated with HbA1c and LDL-C, and SPD to be significantly associated only with LDL-C. In the fully adjusted model, DD remained significantly associated with HbA1c ((beta = 4349; 95% CI (-0.649, 2.222)).
Conclusions: In this sample of adults with T2DM, DD and SPD were significantly associated with CVD risk factors; however, after controlling for covariates, only DD was shown to be significantly associated with poor glycemic control.
Practice implications: Strategies are warranted to examine the relationship between DD and CVD risk factor control in patients with T2DM. Published by Elsevier Inc.
C1 [Winchester, Rhonda J.; Williams, Joni S.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA.
[Williams, Joni S.; Wolfman, Tamara E.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, 96 Jonathan Lucas St,Suite 803,MSC 623, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, 109 Beet St, Charleston, SC 29401 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Hlth Equ & Rural Outreach Innovat Ctr, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA.
EM runwithjane@gmail.com; stromjl@musc.edu; wolfmant@musc.edu;
egedel@musc.edu
FU National Institute of Diabetes and Digestive and Kidney Disease
[K24DK093699]
FX Funding Source: This study was supported by Grant K24DK093699 from The
National Institute of Diabetes and Digestive and Kidney Disease (PI:
Leonard Egede). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 30
TC 0
Z9 0
U1 9
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
EI 1873-460X
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAR
PY 2016
VL 30
IS 2
BP 312
EP 317
DI 10.1016/j.jdiacomp.2015.11.010
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DF2SW
UT WOS:000371195100022
PM 26657725
ER
PT J
AU Gokduman, K
Avsaroglu, MD
Cakiris, A
Ustek, D
Gurakan, GC
AF Gokduman, Kurtulus
Avsaroglu, M. Dilek
Cakiris, Aris
Ustek, Duran
Gurakan, G. Candan
TI Recombinant plasmid-based quantitative Real-Time PCR analysis of
Salmonella enterica serotypes and its application to milk samples
SO JOURNAL OF MICROBIOLOGICAL METHODS
LA English
DT Article
DE Salmonella; invA; ttrRSBC; Recombinant plasmids; Real-Time PCR; Milk
ID MEDIATED ISOTHERMAL AMPLIFICATION; POLYMERASE-CHAIN-REACTION;
ESCHERICHIA-COLI; FECAL SAMPLES; LISTERIA-MONOCYTOGENES; VIABLE
SALMONELLAE; RAPID DETECTION; RISK-ASSESSMENT; MULTIPLEX PCR;
MESSENGER-RNA
AB The aim of the current study was to develop, a new, rapid, sensitive and quantitative Salmonella detection method using a Real-Time PCR technique based on an inexpensive, easy to produce, convenient and standardized recombinant plasmid positive control. To achieve this, two recombinant plasmids were constructed as reference molecules by cloning the two most commonly used Salmonella-specific target gene regions, invA and ttrRSBC The more rapid detection enabled by the developed method (21 h) compared to the traditional culture method (90 h) allows the quantitative evaluation of Salmonella (quantification limits of 10(1) CFU/ml and 10(0) CFU/ml for the invA target and the ttrRSBC target, respectively), as illustrated using milk samples. Three advantages illustrated by the current study demonstrate the potential of the newly developed method to be used in routine analyses in the medical, veterinary, food and water/environmental sectors: I - The method provides fast analyses including the simultaneous detection and determination of correct pathogen counts; II - The method is applicable to challenging samples, such as milk; III - The method's positive controls (recombinant plasmids) are reproducible in large quantities without the need to construct new calibration curves. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Gokduman, Kurtulus; Gurakan, G. Candan] Middle E Tech Univ, Dept Biotechnol, TR-06800 Ankara, Turkey.
[Avsaroglu, M. Dilek] Ahi Evran Univ, Dept Agr Biotechnol, TR-40100 Kirsehir, Turkey.
[Cakiris, Aris; Ustek, Duran] Istanbul Univ, Expt Med Res Inst, TR-34393 Istanbul, Turkey.
[Gurakan, G. Candan] Middle E Tech Univ, Dept Food Engn, TR-06800 Ankara, Turkey.
[Gokduman, Kurtulus] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA.
[Gokduman, Kurtulus] Beykent Univ, TR-34500 Istanbul, Turkey.
[Ustek, Duran] Medipol Univ, Sch Med, Dept Med Genet, TR-34810 Istanbul, Turkey.
[Ustek, Duran] Medipol Univ, Sch Med, REMER, TR-34810 Istanbul, Turkey.
RP Gokduman, K (reprint author), Middle E Tech Univ, Dept Biotechnol, TR-06800 Ankara, Turkey.
EM k.gokduman@gmail.com
RI Ustek, Duran/C-3484-2009;
OI Ustek, Duran/0000-0002-0060-2859; Gokduman, Kurtulus/0000-0003-2692-5434
FU Middle East Technical University (METU) [BAP-03-14-2010-05]
FX This study was supported by Middle East Technical University (METU)
research fund: BAP-03-14-2010-05.
NR 65
TC 0
Z9 0
U1 3
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-7012
EI 1872-8359
J9 J MICROBIOL METH
JI J. Microbiol. Methods
PD MAR
PY 2016
VL 122
BP 50
EP 58
DI 10.1016/j.mimet.2016.01.008
PG 9
WC Biochemical Research Methods; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA DF5CA
UT WOS:000371368200011
PM 26820062
ER
PT J
AU Hirsch, JA
Falcone, GJ
Brook, AL
Fiorella, D
Gonzalez, RG
Leslie-Mazwi, TM
AF Hirsch, Joshua A.
Falcone, Guido J.
Brook, Allan L.
Fiorella, David
Gonzalez, R. Gilberto
Leslie-Mazwi, Thabele M.
TI Stroke is ascendant: is it time for TICI to be more than just a score?
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Editorial Material
DE Stroke
ID ACUTE ISCHEMIC-STROKE; RANDOMIZED-TRIAL
C1 [Hirsch, Joshua A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroendovasc Serv, Boston, MA 02114 USA.
[Falcone, Guido J.] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Boston, MA 02114 USA.
[Brook, Allan L.] Montefiore Med Ctr, Albert Einstein Coll Med, Intervent Neuroradiol, Bronx, NY 10467 USA.
[Fiorella, David] SUNY Stony Brook, Cerebrovasc Ctr, Dept Neurosurg, Med Ctr, Stony Brook, NY 11794 USA.
[Gonzalez, R. Gilberto] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Neuroradiol, Boston, MA 02115 USA.
[Leslie-Mazwi, Thabele M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurol Crit Care,Neuroendovasc Serv, Boston, MA 02115 USA.
RP Hirsch, JA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroendovasc Serv, Boston, MA 02114 USA.
EM Hirsch@snisonline.org
RI Falcone, Guido/L-2287-2016
OI Falcone, Guido/0000-0002-6407-0302
NR 8
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAR
PY 2016
VL 8
IS 3
BP 221
EP 223
DI 10.1136/neurintsurg-2015-012160
PG 3
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA DF4NW
UT WOS:000371327000005
PM 26658463
ER
PT J
AU Linfante, I
Starosciak, AK
Walker, GR
Dabus, G
Castonguay, AC
Gupta, R
Sun, CHJ
Martin, C
Holloway, WE
Mueller-Kronast, N
English, JD
Malisch, TW
Marden, FA
Bozorgchami, H
Xavier, A
Rai, AT
Froehler, MT
Badruddin, A
Nguyen, TN
Taqi, MA
Abraham, MG
Janardhan, V
Shaltoni, H
Novakovic, R
Yoo, AJ
Abou-Chebl, A
Chen, PR
Britz, GW
Kaushal, R
Nanda, A
Issa, MA
Nogueira, RG
Zaidat, OO
AF Linfante, Italo
Starosciak, Amy K.
Walker, Gail R.
Dabus, Guilherme
Castonguay, Alicia C.
Gupta, Rishi
Sun, Chung-Huan J.
Martin, Coleman
Holloway, William E.
Mueller-Kronast, Nils
English, Joey D.
Malisch, Tim W.
Marden, Franklin A.
Bozorgchami, Hormozd
Xavier, Andrew
Rai, Ansaar T.
Froehler, Michael T.
Badruddin, Aamir
Thanh N Nguyen
Taqi, M. Asif
Abraham, Michael G.
Janardhan, Vallabh
Shaltoni, Hashem
Novakovic, Roberta
Yoo, Albert J.
Abou-Chebl, Alex
Chen, Peng R.
Britz, Gavin W.
Kaushal, Ritesh
Nanda, Ashish
Issa, Mohammad A.
Nogueira, Raul G.
Zaidat, Osama O.
TI Predictors of poor outcome despite recanalization: a multiple regression
analysis of the NASA registry
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE Intervention; Stroke; Thrombectomy; Angiography
ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; INTERNAL
CAROTID-ARTERY; MECHANICAL THROMBECTOMY; ENDOVASCULAR TREATMENT; INFARCT
VOLUME; MERCI TRIAL; THERAPY; INTRAARTERIAL; OCCLUSION
AB Background Mechanical thrombectomy with stent-retrievers results in higher recanalization rates compared with previous devices. Despite successful recanalization rates (Thrombolysis in Cerebral Infarction (TICI) score 2b) of 70-83%, good outcomes by 90-day modified Rankin Scale (mRS) score 2 are achieved in only 40-55% of patients. We evaluated predictors of poor outcomes (mRS >2) despite successful recanalization (TICI 2b) in the North American Solitaire Stent Retriever Acute Stroke (NASA) registry.
Methods Logistic regression was used to evaluate baseline characteristics and recanalization outcomes for association with 90-day mRS score of 0-2 (good outcome) vs 3-6 (poor outcome). Univariate tests were carried out for all factors. A multivariable model was developed based on backwards selection from the factors with at least marginal significance (p0.10) on univariate analysis with the retention criterion set at p0.05. The model was refit to minimize the number of cases excluded because of missing covariate values; the c-statistic was a measure of predictive power.
Results Of 354 patients, 256 (72.3%) were recanalized successfully. Based on 234 recanalized patients evaluated for 90-day mRS score, 116 (49.6%) had poor outcomes. Univariate analysis identified an increased risk of poor outcome for age 80years, occlusion site of internal carotid artery (ICA)/basilar artery, National Institute of Health Stroke Scale (NIHSS) score 18, history of diabetes mellitus, TICI 2b, use of rescue therapy, not using a balloon-guided catheter or intravenous tissue plasminogen activator (IV t-PA), and >30min to recanalization (p0.05). In multivariable analysis, age 80years, occlusion site ICA/basilar, initial NIHSS score 18, diabetes, absence of IV t-PA, 3 passes, and use of rescue therapy were significant independent predictors of poor 90-day outcome in a model with good predictive power (c-index=0.80).
Conclusions Age, occlusion site, high NIHSS, diabetes, no IV t-PA, 3 passes, and use of rescue therapy are associated with poor 90-day outcome despite successful recanalization.
C1 [Linfante, Italo; Dabus, Guilherme] Baptist Hosp Miami, Miami Cardiac & Vasc Inst, Miami, FL USA.
[Linfante, Italo; Starosciak, Amy K.; Dabus, Guilherme] Baptist Hosp Miami, Neurosci Ctr, Miami, FL USA.
[Starosciak, Amy K.; Walker, Gail R.] Baptist Hlth South Florida, Ctr Res & Grants, Coral Gables, FL USA.
[Castonguay, Alicia C.; Issa, Mohammad A.; Zaidat, Osama O.] Froedtert Hosp, Med Coll Wisconsin, Milwaukee, WI USA.
[Gupta, Rishi; Sun, Chung-Huan J.; Nogueira, Raul G.] Emory Univ, Sch Med, Atlanta, GA USA.
[Martin, Coleman; Holloway, William E.; Taqi, M. Asif] St Lukes Kansas City, Kansas City, MO USA.
[Mueller-Kronast, Nils] Delray Med Ctr, Delray Beach, FL USA.
[English, Joey D.] Calif Pacific Med Ctr, San Francisco, CA USA.
[Malisch, Tim W.; Marden, Franklin A.] Alexian Bros Med Ctr, Elk Grove Village, IL USA.
[Bozorgchami, Hormozd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Xavier, Andrew] Wayne State Univ, Sch Med, Detroit, MI USA.
[Rai, Ansaar T.] West Virginia Univ Hosp, Morgantown, WV USA.
[Froehler, Michael T.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Badruddin, Aamir] Provena St Joseph Med Ctr, Joliet, IL USA.
[Thanh N Nguyen] Boston Med Ctr, Boston, MA USA.
Desert Reg Med Ctr, Palm Springs, CA USA.
[Abraham, Michael G.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Janardhan, Vallabh] Texas Stroke Inst, Plano, TX USA.
[Shaltoni, Hashem] Baylor Coll Med, Houston, TX 77030 USA.
[Novakovic, Roberta] UT Southwest Med Ctr, Dallas, TX USA.
[Yoo, Albert J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Abou-Chebl, Alex] Baptist Hlth Louisville, Louisville, KY USA.
[Chen, Peng R.] Univ Texas Houston, Sch Med, Houston, TX USA.
[Britz, Gavin W.] Methodist Neurol Inst, Houston, TX USA.
[Kaushal, Ritesh] St Louis Univ, St Louis, MO 63103 USA.
[Nanda, Ashish] Univ Missouri, Columbia, MO USA.
RP Linfante, I (reprint author), Baptist Hosp Miami, Miami Cardiac & Vasc Inst, Miami, FL USA.; Linfante, I (reprint author), Baptist Hosp Miami, Neurosci Ctr, Miami, FL USA.
EM linfante.italo@gmail.com
NR 31
TC 11
Z9 11
U1 3
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAR
PY 2016
VL 8
IS 3
BP 224
EP 229
DI 10.1136/neurintsurg-2014-011525
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA DF4NW
UT WOS:000371327000006
PM 25564538
ER
PT J
AU Chittle, MD
Vanderboom, T
Borsody-Lotti, J
Ganguli, S
Hanley, P
Martino, J
Mueller, P
Penzias, A
Saltalamacchia, C
Sheridan, RM
Hirsch, JA
AF Chittle, Melissa D.
Vanderboom, Teresa
Borsody-Lotti, Judith
Ganguli, Suvranu
Hanley, Patricia
Martino, JoAnne
Mueller, Peter
Penzias, Alexandra
Saltalamacchia, Catherine
Sheridan, Robert M.
Hirsch, Joshua A.
TI An overview of clinical associate roles in the neurointerventional
specialty
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Review
DE History
ID INTERVENTIONAL RADIOLOGY; PHYSICIAN ASSISTANTS
AB Neurointerventionalists have long partnered with certain types of clinical associates to provide longitudinal care. This overview summarizes differences in education, background, roles, and scopes of practice of the various clinical associates (physician assistants, nurse practitioners, clinical nurse specialists, radiology practitioner assistants, radiologist assistants, and nursing care coordinators). Key differences and similarities are highlighted to alleviate confusion about the roles clinical associates can assume on a neurointerventional service. This overview is intended to guide practices as they consider broadening their clinical support teams.
C1 [Chittle, Melissa D.; Borsody-Lotti, Judith; Ganguli, Suvranu; Hanley, Patricia; Martino, JoAnne; Mueller, Peter; Penzias, Alexandra; Saltalamacchia, Catherine; Sheridan, Robert M.] Massachusetts Gen Hosp, Div Intervent Radiol, Dept Radiol, Boston, MA 02114 USA.
[Chittle, Melissa D.; Vanderboom, Teresa; Borsody-Lotti, Judith; Ganguli, Suvranu; Hanley, Patricia; Martino, JoAnne; Mueller, Peter; Penzias, Alexandra; Saltalamacchia, Catherine; Sheridan, Robert M.; Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
[Vanderboom, Teresa; Hirsch, Joshua A.] Massachusetts Gen Hosp, Div Neurointervent Radiol, Dept Radiol, Boston, MA 02114 USA.
RP Chittle, MD (reprint author), Massachusetts Gen Hosp, Intervent Radiol, 55 Fruit St Blake 298, Boston, MA 02114 USA.
EM mchittle@partners.org
NR 25
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAR
PY 2016
VL 8
IS 3
BP 323
EP 327
DI 10.1136/neurintsurg-2014-011576
PG 5
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA DF4NW
UT WOS:000371327000023
PM 25561584
ER
PT J
AU Charidimou, A
Fox, Z
Werring, DJ
Song, M
AF Charidimou, Andreas
Fox, Zoe
Werring, David J.
Song, Min
TI Mapping the landscape of cerebral amyloid angiopathy research: an
informetric analysis perspective
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Review
ID ALZHEIMERS-DISEASE RESEARCH; INTRACEREBRAL HEMORRHAGE; NETWORK; SYSTEM;
IMPACT; FIELD; TEXT
AB To quantitatively analyse the research output and major trends in the field of cerebral amyloid angiopathy (CAA) over six decades, from 1954 to 2014, using advanced informetrics methods, we systematically identified CAA-related articles from PubMed, collected metadata and performed productivity analysis, copublication analysis, and network and content analysis over defined time periods. Linear regression was used to investigate these relationships. Changes in CAA research themes (2000-2014) were defined using a topic modelling technique. A total of 2340 CAA papers were published between 1954 and 2014. The mean number (3.03; 95% CI 2.62 to3.45; p<0.0001) and mean rate (0.13%; 95% CI 0.11% to 0.15%; p<0.0001) of CAA publications increased yearly. Analysis of copublication networks over 5-year periods from 1990 to 2014, revealed a great increase in the total number of connected investigators publishing on CAA (coefficient 16.74; 95% CI 14 to 19.49; p<0.0001) as well as the interactions between them (coefficient 73.53; 95% CI 52.03 to 89.03; p<0.0001). Further analysis of the network characteristics showed that in the past 15 years, copublication networks became not only larger, but also more connected and coherent. Content analysis identified 16 major CAA research themes and their differential evolution in the past 15 years, with the following main trends: (A) limited focus on vascular cognitive impairment; (B) a shift in emphasis towards neuroimaging, cerebral microbleeds and diagnostic aspects and away from pathological aspects; and (3) a reduced emphasis on basic biology apart from an increased focus on mouse models and perivascular drainage. Our study reveals the rapidly developing nature of the CAA research landscape, providing a novel quantitative and objective basis for identifying unmet needs and new directions. Our findings support the idea of a collaborative culture in the field, encouraging international research initiatives.
C1 [Charidimou, Andreas; Werring, David J.] UCL Inst Neurol, Dept Brain Repair & Rehabil, Stroke Res Grp, London, England.
[Charidimou, Andreas; Werring, David J.] Natl Hosp Neurol & Neurosurg, London, England.
[Charidimou, Andreas] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Stroke Res Ctr, Hemorrhag Stroke Res Program,Dept Neurol, Boston, MA 02115 USA.
[Fox, Zoe] UCL, London, England.
[Fox, Zoe] UCL Inst Neurol, Biomed Res Ctr, Educ Unit, London, England.
[Song, Min] Yonsei Univ, Dept Lib & Informat Sci, Seoul 120749, South Korea.
RP Charidimou, A (reprint author), Harvard Univ, Sch Med, J Kistler Stroke Res Ctr, Massachusetts Gen Hosp, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
EM andreas.charidimou.09@ucl.ac.uk
FU Greek State Scholarship Foundation; Stroke Association; British Heart
Foundation; Rosetrees Trust; Bio-Synergy Research Project of the
Ministry of Science, ICT and Future Planning through the National
Research Foundation [2013M3A9C4078138]
FX AC receives research support from the Greek State Scholarship
Foundation, the Stroke Association and the British Heart Foundation. ZF
reports no disclosure. DJW receives funding from the Stroke Association,
the British Heart Foundation, and the Rosetrees Trust and its partners.
MS receives funding from the Bio-Synergy Research Project
(2013M3A9C4078138) of the Ministry of Science, ICT and Future Planning
through the National Research Foundation.
NR 30
TC 2
Z9 2
U1 3
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD MAR
PY 2016
VL 87
IS 3
BP 252
EP 259
DI 10.1136/jnnp-2015-310690
PG 8
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA DF4OG
UT WOS:000371328100007
PM 26071214
ER
PT J
AU Tran, T
Cotlarciuc, I
Yadav, S
Hasan, N
Bentley, P
Levi, C
Worrall, BB
Meschia, JF
Rost, N
Sharma, P
AF Tran, Theresa
Cotlarciuc, Ioana
Yadav, Sunaina
Hasan, Nazeeha
Bentley, Paul
Levi, Christopher
Worrall, Bradford B.
Meschia, James F.
Rost, Natalia
Sharma, Pankaj
TI Candidate-gene analysis of white matter hyperintensities on neuroimaging
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID SMALL-VESSEL DISEASE; APOLIPOPROTEIN-E EPSILON-4; CEREBRAL AMYLOID
ANGIOPATHY; RENIN-ANGIOTENSIN SYSTEM; PLASMA HOMOCYSTEINE LEVELS;
ALZHEIMERS-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; MENDELIAN
RANDOMIZATION; CEREBROVASCULAR-DISEASE
AB Background White matter hyperintensities (WMH) are a common radiographic finding and may be a useful endophenotype for small vessel diseases. Given high heritability of WMH, we hypothesised that certain genotypes may predispose individuals to these lesions and consequently, to an increased risk of stroke, dementia and death. We performed a meta-analysis of studies investigating candidate genes and WMH to elucidate the genetic susceptibility to WMH and tested associated variants in a new independent WMH cohort. We assessed a causal relationship of WMH to methylene tetrahydrofolate reductase (MTHFR).
Methods Database searches through March 2014 were undertaken and studies investigating candidate genes in WMH were assessed. Associated variants were tested in a new independent ischaemic cohort of 1202 WMH patients. Mendelian randomization was undertaken to assess a causal relationship between WMH and MTHFR.
Results We identified 43 case-control studies interrogating eight polymorphisms in seven genes covering 6,314 WMH cases and 15,461 controls. Fixed-effects meta-analysis found that the C-allele containing genotypes of the aldosterone synthase CYP11B2 T(-344) C gene polymorphism were associated with a decreased risk of WMH (OR=0.61; 95% CI, 0.44 to 0.84; p=0.003). Using mendelian randomisation the association among MTHFR C677T, homocysteine levels and WMH, approached, but did not reach, significance (expected OR=1.75; 95% CI, 0.90-3.41; observed OR=1.68; 95% CI, 0.97-2.94). Neither CYP11B2 T(-344) C nor MTHFR C677T were significantly associated when tested in a new independent cohort of 1202 patients with WMH.
Conclusions There is a genetic basis to WMH but anonymous genome wide and exome studies are more likely to provide novel loci of interest.
C1 [Tran, Theresa; Cotlarciuc, Ioana; Sharma, Pankaj] Royal Holloway Univ London ICR2UL, Inst Cardiovasc Res, London, England.
[Tran, Theresa; Cotlarciuc, Ioana; Sharma, Pankaj] Ashford & St Peters NHS Fdn Trust, London, England.
[Tran, Theresa; Yadav, Sunaina; Hasan, Nazeeha; Bentley, Paul; Sharma, Pankaj] Univ London Imperial Coll Sci Technol & Med, ICCRU, London, England.
[Levi, Christopher] John Hunter Hosp, Hunter Med Res Inst, Dept Neurol, Newcastle, NSW, Australia.
[Worrall, Bradford B.] Univ Virginia Hlth Syst, Dept Neurol, Charlottesville, VA USA.
[Worrall, Bradford B.] Univ Virginia Hlth Syst, Dept Publ Hlth Sci, Charlottesville, VA USA.
[Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[Rost, Natalia] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
RP Sharma, P (reprint author), Royal Holloway Univ London, Inst Cardiovasc Res, Egham TW20 OEX, Surrey, England.
EM pankaj.sharma@rhul.ac.uk
FU MRC (UK) PhD studentship; British Council/UK-India Education Research
Initiative (UKIERI)
FX NH is funded by a MRC (UK) PhD studentship and SY through a British
Council/UK-India Education Research Initiative (UKIERI) awarded to PS.
NR 75
TC 1
Z9 1
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD MAR
PY 2016
VL 87
IS 3
BP 260
EP 266
DI 10.1136/jnnp-2014-309685
PG 7
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA DF4OG
UT WOS:000371328100008
PM 25835038
ER
PT J
AU Joshi, SK
Lee, L
Lovett, DH
Kang, H
Kim, HT
Delgado, C
Liu, XH
AF Joshi, Sunil K.
Lee, Lawrence
Lovett, David H.
Kang, Heejae
Kim, Hubert T.
Delgado, Cynthia
Liu, Xuhui
TI Novel intracellular N-terminal truncated matrix metalloproteinase-2
isoform in skeletal muscle ischemia-reperfusion injury
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE matrix metalloproteinase-2; N-terminal truncated matrix
metalloproteinase-2; skeletal muscle; hindlimb ischemia-reperfusion
injury; hypoxia
ID FOCAL CEREBRAL-ISCHEMIA; KAPPA-B INHIBITOR; TOLL-LIKE; PYRROLIDINE
DITHIOCARBAMATE; ISCHEMIA/REPERFUSION INJURY; MYOCARDIAL-ISCHEMIA;
CARDIAC ISCHEMIA; MURINE HINDLIMB; UP-REGULATION; EXPRESSION
AB Ischemia-reperfusion injury (IRI) occurs when blood returns to tissues following a period of ischemia. Reintroduction of blood flow results in the production of free radicals and reactive oxygen species that damage cells. Skeletal muscle IRI is commonly seen in orthopedic trauma patients. Experimental studies in other organ systems have elucidated the importance of extracellular and intracellular matrix metalloproteinase-2 (MMP-2) isoforms in regulating tissue damage in the setting of oxidant stress resulting from IRI. Although the extracellular full-length isoform of MMP-2 (FL-MMP-2) has been previously studied in the setting of skeletal muscle IRI, studies investigating the role of the N-terminal truncated isoform (NTT-MMP-2) in this setting are lacking. In this study, we first demonstrated significant increases in FL- and NTT-MMP-2 gene expression in C2C12 myoblast cells responding to re-oxygenation following hypoxia in vitro. We then evaluated the expression of FL- and NTT-MMP-2 in modulating skeletal muscle IRI using a previously validated murine model. NTT-MMP-2, but not FL-MMP-2 expression was significantly increased in skeletal muscle following IRI. Moreover, the expression of toll-like receptors (TLRs) -2 and -4, IL-6, OAS-1A, and CXCL1 was also significantly up-regulated following IRI. Treatment with the potent anti-oxidant pyrrolidine dithiocarbamate (PDTC) significantly suppressed NTT-MMP-2, but not FL-MMP-2 expression and improved muscle viability following IRI. This data suggests that NTT-MMP-2, but not FL-MMP-2, is the major isoform of MMP-2 involved in skeletal muscle IRI. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:502-509, 2016.
C1 [Joshi, Sunil K.; Lee, Lawrence; Lovett, David H.; Kang, Heejae; Kim, Hubert T.; Delgado, Cynthia; Liu, Xuhui] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.
[Joshi, Sunil K.; Lovett, David H.; Delgado, Cynthia] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Kim, Hubert T.; Liu, Xuhui] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA.
RP Liu, XH (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.; Liu, XH (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA.
EM Liux@orthosurg.ucsf.edu
FU Veterans Affairs Rehabilitation Research and Development Merit Review
[RX000195]
FX Grant sponsor: Veterans Affairs Rehabilitation Research and Development
Merit Review; Grant number: RX000195.
NR 49
TC 0
Z9 0
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
EI 1554-527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD MAR
PY 2016
VL 34
IS 3
BP 502
EP 509
DI 10.1002/jor.22992
PG 8
WC Orthopedics
SC Orthopedics
GA DF5UT
UT WOS:000371418700015
PM 26213293
ER
PT J
AU Matossian-Motley, DL
Drake, DA
Samimi, JS
Camargo, CA
Quraishi, SA
AF Matossian-Motley, Debbie L.
Drake, Diane A.
Samimi, John S.
Camargo, Carlos A., Jr.
Quraishi, Sadeq A.
TI Association Between Serum 25(OH)D Level and Nonspecific Musculoskeletal
Pain in Acute Rehabilitation Unit Patients
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article
DE vitamin D; pain; musculoskeletal; acute rehabilitation
ID VITAMIN-D DEFICIENCY; SPINAL-CORD-INJURY; LOCALLY WEIGHTED REGRESSION;
INPATIENT REHABILITATION; D SUPPLEMENTATION; CHANNEL BLOCKERS;
NEUROPATHIC PAIN; CONTROLLED-TRIAL; OLDER-ADULTS; KNEE
AB Objective: Nonspecific musculoskeletal pain can be difficult to manage in acute rehabilitation unit (ARU) patients. We investigated whether vitamin D status is a potential modifiable risk factor for nonspecific musculoskeletal pain in ARU patients. Materials and Methods: This cross-sectional study focused on 414 adults from an inpatient ARU in Mission Viejo, California, between July 2011 and June 2012. On ARU admission, all patients had serum 25-hydroxyvitamin D (25(OH)D) levels measured and were assessed for nonspecific musculoskeletal pain. We performed multivariable logistic regression to test the association of serum 25(OH)D level with nonspecific musculoskeletal pain while adjusting for clinically relevant covariates. Results: Among these 414 patients, mean (SD) 25(OH)D level was 29 (12) ng/mL, and 30% had nonspecific musculoskeletal pain. After adjustment for age, sex, race, body mass index, Functional Independence Measure score, Deyo-Charlson Comorbidity Index, fractures, steroid use, history of osteoporosis/osteomalacia, and patient type (orthopedic, cardiac, neurological, spinal cord injury, or traumatic brain injury), serum 25(OH)D level was inversely associated with nonspecific musculoskeletal pain (odds ratio [OR] per 10 ng/mL, 0.67; 95% confidence interval [CI], 0.48-0.82). When 25(OH)D level was dichotomized, patients with levels <20 ng/mL had higher odds of nonspecific musculoskeletal pain (OR, 2.33; 95% CI, 1.23-4.17) compared with patients with levels 20 ng/mL. Conclusions: In adult patients, serum 25(OH)D level on admission to ARU was inversely associated with nonspecific musculoskeletal pain. These data support the need for randomized, controlled trials to test the role of vitamin D supplementation to improve nonspecific musculoskeletal pain in ARU patients.
C1 [Matossian-Motley, Debbie L.] Mission Hosp, St Joseph Hlth, Nutr Care Serv, Mission Viejo, CA USA.
[Drake, Diane A.] Mission Hosp, St Joseph Hlth, Nurse Res Scientist Consultant, Mission Viejo, CA USA.
[Samimi, John S.] Mission Hosp, St Joseph Hlth, Dept Pharm, Mission Viejo, CA USA.
[Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Quraishi, Sadeq A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRJ 402, Boston, MA 02114 USA.
[Quraishi, Sadeq A.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.
RP Quraishi, SA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRJ 402, Boston, MA 02114 USA.; Quraishi, SA (reprint author), Harvard Univ, Sch Med, Anesthesia, 55 Fruit St,GRJ 402, Boston, MA 02114 USA.
EM squraishi@mgh.harvard.edu
FU National Institutes of Health [5T32GM007592]
FX S.A.Q. received support from the National Institutes of Health (grant
number 5T32GM007592).
NR 48
TC 0
Z9 1
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD MAR
PY 2016
VL 40
IS 3
BP 367
EP 373
DI 10.1177/0148607114555909
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DF4JZ
UT WOS:000371315200010
PM 25316682
ER
PT J
AU Nelson, S
Chung, DY
Rordorf, G
AF Nelson, Sarah
Chung, David Y.
Rordorf, Guy
TI Recanalization and Remarkable Outcome after Subocclusive Thrombus: A
Case Report
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Acute ischemic stroke; subocclusive thrombus; intraluminal thrombus;
anticoagulation; endovascular therapy; computed tomography
ID ACUTE ISCHEMIC-STROKE; INTRAARTERIAL THROMBOLYSIS; INTRALUMINAL
THROMBUS; MANAGEMENT; OCCLUSION
AB Minimal literature exists regarding subocclusive thrombi and their management in acute ischemic stroke, and no randomized trials or guidelines are currently available. We present the case of an 83-year-old man with multiple vascular risk factors and recent cardiac surgery who presented with a severe left middle cerebral artery (MCA) syndrome due to a subocclusive thrombus. Intravenous (IV) tissue plasminogen activator was contraindicated given the patient's recent surgery, and endovascular therapy was deferred given improvement in symptoms. He was placed on IV heparin. His symptoms improved with recanalization of the MCA. Optimal management of subocclusive thrombi, which appear to have better outcomes than occlusive thrombi, has yet to be elucidated. Acute anticoagulation and endovascular therapy may both be reasonable; however, there are minimal data supporting the use of either and further studies are needed to develop the most favorable treatment algorithm. In the meantime, management decisions should be made on a case-by-case basis by multidisciplinary care teams.
C1 [Nelson, Sarah; Chung, David Y.; Rordorf, Guy] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Nelson, S (reprint author), 55 Fruit St, Boston, MA 02114 USA.
EM senelson13@gmail.com
NR 9
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD MAR
PY 2016
VL 25
IS 3
BP E28
EP E30
DI 10.1016/j.jstrokecerebrovasdis.2015.11.024
PG 3
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DF2LY
UT WOS:000371175900003
PM 26725124
ER
PT J
AU Kidd, CL
Hershman, S
Accordino, RE
AF Kidd, Christen L.
Hershman, Susan
Accordino, Robert E.
TI The Curious Incident of the Dog in the Night-Time.
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Book Review
C1 [Kidd, Christen L.] New York Presbyterian Hosp, New York, NY USA.
[Kidd, Christen L.] Weill Cornell Med Ctr, New York, NY USA.
[Hershman, Susan] NYU, New York, NY USA.
[Accordino, Robert E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Accordino, Robert E.] Harvard Univ, Sch Med, Boston, MA USA.
RP Kidd, CL (reprint author), New York Presbyterian Hosp, New York, NY USA.; Kidd, CL (reprint author), Weill Cornell Med Ctr, New York, NY USA.
EM clk9018@nyp.org
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0890-8567
EI 1527-5418
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD MAR
PY 2016
VL 55
IS 3
BP 246
EP 247
DI 10.1016/j.jaac.2016.01.002
PG 2
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA DF2RT
UT WOS:000371192200017
ER
PT J
AU Rudolph, JL
Doherty, K
Kelly, B
Driver, JA
Archambault, E
AF Rudolph, James L.
Doherty, Kelly
Kelly, Brittany
Driver, Jane A.
Archambault, Elizabeth
TI Validation of a Delirium Risk Assessment Using Electronic Medical Record
Information
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Delirium; risk assessment; patient safety; patient-centered outcomes
research
ID MENTAL-STATE-EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; PREDICTION
MODELS; IMPAIRMENT; MORTALITY; FACILITY; ADULTS; CARE
AB Objective: Identifying patients at risk for delirium allows prompt application of prevention, diagnostic, and treatment strategies; but is rarely done. Once delirium develops, patients are more likely to need posthospitalization skilled care. This study developed an a priori electronic prediction rule using independent risk factors identified in a National Center of Clinical Excellence meta-analysis and validated the ability to predict delirium in 2 cohorts.
Design: Retrospective analysis followed by prospective validation.
Setting: Tertiary VA Hospital in New England.
Participants: A total of 27,625 medical records of hospitalized patients and 246 prospectively enrolled patients admitted to the hospital.
Measurements: The electronic delirium risk prediction rule was created using data obtained from the patient electronic medical record (EMR). The primary outcome, delirium, was identified 2 ways: (1) from the EMR (retrospective cohort) and (2) clinical assessment on enrollment and daily thereafter (prospective participants). We assessed discrimination of the delirium prediction rule with the C-statistic. Secondary outcomes were length of stay and discharge to rehabilitation.
Results: Retrospectively, delirium was identified in 8% of medical records (n = 2343); prospectively, delirium during hospitalization was present in 26% of participants (n = 64). In the retrospective cohort, medical record delirium was identified in 2%, 3%, 11%, and 38% of the low, intermediate, high, and very high-risk groups, respectively (C-statistic = 0.81; 95% confidence interval 0.80-0.82). Prospectively, the electronic prediction rule identified delirium in 15%, 18%, 31%, and 55% of these groups (C-statistic = 0.69; 95% confidence interval 0.61-0.77). Compared with low-risk patients, those at high-or very high delirium risk had increased length of stay (5.7 +/- 5.6 vs 3.7 +/- 2.7 days; P =.001) and higher rates of discharge to rehabilitation (8.9% vs 20.8%; P =.02).
Conclusions: Automatic calculation of delirium risk using an EMR algorithm identifies patients at risk for delirium, which creates a critical opportunity for gaining clinical efficiencies and improving delirium identification, including those needing skilled care. Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine.
C1 [Rudolph, James L.] Providence VA Med Ctr, Ctr Innovat Long Term Serv Supports, Providence, RI USA.
[Rudolph, James L.; Doherty, Kelly; Kelly, Brittany; Driver, Jane A.; Archambault, Elizabeth] VA Boston Healthcare Syst, Delirium Patient Safety Ctr Inquiry, Boston, MA USA.
[Rudolph, James L.; Kelly, Brittany; Driver, Jane A.; Archambault, Elizabeth] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
[Rudolph, James L.; Driver, Jane A.] Brigham & Womens Hosp, Div Aging, 75 Francis St, Boston, MA 02115 USA.
[Rudolph, James L.; Driver, Jane A.] Harvard Univ, Sch Med, Boston, MA USA.
[Kelly, Brittany] Regis Coll, Sch Nursing Sci & Hlth Profess, Weston, MA USA.
RP Rudolph, JL (reprint author), Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM James.Rudolph@va.gov
FU VA Office of Patient Safety, Delirium Patient Safety Center of Inquiry
FX This study was funded by the VA Office of Patient Safety, Delirium
Patient Safety Center of Inquiry. The study authors retained full
independence in the conduct and reporting of this study.
NR 27
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD MAR 1
PY 2016
VL 17
IS 3
BP 244
EP 248
DI 10.1016/j.jamda.2015.10.020
PG 5
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA DE9IK
UT WOS:000370950000011
PM 26705000
ER
PT J
AU Burke, RE
Whitfield, EA
Hittle, D
Min, SJ
Levy, C
Prochazka, AV
Coleman, EA
Schwartz, R
Ginde, AA
AF Burke, Robert E.
Whitfield, Emily A.
Hittle, David
Min, Sung-joon
Levy, Cari
Prochazka, Allan V.
Coleman, Eric A.
Schwartz, Robert
Ginde, Adit A.
TI Hospital Readmission From Post-Acute Care Facilities: Risk Factors,
Timing, and Outcomes
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Post-acute care; readmission; care transition
ID SKILLED NURSING FACILITIES; PROSPECTIVE-PAYMENT SYSTEM; QUALITY-OF-CARE;
POSTACUTE CARE; HOME RESIDENTS; OLDER-ADULTS; GEOGRAPHIC-VARIATION;
FUNCTIONAL OUTCOMES; THERAPY INTENSITY; POSTHOSPITAL CARE
AB Objectives: Hospital discharges to post-acute care (PAC) facilities have increased rapidly. This increase may lead to more hospital readmissions from PAC facilities, which are common and poorly understood. We sought to determine the risk factors and timing for hospital readmission from PAC facilities and evaluate the impact of readmission on patient outcomes.
Design: Retrospective analysis of Medicare Current Beneficiary Survey (MCBS) from 2003-2009.
Setting: The MCBS is a nationally representative survey of beneficiaries matched with claims data.
Participants: Community-dwelling beneficiaries who were hospitalized and discharged to a PAC facility for rehabilitation.
Intervention/Exposure: Potential readmission risk factors included patient demographics, health utilization, active medical conditions at time of PAC admission, and PAC characteristics.
Measurements: Hospital readmission during the PAC stay, return to community residence, and all-cause mortality.
Results: Of 3246 acute hospitalizations followed by PAC facility stays, 739 (22.8%) included at least 1 hospital readmission. The strongest risk factors for readmission included impaired functional status (HR 4.78, 95% CI 3.21-7.10), markers of increased acuity such as need for intravenous medications in PAC (1.63, 1.39-1.92), and for-profit PAC ownership (1.43, 1.21-1.69). Readmitted patients had a higher mortality rate at both 30 days (18.9% vs 8.6%, P <. 001) and 100 days (39.9% vs 14.5%, P <. 001) even after adjusting for age, comorbidities, and prior health care utilization (30 days: OR 2.01, 95% CI 1.60-2.54; 100 days: OR 3.79, 95% CI 3.13-4.59).
Conclusions: Hospital readmission from PAC facilities is common and associated with a high mortality rate. Readmission risk factors may signify inadequate transitional care processes or a mismatch between patient needs and PAC resources. Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine.
C1 [Burke, Robert E.; Whitfield, Emily A.; Levy, Cari; Prochazka, Allan V.] Denver VA Med Ctr, Denver Seattle Ctr Innovat, Denver, CO USA.
[Burke, Robert E.; Prochazka, Allan V.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO USA.
[Hittle, David; Min, Sung-joon; Levy, Cari; Coleman, Eric A.] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA.
[Schwartz, Robert] Univ Colorado, Sch Med, Dept Med, Div Geriatr Med, Aurora, CO USA.
[Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA.
RP Burke, RE (reprint author), Denver VA Med Ctr, Hosp Med Sect, 1055 Clermont St, Denver, CO 80220 USA.
EM Robert.Burke5@va.gov
RI bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017
FU NIA NIH HHS [R03 AG050885]
NR 58
TC 6
Z9 6
U1 6
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD MAR 1
PY 2016
VL 17
IS 3
BP 249
EP 255
DI 10.1016/j.jamda.2015.11.005
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA DE9IK
UT WOS:000370950000012
PM 26715357
ER
PT J
AU Krop, IE
AF Krop, Ian E.
TI Lessons from breast cancer trials of HER2-kinase inhibitors
SO LANCET ONCOLOGY
LA English
DT Editorial Material
ID TRASTUZUMAB; LAPATINIB; THERAPY
C1 [Krop, Ian E.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Krop, IE (reprint author), Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02215 USA.
EM Ian_Krop@dfci.harvard.edu
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAR
PY 2016
VL 17
IS 3
BP 267
EP 268
DI 10.1016/S1470-2045(16)00004-8
PG 2
WC Oncology
SC Oncology
GA DF3HN
UT WOS:000371234900028
PM 26822399
ER
PT J
AU Yock, TI
Yeap, BY
Ebb, DH
Weyman, E
Eaton, BR
Sherry, NA
Jones, RM
MacDonald, SM
Pulsifer, MB
Lavally, B
Abrams, AN
Huang, MS
Marcus, KJ
Tarbell, NJ
AF Yock, Torunn I.
Yeap, Beow Y.
Ebb, David H.
Weyman, Elizabeth
Eaton, Bree R.
Sherry, Nicole A.
Jones, Robin M.
MacDonald, Shannon M.
Pulsifer, Margaret B.
Lavally, Beverly
Abrams, Annah N.
Huang, Mary S.
Marcus, Karen J.
Tarbell, Nancy J.
TI Long-term toxic eff ects of proton radiotherapy for paediatric
medulloblastoma: a phase 2 single-arm study
SO LANCET ONCOLOGY
LA English
DT Article
ID AVERAGE-RISK MEDULLOBLASTOMA; CHILDHOOD-CANCER SURVIVOR; CHILDRENS
ONCOLOGY GROUP; PRIMITIVE NEUROECTODERMAL TUMORS; NEWLY-DIAGNOSED
MEDULLOBLASTOMA; CRANIOSPINAL RADIATION-THERAPY; NERVOUS-SYSTEM
MALIGNANCIES; ADJUVANT CHEMOTHERAPY; BRAIN-TUMORS; SPINAL IRRADIATION
AB Background Compared with traditional photon radiotherapy, proton radiotherapy irradiates less normal tissue and might improve health outcomes associated with photon radiotherapy by reducing toxic effects to normal tissue. We did a trial to assess late complications, acute side-effects, and survival associated with proton radiotherapy in children with medulloblastoma.
Methods In this non-randomised, open-label, single-centre, phase 2 trial, we enrolled patients aged 3-21 years who had medulloblastoma. Patients had craniospinal irradiation of 18-36 Gy radiobiological equivalents (GyRBE) delivered at 1.8 GyRBE per fraction followed by a boost dose. The primary outcome was cumulative incidence of ototoxicity at 3 years, graded with the Pediatric Oncology Group ototoxicity scale (0-4), in the intention-to-treat population. Secondary outcomes were neuroendocrine toxic effects and neurocognitive toxic effects, assessed by intention-to-treat. This study is registered at ClinicalTrials.gov, number NCT00105560.
Findings We enrolled 59 patients from May 20, 2003, to Dec 10, 2009: 39 with standard-risk disease, six with intermediate-risk disease, and 14 with high-risk disease. 59 patients received chemotherapy. Median follow-up of survivors was 7.0 years (IQR 5.2-8.6). All patients received the intended doses of proton radiotherapy. The median craniospinal irradiation dose was 23.4 GyRBE (IQR 23.4-27.0) and median boost dose was 54.0 GyRBE (IQR 54.0-54.0). Four (9%) of 45 evaluable patients had grade 3-4 ototoxicity according to Pediatric Oncology Group ototoxicity scale in both ears at follow-up, and three (7%) of 45 patients developed grade 3-4 ototoxicity in one ear, although one later reverted to grade 2. The cumulative incidence of grade 3-4 hearing loss at 3 years was 12% (95% CI 4-25). At 5 years, it was 16% (95% CI 6-29). Pediatric Oncology Group hearing ototoxicity score at a follow-up of 5.0 years (IQR 2.9-6.4) was the same as at baseline or improved by 1 point in 34 (35%) of 98 ears, worsened by 1 point in 21 (21%), worsened by 2 points in 35 (36%), worsened by 3 points in six (6%), and worsened by 4 points in two (2%). Full Scale Intelligence Quotient decreased by 1.5 points (95% CI 0.9-2.1) per year after median follow-up up of 5.2 years (IQR 2.6-6.4), driven by decrements in processing speed and verbal comprehension index. Perceptual reasoning index and working memory did not change significantly. Cumulative incidence of any neuroendocrine deficit at 5 years was 55% (95% CI 41-67), with growth hormone deficit being most common. We recorded no cardiac, pulmonary, or gastrointestinal late toxic effects. 3-year progression-free survival was 83% (95% CI 71-90) for all patients. In post-hoc analyses, 5-year progression-free survival was 80% (95% CI 67-88) and 5-year overall survival was 83% (95% CI 70-90).
Interpretation Proton radiotherapy resulted in acceptable toxicity and had similar survival outcomes to those noted with conventional radiotherapy, suggesting that the use of the treatment may be an alternative to photon-based treatments.
C1 [Yock, Torunn I.; Weyman, Elizabeth; Eaton, Bree R.; MacDonald, Shannon M.; Tarbell, Nancy J.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Ebb, David H.; Lavally, Beverly; Huang, Mary S.] Massachusetts Gen Hosp, Dept Pediat Oncol, Boston, MA 02114 USA.
[Sherry, Nicole A.] Massachusetts Gen Hosp, Dept Pediat Endocrinol, Boston, MA 02114 USA.
[Jones, Robin M.] Massachusetts Gen Hosp, Dept Pediat Neurol, Boston, MA 02114 USA.
[Pulsifer, Margaret B.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Abrams, Annah N.] Massachusetts Gen Hosp, Dept Child Psychiat, Boston, MA 02114 USA.
[Eaton, Bree R.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Marcus, Karen J.] Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
RP Yock, TI (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Proton Ctr, Boston, MA 02114 USA.
EM tyock@partners.org
FU US National Cancer Institute; Massachusetts General Hospital
FX US National Cancer Institute and Massachusetts General Hospital.
NR 54
TC 17
Z9 17
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAR
PY 2016
VL 17
IS 3
BP 287
EP 298
DI 10.1016/S1470-2045(15)00167-9
PG 12
WC Oncology
SC Oncology
GA DF3HN
UT WOS:000371234900042
PM 26830377
ER
PT J
AU Chan, A
Delaloge, S
Holmes, FA
Moy, B
Iwata, H
Harvey, VJ
Robert, NJ
Silovski, T
Gokmen, E
Von Minckwitz, G
Ejlertsen, B
Chia, SKL
Mansi, J
Barrios, CH
Gnant, M
Buyse, M
Gore, I
Smith, J
Harker, G
Masuda, N
Petrakova, K
Zotano, AG
Iannotti, ZN
Rodriguez, G
Tassone, P
Wong, A
Bryce, R
Ye, YN
Yao, B
Martin, M
AF Chan, Arlene
Delaloge, Suzette
Holmes, Frankie A.
Moy, Beverly
Iwata, Hiroji
Harvey, Vernon J.
Robert, Nicholas J.
Silovski, Tajana
Gokmen, Erhan
von Minckwitz, Gunter
Ejlertsen, Bent
Chia, Stephen K. L.
Mansi, Janine
Barrios, Carlos H.
Gnant, Michael
Buyse, Marc
Gore, Ira
Smith, John, II
Harker, Graydon
Masuda, Norikazu
Petrakova, Katarina
Guerrero Zotano, Angel
Iannotti, Nicholas
Rodriguez, Gladys
Tassone, Pierfrancesco
Wong, Alvin
Bryce, Richard
Ye, Yining
Yao, Bin
Martin, Miguel
CA ExteNET Study Grp
TI Neratinib after trastuzumab-based adjuvant therapy in patients with
HER2-positive breast cancer (ExteNET): a multicentre, randomised,
double-blind, placebo-controlled, phase 3 trial
SO LANCET ONCOLOGY
LA English
DT Article
ID MINIMALLY IMPORTANT DIFFERENCES; TYROSINE KINASE INHIBITOR; OPEN-LABEL;
ONCOGENE ADDICTION; ESTROGEN-RECEPTOR; HERA TRIAL; CHEMOTHERAPY;
COMBINATION; LAPATINIB; WOMEN
AB Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.
Methods We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged >= 18 years, or >= 20 years in Japan) had stage 1-3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1: 1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1-3, or >= 4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709.
Findings Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20-25) in the neratinib group and 24 months (22-25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0.67, 95% CI 0.50-0.91; p=0.0091). The 2-year invasive disease-free survival rate was 93.9% (95% CI 92.4-95.2) in the neratinib group and 91.6% (90.0-93.0) in the placebo group. The most common grade 3-4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (>= grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group.
Interpretation Neratinib for 12 months signifi cantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained.
C1 [Chan, Arlene] Breast Canc Res Ctr Western Australia, Perth, WA, Australia.
[Chan, Arlene] Curtin Univ, Perth, WA 6845, Australia.
[Delaloge, Suzette] Inst Gustave Roussy, Villejuif, France.
[Holmes, Frankie A.] Texas Oncol, Houston, TX USA.
[Moy, Beverly] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Iwata, Hiroji] Aichi Canc Ctr, Chikusa Ku, Nagoya, Aichi 464, Japan.
[Harvey, Vernon J.] Auckland Hosp, Auckland, New Zealand.
[Robert, Nicholas J.] Virginia Canc Specialists, US Oncol Network, Fairfax, VA USA.
[Silovski, Tajana] Univ Hosp Tumors, Univ Hosp Ctr Sestre Milosrdnice, Zagreb, Croatia.
[Gokmen, Erhan] Ege Univ, Fac Med, Izmir, Turkey.
[von Minckwitz, Gunter] German Breast Grp Forsch GmbH, Luisenkrankenhaus, Dusseldorf, Neu Isenburg, Germany.
[Ejlertsen, Bent] Rigshosp, DK-2100 Copenhagen, Denmark.
[Chia, Stephen K. L.] BC Canc Agcy, Vancouver, BC, Canada.
[Mansi, Janine] Guys & St Thomas NHS Fdn Trust, London, England.
[Mansi, Janine] Kings Coll London, Biomed Res Ctr, London WC2R 2LS, England.
[Barrios, Carlos H.] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil.
[Gnant, Michael] Med Univ Vienna, Dept Surg, Vienna, Austria.
[Gnant, Michael] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria.
[Buyse, Marc] IDDI, Louvain La Neuve, Belgium.
[Gore, Ira] Alabama Oncol, Birmingham, AL USA.
[Smith, John, II] Northwest Canc Specialists, Vancouver, VA USA.
[Harker, Graydon] Utah Canc Specialists, Salt Lake City, UT USA.
[Masuda, Norikazu] Natl Hosp Org, Osaka Natl Hosp, Chuou Ku, Osaka, Japan.
[Petrakova, Katarina] Masaryk Mem Canc Inst, Brno, Czech Republic.
[Guerrero Zotano, Angel] Inst Valenciano Oncol, Valencia, Spain.
[Iannotti, Nicholas] Hematol Oncol Associates Treasure Coast, Port St Lucie, FL USA.
[Rodriguez, Gladys] South Texas Oncol & Hematol, San Antonio, TX USA.
[Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy.
[Wong, Alvin; Bryce, Richard; Ye, Yining; Yao, Bin] Puma Biotechnol, Los Angeles, CA USA.
[Martin, Miguel] Univ Complutense Madrid, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
RP Chan, A (reprint author), Breast Canc Res Ctr Western Australia, Perth, WA, Australia.
EM arlenechan@me.com
FU Wyeth; Pfizer; Puma Biotechnology
FX Wyeth, Pfizer, Puma Biotechnology.
NR 38
TC 24
Z9 25
U1 7
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAR
PY 2016
VL 17
IS 3
BP 367
EP 377
DI 10.1016/S1470-2045(15)00551-3
PG 11
WC Oncology
SC Oncology
GA DF3HN
UT WOS:000371234900049
PM 26874901
ER
PT J
AU Cohen, MS
Landegger, LD
Kozin, ED
Lee, DJ
AF Cohen, Michael S.
Landegger, Lukas D.
Kozin, Elliott D.
Lee, Daniel J.
TI Pediatric endoscopic ear surgery in clinical practice: Lessons learned
and early outcomes
SO LARYNGOSCOPE
LA English
DT Article
DE Transcanal; endoscopic ear surgery; pediatric; tympanoplasty; otology
ID MIDDLE-EAR; CONGENITAL CHOLESTEATOMA; ACQUIRED CHOLESTEATOMA;
TYMPANOPLASTY; CHILDREN; MANAGEMENT; ANATOMY
AB Objectives/HypothesisOnly a few reports describe the outcomes following endoscopic ear surgery (EES) in children for chronic ear disease. We differentiate between transcanal endoscopic ear surgery (TEES), where the case is performed with only endoscopic visualization, from non-TEES, where the endoscope is not used at all or used as an adjunct to the microscope. We hypothesize that EES is an effective approach to manage middle ear pathology using a transcanal approach in most cases, and can be incorporated into a pediatric otology practice with a neutral or positive effect on outcomes. Lessons learned during this process are analyzed and discussed.
Study DesignSingle-institution, retrospective chart review of outcomes following TEES and non-TEES in children from January 1, 2013 through July 1, 2014.
MethodsProcedures included tympanoplasty, ossiculoplasty, and cholesteatoma resection. Primary outcome measures included closure rate of tympanic membrane perforations, audiometric outcomes, and complications. Surgical times were reported as secondary measures.
ResultsNinety-four patients underwent 121 middle ear procedures. TEES was performed in 51/121 of cases (42.1%). Comparison of TEES versus non-TEES cases showed no significant difference in rate of tympanoplasty closure (P>.99). The mean pure-tone improvement following TEES tympanoplasty was -7.8 dB versus -1.33 dB for non-TEES cases (P=.03). Surgical times were similar between groups.
ConclusionsEES techniques were readily incorporated into a pediatric otology practice. A standardized EES classification system is useful for analyzing utilization patterns and results across institutions. Tympanic membrane closure rates and hearing outcomes were similar in TEES and non-TEES cases.
C1 Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Cohen, MS (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM michael_cohen@meei.harvard.edu
RI Kozin, Elliott/J-1225-2014;
OI Kozin, Elliott/0000-0002-0305-0682; Landegger, Lukas
D./0000-0002-9660-2625
NR 24
TC 8
Z9 8
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD MAR
PY 2016
VL 126
IS 3
BP 732
EP 738
DI 10.1002/lary.25410
PG 7
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA DF3KM
UT WOS:000371242800046
PM 26228434
ER
PT J
AU Al-Qurayshi, Z
Randolph, GW
Srivastav, S
Kandil, E
AF Al-Qurayshi, Zaid
Randolph, Gregory W.
Srivastav, Sudesh
Kandil, Emad
TI Outcomes in endocrine cancer surgery are affected by racial, economic,
and healthcare system demographics
SO LARYNGOSCOPE
LA English
DT Article
DE Thyroid cancer; thyroidectomy; parathyroid cancer; parathyroidectomy;
endocrine cancer; surgeon volume; patient environment; patient
community; demographic
ID HOSPITAL VOLUME; UNITED-STATES; THYROIDECTOMY; MORTALITY; DISPARITIES;
COMPLICATIONS; ASSOCIATION; ENVIRONMENT; AMERICANS; RESIDENCE
AB Objectives/HypothesisSurgeon experience has been recognized in several clinical fields as a significant element of superior management outcomes. In this study, we seek to assess the association between surgeon volume and patients' community health status with the outcomes of thyroid and parathyroid surgery indicated for primary malignancies.
Study DesignA cross-sectional study utilizing the State Inpatient Databases, 2010-2011, for Florida, New York, and Washington was merged with the County Health Rankings database.
MethodsInternational Classification of Diseases, Ninth Revision codes were used to identify adult (18 years) patients who underwent thyroidectomy or parathyroidectomy indicated for primary malignancies.
ResultsA total of 6,347 records were included. Compared to high-volume surgeons, patients treated by low-volume surgeons were more likely to develop postoperative complications in the 1-month period after the operation (odds ratio: 4.34, 95% confidence interval: 3.31-5.70, P<.001). Furthermore, both low- and intermediate-volume surgeons were associated with a longer hospital stay (>2 days) and a higher risk of admission to the intensive care unit (P<.01 each). Cost of health services was significantly in the highest quartile (>$10,254.66) for patients treated by low-volume surgeons (P<.001). Patients who lived in communities of poor health measures had a higher risk of postoperative complications (16.3% vs. 11.8%, P=.030) independent of the clinical presentation and management type. Patients living in high health-risk communities and those of black and Hispanic backgrounds were more likely to be treated by low-volume surgeons (P<.001 each).
ConclusionsThe surgeon's volume and the patient's living conditions are crucial and independent factors in multiple aspects of endocrine cancer management.
Level of Evidence4 Laryngoscope, 126:775-781, 2016
C1 [Al-Qurayshi, Zaid; Kandil, Emad] Tulane Univ, Sch Med, Dept Surg, 1430 Tulane Ave,SL-22, New Orleans, LA 70112 USA.
[Randolph, Gregory W.] Massachusetts Eye & Ear Infirm, Div Thyroid & Parathyroid Endocrine Surg, Boston, MA 02114 USA.
[Srivastav, Sudesh] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat & Bioinformat, New Orleans, LA 70118 USA.
RP Kandil, E (reprint author), Tulane Univ, Sch Med, Dept Surg, 1430 Tulane Ave,SL-22, New Orleans, LA 70112 USA.
EM ekandil@tulane.edu
OI Al-Qurayshi, Zaid/0000-0002-3534-7253
NR 27
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD MAR
PY 2016
VL 126
IS 3
BP 775
EP 781
DI 10.1002/lary.25606
PG 7
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA DF3KM
UT WOS:000371242800053
PM 26372521
ER
PT J
AU Zhao, K
Craig, JR
Cohen, NA
Adappa, ND
Khalili, S
Palmer, JN
AF Zhao, Kai
Craig, John R.
Cohen, Noam A.
Adappa, Nithin D.
Khalili, Sammy
Palmer, James N.
TI Sinus irrigations before and after surgeryVisualization through
computational fluid dynamics simulations
SO LARYNGOSCOPE
LA English
DT Article
DE Nasal irrigation; computational fluid dynamics; modeling; sinus surgery;
sinusitis; frontal; maxillary; sphenoid; head position
ID NASAL AIR-FLOW; CHRONIC RHINOSINUSITIS; ODORANT TRANSPORT; PARANASAL
SINUSES; HUMAN NOSE; OLFACTION; DELIVERY; SURGERY; PENETRATION; MODEL
AB Objectives/HypothesisTopical sinus irrigations play a critical role in the management of sinonasal disease, and the improvement in irrigant penetration into the sinuses postoperatively greatly contributes to the success of endoscopic sinus surgery. Prior investigations on postoperative sinus irrigations have been mostly limited to cadaver studies, which are labor intensive and do not capture the full dynamics of the flows. A pilot study was conducted to investigate the impact of surgery on sinus irrigation through computational fluid dynamics (CFD) simulations.
Study DesignRetrospective computational study.
MethodsPre- and postoperative computed tomography (CT) scans were obtained on a patient who underwent standard endoscopic surgeries for all sinuses, including a Draf III frontal sinusotomy. CT-based pre- and postoperative CFD models then simulated irrigations of 120 mL saline per nostril at 12 mL/s (typical of Sinugator) and 60 mL/s (SinusRinse Bottle), in two head positions: face parallel and at a 45 degrees angle to the ground.
ResultsOverall, surgery most significantly improved frontal sinus irrigation, but surprisingly resulted in less maxillary and ethmoid sinuses penetration. This may due to the partial removal of the septum during the Draf III, causing most fluid to exit prematurely across the resected septum. Higher flow rate slightly improved ethmoid sinus irrigation, but resulted in less preoperative contralateral maxillary sinus penetration.
ConclusionsCFD modeling of sinonasal irrigations is a novel technique for evaluating irrigant penetration of individual sinus cavities. It may prove useful in determining the optimal degree of surgery or the ideal irrigation strategy to allow for maximal and targeted sinus irrigant penetration.
C1 [Zhao, Kai] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 915 Olentangy River Rd, Columbus, OH 43212 USA.
[Craig, John R.; Cohen, Noam A.; Adappa, Nithin D.; Khalili, Sammy; Palmer, James N.] Univ Penn, Dept Otorhinolaryngol, 5 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Zhao, K (reprint author), Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 915 Olentangy River Rd, Columbus, OH 43212 USA.; Palmer, JN (reprint author), Univ Penn, Dept Otorhinolaryngol, 5 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA.
EM zhao.1949@osu.edu; james.palmer@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932
FU NIH NIDCD [R01 DC013626]
FX This work was supported by NIH NIDCD R01 DC013626 to K.Z.
NR 24
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD MAR
PY 2016
VL 126
IS 3
BP E90
EP E96
DI 10.1002/lary.25666
PG 7
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA DF3KM
UT WOS:000371242800001
PM 26467934
ER
PT J
AU Malyarenko, DI
Newitt, D
Wilmes, LJ
Tudorica, A
Helmer, KG
Arlinghaus, LR
Jacobs, MA
Jajamovich, G
Taouli, B
Yankeelov, TE
Huang, W
Chenevert, TL
AF Malyarenko, Dariya I.
Newitt, David
Wilmes, Lisa J.
Tudorica, Alina
Helmer, Karl G.
Arlinghaus, Lori R.
Jacobs, Michael A.
Jajamovich, Guido
Taouli, Bachir
Yankeelov, Thomas E.
Huang, Wei
Chenevert, Thomas L.
TI Demonstration of nonlinearity bias in the measurement of the apparent
diffusion coefficient in multicenter trials
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE quantitative diffusion MRI; multicenter trials; gradient nonlinearity;
ADC mapping
ID QUANTITATIVE IMAGING BIOMARKERS; GRADIENT NONLINEARITY; TREATMENT
RESPONSE; PROSTATE-CANCER; MRI; ONCOLOGY; VALUES; ADC; REPEATABILITY;
CELLULARITY
AB PurposeCharacterize system-specific bias across common magnetic resonance imaging (MRI) platforms for quantitative diffusion measurements in multicenter trials.
MethodsDiffusion weighted imaging (DWI) was performed on an ice-water phantom along the superior-inferior (SI) and right-left (RL) orientations spanning 150 mm. The same scanning protocol was implemented on 14 MRI systems at seven imaging centers. The bias was estimated as a deviation of measured from known apparent diffusion coefficient (ADC) along individual DWI directions. The relative contributions of gradient nonlinearity, shim errors, imaging gradients, and eddy currents were assessed independently. The observed bias errors were compared with numerical models.
ResultsThe measured systematic ADC errors scaled quadratically with offset from isocenter, and ranged between -55% (SI) and 25% (RL). Nonlinearity bias was dependent on system design and diffusion gradient direction. Consistent with numerical models, minor ADC errors (+/- 5%) due to shim, imaging and eddy currents were mitigated by double echo DWI and image coregistration of individual gradient directions.
ConclusionThe analysis confirms gradient nonlinearity as a major source of spatial DW bias and variability in off-center ADC measurements across MRI platforms, with minor contributions from shim, imaging gradients and eddy currents. The developed protocol enables empiric description of systematic bias in multicenter quantitative DWI studies. Magn Reson Med 75:1312-1323, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Malyarenko, Dariya I.; Chenevert, Thomas L.] Univ Michigan, Radiol, Ann Arbor, MI 48109 USA.
[Newitt, David; Wilmes, Lisa J.] Univ Calif San Francisco, Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Tudorica, Alina] Oregon Hlth & Sci Univ, Diagnost Radiol, Portland, OR 97201 USA.
[Helmer, Karl G.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Arlinghaus, Lori R.; Yankeelov, Thomas E.] Vanderbilt Univ, Inst Imaging Sci, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Jacobs, Michael A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Jajamovich, Guido; Taouli, Bachir] Icahn Sch Med Mt Sinai, Translat & Mol Imaging Inst, New York, NY 10029 USA.
[Yankeelov, Thomas E.] Vanderbilt Univ, Dept Radiol, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Yankeelov, Thomas E.] Vanderbilt Univ, Dept Phys, Nashville, TN 37235 USA.
[Yankeelov, Thomas E.] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Huang, Wei] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA.
RP Malyarenko, DI (reprint author), Univ Michigan Hosp, 1500 E Med Ctr Dr,UHB2 Room A205F, Ann Arbor, MI 48109 USA.
EM dariya@umich.edu
FU National Institutes of Health [U01-CA166104, U01-CA151235, U01-CA154602,
U01-CA154601, U01-CA140204, U01-CA142565, U01-CA172320]
FX Grant sponsor: National Institutes of Health; Grant numbers:
U01-CA166104; U01-CA151235, U01-CA154602, U01-CA154601, U01-CA140204,
U01-CA142565, U01-CA172320.
NR 38
TC 5
Z9 5
U1 2
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
EI 1522-2594
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD MAR
PY 2016
VL 75
IS 3
BP 1312
EP 1323
DI 10.1002/mrm.25754
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DE4IZ
UT WOS:000370593700037
PM 25940607
ER
PT J
AU Kyle, RA
Steensma, DP
Shampo, MA
AF Kyle, Robert A.
Steensma, David P.
Shampo, Marc A.
TI Otto Wichterle-Inventor of the First Soft Contact Lenses
SO MAYO CLINIC PROCEEDINGS
LA English
DT Editorial Material
C1 [Kyle, Robert A.; Shampo, Marc A.] Mayo Clin, Rochester, MN USA.
[Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Steensma, David P.] Harvard Univ, Sch Med, Boston, MA USA.
RP Kyle, RA (reprint author), Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD MAR
PY 2016
VL 91
IS 3
BP E45
EP E46
DI 10.1016/j.mayocp.2016.01.016
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DF3MR
UT WOS:000371248900004
PM 26944252
ER
PT J
AU Oxnard, GR
AF Oxnard, Geoffrey R.
TI The cellular origins of drug resistance in cancer
SO NATURE MEDICINE
LA English
DT Editorial Material
ID MUTANT LUNG-CANCER; EGFR T790M; AZD9291
AB Two new studies show that mechanisms of acquired resistance to targeted therapy in lung cancer do not necessarily pre-exist in resistant subclones. Instead, some cancers may harbor the potential to acquire a variety of drug-resistance mechanisms after response to targeted therapy.
C1 [Oxnard, Geoffrey R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 44 Binney St, Boston, MA 02115 USA.
RP Oxnard, GR (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 44 Binney St, Boston, MA 02115 USA.
EM geoffrey_oxnard@dfci.harvard.edu
NR 12
TC 5
Z9 5
U1 4
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2016
VL 22
IS 3
BP 232
EP 234
PG 3
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DF6DC
UT WOS:000371445100007
PM 26937615
ER
PT J
AU Hata, AN
Niederst, MJ
Archibald, HL
Gomez-Caraballo, M
Siddiqui, FM
Mulvey, HE
Maruvka, YE
Ji, F
Bhang, HEC
Radhakrishna, VK
Siravegna, G
Hu, HC
Raoof, S
Lockerman, E
Kalsy, A
Lee, D
Keating, CL
Ruddy, DA
Damon, LJ
Crystal, AS
Costa, C
Piotrowska, Z
Bardelli, A
Iafrate, AJ
Sadreyev, RI
Stegmeier, F
Getz, G
Sequist, LV
Faber, AC
Engelman, JA
AF Hata, Aaron N.
Niederst, Matthew J.
Archibald, Hannah L.
Gomez-Caraballo, Maria
Siddiqui, Faria M.
Mulvey, Hillary E.
Maruvka, Yosef E.
Ji, Fei
Bhang, Hyo-eun C.
Radhakrishna, Viveksagar Krishnamurthy
Siravegna, Giulia
Hu, Haichuan
Raoof, Sana
Lockerman, Elizabeth
Kalsy, Anuj
Lee, Dana
Keating, Celina L.
Ruddy, David A.
Damon, Leah J.
Crystal, Adam S.
Costa, Carlotta
Piotrowska, Zofia
Bardelli, Alberto
Iafrate, Anthony J.
Sadreyev, Ruslan I.
Stegmeier, Frank
Getz, Gad
Sequist, Lecia V.
Faber, Anthony C.
Engelman, Jeffrey A.
TI Tumor cells can follow distinct evolutionary paths to become resistant
to epidermal growth factor receptor inhibition
SO NATURE MEDICINE
LA English
DT Article
ID EGFR KINASE INHIBITORS; LUNG-CANCER; ACQUIRED-RESISTANCE; MET
AMPLIFICATION; GEFITINIB; MUTATION; AZD9291; T790M; HETEROGENEITY;
MODELS
AB Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non -small -cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe that acquired resistance caused by the EGFR(T79OM) gatekeeper mutation can occur either by selectiori of pre-existing EGFR(T79M)-positive clones or via genetic evolution of initially EGFR(T790M)-negative drug -tolerant cells. The path to resistance impacts the biology of the resistant clone, as those that evolved from drug -tolerant cells had a diminished apoptotic response to third generation EGFR inhibitors that target EGFR(T790M); treatment with navitoclax, an inhibitor of the anti-apoptotic factors BCL-xL and BCL-2 restored sensitivity. We corroborated these findings using cultures derived directly from EGFR inhibitor -resistant patient tumors. These findings provide evidence that clinically relevant drug -resistant cancer cells can both pre-exist and evolve from drug -tolerant cells, and they point to therapeutic opportunities to prevent or overcome resistance in the clinic.
C1 [Hata, Aaron N.; Niederst, Matthew J.; Archibald, Hannah L.; Gomez-Caraballo, Maria; Siddiqui, Faria M.; Mulvey, Hillary E.; Maruvka, Yosef E.; Hu, Haichuan; Raoof, Sana; Lockerman, Elizabeth; Kalsy, Anuj; Lee, Dana; Damon, Leah J.; Crystal, Adam S.; Costa, Carlotta; Piotrowska, Zofia; Getz, Gad; Sequist, Lecia V.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
[Hata, Aaron N.; Niederst, Matthew J.; Raoof, Sana; Costa, Carlotta; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Maruvka, Yosef E.; Getz, Gad] Broad Inst MIT & Harvard Univ, Cambridge, MA USA.
[Ji, Fei; Sadreyev, Ruslan I.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Bhang, Hyo-eun C.; Radhakrishna, Viveksagar Krishnamurthy; Keating, Celina L.; Stegmeier, Frank] Novartis Inst Biomed Res, Oncol Dis Area, Cambridge, MA USA.
[Siravegna, Giulia; Bardelli, Alberto] Univ Turin, Dept Oncol, Turin, Italy.
[Siravegna, Giulia; Bardelli, Alberto] IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy.
[Ruddy, David A.] Novartis Inst Biomed Res, Translat Clin Oncol, Cambridge, England.
[Iafrate, Anthony J.; Sadreyev, Ruslan I.; Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Getz, Gad] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Faber, Anthony C.] Virginia Commonwealth Univ, Philips Inst Oral Hlth Res, Sch Dent, Richmond, VA USA.
[Faber, Anthony C.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA.
[Crystal, Adam S.] Novartis Inst Biomed Res, Translat Clin Oncol, Cambridge, MA USA.
RP Engelman, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.; Engelman, JA (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
EM jengelman@partners.org
FU US National Institutes of Health (NIH) [R01CA137008]; Department of
Defense; LunGevity; Uniting Against Lung Cancer; Conquer Cancer
Foundation of the American Society of Clinical Oncology; Lung Cancer
Research Foundation; Targeting a Cure for Lung Cancer; Be a Piece of the
Solution; John and Carol Barry Foundation
FX We thank C. Benes and all members of the Engelman and Benes laboratories
for helpful discussions and feedback. This study was funded by support
from the US National Institutes of Health (NIH) (grant R01CA137008;
J.A.E.), the Department of Defense (L.V.S. and J.A.E.), LunGevity
(L.V.S. and J.A.E.), Uniting Against Lung Cancer (A.N.H. and M.J.N.),
the Conquer Cancer Foundation of the American Society of Clinical
Oncology (A.N.H.), the Lung Cancer Research Foundation (M.J.N.),
Targeting a Cure for Lung Cancer (J.A.E.), Be a Piece of the Solution
(J.A.E.), and the John and Carol Barry Foundation (A.N.H.).
NR 39
TC 53
Z9 53
U1 31
U2 57
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2016
VL 22
IS 3
BP 262
EP 269
DI 10.1038/nm.4040
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DF6DC
UT WOS:000371445100013
PM 26828195
ER
PT J
AU Noll, EM
Eisen, C
Stenzinger, A
Espinet, E
Muckenhuber, A
Klein, C
Vogel, V
Klaus, B
Nadler, W
Rosli, C
Lutz, C
Kulke, M
Engelhardt, J
Zickgraf, FM
Espinosa, O
Schlesner, M
Jiang, XQ
Kopp-Schneider, A
Neuhaus, P
Bahra, M
Sinn, BV
Eils, R
Giese, NA
Hackert, T
Strobel, O
Werner, J
Buchler, MW
Weichert, W
Trumpp, A
Sprick, MR
AF Noll, Elisa M.
Eisen, Christian
Stenzinger, Albrecht
Espinet, Elisa
Muckenhuber, Alexander
Klein, Corinna
Vogel, Vanessa
Klaus, Bernd
Nadler, Wiebke
Roesli, Christoph
Lutz, Christian
Kulke, Michael
Engelhardt, Jan
Zickgraf, Franziska M.
Espinosa, Octavio
Schlesner, Matthias
Jiang, Xiaoqi
Kopp-Schneider, Annette
Neuhaus, Peter
Bahra, Marcus
Sinn, Bruno V.
Eils, Roland
Giese, Nathalia A.
Hackert, Thilo
Strobel, Oliver
Werner, Jens
Buechler, Markus W.
Weichert, Wilko
Trumpp, Andreas
Sprick, Martin R.
TI CYP3A5 mediates basal and acquired therapy resistance in different
subtypes of pancreatic ductal adenocarcinoma
SO NATURE MEDICINE
LA English
DT Article
ID ORPHAN NUCLEAR RECEPTOR; DRUG-METABOLISM; CYTOCHROME-P450 ENZYMES; PLUS
GEMCITABINE; CELL CARCINOMA; BREAST-CANCER; HUMAN LIVER; EXPRESSION;
INDUCTION; PXR
AB Although subtypes of pancreatic ductal adenocarcinoma (PDAC) have been described, this malignancy is clinically still treated as a single disease. Here we present patient-derived models representing the full spectrum of previously identified quasi-mesenchymal (QM-PDA), classical and exocrine-like PDAC subtypes, and identify two markers HNF1A and KRT81 that enable stratification of tumors into different subtypes by using immunohistochemistry. Individuals with tumors of these subtypes showed substantial differences in overall survival, and their tumors differed in drug sensitivity, with the exocrine-like subtype being resistant to tyrosine kinase inhibitors and paclitaxel. Cytochrome P450 3A5 (CYP3A5) metabolizes these compounds in tumors of the exocrine-like subtype, and pharmacological or short hairpin RNA (shRNA)-mediated CYP3A5 inhibition sensitizes tumor cells to these drugs. Whereas hepatocyte nuclear factor 4, alpha (HNF4A) controls basal expression of CYP3A5, drug-induced CYP3A5 upregulation is mediated by the nuclear receptor NR112. CYP3A5 also contributes to acquired drug resistance in QM-PDA and classical PDAC, and it is highly expressed in several additional malignancies. These findings designate CYP3A5 as a predictor of therapy response and as a tumor cell-autonomous detoxification mechanism that must be overcome to prevent drug resistance.
C1 [Noll, Elisa M.; Eisen, Christian; Espinet, Elisa; Klein, Corinna; Vogel, Vanessa; Nadler, Wiebke; Roesli, Christoph; Engelhardt, Jan; Zickgraf, Franziska M.; Trumpp, Andreas; Sprick, Martin R.] Heidelberg Inst Stem Cell Technol & Expt Med HI S, Heidelberg, Germany.
[Noll, Elisa M.; Eisen, Christian; Espinet, Elisa; Nadler, Wiebke; Engelhardt, Jan; Zickgraf, Franziska M.; Trumpp, Andreas; Sprick, Martin R.] German Canc Res Ctr, Divison Stem Cells & Canc, Heidelberg, Germany.
[Stenzinger, Albrecht; Muckenhuber, Alexander; Weichert, Wilko] Heidelberg Univ, Dept Pathol, Heidelberg, Germany.
[Stenzinger, Albrecht; Weichert, Wilko] Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
[Klaus, Bernd] European Mol Biol Lab, Genome Biol Unit, Heidelberg, Germany.
[Lutz, Christian; Kulke, Michael] Heidelberg Pharma GmbH, Ladenburg, Germany.
[Espinosa, Octavio; Schlesner, Matthias; Eils, Roland] German Canc Res Ctr, Div Theoret Bioinformat, Heidelberg, Germany.
[Jiang, Xiaoqi; Kopp-Schneider, Annette] German Canc Res Ctr, Div Biostat, Heidelberg, Germany.
[Neuhaus, Peter; Bahra, Marcus] Charite, Dept Gen Visceral & Transplantat Surg, D-13353 Berlin, Germany.
[Sinn, Bruno V.] Charite, Inst Pathol, D-13353 Berlin, Germany.
[Eils, Roland] Heidelberg Univ, Bioquant, Inst Pharm & Mol Biotechnol, Heidelberg, Germany.
[Eils, Roland] German Canc Res Ctr, Heidelberg Ctr Personalized Oncol DKFZ HIPO, Heidelberg, Germany.
[Giese, Nathalia A.; Hackert, Thilo; Strobel, Oliver; Werner, Jens; Buechler, Markus W.] Univ Heidelberg Hosp, Dept Gen & Visceral Surg, Heidelberg, Germany.
[Buechler, Markus W.; Weichert, Wilko; Trumpp, Andreas; Sprick, Martin R.] German Canc Consortium DKTK, Heidelberg, Germany.
[Stenzinger, Albrecht] Massachusetts Gen Hosp, Dept Pathol, Ctr Integrated Diagnost, Boston, MA 02114 USA.
[Muckenhuber, Alexander; Weichert, Wilko] Tech Univ Munich, Inst Pathol, D-80290 Munich, Germany.
[Roesli, Christoph] Sandoz Biopharmaceut, Oberhaching, Germany.
[Werner, Jens] Univ Munich, Dept Gen Visceral & Transplant Surg, Munich, Germany.
RP Trumpp, A; Sprick, MR (reprint author), Heidelberg Inst Stem Cell Technol & Expt Med HI S, Heidelberg, Germany.; Trumpp, A; Sprick, MR (reprint author), German Canc Res Ctr, Divison Stem Cells & Canc, Heidelberg, Germany.; Trumpp, A; Sprick, MR (reprint author), German Canc Consortium DKTK, Heidelberg, Germany.
EM a.trumpp@dkfz.de; martin.sprick@hi-stem.de
RI Eils, Roland/B-6121-2009;
OI Eils, Roland/0000-0002-0034-4036; Sprick, Martin/0000-0001-9691-7574
FU DKFZ-HIPO [HIPO-015]; Dietmar Hopp Foundation; BioRN Spitzencluster
'Molecular- and Cell-based Medicine'; German Bundesministerium fur
Bildung and Forschung (BMBF) e:Med program for systems biology
(PANC-STRAT consortium) [01ZX1305]; Helmholtz Preclinical Comprehensive
Cancer Center; DKFZ-NCT program [NCT3.0]; NCT-Heidelberg School of
Oncology (HSO); EMBO long-term fellowship [ALTF 344-2013]; Heidelberger
Stiftung Chirurgie; BMBF [01GS08114]; Biomaterial Bank Heidelberg-BMBH
(BMBF) [01EY1101]
FX We thank E. Soyka, S. Bauer and A. Hieronymus for excellent technical
assistance. We also thank the microarray and the next-generation
sequencing (NGS) unit of the Genomics and Proteomics Core Facility,
DKFZ, for providing expression profiling, NGS and related services, and
all members of the flow cytometry core facility for excellent support.
We thank DKFZ-HIPO for technical support and funding through grant no.
HIPO-015 (M.S., R.E.,N.A.G., O.S., T.H., A.T. and M.R.S.). This work was
supported in part by the Dietmar Hopp Foundation and the BioRN
Spitzencluster 'Molecular- and Cell-based Medicine' (E.M.N., C.E., E.E.,
C.K., V.V., W.N., C.R., J.E., F.M.Z., A.T. and M.R.S.), the German
Bundesministerium fur Bildung and Forschung (BMBF) e:Med program for
systems biology (PANC-STRAT consortium, grant no. 01ZX1305; AT., M.R.S.,
MS., RE., N.A.G., T.H., O.S., A.S., A.M. and W.W.), the Helmholtz
Preclinical Comprehensive Cancer Center (E.E., A.T. and M.R.S.) and the
DKFZ-NCT program NCT3.0 (A.T., M.R.S., O.E., MS., RE., N.A.G., T.H. and
O.S.). A.S. was supported by a fellowship from the NCT-Heidelberg School
of Oncology (HSO). E.E. is recipient of an EMBO long-term fellowship
(ALTF 344-2013). The collection and processing of the specimens via
PancoBank was supported by Heidelberger Stiftung Chirurgie (M.W.B.),
BMBF (grant no. 01GS08114; M.W.B.) and Biomaterial Bank Heidelberg-BMBH
(BMBF grant no. 01EY1101; A.S. and WW.).
NR 58
TC 11
Z9 11
U1 4
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2016
VL 22
IS 3
BP 278
EP 287
DI 10.1038/nm.4038
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DF6DC
UT WOS:000371445100015
PM 26855150
ER
PT J
AU Schneider, RK
Schenone, M
Ferreira, MV
Kramann, R
Joyce, CE
Hartigan, C
Beier, F
Brummendorf, TH
Germing, U
Platzbecker, U
Busche, G
Knuchel, R
Chen, MC
Waters, CS
Chen, E
Chu, LP
Novina, CD
Lindsley, RC
Carr, SA
Ebert, BL
AF Schneider, Rebekka K.
Schenone, Monica
Ferreira, Monica Ventura
Kramann, Rafael
Joyce, Cailin E.
Hartigan, Christina
Beier, Fabian
Bruemmendorf, Tim H.
Germing, Ulrich
Platzbecker, Uwe
Buesche, Guntram
Knuechel, Ruth
Chen, Michelle C.
Waters, Christopher S.
Chen, Edwin
Chu, Lisa P.
Novina, Carl D.
Lindsley, R. Coleman
Carr, Steven A.
Ebert, Benjamin L.
TI Rps14 haploinsufficiency causes a block in erythroid differentiation
mediated by S100A8 and S100A9
SO NATURE MEDICINE
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; RISK MYELODYSPLASTIC SYNDROME;
DIAMOND-BLACKFAN ANEMIA; BONE-MARROW; MYELOID-LEUKEMIA; HUMAN
5Q-SYNDROME; SUPPRESSOR-CELLS; UP-REGULATION; DELETION 5Q; MOUSE MODEL
AB Impaired erythropoiesis in the deletion 5q (del(5q)) subtype of myelodysplastic syndrome (MDS) has been linked to heterozygous deletion of RPS14; which encodes the ribosomal protein small subunit 14. We generated mice with conditional inactivation of Rps14 and demonstrated an erythroid differentiation defect that is dependent on the tumor suppressor protein p53 (encoded by Trp53 in mice) and is characterized by apoptosis at the transition from polychromatic to orthochromatic erythroblasts. This defect resulted in age-dependent progressive anemia, megakaryocyte dysplasia and loss of hematopoietic stem cell (HSC) quiescence. As assessed by quantitative proteomics, mutant erythroblasts expressed higher levels of proteins involved in innate immune signaling, notably the heterodimeric S100 calcium-binding proteins S100a8 and S100a9. S100a8 whose expression was increased in mutant erythroblasts, monocytes and macrophages is functionally involved in the erythroid defect caused by the Rps14 deletion, as addition of recombinant S100a8 was sufficient to induce a differentiation defect in wild-type erythroid cells, and genetic inactivation of S100a8 expression rescued the erythroid differentiation defect of Rps14-haploinsufficient HSCs. Our data link Rps14 haploinsufficiency in del(5q) MDS to activation of the innate immune system and induction of S100A8-S100A9 expression, leading to a p53-dependent erythroid differentiation defect.
C1 [Schneider, Rebekka K.; Chen, Michelle C.; Waters, Christopher S.; Chen, Edwin; Chu, Lisa P.; Lindsley, R. Coleman; Ebert, Benjamin L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA.
[Schneider, Rebekka K.; Ferreira, Monica Ventura; Beier, Fabian; Bruemmendorf, Tim H.; Carr, Steven A.] Univ Hosp Rheinisch Westfal Tech Hsch RWTH Aachen, Dept Hematol Hemostaseol Oncol & Stem Cell Transp, Aachen, Germany.
[Schenone, Monica; Hartigan, Christina; Ebert, Benjamin L.] Broad Inst Harvard Univ & Massachusetts Inst Tech, Cambridge, MA USA.
[Kramann, Rafael] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA.
[Joyce, Cailin E.; Novina, Carl D.; Lindsley, R. Coleman] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Germing, Ulrich] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany.
[Platzbecker, Uwe] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Med 1, Dresden, Germany.
[Buesche, Guntram] Hannover Med Sch, Inst Pathol, Hannover, Germany.
[Knuechel, Ruth] Univ Hosp Rheinisch Westfal Tech Hsch RWTH Aachen, Inst Pathol, Aachen, Germany.
RP Ebert, BL (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA.; Ebert, BL (reprint author), Broad Inst Harvard Univ & Massachusetts Inst Tech, Cambridge, MA USA.
EM bebert@partners.org
FU US National Institutes of Health (NIH) [R01HL082945]; Gabrielle's Angel
Award; Leukemia and Lymphoma Society Scholar and Specialized Center of
Research (SCOR) award; German Research Foundation [DFG1188/3-1]; German
Cancer Aid (Deutsche Krebshilfe) [111750]; Edward P. Evans Foundation;
German Cluster of Excellence program Regenerative Biology to
Reconstructive Therapy (REBIRTH); confocal microscope facility, a core
facility of the Interdisciplinary Center for Clinical Research
(Interdisziplinares Zentrum fur klinische Forschung; IZKF) Aachen within
the Faculty of Medicine at RWTH Aachen University
FX This work was supported by the US National Institutes of Health (NIH)
(grant no. R01HL082945; B.L.E.), a Gabrielle's Angel Award (B.L.E.), a
Leukemia and Lymphoma Society Scholar and Specialized Center of Research
(SCOR) award (B.L.E.), the German Research Foundation (DFG1188/3-1;
R.K.S.), a Max Eder fellowship provided by the German Cancer Aid
(Deutsche Krebshilfe, grant no. 111750; R.K.S.), the Edward P. Evans
Foundation (R.K.S.) and the German Cluster of Excellence program
Regenerative Biology to Reconstructive Therapy (REBIRTH; to G.B.). We
thank D. Haase (Georg-August-Universitat Gottingen) for the cytogenetic
(karyotype) analysis in individuals with del(5q) MDS. This work was
supported by the confocal microscope facility, a core facility of the
Interdisciplinary Center for Clinical Research (Interdisziplinares
Zentrum fur klinische Forschung; IZKF) Aachen, within the Faculty of
Medicine at RWTH Aachen University.
NR 52
TC 12
Z9 12
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2016
VL 22
IS 3
BP 288
EP 297
DI 10.1038/nm.4047
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DF6DC
UT WOS:000371445100016
PM 26878232
ER
PT J
AU Beltran, H
Prandi, D
Mosquera, JM
Benelli, M
Puca, L
Cyrta, J
Marotz, C
Giannopoulou, E
Chakravarthi, BVSK
Varambally, S
Tomlins, SA
Nanus, DM
Tagawa, ST
Van Allen, EM
Elemento, O
Sboner, A
Garraway, LA
Rubin, MA
Demichelis, F
AF Beltran, Himisha
Prandi, Davide
Mosquera, Juan Miguel
Benelli, Matteo
Puca, Loredana
Cyrta, Joanna
Marotz, Clarisse
Giannopoulou, Eugenia
Chakravarthi, Balabhadrapatruni V. S. K.
Varambally, Sooryanarayana
Tomlins, Scott A.
Nanus, David M.
Tagawa, Scott T.
Van Allen, Eliezer M.
Elemento, Olivier
Sboner, Andrea
Garraway, Levi A.
Rubin, Mark A.
Demichelis, Francesca
TI Divergent clonal evolution of castration-resistant neuroendocrine
prostate cancer
SO NATURE MEDICINE
LA English
DT Article
ID SMALL-CELL CARCINOMA; INCREASED SURVIVAL; ADENOCARCINOMA; EZH2;
ENZALUTAMIDE; PROGRESSION; ABIRATERONE; REPRESSION; SIGNATURE; ESTROGEN
AB An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to absent AR expression and often have neuroendocrine features. The etiology and molecular basis for this 'alternative' treatment-resistant cell state remain incompletely understood. Here, by analyzing whole-exome sequencing data of metastatic biopsies from patients, we observed substantial genomic overlap between castration-resistant tumors that were histologically characterized as prostate adenocarcinomas (CRPC-Adeno) and neuroendocrine prostate cancer (CRPC-NE); analysis of biopsy samples from the same individuals over time points to a model most consistent with divergent clonal evolution. Genome-wide DNA methylation analysis revealed marked epigenetic differences between CRPC-NE tumors and CRPC-Adeno, and also designated samples of CRPC-Adeno with clinical features of AR independence as CRPC-NE, suggesting that epigenetic modifiers may play a role in the induction and/or maintenance of this treatment-resistant state. This study supports the emergence of an alternative, 'AR-indifferent' cell state through divergent clonal evolution as a mechanism of treatment resistance in advanced prostate cancer.
C1 [Beltran, Himisha; Mosquera, Juan Miguel; Puca, Loredana; Cyrta, Joanna; Marotz, Clarisse; Elemento, Olivier; Sboner, Andrea; Rubin, Mark A.; Demichelis, Francesca] Weill Cornell Med, New York Presbyterian Hosp, Caryl & Israel Englander Inst Precis Med, New York, NY USA.
[Beltran, Himisha; Nanus, David M.; Tagawa, Scott T.] Weill Cornell Med, Div Hematol & Med Oncol, Dept Med, New York, NY USA.
[Beltran, Himisha; Nanus, David M.; Tagawa, Scott T.; Rubin, Mark A.] Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY USA.
[Prandi, Davide; Benelli, Matteo; Demichelis, Francesca] Univ Trento, Ctr Integrat Biol, Trento, Italy.
[Mosquera, Juan Miguel; Sboner, Andrea; Rubin, Mark A.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA.
[Giannopoulou, Eugenia; Elemento, Olivier] Weill Cornell Med, Dept Physiol & Biophys, New York, NY USA.
[Chakravarthi, Balabhadrapatruni V. S. K.; Varambally, Sooryanarayana] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Tomlins, Scott A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Van Allen, Eliezer M.; Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Van Allen, Eliezer M.; Garraway, Levi A.] Broad Inst MIT & Harvard Univ, Cambridge, MA USA.
[Sboner, Andrea; Demichelis, Francesca] Weill Cornell Med, Inst Computat Biomed, New York, NY USA.
[Garraway, Levi A.] Dana Farber Canc Inst, Ctr Canc Precis Med, Boston, MA 02115 USA.
[Garraway, Levi A.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
RP Beltran, H (reprint author), Weill Cornell Med, New York Presbyterian Hosp, Caryl & Israel Englander Inst Precis Med, New York, NY USA.; Beltran, H (reprint author), Weill Cornell Med, Div Hematol & Med Oncol, Dept Med, New York, NY USA.; Beltran, H (reprint author), Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY USA.
EM hip9004@med.cornell.edu; rubinma@med.cornell.edu; f.demichelis@unitn.it
OI Prandi, Davide/0000-0001-9885-6074; Rubin, Mark/0000-0002-8321-9950;
Benelli, Matteo/0000-0003-1227-356X
FU Damon Runyon Cancer Research Foundation [CI-67-13]; Ann and William
Bresnan Foundation; Department of Defense [PC121341]; US National
Institutes of Health (NIH) [R01 CA116337, R01CA157845, R01 CA183857,
1K08CA188615, U54 HG003067, U01CA162148, 5U01 CA111275-09]; Starr Cancer
Consortium; American-Italian Cancer Foundation; Nuovo Soldati
Foundation; A. Alfred Taubman Medical Institute; Prostate Cancer
Foundation Young Investigator Award; Associazione Italians per la
Ricerca sul Cancro (AIRC) [IG 13562]; European Research Council;
Prostate Cancer Foundation; Stand Up To Cancer-Prostate Cancer
Foundation Prostate Dream Team translational cancer research grant;
Entertainment Industry Foundation [SU2C-AACR-DT0712]
FX We thank our patients and their families for participation in this
study. We would also like to acknowledge R. Montgomery, A. Armstrong and
R. Szmulewitz for contributing samples and S.S. Chae for his technical
assistance. H.B. is the Damon Runyon-Gordon Family Clinical Investigator
and is supported (in part) by the Damon Runyon Cancer Research
Foundation (award no. CI-67-13). This work was also supported by the Ann
and William Bresnan Foundation (H.B. and D.M.N.), the Department of
Defense (grant no. PC121341; H.B.), the US National Institutes of Health
(NIH) (grant no. R01 CA116337 (H.B., F.D. and M.A.R.), R01CA157845
(S.V.), R01 CA183857 (S.A.T.), 1K08CA188615 (E.M.V.A.), U54 HG003067
(L.A.G.), U01CA162148 (L.A.G.), 5U01 CA111275-09 (J.M.M., M.A.R. and
F.D.), the Starr Cancer Consortium (H.B., L.A.G. and M.A.R), the
American-Italian Cancer Foundation (L.P.), the Nuovo Soldati Foundation
(J.C.), the A. Alfred Taubman Medical Institute (S.A.T.), a Prostate
Cancer Foundation Young Investigator Award (E.M.V.A.), the Associazione
Italians per la Ricerca sul Cancro (AIRC; grant no. IG 13562; F.D.), the
European Research Council (consolidator grant (CoG) SPICE (Synthetic
lethal phenotype identification through cancer evolution analysis);
F.D.) and the Prostate Cancer Foundation (H.B., S.A.T., M.A.R. and
F.D.). H.B., J.M.M., SAT., D.M.N., S.T.T., E.M.V.A., O.E., AS., L.A.G.,
M.A.R and F.D. are supported by a Stand Up To Cancer-Prostate Cancer
Foundation Prostate Dream Team translational cancer research grant.
Stand Up To Cancer is a program of the Entertainment Industry Foundation
that is administered by the American Association for Cancer Research
(grant no. SU2C-AACR-DT0712).
NR 48
TC 53
Z9 53
U1 8
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2016
VL 22
IS 3
BP 298
EP 305
DI 10.1038/nm.4045
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DF6DC
UT WOS:000371445100017
PM 26855148
ER
PT J
AU Vegas, AJ
Veiseh, O
Gurtler, M
Millman, JR
Pagliuca, FW
Bader, AR
Doloff, JC
Li, J
Chen, M
Olejnik, K
Tam, HH
Jhunjhunwala, S
Langan, E
Aresta-Dasilva, S
Gandham, S
McGarrigle, JJ
Bochenek, MA
Hollister-Lock, J
Oberholzer, J
Greiner, DL
Weir, GC
Melton, DA
Langer, R
Anderson, DG
AF Vegas, Arturo J.
Veiseh, Omid
Guertler, Mads
Millman, Jeffrey R.
Pagliuca, Felicia W.
Bader, Andrew R.
Doloff, Joshua C.
Li, Jie
Chen, Michael
Olejnik, Karsten
Tam, Hok Hei
Jhunjhunwala, Siddharth
Langan, Erin
Aresta-Dasilva, Stephanie
Gandham, Srujan
McGarrigle, James J.
Bochenek, Matthew A.
Hollister-Lock, Jennifer
Oberholzer, Jose
Greiner, Dale L.
Weir, Gordon C.
Melton, Douglas A.
Langer, Robert
Anderson, Daniel G.
TI Long-term glycemic control using polymer-encapsulated human stem
cell-derived beta cells in immune-competent mice
SO NATURE MEDICINE
LA English
DT Article
ID IMMUNOCOMPETENT DIABETIC MICE; INSULIN-PRODUCING CELLS; ISLET
TRANSPLANTATION; NONIMMUNOSUPPRESSED PATIENTS; FOLLOW-UP; IN-VITRO;
IMMUNOISOLATION; MATURATION; ALLOGRAFTS; PRIMATES
AB The transplantation of glucose-responsive, insulin-producing cells offers the potential for restoring glycemic control in individuals with diabetes'. Pancreas transplantation and the infusion of cadaveric islets are currently implemented clinically(2), but these approaches are limited by the adverse effects of immunosuppressive therapy over the lifetime of the recipient and the limited supply of donor tissue(3). The latter concern may be addressed by recently described glucose-responsive mature beta cells that are derived from human embryonic stem cells (referred to as SC-beta cells), which may represent an unlimited source of human cells for pancreas replacement therapy(4). Strategies to address the immunosuppression concerns include immunoisolation of insulin-producing cells with porous biomaterials that function as an immune barrier(5,6). However, clinical implementation has been challenging because of host immune responses to the implant materials(7). Here we report the first long-term glycemic correction of a diabetic, immunocompetent animal model using human SC-beta cells. SC-beta cells were encapsulated with alginate derivatives capable of mitigating foreign-body responses in vivo and implanted into the intraperitoneal space of C57BL/6J mice treated with streptozotocin, which is an animal model for chemically induced type 1 diabetes. These implants induced glycemic correction without any immunosuppression until their removal at 174 d after implantation. Human C-peptide concentrations and in vivo glucose responsiveness demonstrated therapeutically relevant glycemic control. Implants retrieved after 174 d contained viable insulin-producing cells.
C1 [Vegas, Arturo J.; Veiseh, Omid; Bader, Andrew R.; Doloff, Joshua C.; Li, Jie; Chen, Michael; Olejnik, Karsten; Tam, Hok Hei; Jhunjhunwala, Siddharth; Langan, Erin; Aresta-Dasilva, Stephanie; Gandham, Srujan; Langer, Robert; Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Vegas, Arturo J.; Veiseh, Omid; Bader, Andrew R.; Doloff, Joshua C.; Li, Jie; Chen, Michael; Olejnik, Karsten; Tam, Hok Hei; Jhunjhunwala, Siddharth; Langan, Erin; Aresta-Dasilva, Stephanie; Gandham, Srujan; Langer, Robert; Anderson, Daniel G.] Boston Childrens Hosp, Dept Anesthesiol, Boston, MA USA.
[Veiseh, Omid; Tam, Hok Hei; Langer, Robert; Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Guertler, Mads; Millman, Jeffrey R.; Pagliuca, Felicia W.; Melton, Douglas A.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[McGarrigle, James J.; Bochenek, Matthew A.; Oberholzer, Jose] Univ Illinois, Dept Surg, Div Transplantat, Chicago, IL 60680 USA.
[Hollister-Lock, Jennifer; Weir, Gordon C.] Joslin Diabet Ctr, Div Res, Sect Islet Cell & Regenerat Biol, 1 Joslin Pl, Boston, MA 02215 USA.
[Greiner, Dale L.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA.
[Melton, Douglas A.] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
[Langer, Robert; Anderson, Daniel G.] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Langer, Robert; Anderson, Daniel G.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Vegas, Arturo J.] Boston Univ, Dept Chem, 590 Commonwealth Ave, Boston, MA 02215 USA.
[Bader, Andrew R.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Millman, Jeffrey R.] Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO USA.
[Millman, Jeffrey R.] Washington Univ, Dept Biomed Engn, St Louis, MO USA.
RP Anderson, DG (reprint author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Anderson, DG (reprint author), Boston Childrens Hosp, Dept Anesthesiol, Boston, MA USA.; Anderson, DG (reprint author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.; Anderson, DG (reprint author), MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.; Anderson, DG (reprint author), MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM dgander@mit.edu
OI Chen, Michael/0000-0002-1590-768X
FU JDRF; Leona M. and Harry B. Helmsley Charitable Trust
[3-SRA-2014-285-M-R]; US National Institutes of Health [EB000244,
EB000351, DE013023, CA151884, UC4DK104218]; Department of Defense
Congressionally Directed Medical Research Program (DOD/CDMRP)
postdoctoral fellowships [3-2013-178, W81XWH-13-1-0215]; Harvard Stem
Cell Institute; Chicago Diabetes Project
FX This work was supported jointly by the JDRF and the Leona M. and Harry
B. Helmsley Charitable Trust (grant no. 3-SRA-2014-285-M-R (R.L. and
D.G.A.)), the US National Institutes of Health (grants EB000244 (R.L.),
EB000351 (R.L.), DE013023 (R.L.), CA151884 (R.L.) and UC4DK104218
(D.L.G.)), and through a generous gift from the Tayebati Family
Foundation (D.G.A. and R.L.). O.V. was supported by JDRF and Department
of Defense Congressionally Directed Medical Research Program (DOD/CDMRP)
postdoctoral fellowships (grants 3-2013-178 and W81XWH-13-1-0215,
respectively). J.R.M. was supported by a fellowship from the Harvard
Stem Cell Institute. J.O. is supported by the Chicago Diabetes Project.
The authors acknowledge R. Bogorad for useful discussions and,
assistance and the Koch Institute Swanson Biotechnology Center for
technical support, specifically for the use of the Hope Babette Tang
Histology, Microscopy, Flow Cytometry and Animal Imaging and preclinical
testing core facilities. We acknowledge the use of imaging resources at
the Harvard University Center for Nanoscale Systems, the W.M. Keck
Biological Imaging Facility (Whitehead Institute) and the histology core
of the Harvard Stem Cell Institute. We would like to thank A. Graham, W
Salmon, C. MacGillivray and J. Wyckoff for their assistance.
NR 35
TC 46
Z9 46
U1 36
U2 97
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2016
VL 22
IS 3
BP 306
EP 311
DI 10.1038/nm.4030
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DF6DC
UT WOS:000371445100018
PM 26808346
ER
PT J
AU Bleier, BS
Kohman, RE
Guerra, K
Nocera, AL
Ramanlal, S
Kocharyan, AH
Curry, WT
Han, X
AF Bleier, Benjamin S.
Kohman, Richie E.
Guerra, Kevin
Nocera, Angela L.
Ramanlal, Shreshtha
Kocharyan, Armine H.
Curry, William T.
Han, Xue
TI Heterotopic Mucosal Grafting Enables the Delivery of Therapeutic
Neuropeptides Across the Blood Brain Barrier
SO NEUROSURGERY
LA English
DT Article
DE Blood-brain barrier; Drug delivery; Glial cell line-derived neurotrophic
factor; Parkinson disease; Therapeutic protein
ID NIGROSTRIATAL 6-HYDROXYDOPAMINE LESIONS; SKULL BASE RECONSTRUCTION;
CEREBROSPINAL-FLUID LEAKS; PARKINSONS-DISEASE; INTRAVENOUS DELIVERY;
NEUROTROPHIC FACTOR; INTRANASAL INSULIN; NASOSEPTAL FLAP; MOUSE MODEL;
NASAL
C1 [Bleier, Benjamin S.; Nocera, Angela L.; Kocharyan, Armine H.] Harvard Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Massachusetts Eye & Ear Infirm, Boston, MA USA.
[Kohman, Richie E.; Guerra, Kevin; Ramanlal, Shreshtha; Han, Xue] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Curry, William T.] Harvard Univ, Dept Neurosurg, Massachusetts Gen Hosp, Boston, MA USA.
RP Bleier, BS (reprint author), Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA.
EM benjamin_bleier@meei.harvard.edu
FU Michael J. Fox Foundation for Parkinson's Research Rapid Response
Innovation Award
FX This study was funded by the Michael J. Fox Foundation for Parkinson's
Research Rapid Response Innovation Award. Dr Bleier has a patent on the
clinical surgical technique described in the manuscript that is assigned
to his institution, which also oversees and manages his conflict of
interest policies. The authors have no personal, financial, or
institutional interest in any of the drugs, materials, or devices
described in this article.
NR 46
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD MAR
PY 2016
VL 78
IS 3
BP 448
EP 457
DI 10.1227/NEU.0000000000001016
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA DE2DY
UT WOS:000370438000035
PM 26352099
ER
PT J
AU Saleh, MG
Alhamud, A
Near, J
van der Kouwe, AJW
Meintjes, EM
AF Saleh, Muhammad G.
Alhamud, A.
Near, Jamie
van der Kouwe, Andre J. W.
Meintjes, Ernesta M.
TI Volumetric navigated MEGA-SPECIAL for real-time motion and shim
corrected GABA editing
SO NMR IN BIOMEDICINE
LA English
DT Article
DE GABA; MEGA-SPECIAL; edited spectrum; prospective correction; real-time
motion correction; real-time shim correction; zero-order shim term;
first-order shim term
ID MAGNETIC-RESONANCE-SPECTROSCOPY; IN-VIVO; 3 TESLA; BRAIN; FREQUENCY;
ECHOES; FMRI; MRS
AB Mescher-Garwood (MEGA) editing with spin echo full intensity acquired localization (MEGA-SPECIAL, MSpc) is a technique to acquire -aminobutyric acid (GABA) without macromolecule (MM) contamination at a T-E of 68 ms. However, due to the requirement of multiple shot-localization, it is often susceptible to subject motion and B-0 inhomogeneity. A method is presented for real-time shim and motion correction (ShMoCo) using volumetric navigators to correct for motion and motion-related B-0 inhomogeneity during MSpc acquisition. A phantom experiment demonstrates that ShMoCo restores the GABA peak and improves spectral quality in the presence of motion and zero- and first-order shim changes. The ShMoCo scans were validated in three subjects who performed up-down and left-right head rotations. Qualitative assessment of these scans indicates effective reduction of subtraction artefacts and well edited GABA peaks, while quantitative analysis indicates superior fitting and spectral quality relative to scans with no correction. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Saleh, Muhammad G.; Alhamud, A.; Meintjes, Ernesta M.] Univ Cape Town, MRC UCT Med Imaging Res Unit, Dept Human Biol, ZA-7925 Cape Town, Western Cape, South Africa.
[Near, Jamie] McGill Univ, Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada.
[Near, Jamie] McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
[van der Kouwe, Andre J. W.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
RP Saleh, MG (reprint author), Univ Cape Town, MRC UCT Med Imaging Res Unit, Human Biol, ZA-7925 Cape Town, Western Cape, South Africa.
EM mgsaleh7@gmail.com
FU NRF/DST South African Research Chairs Initiative; NIH [R01HD071664];
South African Medical Research Council (MRC)
FX Support was provided by the NRF/DST South African Research Chairs
Initiative, NIH grant R01HD071664 and the South African Medical Research
Council (MRC).
NR 31
TC 2
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-3480
EI 1099-1492
J9 NMR BIOMED
JI NMR Biomed.
PD MAR
PY 2016
VL 29
IS 3
BP 248
EP 255
DI 10.1002/nbm.3454
PG 8
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA DF5XK
UT WOS:000371426000005
PM 26663075
ER
PT J
AU Barth, WH
AF Barth, William H., Jr.
TI Lost in Translation The Changing Language of Our Specialty
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Editorial Material
ID NATIONAL-INSTITUTE; CHILD-HEALTH; DEFINITIONS; TERMINOLOGY; WORKSHOP;
SOCIETY
C1 [Barth, William H., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Div Maternal Fetal Med, Boston, MA USA.
RP Barth, WH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Div Maternal Fetal Med, Boston, MA USA.
EM wbarthjr@mgh.harvard.edu
NR 8
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD MAR
PY 2016
VL 127
IS 3
BP 423
EP 425
DI 10.1097/AOG.0000000000001326
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DE6DE
UT WOS:000370723000001
PM 26855113
ER
PT J
AU Solomon, DH
Ruppert, K
Zhao, Z
Lian, YJ
Kuo, IH
Greendale, GA
Finkelstein, JS
AF Solomon, D. H.
Ruppert, K.
Zhao, Z.
Lian, Y. J.
Kuo, I. -H.
Greendale, G. A.
Finkelstein, J. S.
TI Bone mineral density changes among women initiating blood pressure
lowering drugs: a SWAN cohort study
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Cohort; Epidemiology; Hypertension; Osteoporosis
ID CONVERTING ENZYME-INHIBITOR; POSTMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY;
CONTROLLED-TRIAL; HEART-DISEASE; BETA-BLOCKERS; HYDROCHLOROTHIAZIDE;
OSTEOPOROSIS; PREVENTION; FRACTURES
AB A Summary We examined the effect of blood pressure lowering drugs on BMD using data from the Study of Women's Health Across the Nation. Thiazide users had a slower decline in BMD compared to nonusers, while decline among ACE inhibitor and beta blocker users were similar to rates in nonusers.
Introduction Several blood pressure lowering drugs may affect bone mineral density (BMD), leading to altered fracture risk. We examined the effect of blood pressure lowering drugs on BMD using data from the Study of Women's Health Across the Nation.
Methods We conducted a propensity score matched cohort study. Women were initiators of ACE inhibitors (ACEi), beta-blockers (BB), or thiazide diuretics (THZD). Their annualized BMD changes during the 14 years of observation were compared with nonusers.
Results Among the 2312 eligible women, we found 69 ACEi, 71 BB, and 74 THZD users who were matched by a propensity score with the same number of nonusers. THZD users had a slower annual percent decline in BMD compared to nonusers at the femoral neck (FN) (-0.28 % vs -0.88 %; p=0.008) and the spine (-0.74 % vs -1.0 %; p=0.34), albeit not statistically significant. Annual percent changes in BMD among ACEi and BB users were similar to rates in nonusers. In comparison with BB, THZD use was associated with a trend toward less annualized BMD loss at the spine (-0.35 % vs -0.60 %; p=0.08) and a similar trend at the FN (-0.39 % vs -0.64 %; p=0.08); in comparisons with ACEi, THZD was also associated with less loss at the FN (-0.48 % vs -0.82 %; p=0.02), but not at the spine (-0.40 % vs -0.56 %; p=0.23).
Conclusions Neither ACEi nor BB was associated with improvements in BMD. THZD use was associated with less annualized loss of BMD compared with nonusers, as well as compared with ACEi and BB.
C1 [Solomon, D. H.; Lian, Y. J.; Kuo, I. -H.] Brigham & Womens Hosp, Div Rheumatol, 75 Francis St, Boston, MA 02115 USA.
[Solomon, D. H.] Brigham & Womens Hosp, Div Pharmacoepidemiol, 75 Francis St, Boston, MA 02115 USA.
[Ruppert, K.; Zhao, Z.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Zhao, Z.; Lian, Y. J.] Univ Pittsburgh, Dept Epidemiol, Div Epidemiol & Community Hlth, Pittsburgh, PA 15261 USA.
[Greendale, G. A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Finkelstein, J. S.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
RP Solomon, DH (reprint author), Brigham & Womens Hosp, Div Rheumatol, 75 Francis St, Boston, MA 02115 USA.; Solomon, DH (reprint author), Brigham & Womens Hosp, Div Pharmacoepidemiol, 75 Francis St, Boston, MA 02115 USA.
EM dsolomon@partners.org; ruppertk@pitt.edu; zhpzhao@126.com;
liany@edc.pitt.edu; ikuo1@partners.org; ggreenda@mednet.ucla.edu;
jfinkelstein@partners.org
RI Ruppert, Kristine/C-2555-2016
OI Ruppert, Kristine/0000-0002-3008-6584
FU National Institutes of Health (NIH), DHHS, through the National
Institute on Aging (NIA); National Institute of Nursing Research (NINR);
NIH Office of Research on Women's Health (ORWH) [NR004061, AG012505,
AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495]
FX The Study of Women's Health Across the Nation (SWAN) has grant support
from the National Institutes of Health (NIH), DHHS, through the National
Institute on Aging (NIA), the National Institute of Nursing Research
(NINR), and the NIH Office of Research on Women's Health (ORWH) (Grants
NR004061; AG012505, AG012535, AG012531, AG012539, AG012546, AG012553,
AG012554, AG012495). The funding agencies had no direct role in the
design or conduct of the study, the collection, management, analyses,
and interpretation of the data, or preparation or approval of the
manuscript.
NR 29
TC 4
Z9 4
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2016
VL 27
IS 3
BP 1181
EP 1189
DI 10.1007/s00198-015-3332-6
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DF4IO
UT WOS:000371311400037
PM 26449354
ER
PT J
AU Raol, N
Zogg, CK
Boss, EF
Weissman, JS
AF Raol, Nikhila
Zogg, Cheryl K.
Boss, Emily F.
Weissman, Joel S.
TI Inpatient Pediatric Tonsillectomy: Does Hospital Type Affect Cost and
Outcomes of Care?
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE cost of care; cost variation; tonsillectomy; children's hospitals;
academic medical centers; teaching hospitals
ID FREESTANDING CHILDRENS HOSPITALS; CONGENITAL HEART-SURGERY;
UNITED-STATES; ADENOTONSILLECTOMY COSTS; VOLUME; APPENDICITIS;
MORTALITY; QUALITY; OTOLARYNGOLOGY; MANAGEMENT
AB Objective To ascertain whether hospital type is associated with differences in total cost and outcomes for inpatient tonsillectomy.
Study Design Cross-sectional analysis of the 2006, 2009, and 2012 Kids' Inpatient Database (KID).
Subjects and Methods Children 18 years of age undergoing tonsillectomy with/without adenoidectomy were included. Risk-adjusted generalized linear models assessed for differences in hospital cost and length of stay (LOS) among children managed by (1) non-children's teaching hospitals (NCTHs), (2) children's teaching hospitals (CTHs), and (3) nonteaching hospitals (NTHs). Risk-adjusted logistic regression compared the odds of major perioperative complications (hemorrhage, respiratory failure, death). Models accounted for clustering of patients within hospitals, were weighted to provide national estimates, and controlled for comorbidities.
Results The 25,685 tonsillectomies recorded in the KID yielded a national estimate of 40,591 inpatient tonsillectomies performed in 2006, 2009, and 2012. The CTHs had significantly higher risk-adjusted total cost and LOS per tonsillectomy compared with NCTHs and NTHs ($9423.34/2.8 days, $6250.78/2.11 days, and $5905.10/2.08 days, respectively; P < .001). The CTHs had higher odds of complications compared with NCTHs (odds ratio [OR], 1.48; 95% CI, 1.15-1.91; P = .002) but not when compared with NTHs (OR, 1.19; 95% CI, 0.89-1.59; P = .23). The CTHs were significantly more likely to care for patients with comorbidities (P < .001).
Conclusion Significant differences in costs, outcomes, and patient factors exist for inpatient tonsillectomy based on hospital type. Although reasons for these differences are not discernable using isolated claims data, findings provide a foundation to further evaluate patient, institutional, and system-level factors that may reduce cost of care and improve value for inpatient tonsillectomy.
C1 [Raol, Nikhila; Zogg, Cheryl K.; Weissman, Joel S.] Harvard Univ, Sch Med, Ctr Surg & Publ Hlth, Boston, MA USA.
[Raol, Nikhila; Zogg, Cheryl K.; Weissman, Joel S.] Brigham & Womens Hosp, Harvard TH Chan Sch Publ Hlth, Dept Surg, One Brigham Circle,1620 Tremont St ,4-020, Boston, MA 02120 USA.
[Raol, Nikhila] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol, Boston, MA USA.
[Boss, Emily F.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.
[Boss, Emily F.] Johns Hopkins Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA.
RP Raol, N (reprint author), Brigham & Womens Hosp, Ctr Surg & Publ Hlth, One Brigham Circle,1620 Tremont St ,4-020, Boston, MA 02120 USA.
EM nraol@partners.org
FU Agency for Healthcare Research and Quality [1K08 HS22932-01]; Johns
Hopkins Clinician Scientist Award; American Society of Pediatric
Otolaryngology Career Development Award
FX Emily F. Boss received a grant (1K08 HS22932-01) from the Agency for
Healthcare Research and Quality, the Johns Hopkins Clinician Scientist
Award, and the American Society of Pediatric Otolaryngology Career
Development Award. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
Agency for Healthcare Research and Quality.
NR 32
TC 4
Z9 4
U1 2
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD MAR
PY 2016
VL 154
IS 3
BP 486
EP 493
DI 10.1177/0194599815621739
PG 8
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA DF4JY
UT WOS:000371315100014
PM 26701174
ER
PT J
AU Naunheim, MR
Plotkin, SR
Franco, RA
Song, PC
AF Naunheim, Matthew R.
Plotkin, Scott R.
Franco, Ramon A.
Song, Phillip C.
TI Laryngeal Manifestations of Neurofibromatosis
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE neurofibromatosis; neurofibroma; NF-1; NF-2; vocal cord paralysis
ID TYPE-1; PATIENT; ADULTS; MANAGEMENT
AB Objectives To describe the range of findings in patients with neurofibromatosis (NF) presenting to a laryngology clinic and to analyze the etiologic factors of vocal fold dysfunction in this cohort.
Study Design Case series with chart review.
Setting Tertiary laryngology practice.
Subjects and Methods All cases of NF presenting to an academic laryngology practice were retrospectively reviewed (August 2005 to May 2014), with a total of 34 cases. Demographic data, symptoms, and endoscopic examination findings were reviewed. Etiologic factors of laryngeal complaints were analyzed with reference to NF-associated pathologies and surgical history.
Results Thirty-four patients with NF-1 or NF-2 were evaluated, and 28 of these patients (6 NF-1 and 22 NF-2) had laryngeal pathology. The most common presenting symptoms were vocal weakness (n = 21), dysphagia (n = 5), and globus (n = 4). Three patients had NF-related vocal fold masses on examination, including 2 neurofibromas and 1 schwannoma. Unilateral vocal cord paralysis was seen in 17 patients; bilateral paralysis was observed in 5 patients. Of patients with unilateral or bilateral paralysis, 20 had intracranial masses (vestibular schwannoma, meningioma, or skull base tumors), and 16 had previously undergone surgery for these lesions. Of the patients with NF-associated intracranial tumors, 87.0% presented with vocal cord paralysis, whereas only 40.0% of those without intracranial masses had paralysis (P = .0560). Seven patients underwent medialization procedures.
Conclusion Neurofibromatosis patients may present to laryngology clinic with primary laryngeal tumors or, more commonly, unilateral or bilateral paralysis. Otolaryngologists should be keenly aware of vocal fold paralysis caused by the NF-associated tumors, with particular attention to bilateral paralysis in NF-2.
C1 [Naunheim, Matthew R.; Franco, Ramon A.; Song, Phillip C.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
[Naunheim, Matthew R.; Franco, Ramon A.; Song, Phillip C.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Naunheim, MR (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM Matthew_Naunheim@meei.harvard.edu
NR 22
TC 0
Z9 0
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD MAR
PY 2016
VL 154
IS 3
BP 494
EP 497
DI 10.1177/0194599815626133
PG 4
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA DF4JY
UT WOS:000371315100015
PM 26786267
ER
PT J
AU Anthony, L
Horsch, D
Ervin, C
Kulke, MH
Pavel, M
Bergsland, E
Caplin, M
Oeberg, K
Warner, R
Kunz, P
Metz, DC
Pasieka, J
Pavlakis, N
DiBenedetti, D
Haydysch, E
Yang, QM
Jackson, S
Arnold, K
Law, L
Lapuerta, P
AF Anthony, Lowell
Hoersch, Dieter
Ervin, Claire
Kulke, Matthew H.
Pavel, Marianne
Bergsland, Emily
Caplin, Martyn
Oberg, Kjell
Warner, Richard
Kunz, Pamela
Metz, David C.
Pasieka, Janice
Pavlakis, Nick
DiBenedetti, Dana
Haydysch, Emily
Yang, Qi Melissa
Jackson, Shanna
Arnold, Karie
Law, Linda
Lapuerta, Pablo
TI Assessing Treatment Benefit of Telotristat Etiprate in Patients with
Carcinoid Syndrome: Patient Exit Interviews
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Anthony, Lowell] Univ Kentucky, Lexington, KY USA.
[Hoersch, Dieter] Zentralklin Bad Berka, Bad Berka, Germany.
[Ervin, Claire; DiBenedetti, Dana; Haydysch, Emily] RTI Hlth Solut, Res Triangle Pk, NC USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pavel, Marianne] Charite, D-13353 Berlin, Germany.
[Bergsland, Emily] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Caplin, Martyn] Royal Free Hosp, Pond St, London NW3 2QG, England.
[Oberg, Kjell] Uppsala Univ, Uppsala, Sweden.
[Warner, Richard] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Kunz, Pamela] Stanford Univ, Palo Alto, CA 94304 USA.
[Metz, David C.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Pasieka, Janice] Tom Baker Canc Ctr Calgary, Calgary, AB, Canada.
[Pavlakis, Nick] Royal N Shore Hosp, St Leonards, NSW 2065, Australia.
[Yang, Qi Melissa; Jackson, Shanna; Arnold, Karie; Law, Linda; Lapuerta, Pablo] Lexicon Pharmaceut Inc, The Woodlands, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 470
EP 470
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600035
ER
PT J
AU Fisher, MD
Pulgar, S
Kulke, MH
Lowenthal, SP
Cox, D
Miller, PJ
Walker, MS
Schwartzberg, LS
AF Fisher, Maxine D.
Pulgar, Sonia
Kulke, Matthew H.
Lowenthal, Susan Pitman
Cox, David
Miller, Paul J.
Walker, Mark S.
Schwartzberg, Lee S.
TI Treatment Patterns and Outcomes in Metastatic Neuroendocrine Tumors:
Results From a Retrospective Community Oncology Database
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Fisher, Maxine D.; Miller, Paul J.; Walker, Mark S.] Vector Oncol, Memphis, TN USA.
[Pulgar, Sonia; Lowenthal, Susan Pitman; Cox, David] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Program Neuroendocrine & Carcinoid Tumors, Boston, MA 02115 USA.
[Schwartzberg, Lee S.] West Clin, Memphis, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 475
EP 475
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600050
ER
PT J
AU Kulke, MH
Niedzwiecki, D
Foster, NR
Fruth, B
Kunz, PL
Kennecke, H
Wolin, EM
Venook, AP
AF Kulke, Matthew H.
Niedzwiecki, Donna
Foster, Nathan R.
Fruth, Briant
Kunz, Pamela L.
Kennecke, Hagen
Wolin, Edward M.
Venook, Alan P.
TI Randomized Phase II Study of Everolimus (E) Versus Everolimus plus
Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or
Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701
(Alliance)
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Niedzwiecki, Donna] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA.
[Niedzwiecki, Donna] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA.
[Foster, Nathan R.; Fruth, Briant] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA.
[Kunz, Pamela L.] Stanford Canc Inst, Palo Alto, CA USA.
[Kennecke, Hagen] BC Canc Agcy, Vancouver Ctr, Vancouver, CA USA.
[Wolin, Edward M.] Univ Kentucky, Lexington, KY USA.
[Venook, Alan P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 477
EP 477
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600057
ER
PT J
AU Kulke, MH
Horsch, D
Caplin, M
Anthony, L
Bergsland, E
Oberg, K
Welin, S
Warner, R
Lombard-Bohas, C
Kunz, P
Grande, E
Valle, JW
Fleming, D
Lapuerta, P
Banks, P
Jackson, S
Wheeler, D
Zambrowicz, B
Sands, A
Pavel, M
AF Kulke, Matthew H.
Hoersch, Dieter
Caplin, Martyn
Anthony, Lowell
Bergsland, Emily
Oberg, Kjell
Welin, Staffan
Warner, Richard
Lombard-Bohas, Catherine
Kunz, Pamela
Grande, Enrique
Valle, Juan W.
Fleming, Douglas
Lapuerta, Pablo
Banks, Phillip
Jackson, Shanna
Wheeler, Darren
Zambrowicz, Brian
Sands, Arthur
Pavel, Marianne
TI Telotristat Etiprate Shows Benefit in Treating Patients With Carcinoid
Syndrome That is Inadequately Controlled by Somatostatin Analog Therapy
in the Phase 3 TELESTAR Clinical Trial
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hoersch, Dieter] Zentralklin Bad Berka, Bad Berka, Germany.
[Caplin, Martyn] Royal Free Hosp, Pond St, London NW3 2QG, England.
[Anthony, Lowell] Univ Kentucky, Lexington, KY USA.
[Bergsland, Emily] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Oberg, Kjell; Welin, Staffan] Uppsala Univ, Uppsala, Sweden.
[Warner, Richard] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Lombard-Bohas, Catherine] Hos Civils Lyon, Hop Edouard Herriot, Lyon, France.
[Kunz, Pamela] Stanford Univ, Palo Alto, CA 94304 USA.
[Grande, Enrique] Hosp Univ Ramon & Cajal, Madrid, Spain.
[Valle, Juan W.] Univ Manchester, Christie NHS Fdon Trust, Manchester, Lancs, England.
[Fleming, Douglas] Ipsen BioSci, Cambridge, MA USA.
[Lapuerta, Pablo; Banks, Phillip; Jackson, Shanna; Wheeler, Darren; Zambrowicz, Brian; Sands, Arthur] Lexicon Pharmaceut Inc, The Woodlands, TX USA.
[Pavel, Marianne] Charite, D-13353 Berlin, Germany.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 478
EP 478
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600058
ER
PT J
AU Reidy-Lagunes, D
Wolin, EM
Pitman-Lowenthal, S
Cox, D
Kulke, MH
AF Reidy-Lagunes, Diane
Wolin, Edward M.
Pitman-Lowenthal, Susan
Cox, David
Kulke, Matthew H.
TI Design of a Phase 2, Prospective, Randomized, Double-Blind,
Placebo-Controlled Study Assessing the Efficacy and Safety of Lanreotide
Depot 120 mg in Patients With Well Differentiated, Advanced Lung, or
Thymus Neuroendocrine Tumors (NETs)
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Reidy-Lagunes, Diane] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Wolin, Edward M.] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
[Pitman-Lowenthal, Susan; Cox, David] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Program Neuroendocrine & Carcinoid Tumors, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 480
EP 481
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600067
ER
PT J
AU Strosberg, J
Wolin, E
Chasen, B
Kulke, M
Bushnell, D
Caplin, M
Baum, RP
Mittra, E
Hobday, T
Hendifar, A
Oberg, K
Sierra, ML
Kwekkeboom, D
Ruszniewski, P
Krenning, E
AF Strosberg, Jonathan
Wolin, Edward
Chasen, Beth
Kulke, Matthew
Bushnell, David
Caplin, Martyn
Baum, Richard P.
Mittra, Erik
Hobday, Timothy
Hendifar, Andrew
Oberg, Kjell
Sierra, Maribel Lopera
Kwekkeboom, Dik
Ruszniewski, Philippe
Krenning, Eric
TI 177-Lu-Dotatate Significantly Improves Progression-Free Survival in
Patients with Midgut Neuroendocrine Tumors: Results of the Phase III
NETTER-1 Trial
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Strosberg, Jonathan] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Wolin, Edward] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
[Chasen, Beth] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Kulke, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bushnell, David] Univ Iowa, Iowa City, IA USA.
[Caplin, Martyn] Royal Free Hosp, Pond St, London NW3 2QG, England.
[Baum, Richard P.] Zentralklin, Bad Berka, Germany.
[Mittra, Erik] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Hobday, Timothy] Mayo Clin, Coll Med, Rochester, MN USA.
[Hendifar, Andrew] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Oberg, Kjell] Uppsala Univ, Univ Hosp, Uppsala, Sweden.
[Sierra, Maribel Lopera] Adv Accelerator Applicat, New York, NY USA.
[Kwekkeboom, Dik; Krenning, Eric] Erasmus MC, Rotterdam, Netherlands.
[Ruszniewski, Philippe] Hop Beaujon, Clichy, France.
NR 0
TC 1
Z9 1
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 483
EP 483
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600073
ER
PT J
AU Ter-Minassian, M
Brooks, NV
Brais, LK
Chan, JA
Christiani, DC
Lin, XH
Gabriel, S
Dinet, J
Kulke, MH
AF Ter-Minassian, Monica
Brooks, Nichole V.
Brais, Lauren K.
Chan, Jennifer A.
Christiani, David C.
Lin, Xihong
Gabriel, Sylvie
Dinet, Jerome
Kulke, Matthew H.
TI Patterns and Sequencing of Systemic Therapies in Patients With Advanced
Neuroendocrine Tumors (NET)
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Ter-Minassian, Monica; Brooks, Nichole V.; Brais, Lauren K.; Chan, Jennifer A.; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Lin, Xihong] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Gabriel, Sylvie; Dinet, Jerome] Ipsen Pharma, Boulogne, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 483
EP 483
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600075
ER
PT J
AU Ter-Minassian, M
Brooks, NV
Brais, LK
Chan, JA
Christiani, DC
Lin, XH
Gabriel, S
Dinet, J
Kulke, MH
AF Ter-Minassian, Monica
Brooks, Nichole V.
Brais, Lauren K.
Chan, Jennifer A.
Christiani, David C.
Lin, Xihong
Gabriel, Sylvie
Dinet, Jerome
Kulke, Matthew H.
TI Association of Progression-Free Survival With Overall Survival in
Patients With Neuroendocrine Tumor Treated With Somatostatin Analogs
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Ter-Minassian, Monica; Brooks, Nichole V.; Brais, Lauren K.; Chan, Jennifer A.; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Lin, Xihong] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Gabriel, Sylvie; Dinet, Jerome] Ipsen Pharma, Boulogne, France.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 483
EP 483
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600074
ER
PT J
AU Van Loon, K
Zhang, L
Creasman, J
Bobiak, S
Zornosa, CC
Choti, MA
Kulke, M
Yao, JC
Nakakura, EK
Bloomston, M
Benson, AB
Shah, MH
Strosberg, JR
Bergsland, EK
AF Van Loon, Katherine
Zhang, Li
Creasman, Jennifer
Bobiak, Sarah
Zornosa, Carrie C.
Choti, Michael A.
Kulke, Matthew
Yao, James C.
Nakakura, Eric K.
Bloomston, Mark
Benson, Al B.
Shah, Manisha H.
Strosberg, Jonathan R.
Bergsland, Emily K.
TI Recurrence Patterns Following Surgical Resection of
Gastroenteropancreatic Neuroendocrine Tumors: An Analysis From the NCCN
Oncology Outcomes Database
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Van Loon, Katherine; Zhang, Li; Creasman, Jennifer; Nakakura, Eric K.; Bergsland, Emily K.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Bobiak, Sarah; Zornosa, Carrie C.] Natl Comprehens Canc Network, Ft Washington, PA USA.
[Choti, Michael A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Kulke, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yao, James C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bloomston, Mark; Shah, Manisha H.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Benson, Al B.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Strosberg, Jonathan R.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 484
EP 484
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600076
ER
PT J
AU Yao, JC
Fazio, N
Singh, S
Buzzoni, R
Carnaghi, C
Wolin, E
Tomasek, J
Raderer, M
Lahner, H
Voi, M
Pacaud, L
Rouyrre, N
Sachs, C
Valle, JW
Delle Fave, G
Van Cutsem, E
Tesselaar, MET
Shimada, Y
Oh, DY
Strosberg, J
Kulke, MH
Pavel, ME
AF Yao, James C.
Fazio, Nicola
Singh, Simron
Buzzoni, Roberto
Carnaghi, Carlo
Wolin, Edward
Tomasek, Jiri
Raderer, Markus
Lahner, Harald
Voi, Maurizio
Pacaud, Lida
Rouyrre, Nicolas
Sachs, Carolin
Valle, Juan W.
Delle Fave, Gianfranco
Van Cutsem, Eric
Tesselaar, M. E. T.
Shimada, Yasuhiro
Oh, Do-Youn
Strosberg, Jonathan
Kulke, Matthew H.
Pavel, Marianne E.
CA RAD001 Adv Neuroendocrine Tumors F
TI Safety and Efficacy of Everolimus in Advanced Nonfunctional
Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin:
Findings of the Randomized, Placebo-Controlled, Double-blind,
Multicenter, Phase 3 RADIANT-4 Study
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Yao, James C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Fazio, Nicola] IRCCS, Ist Europeo Oncol, Milan, Italy.
[Singh, Simron] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
[Buzzoni, Roberto] Ist Nazl Tumori, Fdn IRCCS, Via Venezian 1, I-20133 Milan, Italy.
[Carnaghi, Carlo] Ist Clin Humanitas, IRCCS, Rozzano, Italy.
[Wolin, Edward] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
[Tomasek, Jiri] Masaryk Univ, Fac Med, Masaryk Mem Canc Inst, Brno, Czech Republic.
[Raderer, Markus] Univ Klin Innere Med I, AKH, Vienna, Austria.
[Lahner, Harald] Univ Klinikum Essen, Zentrum Innere Med, Essen, Germany.
[Voi, Maurizio] Novartis Pharmaceut, E Hanover, NJ USA.
[Pacaud, Lida; Rouyrre, Nicolas; Sachs, Carolin] Novartis Pharma AG, Basel, Switzerland.
[Valle, Juan W.] Univ Manchester, Christie Hosp, Inst Canc Studies, Manchester, Lancs, England.
[Delle Fave, Gianfranco] Univ Roma La Sapienza, Azienda Osped St Andrea, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
[Van Cutsem, Eric] Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium.
[Van Cutsem, Eric] KULeuven, Leuven, Belgium.
[Tesselaar, M. E. T.] Nederlands Kanker Inst Antoni van Leeuwenhoek, Amsterdam, Netherlands.
[Shimada, Yasuhiro] Natl Canc Ctr, 1-1 Tsukiji 5 chome, Tokyo, Japan.
[Oh, Do-Youn] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
[Strosberg, Jonathan] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Med, Tampa, FL 33682 USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pavel, Marianne E.] Charite, Campus Virchow Klinikum, D-13353 Berlin, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2016
VL 45
IS 3
BP 487
EP 487
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KQ
UT WOS:000370956600085
ER
PT J
AU Weinand, C
Neville, CM
Weinberg, E
Tabata, Y
Vacanti, JP
AF Weinand, Christian
Neville, Craig M.
Weinberg, Eli
Tabata, Yasuhiko
Vacanti, Joseph P.
TI Optimizing Biomaterials for Tissue Engineering Human Bone Using
Mesenchymal Stem Cells
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID MARROW STROMAL CELLS; MORPHOGENETIC PROTEIN-2; MECHANICAL-PROPERTIES;
ADIPOSE-TISSUE; GROWTH-FACTOR; SCAFFOLDS; REGENERATION; DIFFERENTIATION;
HYDROGEL; OSTEOGENESIS
AB Background:
Adequate biomaterials for tissue engineering bone and replacement of bone in clinical settings are still being developed. Previously, the combination of mesenchymal stem cells in hydrogels and calcium-based biomaterials in both in vitro and in vivo experiments has shown promising results. However, results may be optimized by careful selection of the material combination.
Methods:
beta-Tricalcium phosphate scaffolds were three-dimensionally printed with five different hydrogels: collagen I, gelatin, fibrin glue, alginate, and Pluronic F-127. The scaffolds had eight channels, running throughout the entire scaffold, and macropores. Mesenchymal stem cells (2 x 10(6)) were mixed with each hydrogel, and cell/hydrogel mixes were dispersed onto the corresponding beta-tricalcium phosphate/hydrogel scaffold and cultured under dynamic-oscillating conditions for 6 weeks. Specimens were harvested at 1, 2, 4, and 6 weeks and evaluated histologically, radiologically, biomechanically and, at 6 weeks, for expression of bone-specific proteins by reverse-transcriptase polymerase chain reaction. Statistical correlation analysis was performed between radiologic densities in Hounsfield units and biomechanical stiffness.
Results:
Collagen I samples had superior bone formation at 6 weeks as demonstrated by volume computed tomographic scanning, with densities of 300 HU, similar to native bone, and the highest compression values. Bone specificity of new tissue was confirmed histologically and by the expression of alkaline phosphatase, osteonectin, osteopontin, and osteocalcin. The bone density correlated closely with histologic and biomechanical testing results.
Conclusion:
Bone formation is supported best by beta-tricalcium phosphate/collagen I hydrogel and mesenchymal stem cells in collagen I hydrogel.
CLINICAL QUESTION/LEVEL OF EVIDENCE:
Therapeutic, V.
C1 [Weinand, Christian] Ernst Moritz Arndt Univ Greifswald, Dietrich Bonhoeffer Hosp, Dept Plast & Aesthet Surg Hand Surg & Burns, S Allende Str 30, D-17033 Neubrandenburg, Germany.
Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lab Tissue Engn & Organ Fabricat, Cambridge, MA 02138 USA.
Kyoto Univ, Inst Frontier Med Sci, Field Tissue Engn, Dept Biomat, Kyoto 6068501, Japan.
RP Weinand, C (reprint author), Ernst Moritz Arndt Univ Greifswald, Dietrich Bonhoeffer Hosp, Dept Plast & Aesthet Surg Hand Surg & Burns, S Allende Str 30, D-17033 Neubrandenburg, Germany.
EM chwscot@yahoo.com
FU NCATS NIH HHS [TL1 TR000096]
NR 42
TC 0
Z9 1
U1 7
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0032-1052
EI 1529-4242
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD MAR
PY 2016
VL 137
IS 3
BP 854
EP 863
DI 10.1097/01.prs.0000479991.72867.ba
PG 10
WC Surgery
SC Surgery
GA DE7GT
UT WOS:000370804600001
PM 26910665
ER
PT J
AU Syzdek, MR
Green, JD
Lindgren, BR
Addis, ME
AF Syzdek, Matthew R.
Green, Jonathan D.
Lindgren, Bruce R.
Addis, Michael E.
TI Pilot Trial of Gender-Based Motivational Interviewing for Increasing
Mental Health Service Use in College Men
SO PSYCHOTHERAPY
LA English
DT Article
DE motivational interviewing; men; help seeking; depression; masculinity
ID HELP-SEEKING; DEPRESSION; METAANALYSIS; STIGMA; WILLINGNESS; SYMPTOMS
AB Men are considerably less likely to seek professional and nonprofessional help for mental disorders. Prior findings indicate that adherence to masculine norms contributes to stigma about internalizing disorders and help seeking. There are currently no empirically supported interventions for increasing help seeking in men with internalizing symptoms. To address this need, we conducted a pilot study of gender-based motivational interviewing (GBMI) for men with internalizing symptoms. GBMI is a single session of assessment and feedback integrating gender-based and motivational interviewing principles (Addis, 2012). College men (N = 35) with significant internalizing symptoms and no recent help seeking were randomized to either GBMI or a no-treatment control and were followed for 2 months. GBMI had a significant effect on seeking help from parents and a trend for seeking professional help, but did not have a significant effect on seeking help from friends or partners. The size of the effect of GBMI on professional and nonprofessional help seeking ranged from small to medium. GBMI shows promise for improving men's help-seeking behaviors and warrants further development and investigation.
C1 [Syzdek, Matthew R.; Green, Jonathan D.; Addis, Michael E.] Clark Univ, Frances L Hiatt Sch Psychol, Worcester, MA 01610 USA.
[Lindgren, Bruce R.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
[Syzdek, Matthew R.] Hennepin Cty Med Ctr, 701 Pk Ave, Minneapolis, MN 55415 USA.
[Green, Jonathan D.] VA Boston Healthcare Syst, Boston, MA USA.
RP Syzdek, MR (reprint author), Hennepin Cty Med Ctr, 701 Pk Ave, Minneapolis, MN 55415 USA.
EM matthewsyzdek@gmail.com
NR 29
TC 1
Z9 1
U1 0
U2 4
PU AMER PSYCHOLOGICAL ASSOC, DIV PSYCHOTHERAPY
PI CORAL GABLES
PA 1390 SOUTH DIXIE HIGHWAY, STE 2222, CORAL GABLES, FL 33146-2946 USA
SN 0033-3204
EI 1939-1536
J9 PSYCHOTHERAPY
JI Psychotherapy
PD MAR
PY 2016
VL 53
IS 1
BP 124
EP 129
DI 10.1037/pst0000043
PG 6
WC Psychology, Clinical
SC Psychology
GA DF4UA
UT WOS:000371345200012
PM 26928137
ER
PT J
AU Ball, L
Sutherasan, Y
Caratto, V
Sanguineti, E
Marsili, M
Raimondo, P
Ferretti, M
Kacmarek, RM
Pelosi, P
AF Ball, Lorenzo
Sutherasan, Yuda
Caratto, Valentina
Sanguineti, Elisa
Marsili, Maria
Raimondo, Pasquale
Ferretti, Maurizio
Kacmarek, Robert M.
Pelosi, Paolo
TI Effects of Nebulizer Position, Gas Flow, and CPAP on Aerosol
Bronchodilator Delivery: An In Vitro Study
SO RESPIRATORY CARE
LA English
DT Article
DE aerosol; bronchodilators; albuterol; continuous positive airway
pressure; cpap; nebulizers
ID MECHANICALLY VENTILATED PATIENTS; AIRWAY PRESSURE GENERATOR; ALBUTEROL
DELIVERY; PERFORMANCE; BENCH
AB BACKGROUND: The aim of this study was to investigate the effects of different delivery circuit configurations, nebulizer positions, CPAP levels, and gas flow on the amount of aerosol bronchodilator delivered during simulated spontaneous breathing in an in vitro model. METHODS: A pneumatic lung simulator was connected to 5 different circuits for aerosol delivery, 2 delivering CPAP through a high-flow generator tested at 30, 60, and 90 L/min supplementary flow and 5, 10, and 15 cm H2O CPAP and 3 with no CPAP: a T-piece configuration with one extremity closed with a cap, a T-piece configuration without cap and nebulizer positioned proximally, and a T-piece configuration without cap and nebulizer positioned distally. Albuterol was collected with a filter, and the percentage amount delivered was measured by infrared spectrophotometry. RESULTS: Configurations with continuous high-flow CPAP delivered higher percentage amounts of albuterol compared with the configurations without CPAP (9.1 +/- 6.0% vs 6.2 +/- 2.8%, P = .03). Among configurations without CPAP, the best performance was obtained with a T-piece with one extremity closed with a cap. In CPAP configurations, the highest delivery (13.8 +/- 4.4%) was obtained with the nebulizer placed proximal to the lung simulator, independent of flow. CPAP at 15 cm H2O resulted in the highest albuterol delivery (P = .02). CONCLUSIONS: Based on our in vitro study, without CPAP, a T-piece with a cap at one extremity maximizes albuterol delivery. During high-flow CPAP, the nebulizer should always be placed proximal to the patient, after the T-piece, using the highest CPAP clinically indicated. (C) 2016 Daedalus Enterprises
C1 [Ball, Lorenzo; Sutherasan, Yuda; Marsili, Maria; Raimondo, Pasquale; Pelosi, Paolo] Univ Genoa, IRCCS AOU San Martino IST, Dept Surg Sci & Integrated Diagnost, Largo Rosanna Benzi 8, I-16132 Genoa, Italy.
[Sutherasan, Yuda] Mahidol Univ, Div Pulm & Crit Care Med, Fac Med, Ramathibodi Hosp, Bangkok 10700, Thailand.
[Raimondo, Pasquale] Univ Foggia, Dept Anesthesiol Resuscitat & Intens Care, Foggia, Italy.
[Caratto, Valentina; Sanguineti, Elisa; Ferretti, Maurizio] Univ Genoa, Dept Chem & Ind Chem, I-16132 Genoa, Italy.
[Caratto, Valentina; Sanguineti, Elisa; Ferretti, Maurizio] SPIN CNR, Genoa, Italy.
[Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care, Boston, MA 02114 USA.
[Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
RP Ball, L (reprint author), Univ Genoa, IRCCS AOU San Martino IST, Dept Surg Sci & Integrated Diagnost, Largo Rosanna Benzi 8, I-16132 Genoa, Italy.
EM lorenzo.ball@edu.unige.it
RI Ball, Lorenzo/K-7612-2016;
OI Ball, Lorenzo/0000-0002-3876-4730; Ferretti,
Maurizio/0000-0003-0709-3281; Raimondo, Pasquale/0000-0002-4076-588X
NR 22
TC 2
Z9 2
U1 0
U2 1
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD MAR
PY 2016
VL 61
IS 3
BP 263
EP 268
DI 10.4187/respcare.04275
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DF2RR
UT WOS:000371192000002
PM 26577198
ER
PT J
AU Piriyapatsom, A
Lin, H
Pirrone, M
De Pascale, G
De Lapuerta, JC
Bittner, EA
Schmidt, UH
De Moya, M
Berra, L
AF Piriyapatsom, Annop
Lin, Hsin
Pirrone, Massimiliano
De Pascale, Gennaro
De Lapuerta, Javier Corona
Bittner, Edward A.
Schmidt, Ulrich H.
De Moya, Marc
Berra, Lorenzo
TI Evaluation of the Infection-Related Ventilator-Associated Events
Algorithm for Ventilator-Associated Pneumonia Surveillance in a Trauma
Population
SO RESPIRATORY CARE
LA English
DT Article
DE accuracy; critical care; trauma; ventilator-associated events;
ventilator-associated pneumonia
ID CRITICALLY-ILL PATIENTS; INJURY SEVERITY SCORE; INTENSIVE-CARE-UNIT;
PULMONARY MORBIDITY; TRANSFUSIONS RESULT; IMPROVES ACCURACY; MODERATE
DEGREE; SAFETY NETWORK; RISK-FACTORS; VALIDATION
AB BACKGROUND: The Centers for Disease Control and Prevention have recently introduced new ventilator-associated pneumonia (VAP) surveillance on the basis of the infection-related ventilator-associated complication (IVAC) definition. We aim to evaluate the accuracy of this new IVAC algorithm for detecting VAP according to the 2008 Centers for Disease Control and Prevention/National Healthcare Safety Network (NHSN) definition as the reference diagnosis (VAP-NHSN) in high-risk trauma patients. METHODS: This retrospective single-center study included all trauma subjects who were admitted to the ICU, required mechanical ventilation for >48 h, and received a blood transfusion. The new IVAC surveillance and the criteria for VAP-NHSN diagnosis were applied. The accuracy of the new IVAC surveillance for detecting VAP-NHSN was determined, and the clinical outcomes were compared between groups. RESULTS: The sensitivity, specificity, and positive and negative predictive values of IVAC for VAP-NSHN identification were 28.12%, 91.45, 58.06%, and 75.14%, respectively. Subjects with IVAC, VAP-NHSN, or both had higher morbidity when compared with those without IVAC and VAP-NHSN. Subjects with IVAC only had lower morbidity compared with those with VAP-NHSN only or those with both IVAC and VAP-NHSN. There was no significant difference in clinical outcomes between subjects with VAP-NHSN only and those with both IVAC and VAP-NHSN. CONCLUSIONS: IVAC criteria had a low accuracy for identifying VAP-NHSN in subjects with high-risk trauma. (C) 2016 Daedalus Enterprises
C1 [Piriyapatsom, Annop] Mahidol Univ, Siriraj Hosp, Dept Anesthesiol, Bangkok 10700, Thailand.
[Lin, Hsin] Harvard Univ, Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA.
[Pirrone, Massimiliano; De Pascale, Gennaro; De Lapuerta, Javier Corona; Bittner, Edward A.; Berra, Lorenzo] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 2 Fruit St, Boston, MA 02114 USA.
[De Moya, Marc] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA.
[Schmidt, Ulrich H.] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA.
RP Berra, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 2 Fruit St, Boston, MA 02114 USA.
EM lberra@mgh.harvard.edu
NR 30
TC 3
Z9 3
U1 4
U2 4
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD MAR
PY 2016
VL 61
IS 3
BP 269
EP 276
DI 10.4187/respcare.04280
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DF2RR
UT WOS:000371192000003
PM 26556896
ER
PT J
AU Piriyapatsom, A
Williams, EC
Waak, K
Ladha, KS
Eikermann, M
Schmidt, UH
AF Piriyapatsom, Annop
Williams, Elizabeth C.
Waak, Karen
Ladha, Karim S.
Eikermann, Matthias
Schmidt, Ulrich H.
TI Prospective Observational Study of Predictors of Re-Intubation Following
Extubation in the Surgical ICU
SO RESPIRATORY CARE
LA English
DT Article
DE critically ill; prediction score; re-intubation; risk factors; surgical
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; PROLONGED MECHANICAL
VENTILATION; SPONTANEOUS BREATHING TRIAL; ACUTE KIDNEY INJURY;
LENGTH-OF-STAY; MUSCLE STRENGTH; INTEROBSERVER AGREEMENT; TRACHEAL
REINTUBATION; RESPIRATORY-FAILURE
AB BACKGROUND: Re-intubation is associated with high morbidity and mortality. There is limited information regarding the risk factors that predispose patients admitted to the surgical ICU to re-intubation. We hypothesized that preoperative comorbidities, acquired muscular weakness, and renal dysfunction would be predictors of re-intubation in the surgical ICU population. METHODS: This was a prospective observational study in 2 surgical ICUs of a large tertiary hospital. All patients who were extubated during their surgical ICU stay were included. Demographic and clinical data were collected before and after extubation. The primary outcome was re-intubation within 72 h. Using multivariate logistic regression analysis, independent risk factors of re-intubation were determined, and a prediction score was developed. RESULTS: Between December 1, 2012, and January 31, 2014, we included 764 consecutive subjects. Of these, 65 subjects (8.5%) required re-intubation. Independent risk factors of re-intubation were blood urea nitrogen level of >8.2 mmol/L (odds ratio [OR] 3.66, 95% CI 1.97-6.80), hemoglobin level of <75 g/L (OR 2.10, 95% CI 1.23-3.61), and muscle strength of <= 3 (OR 2.03, 95% CI 1.16-3.55). The presence of all 3 risk factors was associated with an estimated probability for re-intubation of 26.8%. CONCLUSIONS: In noncardiac surgery, surgical ICU subjects, elevated blood urea nitrogen level, low hemoglobin level, and muscle weakness were identified as independent risk factors for re-intubation. The presence of these risk factors can potentially aid clinicians in making informed decisions regarding optimal airway management in patients considered for an extubation attempt. (ClinicalTrials.gov registration NCT01967056.) (C) 2016 Daedalus Enterprises
C1 [Piriyapatsom, Annop] Mahidol Univ, Siriraj Hosp, Dept Anesthesiol, Bangkok 10700, Thailand.
[Williams, Elizabeth C.; Ladha, Karim S.; Eikermann, Matthias] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Waak, Karen] Harvard Univ, Massachusetts Gen Hosp, Dept Phys & Occupat Therapy, Boston, MA USA.
[Schmidt, Ulrich H.] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA.
RP Schmidt, UH (reprint author), 200 West Arbor Dr 8770, San Diego, CA 92103 USA.
EM uschmidt@ucsd.edu
NR 56
TC 1
Z9 1
U1 0
U2 0
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD MAR
PY 2016
VL 61
IS 3
BP 306
EP 315
DI 10.4187/respcare.04269
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DF2RR
UT WOS:000371192000008
PM 26556899
ER
PT J
AU Gagnon, I
Grilli, L
Friedman, D
Iverson, GL
AF Gagnon, I.
Grilli, L.
Friedman, D.
Iverson, G. L.
TI A pilot study of active rehabilitation for adolescents who are slow to
recover from sport-related concussion
SO SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS
LA English
DT Article
DE Pediatric; mild traumatic brain injury; children; physiotherapy; sports;
post-concussion symptoms; aerobics
ID TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; INTERNATIONAL-CONFERENCE;
VOLUNTARY EXERCISE; CONSENSUS STATEMENT; NEUROTROPHIC FACTOR;
PHYSICAL-EXERCISE; CONTUSION INJURY; TEMPORAL WINDOW; DEPRESSION
AB The purpose of this study was to examine the effectiveness of an active rehabilitation intervention for adolescents who are slow-to-recover after a sport-related concussion. Ten adolescents (three girls and seven boys) seen at the Montreal Children's Hospital Concussion Clinic participated in this case series. Adolescents who were symptomatic more than 4 weeks after the injury were provided with an active rehabilitation intervention (M=7.9 weeks following injury; range=3.7 to 26.2 weeks). The rehabilitation program includes gradual, closely monitored light aerobic exercise, general coordination exercises, mental imagery, as well as reassurance, normalization of recovery, and stress/anxiety reduction strategies. The program continued until complete symptom resolution and readiness to begin stepwise return to activities. The primary outcome of the study was evolution of post-concussion symptoms. Secondary outcomes included mood, energy, balance, and cognition. After the intervention, post-concussion symptoms significantly decreased for the group of participants. They also had decreased fatigue and improved mood after 6 weeks of initiating the rehabilitation intervention. This case series shows that postconcussive symptoms and functioning in adolescents following sports-related concussion can be improved after participation in an active rehabilitation intervention. The introduction of graded light intensity exercise in the post-acute period following concussion is safe, feasible and appears to have a positive impact on adolescents' functioning.
C1 [Gagnon, I.] McGill Univ, Fac Med, Sch Phys & Occupat Therapy, Montreal, PQ, Canada.
[Gagnon, I.; Grilli, L.; Friedman, D.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Trauma Ctr, Montreal, PQ, Canada.
[Gagnon, I.; Friedman, D.] McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada.
[Friedman, D.] Canadian Hosp Injury Reporting & Prevent Program, Montreal, PQ, Canada.
[Iverson, G. L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Iverson, G. L.] Spaulding Rehabil Hosp, Boston, MA USA.
[Iverson, G. L.] Mass Gen Hosp, Children Sports Concuss Program, Boston, MA USA.
[Iverson, G. L.] Red Sox Fdn, Boston, MA USA.
[Iverson, G. L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.
RP Gagnon, I (reprint author), Montreal Childrens Hosp, Trauma Programs C 833, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.
EM Isabelle.gagnon8@mcgill.ca
RI Meijer, Anna/K-5118-2016
FU Research Institute of the McGill University Health Center; The Montreal
Children's Hospital Trauma Programs
FX We would like to thank the children and their families for participating
in this study and The Montreal Children's Hospital Trauma Programs
professionals for their support. As well, we wish to thank the Research
Institute of the McGill University Health Center for its support of this
research.
NR 61
TC 8
Z9 8
U1 5
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7188
EI 1600-0838
J9 SCAND J MED SCI SPOR
JI Scand. J. Med. Sci. Sports
PD MAR
PY 2016
VL 26
IS 3
BP 299
EP 306
DI 10.1111/sms.12441
PG 8
WC Sport Sciences
SC Sport Sciences
GA DF3MB
UT WOS:000371247200007
PM 25735821
ER
PT J
AU Zhang, Y
Meng, H
Ma, RS
He, ZX
Wu, XM
Cao, MH
Yao, ZP
Zhao, L
Li, T
Deng, RJ
Dong, ZX
Tian, Y
Bi, YY
Kou, JJ
Thatte, HS
Zhou, J
Shi, JL
AF Zhang, Yan
Meng, Huan
Ma, Ruishuang
He, Zhangxiu
Wu, Xiaoming
Cao, Muhua
Yao, Zhipeng
Zhao, Lu
Li, Tao
Deng, Ruijuan
Dong, Zengxiang
Tian, Ye
Bi, Yayan
Kou, Junjie
Thatte, Hemant S.
Zhou, Jin
Shi, Jialan
TI CIRCULATING MICROPARTICLES, BLOOD CELLS, AND ENDOTHELIUM INDUCE
PROCOAGULANT ACTIVITY IN SEPSIS THROUGH PHOSPHATIDYLSERINE EXPOSURE
SO SHOCK
LA English
DT Article
DE sepsis; Cells; phosphatidylserine; microparticles; procoagulant
activity; PMN; T LyMPs; human umbilical vein endothelial cells; MMPs;
tissue factor; PS; endothelial cell-derived MPs; EMPs; MP;
platelet-derived MPs; MNC; erythrocyte-derived MPs; disseminated
intravascular coagulation; monocyte-derived MPs; platelet-rich plasma;
TF; PLT; neutrophil; PMPs; microparticle; PRP; RBC; HUVECs; endothelial
cells; lymphocyte; procoagulant activity; ECs; MP-depleted plasma; PFP;
monocyte; red blood cell; MDP; DIC; B LyMPs; PCA; NMPs; RMPs; platelet;
platelet-free plasma; phosphatidylserine; LYM; B lymphocyte-derived MPs;
neutrophil-derived MPs; T lymphocyte-derived MPs
ID ACUTE PROMYELOCYTIC LEUKEMIA; TISSUE FACTOR; ORGAN DYSFUNCTION; SEPTIC
SHOCK; COAGULATION; THROMBOSIS; BINDING; INFLAMMATION; ACTIVATION;
MECHANISMS
AB Sepsis is invariably accompanied by altered coagulation cascade; however, the precise role of phosphatidylserine (PS) in inflammation-associated coagulopathy in sepsis has not been well elucidated. We explored the possibility of exposed PS on microparticles (MPs), blood cells, as well as on endothelium, and defined its role in procoagulant activity (PCA) in sepsis. PS-positive MPs and cells were detected by flow cytometry, while PCA was assessed with clotting time, purified coagulation complex, and fibrin formation assays. Plasma levels of PS+ MPs derived from platelets, leukocytes (including neutrophils, monocytes, and lymphocytes), erythrocytes, and endothelial cells were elevated by 1.49-, 1.60-, 2.93-, and 1.53-fold, respectively, in septic patients. Meanwhile, PS exposure on blood cells was markedly higher in septic patients than in controls. Additionally, we found that the endothelial cells (ECs) treated with septic serum in vitro exposed more PS than with healthy serum. Isolated MPs/blood cells from septic patients and cultured ECs treated with septic serum in vitro demonstrated significantly shortened coagulation time, greatly enhanced intrinsic/extrinsic FXa generation, and increased thrombin formation. Importantly, confocal imaging of MPs or septic serum-treated ECs identified binding sites for FVa and FXa to form prothrombinase, and further supported fibrin formation in the area where PS exposure was abundant. Pretreatment with lactadherin blocked PS on MPs/blood cells/ECs, prolonged coagulation time by at least 25%, reduced FXa/thrombin generation, and inhibited fibrin formation by approximately 85%. Our findings suggest a key role for PS exposed on MPs, blood cells, and endothelium in augmenting coagulation in sepsis. Therefore, therapies targeting PS may be of particular importance.
C1 [Zhang, Yan; Ma, Ruishuang; Wu, Xiaoming; Cao, Muhua; Yao, Zhipeng; Zhao, Lu; Li, Tao; Deng, Ruijuan; Zhou, Jin; Shi, Jialan] Harbin Med Univ, Hosp 1, Dept Hematol, 23 Youzheng St, Harbin 150001, Peoples R China.
[Meng, Huan; Kou, Junjie] Harbin Med Univ, Hosp 2, Dept Cardiol, Harbin, Peoples R China.
[He, Zhangxiu] Harbin Med Univ, Dept Nephrol, Harbin, Peoples R China.
[Dong, Zengxiang; Tian, Ye; Bi, Yayan] Harbin Med Univ, Hosp 1, Dept Cardiol, Harbin, Peoples R China.
[Thatte, Hemant S.; Shi, Jialan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,VA Boston Healthcare Syst, Boston, MA USA.
RP Zhou, J; Shi, JL (reprint author), Harbin Med Univ, Hosp 1, Dept Hematol, 23 Youzheng St, Harbin 150001, Peoples R China.; Zhou, J; Shi, JL (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,VA Boston Healthcare Syst, 1400 VFW Pkway, West Roxbury, MA 02132 USA.
EM jialan_shi@hms.harvard.edu
FU National Science Foundation of China [81270588, 81470301]
FX This work was in part supported by grants (81270588, 81470301) from the
National Science Foundation of China.
NR 41
TC 3
Z9 3
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD MAR
PY 2016
VL 45
IS 3
BP 299
EP 307
DI 10.1097/SHK.0000000000000509
PG 9
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA DE9MU
UT WOS:000370962600007
PM 26513704
ER
PT J
AU Konadhode, RR
Pelluru, D
Shiromani, PJ
AF Konadhode, Roda Rani
Pelluru, Dheeraj
Shiromani, Priyattam J.
TI Unihemispheric Sleep: An Enigma for Current Models of Sleep-Wake
Regulation
SO SLEEP
LA English
DT Editorial Material
ID SLOW-WAVE SLEEP; GABA RELEASE; MAMMALIAN SLEEP; LOCUS-COERULEUS; WAKING
CYCLE; MCH NEURONS; REM-SLEEP; FUR SEALS; DISCHARGE; STATE
C1 [Konadhode, Roda Rani; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[Konadhode, Roda Rani; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Behav Sci, Charleston, SC 29425 USA.
[Shiromani, Priyattam J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Shiromani, PJ (reprint author), Med Univ S Carolina, Dept Psychiat, Ralph H Johnson VA Med Ctr, 114 Doughty St, Charleston, SC 29425 USA.
EM shiroman@musc.edu
FU BLRD VA [I01 BX000798]; NINDS NIH HHS [NS079940, NS084477, R01 NS052287,
NS052287]
NR 50
TC 0
Z9 0
U1 12
U2 17
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD MAR 1
PY 2016
VL 39
IS 3
BP 491
EP 494
AR PII sp-00020-16
DI 10.5665/sleep.5508
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DF1RB
UT WOS:000371115800001
PM 26856898
ER
PT J
AU Fields, BG
Behari, PP
McCloskey, S
True, G
Richardson, D
Thomasson, A
Korom-Djakovic, D
Davies, K
Kuna, ST
AF Fields, Barry G.
Behari, Pratima Pathak
McCloskey, Susan
True, Gala
Richardson, Diane
Thomasson, Arwin
Korom-Djakovic, Danijela
Davies, Keith
Kuna, Samuel T.
TI Remote Ambulatory Management of Veterans with Obstructive Sleep Apnea
SO SLEEP
LA English
DT Article
DE obstructive sleep apnea; telemedicine; home sleep testing;
auto-titrating positive airway pressure
ID POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL; DIAGNOSIS;
POLYSOMNOGRAPHY; TELEMEDICINE; TELEHEALTH; ADHERENCE; CARE;
AUTOTITRATION; VALIDATION
AB Study Objectives: Despite significant medical sequelae of obstructive sleep apnea (OSA), the condition remains undiagnosed and untreated in many affected individuals. We explored the feasibility of a comprehensive, telemedicine-based OSA management pathway in a community-based Veteran cohort.
Methods: This prospective, parallel-group randomized pilot study assessed feasibility of a telemedicine-based pathway for OSA evaluation and management in comparison to a more traditional, in-person care model. The study included 60 Veterans at the Philadelphia Veterans Affairs Medical Center and two affiliated community-based outpatient clinics. Telemedicine pathway feasibility, acceptability, and outcomes were assessed through a variety of quantitative (Functional Outcomes of Sleep Questionnaire, dropout rates, positive airway pressure [PAP] adherence rates, participant satisfaction ratings) and qualitative (verbal feedback) metrics.
Results: There was no significant difference in functional outcome changes, patient satisfaction, dropout rates, or objectively measured PAP adherence between groups after 3 months of treatment. Telemedicine participants showed greater improvement in mental health scores, and their feedback was overwhelmingly positive.
Conclusions: Our pilot study suggests that telemedicine-based management of OSA patients is feasible in terms of patient functional outcomes and overall satisfaction with care. Future studies should include larger populations to further elucidate these findings while assessing provider-and patient-related cost effectiveness.
C1 [Fields, Barry G.] Emory Univ, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA.
[Fields, Barry G.] Atlanta Vet Affairs Med Ctr, Decatur, GA 30030 USA.
[Behari, Pratima Pathak; McCloskey, Susan; True, Gala; Richardson, Diane; Thomasson, Arwin; Korom-Djakovic, Danijela; Davies, Keith; Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Behari, Pratima Pathak; Kuna, Samuel T.] Univ Penn, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19104 USA.
[Behari, Pratima Pathak; Kuna, Samuel T.] Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA.
[Thomasson, Arwin] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Fields, BG (reprint author), Atlanta Vet Affairs Med Ctr, Sleep Med Ctr, 250 N Arcadia Ave, Decatur, GA 30030 USA.
EM barry.fields@va.gov
FU VISN 4 Competitive Pilot Project Fund
FX This was not an industry supported study. Financial support was provided
by VISN 4 Competitive Pilot Project Fund. The authors have indicated no
financial conflicts of interest.
NR 40
TC 5
Z9 5
U1 1
U2 3
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD MAR 1
PY 2016
VL 39
IS 3
BP 501
EP 509
AR PII sp-00254-15
DI 10.5665/sleep.5514
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DF1RB
UT WOS:000371115800004
PM 26446115
ER
PT J
AU Stone, KL
Blackwell, TL
Ancoli-Israel, S
Barrett-Connor, E
Bauer, DC
Cauley, JA
Ensrud, KE
Hoffman, AR
Mehra, R
Stefanick, ML
Varosy, PD
Yaffe, K
Redline, S
AF Stone, Katie L.
Blackwell, Terri L.
Ancoli-Israel, Sonia
Barrett-Connor, Elizabeth
Bauer, Douglas C.
Cauley, Jane A.
Ensrud, Kristine E.
Hoffman, Andrew R.
Mehra, Reena
Stefanick, Marcia L.
Varosy, Paul D.
Yaffe, Kristine
Redline, Susan
CA Osteoporotic Fractures Men MrOS St
TI Sleep Disordered Breathing and Risk of Stroke in Older
Community-Dwelling Men
SO SLEEP
LA English
DT Article
DE stroke; sleep disordered breathing; nocturnal hypoxemia
ID OSTEOPOROTIC FRACTURES; INSULIN-RESISTANCE; ISCHEMIC-STROKE; APNEA;
SCALE; DETERMINANTS; ASSOCIATION; UPDATE; HEALTH; MROS
AB Study Objectives: Men with sleep disordered breathing (SDB) may be at increased stroke risk, due to nocturnal hypoxemia, sleep loss or fragmentation, or other mechanisms. We examined the association of SDB with risk of incident stroke in a large cohort of older men.
Methods: Participants were 2,872 community-dwelling men (mean age 76 years) enrolled in the MrOS Sleep Study, which gathered data from 2003 to 2005 at six clinical sites in the Unites States. SDB predictors (obstructive apnea-hypopnea index, apnea-hypopnea index, central apnea index, and nocturnal hypoxemia) were measured using overnight polysomnography. Incident stroke over an average follow-up of 7.3 years was centrally adjudicated by physician review of medical records.
Results: One hundred fifty-six men (5.4%) had a stroke during follow-up. After adjustment for age, clinic site, race, body mass index, and smoking status, older men with severe nocturnal hypoxemia (>= 10% of the night with SpO(2) levels below 90%) had a 1.8-fold increased risk of incident stroke compared to those without nocturnal hypoxemia (relative hazard = 1.83; 95% confidence interval 1.12-2.98; P trend = 0.02). Results were similar after further adjustment for other potential covariates and after excluding men with a history of stroke. Other indices of SDB were not associated with incident stroke.
Conclusions: Older men with severe nocturnal hypoxemia are at significantly increased risk of incident stroke. Measures of overnight oxygen saturation may better identify older men at risk for stroke than measures of apnea frequency.
C1 [Stone, Katie L.; Blackwell, Terri L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Stone, Katie L.; Blackwell, Terri L.] San Francisco Coordinating Ctr, San Francisco, CA 94158 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Barrett-Connor, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA.
[Bauer, Douglas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Ensrud, Kristine E.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Ensrud, Kristine E.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
[Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Hoffman, Andrew R.; Stefanick, Marcia L.] Stanford Univ, Stanford Prevent Res Ctr, Dept Med, Palo Alto, CA 94304 USA.
[Mehra, Reena] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Sleep Ctr,Neurol Inst, Cleveland, OH 44106 USA.
[Varosy, Paul D.] Univ Colorado, Denver, CO 80202 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA.
[Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
RP Stone, KL (reprint author), San Francisco Coordinating Ctr, Res Inst, Calif Pacific Med Ctr, Mission Hall Global Hlth & Clin Sci Bldg, San Francisco, CA 94158 USA.
EM kstone@sfcc-cpmc.net
RI Cauley, Jane/N-4836-2015;
OI Cauley, Jane/0000-0003-0752-4408; Mehra, Reena/0000-0002-6222-2675
FU National Institutes of Health; National Institute on Aging (NIA);
National Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS); National Center for Advancing Translational Sciences (NCATS);
NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01
AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01
AR066160, UL1 TR000128]; National Heart, Lung, and Blood Institute
(NHLBI) [R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01
HL070841, R01 HL070837, R01 HL070838, R01 HL070839, R01 HL089467]; K 24
grant [AG031155]; ResMed, Inc; Philips Respironics; ResMed Foundation
FX This was not an industry supported study. The Osteoporotic Fractures in
Men (MrOS) Study is supported by National Institutes of Health funding.
The following institutes provide support: the National Institute on
Aging (NIA), the National Institute of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS), the National Center for Advancing Translational
Sciences (NCATS), and NIH Roadmap for Medical Research under the
following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01
AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and
UL1 TR000128. The National Heart, Lung, and Blood Institute (NHLBI)
provides funding for the MrOS Sleep ancillary study "Outcomes of Sleep
Disorders in Older Men" under the following grant numbers: R01 HL071194,
R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837,
R01 HL070838, and R01 HL070839. Dr Yaffe received funding from K 24
grant AG031155. The measurement of inflammation markers was funded by
the NHLBI, grant number R01 HL089467. The funding sources had no role in
the design and conduct of the study; collection, management, analysis,
and interpretation of the data; or the decision to submit the manuscript
for publication. Dr. Stone has consulted for Merck. Dr. Ancoli-Israel is
a consultant for Merck and Purdue University. Dr. Redline's institution
has received grant funding from ResMed, Inc, Philips Respironics, and
ResMed Foundation and equipment from them for use in NIH studies. The
other authors have indicated no financial conflicts of interest.
Analysis was performed at California Pacific Medical Center, Research
Institute.
NR 29
TC 1
Z9 1
U1 0
U2 2
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD MAR 1
PY 2016
VL 39
IS 3
BP 531
EP 540
AR PII sp-00349-15
DI 10.5665/sleep.5520
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DF1RB
UT WOS:000371115800007
PM 26943468
ER
PT J
AU Bertisch, SM
Muresan, C
Schoerning, L
Winkelman, JW
Taylor, JA
AF Bertisch, Suzanne M.
Muresan, Cristen
Schoerning, Laura
Winkelman, John W.
Taylor, J. Andrew
TI Impact of Restless Legs Syndrome on Cardiovascular Autonomic Control
SO SLEEP
LA English
DT Article
DE baroreflex; sleep; heart rate variability; restless legs syndrome;
periodic leg movements of sleep
ID PERIODIC LIMB MOVEMENTS; HEART-RATE-VARIABILITY; BLOOD-PRESSURE CHANGES;
VASCULAR RISK-FACTORS; WILLIS-EKBOM DISEASE; BAROREFLEX SENSITIVITY;
MYOCARDIAL-INFARCTION; ISOMETRIC-EXERCISE; HEALTHY-SUBJECTS;
NITRIC-OXIDE
AB Study Objectives: To examine whether patients with restless legs syndrome demonstrate specific alterations in cardiovascular autonomic control.
Methods: Patients with moderate-severe restless legs syndrome (n = 20, 80% female) and controls (n = 20) matched for age, sex, body mass index, and free of hypertension and cardiovascular disease were enrolled. We assessed cardiovagal baroreflex gain via the modified Oxford technique, sympathetically mediated vascular responses to isometric exercise to fatigue, bradycardiac response to Valsalva maneuver, and respiratory sinus arrhythmia during paced breathing. Standard electrocardiography, beat-by-beat arterial pressure, respiration, and popliteal blood flow velocity were recorded continuously.
Results: Resting blood pressure and heart rate were similar between groups. However, baroreflex gain averaged 14.3 +/- 1.4 msec/mm Hg in restless legs syndrome and was lower than in controls (22.6 +/- 3.5 msec/mm Hg, P = 0.04). Hemodynamic responses to isometric exercise were similar between groups, though participants with restless legs syndrome had lower leg blood flow (P < 0.001), with greater leg vascular resistance (P < 0.0001), before and during isometric exercise. Respiratory sinus arrhythmia and Valsalva ratios were similar between groups. Neither baroreflex gain nor vascular resistance was correlated with sleep duration, sleep quality, or symptom duration.
Conclusion: Patients with restless legs syndrome demonstrate compromised cardiovagal control, specific to the arterial baroreflex, with greater peripheral vascular resistance, potentially due to heightened sympathetic outflow. These autonomic alterations may directly relate to the higher prevalence of cardiovascular disease in restless legs syndrome.
C1 [Bertisch, Suzanne M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Pulm Crit Care & Sleep Med,Dept Med, Boston, MA 02215 USA.
[Bertisch, Suzanne M.; Muresan, Cristen; Taylor, J. Andrew] Spaulding Hosp Cambridge, Cardiovasc Res Lab, Cambridge, MA USA.
[Schoerning, Laura; Winkelman, John W.] Massachusetts Gen Hosp, Dept Psychiat, Sleep Disorders Clin Res Program, Boston, MA 02114 USA.
[Schoerning, Laura; Winkelman, John W.] Massachusetts Gen Hosp, Dept Neurol, Sleep Disorders Clin Res Program, Boston, MA 02114 USA.
[Winkelman, John W.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Taylor, J. Andrew] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
RP Bertisch, SM (reprint author), Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, 330 Brookline Ave,KS-B23, Boston, MA 02215 USA.
EM sbertisc@bidmc.harvard.edu
FU Schwarz Pharma Ltd.; NIH [K23AT005104]; Harvard Catalyst \ The Harvard
Clinical and Translational Science Center (National Center for Research
Resources; National Center for Advancing Translational Sciences,
National Institutes of Health [UL1 TR001102]; Harvard University;
UCB/Schwarz Pharma; GlaxoSmithKline; Impax Pharmaceuticals
FX Supported for this study was provided by Schwarz Pharma Ltd. and by NIH
(K23AT005104). This work was conducted with support from Harvard
Catalyst vertical bar The Harvard Clinical and Translational Science
Center (National Center for Research Resources and the National Center
for Advancing Translational Sciences, National Institutes of Health
Award UL1 TR001102), and financial contributions from Harvard University
and its affiliated academic healthcare centers. The content is solely
the responsibility of the authors and does not necessarily represent the
official views of Harvard Catalyst, Harvard University and its
affiliated academic healthcare centers, or the National Institutes of
Health. Dr. Winkelman has consulting/advisory arrangements with
UCB/Schwarz Pharma, Impax Pharmaceuticals, Xenoport, and Oakstone
Publishing, and has received research support from UCB/Schwarz Pharma,
GlaxoSmithKline, and Impax Pharmaceuticals. The other authors have
indicated no financial conflicts of interest. The work for the study was
performed at Spaulding Hospital Cambridge and Massachusetts General
Hospital.
NR 46
TC 2
Z9 2
U1 0
U2 3
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD MAR 1
PY 2016
VL 39
IS 3
BP 565
EP 571
AR PII sp-00369-15
DI 10.5665/sleep.5528
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DF1RB
UT WOS:000371115800011
PM 26564128
ER
PT J
AU Lyamin, OI
Lapierre, JL
Kosenko, PO
Kodama, T
Bhagwandin, A
Korneva, SM
Peever, JH
Mukhametov, LM
Siegel, JM
AF Lyamin, Oleg I.
Lapierre, Jennifer L.
Kosenko, Peter O.
Kodama, Tohru
Bhagwandin, Adhil
Korneva, Svetlana M.
Peever, John H.
Mukhametov, Lev M.
Siegel, Jerome M.
TI Monoamine Release during Unihemispheric Sleep and Unihemispheric Waking
in the Fur Seal
SO SLEEP
LA English
DT Article
DE unihemispheric sleep; norepinephrine; histamine; serotonin;
acetylcholine; fur seal; marine mammals
ID SLOW-WAVE SLEEP; BASAL FOREBRAIN NEURONS; SEROTONERGIC NEURONS; WAKE
CYCLE; ACETYLCHOLINE-RELEASE; NUCLEUS BASALIS; WAKEFULNESS; HYPOCRETIN;
HISTAMINE; CATAPLEXY
AB Study Objectives: Our understanding of the role of neurotransmitters in the control of the electroencephalogram (EEG) has been entirely based on studies of animals with bilateral sleep. The study of animals with unihemispheric sleep presents the opportunity of separating the neurochemical substrates of waking and sleep EEG from the systemic, bilateral correlates of sleep and waking states.
Methods: The release of histamine (HI), norepinephrine (NE), and serotonin (5HT) in cortical and subcortical areas (hypothalamus, thalamus and caudate nucleus) was measured in unrestrained northern fur seals (Callorhinus ursinus) using in vivo microdialysis, in combination with, polygraphic recording of EEG, electrooculogram, and neck electromyogram.
Results: The pattern of cortical and subcortical HI, NE, and 5HT release in fur seals is similar during bilaterally symmetrical states: highest in active waking, reduced in quiet waking and bilateral slow wave sleep, and lowest in rapid eye movement (REM) sleep. Cortical and subcortical HI, NE, and 5HT release in seals is highly elevated during certain waking stimuli and behaviors, such as being sprayed with water and feeding. However, in contrast to acetylcholine (ACh), which we have previously studied, the release of HI, NE, and 5HT during unihemispheric sleep is not lateralized in the fur seal.
Conclusions: Among the studied neurotransmitters most strongly implicated in waking control, only ACh release is asymmetric in unihemispheric sleep and waking, being greatly increased on the activated side of the brain.
C1 [Lyamin, Oleg I.; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Lyamin, Oleg I.; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
[Lyamin, Oleg I.; Mukhametov, Lev M.] RAS, Severtsov Inst Ecol & Evolut, Moscow 117901, Russia.
[Lyamin, Oleg I.; Kosenko, Peter O.; Korneva, Svetlana M.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow, Russia.
[Lapierre, Jennifer L.; Peever, John H.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada.
[Kosenko, Peter O.] Southern Fed Univ, Rostov Na Donu, Russia.
[Kodama, Tohru] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Tokyo 113, Japan.
[Bhagwandin, Adhil] Univ Witwatersrand, Fac Hlth Sci, Sch Anat Sci, Johannesburg, South Africa.
RP Siegel, JM (reprint author), Univ Calif Los Angeles, VA GLAHS Sepulveda, Neurobiol Res 151A3, 16111 Plummer St North Hills, Los Angeles, CA 91343 USA.
EM jsiegel@ucla.edu
FU National Science Foundation [0919929]; National Institute of Health
[MH064109, DA034748]; Russian Fund for Basic Research [13-04-01704,
14-04-32075]; Medical Research Service of the Dept. of Veterans Affairs;
Utrish Dolphinarium Ltd.; National Science and Engineering Council of
Canada; Canadian Institutes of Health Research
FX This was not an industry supported study. This study was supported by
grants from National Science Foundation (0919929), National Institute of
Health MH064109, DA034748, Russian Fund for Basic Research (13-04-01704,
14-04-32075), Medical Research Service of the Dept. of Veterans Affairs,
Utrish Dolphinarium Ltd., National Science and Engineering Council of
Canada, and Canadian Institutes of Health Research. The authors have
indicated no financial conflicts of interest. This study was performed
at the University of California Los Angeles, Los Angeles, USA and
Severtsov Institute of Ecology and Evolution, Moscow, Russia.
NR 39
TC 2
Z9 2
U1 5
U2 9
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD MAR 1
PY 2016
VL 39
IS 3
BP 625
EP 636
AR PII sp-00454-15
DI 10.5665/sleep.5540
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DF1RB
UT WOS:000371115800017
PM 26715233
ER
PT J
AU Manchikanti, L
Boswell, MV
Kaye, AD
Hirsch, JA
AF Manchikanti, Laxmaiah
Boswell, Mark V.
Kaye, Alan David
Hirsch, Joshua A.
TI Re: Goni VG, Singh Jhala S, Gopinathan NR, et al. Efficacy of epidural
perineural injection of autologous conditioned serum in unilateral
cervical radiculopathy: a pilot study. Spine (Phila Pa 1976) 2015 Apr
14. [Epub ahead of print]
SO SPINE
LA English
DT Letter
C1 [Manchikanti, Laxmaiah] Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
[Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Boswell, Mark V.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
[Kaye, Alan David] LSU Hlth Sci Ctr, Dept Anesthesia, New Orleans, LA USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, NeuroIntervent Spine Serv Intervent Care, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Radiol, Boston, MA USA.
RP Manchikanti, L (reprint author), Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.; Manchikanti, L (reprint author), Pain Management Ctr Paducah, Paducah, KY USA.
EM drlm@thepainmd.com
NR 3
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD MAR
PY 2016
VL 41
IS 5
BP E300
EP E300
DI 10.1097/BRS.0000000000001400
PG 1
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA DE9MO
UT WOS:000370962000010
ER
PT J
AU Shields, PW
Jakobiec, FA
Stagner, AM
Yoon, MK
AF Shields, Patrick W.
Jakobiec, Frederick A.
Stagner, Anna M.
Yoon, Michael K.
TI Spitz nevus arising in the eyelid of a teenager
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE spitz nevus; eyelid; benign juvenile melanoma; epithelioid cell nevus;
p16
ID SPINDLE-CELL NEVUS; BAP1 EXPRESSION; MANAGEMENT; MELANOMAS; TUMORS;
CONJUNCTIVA; MUTATIONS; NEOPLASMS
AB A 16-year-old boy developed over a 2-month interval a lightly pigmented left upper eyelid lesion measuring 1.5 mm in greatest diameter that, when excised, microscopically was hypercellular and composed almost exclusively of nonpigmented epithelioid cells that created florid, large intraepidermal junctional nests and sheets and nests of subepidermal cells. The diagnosis was a Spitz nevus. HMB-45, MART-1, and microphthalmia-associated transcription factor were all positive and established the melanocytic nature of the benign tumor. The Ki-67 proliferation index (5%) and 2 mitoses/mm(2) were both low; p16 protein was immunohistochemically identified in the nevoid cells. We review the clinical, histopathologic, and other immunohistochemical features of this entity and provide a brief differential diagnosis (including separation from a Spitzoid melanoma). This is only the third eyelid Spitz nevus reported in the literature and is the most fully characterized immunohistochemically. At their present stage of development, contemporary immunohistochemical biomarkers, while providing supplemental information, nonetheless remain less than definitive in terms of reliably distinguishing benign from malignant Spitz lesions. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Shields, Patrick W.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Ophthalmol, Philadelphia, PA 19107 USA.
[Jakobiec, Frederick A.; Stagner, Anna M.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, David G Cogan Lab Ophthalm Pathol, Suite 328,243 Charles St, Boston, MA 02114 USA.
[Jakobiec, Frederick A.; Stagner, Anna M.; Yoon, Michael K.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Yoon, Michael K.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol Ophthalm Plast Surg, Suite 328,243 Charles St, Boston, MA 02114 USA.
RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Ophthalm Pathol Lab, Suite 328,243 Charles St, Boston, MA 02114 USA.
EM Fred_Jakobiec@meei.harvard.edu
NR 31
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2016
VL 61
IS 2
BP 228
EP 235
DI 10.1016/j.survophthal.2015.10.002
PG 8
WC Ophthalmology
SC Ophthalmology
GA DF6EB
UT WOS:000371447600008
PM 26498574
ER
PT J
AU Johnson, RF
Bagci, U
Keith, L
Tang, XC
Mollura, DJ
Zeitlin, L
Qin, J
Huzella, L
Bartos, CJ
Bohorova, N
Bohorov, O
Goodman, C
Kim, DH
Paulty, MH
Velasco, J
Whaley, KJ
Johnson, JC
Pettitt, J
Ork, BL
Solomon, J
Oberlander, N
Zhu, Q
Sun, JS
Holbrook, MR
Olinger, GG
Baric, RS
Hensley, LE
Jahrling, PB
Marasco, WA
AF Johnson, Reed F.
Bagci, Ulas
Keith, Lauren
Tang, Xianchun
Mollura, Daniel J.
Zeitlin, Larry
Qin, Jing
Huzella, Louis
Bartos, Christopher J.
Bohorova, Natasha
Bohorov, Ognian
Goodman, Charles
Kim, Do H.
Paulty, Michael H.
Velasco, Jesus
Whaley, Kevin J.
Johnson, Joshua C.
Pettitt, James
Ork, Britini L.
Solomon, Jeffrey
Oberlander, Nicholas
Zhu, Quan
Sun, Jiusong
Holbrook, Michael R.
Olinger, Gene G.
Baric, Ralph S.
Hensley, Lisa E.
Jahrling, Peter B.
Marasco, Wayne A.
TI 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology
in rhesus monkeys following intratracheal inoculation of MERS-CoV
Jordan-n3/2012
SO VIROLOGY
LA English
DT Article
DE MERS-CoV; Antibody therapy; Animal model, MERS; Respiratory syndrome;
Human monoclonal antibody therapy
ID EAST RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS INFECTION; MOUSE MODEL;
NEUTRALIZING ANTIBODIES; DROMEDARY CAMELS; SAUDI-ARABIA; VIRUS; TRACT;
GENERATION; IDENTIFICATION
AB Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5 x 10(6) PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment. Published by Elsevier Inc.
C1 [Johnson, Reed F.; Jahrling, Peter B.] NIAID, Emerging Viral Pathogens Sect, NIH, Frederick, MD 21702 USA.
[Bagci, Ulas; Mollura, Daniel J.] NIH, Ctr Infect Dis Imaging, Ctr Clin, Bethesda, MD 20892 USA.
[Keith, Lauren; Huzella, Louis; Bartos, Christopher J.; Johnson, Joshua C.; Pettitt, James; Ork, Britini L.; Oberlander, Nicholas; Holbrook, Michael R.; Olinger, Gene G.; Hensley, Lisa E.; Jahrling, Peter B.] NIAID, Integrated Res Facil, NIH, Frederick, MD 21702 USA.
[Tang, Xianchun; Zhu, Quan; Sun, Jiusong; Marasco, Wayne A.] Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Zeitlin, Larry; Bohorova, Natasha; Bohorov, Ognian; Goodman, Charles; Kim, Do H.; Paulty, Michael H.; Velasco, Jesus; Whaley, Kevin J.] Mapp Biopharmaceut Inc, San Diego, CA 92121 USA.
[Qin, Jing] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA.
[Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Dept Epidemiol, Chapel Hill, NC 27599 USA.
[Bagci, Ulas] Univ Cent Florida, CRCV, Dept Elect Elect & Comp Sci, Orlando, FL 32816 USA.
[Solomon, Jeffrey] Leidos Biomed Res Inc, Clin Res Directorate, Clin Monitoring Res Program, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
RP Johnson, RF (reprint author), NIAID, Emerging Viral Pathogens Sect, NIH, Frederick, MD 21702 USA.
EM johnsonreed@mail.nih.gov
OI Bagci, Ulas/0000-0001-7379-6829
FU NIAID Division of Intramural Research; Battelle Memorial Institute; US
National Institute of Allergy and Infectious Diseases (NIAID)
[HHSN272200700016I]; National Cancer Institute, National Institutes of
Health [HHSN261200800001E]; NIAID [R01AI085524]; Defense Advanced
Research Projects Agency [W911NF-10-0226]
FX This work was supported by the NIAID Division of Intramural Research. We
are grateful to Marisa St Claire, Russell Byrum, Dan Ragland, and the
entire EVPS and IRF team for their contributions to these studies. We
thank Jiro Wada for his contribution to the preparation of figures. The
content of this publication does not necessarily reflect the views or
policies of the US Department of Health and Human Services (DHHS) or of
the institutions and companies affiliated with the authors. This work
was funded in part through Battelle Memorial Institute's prime contract
with the US National Institute of Allergy and Infectious Diseases
(NIAID) under Contract no. HHSN272200700016I. B.L.O., M.R.H., J.C.J.
performed this work as employees of Battelle Memorial Institute.
Subcontractors to Battelle Memorial Institute who performed this work
are: E.P. an employee of Tunnell Government Services, Inc; N.O., S.Y.
and L.H. are employees of Charles River Laboratories, S.M. an employee
of MRI Global, CB an employee of MedRelief. J.S. is an employee with
Lei-dos. His part in the project has been funded in whole or in part
with federal funds from the National Cancer Institute, National
Institutes of Health, under Contract No. HHSN261200800001E. W.A.M. and
R.S.B. were supported by Grant R01AI085524 from NIAID. W.A.M also
received support from Defense Advanced Research Projects Agency Grant
W911NF-10-0226. The authors thank Drs. Yuri Gleba and Victor Klimyuk
(Icon Genetics) for access to the magnICON expression technology and Dr.
Herta Steinkellner (BOKU) for access to the N. benthamiana seed.
NR 36
TC 8
Z9 8
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAR
PY 2016
VL 490
BP 49
EP 58
DI 10.1016/j.virol.2016.01.004
PG 10
WC Virology
SC Virology
GA DF6DF
UT WOS:000371445400006
PM 26828465
ER
PT J
AU Bacuzzi, A
Dralle, H
Randolph, GW
Chiang, FY
Kim, HY
Barczynski, M
Dionigi, G
AF Bacuzzi, Alessandro
Dralle, Henning
Randolph, Gregory W.
Chiang, Feng-Yu
Kim, Hoon Yub
Barczynski, Marcin
Dionigi, Gianlorenzo
TI Safety of Continuous Intraoperative Neuromonitoring (C-IONM) in Thyroid
Surgery
SO WORLD JOURNAL OF SURGERY
LA English
DT Letter
ID NERVE-STIMULATION
C1 [Bacuzzi, Alessandro] Azienda Osped Univ, Dept Anaesthesia & Palliat Care, Fdn Macchi, Varese, Italy.
[Dralle, Henning] Univ Klinikum Halle Saale, Univ Klin Allgemein Viszeral & Gefasschirurg, Fak Med, Ernst Grube Str 40, D-06097 Halle, Saale, Germany.
[Randolph, Gregory W.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Div Thyroid & Parathyroid Endocrine Surg,Dept Lar, Boston, MA 02115 USA.
[Chiang, Feng-Yu] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Inst Clin Med, Kaohsiung, Taiwan.
[Chiang, Feng-Yu] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Fac Med, Coll Med, Kaohsiung, Taiwan.
[Chiang, Feng-Yu] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Otolaryngol Head & Neck Surg, Kaohsiung, Taiwan.
[Kim, Hoon Yub] Korea Univ, Coll Med, KUMC Thyroid Ctr, Dept Surg,Anam Hosp, Seoul 136705, South Korea.
[Barczynski, Marcin] Jagiellonian Univ, Coll Med, Chair 3, Krakow, Poland.
[Barczynski, Marcin] Jagiellonian Univ, Coll Med, Dept Gen Surg, Krakow, Poland.
[Dionigi, Gianlorenzo] Univ Insubria Como Varese, Dept Surg Sci & Human Morphol, Div Surg 1, Res Ctr Endocrine Surg, Via Guicciardini 9, I-21100 Varese, Italy.
RP Dionigi, G (reprint author), Univ Insubria Como Varese, Dept Surg Sci & Human Morphol, Div Surg 1, Res Ctr Endocrine Surg, Via Guicciardini 9, I-21100 Varese, Italy.
EM gianlorenzo.dionigi@uninsubria.it
RI Bacuzzi, Alessandro/K-3120-2016;
OI Bacuzzi, Alessandro/0000-0002-4108-156X; dionigi,
gianlorenzo/0000-0003-0864-6087
NR 5
TC 3
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2313
EI 1432-2323
J9 WORLD J SURG
JI World J.Surg.
PD MAR
PY 2016
VL 40
IS 3
BP 768
EP 769
DI 10.1007/s00268-015-3288-x
PG 2
WC Surgery
SC Surgery
GA DF4GH
UT WOS:000371305500040
PM 26530692
ER
PT J
AU Manchikanti, L
Boswell, MV
Kaye, AD
Hirsch, JA
AF Manchikanti, Laxmaiah
Boswell, Mark V.
Kaye, Alan David
Hirsch, Joshua A.
TI Untitled
SO SPINE
LA English
DT Letter
ID INJECTIONS
C1 [Manchikanti, Laxmaiah] Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
[Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Boswell, Mark V.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
[Kaye, Alan David] LSU Hlth Sci Ctr, Dept Anesthesia, New Orleans, LA USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Neurolntervent Spine Serv, Intervent Care, Boston, MA USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Radiol, Boston, MA USA.
RP Manchikanti, L (reprint author), Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.; Manchikanti, L (reprint author), Pain Management Ctr Paducah, Paducah, KY USA.
EM drlm@thepainmd.com
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD MAR
PY 2016
VL 41
IS 5
BP E300
EP E300
DI 10.1097/BRS.0000000000001400
PG 1
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA DE9MP
UT WOS:000370962100001
ER
PT J
AU Chiao, E
Stier, EA
AF Chiao, Elizabeth
Stier, Elizabeth A.
TI Prevalence of anal human papillomavirus infection and anal human
papillomavirus-related disorders in women: a systematic review REPLY
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Letter
C1 [Chiao, Elizabeth] Baylor Coll Med, Dept Med, Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Stier, Elizabeth A.] Boston Med Ctr, Dept Obstet & Gynecol, Boston, MA USA.
RP Chiao, E (reprint author), Baylor Coll Med, Dept Med, Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA.
EM echiao@bcm.edu
NR 3
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD MAR
PY 2016
VL 214
IS 3
BP 411
EP 412
DI 10.1016/j.ajog.2015.10.917
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DF0JC
UT WOS:000371024100049
PM 26522860
ER
PT J
AU Easter, SR
Cantonwine, DE
Zera, CA
Lim, KH
Parry, SI
McElrath, TF
AF Easter, Sarah Rae
Cantonwine, David E.
Zera, Chloe A.
Lim, Kee-Hak
Parry, Samuel I.
McElrath, Thomas F.
TI Urinary tract infection during pregnancy, angiogenic factor profiles,
and risk of preeclampsia
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID ASYMPTOMATIC BACTERIURIA; WOMEN; HYPERTENSION; SFLT1
AB BACKGROUND: Despite decades of research, and much progress in discernment of biomarkers in the maternal circulation, the pathogenesis of preeclampsia (PE) remains elusive. The pathophysiology of PE is believed to involve aberrant placentation and an associated increase in systemic inflammation. In this conceptualization, PE becomes more likely when the level of systemic inflammatory burden inherent in pregnancy itself exceeds the maternal capacity to compensate for this additional stress. If this is the case, then it is possible to hypothesize that conditions, such as infectious disease, that increase systemic inflammatory burden should also increase the risk of PE. As urinary tract infection (UTI) represents a common source of inflammation during pregnancy, we tested whether presence of UTI during pregnancy increased the odds of developing PE. Prior work has documented this association. However many of these studies were limited by small cohort sizes and insufficient control for covariates.
OBJECTIVE: The present study is a secondary analysis of a robust contemporary obstetrical cohort recruited to examine the ability of longitudinally sampled maternal angiogenic concentrations to predict PE. We hypothesize that the occurrence of UTI during a pregnancy is associated with the later occurrence of PE in that pregnancy. As PE is believed to be associated with aberrations in systemic angiogenic levels (placental growth factor and soluble isoform of VEGF receptor), we further hypothesize that there will be significant interactions between maternal angiogenic protein levels and the occurrence of UTI.
STUDY DESIGN: Women aged >= 18 years (n = 2607) were recruited and followed up prospectively from the initiation of prenatal care through delivery at 3 regional academic centers. PE was defined by American Congress of Obstetricians and Gynecologists criteria and was independently validated by a panel of physicians. UTI was defined by the presence of clinical symptoms necessitating treatment in addition to supportive laboratory evidence. Multivariate logistic regression models were used and controlled for maternal age, race, parity, body mass index, hypertension, diabetes, in vitro fertilization, and smoking status.
RESULTS: There were 129 women with diagnosed UTIs and 235 with PE. Patients with UTI in pregnancy had higher rates of PE (31.1% vs 7.8%, P<.001) compared to those without reported UTI. The mean gestational age (SD) for UTI diagnosis in PE cases and controls was 25.6 (10.4) and 21.9 (10.9) weeks, respectively (P=.08). The unadjusted odds ratio for PE in the setting of UTI was 5.29 (95% confidence interval, 3.54-7.89). After controlling for confounders, UTI was associated with an odds ratio for PE of 3.2 (95% confidence interval, 2.0-5.1).
CONCLUSION: Presence of UTI in pregnancy, particularly in the third trimester, is strongly associated with PE. This association supports the hypothesis that the risk of PE is enhanced by an increased maternal inflammatory burden. Prophylaxis against UTI represents a potentially low-cost global intervention to slow or halt the development of PE.
C1 [Easter, Sarah Rae] Massachusetts Gen Hosp, Brigham & Womens Hosp, Integrated Residency Program Obstetr & Gynecol, Boston, MA 02114 USA.
[Cantonwine, David E.; Zera, Chloe A.; McElrath, Thomas F.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, 75 Francis St, Boston, MA 02115 USA.
[Lim, Kee-Hak] Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA 02215 USA.
[Parry, Samuel I.] Hosp Univ Penn, Dept Obstet & Gynecol, Div Maternal Fetal Med, Philadelphia, PA 19104 USA.
RP Easter, SR (reprint author), Massachusetts Gen Hosp, Brigham & Womens Hosp, Integrated Residency Program Obstetr & Gynecol, Boston, MA 02114 USA.
EM sreaster@partners.org
OI Easter, Sarah Rae/0000-0002-0150-3537
FU Abbott Diagnostics Division [9MZ-04-06N03]
FX This research was supported by an unrestricted grant from Abbott
Diagnostics Division (9MZ-04-06N03).
NR 33
TC 0
Z9 0
U1 0
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD MAR
PY 2016
VL 214
IS 3
AR 387.e1-e7
DI 10.1016/j.ajog.2015.09.101
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DF0JC
UT WOS:000371024100035
PM 26450405
ER
PT J
AU Rahangdale, L
Cates, J
Potter, J
Badell, ML
Seidman, D
Miller, ES
Coleman, JS
Lazenby, GB
Levison, J
Short, WR
Yawetz, S
Ciaranello, A
Livingston, E
Duthely, L
Rimawi, BH
Anderson, JR
Stringer, EM
AF Rahangdale, Lisa
Cates, Jordan
Potter, JoNell
Badell, Martina L.
Seidman, Dominika
Miller, Emilly S.
Coleman, Jenell S.
Lazenby, Gweneth B.
Levison, Judy
Short, William R.
Yawetz, Sigal
Ciaranello, Andrea
Livingston, Elizabeth
Duthely, Lunthita
Rimawi, Bassam H.
Anderson, Jean R.
Stringer, Elizabeth M.
CA HOPES Grp
TI Integrase inhibitors in late pregnancy and rapid HIV viral load
reduction
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE HIV; integrase inhibitors; pregnancy
ID ACTIVE ANTIRETROVIRAL THERAPY; TO-CHILD TRANSMISSION; CASE SERIES;
RALTEGRAVIR; WOMEN; PHARMACOKINETICS; DECLINE; SUPPRESSION; INITIATION;
DELIVERY
AB BACKGROUND: Minimizing time to HIV viral suppression is critical in pregnancy. Integrase strand transfer inhibitors (INSTIs), like raltegravir, are known to rapidly suppress plasma HIV RNA in nonpregnant adults. There are limited data in pregnant women.
OBJECTIVE: We describe time to clinically relevant reduction in HIV RNA in pregnant women using INSTI-containing and non-INSTI-containing antiretroviral therapy (ART) options.
STUDY DESIGN: We conducted a retrospective cohort study of pregnant HIV-infected women in the United States from 2009 through 2015. We included women who initiated ART, intensified their regimen, or switched to a new regimen due to detectable viremia (HIV RNA >40 copies/mL) at >= 20 weeks gestation. Among women with a baseline HIV RNA permitting 1-log reduction, we estimated time to 1-log RNA reduction using the Kaplan-Meier estimator comparing women starting/adding an INSTI in their regimen vs other ART. To compare groups with similar follow-up time, we also conducted a subgroup analysis limited to women with <= 14 days between baseline and follow-up RNA data.
RESULTS: This study describes 101 HIV-infected pregnant women from 11 US clinics. In all, 75% (76/101) of women were not taking ART at baseline; 24 were taking non-INSTI containing ART, and 1 received zidovudine monotherapy. In all, 39% (39/101) of women started an INSTI-containing regimen or added an INSTI to their ART regimen. Among 90 women with a baseline HIV RNA permitting 1-log reduction, the median time to 1-log RNA reduction was 8 days (interquartile range [IQR], 7-14) in the INSTI group vs 35 days (IQR, 20-53) in the non-INSTI ART group (P<.01). In a subgroup of 39 women with first and last RNA measurements <= 14 days apart, median time to 1-log reduction was 7 days (IQR, 6-10) in the INSTI group vs 11 days (IQR, 10-14) in the non-INSTI group (P<.01).
CONCLUSION: ART that includes INSTIs appears to induce more rapid viral suppression than other ART regimens in pregnancy. Inclusion of an INSTI may play a role in optimal reduction of HIV RNA for HIV-infected pregnant women presenting late to care or failing initial therapy. Larger studies are urgently needed to assess the safety and effectiveness of this approach.
C1 [Rahangdale, Lisa; Stringer, Elizabeth M.] Univ N Carolina, Sch Med, Dept Obstet, Chapel Hill, NC USA.
[Rahangdale, Lisa; Stringer, Elizabeth M.] Univ N Carolina, Sch Med, Dept Gynecol, Chapel Hill, NC USA.
[Potter, JoNell; Duthely, Lunthita] Univ Miami, Miller Sch Med, Div Res, Dept Obstet & Gynecol, Miami, FL 33136 USA.
[Miller, Emilly S.] Northwestern Univ, Feinberg Sch Med, Div Maternal Fetal Med, Chicago, IL 60611 USA.
[Lazenby, Gweneth B.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Levison, Judy] Baylor Coll Med, Houston, TX 77030 USA.
[Livingston, Elizabeth] Duke Univ, Durham, NC USA.
[Cates, Jordan] Univ N Carolina, Dept Epidemiol, Gillings Sch Publ Hlth, Chapel Hill, NC USA.
[Badell, Martina L.] Emory Univ, Div Maternal Fetal Med, Dept Gynecol, Atlanta, GA 30322 USA.
[Badell, Martina L.] Emory Univ, Div Maternal Fetal Med, Dept Obstet, Atlanta, GA 30322 USA.
[Rimawi, Bassam H.] Emory Univ, Sch Med, Atlanta, GA USA.
[Coleman, Jenell S.; Anderson, Jean R.] Johns Hopkins Univ, Baltimore, MD USA.
[Seidman, Dominika] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA.
[Short, William R.] Univ Penn, Perelmen Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Short, William R.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Moscow, Russia.
[Yawetz, Sigal] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
[Ciaranello, Andrea] Massachusetts Gen Hosp, Div Infect Dis, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
RP Rahangdale, L (reprint author), Univ N Carolina, Sch Med, Dept Obstet, Chapel Hill, NC USA.; Rahangdale, L (reprint author), Univ N Carolina, Sch Med, Dept Gynecol, Chapel Hill, NC USA.
EM lisa_rahangdale@med.unc.edu
OI Cates, Jordan/0000-0003-4300-7416
FU NIAID NIH HHS [T32 AI070114]
NR 26
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD MAR
PY 2016
VL 214
IS 3
AR 385.e1-e7
DI 10.1016/j.ajog.2015.12.052
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DF0JC
UT WOS:000371024100033
PM 26928154
ER
PT J
AU Luo, SX
Huang, EJ
AF Luo, Sarah X.
Huang, Eric J.
TI Dopaminergic Neurons and Brain Reward Pathways From Neurogenesis to
Circuit Assembly
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Review
ID ENTERIC NERVOUS-SYSTEM; TGF-BETA SUPERFAMILY; EMBRYONIC STEM-CELLS;
GROWTH-FACTOR-BETA; SURVIVAL IN-VIVO; SONIC-HEDGEHOG; VENTRAL MIDBRAIN;
BASAL GANGLIA; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA
AB Midbrain dopaminergic (DA) neurons in the substantia nigra pars compacta and ventral tegmental area regulate extrapyramidal movement and important cognitive functions, including motivation, reward associations, and habit learning. Dysfunctions in DA neuron circuitry have been implicated in several neuropsychiatric disorders, including addiction and schizophrenia, whereas selective degeneration of DA neurons in substantia nigra pars compacta is a key neuropathological feature in Parkinson disease. Efforts to understand these disorders have focused on dissecting the underlying causes, as well as developing therapeutic strategies to replenish dopamine deficiency. In particular, the promise of cell replacement therapies for clinical intervention has led to extensive research in the identification of mechanisms involved in DA neuron development. It is hoped that a comprehensive understanding of these mechanisms will Lead to therapeutic strategies that improve the efficiency of DA neuron production, engraftment, and function. This review provides a comprehensive discussion on how Wnta-catenin and sonic hedgehog Smoothened signaling mechanisms control the specification and expansion of DA progenitors and the differentiation of DA neurons. We also discuss how mechanisms involving transforming growth factor-beta and transcriptional cofactor homeodomain interacting protein kinase 2 regulate the survival and maturation of DA neurons in early postnatal life. These results not only reveal fundamental mechanisms regulating DA neuron development, but also provide important insights to their potential contributions to neuropsychiatric and neurodegenerative diseases.
C1 [Luo, Sarah X.; Huang, Eric J.] Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA.
[Luo, Sarah X.; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA.
[Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, San Francisco, CA USA.
RP Huang, EJ (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA.
EM eric.huang2@ucsf.edu
OI Huang, Eric/0000-0002-5381-3801
FU NIH [OD010927, OD011915]; Department of Veterans Affairs [BX001108,
BX001625]; Singapore Agency for Science, Technology, and Research
(A*STAR) Scholar Program; University of California San Francisco
Graduate Education in Medical Sciences (GEMS) Scholar Award
FX Supported by NIH grants OD010927 and OD011915; the Department of
Veterans Affairs grants BX001108 and BX001625 (E.J.H.); the Singapore
Agency for Science, Technology, and Research (A*STAR) Scholar Program
(S.X.L.); and the University of California San Francisco Graduate
Education in Medical Sciences (GEMS) Scholar Award (S.X.L.).
NR 100
TC 9
Z9 9
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAR
PY 2016
VL 186
IS 3
BP 478
EP 488
DI 10.1016/j.ajpath.2015.09.023
PG 11
WC Pathology
SC Pathology
GA DE9WY
UT WOS:000370991800003
PM 26724386
ER
PT J
AU Cholerton, B
Larson, EB
Quinn, JF
Zabetian, CP
Mata, IF
Keene, CD
Flanagan, M
Crane, PK
Grabowski, TJ
Montine, KS
Montine, TJ
AF Cholerton, Brenna
Larson, Eric B.
Quinn, Joseph F.
Zabetian, Cyrus P.
Mata, Ignacio F.
Keene, C. Dirk
Flanagan, Margaret
Crane, Paul K.
Grabowski, Thomas J.
Montine, Kathleen S.
Montine, Thomas J.
TI Precision Medicine Clarity for the Complexity of Dementia
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Review
ID ALZHEIMERS ASSOCIATION GUIDELINES; MILD COGNITIVE IMPAIRMENT;
CEREBROSPINAL-FLUID TAU; PARKINSONS-DISEASE; NATIONAL INSTITUTE;
NEUROPATHOLOGIC ASSESSMENT; SYSTEMATIC ANALYSIS; GLOBAL BURDEN; COHORT;
BETA
AB Three key elements to precision medicine are stratification by risk, detection of pathophysiological processes as early as possible (even before clinical presentation), and alignment of mechanism of action of intervention(s) with an individual's molecular driver(s) of disease. Used for decades in the management of some rare diseases and now gaining broad currency in cancer care, a precision medicine approach is beginning to be adapted to cognitive impairment and dementia. This review focuses on the application of precision medicine to address the clinical and biological complexity of two common neurodegenerative causes of dementia: Alzheimer disease and Parkinson disease.
C1 [Cholerton, Brenna] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Zabetian, Cyrus P.; Mata, Ignacio F.; Grabowski, Thomas J.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Keene, C. Dirk; Flanagan, Margaret; Montine, Kathleen S.; Montine, Thomas J.] Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.
[Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Grabowski, Thomas J.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA.
[Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA.
[Zabetian, Cyrus P.; Mata, Ignacio F.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA.
RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.
EM tmontine@uw.edu
RI Keene, Christopher/N-1806-2015
FU NIH [P50 AG005136, P50 NS062684, R01 AG042437, R01 NS065070, U01
AG006781]; Office of Research and Development Medical Research Service,
Department of Veterans Affairs; Nancy and Buster Alvord Endowment
FX Supported by NIH grants P50 AG005136 (T.J.M., C.D.K., T.J.G.), P50
NS062684 (T.J.M., C.P.Z., J.F.Q., T.J.G.), R01 AG042437 (P.K.C.), R01
NS065070 (C.P.Z.), and U01 AG006781 (E.B.L.); the Office of Research and
Development Medical Research Service, Department of Veterans Affairs
(C.P.Z., J.F.Q.); and the Nancy and Buster Alvord Endowment (T.J.M.).
NR 56
TC 6
Z9 6
U1 4
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAR
PY 2016
VL 186
IS 3
BP 500
EP 506
DI 10.1016/j.ajpath.2015.12.001
PG 7
WC Pathology
SC Pathology
GA DE9WY
UT WOS:000370991800005
PM 26724389
ER
PT J
AU Zamakhchari, MF
Sima, C
Sama, K
Fine, N
Glogauer, M
Van Dyke, TE
Gyurko, R
AF Zamakhchari, Mai F.
Sima, Corneliu
Sama, Kishore
Fine, Noah
Glogauer, Michael
Van Dyke, Thomas E.
Gyurko, Robert
TI Lack of p47(phox) in Akita Diabetic Mice Is Associated with Interstitial
Pneumonia, Fibrosis, and Oral Inflammation
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID CHRONIC GRANULOMATOUS-DISEASE; PERIODONTAL-DISEASE; PHYSIOLOGICAL
FUNCTIONS; FREE-RADICALS; BONE LOSS; COMPLICATIONS; MODEL;
HYPERGLYCEMIA; ANTIOXIDANTS; PREDISPOSES
AB Excess reactive oxygen species production is central to the development of diabetic complications. The contribution of Leukocyte reactive oxygen species produced by the NADPH oxidase to altered inflammatory responses associated with uncontrolled hyperglycemia is poorly understood. To get insight into the role of phagocytic superoxide in the onset of diabetic complications, we used a model of periodontitis in mice with chronic hyperglycemia and lack of leukocyte p47(phox) (Akita/Ncf1) bred from C57BL/6-Ins2(Akita)/J (Akita) and neutrophil cytosolic factor 1 knockout (Ncf1) mice. Akita/Nfc1 mice showed progressive cachexia starting at early age and increased mortality by six months. Their Lungs developed infiltrative interstitial Lesions that obliterated air spaces as early as 12 weeks when fungal colonization of lungs also was observed. Neutrophils of Akita/Ncf1 mice had normal degranulation and phagocytic efficiency when compared with wild-type mice. Although Akita/Ncf1 mice had increased prevalence of oral infections and more severe periodontitis compared with wild-type mice, bone Loss was only marginally higher compared with Akita and Ncf1 null mice. Altogether these results indicate that lack of leukocyte superoxide production in mice with chronic hyperglycemia results in interstitial pneumonia and increased susceptibility to infections.
C1 [Zamakhchari, Mai F.; Sama, Kishore; Gyurko, Robert] Boston Univ, Henry M Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02215 USA.
[Sima, Corneliu; Van Dyke, Thomas E.] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA USA.
[Sima, Corneliu; Van Dyke, Thomas E.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immunity, 188 Longwood Ave, Boston, MA 02115 USA.
[Fine, Noah; Glogauer, Michael] Univ Toronto, Matrix Dynam Grp, Toronto, ON, Canada.
[Gyurko, Robert] Tufts Univ, Sch Dent Med, Dept Periodontol, Boston, MA 02111 USA.
RP Gyurko, R (reprint author), Tufts Univ, Sch Dent Med, 1 Kneeland St, Boston, MA 02111 USA.
EM robert.gyurko@tufts.edu
FU USPHS from National Institute of Dental and Craniofacial Research, NIH
[DE016933, DE015566]
FX Supported by USPHS grants DE016933 (R.G.) and DE015566 (T.E.V.D.) from
the National Institute of Dental and Craniofacial Research, NIH.
NR 48
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAR
PY 2016
VL 186
IS 3
BP 659
EP 670
DI 10.1016/j.ajpath.2015.10.026
PG 12
WC Pathology
SC Pathology
GA DE9WY
UT WOS:000370991800020
PM 26747235
ER
PT J
AU Benfield, J
Maknojia, A
Epstein, F
AF Benfield, Jon
Maknojia, Asif
Epstein, Franklin
TI Progressive Paraplegia from Spinal Cord Stimulator Lead Fibrotic
Encapsulation A Case Report
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Epidural Electrode; Dorsal Myelopathy; Epidural Scar Tissue; Paraplegia;
Spinal Cord Stimulator
ID REGIONAL PAIN SYNDROME; MYELOPATHY SECONDARY; SCAR TISSUE; FOLLOW-UP;
ELECTRODE; COMPLICATIONS; EXPERIENCE; HARDWARE; SURGERY
AB Ten years after placement of a spinal cord stimulator (SCS) and resolution of pain, this patient presented with progressive paraplegia, worsening thoracic radicular pain at the same dermatome level of the electrodes, and bowel and bladder incontinence. Computed tomographic myelogram confirmed thoracic spinal cord central canal stenosis at the level of electrodes. After removal of the fibrotic tissue and electrodes, the patient had resolution of his thoracic radicular pain and a return of his pre-SCS pain and minimal neurologic and functional return. To the authors' knowledge, no studies have been identified with thoracic SCS lead fibrosis in the United States causing permanent paraplegia. Only one other case has been reported in Madrid, Spain. Patients with SCS presenting with loss of pain relief, new-onset radicular or neuropathic pain in same dermatome(s) as SCS electrodes, worsening neuromuscular examination, or new bladder or bowel incontinence need to be evaluated for complications regarding SCS implantation causing spinal stenosis and subsequent cord compression to avoid permanent neurologic deficits.
C1 [Benfield, Jon] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA.
[Maknojia, Asif] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA.
[Epstein, Franklin] Audie L Murphy Vet Affairs Hosp, Dept Surg, San Antonio, TX USA.
RP Benfield, J (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA.
NR 21
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0894-9115
EI 1537-7385
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD MAR
PY 2016
VL 95
IS 3
BP E30
EP E33
DI 10.1097/PHM.0000000000000411
PG 4
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA DE9LJ
UT WOS:000370958700001
PM 26495817
ER
PT J
AU Anvari, A
Dhyani, M
Stephen, AE
Samir, AE
AF Anvari, Arash
Dhyani, Manish
Stephen, Antonia E.
Samir, Anthony E.
TI Reliability of Shear-Wave Elastography Estimates of the Young Modulus of
Tissue in Follicular Thyroid Neoplasms
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE elasticity imaging techniques; follicular thyroid neoplasm; reliability;
reproducibility; ROI; shear-wave elastography; Young modulus
ID FINE-NEEDLE-ASPIRATION; ULTRASOUND ELASTOGRAPHY; INTEROBSERVER
AGREEMENT; DIFFERENTIAL-DIAGNOSIS; NODULES; LESIONS; SONOELASTOGRAPHY;
SYSTEM; RISK
AB OBJECTIVE. The purpose of this study is to determine the reliability of shear-wave elastographic estimates of the Young modulus in thyroid follicular neoplasms.
SUBJECTS AND METHODS. In this study, 35 adults with follicular nodules diagnosed by fine-needle aspiration (FNA) biopsy were enrolled. A single sonographer examined all nodules in three planes (sagittal, transverse, and transverse center). Two raters independently placed ROIs in each nodule. Intra-and interrater reliability were computed as intraclass correlation coefficients (ICCs) and were reported using the Guidelines for Reporting Reliability and Agreement Studies.
RESULTS. Thirty-five subjects with 35 follicular pattern nodules diagnosed by FNA biopsy were enrolled; 23 (65.7%) patients were female, with a mean age of 55.1 years (range, 23-85 years). For rater 1, intrarater agreement showed ICCs for single measurements of 0.87, 0.87, and 0.90 in the sagittal, transverse, and transverse center plans, respectively; ICCs for the median of multiple measurements were 0.97, 0.94, and 0.96 in the sagittal, transverse, and transverse center planes, respectively. For rater 2, intrarater agreement showed ICCs for single measurements of 0.94, 0.86, and 0.92 in the sagittal, transverse, and transverse center planes, respectively; ICCs for the median of multiple measurements were 0.97, 0.92, and 0.96 in the sagittal, transverse, and transverse center planes, respectively. Interrater agreement between measurements performed for the same subject showed ICCs for single measurements of 0.87, 0.87, and 0.80 in the sagittal, transverse, and transverse center planes, respectively; ICCs for the median of multiple measurements were 0.96, 0.93, and 0.92 in the sagittal, transverse, and transverse center planes, respectively.
CONCLUSION. ROI placement is a reliable method for estimating the Young modulus of tissue in follicular thyroid nodules.
C1 [Anvari, Arash; Dhyani, Manish; Samir, Anthony E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent Radiol,Dept Rad, 55 Fruit St,White 270, Boston, MA 02114 USA.
[Stephen, Antonia E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
RP Anvari, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent Radiol,Dept Rad, 55 Fruit St,White 270, Boston, MA 02114 USA.
EM anvari.arash@mgh.harvard.edu
RI Anvari, Arash/B-4329-2014
OI Anvari, Arash/0000-0001-5887-581X
NR 22
TC 0
Z9 0
U1 2
U2 2
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAR
PY 2016
VL 206
IS 3
BP 609
EP 616
DI 10.2214/AJR.15.14676
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DE7WU
UT WOS:000370848400027
PM 26901019
ER
PT J
AU Sylvia, LG
Gold, AK
Stange, JP
Peckham, AD
Deckersbach, T
Calabrese, JR
Weiss, RD
Perlis, RH
Nierenberg, AA
Ostacher, MJ
AF Sylvia, Louisa G.
Gold, Alexandra K.
Stange, Jonathan P.
Peckham, Andrew D.
Deckersbach, Thilo
Calabrese, Joseph R.
Weiss, Roger D.
Perlis, Roy H.
Nierenberg, Andrew A.
Ostacher, Michael J.
TI A randomized, placebo-controlled proof-of-concept trial of adjunctive
topiramate for alcohol use disorders in bipolar disorder
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID DOUBLE-BLIND; DEPENDENCE
AB Background and ObjectivesTopiramate is effective for alcohol use disorders (AUDs) among non-psychiatric patients. We examined topiramate for treating comorbid AUDs in bipolar disorder (BD).
MethodsTwelve participants were randomized to topiramate or placebo for 12 weeks.
ResultsThe topiramate group, with two out of five participants (40%) completing treatment, experienced less improvement in drinking patterns than the placebo group, with five out of seven participants (71%) completing treatment.
Discussion and ConclusionsTopiramate did not improve drinking behavior and was not well-tolerated. This study failed to recruit adequately. Problems surrounding high attrition, a small study sample, and missing data preclude interpretation of study findings.
Scientific SignificanceThis is the first randomized, placebo-controlled trial of topiramate for AUDs in BD. (Am J Addict 2016;25:94-98)
C1 [Sylvia, Louisa G.; Gold, Alexandra K.; Deckersbach, Thilo; Perlis, Roy H.; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,Suite 580, Boston, MA 02114 USA.
[Sylvia, Louisa G.; Deckersbach, Thilo; Weiss, Roger D.; Perlis, Roy H.; Nierenberg, Andrew A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Stange, Jonathan P.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA.
[Peckham, Andrew D.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA.
[Calabrese, Joseph R.] Case Western Reserve Univ, Bipolar Disorders Res Ctr, Univ Hosp, Case Med Ctr, Cleveland, OH 44106 USA.
[Weiss, Roger D.] McLean Hosp, Div Alcohol & Drug Abuse, 115 Mill St, Belmont, MA 02178 USA.
[Ostacher, Michael J.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
RP Sylvia, LG (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,Suite 580, Boston, MA 02114 USA.
EM lsylvia2@partners.org
FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) K-23 grant
[5K23AA016340-02]; National Institutes of Health, Bethesda, Maryland
FX This work was supported by a National Institute on Alcohol Abuse and
Alcoholism (NIAAA) K-23 grant (5K23AA016340-02) awarded to Dr. Michael
J. Ostacher.; Address of Funding Agency: National Institutes of Health,
9000 Rockville Pike, Bethesda, Maryland 20892.
NR 12
TC 2
Z9 2
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAR
PY 2016
VL 25
IS 2
BP 94
EP 98
DI 10.1111/ajad.12346
PG 5
WC Substance Abuse
SC Substance Abuse
GA DF3IV
UT WOS:000371238400003
PM 26894822
ER
PT J
AU Krenek, M
Lyons, R
Simpson, TL
AF Krenek, Marketa
Lyons, Robert
Simpson, Tracy L.
TI Degree of correspondence between daily monitoring and retrospective
recall of alcohol use among men and women with comorbid AUD and PTSD
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID TIMELINE FOLLOW-BACK; ECOLOGICAL MOMENTARY ASSESSMENT;
POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; VOICE
RESPONSE IVR; DRINKING PATTERNS; CONSUMPTION; RELIABILITY; TECHNOLOGY;
INSTRUMENT
AB Background and ObjectivesThe majority of studies that have identified good correspondence between daily monitoring and retrospective recall of alcohol use have included participants who are relatively stable, are moderate drinkers, report abstinence, and are not diagnosed with comorbid disorders. The current study examined degree of correspondence between alcohol use that was reported daily via interactive voice response (IVR) telephone monitoring and retrospectively using an abbreviated Form-90 (Form-35) covering the same 35-day time period.
MethodsParticipants were 54 men and women with comorbid alcohol dependence and posttraumatic stress disorder (PTSD) who reported drinking during the time period.
ResultsResults indicated that participants reported more drinking days via IVR. Correspondence was strong between the reporting methods for aggregate-level alcohol use variables, including presence/absence of drinking days and heavy drinking days and standard drinks, and associations increased for weeks closer to the assessment date for drinking days and heavy drinking days. Day-to-day agreement was moderate for drinking days and heavy drinking days, though there was large between-person variability in correspondence between reporting methods. Post-hoc analyzes suggested that men and participants who drink more tend to have lower correspondence between assessment methods.
Discussion and ConclusionsOverall, findings partially replicated previous research and extend our knowledge of alcohol assessment in a comorbid sample.
Scientific SignificanceFindings highlight the importance of considering the influence that moderating variables have on reporting of alcohol use. (Am J Addict 2016;25:145-151)
C1 [Krenek, Marketa; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
[Lyons, Robert] Seattle Inst Biomed & Clin Res, Seattle, WA USA.
[Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA.
[Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Krenek, M (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM marketa.krenek@va.gov
FU National Institute on Alcohol Abuse and Alcoholism [1 R21 AA 17130-01];
Department of Defense CDMRP [11152009, W81XWH-BAA-11-1]; NIH/NIAAA [R01
AA 020252-01]
FX This work was supported, in part by a grant from the National Institute
on Alcohol Abuse and Alcoholism (1 R21 AA 17130-01) awarded to Tracy L.
Simpson, PhD and Department of Defense CDMRP grant (11152009,
W81XWH-BAA-11-1).; This work also supported in part by a grant from
NIH/NIAAA (R01 AA 020252-01).
NR 31
TC 1
Z9 1
U1 6
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAR
PY 2016
VL 25
IS 2
BP 145
EP 151
DI 10.1111/ajad.12342
PG 7
WC Substance Abuse
SC Substance Abuse
GA DF3IV
UT WOS:000371238400011
PM 26824635
ER
PT J
AU Qaseem, A
Barry, MJ
Kansagara, D
AF Qaseem, Amir
Barry, Michael J.
Kansagara, Devan
CA Amer Coll Phys
TI Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With
Major Depressive Disorder: A Clinical Practice Guideline From the
American College of Physicians
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID ST-JOHNS-WORT; RANDOMIZED CONTROLLED-TRIAL; COMORBIDITY SURVEY
REPLICATION; TO-MODERATE DEPRESSION; PRIMARY-CARE PATIENTS; ONCE-DAILY
DOSAGE; DOUBLE-BLIND; COGNITIVE THERAPY; 2ND-GENERATION ANTIDEPRESSANTS;
PSYCHODYNAMIC PSYCHOTHERAPY
AB Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness of treatment with second-generation antidepressants versus nonpharmacologic treatments for major depressive disorder in adults.
Methods: This guideline is based on a systematic review of published, English-language, randomized, controlled trials from 1990 through September 2015 identified using several data-bases and through hand searches of references of relevant studies. Interventions evaluated include psychotherapies, complementary and alternative medicines (including acupuncture, omega-3 fatty acids, S-adenosyl-L-methionine, St. John's wort [Hypericum perforatum]), exercise, and second-generation antidepressants. Evaluated outcomes included response, remission, functional capacity, quality of life, reduction of suicidality or hospitalizations, and harms. The target audience for this guideline includes all clinicians, and the target patient population includes adults with major depressive disorder. This guideline grades the evidence and recommendations using ACP's clinical practice guidelines grading system.
Recommendation: ACP recommends that clinicians select between either cognitive behavioral therapy or second-generation antidepressants to treat patients with major depressive disorder after discussing treatment effects, adverse effect profiles, cost, accessibility, and preferences with the patient (Grade: strong recommendation, moderate-quality evidence).
C1 [Qaseem, Amir] Amer Coll Physicians, 190 Independence Mall West, Philadelphia, PA 19106 USA.
[Barry, Michael J.] Massachusetts Gen Hosp, 50 Staniford St, Boston, MA 02114 USA.
[Kansagara, Devan] Portland VA Med Ctr, Mail Code RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, 190 Independence Mall West, Philadelphia, PA 19106 USA.
EM aqaseem@acponline.org
FU ACP operating budget
FX Financial support for the development of this guideline comes
exclusively from the ACP operating budget.
NR 71
TC 6
Z9 6
U1 9
U2 29
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAR 1
PY 2016
VL 164
IS 5
BP 350
EP +
DI 10.7326/M15-2570
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA DF3CC
UT WOS:000371220300006
PM 26857948
ER
PT J
AU Chien, YC
Burwell, AK
Saeki, K
Fernandez-Martinez, A
Pugach, MK
Nonomura, G
Habelitz, S
Ho, SP
Rapozo-Hilo, M
Featherstone, JD
Marshall, SJ
Marshall, GW
AF Chien, Y-C
Burwell, A. K.
Saeki, K.
Fernandez-Martinez, A.
Pugach, M. K.
Nonomura, G.
Habelitz, S.
Ho, S. P.
Rapozo-Hilo, M.
Featherstone, J. D.
Marshall, S. J.
Marshall, G. W.
TI Distinct decalcification process of dentin by different cariogenic
organic acids: Kinetics, ultrastructure and mechanical properties
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Dentin caries models; Demineralization kinetics; AFM-nanoindenation;
MicroXCT; TEM; SAXS
ID X-RAY-SCATTERING; ATOMIC-FORCE MICROSCOPY; COLLAGEN IN-SITU; CARIES
LESIONS; MATRIX METALLOPROTEINASES; ENAMEL DEMINERALIZATION;
QUANTITATIVE-ANALYSIS; ELECTRON-MICROSCOPY; MINERAL CRYSTALS;
REMINERALIZATION
AB Objectives: We studied artificial dentin lesions in human teeth generated by lactate and acetate buffers (pH 5.0), the two most abundant acids in caries. The objective of this study was to determine differences in mechanical properties, mineral density profiles and ultrastructural variations of two different artificial lesions with the same approximate depth.
Methods: 0.05 M (pH 5.0) acetate or lactate buffer was used to create 1) 180 mu m-deep lesions in non-carious human dentin blocks (acetate 130 h; lactate 14days); (2) demineralized, similar to 180 mu m-thick non-carious dentin discs (3 weeks). We performed nanoindentation to determine mechanical properties across the hydrated lesions, and micro X-ray computed tomography (MicroXCT) to determine mineral profiles. Ultrastructure in lesions was analyzed by TEM/selected area electron diffraction (SAED). Demineralized dentin discs were analyzed by small angle X-ray scattering (SAXS).
Results: Diffusion-dominated demineralization was shown based on the linearity between lesion depths versus the square root of exposure time in either solution, with faster kinetics in acetate buffer. Nanoindentation revealed lactate induced a significantly sharper transition in reduced elastic modulus across the lesions. MicroXCT showed lactate demineralized lesions had swelling and more disorganized matrix structure, whereas acetate lesions had abrupt X-ray absorption near the margin. At the ultrastructural level, TEM showed lactate was more effective in removing minerals from the collagenous matrix, which was confirmed by SAXS analysis.
Conclusions: These findings indicated the different acids yielded lesions with different characteristics that could influence lesion formation resulting in their distinct predominance in different caries activities, and these differences may impact strategies for dentin caries remineralization. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Chien, Y-C; Burwell, A. K.; Saeki, K.; Pugach, M. K.; Nonomura, G.; Habelitz, S.; Ho, S. P.; Rapozo-Hilo, M.; Featherstone, J. D.; Marshall, S. J.; Marshall, G. W.] Univ Calif San Francisco, Dept Prevent & Restorat Dent Sci, Div Biomat & Bioengn, San Francisco, CA 94143 USA.
[Chien, Y-C; Fernandez-Martinez, A.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Mol Foundry, Berkeley, CA 94720 USA.
[Fernandez-Martinez, A.] CNRS, ISTerre, BP 53X, F-38041 Grenoble 9, France.
[Fernandez-Martinez, A.] Univ Grenoble, BP 53X, F-38041 Grenoble 9, France.
[Pugach, M. K.] Forsyth Inst, Dept Mineralized Tissue Biol, 245 First St, Cambridge, MA 02142 USA.
RP Marshall, GW (reprint author), Univ Calif San Francisco, Dept Prevent & Restorat Dent Sci, San Francisco, CA 94143 USA.
EM gw.marshall@ucsf.edu
FU National Institute of Dental and Craniofacial Research of the National
Institutes of Health [R01DE016849]; NIH/NCRR [S10RR026645]; CTSI-SOS
[000166]; Fonds de recherche en sante du Quebec (FRSQ); Office of
Science, Office of Basic Energy Sciences of the U.S. Department of
Energy [DE-AC02-05CH11231]
FX Research reported in this publication was supported by the National
Institute of Dental and Craniofacial Research of the National Institutes
of Health under grant number R01DE016849. Additional support was
provided by NIH/NCRR S10RR026645 for MicroXCT and CTSI-SOS Grant Award #
000166 for AFM and nanoindentation. Fellowship support was provided for
Y-C Chien by Fonds de recherche en sante du Quebec (FRSQ). SAXS studies
were carried out at the Advanced Light Source at Lawrence Berkeley
National Laboratory and were supported by the Director, Office of
Science, Office of Basic Energy Sciences, of the U.S. Department of
Energy under Contract No. DE-AC02-05CH11231. Conceived and designed the
experiments: YCC, AB, KS, JDF, SJM, GWM. Performed the experiments: YCC,
AB, KS, AFM, MKP, GN, MRH. Analyzed the data: YCC, AB, KS, AFM, MKP, SH,
SPH. Wrote the paper: YCC, AB, AFM, MKP. Edited and contributed
interpretation: KS, SH, SPH, JDF, SJM, GWM.
NR 72
TC 0
Z9 0
U1 4
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003-9969
EI 1879-1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD MAR
PY 2016
VL 63
BP 93
EP 105
DI 10.1016/j.archoralbio.2015.10.001
PG 13
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DE7RD
UT WOS:000370833500012
PM 26745819
ER
PT J
AU Bamman, MM
Wick, TM
Carmona-Moran, CA
Bridges, SL
AF Bamman, Marcas M.
Wick, Timothy M.
Carmona-Moran, Carlos A.
Bridges, S. Louis, Jr.
TI Exercise Medicine for Osteoarthritis: Research Strategies to Maximize
Effectiveness
SO ARTHRITIS CARE & RESEARCH
LA English
DT Review
ID TRANSDERMAL DRUG-DELIVERY; TOTAL HIP-ARTHROPLASTY; KNEE OSTEOARTHRITIS;
ARTICULAR-CARTILAGE; CLUSTER-ANALYSIS; OLDER-ADULTS; INFLAMMATION;
HEALTH; TRIAL; METAANALYSIS
C1 [Bamman, Marcas M.] Univ Alabama Birmingham, Ctr Exercise Med & Comprehens Arthrit, Musculoskeletal Bone & Autoimmun Ctr, Birmingham, AL 35294 USA.
[Bamman, Marcas M.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Wick, Timothy M.; Bridges, S. Louis, Jr.] Univ Alabama Birmingham, Ctr Exercise Med, BioMatrix Engn & Regenerat Med Ctr, Birmingham, AL 35294 USA.
[Wick, Timothy M.; Bridges, S. Louis, Jr.] Univ Alabama Birmingham, Comprehens Arthrit Musculoskeletal Bone & Autoimm, Birmingham, AL 35294 USA.
[Carmona-Moran, Carlos A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
RP Bamman, MM (reprint author), Univ Alabama Birmingham, 966 McCallum Bldg,1720 Second Ave South, Birmingham, AL 35294 USA.
EM mbamman@uab.edu
FU NIH [RO1-HD-084124]
FX Drs. Bamman and Bridges' work was supported by the NIH (grant
RO1-HD-084124).
NR 42
TC 0
Z9 0
U1 3
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD MAR
PY 2016
VL 68
IS 3
BP 288
EP 291
DI 10.1002/acr.22680
PG 4
WC Rheumatology
SC Rheumatology
GA DF0VG
UT WOS:000371056700002
PM 26239196
ER
PT J
AU Stowkowy, J
Liu, L
Cadenhead, KS
Cannon, TD
Cornblatt, BA
McGlashan, TH
Perkins, DO
Seidman, LJ
Tsuang, MT
Walker, EF
Woods, SW
Bearden, CE
Mathalon, DH
Heinssen, R
Addington, J
AF Stowkowy, Jacqueline
Liu, Lu
Cadenhead, Kristin S.
Cannon, Tyrone D.
Cornblatt, Barbara A.
McGlashan, Thomas H.
Perkins, Diana O.
Seidman, Larry J.
Tsuang, Ming T.
Walker, Elaine F.
Woods, Scott W.
Bearden, Carrie E.
Mathalon, Daniel H.
Heinssen, Robert
Addington, Jean
TI Core Schemas in Youth at Clinical High Risk for Psychosis
SO BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY
LA English
DT Article
DE Clinical high risk; psychosis; schemas; beliefs; NAPLS
ID CALGARY DEPRESSION SCALE; SCHIZOPHRENIA
AB Background: Schema Theory proposes that the development of maladaptive schemas are based on a combination of memories, emotions and cognitions regarding oneself and one's relationship to others. A cognitive model of psychosis suggests that schemas are crucial to the development and persistence of psychosis. Little is known about the impact that schemas may have on those considered to be at clinical high risk (CHR) of developing psychosis. Aims: To investigate schemas over time in a large sample of CHR individuals and healthy controls. Method: Sample included 765 CHR participants and 280 healthy controls. Schemas were assessed at baseline, 6 and 12 months using the Brief Core Schema Scale (BCSS). Baseline schemas were compared to 2-year clinical outcome. Results: CHR participants evidenced stable and more maladaptive schemas over time compared to controls. Schemas at initial contact did not vary amongst the different clinical outcome groups at 2 years although all CHR outcome groups evidenced significantly worse schemas than healthy controls. Although there were no differences on baseline schemas between those who later transitioned to psychosis compared to those who did not, those who transitioned to psychosis had more maladaptive negative self-schemas at the time of transition. Associations between negative schemas were positively correlated with earlier abuse and bullying. Conclusions: These findings demonstrate a need for interventions that aim to improve maladaptive schemas among the CHR population. Therapies targeting self-esteem, as well as schema therapy may be important work for future studies.
C1 [Stowkowy, Jacqueline; Liu, Lu; Addington, Jean] Univ Calgary, Calgary, AB T2N 4Z6, Canada.
[Cadenhead, Kristin S.; Tsuang, Ming T.] UCSD, La Jolla, CA USA.
[Cannon, Tyrone D.; McGlashan, Thomas H.; Woods, Scott W.] Yale Univ, New Haven, CT USA.
[Cornblatt, Barbara A.] Zucker Hillside Hosp, Long Isl City, NY USA.
[Perkins, Diana O.] Univ N Carolina, Chapel Hill, NC USA.
[Seidman, Larry J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Walker, Elaine F.] Emory Univ, Atlanta, GA 30322 USA.
[Bearden, Carrie E.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Mathalon, Daniel H.] UCSF, San Francisco, CA USA.
[Heinssen, Robert] NIMH, Bethesda, MD 20892 USA.
RP Stowkowy, J (reprint author), Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, 3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada.
EM stowkowy@ucalgary.ca
FU National Institute of Mental Health [U01MH081984, U01 MH081928, P50
MH080272, SCDMH82101008006, R01 MH60720, U01MH082022, K24 MH76191,
U01MH081902, P50 MH066286, U01MH082004, U01MH081988, UO1 MH081857-05]
FX This study was supported by the National Institute of Mental Health
(grant U01MH081984 to Dr Addington; grants U01 MH081928; P50 MH080272;
Commonwealth of Massachusetts SCDMH82101008006 to Dr Seidman; grants R01
MH60720, U01MH082022 and K24 MH76191 to Dr Cadenhead; grant U01MH081902
to Dr Cannon; P50 MH066286 (Prodromal Core) to Dr Bearden; grant
U01MH082004to Dr Perkins; grant U01MH081988 to Dr Walker; grant
U01MH082022 to Dr Woods; and UO1 MH081857-05 grant to Dr Cornblatt. The
NIMH had no further role in study design; in the collection, analysis
and interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.
NR 15
TC 0
Z9 0
U1 1
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1352-4658
EI 1469-1833
J9 BEHAV COGN PSYCHOTH
JI Behav. Cognit. Psychther.
PD MAR
PY 2016
VL 44
IS 2
BP 203
EP 213
DI 10.1017/S1352465815000144
PG 11
WC Psychology, Clinical
SC Psychology
GA DE8AA
UT WOS:000370857000007
PM 25896713
ER
PT J
AU Barrera, TL
Szafranski, DD
Ratcliff, CG
Garnaat, SL
Norton, PJ
AF Barrera, Terri L.
Szafranski, Derek D.
Ratcliff, Chelsea G.
Garnaat, Sarah L.
Norton, Peter J.
TI An Experimental Comparison of Techniques: Cognitive Defusion, Cognitive
Restructuring, and in-vivo Exposure for Social Anxiety
SO BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY
LA English
DT Article
DE Cognitive defusion; cognitive restructuring; exposure; social anxiety
disorder
ID THOUGHTS; THERAPY
AB Background: One of the primary differences between Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) for anxiety is the approach to managing negative thoughts. CBT focuses on challenging the accuracy of dysfunctional thoughts through cognitive restructuring exercises, whereas ACT attempts to foster acceptance of such thoughts through cognitive defusion exercises. Previous research suggests that both techniques reduce the distress associated with negative thoughts, though questions remain regarding the benefit of these techniques above and beyond exposure to feared stimuli. Aims: In the present study, we conducted a brief experimental intervention to examine the utility of cognitive defusion + in-vivo exposure, cognitive restructuring + in-vivo exposure, and in-vivo exposure alone in reducing the impact of negative thoughts in patients with social anxiety disorder. Method: All participants completed a brief public speaking exposure and those in the cognitive conditions received training in the assigned cognitive technique. Participants returned a week later to complete a second exposure task and self-report measures. Results: All three conditions resulted in similar decreases in discomfort related to negative thoughts. ANOVA models failed to find an interaction between change in accuracy or importance and assignment to condition in predicting decreased distress of negative thoughts. Conclusions: These preliminary results suggest that changes in perceived importance and accuracy of negative thoughts may not be the mechanisms by which cognitive defusion and cognitive restructuring affect distress in the short-term.
C1 [Barrera, Terri L.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Barrera, Terri L.] South Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA.
[Szafranski, Derek D.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Ratcliff, Chelsea G.] Univ Houston, Houston, TX 77004 USA.
[Garnaat, Sarah L.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Norton, Peter J.] Monash Univ, Clayton, Vic 3800, Australia.
RP Barrera, TL (reprint author), VA HSR&D Houston Ctr Excellence MEDVAMC 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM terrib@bcm.edu
FU University of Houston; Department of Veterans Affairs South Central
Mental Illness Research Education and Clinical Center (MIRECC);
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development; Center for Innovations in Quality,
Effectiveness and Safety [CIN 13-413]
FX This research was supported by an internal grant from the University of
Houston. The research was supported in part by the Department of
Veterans Affairs South Central Mental Illness Research Education and
Clinical Center (MIRECC), and the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development, and
the Center for Innovations in Quality, Effectiveness and Safety (CIN
13-413). The views expressed reflect those of the authors and not
necessarily those of the Department of Veterans Affairs or the US
Government. Conflict of Interest Statement: The authors declare they
have no conflicts of interest to report.
NR 6
TC 0
Z9 0
U1 6
U2 17
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1352-4658
EI 1469-1833
J9 BEHAV COGN PSYCHOTH
JI Behav. Cognit. Psychther.
PD MAR
PY 2016
VL 44
IS 2
BP 249
EP 254
DI 10.1017/S1352465814000630
PG 6
WC Psychology, Clinical
SC Psychology
GA DE8AA
UT WOS:000370857000011
PM 25683574
ER
PT J
AU Arora, M
Cutler, CS
Jagasia, MH
Pidala, J
Chai, XY
Martin, PJ
Flowers, MED
Inamoto, Y
Chen, GL
Wood, WA
Khera, N
Palmer, J
Duong, H
Arai, S
Mayer, S
Pusic, I
Lee, SJ
AF Arora, Mukta
Cutler, Corey S.
Jagasia, Madan H.
Pidala, Joseph
Chai, Xiaoyu
Martin, Paul J.
Flowers, Mary E. D.
Inamoto, Yoshihiro
Chen, George L.
Wood, William A.
Khera, Nandita
Palmer, Jeanne
Duong, Hien
Arai, Sally
Mayer, Sebastian
Pusic, Iskra
Lee, Stephanie J.
TI Late Acute and Chronic Graft-versus-Host Disease after Allogeneic
Hematopoietic Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Hematopoietic cell transplantation; Graft-versus-host disease syndromes;
Late acute graft-versus-host disease; Chronic graft-versus-host disease;
Bronchiolitis obliterans syndrome; Cutaneous sclerosis
ID NIH CONSENSUS CRITERIA; WORKING GROUP-REPORT; DEVELOPMENT PROJECT;
CLINICAL-TRIALS; DIAGNOSIS; SURVIVAL; OUTCOMES
AB Several distinct graft-versus-host disease (GVHD)-related syndromes have been defined by the National Institutes of Health Consensus Conference. We enrolled a prospective cohort of 911 hematopoietic cell transplantation (HCT) recipients at 13 centers between March 2011 and May 2014 to evaluate 4 GVHD syndromes: late acute GVHD (aGVHD), chronic GVHD (cGVHD), bronchiolitis obliterans syndrome, and cutaneous sclerosis. The median age at HCT was 53.7 years. The majority of patients received a peripheral blood stem cell transplant (81%) following nonmyeloablative or reduced-intensity conditioning (55%). Pediatric age group and use of bone marrow and umbilical cord blood grafts were underrepresented in our cohort (<= 11%). The cumulative incidence of late aGVHD (late onset and recurrent) was 10% at a median of 5.5 months post-HCT, that of cGVHD was 47% at a median of 7.4 months, that of bronchiolitis obliterans was 3% at a median of 12.2 months, and that of cutaneous sclerosis was 8% at a median onset of 14.0 months. Late aGVHD and bronchiolitis obliterans had particularly high nonrelapse mortality of 23% and 32%, respectively, by 2 years after diagnosis. The probability of late aGVHD- and cGVHD-free, relapse-free survival was 38% at 1 year post-HCT and 26% at 2 years post-HCT. This multicenter prospective study confirms the high rate of late aGVHD and cGVHD syndromes and supports the need for continuous close monitoring and development of more effective GVHD treatment strategies to improve HCT success. (C) 2016 American Society for Blood and Marrow Transplantation.
C1 [Arora, Mukta] Univ Minnesota, Sch Med, Div Hematol Oncol & Transplant, 420 Delaware St SE, Minneapolis, MN 55455 USA.
[Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.
[Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Div Hematol & Stem Cell Transplant, Nashville, TN USA.
[Pidala, Joseph] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat Program, Tampa, FL 33682 USA.
[Chai, Xiaoyu; Martin, Paul J.; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Inamoto, Yoshihiro] Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan.
[Chen, George L.] Roswell Pk Canc Inst, Dept Med, BMT Program, Buffalo, NY 14263 USA.
[Wood, William A.] Univ North Carolina Hosp, Div Hematol & Oncol, Chapel Hill, NC USA.
[Khera, Nandita; Palmer, Jeanne] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA.
[Duong, Hien] Cleveland Clin, Taussig Canc Inst, Div Hematol & Oncol, Cleveland, OH 44106 USA.
[Arai, Sally] Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA.
[Mayer, Sebastian] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Hematol & Med Oncol, New York, NY USA.
[Pusic, Iskra] Washington Univ, Sch Med, Dept Med, Sect Bone Marrow Transplant & Leukemia, St Louis, MO 63110 USA.
RP Arora, M (reprint author), Univ Minnesota, Div Hematol Oncol & Transplantat, 420 Delaware St SE, Minneapolis, MN 55455 USA.
EM arora005@umn.edu
FU NCATS [U54CA163438-03]; National Cancer Institute [U54CA163438-03]
FX The Chronic GVHD Consortium (U54 CA163438) is part of the National
Center for Advancing Translational Sciences (NCATS) Rare Diseases
Clinical Research Network (RDCRN). The RDCRN is an initiative of the
NCATS Office of Rare Disease Research, funded through a collaboration
between NCATS and the National Cancer Institute (grant no.
U54CA163438-03).
NR 22
TC 10
Z9 11
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
BP 449
EP 455
DI 10.1016/j.bbmt.2015.10.018
PG 7
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TS
UT WOS:000370910200009
PM 26541363
ER
PT J
AU Barba, P
Burns, LJ
Litzow, MR
Juckett, MB
Komanduri, KV
Lee, SJ
Devlin, SM
Costa, LJ
Khan, S
King, A
Klein, A
Krishnan, A
Malone, A
Mir, MA
Moravec, C
Selby, G
Roy, V
Cochran, M
Stricherz, MK
Westmoreland, MD
Perales, MA
Wood, WA
AF Barba, Pere
Burns, Linda J.
Litzow, Mark R.
Juckett, Mark B.
Komanduri, Krishna V.
Lee, Stephanie J.
Devlin, Sean M.
Costa, Luciano J.
Khan, Shakila
King, Andrea
Klein, Andreas
Krishnan, Amrita
Malone, Adriana
Mir, Muhammad A.
Moravec, Carina
Selby, George
Roy, Vivek
Cochran, Melissa
Stricherz, Melisa K.
Westmoreland, Michael D.
Perales, Miguel-Angel
Wood, William A.
CA Amer Soc Blood Marrow Transplantat
TI Success of an International Learning Health Care System in Hematopoietic
Cell Transplantation: The American Society of Blood and Marrow
Transplantation Clinical Case Forum
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Autologous stem cell transplantation; Allogeneic hematopoietic stem cell
transplantation; Case discussions
ID LYMPHOBLASTIC-LEUKEMIA UPDATE; CYTOTOXIC THERAPY; GUIDELINES; LYMPHOMA;
MOBILIZATION
AB The American Society for Blood and Marrow Transplantation (ASBMT) Clinical Case Forum (CCF) was launched in 2014 as an online secure tool to enhance interaction and communication among hematopoietic cell transplantation (HCT) professionals worldwide through the discussion of challenging clinical care issues. After 14 months, we reviewed clinical and demographical data of cases posted in the CCF from January 29, 2014 to March 18, 2015. A total of 137 cases were posted during the study periOd. Ninety-two cases (67%) were allogeneic HCT, 29 (21%) were autologous HCT, and in 16 (12%), the type of transplantation (autologous versus allogeneic) was still under consideration. The diseases most frequently discussed included non Hodgkin lymphoma (NHL; n = 30, 22%), acute myeloid leukemia (n = 23, 17%), and multiple myeloma (MM; n = 20, 15%). When compared with the US transplantation activity reported by the US Department of Health and Human Services, NHL and acute lymphoblastic leukemia cases were over-represented in the CCF, whereas MM was under -represented (P < .001). A total of 259 topics were addressed in the CCF with a median of 2 topics/case (range, 1 to 6). Particularly common topics included whether transplantation was indicated (n = 57, 41%), conditioning regimen choice (n = 44, 32%), and post-HCT complications after day 100 (n = 43, 31%). The ASBMT CCF is a successful tool for collaborative discussion of complex cases in the HCT community worldwide and may allow identification of areas of controversy or unmet need from clinical, educational and research perspectives. (C) 2016 American Society for Blood and Marrow Transplantation.
C1 [Barba, Pere; Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave,Box 298, New York, NY 10021 USA.
[Barba, Pere] Univ Autonoma Barcelona, Hosp Univ Vall dHerbon, Dept Hematol, E-08193 Barcelona, Spain.
[Burns, Linda J.] Univ Minnesota, Natl Marrow Donor Program, Minneapolis, MN USA.
[Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA.
[Juckett, Mark B.] Univ Wisconsin, Dept Med, Madison, WI USA.
[Komanduri, Krishna V.] Univ Miami, Adult Stem Cell Transplant Program, Sylvester Canc Ctr, Miami, FL USA.
[Lee, Stephanie J.; Moravec, Carina] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Devlin, Sean M.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
[Costa, Luciano J.] Univ Alabama Birmingham, Blood & Marrow Transplantat & Cell Therapy Progr, Birmingham, AL USA.
[Khan, Shakila] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA.
[King, Andrea] Amer Soc Blood & Marrow Transplantat, Arlington Hts, IL USA.
[Klein, Andreas] Tufts Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA USA.
[Krishnan, Amrita] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA.
[Malone, Adriana] Icahn Sch Med Mt Sinai, Dept Med Oncol, New York, NY 10029 USA.
[Mir, Muhammad A.] Penn State Hershey Canc Inst, Hershey, PA USA.
[Selby, George] Univ Oklahoma, Dept Med Hematol Oncol, Oklahoma City, OK USA.
[Roy, Vivek] Mayo Clin, Stem Cell Transplant Program, Jacksonville, FL 32224 USA.
[Cochran, Melissa] Dana Farber Canc Inst, Stem Cell Transplant Program, Boston, MA 02115 USA.
[Stricherz, Melisa K.] Univ Minnesota, Mason Childrens Hosp, Blood & Marrow Transplant Program, Minneapolis, MN USA.
[Westmoreland, Michael D.] Univ Texas MD Anderson Canc Ctr, Dept Pharm, Houston, TX 77030 USA.
[Wood, William A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Phys Off Bldg,170 Manning Dr,3rd Floor, Chapel Hill, NC 27599 USA.
RP Perales, MA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave,Box 298, New York, NY 10021 USA.; Wood, WA (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Phys Off Bldg,170 Manning Dr,3rd Floor, Chapel Hill, NC 27599 USA.
EM peralesm@mskcc.org; wawood@med.unc.edu
FU NCI NIH HHS [P30 CA008748]
NR 20
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
BP 564
EP 570
DI 10.1016/j.bbmt.2015.12.008
PG 7
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TS
UT WOS:000370910200026
PM 26718665
ER
PT J
AU Arai, S
Richardson, PG
Smith, AR
Triplett, BM
Kernan, NA
Grupp, SA
Antin, JH
Lehmann, L
Liang, W
Hume, R
Hannah, AL
Nejadnik, B
Soiffer, RJ
AF Arai, Sally
Richardson, Paul G.
Smith, Angela R.
Triplett, Brandon M.
Kernan, Nancy A.
Grupp, Stephan A.
Antin, Joseph H.
Lehmann, Leslie
Liang, Wei
Hume, Robin
Hannah, Alison L.
Nejadnik, Bijan
Soiffer, Robert J.
TI Efficacy and Safety of Defibrotide in a Subset Analysis of Late-Onset
Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS)
Patients from an Ongoing, Expanded-Access Program
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Arai, Sally] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Richardson, Paul G.; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Smith, Angela R.] Univ Minnesota, Minneapolis, MN USA.
[Triplett, Brandon M.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
[Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, Bone Marrow Transplant Serv, New York, NY 10021 USA.
[Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Lehmann, Leslie] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA USA.
[Liang, Wei; Hume, Robin; Hannah, Alison L.; Nejadnik, Bijan] Jazz Pharmaceut Inc, Palo Alto, CA USA.
[Soiffer, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 446
BP S303
EP S303
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300448
ER
PT J
AU Barba, P
Burns, LJ
Juckett, MB
Komanduri, KV
Litzow, MR
Lee, SJ
Devlin, SM
Costa, LJ
Khan, SP
Klein, AK
Krishnan, A
Malone, AK
Moravec, CG
Mir, M
Selby, GB
Vivek, R
Cochran, M
Stricherz, M
Westmoreland, M
Tierney, DK
Wood, WA
Perales, MA
AF Barba, Pere
Burns, Linda J.
Juckett, Mark B.
Komanduri, Krishna V.
Litzow, Mark R.
Lee, Stephanie J.
Devlin, Sean M.
Costa, Luciano J.
Khan, Shakila P.
Klein, Andreas K.
Krishnan, Amrita
Malone, Adriana K.
Moravec, Carina G.
Mir, Muhammad
Selby, George B.
Vivek, Roy
Cochran, Melissa
Stricherz, Melisa
Westmoreland, Michael
Tierney, D. Kathryn
Wood, William A.
Perales, Miguel-Angel
TI Success of an International Learning Healthcare System in Hematopoietic
Cell Transplantation: The American Society of Blood and Marrow
Transplantation Clinical Case Forum
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Barba, Pere; Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Burns, Linda J.] Natl Marrow Donor Program Be The Match, Minneapolis, MN USA.
[Juckett, Mark B.] Univ Wisconsin, Sect Hematol BMT, Madison, WI USA.
[Komanduri, Krishna V.] Univ Miami, Sylvester Comprehens Canc Ctr, Adult Stem Cell Transplant Program, Miami, FL USA.
[Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA.
[Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Devlin, Sean M.] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 1275 York Ave, New York, NY 10021 USA.
[Costa, Luciano J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Khan, Shakila P.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA.
[Klein, Andreas K.] Tufts Med Ctr, Hematol Oncol, Boston, MA USA.
[Krishnan, Amrita] City Hope Natl Med Ctr, Duarte, CA USA.
[Malone, Adriana K.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
[Moravec, Carina G.] Fred Hutchinson Canc Res Ctr, Kirkland, WA USA.
[Mir, Muhammad] Mayo Clin, Hematol Blood & Marrow Transplant, Rochester, MN USA.
[Selby, George B.] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA.
[Vivek, Roy] Mayo Clin, Jacksonville, FL 32224 USA.
[Cochran, Melissa] Dana Farber Canc Inst, Heme Malignancies, Boston, MA 02115 USA.
[Stricherz, Melisa] Univ Minnesota, Childrens Hosp, Dept Pharm, Minneapolis, MN USA.
[Westmoreland, Michael] Univ Texas MD Anderson Canc Ctr, Pharm, Houston, TX 77030 USA.
[Tierney, D. Kathryn] Stanford Hlth Care, Blood & Marrow Transplantat, Stanford, CA USA.
[Wood, William A.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 384
BP S266
EP S267
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300387
ER
PT J
AU Brunner, AM
Li, SL
Fathi, AT
Ho, VT
Stone, RM
Soiffers, RJ
Chen, YB
AF Brunner, Andrew M.
Li, Shuli
Fathi, Amir T.
Ho, Vincent T.
Stone, Richard M.
Soiffers, Robert J.
Chen, Yi-Bin
TI Hematopoietic Cell Transplantation with and without Sorafenib
Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Brunner, Andrew M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Brunner, Andrew M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Li, Shuli] Dana Farber Canc Inst, Biostat, Boston, MA 02115 USA.
[Fathi, Amir T.] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA.
[Ho, Vincent T.] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA.
[Stone, Richard M.; Soiffers, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
[Chen, Yi-Bin] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 272
BP S198
EP S199
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300277
ER
PT J
AU Brunner, AM
Jacobsen, E
Brown, JR
Fisher, DC
McAfee, SL
Soiffer, RJ
Armand, P
Chen, YB
AF Brunner, Andrew M.
Jacobsen, Eric
Brown, Jennifer R.
Fisher, David C.
McAfee, Steven L.
Soiffer, Robert J.
Armand, Philippe
Chen, Yi-Bin
TI Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and
Autologous Transplantation As Consolidation for Systemic Non-Hodgkin
Lymphoma with Synchronous CNS Involvement
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Brunner, Andrew M.; Jacobsen, Eric; Brown, Jennifer R.; Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fisher, David C.; Soiffer, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
[McAfee, Steven L.] Massachusetts Gen Hosp, BMT Program, Dept Med, Boston, MA 02114 USA.
[Chen, Yi-Bin] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 137
BP S120
EP S121
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300142
ER
PT J
AU Carpenter, PA
Logan, BR
Lee, SJ
Weisdorf, DJ
Johnston, L
Costa, LJ
Kitko, CL
Bolanos-Meade, J
Alousi, AM
Horowitz, MM
Abhyankar, S
Waller, EK
Mendizabal, A
Wang, YL
Lazaryan, A
Carter, SL
Nemecek, ER
Pavletic, SZ
Cutler, CS
Arora, M
AF Carpenter, Paul A.
Logan, Brent R.
Lee, Stephanie J.
Weisdorf, Daniel J.
Johnston, Laura
Costa, Luciano J.
Kitko, Carrie L.
Bolanos-Meade, Javier
Alousi, Amin M.
Horowitz, Mary M.
Abhyankar, Sunil
Waller, Edmund K.
Mendizabal, Adam
Wang, Yanli
Lazaryan, Aleksandr
Carter, Shelly L.
Nemecek, Eneida R.
Pavletic, Steven Z.
Cutler, Corey S.
Arora, Mukta
CA BMT CTN
TI Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin
Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease
(cGVHD): A Randomized Phase II Study from the Blood and Marrow
Transplant Clinical Trials Network
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Carpenter, Paul A.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Logan, Brent R.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Div Hematol Oncol & Transplantat, Med, Minneapolis, MN USA.
[Johnston, Laura] Stanford Univ, Med Ctr, Blood & Marrow Transplantat, Stanford, CA 94305 USA.
[Costa, Luciano J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Kitko, Carrie L.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Bolanos-Meade, Javier] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Alousi, Amin M.] UT MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX USA.
[Horowitz, Mary M.] CIBMTR, Dept Med, Milwaukee, WI USA.
[Horowitz, Mary M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Abhyankar, Sunil] Univ Kansas, Med Ctr, Blood & Marrow Transplant, Westwood, KS USA.
[Waller, Edmund K.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Div BMT, Atlanta, GA 30322 USA.
[Mendizabal, Adam; Wang, Yanli; Carter, Shelly L.] EMMES Corp, Rockville, MD USA.
[Lazaryan, Aleksandr; Arora, Mukta] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN USA.
[Nemecek, Eneida R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA.
[BMT CTN] BMT CTN, Milwaukee, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 42
BP S50
EP S52
PG 3
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300047
ER
PT J
AU Chen, YB
Perales, MA
Li, SL
Konkel, S
Loiselle, C
Efebera, YA
Devine, SM
EI-Jawahri, A
McAfee, SL
Soiffer, RJ
Ritz, J
Cutler, CS
AF Chen, Yi-Bin
Perales, Miguel-Angel
Li, Shuli
Konkel, Sarah
Loiselle, Colleen
Efebera, Yvonne A.
Devine, Steven M.
EI-Jawahri, Areej
McAfee, Steven L.
Soiffer, Robert J.
Ritz, Jerome
Cutler, Corey S.
TI Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory
Acute Graft-Vs.-Host Disease (GVHD)
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Chen, Yi-Bin; EI-Jawahri, Areej] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Li, Shuli] Dana Farber Canc Inst, Biostat, Boston, MA 02115 USA.
[Konkel, Sarah; Loiselle, Colleen] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA.
[Efebera, Yvonne A.] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA.
[Devine, Steven M.] Ohio State Med Ctr, Div Hematol, James Canc Ctr, Columbus, OH USA.
[McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA.
[Soiffer, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
[Ritz, Jerome; Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA.
RI Efebera, Yvonne/E-3012-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 589
BP S391
EP S391
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300590
ER
PT J
AU Duncan, C
Brazauskas, R
Huang, JX
Shaw, BE
Majhail, NS
Savani, BN
Flowers, MED
Battiwalla, M
Beebe, K
Dietz, AC
Dvorak, CC
Giller, R
Jacobsohn, DA
Kletzel, M
Martin, PJ
Nemecek, ER
Talano, JAM
Pulsipher, MA
Baker, KS
AF Duncan, Christine
Brazauskas, Ruta
Huang, Jiaxing
Shaw, Bronwen E.
Majhail, Navneet S.
Savani, Bipin N.
Flowers, Mary E. D.
Battiwalla, Minoo
Beebe, Kristen
Dietz, Andrew C.
Dvorak, Christopher C.
Giller, Roger
Jacobsohn, David A.
Kletzel, Morris
Martin, Paul J.
Nemecek, Eneida R.
Talano, Julie-An M.
Pulsipher, Michael A.
Baker, K. Scott
TI Late Cardiovascular Morbidity Following Pediatric Allogeneic
Hematopoietic Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Duncan, Christine] Boston Childrens Hosp, Dept Pediat Oncol, Boston, MA USA.
[Duncan, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Brazauskas, Ruta] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
[Huang, Jiaxing] Med Coll Wisconsin, CIBMTR, Dept Med, Milwaukee, WI 53226 USA.
[Shaw, Bronwen E.] CIBMTR, Dept Med, Milwaukee, WI USA.
[Shaw, Bronwen E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Majhail, Navneet S.] Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA.
[Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.
[Flowers, Mary E. D.; Martin, Paul J.; Baker, K. Scott] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Battiwalla, Minoo] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
[Beebe, Kristen] Mayo Clin Arizonia, Phoenix, AZ USA.
[Beebe, Kristen] Phoenix Childrens Hosp, Phoenix, AZ USA.
[Dietz, Andrew C.] Childrens Hosp Los Angeles, Pediat Heme Onc BMT, Los Angeles, CA 90027 USA.
[Dvorak, Christopher C.] Univ Calif San Francisco, Dept Pediat, Med Ctr, San Francisco, CA USA.
[Giller, Roger] Childrens Hosp Colorado, Dept Pediat, Sect Hematol Oncol & BMT, Aurora, CO USA.
[Jacobsohn, David A.] Childrens Natl Hlth Syst, Div Blood & Marrow Transplantat, Ctr Canc & Blood Disorders, Washington, DC USA.
[Kletzel, Morris] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Div Hematol Oncol & Stem Cell Transplantat, Chicago, IL 60611 USA.
[Nemecek, Eneida R.] Doernbecher Childrens Hosp, Dept Pediat, Pediat Blood & Marrow Transplant Program, Portland, OR USA.
[Nemecek, Eneida R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Talano, Julie-An M.] Med Coll Wisconsin, Pediat Hematol Oncol & BMT, Milwaukee, WI 53226 USA.
[Pulsipher, Michael A.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
RI Huang, Jiaxing/B-7521-2009
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 55
BP S60
EP S60
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300060
ER
PT J
AU Duran-Struuck, R
Matar, AJ
Crepeau, RL
Pathiraja, V
Spitzer, TR
Bronson, RT
Sachs, DH
Huang, CA
AF Duran-Struuck, Raimon
Matar, Abraham J.
Crepeau, Rebecca L.
Pathiraja, Vimukthi
Spitzer, Thomas R.
Bronson, Roderick T.
Sachs, David H.
Huang, Christene A.
TI Donor Leukocyte Infusion Mediated Graft-Versus-Host Responses in a
Pre-Clinical Swine Model of Haploidentical Hematopoietic Cell
Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Duran-Struuck, Raimon] Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA.
[Matar, Abraham J.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA.
[Crepeau, Rebecca L.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Immunol, Hanover, NH 03756 USA.
[Pathiraja, Vimukthi] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Spitzer, Thomas R.] MGH Inst Hlth Profess, Boston, MA USA.
[Bronson, Roderick T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Sachs, David H.; Huang, Christene A.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 466
BP S316
EP S316
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300467
ER
PT J
AU El-Jawahri, A
Wood, B
Cutler, CS
Pidala, JA
Flowers, MED
Arora, M
Jagasia, MH
Palmer, J
Chen, YB
Lee, SJ
AF El-Jawahri, Areej
Wood, Bill
Cutler, Corey S.
Pidala, Joseph A.
Flowers, Mary E. D.
Arora, Mukta
Jagasia, Madan H.
Palmer, Jeanne
Chen, Yi-Bin
Lee, Stephanie J.
TI Self-Reported Depression and Anxiety By Patients with Chronic
Graft-Versus-Host Disease Identify a Group with Worse Quality of Life,
Symptoms, and Functional Status
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [El-Jawahri, Areej] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA.
[Wood, Bill] Univ N Carolina, Chapel Hill, NC USA.
[Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA.
[Pidala, Joseph A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL 33612 USA.
[Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Arora, Mukta] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN USA.
[Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Palmer, Jeanne] Mayo Clin Arizona, Hematol Oncol Blood & Marrow Transplant, Phoenix, AZ USA.
[Chen, Yi-Bin] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 10
BP S27
EP S27
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300015
ER
PT J
AU El-Jawahri, A
Chen, YB
Brazauskas, R
He, N
Lee, SJ
Knight, J
Atsuta, Y
Bonfim, C
Dalal, JD
Khera, N
Hahn, TE
Saber, W
AF El-Jawahri, Areej
Chen, Yi-Bin
Brazauskas, Ruta
He, Naya
Lee, Stephanie J.
Knight, Jennifer
Atsuta, Yoshiko
Bonfim, Carmem
Dalal, Jignesh D.
Khera, Nandita
Hahn, Theresa E.
Saber, Wael
TI Association of Pre-Transplant Depression with Clinical Outcomes and
Resource Utilization after Allogeneic Hematopoietic Stem Cell
Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [El-Jawahri, Areej; Chen, Yi-Bin] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[Brazauskas, Ruta] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
[Brazauskas, Ruta; He, Naya; Saber, Wael] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
[Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Knight, Jennifer] Med Coll Wisconsin, Psychiat, Milwaukee, WI 53226 USA.
[Atsuta, Yoshiko] Nagoya Univ, Grad Sch Med, Dept Healthcare Adm, Nagoya, Aichi 4648601, Japan.
[Bonfim, Carmem] Univ Fed Parana, Hosp Clin, Pediat Blood & Marrow Transplantat Serv, BR-80060000 Curitiba, Parana, Brazil.
[Dalal, Jignesh D.] Rainbow Babies & Childrends Hosp, Bone Marrow Transplantat Pediat Hematol Oncol, Cleveland, OH USA.
[Khera, Nandita] Mayo Clin, Dept Hematol Oncol, Phoenix, AZ USA.
[Hahn, Theresa E.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 4
BP S22
EP S23
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300009
ER
PT J
AU Emmert, A
Nikiforow, S
Savage, WJ
King, B
McDermott, K
Crown, D
Bagley, J
Phicil, S
Antin, JH
AF Emmert, Amy
Nikiforow, Sarah
Savage, William J.
King, Bethany
McDermott, Kathleen
Crown, Donna
Bagley, Janet
Phicil, Shiela
Antin, Joseph H.
TI Building Value and Capacity with Practice Standards - Autologous Product
Collection
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Emmert, Amy; Nikiforow, Sarah] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Savage, William J.] Brigham & Womens Hosp, Transfus Med, 75 Francis St, Boston, MA 02115 USA.
[King, Bethany] Dana Farber Canc Inst, Cell Therapy Qual Assurance, Boston, MA 02115 USA.
[McDermott, Kathleen] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA.
[Crown, Donna] Brigham & Womens Hosp, Kraft Family Blood Donor Ctr, 75 Francis St, Boston, MA 02115 USA.
[Bagley, Janet] Dana Farber Canc Inst, Nursing Serv, Boston, MA 02115 USA.
[Bagley, Janet] Dana Farber Canc Inst, Patient Care Serv, Boston, MA 02115 USA.
[Phicil, Shiela] Brigham & Womens Hosp, Oncol Serv, 75 Francis St, Boston, MA 02115 USA.
[Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 399
BP S276
EP S276
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300401
ER
PT J
AU Falconer, S
Moss, E
Andermann, T
Systrom, H
Mahabamunuge, J
Hohmann, E
Bhatt, AS
AF Falconer, Shannon
Moss, Eli
Andermann, Tessa
Systrom, Hannah
Mahabamunuge, Jasmin
Hohmann, Elizabeth
Bhatt, Ami S.
TI Fecal Microbiota Transplant Is a Potentially Safe and Effective
Treatment for Clostridium Difficile Infection in Hematopoietic Stem Cell
Recipients
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Falconer, Shannon; Moss, Eli] Stanford Univ, Genet, Stanford, CA 94305 USA.
[Andermann, Tessa] Stanford Univ, Infect Dis, Stanford, CA 94305 USA.
[Systrom, Hannah; Mahabamunuge, Jasmin] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hohmann, Elizabeth] Massachusetts Gen Hosp, Infect Dis, Boston, MA 02114 USA.
[Bhatt, Ami S.] Stanford Univ, Genet & Hematol, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 45
BP S53
EP S54
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300050
ER
PT J
AU Goldstein, SC
Koreth, J
Magenau, JM
Soiffer, RJ
Braun, T
Kennel, M
Goyetche, R
Pawarode, A
Riwes, MM
Antin, JH
Cutler, CS
Ho, VT
Alyea, EP
Parkin, BL
Yanik, GA
Choi, SW
Couriel, DR
Levine, JE
Radojcic, V
Dinarello, C
Reddy, P
AF Goldstein, Steven C.
Koreth, John
Magenau, John M.
Soiffer, Robert J.
Braun, Thomas
Kennel, Maggi
Goyetche, Reaha
Pawarode, Attaphol
Riwes, Mary M.
Antin, Joseph H.
Cutler, Corey S.
Ho, Vincent T.
Alyea, Edwin P., III
Parkin, Brian L.
Yanik, Gregory A.
Choi, Sung Won
Couriel, Daniel R.
Levine, John E.
Radojcic, Vedran
Dinarello, Charles
Reddy, Pavan
TI Alpha 1 Anti-Trypsin (AAT): Novel Strategy to Treat Steroid Refractory
Acute Graft Versus Host Disease
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Goldstein, Steven C.; Magenau, John M.; Kennel, Maggi; Pawarode, Attaphol; Riwes, Mary M.; Parkin, Brian L.; Radojcic, Vedran; Reddy, Pavan] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Blood & Marrow Transplantat Program, Ann Arbor, MI 48109 USA.
[Koreth, John] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
[Soiffer, Robert J.; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Stem Cell Bone Marrow Transplantat Program,Div He, 44 Binney St, Boston, MA 02115 USA.
[Braun, Thomas] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.
[Goyetche, Reaha] Dana Farber Canc Ctr, Boston, MA USA.
[Cutler, Corey S.; Ho, Vincent T.; Alyea, Edwin P., III] Harvard Univ, Sch Med, Dana Farber Canc Inst, Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA.
[Yanik, Gregory A.; Choi, Sung Won] Univ Michigan, Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA.
[Couriel, Daniel R.] Univ Utah, Salt Lake City, UT USA.
[Levine, John E.] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA.
[Dinarello, Charles] Univ Colorado, Internal Med & Immunol, Aurora, CO USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 50
BP S57
EP S57
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300055
ER
PT J
AU Iliopoulou, BP
Hsu, K
Pierini, A
Freeman, GJ
Dekruyff, RH
Meyer, E
AF Iliopoulou, Bettina P.
Hsu, Katie
Pierini, Antonio
Freeman, Gordon J.
Dekruyff, Rosemarie H.
Meyer, Everett
TI TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal
Gvhd
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Iliopoulou, Bettina P.; Hsu, Katie; Pierini, Antonio; Meyer, Everett] Stanford Univ, Dept Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA.
[Freeman, Gordon J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Dekruyff, Rosemarie H.] Stanford Univ, Sch Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 599
BP S398
EP S399
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300600
ER
PT J
AU Jagasia, MH
Basu, T
Engelhardt, BG
Chen, HD
Clark, W
Waller, EK
Giver, C
Chen, YB
Savani, BN
Kassim, AA
Jung, DK
Polikowsky, H
Benmebarek, R
Heck, S
Ellis, R
Seidl, T
Mufti, G
Irish, J
Kordasti, S
AF Jagasia, Madan H.
Basu, Tanya
Engelhardt, Brian G.
Chen, Heidi
Clark, William
Waller, Edmund K.
Giver, Cynthia
Chen, Yi-Bin
Savani, Bipin N.
Kassim, Adetola A.
Jung, Dae Kwang
Polikowsky, Hannah
Benmebarek, Reda
Heck, Susanne
Ellis, Richard
Seidl, Thomas
Mufti, G.
Irish, Jonathan
Kordasti, Shahram
TI Single Cell Mass Cytometry Identifies T-Regulatory Cell Subsets
Associated with ECP Response in Chronic GVHD
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Jagasia, Madan H.; Engelhardt, Brian G.; Chen, Heidi; Kassim, Adetola A.; Jung, Dae Kwang; Irish, Jonathan] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Basu, Tanya; Benmebarek, Reda; Heck, Susanne; Ellis, Richard; Seidl, Thomas; Mufti, G.; Kordasti, Shahram] Kings Coll London, London WC2R 2LS, England.
[Clark, William] VCU Massey Canc Ctr, Richmond, VA USA.
[Waller, Edmund K.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Div BMT, Atlanta, GA 30322 USA.
[Giver, Cynthia] Emory Univ, Atlanta, GA 30322 USA.
[Chen, Yi-Bin] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.
[Polikowsky, Hannah] Cytobank, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 603
BP S400
EP S401
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300603
ER
PT J
AU Karmali, R
Ghosh, N
Rocha, VG
Ahn, KW
DiGilio, A
Armand, P
Salit, RB
Fenske, TS
Smith, SM
Sureda, A
Wagner-Johnston, N
Meade, JB
Hamadani, M
AF Karmali, Reem
Ghosh, Nilanjan
Rocha, Vanderson G.
Ahn, Kwang Woo
DiGilio, Alyssa
Armand, Philippe
Salit, Rachel B.
Fenske, Timothy S.
Smith, Sonali M.
Sureda, Anna
Wagner-Johnston, Nina
Meade, Javier Bolanos
Hamadani, Mehdi
TI Survival after T-Cell Replete Haploidentical Related Donor Hematopoietic
Cell Transplantation (Haplo-HCT) Using Post-Transplant Cyclophosphamide
(PT-CY) Compared with HLA-Matched Related Donor (MRD) Transplant for
Lymphomas
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Karmali, Reem] Rush Univ, Med Ctr, Div Hematol Oncol & Cell Therapy, Chicago, IL 60612 USA.
[Ghosh, Nilanjan] Levine Canc Inst, Charlotte, NC USA.
[Rocha, Vanderson G.] Oxford Univ Hosp NHS Trust, Dept Clin Oncol, Oxford, England.
[Ahn, Kwang Woo] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.
[DiGilio, Alyssa; Hamadani, Mehdi] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA.
[Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Salit, Rachel B.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Fenske, Timothy S.] Med Coll Wisconsin, Hematol Oncol, Milwaukee, WI 53226 USA.
[Smith, Sonali M.] Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA.
[Sureda, Anna] Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain.
[Wagner-Johnston, Nina; Meade, Javier Bolanos] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 75
BP S75
EP S76
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300080
ER
PT J
AU Kekre, N
Kim, HT
Ho, VT
Koreth, J
Armand, P
Glotzbecker, B
Nikiforow, S
Alyea, EP
Soiffer, RJ
Antin, JH
Marty, F
Cutler, CS
AF Kekre, Natasha
Kim, Haesook T.
Ho, Vincent T.
Koreth, John
Armand, Philippe
Glotzbecker, Brett
Nikiforow, Sarah
Alyea, Edwin P., III
Soiffer, Robert J.
Antin, Joseph H.
Marty, Francisco
Cutler, Corey S.
TI Cytomegalovirus Reactivation Does Not Reduce the Risk of Disease Relapse
after Allogeneic Hematopoietic Stem Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Kekre, Natasha] Ottawa Hosp, Hematol, Ottawa, ON, Canada.
[Kim, Haesook T.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA.
[Ho, Vincent T.; Koreth, John; Armand, Philippe; Glotzbecker, Brett; Alyea, Edwin P., III; Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA.
[Nikiforow, Sarah] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Soiffer, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
[Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[Marty, Francisco] Dana Farber Canc Inst, Infect Dis, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 485
BP S329
EP S329
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300486
ER
PT J
AU Kernan, NA
Grupp, SA
Banerjee, K
Hannah, AL
Hume, R
Nejadnik, B
Richardson, PG
AF Kernan, Nancy A.
Grupp, Stephan A.
Banerjee, Kamalika
Hannah, Alison L.
Hume, Robin
Nejadnik, Bijan
Richardson, Paul G.
TI Pooled Treatment Analysis of Pediatric Patients with Defibrotide for
Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and
Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Banerjee, Kamalika; Hannah, Alison L.; Hume, Robin; Nejadnik, Bijan] Jazz Pharmaceut Inc, Palo Alto, CA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 255
BP S188
EP S189
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300260
ER
PT J
AU Kernan, NA
Richardson, PG
Triplett, BM
Grupp, SA
Antin, JH
Lehmann, L
Liang, W
Hume, R
Hannah, AL
Nejadnik, B
Soiffer, RJ
AF Kernan, Nancy A.
Richardson, Paul G.
Triplett, Brandon M.
Grupp, Stephan A.
Antin, Joseph H.
Lehmann, Leslie
Liang, Wei
Hume, Robin
Hannah, Alison L.
Nejadnik, Bijan
Soiffer, Robert J.
TI Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive
Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ
Dysfunction Following Chemotherapy: Subset Analysis Results from an
Ongoing Expanded Access Program
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Richardson, Paul G.; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[Triplett, Brandon M.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
[Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Lehmann, Leslie] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA USA.
[Liang, Wei; Hume, Robin; Hannah, Alison L.; Nejadnik, Bijan] Jazz Pharmaceut Inc, Palo Alto, CA USA.
[Soiffer, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 254
BP S188
EP S188
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300259
ER
PT J
AU Martin, PL
Steinbach, G
Chen, AR
Krishnan, A
Kernan, NA
Avigan, DE
Spitzer, TR
Richardson, PG
AF Martin, Paul L.
Steinbach, Gideon
Chen, Allen R.
Krishnan, Amrita
Kernan, Nancy A.
Avigan, David E.
Spitzer, Thomas R.
Richardson, Paul G.
TI Pooled Dose Response Analysis of Defibrotide in > 1600 Patients for the
Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction
Syndrome
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Martin, Paul L.] Duke Univ, Med Ctr, Durham, NC USA.
[Steinbach, Gideon] Univ Washington, Sch Med, Seattle, WA USA.
[Steinbach, Gideon] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Chen, Allen R.] Johns Hopkins Sch Med, Baltimore, MD USA.
[Krishnan, Amrita] City Hope Natl Med Ctr, Duarte, CA USA.
[Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Avigan, David E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Avigan, David E.] Harvard Univ, Sch Med, Boston, MA USA.
[Spitzer, Thomas R.] MGH Inst Hlth Profess, Boston, MA USA.
[Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 500
BP S337
EP S338
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300501
ER
PT J
AU Marty, FM
Winston, DJ
Chemaly, RF
Boeckh, MJ
Mullane, KM
Shore, TB
Papanicolaou, GA
Morrison, ME
Brundage, TM
Mommeja-Marin, H
AF Marty, Francisco M.
Winston, Drew J.
Chemaly, Roy F.
Boeckh, Michael J.
Mullane, Kathlene M.
Shore, Tsiporah B.
Papanicolaou, Genovefa A.
Morrison, Marion E.
Brundage, Thomas M.
Mommeja-Marin, Herve
TI Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic
Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3
Trial
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Marty, Francisco M.] Dana Farber Canc Inst, Infect Dis, Boston, MA 02115 USA.
[Marty, Francisco M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Winston, Drew J.] Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90024 USA.
[Chemaly, Roy F.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA.
[Boeckh, Michael J.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Mullane, Kathlene M.] Univ Chicago, Chicago, IL 60637 USA.
[Shore, Tsiporah B.] New York Hosp, Cornell Med Ctr Hematol Oncol, New York, NY 10021 USA.
[Papanicolaou, Genovefa A.] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, New York, NY 10021 USA.
[Morrison, Marion E.; Brundage, Thomas M.; Mommeja-Marin, Herve] Chimerix Inc, Durham, NC USA.
NR 0
TC 3
Z9 3
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 5
BP S23
EP S23
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300010
ER
PT J
AU Moffet, JR
Mahadeo, KM
Fitzgerald, J
Gertz, S
Hall, M
Loomis, AL
McArthur, J
Nitu, M
Tamburro, R
Duncan, C
Rowan, C
AF Moffet, Jerelyn R.
Mahadeo, Kris Michael
Fitzgerald, Julie
Gertz, Shira
Hall, Mark
Loomis, Ashley Loomis
McArthur, Jennifer
Nitu, Mara
Tamburro, Robert
Duncan, Christine
Rowan, Courtney
TI The Impact of Neutrophil Engraftment on the Survival of Intubated
Pediatric HCT Patients: A Pediatric Acute Lung Injury and Sepsis Network
Study
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Moffet, Jerelyn R.] Duke Univ, Med Ctr, Pediat BMT Program, Durham, NC USA.
[Mahadeo, Kris Michael] Childrens Hosp Montefiore, Pediat Hematol Oncol & Blood & Marrow Cell Transp, Bronx, NY USA.
[Fitzgerald, Julie] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Gertz, Shira] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Hall, Mark] Nationwide Childrens Hosp, Intens Care Unit, Columbus, OH USA.
[Loomis, Ashley Loomis] Univ Minnesota, Pediat Crit Care, Minneapolis, MN USA.
[McArthur, Jennifer] Med Coll Wisconsin, Pediat Crit Care, Milwaukee, WI 53226 USA.
[Nitu, Mara; Rowan, Courtney] Indiana Univ, Indianapolis, IN 46204 USA.
[Tamburro, Robert] NIH, Rockville, MD USA.
[Duncan, Christine] Boston Childrens Hosp, Dept Pediat Oncol, Boston, MA USA.
[Rowan, Courtney] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 56
BP S60
EP S61
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300061
ER
PT J
AU Muffly, L
Pasquini, MC
Martens, M
Brazauskas, R
Zhu, XC
Adekola, K
Aljurf, MD
Artz, AS
Bajel, A
Ballen, KK
Battiwalla, M
Beitinjaneh, A
Cahn, JY
Carabasi, M
Chen, YB
Chhabra, S
Ciurea, SO
Copelan, EA
D'Souza, A
Edwards, J
Freytes, CO
Fung, HC
Gale, RP
Giralt, SA
Hashmi, SK
Hematti, P
Hildebrandt, GC
Ho, VT
Jakubowski, AA
Lazarus, HM
McCarthy, PL
Olin, RL
Olsson, R
Rezvani, A
Rizzieri, DA
Seftel, M
Seo, S
Sorror, ML
Szer, J
Wood, WA
AF Muffly, Lori
Pasquini, Marcelo C.
Martens, Michael
Brazauskas, Ruta
Zhu, Xiaochun
Adekola, Kehinde
Aljurf, Mahmoud D.
Artz, Andrew S.
Bajel, Ashish
Ballen, Karen K.
Battiwalla, Minoo
Beitinjaneh, Amer
Cahn, Jean-Yves
Carabasi, Matthew
Chen, Yi-Bin
Chhabra, Saurabh
Ciurea, Stefan O.
Copelan, Edward A.
D'Souza, Anita
Edwards, John
Freytes, Cesar O.
Fung, Henry C.
Gale, Robert Peter
Giralt, Sergio A.
Hashmi, Shahrukh K.
Hematti, Peiman
Hildebrandt, Gerhard C.
Ho, Vincent T.
Jakubowski, Ann A.
Lazarus, Hillard M.
McCarthy, Philip L.
Olin, Rebecca L.
Olsson, Richard
Rezvani, Andrew
Rizzieri, David A.
Seftel, Matthew
Seo, Sachiko
Sorror, Mohamed L.
Szer, Jeffrey
Wood, William A.
TI Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in
Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Muffly, Lori] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA.
[Pasquini, Marcelo C.; Zhu, Xiaochun; D'Souza, Anita] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
[Martens, Michael] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.
[Brazauskas, Ruta] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
[Adekola, Kehinde] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Aljurf, Mahmoud D.] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.
[Artz, Andrew S.] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA.
[Bajel, Ashish; Szer, Jeffrey] Royal Melbourne Hosp, Clin Haematol & Bone Marrow Transplant Serv, Parkville, Vic 3050, Australia.
[Ballen, Karen K.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA.
[Battiwalla, Minoo] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
[Beitinjaneh, Amer] Univ Virginia, Sch Med, Hematol Oncol, Charlottesville, VA 22908 USA.
[Cahn, Jean-Yves] Univ Hosp, Dept Hematol, Grenoble, France.
[Carabasi, Matthew] Thomas Jefferson Univ, Med Oncol, Philadelphia, PA 19107 USA.
[Chen, Yi-Bin] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[Chhabra, Saurabh] Med Univ S Carolina, Blood & Marrow Transplant Program, Charleston, SC 29425 USA.
[Ciurea, Stefan O.] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.
[Copelan, Edward A.] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA.
[Edwards, John] Indiana Blood & Marrow Transplantat, Indianapolis, IN USA.
[Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Fung, Henry C.] Temple Univ Hosp & Med Sch, Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA 19140 USA.
[Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.
[Giralt, Sergio A.; Jakubowski, Ann A.] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Hashmi, Shahrukh K.] Mayo Clin, Div Hematol, Rochester, MN USA.
[Hematti, Peiman] Univ Wisconsin Hosp & Clin, Dept Med, Div Hematol Oncol Bone Marrow Transplantat, Madison, WI 53792 USA.
[Hildebrandt, Gerhard C.] Univ Kentucky, Chandler Med Ctr, Hematol & Blood & Marrow Transplant, Lexington, KY USA.
[Ho, Vincent T.] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA.
[Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Cleveland, OH USA.
[McCarthy, Philip L.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.
[Olin, Rebecca L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Olsson, Richard] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden.
[Rezvani, Andrew] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Rizzieri, David A.] Duke Univ, Med Ctr, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.
[Seftel, Matthew] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada.
[Seo, Sachiko; Sorror, Mohamed L.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Wood, William A.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA.
NR 0
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 67
BP S68
EP S69
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300072
ER
PT J
AU Newell, LF
Verneris, MR
Panoskaltsis-Mortari, A
Defor, TE
Blazar, BR
Cutler, CS
Antin, JH
MacMillan, ML
Weisdorf, D
Holtan, S
AF Newell, Laura F.
Verneris, Michael R.
Panoskaltsis-Mortari, Angela
Defor, Todd E.
Blazar, Bruce R.
Cutler, Corey S.
Antin, Joseph H.
MacMillan, Margaret L.
Weisdorf, Daniell
Holtan, Shernan
TI Angiogenic Factors, Inflammation, and Outcomes in Myeloablative
Allogeneic Hematopoietic Cell Transplantation: A Biomarker Analysis of
Gvhd Prophylaxis in Blood and Marrow Transplant Clinical Trials Network
Protocol (BMT CTN) 0402
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Newell, Laura F.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA.
[Verneris, Michael R.; Blazar, Bruce R.; MacMillan, Margaret L.] Univ Minnesota, Dept Pediat, Blood & Marrow Transplantat, Minneapolis, MN 55455 USA.
[Panoskaltsis-Mortari, Angela; Defor, Todd E.] Univ Minnesota, Minneapolis, MN USA.
[Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA.
[Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[Weisdorf, Daniell] Univ Minnesota, Div Hematol Oncol & Transplantat, Med, Minneapolis, MN USA.
[Holtan, Shernan] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 70
BP S70
EP S71
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300075
ER
PT J
AU Perales, MA
Sauter, CS
Armand, P
AF Perales, Miguel-Angel
Sauter, Craig S.
Armand, Philippe
TI Reprint of: Fast Cars and No Brakes: Autologous Stem Cell
Transplantation as a Platform for Novel Immunotherapies
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Reprint
DE Immunotherapy; Autologous stem cell transplantation; Checkpoint
inhibitors; Lymphoma; Myeloma; Adoptive cell therapy
ID CHIMERIC ANTIGEN RECEPTOR; ENGINEERED T-CELLS; IMMUNE CHECKPOINT
BLOCKADE; NATURAL-KILLER-CELLS; HIGH-DOSE THERAPY; MULTIPLE-MYELOMA;
HODGKIN-LYMPHOMA; HEMATOLOGIC MALIGNANCIES; MARROW TRANSPLANTATION;
CYTOTOXIC THERAPY
AB Autologous stem cell transplantation (ASCT) is indicated in a number of hematologic malignancies, including multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Relapse, however, remains 1 of the main causes of post-ASCT failure, and several strategies are being investigated to decrease the risk of relapse of progression. Recent advances in the treatment of hematological malignancies have included adoptive transfer of genetically modified T cells that express chimeric antigen receptors or T cell receptors, as well the use of checkpoint inhibitors. Early clinical results in nontransplantation patients have been very promising. This review will focus on the use of gene-modified T cells and checkpoint inhibitors in stem cell transplantation. (c) 2016 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.
C1 [Perales, Miguel-Angel; Sauter, Craig S.] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Perales, Miguel-Angel; Sauter, Craig S.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
[Armand, Philippe] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Perales, MA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, 1275 York Ave,Box 298, New York, NY 10065 USA.
EM peralesm@mskcc.org
NR 83
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
BP S9
EP S14
DI 10.1016/j.bbmt.2016.01.005
PG 6
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300003
PM 26899275
ER
PT J
AU Rashidi, A
Wolach, O
El-Jawahri, A
Ho, VT
DiPersio, JF
Soiffer, RJ
Stone, RM
Chen, YB
AF Rashidi, Armin
Wolach, Ofir
El-Jawahri, Areej
Ho, Vincent T.
DiPersio, John F.
Soiffer, Robert J.
Stone, Richard M.
Chen, Yi-Bin
TI The Effect of FLT3 and NPM1 Mutation Status on Outcomes of Transplanted
Vs. Non-Transplant Treated Elderly Patients with Normal Karyotype AML: A
Retrospective Multicenter Study
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Rashidi, Armin; DiPersio, John F.] Washington Univ, Sch Med, Div Oncol, Bone Marrow Transplantat & Leukemia Sect, St Louis, MO USA.
[Wolach, Ofir; Soiffer, Robert J.; Stone, Richard M.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
[El-Jawahri, Areej; Chen, Yi-Bin] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[Ho, Vincent T.] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 523
BP S350
EP S351
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300524
ER
PT J
AU Reddy, P
Cutler, C
AF Reddy, Pavan
Cutler, Corey
TI Selected Reviews from the 2016 BMT Tandem Meetings
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Editorial Material
C1 [Reddy, Pavan] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Cutler, Corey] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Reddy, P (reprint author), Univ Michigan, Ctr Canc, Dept Internal Med, Blood & Marrow Transplantat Program, 3312 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM reddypr@umich.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
BP S1
EP S2
DI 10.1016/j.bbmt.2016.01.011
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300001
PM 26899272
ER
PT J
AU Richardson, PG
Riches, ML
Kernan, NA
Brochstein, JA
Mineishi, S
Termuhlen, AM
Arai, S
Grupp, SA
Miloslavsky, M
Nejadnik, B
Hannah, AL
Soiffer, RJ
AF Richardson, Paul G.
Riches, Marcie L.
Kernan, Nancy A.
Brochstein, Joel A.
Mineishi, Shin
Termuhlen, Amanda M.
Arai, Sally
Grupp, Stephan A.
Miloslavsky, Maja
Nejadnik, Bijan
Hannah, Alison L.
Soiffer, Robert J.
TI Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction
Syndrome with Multi-Organ Dysfunction: A Concordance Analysis Between
Day+100 Complete Response and Survival
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[Riches, Marcie L.] Univ North Carolina Hosp, Bone Marrow & Stem Cell Transplant Clin, North Carolina Canc Hosp, Chapel Hill, NC USA.
[Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Bone Marrow Transplant Serv, Dept Pediat, 1275 York Ave, New York, NY 10021 USA.
[Brochstein, Joel A.] Cohen Childrens Med Ctr New York, New Hyde Pk, NY USA.
[Mineishi, Shin] Univ Alabama Birmingham, Birmingham, AL USA.
[Termuhlen, Amanda M.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Arai, Sally] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Miloslavsky, Maja; Nejadnik, Bijan; Hannah, Alison L.] Jazz Pharmaceut Inc, Palo Alto, CA USA.
[Soiffer, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 524
BP S351
EP S351
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300525
ER
PT J
AU Richardson, PG
Triplett, BM
Kernan, NA
Grupp, SA
Antin, JH
Lehmann, L
Miloslavsky, M
Hume, R
Hannah, AL
Nejadnik, B
Soiffer, RJ
AF Richardson, Paul G.
Triplett, Brandon M.
Kernan, Nancy A.
Grupp, Stephan A.
Antin, Joseph H.
Lehmann, Leslie
Miloslavsky, Maja
Hume, Robin
Hannah, Alison L.
Nejadnik, Bijan
Soiffer, Robert J.
TI Early Initiation of Defibrotide in Patients with Hepatic Veno-Occlusive
Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem
Cell Transplantation Improves Day+100 Survival
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Richardson, Paul G.; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[Triplett, Brandon M.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
[Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Lehmann, Leslie] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA USA.
[Miloslavsky, Maja; Hume, Robin; Hannah, Alison L.; Nejadnik, Bijan] Jazz Pharmaceut Inc, Palo Alto, CA USA.
[Soiffer, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 83
BP S82
EP S83
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300088
ER
PT J
AU Richardson, PG
Kernan, NA
Brochstein, JA
Mineishi, S
Arai, S
Grupp, SA
Guinan, E
Martin, PL
Steinbach, G
Krishnan, A
Nemecek, ER
Duerst, RE
Antin, JH
Lehmann, L
Gillio, AP
Bajwa, R
Miloslavsky, M
Hume, R
Iacobelli, M
Nejadnik, B
Hannah, AL
Soiffer, RJ
AF Richardson, Paul G.
Kernan, Nancy A.
Brochstein, Joel A.
Mineishi, Shin
Arai, Sally
Grupp, Stephan A.
Guinan, Eva
Martin, Paul L.
Steinbach, Gideon
Krishnan, Amrita
Nemecek, Eneida R.
Duerst, Reggie E.
Antin, Joseph H.
Lehmann, Leslie
Gillio, Alfred P.
Bajwa, Rajinder
Miloslavsky, Maja
Hume, Robin
Iacobelli, Massimo
Nejadnik, Bijan
Hannah, Alison L.
Soiffer, Robert J.
TI Defibrotide for the Treatment of Hepatic Veno-Occlusive
Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction:
Final Results from a Pivotal, Historically Controlled, Phase 3 Trial
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Richardson, Paul G.; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
[Brochstein, Joel A.] Cohen Childrens Med Ctr New York, New Hyde Pk, NY USA.
[Mineishi, Shin] Univ Alabama Birmingham, Bone Marrow Transplantat Program, Birmingham, AL USA.
[Arai, Sally] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Guinan, Eva] Dana Farber Canc Inst, Ctr Clin & Translat Res, Boston, MA 02115 USA.
[Martin, Paul L.] Duke Univ, Med Ctr, Pediat Blood & Marrow Transplantat, Durham, NC USA.
[Steinbach, Gideon] Univ Washington, Sch Med, Seattle, WA USA.
[Steinbach, Gideon] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Krishnan, Amrita] City Hope Natl Med Ctr, Duarte, CA USA.
[Nemecek, Eneida R.] Doernbecher Childrens Hosp, Dept Pediat, Pediat Blood & Marrow Transplant Program, Portland, OR USA.
[Nemecek, Eneida R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Duerst, Reggie E.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol & Stem Cell Transplantat, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA.
[Lehmann, Leslie] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA USA.
[Gillio, Alfred P.] Hackensack Univ, Med Ctr, Inst Pediat Canc & Blood Disorders, Hackensack, NJ USA.
[Bajwa, Rajinder] Nationwide Childrens, Bone Marrow Transplantat, Columbus, OH USA.
[Miloslavsky, Maja; Hume, Robin; Nejadnik, Bijan; Hannah, Alison L.] Jazz Pharmaceut Inc, Palo Alto, CA USA.
[Iacobelli, Massimo] Gentium SpA, Villa Guardia, Italy.
[Soiffer, Robert J.] Dana Farber Canc Inst, Hematol Malignancies, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 7
BP S25
EP S25
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300012
ER
PT J
AU Rosati, C
Lehmann, L
AF Rosati, Christine
Lehmann, Leslie
TI Increasing Vaccination Compliance in the Pediatric Hematopoietic Stem
Cell Transplant Population
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Rosati, Christine] Dana Farber Boston Childrens Hosp, Canc & Blood Disorders Ctr, Pediat Stem Cell Transplant Program, Boston, MA USA.
[Lehmann, Leslie] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 658
BP S433
EP S434
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300655
ER
PT J
AU Salit, RB
Emerson, R
Karanes, C
Gutman, JA
Nikiforow, S
Duncan, C
Kurtzberg, J
Robins, H
Rieder, M
Delaney, C
AF Salit, Rachel B.
Emerson, Ryan
Karanes, Chatchada
Gutman, Jonathan A.
Nikiforow, Sarah
Duncan, Christine
Kurtzberg, Joanne
Robins, Harlan
Rieder, Mark
Delaney, Colleen
TI Interim Analysis of an Observational Study Assessing T Cell Receptor
Diversity As an Early Predictor of NRM in Cord Blood Transplant
Recipients
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Salit, Rachel B.; Delaney, Colleen] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Emerson, Ryan; Robins, Harlan; Rieder, Mark] Adapt Biotechnol, Seattle, WA USA.
[Karanes, Chatchada] City Hope Natl Med Ctr, Hematol Hematopoiet Cell Transplant, 1500 E Duarte Rd, Duarte, CA 91010 USA.
[Gutman, Jonathan A.] Univ Colorado, Aurora, CO USA.
[Nikiforow, Sarah; Duncan, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Duncan, Christine] Boston Childrens Hosp, Dept Pediat Oncol, Boston, MA USA.
[Kurtzberg, Joanne] Duke Univ, Med Ctr, Carolinas Cord Blood Bank, Durham, NC USA.
[Robins, Harlan] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 33
BP S44
EP S44
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300038
ER
PT J
AU Ullrich, C
Lehmann, L
London, WB
Guo, DJ
Sridharan, M
Wolfe, J
AF Ullrich, Christina
Lehmann, Leslie
London, Wendy B.
Guo, Dongjing
Sridharan, Madhumitha
Wolfe, Joanne
TI Pediatric Palliative Care and End of Life Outcomes for Pediatric
Hematopoietic Stem Cell Transplant Recipients Who Do Not Survive
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Ullrich, Christina; Wolfe, Joanne] Boston Childrens Hosp, Dana Farber Canc Inst, Psychosocial Oncol & Palliat Care, Boston, MA USA.
[Ullrich, Christina; Lehmann, Leslie; London, Wendy B.; Guo, Dongjing; Sridharan, Madhumitha; Wolfe, Joanne] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 432
BP S295
EP S295
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300434
ER
PT J
AU Vrooman, L
Millard, H
Brazauskas, R
Majhail, NS
Battiwallas, M
Flowers, MED
Savani, BN
Akpek, G
Aljurf, MD
Bajwa, R
Baker, KS
Beitinjaneh, A
Bitan, M
Buchbinder, D
Dandoy, CE
Gale, RP
Hayashi, RJ
Hematti, P
Kamble, RT
Kasow, KA
Kletzel, M
Lazarus, HM
Malone, AK
O'Brien, T
Olsson, R
Reddy, V
Willert, JR
Ringden, O
Schears, RM
Seo, S
Steinberg, A
Yu, LC
Shaw, BE
Duncan, C
AF Vrooman, Lynda
Millard, Heather
Brazauskas, Ruta
Majhail, Navneet S.
Battiwallas, Minoo
Flowers, Mary E. D.
Savani, Bipin N.
Akpek, Goerguen
Aljurf, Mahmoud D.
Bajwa, Rajinder
Baker, K. Scott
Beitinjaneh, Amer
Bitan, Menachem
Buchbinder, David
Dandoy, Christopher E.
Gale, Robert Peter
Hayashi, Robert J.
Hematti, Peiman
Kamble, Rammurti T.
Kasow, Kimberly A.
Kletzel, Morris
Lazarus, Hillard M.
Malone, Adriana K.
O'Brien, Tracey
Olsson, Richard
Reddy, Vijay
Willert, Jennifer Reikes
Ringden, Olle
Schears, Raquel M.
Seo, Sachiko
Steinberg, Amir
Yu, Lolie C.
Shaw, Bronwen E.
Duncan, Christine
TI Survival and Late Effects of Children Undergoing Myeloablative
Allogeneic HCT at Less Than Three Years of Age: A Report from the Center
for International Blood and Marrow Transplant Research
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Vrooman, Lynda] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Millard, Heather] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
[Brazauskas, Ruta] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
[Majhail, Navneet S.] Cleveland Clin, Blood & Marrow Transplant Program, Taussig Canc Inst, Cleveland, OH 44106 USA.
[Battiwallas, Minoo] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
[Flowers, Mary E. D.; Baker, K. Scott] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.
[Akpek, Goerguen] Banner MD Anderson Canc Ctr, Gilbert, AZ USA.
[Aljurf, Mahmoud D.] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.
[Bajwa, Rajinder] Nationwide Childrens, Bone Marrow Transplantat, Columbus, OH USA.
[Beitinjaneh, Amer] Univ Virginia, Sch Med, Hematol Oncol, Charlottesville, VA 22908 USA.
[Bitan, Menachem] Tel Aviv Sourasky Med Ctr, Pediat Hematol Oncol & BMT, Tel Aviv, Israel.
[Buchbinder, David] Childrens Hosp Orange Cty, Div Pediat Hematol, Orange, CA 92668 USA.
[Dandoy, Christopher E.] Cincinnati Childrens Hosp Med Ctr, Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA.
[Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.
[Hayashi, Robert J.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, St Louis, MO 63110 USA.
[Hematti, Peiman] Univ Wisconsin Hosp & Clin, Dept Med, Div Hematol Oncol Bone Marrow Transplantat, Madison, WI 53792 USA.
[Kamble, Rammurti T.] Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.
[Kasow, Kimberly A.] Univ N Carolina, Div Hematol Oncol, Dept Pediat, Chapel Hill, NC USA.
[Kletzel, Morris] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Div Hematol Oncol & Stem Cell Transplantat, Chicago, IL 60611 USA.
[Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Cleveland, OH USA.
[Malone, Adriana K.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
[O'Brien, Tracey] Sydney Childrens Hosp, Kids Canc Ctr, Blood & Marrow Transplant Program, Sydney, NSW, Australia.
[Olsson, Richard] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden.
[Olsson, Richard; Ringden, Olle] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden.
[Reddy, Vijay] Univ Cent Florida, Dept Internal Med, Gainesville, FL USA.
[Willert, Jennifer Reikes] Univ Calif San Diego, Rady Childrens Hosp, Pediat Hematol Oncol BMT, San Diego, CA USA.
[Ringden, Olle] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden.
[Schears, Raquel M.] Mayo Clin, Rochester, MN USA.
[Seo, Sachiko] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Steinberg, Amir] Mt Sinai Hosp, Dept Hematol Oncol, New York, NY 10029 USA.
[Yu, Lolie C.] Louisiana State Univ, Med Ctr, Childrens Hosp, Div Hematol Oncol, New Orleans, LA USA.
[Yu, Lolie C.] Louisiana State Univ, Med Ctr, Childrens Hosp, Ctr Canc & Blood Disorders,HSCT, New Orleans, LA USA.
[Shaw, Bronwen E.] CIBMTR, Dept Med, Milwaukee, WI USA.
[Shaw, Bronwen E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Duncan, Christine] Boston Childrens Hosp, Dept Pediat Oncol, Boston, MA USA.
[Duncan, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 12
BP S28
EP S29
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300017
ER
PT J
AU Vusirikala, M
Naik, S
Maziarz, RT
Baumeister, S
Aquino, V
Ma, H
Moseley, A
Woolfrey, AE
Krishnamurti, L
Chen, GL
Sandmaier, BM
Bertaina, A
Perales, MA
Williams, DA
Kapoor, N
AF Vusirikala, Madhuri
Naik, Swati
Maziarz, Richard T.
Baumeister, Susanne
Aquino, Victor
Ma, Hong
Moseley, Annemarie
Woolfrey, Ann E.
Krishnamurti, Lakshmanan
Chen, George L.
Sandmaier, Brenda M.
Bertaina, Alice
Perales, Miguel-Angel
Williams, David A.
Kapoor, Neena
TI BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) Treatment
Following TCR Alpha Beta Depleted Stem Cell Transplantation in Adults
and Children with Hematological Disorders
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Vusirikala, Madhuri] Univ Texas SW Med Ctr Dallas, Harold C Simmons Comprehens Canc C, Dallas, TX 75390 USA.
[Naik, Swati] Baylor Coll Med, Texas Childrens Hosp Canc Ctr, Methodist Hosp Houston, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA.
[Baumeister, Susanne] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Aquino, Victor] Univ Texas SW Med Ctr Dallas, Pediat, Dallas, TX 75390 USA.
[Ma, Hong; Moseley, Annemarie] Bellicum Pharmaceut, Houston, TX USA.
[Woolfrey, Ann E.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Krishnamurti, Lakshmanan] Emory Sch Med, Childrens Healthcare Atlanta, Atlanta, GA USA.
[Chen, George L.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.
[Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Bertaina, Alice] Bambino Gesu Pediat Hosp, Stem Cell Transplant Unit, Rome, Italy.
[Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplant Serv, Dept Med, 1275 York Ave, New York, NY 10021 USA.
[Williams, David A.] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA.
[Kapoor, Neena] Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Blood & Marrow Transplant Program, Los Angeles, CA 90027 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 541
BP S361
EP S361
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300542
ER
PT J
AU Zimmerman, TM
Griffith, K
Jasielec, JK
Rosenbaum, CA
Berdeja, JG
Vij, R
Raje, N
Reece, DE
Vesole, DH
Jagannath, S
Kaminski, M
Cole, C
Nam, J
Stephens, LA
Rosebeck, S
Gurbuxani, S
Dytfeld, D
Jakubowiak, AJ
AF Zimmerman, Todd M.
Griffith, Kent
Jasielec, Jagoda K.
Rosenbaum, Cara A.
Berdeja, Jesus G.
Vij, Ravi
Raje, Noopur
Reece, Donna E.
Vesole, David H.
Jagannath, Sundar
Kaminski, Mark
Cole, Craig
Nam, Jennifer
Stephens, Leonor A.
Rosebeck, Shaun
Gurbuxani, Sandeep
Dytfeld, Dominik
Jakubowiak, Andrzej J.
TI Carfilzomib (CFZ, Kyprolis (R)), Lenalidomide (LEN, Revlimide (R)), and
Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant
(ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly
Diagnosed Multiple Myeloma (NDMM)
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Zimmerman, Todd M.; Rosenbaum, Cara A.; Nam, Jennifer; Stephens, Leonor A.; Rosebeck, Shaun; Gurbuxani, Sandeep; Jakubowiak, Andrzej J.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Griffith, Kent; Kaminski, Mark; Cole, Craig] Univ Michigan, Ann Arbor, MI 48109 USA.
[Jasielec, Jagoda K.] Northshore Univ Hlth Syst, Evanston, IL USA.
[Berdeja, Jesus G.] Sarah Cannon BMT Program, Nashville, TN USA.
[Vij, Ravi] Washington Univ, Sch Med, Div Oncol, Bone Marrow Transplantat & Leukemia Sect, St Louis, MO USA.
[Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Reece, Donna E.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Vesole, David H.] John Theurer Canc Ctr Hackensack UMC, Myeloma Div, Hackenscak, NJ USA.
[Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Dytfeld, Dominik] Univ Med Sci, Poznan, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 28
BP S40
EP S40
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300033
ER
PT J
AU Singh, JA
Shah, N
Edwards, NL
AF Singh, Jasvinder A.
Shah, Nipam
Edwards, N. Lawrence
TI A cross-sectional internet-based patient survey of the management
strategies for gout
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Gout; Cherry extract; Cherry juice; Complementary medicine; Allopurinol;
Febuxostat; Internet study; Survey; Natural supplements; Diet
modification
ID QUALITY-OF-LIFE; PURINE-RICH FOODS; RISK; CARE; ADHERENCE; HEALTH; MEN;
HYPERURICEMIA; BARRIERS; PERSPECTIVE
AB Background: Almost half of the patients with gout are not prescribed urate-lowering therapy (ULT) by their health care provider and > 50 % use complementary and alternative therapies. Diet modification is popular among gout patients due to known associations of certain foods with gout flares. The interplay of the use of dietary supplements, diet modification, and ULT adherence in gout patients is not known. Despite the recent interest in diet and supplements, there are limited data on their use. Our objective was to assess ULT use and adherence and patient preference for non-pharmacological interventions by patients with gout, using a cross-sectional survey.
Methods: People who self-reported physician-diagnosed gout during their visit to a gout website (http://gouteducation.org) were invited to participate in a brief anonymous cross-sectional Internet survey between 08/11/2014 to 04/14/2015 about the management of their gout. The survey queried ULT prescription, ULT adherence, the use of non-pharmacological interventions (cherry extract, diet modification) and the likelihood of making a lifelong diet modification for gout management.
Results: A total of 499 respondents with a mean age 56.3 years were included; 74 % were males and 74 % were White. Of these, 57 % (285/499) participants were prescribed a ULT for gout, of whom 88 % (251/285) were currently taking ULT. Of those using ULT, 78 % (97/251) reported ULT adherence > 80 %. Gender, race, and age were not significantly associated with the likelihood of receiving a ULT prescription or ULT adherence > 80 %. Fifty-six percent of patients with gout preferred ULT as a lifelong treatment for gout, 24 % preferred cherry extract and 16 % preferred diet modification (4 % preferred none). Men had significantly lower odds of preferring ULT as the lifelong treatment choice for gout vs. other choices (p = 0.03). We found that 38.3 % participants were highly motivated to make a lifelong dietary modification to improve their gout (score of 9-10 on a 0-10 likelihood scale). Older age was significantly associated with high level of willingness to modify diet (p = 0.02).
Conclusion: We found that only 57 % of gout patients reported being prescribed ULT. 40 % of gout patients preferred non-pharmacological interventions such as cherry extract and diet modification for gout management. The latter finding requires further investigation.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.; Shah, Nipam] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Shah, Nipam] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
[Edwards, N. Lawrence] Univ Florida, Dept Med, Gainesville, FL USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
EM Jasvinder.md@gmail.com
FU Division of Rheumatology at the University of Alabama at Birmingham
FX This material is the result of work supported by research funds from the
Division of Rheumatology at the University of Alabama at Birmingham and
the resources and use of facilities at the Birmingham VA Medical Center,
Alabama, USA.
NR 37
TC 0
Z9 0
U1 7
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD MAR 1
PY 2016
VL 16
AR 90
DI 10.1186/s12906-016-1067-3
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA DF1RO
UT WOS:000371117100002
PM 26931313
ER
PT J
AU Berkowitz, SA
Hulberg, AC
Hong, C
Stowell, BJ
Tirozzi, KJ
Traore, CY
Atlas, SJ
AF Berkowitz, Seth A.
Hulberg, A. Catherine
Hong, Clemens
Stowell, Brian J.
Tirozzi, Karen J.
Traore, Carine Y.
Atlas, Steven J.
TI Addressing basic resource needs to improve primary care quality: a
community collaboration programme
SO BMJ QUALITY & SAFETY
LA English
DT Article
ID DIRECTLY OBSERVED THERAPY; PEDIATRIC PRIMARY-CARE; SOCIAL DETERMINANTS;
FOOD INSECURITY; MEDICAL HOME; HEALTH-CARE; SAFETY-NET; REDUCE
DISPARITIES; PATIENT NAVIGATION; GLYCEMIC CONTROL
AB Background Unmet basic resource needs, such as difficulty affording healthcare, medications, food and housing, may contribute to worse healthcare quality indicators, but interventions are hampered by lack of specific knowledge regarding the distribution of unmet basic resource needs and their association with priority clinical conditions and health service use patterns.
Methods Cross-sectional study of primary care patients in two urban academic practices from 1 October 2013 to 30 April 2014. Patients were screened for unmet needs and enrolled in a programme to link them with community resources. Key measures included patient report of unmet basic resource needs, clinical conditions prioritised by quality improvement programmes (hypertension, diabetes and depression), and health service use patterns such as frequent emergency department (ED) visits (>2 in the preceding year) and frequent clinic 'no-shows' (>1 in the preceding year).
Results 416 patients with unmet needs were included, and compared with 2750 patients who did not report needs. The most common types of needs reported were: difficulties affording healthcare (46.5%), food (40.1%) and utilities (36.3%). Patients who reported unmet needs were more likely to have depression (17.8% vs 9.5%, p<0.0001), diabetes (32.7% vs 20.4%, p<0.0001), hypertension (54.3% vs 46.3%, p=0.002), be frequent ED users (11.3% vs 5.4%, p<0.0001), and have frequent 'no-shows' to clinic (21.6% vs 11.9%, p<0.0001).
Conclusions Difficulty affording healthcare and food are particularly common needs among patients with priority conditions. Strategies to identify and address unmet needs as part of routine care may be an important way to improve healthcare quality.
C1 [Berkowitz, Seth A.; Hulberg, A. Catherine; Hong, Clemens; Stowell, Brian J.; Tirozzi, Karen J.; Traore, Carine Y.; Atlas, Steven J.] Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02141 USA.
RP Berkowitz, SA (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02141 USA.
EM saberkowitz@partners.org
OI Berkowitz, Seth/0000-0003-1030-4297
NR 48
TC 3
Z9 3
U1 3
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
EI 2044-5423
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD MAR
PY 2016
VL 25
IS 3
BP 164
EP 172
DI 10.1136/bmjqs-2015-004521
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DE7PD
UT WOS:000370828300007
PM 26621916
ER
PT J
AU Castillo, JJ
D'Sa, S
Lunn, MP
Minnema, MC
Tedeschi, A
Lansigan, F
Palomba, ML
Varettoni, M
Garcia-Sanz, R
Nayak, L
Lee, EQ
Rinne, ML
Norden, AD
Ghobrial, IM
Treon, SP
AF Castillo, Jorge J.
D'Sa, Shirley
Lunn, Michael P.
Minnema, Monique C.
Tedeschi, Alessandra
Lansigan, Frederick
Palomba, M. Lia
Varettoni, Marzia
Garcia-Sanz, Ramon
Nayak, Lakshmi
Lee, Eudocia Q.
Rinne, Mikael L.
Norden, Andrew D.
Ghobrial, Irene M.
Treon, Steven P.
TI Central nervous system involvement by Waldenstrom macroglobulinaemia
(Bing-Neel syndrome): a multi-institutional retrospective study
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE Bing-Neel syndrome; Waldenstrom macroglobulinaemia; lymphoplasmacytic
lymphoma; central nervous system
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; PRIMARY CNS LYMPHOMA; END RESULTS
DATABASE; MYD88 L265P; RITUXIMAB; BENDAMUSTINE; EPIDEMIOLOGY;
SURVEILLANCE; INFILTRATION; METHOTREXATE
AB Bing-Neel syndrome (BNS) is a rare complication seen in patients with Waldenstrom macroglobulinaemia (WM), in which lymphoplasmacytic lymphoma cells colonize the central nervous system. In this retrospective multi-centre study, we present the clinicopathological features, imaging findings, therapy, response and outcomes of 34 patients with BNS. The median time from WM diagnosis to BNS diagnosis was 3years, 15% of patients were diagnosed with BNS at the time of WM diagnosis, and 22% of patients developed BNS when responding to active treatment for WM. Patients with BNS presented with variable clinical features including limb motor deficits, change in mental status and cranial nerve palsies. The diagnosis was made using a combination of cerebrospinal fluid cytology, flow cytometry and detection of the MYD88 L265 mutation, and magnetic resonance imaging. The estimated 3-year overall survival rate was 59%. Of the survivors, 40% have evidence of pathological and/or radiological persistence of disease. Age older than 65years, platelet count lower than 100x10(9)/l, and treatment for WM prior to BNS diagnosis were associated with worse outcome. Exposure to rituximab for treatment of BNS was associated with a better outcome. Multi-institutional collaboration is warranted to improve treatment and outcomes in patients with BNS.
C1 [Castillo, Jorge J.; Nayak, Lakshmi; Lee, Eudocia Q.; Rinne, Mikael L.; Norden, Andrew D.; Ghobrial, Irene M.; Treon, Steven P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[D'Sa, Shirley; Lunn, Michael P.] Univ Coll London Hosp, London, England.
[Minnema, Monique C.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Tedeschi, Alessandra] Osped Niguarda Ca Granda, Milan, Italy.
[Lansigan, Frederick] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Palomba, M. Lia] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Varettoni, Marzia] Policlin San Matteo, I-27100 Pavia, Italy.
[Garcia-Sanz, Ramon] Hosp Univ Salamanca, Salamanca, Spain.
RP Castillo, JJ (reprint author), Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, 450 Brookline Ave,M221, Boston, MA 02215 USA.
EM jorgej_castillo@dfci.harvard.edu
RI Garcia-Sanz, Ramon/B-7986-2017;
OI Garcia-Sanz, Ramon/0000-0003-4120-2787; Castillo,
Jorge/0000-0001-9490-7532
FU Gilead Sciences; Millennium Pharmaceuticals; Pharmacyclics; CSL Behring;
Teva Pharmaceuticals; Novartis; Janssen; Onyx
FX JJC: Advisory Board: Gilead Sciences. Consultancy: Biogen Idec, Otsuka
Pharmaceuticals. Research funding: Gilead Sciences, Millennium
Pharmaceuticals, Pharmacyclics. SD: Honoraria: Janssen. MPL: Advisory
Board: CSL Behring, Baxter Pharmaceuticals. Research funding: CSL
Behring. Speaker: CSL Behring, Grifols, Kedrion. Honoraria: CSL Behring,
Grifols. MCM: Consultancy: Amgen, Celgene, Janssen Cilag. AT: No
conflict of interest to disclose. FL: Research funding: Teva
Pharmaceuticals. MLP: No conflict of interest to disclose. MV: No
conflict of interest to disclose. RGS: Honoraria: Novartis, Amgen,
Millennium Pharmaceuticals. Research funding: Novartis. Advisory Board:
Amgen. SW: No conflict of interest to disclose. LN: No conflict of
interest to disclose. EQL: Consultancy: Genentech. MLR: Consultancy:
N-Of-One Therapeutics. ADN: No conflict of interest to disclose. IMG:
Advisory Board: Bristol-Myers-Squibb, Celgene, Novartis, Takeda. SPT:
Research funding, consulting fees, and/or speaking honoraria from
Janssen, Onyx, Pharmacyclics, Gilead Sciences.
NR 34
TC 9
Z9 9
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD MAR
PY 2016
VL 172
IS 5
BP 709
EP 715
DI 10.1111/bjh.13883
PG 7
WC Hematology
SC Hematology
GA DE9LS
UT WOS:000370959600005
PM 26686858
ER
PT J
AU Xu, L
Hunter, ZR
Tsakmaklis, N
Cao, Y
Yang, G
Chen, J
Liu, X
Kanan, S
Castillo, JJ
Tai, YT
Zehnder, JL
Brown, JR
Carrasco, RD
Advani, R
Sabile, JM
Argyropoulos, K
Palomba, ML
Morra, E
Trojani, A
Greco, A
Tedeschi, A
Varettoni, M
Arcaini, L
Munshi, NM
Anderson, KC
Treon, SP
AF Xu, Lian
Hunter, Zachary R.
Tsakmaklis, Nicholas
Cao, Yang
Yang, Guang
Chen, Jie
Liu, Xia
Kanan, Sandra
Castillo, Jorge J.
Tai, Yu-Tzu
Zehnder, James L.
Brown, Jennifer R.
Carrasco, Ruben D.
Advani, Ranjana
Sabile, Jean M.
Argyropoulos, Kimon
Palomba, M. Lia
Morra, Enrica
Trojani, Alessandra
Greco, Antonino
Tedeschi, Alessandra
Varettoni, Marzia
Arcaini, Luca
Munshi, Nikhil M.
Anderson, Kenneth C.
Treon, Steven P.
TI Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom
Macroglobulinaemia
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE Waldenstrom macroglobulinaemia; IgM MGUS; Marginal Zone Lymphoma; CXCR4;
WHIM; MYD88 L265P
ID MARGINAL ZONE LYMPHOMA; L265P SOMATIC MUTATION; MYD88 L265P;
LYMPHOPLASMACYTIC LYMPHOMA; MONOCLONAL GAMMOPATHY; RESISTANCE;
IBRUTINIB; FEATURES
AB CXCR4(WHIM) somatic mutations are distinctive to Waldenstrom Macroglobulinaemia (WM), and impact disease presentation and treatment outcome. The clonal architecture of CXCR4(WHIM) mutations remains to be delineated. We developed highly sensitive allele-specific polymerase chain reaction (AS-PCR) assays for detecting the most common CXCR4(WHIM) mutations (CXCR4(S338X C>A and C>G)) in WM. The AS-PCR assays detected CXCR4(S338X) mutations in WM and IgM monoclonal gammopathy of unknown significance (MGUS) patients not revealed by Sanger sequencing. By combined AS-PCR and Sanger sequencing, CXCR4(WHIM) mutations were identified in 44/102 (43%), 21/62 (34%), 2/12 (17%) and 1/20 (5%) untreated WM, previously treated WM, IgM MGUS and marginal zone lymphoma patients, respectively, but no chronic lymphocytic leukaemia, multiple myeloma, non-IgM MGUS patients or healthy donors. Cancer cell fraction analysis in WM and IgM MGUS patients showed CXCR4(S338X) mutations were primarily subclonal, with highly variable clonal distribution (median 351%, range 12-975%). Combined AS-PCR and Sanger sequencing revealed multiple CXCR4(WHIM) mutations in many individual WM patients, including homozygous and compound heterozygous mutations validated by deep RNA sequencing. The findings show that CXCR4(WHIM) mutations are more common in WM than previously revealed, and are primarily subclonal, supporting their acquisition after MYD88(L265P) in WM oncogenesis. The presence of multiple CXCR4(WHIM) mutations within individual WM patients may be indicative of targeted CXCR4 genomic instability.
C1 [Xu, Lian; Hunter, Zachary R.; Tsakmaklis, Nicholas; Cao, Yang; Yang, Guang; Chen, Jie; Liu, Xia; Kanan, Sandra; Castillo, Jorge J.; Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, M548,450 Brookline Ave, Boston, MA 02115 USA.
[Hunter, Zachary R.; Cao, Yang; Yang, Guang; Liu, Xia; Castillo, Jorge J.; Tai, Yu-Tzu; Brown, Jennifer R.; Carrasco, Ruben D.; Munshi, Nikhil M.; Anderson, Kenneth C.; Treon, Steven P.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Tai, Yu-Tzu; Munshi, Nikhil M.; Anderson, Kenneth C.] Dana Farber Canc Inst, Lipper Ctr Multiple Myeloma, Boston, MA 02115 USA.
[Zehnder, James L.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA.
[Brown, Jennifer R.; Carrasco, Ruben D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Advani, Ranjana; Sabile, Jean M.] Stanford Univ, Med Ctr, Dept Med Oncol, Stanford, CA 94305 USA.
[Argyropoulos, Kimon; Palomba, M. Lia] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA.
[Morra, Enrica; Trojani, Alessandra; Greco, Antonino; Tedeschi, Alessandra] Osped Niguarda Ca Granda, Haematol Unit, Milan, Italy.
[Varettoni, Marzia; Arcaini, Luca] Univ Pavia, Dept Mol Med, Via Palestro 3, I-27100 Pavia, Italy.
[Varettoni, Marzia; Arcaini, Luca] Fdn IRCCS Policlin San Matteo, Dept Haematol Oncol, Pavia, Italy.
RP Treon, SP (reprint author), Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, M548,450 Brookline Ave, Boston, MA 02115 USA.
EM steven_treon@dfci.harvard.edu
OI Castillo, Jorge/0000-0001-9490-7532; Hunter, Zachary/0000-0002-1689-1691
FU Leukemia and Lymphoma Society; International Waldenstrom
Macroglobulinaemia Foundation; Linda and Edward Nelson Fund for WM
Research; D'Amato Fund for Genomic Discovery; Coyote Fund; NIH SPORE
post-doctoral fellowship [P50CA100707]
FX Supported by Peter S. Bing M.D., a translational research grant from the
Leukemia and Lymphoma Society, a research grant from the International
Waldenstrom Macroglobulinaemia Foundation, the Linda and Edward Nelson
Fund for WM Research, the D'Amato Fund for Genomic Discovery, the Coyote
Fund, and an NIH SPORE post-doctoral fellowship award to ZRH
(P50CA100707).
NR 21
TC 7
Z9 7
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD MAR
PY 2016
VL 172
IS 5
BP 735
EP 744
DI 10.1111/bjh.13897
PG 10
WC Hematology
SC Hematology
GA DE9LS
UT WOS:000370959600008
PM 26659815
ER
PT J
AU Davies, EC
Pavan-Langston, D
Chodosh, J
AF Davies, Emma C.
Pavan-Langston, Deborah
Chodosh, James
TI Herpes zoster ophthalmicus: declining age at presentation
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID UNITED-STATES; VARICELLA VACCINATION; RISK-FACTORS; EPIDEMIOLOGY;
CHICKENPOX; COVERAGE; SYSTEM; IMPACT; VIRUS; RATES
AB Objective To investigate changes in the age of occurrence of herpes zoster ophthalmicus (HZO) in patients presenting to the Massachusetts Eye and Ear Infirmary (MEEI) from 2007 through 2013.
Design Retrospective chart review.
Setting Academic tertiary referral centre for ophthalmic conditions.
Participants 913 patients with acute HZO.
Methods A total of 1283 potential cases were identified by searching the MEEI electronic medical record for patient charts with International Classification of Diseases 9 codes for herpes zoster, shingles and varicella from 2007 through 2013. The cases were reviewed to confirm diagnosis of acute HZO, requiring documentation of a skin rash or pain in the V1 distribution, resulting in inclusion of 913 cases.
Main outcome measures Number of HZO cases each year, mean age of HZO cases each year, number of HZO cases with an immunodeficiency state.
Results The number of patients with HZO presenting to MEEI increased from 71 cases in 2007 to 195 cases in 2013. The mean age of patients with acute HZO reduced significantly from 61.2 years in 2007 to 55.8 years in 2013 (p=0.0119). The number of patients with acute HZO in the setting of an immunodeficiency state did not change significantly over the study period.
Conclusions Ever since the introduction of varicella vaccination in children, there has been debate regarding its effect on zoster epidemiology, particularly regarding the potential to reduce population exposure and limit repeated immunological boosts against varicella zoster virus in adults. Patients presenting to MEEI with HZO were younger on average in 2013 than in 2007. Although a population-based study is necessary to test the hypothesis, our study suggests that varicella vaccination of children remains a possible explanation for the increased number of cases and reduction in mean age of newly diagnosed patients.
C1 [Davies, Emma C.; Pavan-Langston, Deborah; Chodosh, James] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
RP Chodosh, J (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab, 243 Charles St, Boston, MA 02114 USA.
EM james_chodosh@meei.harvard.edu
FU N&J Johnstone Fund; G Stevens Fund; Research to Prevent Blindness
FX This work was supported by the N&J Johnstone Fund, G Stevens Fund and an
unrestricted grant from Research to Prevent Blindness.
NR 22
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2016
VL 100
IS 3
BP 312
EP 314
DI 10.1136/bjophthalmol-2015-307157
PG 3
WC Ophthalmology
SC Ophthalmology
GA DE9SN
UT WOS:000370979300005
PM 26178905
ER
PT J
AU Steuer, CE
Behera, M
Berry, L
Kim, S
Rossi, M
Sica, G
Owonikoko, TK
Johnson, BE
Kris, MG
Bunn, PA
Khuri, FR
Garon, EB
Ramalingam, SS
AF Steuer, Conor E.
Behera, Madhusmita
Berry, Lynne
Kim, Sungjin
Rossi, Michael
Sica, Gabriel
Owonikoko, Taofeek K.
Johnson, Bruce E.
Kris, Mark G.
Bunn, Paul A.
Khuri, Fadlo R.
Garon, Edward B.
Ramalingam, Suresh S.
TI Role of race in oncogenic driver prevalence and outcomes in lung
adenocarcinoma: Results from the Lung Cancer Mutation Consortium
SO CANCER
LA English
DT Article
DE disparities; genomics; lung cancer; race; targeted therapy
ID KRAS MUTATIONS; EGFR MUTATIONS; LATIN-AMERICA; FREQUENCY; CHEMOTHERAPY;
CARBOPLATIN; DISPARITIES; PACLITAXEL; GEFITINIB; SMOKING
AB BACKGROUNDThe discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities has been understudied. The Lung Cancer Mutation Consortium 1 (LCMC1) database was investigated to evaluate the frequency and impact of oncogenic drivers in lung adenocarcinomas in the racial/ethnic minority patient population.
METHODSPatients with metastatic lung adenocarcinomas from 14 US sites were enrolled in the LCMC1. Tumor samples were collected from 2009 through 2012 with multiplex genotyping performed on 10 oncogenic drivers (KRAS, epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase (ALK) rearrangements, ERBB2 [formerly human epidermal growth factor receptor 2], BRAF, PIK3CA, MET amplification, NRAS, MEK1, and AKT1). Patients were classified as white, Asian, African American (AA), or Latino. The driver mutation frequency, the treatments, and the survival from diagnosis were determined.
RESULTSOne thousand seven patients were included. Whites represented the majority (n = 838); there were 60 AAs, 48 Asians, and 28 Latinos. Asian patients had the highest rate of oncogenic drivers with 81% (n = 39), and they were followed by Latinos with 68% (n = 19), whites with 61% (n = 511), and AAs with 53% (n = 32). For AAs, the EGFR mutation frequency was 22%, the KRAS frequency was 17%, and the ALK frequency was 4%. Asian patients were most likely to receive targeted therapies (51% vs 27% for AAs). There were no significant differences in overall survival.
CONCLUSIONSDifferences were observed in the prevalence of oncogenic drivers in lung adenocarcinomas and in subsequent treatments among racial groups. The lowest frequency of drivers was seen for AA patients; however, more than half of AA patients had a driver, and those treated with targeted therapy had outcomes similar to those of other races. (c) 2015 American Cancer Society.
C1 [Steuer, Conor E.; Behera, Madhusmita; Rossi, Michael; Sica, Gabriel; Owonikoko, Taofeek K.; Khuri, Fadlo R.; Ramalingam, Suresh S.] Emory Univ, Winship Canc Inst, 1365 Clifton Rd Northeast,Room C-3090, Atlanta, GA 30322 USA.
[Berry, Lynne] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
[Kim, Sungjin] Cedars Sinai Med Ctr, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA.
[Johnson, Bruce E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kris, Mark G.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Bunn, Paul A.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Ramalingam, SS (reprint author), Emory Univ, Winship Canc Inst, 1365 Clifton Rd Northeast,Room C-3090, Atlanta, GA 30322 USA.
EM suresh.ramalingam@emory.edu
OI Kris, Mark/0000-0002-7317-5341
FU National Cancer Institute
FX Edward B. Garon reports a grant from the National Cancer Institute
during the conduct of this study.
NR 28
TC 5
Z9 5
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 1
PY 2016
VL 122
IS 5
BP 766
EP 772
DI 10.1002/cncr.29812
PG 7
WC Oncology
SC Oncology
GA DF2IP
UT WOS:000371166300017
PM 26695526
ER
PT J
AU Mor, V
Joyce, NR
Cote, DL
Gidwani, RA
Ersek, M
Levy, CR
Faricy-Anderson, KE
Miller, SC
Wagner, TH
Kinosian, BP
Lorenz, KA
Shreve, ST
AF Mor, Vincent
Joyce, Nina R.
Cote, Danielle L.
Gidwani, Risha A.
Ersek, Mary
Levy, Cari R.
Faricy-Anderson, Katherine E.
Miller, Susan C.
Wagner, Todd H.
Kinosian, Bruce P.
Lorenz, Karl A.
Shreve, Scott T.
TI The rise of concurrent care for veterans with advanced cancer at the end
of life
SO CANCER
LA English
DT Article
DE end-of-life care; hospices; neoplasms; palliative care; veterans
ID HOSPICE ELIGIBILITY CRITERIA; PALLIATIVE CARE; MEDICARE; QUALITY; COSTS;
ASSOCIATION; OUTCOMES; BENEFIT
AB BACKGROUNDUnlike Medicare, the Veterans Health Administration (VA) health care system does not require veterans with cancer to make the terrible choice between receipt of hospice services or disease-modifying chemotherapy/radiation therapy. For this report, the authors characterized the VA's provision of concurrent care, defined as days in the last 6 months of life during which veterans simultaneously received hospice services and chemotherapy or radiation therapy.
METHODSThis retrospective cohort study included veteran decedents with cancer during 2006 through 2012 who were identified from claims with cancer diagnoses. Hospice and cancer treatment were identified using VA and Medicare administrative data. Descriptive statistics were used to characterize the changes in concurrent care, hospice, palliative care, and chemotherapy or radiation treatment.
RESULTSThe proportion of veterans receiving chemotherapy or radiation therapy remained stable at approximately 45%, whereas the proportion of veterans who received hospice increased from 55% to 68%. The receipt of concurrent care also increased during this time from 16.2% to 24.5%. The median time between hospice initiation and death remained stable at around 21 days. Among veterans who received chemotherapy or radiation therapy in their last 6 months of life, the median time between treatment termination and death ranged from 35 to 40 days. There was considerable variation between VA medical centers in the use of concurrent care (interquartile range, 16%-34% in 2012).
CONCLUSIONSConcurrent receipt of hospice and chemotherapy or radiation therapy increased among veterans dying from cancer without reductions in the receipt of cancer therapy. This approach reflects the expansion of hospice services in the VA with VA policy allowing the concurrent receipt of hospice and antineoplastic therapies. (c) 2015 American Cancer Society.
C1 [Mor, Vincent; Joyce, Nina R.; Cote, Danielle L.; Faricy-Anderson, Katherine E.; Miller, Susan C.] Providence Vet Hlth Adm VA Med Ctr, Ctr Innovat, Providence, RI USA.
[Mor, Vincent; Miller, Susan C.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA.
[Joyce, Nina R.] Harvard Univ, Sch Med, Dept Hlth Policy, Boston, MA USA.
[Gidwani, Risha A.; Wagner, Todd H.] VA Palo Alto Healthcare Syst, VA Hlth Econ Resource Ctr, Palo Alto, CA USA.
[Gidwani, Risha A.; Wagner, Todd H.; Lorenz, Karl A.] VA Palo Alto Healthcare Syst, Ctr Innovat Implementat, Palo Alto, CA USA.
[Gidwani, Risha A.; Wagner, Todd H.; Lorenz, Karl A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Ersek, Mary; Kinosian, Bruce P.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA.
[Ersek, Mary] US Dept Vet Affairs, Natl Performance Reporting & Outcomes Measurement, Washington, DC USA.
[Levy, Cari R.] Eastern Colorado VA Healthcare Syst, Denver, CO USA.
[Faricy-Anderson, Katherine E.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Kinosian, Bruce P.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Shreve, Scott T.] US Dept Vet Affairs, Hosp & Palliat Care Program, Washington, DC USA.
[Shreve, Scott T.] Penn State Coll Med, Hershey, PA USA.
RP Mor, V (reprint author), 121 South Main St,Box G-121-6, Providence, RI 02912 USA.
EM vincent_mor@brown.edu
FU US Department of Veterans Affairs [IIR 12-121]; Merit Review Award from
Health Services Research and Development Service
FX This work was supported by a Merit Review Award (IIR 12-121) from the
Health Services Research and Development Service, US Department of
Veterans Affairs.
NR 21
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 1
PY 2016
VL 122
IS 5
BP 782
EP 790
DI 10.1002/cncr.29827
PG 9
WC Oncology
SC Oncology
GA DF2IP
UT WOS:000371166300019
PM 26670795
ER
PT J
AU El-Jawahri, AR
Vandusen, HB
Traeger, LN
Fishbein, JN
Keenan, T
Gallagher, ER
Greer, JA
Pirl, WF
Jackson, VA
Spitzer, TR
Chen, YBA
Temel, JS
AF El-Jawahri, Areej R.
Vandusen, Harry B.
Traeger, Lara N.
Fishbein, Joel N.
Keenan, Tanya
Gallagher, Emily R.
Greer, Joseph A.
Pirl, William F.
Jackson, Vicki A.
Spitzer, Thomas R.
Chen, Yi-Bin A.
Temel, Jennifer S.
TI Quality of life and mood predict posttraumatic stress disorder after
hematopoietic stem cell transplantation
SO CANCER
LA English
DT Article
DE depression; mood; posttraumatic stress disorder (PTSD); quality of life
(QOL); stem cell transplant
ID BONE-MARROW-TRANSPLANTATION; BREAST-CANCER; CIVILIAN VERSION; PTSD
CHECKLIST; SYMPTOMS; DISTRESS; RECOVERY; SYMPTOMATOLOGY; PREVALENCE;
SURVIVORS
AB BACKGROUNDDuring hospitalization for hematopoietic stem cell transplantation (HCT), patients experience a steep deterioration in quality of life (QOL) and mood. To our knowledge, the impact of this deterioration on patients' QOL and posttraumatic stress disorder (PTSD) symptoms after HCT is unknown.
METHODSWe conducted a prospective longitudinal study of patients hospitalized for HCT. They assessed QOL using the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) and depression and anxiety symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9) at the time of admission for HCT, during hospitalization, and 6 months after HCT. We also used the Hospital Anxiety and Depression Scale (HADS) to measure patients' anxiety and depression symptoms at baseline and during HCT hospitalization. The PTSD Checklist was used to assess for PTSD symptoms. Multivariable linear regression models were used to identify predictors of QOL and PTSD symptoms at 6 months.
RESULTSWe enrolled 90 of 93 consecutively eligible patients (97%) undergoing autologous and allogeneic HCT. Data at 6 months were available for 67 participants. At 6 months, 28.4% of participants met the criteria for PTSD and 43.3% had clinically significant depression. On multivariable regression analyses adjusting for significant covariates, changes in QOL and depression scores from week 2 of HCT hospitalization to baseline predicted worse QOL (changes in scores between week 2 and baseline [] QOL: , 0.94 [P<.0001] and PHQ-9: , -2.59 [P = 0.001]) and PTSD symptoms ( QOL: , -0.40 [P<.0001] and PHQ-9: , 1.26 [P<.0001]) at 6 months after HCT.
CONCLUSIONSSix months after HCT, a significant percentage of patients met the criteria for PTSD and depression. A decline in QOL and an increase in depressive symptoms during hospitalization for HCT were found to be the most important predictors of 6-month QOL impairment and PTSD symptoms. Therefore, managing symptoms of depression and QOL deterioration during HCT hospitalization may be critical to improving QOL at 6 months and reducing the risk of PTSD. Cancer 2016;122:806-812. (c) 2015 American Cancer Society.
A significant percentage of patients undergoing hematopoietic stem cell transplantation (HCT) report symptoms of posttraumatic stress disorder and depression at 6 months after HCT, thereby illustrating the substantial psychological burden endured by this population. It is important to note that patients' experiences during their hospitalization for HCT, particularly their decline in quality of life and increase in depression symptoms, appear to be strongly predictive of an increase in posttraumatic stress disorder symptoms and impaired quality of life at 6 months after HCT.
C1 [El-Jawahri, Areej R.; Vandusen, Harry B.; Fishbein, Joel N.; Gallagher, Emily R.; Spitzer, Thomas R.; Chen, Yi-Bin A.] Massachusetts Gen Hosp, Bone Marrow Transplant Program, Boston, MA 02114 USA.
[Traeger, Lara N.; Greer, Joseph A.; Pirl, William F.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Keenan, Tanya] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Jackson, Vicki A.] Massachusetts Gen Hosp, Palliat Care Dept, Boston, MA 02114 USA.
[Temel, Jennifer S.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA.
RP El-Jawahri, AR (reprint author), Dept Hematol Oncol, Bone Marrow Transplant Program, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM ael-jawahri@partners.org
FU National Palliative Care Research Center; National Institutes of Health
[K24 CA 181253]
FX Supported by funds from the National Palliative Care Research Center (to
Areej El-Jawahri) and National Institutes of Health grant K24 CA 181253
(to Jennifer S. Temel).
NR 29
TC 2
Z9 2
U1 6
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 1
PY 2016
VL 122
IS 5
BP 806
EP 812
DI 10.1002/cncr.29818
PG 7
WC Oncology
SC Oncology
GA DF2IP
UT WOS:000371166300022
PM 26650840
ER
PT J
AU Otani, IM
Banerji, A
AF Otani, Iris M.
Banerji, Aleena
TI Immediate and Delayed Hypersensitivity Reactions to Corticosteroids:
Evaluation and Management
SO CURRENT ALLERGY AND ASTHMA REPORTS
LA English
DT Review
DE Drug allergy; Hypersensitivity reaction; Adverse drug reaction;
Corticosteroids; Allergic contact dermatitis; Skin testing
ID METHYLPREDNISOLONE SODIUM SUCCINATE; ALLERGIC CONTACT-DERMATITIS;
IGE-MEDIATED HYPERSENSITIVITY; RENAL-TRANSPLANT RECIPIENT; PATCH-TEST
REACTIONS; INTRAVENOUS METHYLPREDNISOLONE; TOPICAL CORTICOSTEROIDS;
SUDDEN-DEATH; CARBOXYMETHYLCELLULOSE COMPONENT; INTRAARTICULAR INJECTION
AB Corticosteroids are anti-inflammatory medications used widely to treat allergic inflammation. Although the endocrine and gastrointestinal side effects of corticosteroids have been described, the occurrence of immediate hypersensitivity reactions and delayed contact dermatitis due to corticosteroids remains under-recognized. Hypersensitivity reactions can occur to a corticosteroid itself, or to the additives and vehicles in corticosteroid preparations. Skin testing and oral graded challenge can help confirm the suspected culprit agent in immediate hypersensitivity reactions and help identify an alternative tolerated corticosteroid. Patch testing can help identify the culprit agents in delayed hypersensitivity contact dermatitis. Cross-reactivity patterns have not been observed for immediate hypersensitivity reactions as they have been for delayed contact dermatitis. Sensitization in contact dermatitis exhibits cross-reactivity patterns based on corticosteroid structure. We review the current understanding regarding the clinical presentation, evaluation, and management of immediate and delayed hypersensitivity reactions to corticosteroids.
C1 [Otani, Iris M.; Banerji, Aleena] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Rheumatol Allergy & Immunol, 55 Fruit St, Boston, MA USA.
RP Otani, IM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Rheumatol Allergy & Immunol, 55 Fruit St, Boston, MA USA.
EM iotani@mgh.harvard.edu; abanerji@mgh.harvard.edu
NR 95
TC 1
Z9 1
U1 1
U2 3
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1529-7322
EI 1534-6315
J9 CURR ALLERGY ASTHM R
JI Curr. Allergy Asthma Rep.
PD MAR
PY 2016
VL 16
IS 3
AR 18
DI 10.1007/s11882-016-0596-7
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA DF2KD
UT WOS:000371170800002
PM 26857016
ER
PT J
AU Otani, IM
Banerji, A
AF Otani, Iris M.
Banerji, Aleena
TI Immediate and Delayed Hypersensitivity Reactions to Proton Pump
Inhibitors: Evaluation and Management
SO CURRENT ALLERGY AND ASTHMA REPORTS
LA English
DT Review
DE Drug allergy; Hypersensitivity reaction; Adverse drug reaction; Proton
pump inhibitor; PPI; Skin testing; Patch testing
ID CUTANEOUS LUPUS-ERYTHEMATOSUS; ALLERGIC CONTACT-DERMATITIS;
CROSS-REACTIVITY; ANAPHYLACTIC REACTION; SKIN-TESTS; OMEPRAZOLE;
LANSOPRAZOLE; DIAGNOSIS; ESOMEPRAZOLE; PANTOPRAZOLE
AB PPIs are among the most commonly administered medications in the USA and are generally well tolerated. Immediate and delayed immune-mediated hypersensitivity reactions are rare but increasingly recognized adverse effects of proton pump inhibitors (PPIs). Immediate hypersensitivity reactions can occur due to IgE-mediated hypersensitivity to PPIs and can be evaluated by immediate hypersensitivity skin testing and oral provocation challenge testing. A desensitization protocol can be used when PPI use cannot be avoided in an allergic patient. Delayed hypersensitivity reactions to PPIs have also been reported. Occupational exposures causing cutaneous reactions to PPIs are the most commonly reported delayed hypersensitivity reaction, followed by drug-induced subacute cutaneous lupus erythematosus. This review presents a summary of the clinical presentation, diagnostic evaluation, and management of immune-mediated hypersensitivity reactions to PPIs.
C1 [Otani, Iris M.; Banerji, Aleena] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Rheumatol Allergy Immunol, 55 Fruit St, Boston, MA USA.
RP Otani, IM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Rheumatol Allergy Immunol, 55 Fruit St, Boston, MA USA.
EM iotani@mgh.harvard.edu; abanerji@mgh.harvard.edu
NR 47
TC 3
Z9 3
U1 1
U2 6
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1529-7322
EI 1534-6315
J9 CURR ALLERGY ASTHM R
JI Curr. Allergy Asthma Rep.
PD MAR
PY 2016
VL 16
IS 3
AR 17
DI 10.1007/s11882-016-0595-8
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA DF2KD
UT WOS:000371170800001
PM 26810177
ER
PT J
AU Florez, JC
AF Florez, Jose C.
TI Found in Translation: A Type 1 Diabetes Genetic Risk Score Applied to
Clinical Diagnosis
SO DIABETES CARE
LA English
DT Editorial Material
ID LARGE-SCALE ASSOCIATION; GENOMIC MEDICINE; PREDICTION; VARIANTS;
INSIGHTS; OBESITY; DISEASE; HEART; LOCI
C1 [Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Florez, Jose C.] Broad Inst, Metab Program, Cambridge, MA USA.
[Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
RP Florez, JC (reprint author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.; Florez, JC (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.; Florez, JC (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA USA.; Florez, JC (reprint author), Broad Inst, Metab Program, Cambridge, MA USA.; Florez, JC (reprint author), Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
EM jcflorez@partners.org
NR 18
TC 0
Z9 0
U1 2
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD MAR
PY 2016
VL 39
IS 3
BP 330
EP 332
DI 10.2337/dci15-0029
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DF1HW
UT WOS:000371091500014
PM 26908929
ER
PT J
AU Corey, KE
Kartoun, U
Zheng, H
Shaw, SY
AF Corey, Kathleen E.
Kartoun, Uri
Zheng, Hui
Shaw, Stanley Y.
TI Development and Validation of an Algorithm to Identify Nonalcoholic
Fatty Liver Disease in the Electronic Medical Record
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis;
Electronic medical records; Triglycerides
ID DISCOVERY RESEARCH; FOLLOW-UP; RISK; POPULATION; NAFLD; MORTALITY
AB Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Risk factors for NAFLD disease progression and liver-related outcomes remain incompletely understood due to the lack of computational identification methods. The present study sought to design a classification algorithm for NAFLD within the electronic medical record (EMR) for the development of large-scale longitudinal cohorts.
We implemented feature selection using logistic regression with adaptive LASSO. A training set of 620 patients was randomly selected from the Research Patient Data Registry at Partners Healthcare. To assess a true diagnosis for NAFLD we performed chart reviews and considered either a documentation of a biopsy or a clinical diagnosis of NAFLD. We included in our model variables laboratory measurements, diagnosis codes, and concepts extracted from medical notes. Variables with P < 0.05 were included in the multivariable analysis.
The NAFLD classification algorithm included number of natural language mentions of NAFLD in the EMR, lifetime number of ICD-9 codes for NAFLD, and triglyceride level. This classification algorithm was superior to an algorithm using ICD-9 data alone with AUC of 0.85 versus 0.75 (P < 0.0001) and leads to the creation of a new independent cohort of 8458 individuals with a high probability for NAFLD.
The NAFLD classification algorithm is superior to ICD-9 billing data alone. This approach is simple to develop, deploy, and can be applied across different institutions to create EMR-based cohorts of individuals with NAFLD.
C1 [Corey, Kathleen E.] Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St,Blake 4, Boston, MA 02114 USA.
[Corey, Kathleen E.; Kartoun, Uri; Shaw, Stanley Y.] Harvard Univ, Sch Med, Boston, MA USA.
[Kartoun, Uri; Shaw, Stanley Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Zheng, Hui] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
RP Corey, KE (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St,Blake 4, Boston, MA 02114 USA.; Corey, KE (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
EM kcorey@partners.org
FU NIH [K23 DK099422, U54 LM008748]
FX This study was funded in part by grants from the NIH K23 DK099422 (KEC)
and NIH U54 LM008748 (SYS).
NR 26
TC 1
Z9 1
U1 1
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAR
PY 2016
VL 61
IS 3
BP 913
EP 919
DI 10.1007/s10620-015-3952-x
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KT
UT WOS:000370957000033
PM 26537487
ER
PT J
AU Rogal, SS
Yan, P
Rimland, D
Lo Re, V
Al-Rowais, H
Fried, L
Butt, AA
AF Rogal, Shari S.
Yan, Peng
Rimland, David
Lo Re, Vincent, III
Al-Rowais, Hind
Fried, Linda
Butt, Adeel A.
CA Erchives Elect Retrieved Cohort
TI Incidence and Progression of Chronic Kidney Disease After Hepatitis C
Seroconversion: Results from ERCHIVES
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE CKD; HCV; Progressive CKD
ID VIRUS-INFECTION; RENAL-DISEASE; UNITED-STATES; ASSOCIATION; VETERANS;
RISK; FIBROSIS; SURVIVAL; THERAPY; COHORT
AB We aimed to assess the incidence and progression of chronic kidney disease (CKD) following hepatitis C virus (HCV) seroconversion.
This retrospective cohort study included Veterans with a confirmed HCV seroconversion between 2001 and 2014 and Veterans with negative HCV testing over the same time period. The outcomes included development of advanced CKD (eGFR < 60 mL/min/1.73 m(2) on two separate occasions at least 90 days apart, plus a a parts per thousand yen10 mL/min/1.73 m(2) decline from baseline) and progressive CKD (decline in eGFR of a parts per thousand yen30 mL/min/1.73 m(2) from baseline). Multivariable Cox proportional hazards models were used to evaluate the association between HCV and incident advanced and progressive CKD.
The final cohort consisted of 71,528 Veterans, including 2589 with recently seroconverted HCV. Over a mean follow-up of 6 years, 36 % of patients with and 31 % without HCV developed advanced CKD (p < 0.001), and 35 % of patients with vs. 26 % without HCV developed progressive CKD (p < 0.001). After controlling for traditional risk factors, recently seroconverted HCV+ patients were significantly less likely to develop advanced CKD (HR 0.86; 95 % CI 0.79, 0.92), and HCV status was not significantly associated with progressive CKD (HR 0.93; 95 % CI 0.86, 1.00). Factors associated with developing advanced and progressive CKD included older age, female sex, diabetes, hypertension, development of cirrhosis, and substance abuse.
In this cohort of newly infected US Veterans, HCV infection was associated with decreased incidence of advanced and unchanged risk of progressive CKD, suggesting a larger role for traditional risk factors in the development of CKD after HCV seroconversion.
C1 [Rogal, Shari S.; Yan, Peng; Fried, Linda; Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA.
[Rogal, Shari S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Al-Rowais, Hind] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA.
[Fried, Linda; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Butt, Adeel A.] Hamad Med Corp, Doha, Qatar.
[Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar.
RP Rogal, SS (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA.; Rogal, SS (reprint author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
EM rogalss@upmc.edu
FU Gilead Sciences; AbbVie
FX Dr. Butt reports grants (to the institution) from Gilead Sciences and
AbbVie. Dr. Rogal reports a grant (to the institution) from Gilead
Sciences. The other authors report no conflict of interest related to
the submitted work.
NR 33
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAR
PY 2016
VL 61
IS 3
BP 930
EP 936
DI 10.1007/s10620-015-3918-z
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE9KT
UT WOS:000370957000035
PM 26526451
ER
PT J
AU Lynn, SK
Ibagon, C
Bui, E
Palitz, SA
Simon, NM
Barrett, LF
AF Lynn, Spencer K.
Ibagon, Camila
Bui, Eric
Palitz, Sophie A.
Simon, Naomi M.
Barrett, Lisa Feldman
TI Working Memory Capacity Is Associated With Optimal Adaptation of
Response Bias to Perceptual Sensitivity in Emotion Perception
SO EMOTION
LA English
DT Article
DE working memory capacity; emotion perception; decision making; signal
detection theory; optimality
ID GENERAL FLUID INTELLIGENCE; SIGNAL-DETECTION-THEORY;
INDIVIDUAL-DIFFERENCES; FACIAL EXPRESSIONS; COGNITIVE CONTROL;
BASE-RATE; TASK; CATEGORIZATION; COMPREHENSION; RECOGNITION
AB Emotion perception, inferring the emotional state of another person, is a frequent judgment made under perceptual uncertainty (e.g., a scowling facial expression can indicate anger or concentration) and behavioral risk (e.g., incorrect judgment can be costly to the perceiver). Working memory capacity (WMC), the ability to maintain controlled processing in the face of competing demands, is an important component of many decisions. We investigated the association of WMC and anger perception in a task in which "angry" and "not angry" categories comprised overlapping ranges of scowl intensity, and correct and incorrect responses earned and lost points, respectively. Participants attempted to earn as many points as they could; adopting an optimal response bias would maximize decision utility. Participants with higher WMC more optimally tuned their anger perception response bias to accommodate their perceptual sensitivity (their ability to discriminate the categories) than did participants with lower WMC. Other factors that influence response bias (i.e., the relative base rate of angry vs. not angry faces and the decision costs and benefits) were ruled out as contributors to the WMC-bias relationship. Our results suggest that WMC optimizes emotion perception by contributing to perceivers' ability to adjust their response bias to account for their level of perceptual sensitivity, likely an important component of adapting emotion perception to dynamic social interactions and changing circumstances.
C1 [Lynn, Spencer K.] Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA.
[Ibagon, Camila] Tufts Univ, Dept Psychol, Medford, MA USA.
[Bui, Eric; Palitz, Sophie A.; Simon, Naomi M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Bui, Eric; Simon, Naomi M.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA USA.
[Barrett, Lisa Feldman] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
RP Lynn, SK (reprint author), Northeastern Univ, Psychol NI 125, 360 Huntington Ave, Boston, MA 02115 USA.
EM s.lynn@neu.edu
FU U.S. Army Research Institute for the Behavioral and Social Sciences
[W5J9CQ-12-C-0028]; National Institutes of Health [DP1OD003312,
R01MH093394]
FX This research was supported by the U.S. Army Research Institute for the
Behavioral and Social Sciences (Contract W5J9CQ-12-C-0028 to Spencer K.
Lynn) and the National Institutes of Health (Award DP1OD003312 to Lisa
Feldman Barrett and Grant R01MH093394 to Naomi M. Simon and Spencer K.
Lynn). The views, opinions, and/or findings contained in this paper are
those of the authors and shall not be construed as an official
Department of the Army or National Institutes of Health position,
policy, or decision, unless so designated by other documents.
NR 43
TC 0
Z9 0
U1 6
U2 15
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1528-3542
EI 1931-1516
J9 EMOTION
JI Emotion
PD MAR
PY 2016
VL 16
IS 2
BP 155
EP 163
DI 10.1037/emo0000111
PG 9
WC Psychology, Experimental
SC Psychology
GA DE9PX
UT WOS:000370971400003
PM 26461251
ER
PT J
AU Ginat, DT
Mayich, M
Daftari-Besheli, L
Gupta, R
AF Ginat, Daniel Thomas
Mayich, Michael
Daftari-Besheli, Laleh
Gupta, Rajiv
TI Clinical applications of dual-energy CT in head and neck imaging
SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
LA English
DT Review
DE Dual-energy CT; Head; Neck; Radiation; Lesions
ID COMPUTED-TOMOGRAPHY; ANGIOGRAPHY; EXPERIENCE; REDUCTION; ARTIFACTS;
LARYNGEAL
AB Dual-energy CT provides insights into the material properties of the tissues and can differentiate between tissues that have similar attenuation on conventional, single energy CT imaging. It has several useful and promising applications in head and neck imaging that an otolaryngologist could use to deliver improved clinical care. These applications include metal artifact reduction, atherosclerotic plaque and tumor characterization, detection of parathyroid lesions, and delineation of paranasal sinus ventilation. Dual-energy CT can potentially improve image quality, reduce radiation dose, and provide specific diagnostic information for certain head and neck lesions. This article reviews some current and potential otolaryngology applications of dual-energy CT.
C1 [Ginat, Daniel Thomas; Mayich, Michael] Univ Chicago, Med Ctr, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
[Daftari-Besheli, Laleh; Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.
RP Ginat, DT (reprint author), Univ Chicago, Med Ctr, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM ginatd01@gmail.com
NR 28
TC 0
Z9 0
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0937-4477
EI 1434-4726
J9 EUR ARCH OTO-RHINO-L
JI Eur. Arch. Oto-Rhino-Laryn.
PD MAR
PY 2016
VL 273
IS 3
BP 547
EP 553
DI 10.1007/s00405-014-3417-4
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DF0XV
UT WOS:000371063700003
PM 25472819
ER
PT J
AU Abboud, T
Regelsberger, J
Matschke, J
Jowett, N
Westphal, M
Dalchow, C
AF Abboud, Tammam
Regelsberger, Jan
Matschke, Jakob
Jowett, Nathan
Westphal, Manfred
Dalchow, Carsten
TI Long-term vestibulocochlear functional outcome following retro-sigmoid
approach to resection of vestibular schwannoma
SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
LA English
DT Article; Proceedings Paper
CT Congress of European-Skull-Base-Society
CY JUN 26-28, 2014
CL Paris, FRANCE
SP European Skull Base Soc
DE Vestibular schwannoma; Retro-segmoid approach; Vertigo; Balance
disturbances; Central compensation; Hearing preservation
ID ACOUSTIC TUMOR SURGERY; HEARING PRESERVATION; PROGNOSTIC-FACTORS;
SURGICAL-MANAGEMENT; NEUROMA-ASSOCIATION; TINNITUS; RADIOSURGERY;
DYSFUNCTION; SYMPTOMS; REMOVAL
AB The objective of this study was to evaluate long-term vestibulocochlear functional outcomes of patients operated for unilateral vestibular schwannoma via the retro-sigmoid approach. Patients who underwent vestibular schwannoma resection via retro-sigmoid approach between 2004 and 2008 at our institution, without prior surgical or radio-surgical therapy were considered to be eligible for this study. Preoperative auditory and vestibular symptoms were assessed retrospectively. Postoperative symptoms were prospectively assessed using a standardised questionnaire, pure tone audiometry, video-oculography, and rotary chair testing. Out of a total of 203 patients, 120 were eligible for this study, of whom 64 responded to follow-up requests and could be enrolled. Serviceable hearing was reported in 42 patients (66 %) preoperatively and was maintained in 18 (43 %) postoperatively. While no significant change in rate of tinnitus and balance impairment between pre- and postoperative periods was detected, vertigo decreased significantly (40 to 28 %, p < 0.001). Postoperative video-oculography demonstrated vestibular paresis in 80 %. Rotary chair testing demonstrated normal or central compensation in 84 %. Absence of central compensation was associated with postoperative balance disturbance (p = 0.035). Increasing tumour size and patient age, also decreasing quality of preoperative hearing were independent factors predictive of a postoperative non-serviceable hearing (p = 0.020, p = 0.039 and p = 0.002, respectively). Resection of vestibular schwannoma via the retro-sigmoid approach is associated with improvement in postoperative vertiginous symptoms. Absence of central compensation leads to increased postoperative balance disturbances. Preservation of serviceable postoperative hearing is associated with good preoperative hearing status, younger age, and smaller tumours.
C1 [Abboud, Tammam; Regelsberger, Jan; Westphal, Manfred] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany.
[Matschke, Jakob] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, D-20246 Hamburg, Germany.
[Jowett, Nathan; Dalchow, Carsten] Univ Med Ctr Hamburg Eppendorf, Dept Otorhinolaryngol Head & Neck Surg, D-20246 Hamburg, Germany.
[Jowett, Nathan] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Jowett, Nathan] Harvard Univ, Sch Med, Boston, MA USA.
RP Abboud, T (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany.
EM tabboud@uke.de
RI Matschke, Jakob/F-6641-2013
OI Matschke, Jakob/0000-0001-6080-0198
NR 26
TC 2
Z9 2
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0937-4477
EI 1434-4726
J9 EUR ARCH OTO-RHINO-L
JI Eur. Arch. Oto-Rhino-Laryn.
PD MAR
PY 2016
VL 273
IS 3
BP 719
EP 725
DI 10.1007/s00405-015-3561-5
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DF0XV
UT WOS:000371063700027
PM 25700833
ER
PT J
AU Moghimi, MH
Leonard, DA
Cho, CH
Schoenfeld, AJ
Phan, P
Harris, MB
Bono, CM
AF Moghimi, Michael H.
Leonard, Dana A.
Cho, Charles H.
Schoenfeld, Andrew J.
Phan, Philippe
Harris, Mitchel B.
Bono, Christopher M.
TI Virtually bloodless posterior midline exposure of the lumbar spine using
the "para-midline" fatty plane
SO EUROPEAN SPINE JOURNAL
LA English
DT Article
DE Surgical approach; Lumbar spine; Blood loss; MRI
ID OPERATIVE TIME; FUSION; TRANSFUSION; SURGERY
AB The authors have developed a "para-midline" approach to the posterior lumbar spine using a virtually avascular surgical plane not previously described in the literature. It was their purpose to document consistent MRI presence of this plane and to prospectively evaluate its clinical use in terms of blood loss.
Fifty consecutive patients undergoing primary lumbar surgery on 1-3 levels were prospectively enrolled from September 2014 to May 2015. The para-midline approach was used in all cases. The deep lumbar fascia is longitudinally incised on either side of the spinous processes instead of directly in the midline, which reveals the para-midline fatty plane. Blood loss during the approach and overall blood loss were recorded for all patients. MRIs from each patient were reviewed by an experienced neuroradiologist to determine the presence of the para-midline fatty plane.
There was no recorded blood loss during the approach for all procedures. The average overall blood loss was 60 cc (20-200 cc). No patient required a transfusion intraoperatively or postoperatively. The fatty para-midline plane was noted on preoperative MRI at all operated levels in all patients. The average width of this plane was 6.5 mm (2-17 mm).
The para-midline approach for lumbar surgery is associated with less blood loss than traditional, subperiosteal exposure techniques. The fatty interval through which this approach is made is universally present and identifiable on MRI. The authors offer this approach as a means of decreasing the risks associated with blood loss and transfusion with posterior lumbar surgery.
C1 [Moghimi, Michael H.; Leonard, Dana A.; Cho, Charles H.; Schoenfeld, Andrew J.; Harris, Mitchel B.; Bono, Christopher M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Moghimi, Michael H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
[Phan, Philippe] Univ Ottawa, Ottawa Hosp Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.
RP Leonard, DA (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM dleonard7@partners.org
OI Leonard, Dana Angell/0000-0002-6828-3794; Schoenfeld,
Andrew/0000-0002-3691-1215
FU Arbormetrix; Robert Wood Johnson Foundation; JAAOS
FX Charles H. Cho is on the Board of Directors for the North American Spine
Society. Andrew J. Schoenfeld receives personal fees from Arbormetrix,
royalties from Wolters Kluwer, and grant funding from the Robert Wood
Johnson Foundation. Christopher M. Bono is the president of the North
American Spine Society, consults for United Health Care, gives expert
testimony for Crico, receives royalties from Wolters Kluwer, and
recieves a stipend from JAAOS for being a deputy edictor. None of the
above are relevant to the present article. None reported for all other
authors.
NR 18
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0940-6719
EI 1432-0932
J9 EUR SPINE J
JI Eur. Spine J.
PD MAR
PY 2016
VL 25
IS 3
BP 956
EP 962
DI 10.1007/s00586-015-4319-x
PG 7
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA DE9KX
UT WOS:000370957400040
PM 26582166
ER
PT J
AU Maron, BA
AF Maron, Bradley A.
TI The quest for biomarker discovery in pulmonary arterial hypertension:
the right takes lessons from the left
SO HEART
LA English
DT Editorial Material
ID AMBRISENTAN; TADALAFIL; FAILURE
C1 [Maron, Bradley A.] Brigham & Womens Hosp, Div Cardiovasc Med, Dept Med, 75 Francis St, Boston, MA 02115 USA.
[Maron, Bradley A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Maron, Bradley A.] Boston VA Healthcare Syst, Dept Cardiol, Boston, MA USA.
RP Maron, BA (reprint author), 77 Ave Louis Pasteur,NRB Room 0630-N, Boston, MA 02115 USA.
EM bmaron@partners.org
FU NHLBI NIH HHS [K08 HL111207, K08 HL111207-01A1]
NR 11
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD MAR
PY 2016
VL 102
IS 5
BP 335
EP 336
DI 10.1136/heartjnl-2015-309070
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DF2FK
UT WOS:000371157100002
PM 26869633
ER
PT J
AU Muller, B
Wilcke, A
Boulesteix, AL
Brauer, J
Passarge, E
Boltze, J
Kirsten, H
AF Mueller, Bent
Wilcke, Arndt
Boulesteix, Anne-Laure
Brauer, Jens
Passarge, Eberhard
Boltze, Johannes
Kirsten, Holger
TI Improved prediction of complex diseases by common genetic markers: state
of the art and further perspectives
SO HUMAN GENETICS
LA English
DT Review
ID CORONARY-HEART-DISEASE; SINGLE NUCLEOTIDE POLYMORPHISMS; CANCER RISK
PREDICTION; GENOME-WIDE ASSOCIATION; PROSTATE-SPECIFIC ANTIGEN;
PERSONALIZED MEDICINE; CARDIOVASCULAR EVENTS; ATHEROSCLEROSIS RISK;
ATRIAL-FIBRILLATION; PROSPECTIVE COHORT
AB Reliable risk assessment of frequent, but treatable diseases and disorders has considerable clinical and socio-economic relevance. However, as these conditions usually originate from a complex interplay between genetic and environmental factors, precise prediction remains a considerable challenge. The current progress in genotyping technology has resulted in a substantial increase of knowledge regarding the genetic basis of such diseases and disorders. Consequently, common genetic risk variants are increasingly being included in epidemiological models to improve risk prediction. This work reviews recent high-quality publications targeting the prediction of common complex diseases. To be included in this review, articles had to report both, numerical measures of prediction performance based on traditional (non-genetic) risk factors, as well as measures of prediction performance when adding common genetic variants to the model. Systematic PubMed-based search finally identified 55 eligible studies. These studies were compared with respect to the chosen approach and methodology as well as results and clinical impact. Phenotypes analysed included tumours, diabetes mellitus, and cardiovascular diseases. All studies applied one or more statistical measures reporting on calibration, discrimination, or reclassification to quantify the benefit of including SNPs, but differed substantially regarding the methodological details that were reported. Several examples for improved risk assessments by considering disease-related SNPs were identified. Although the add-on benefit of including SNP genotyping data was mostly moderate, the strategy can be of clinical relevance and may, when being paralleled by an even deeper understanding of disease-related genetics, further explain the development of enhanced predictive and diagnostic strategies for complex diseases.
C1 [Mueller, Bent; Wilcke, Arndt; Boltze, Johannes; Kirsten, Holger] Fraunhofer Inst Cell Therapy & Immunol, Dept Cell Therapy, Perlickstr 1, Leipzig, Germany.
[Wilcke, Arndt; Boltze, Johannes; Kirsten, Holger] Translat Ctr Regenerat Med, Leipzig, Germany.
[Boulesteix, Anne-Laure] Univ Munich, Dept Med Informat Biometry & Epidemiol, Munich, Germany.
[Brauer, Jens] Max Planck Inst Human Cognit & Brain Sci, Dept Neuropsychol, Leipzig, Germany.
[Passarge, Eberhard] Univ Leipzig, Univ Hosp Leipzig, Inst Human Genet, D-04109 Leipzig, Germany.
[Passarge, Eberhard] Univ Duisburg Essen, Univ Hosp Essen, Inst Human Genet, Essen, Germany.
[Boltze, Johannes] Massachusetts Gen Hosp, Charlestown, MA USA.
[Boltze, Johannes] Harvard Univ, Sch Med, Stroke & Neurovasc Regulat Lab, Charlestown, MA USA.
[Boltze, Johannes] Med Univ Lubeck, Fraunhofer Res Inst Marine Biotechnol, D-23538 Lubeck, Germany.
[Boltze, Johannes] Med Univ Lubeck, Inst Med & Marine Biotechnol, D-23538 Lubeck, Germany.
[Kirsten, Holger] Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04109 Leipzig, Germany.
[Kirsten, Holger] Univ Leipzig, LIFE Leipzig Res Ctr Civilizat Dis, D-04109 Leipzig, Germany.
RP Muller, B (reprint author), Fraunhofer Inst Cell Therapy & Immunol, Dept Cell Therapy, Perlickstr 1, Leipzig, Germany.
EM bent.mueller@izi.fraunhofer.de
OI Muller, Bent/0000-0001-8308-6193
FU Fraunhofer Society; MaxPlanckSociety; Leipzig Interdisciplinary Research
Cluster of Genetic Factors, Clinical Phenotypes and Environment (LIFE
Center, Universitat Leipzig)
FX We would like to thank all members of the Legascreen consortium for
their support during this study. Legascreen is funded by the Fraunhofer
Society and the MaxPlanckSociety as a project within the framework of
the "Pakt fur Forschung und Innovation". Dr. Holger Kirsten was also
funded by the Leipzig Interdisciplinary Research Cluster of Genetic
Factors, Clinical Phenotypes and Environment (LIFE Center, Universitat
Leipzig). The Legascreen consortium consists of: Prof. Dr. Dr. h.c.
Angela D. Friederici, Dr. Jens Brauer, Dr. Michael Skeide, Dr. Nicole
Neef, Gesa Schaadt, Indra Kraft, and Nadin Bobovnikov (all Max Planck
Institute for Human Cognitive and Brain Sciences, Leipzig, Germany) as
well as Prof. Dr. Frank Emmrich, Dr. Arndt Wilcke, Dr. Holger Kirsten,
Prof. Dr. Dr. Johannes Boltze, Bent Muller and Ivonne Czepezauer
(Fraunhofer Institute for Cell Therapy and Immunology, Leipzig,
Germany).
NR 91
TC 5
Z9 5
U1 5
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD MAR
PY 2016
VL 135
IS 3
BP 259
EP 272
DI 10.1007/s00439-016-1636-z
PG 14
WC Genetics & Heredity
SC Genetics & Heredity
GA DE7LR
UT WOS:000370818800001
PM 26839113
ER
PT J
AU Herstein, JJ
Biddinger, PD
Kraft, CS
Saiman, L
Gibbs, SG
Le, AB
Smith, PW
Hewlett, AL
Lowe, JJ
AF Herstein, Jocelyn J.
Biddinger, Paul D.
Kraft, Colleen S.
Saiman, Lisa
Gibbs, Shawn G.
Le, Aurora B.
Smith, Philip W.
Hewlett, Angela L.
Lowe, John J.
TI Current Capabilities and Capacity of Ebola Treatment Centers in the
United States
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID HIGHLY INFECTIOUS-DISEASES; LEVEL ISOLATION UNITS; BIOCONTAINMENT UNIT;
VIRUS DISEASE; CONSENSUS
AB OBJECTIVE. To describe current Ebola treatment center (ETC) locations, their capacity to care for Ebola virus disease patients, and infection control infrastructure features.
DESIGN. A 19-question survey was distributed electronically in April 2015. Responses were collected via email by June 2015 and analyzed in an electronic spreadsheet.
SETTING. The survey was sent to and completed by site representatives of each ETC.
PARTICIPANTS. The survey was sent to all 55 ETCs; 47 (85%) responded.
RESULTS. Of the 47 responding ETCs, there are 84 isolation beds available for adults and 91 for children; of these pediatric beds, 35 (38%) are in children's hospitals. In total, the simultaneous capacity of the 47 reporting ETCs is 121 beds. On the basis of the current US census, there are 0.38 beds per million population. Most ETCs have negative pressure isolation rooms, anterooms, and a process for category A waste sterilization, although only 11 facilities (23%) have the capability to sterilize infectious waste on site.
CONCLUSIONS. Facilities developed ETCs on the basis of Centers for Disease Control and Prevention guidance, but specific capabilities are not mandated at this present time. Owing to the complex and costly nature of Ebola virus disease treatment and variability in capabilities from facility to facility, in conjunction with the lack of regulations, nationwide capacity in specialized facilities is limited. Further assessments should determine whether ETCs can adapt to safely manage other highly infectious disease threats.
C1 [Herstein, Jocelyn J.; Le, Aurora B.; Lowe, John J.] Univ Nebraska Med Ctr, Dept Environm Agr & Occupat Hlth, Omaha, NE USA.
[Biddinger, Paul D.] Massachusetts Gen Hosp, Dept Emergency Med, Div Emergency Preparedness, Boston, MA 02114 USA.
[Biddinger, Paul D.] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA USA.
[Kraft, Colleen S.] Emory Univ, Dept Med, Dept Pathol & Lab Med, Div Infect Dis, Atlanta, GA 30322 USA.
[Saiman, Lisa] Columbia Univ, Med Ctr, Dept Pediat, New York, NY USA.
[Saiman, Lisa] New York Presbyterian Hosp, Dept Infect Prevent & Control, New York, NY USA.
[Gibbs, Shawn G.; Smith, Philip W.; Hewlett, Angela L.; Lowe, John J.] Nebraska Med, Nebraska Biocontainment Unit, Omaha, NE USA.
[Gibbs, Shawn G.] Indiana Univ, Sch Publ Hlth, Dept Environm Hlth, Bloomington, IN USA.
[Smith, Philip W.; Hewlett, Angela L.] Univ Nebraska Med Ctr, Div Infect Dis, Dept Internal Med, Omaha, NE 68182 USA.
RP Lowe, JJ (reprint author), 985110 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM jjlowe@unmc.edu
NR 25
TC 1
Z9 1
U1 2
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAR
PY 2016
VL 37
IS 3
BP 313
EP 318
DI 10.1017/ice.2015.300
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DE9ZG
UT WOS:000370997800010
PM 26641267
ER
PT J
AU Elmore, SN
Sethi, RV
Viswanathan, AN
Efstathiou, JA
AF Elmore, Shekinah N.
Sethi, Roshan V.
Viswanathan, Akila N.
Efstathiou, Jason A.
TI Global Radiation Oncology From the Trainee Perspective: A View From
Beyond the Bunker
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID HEALTH SYSTEMS; RADIOTHERAPY; EPIDEMIC; THERAPY; AFRICA; CARE
C1 [Elmore, Shekinah N.] Brigham & Womens Hosp, Dept Internal Med, 75 Francis St, Boston, MA 02215 USA.
[Sethi, Roshan V.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA.
[Viswanathan, Akila N.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Div Gynecol Radiat Oncol, Boston, MA USA.
[Efstathiou, Jason A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Elmore, SN (reprint author), Brigham & Womens Hosp, Dept Internal Med, 75 Francis St, Boston, MA 02215 USA.
EM selmore@partners.org
NR 14
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 1
PY 2016
VL 94
IS 3
BP 438
EP 439
DI 10.1016/j.ijrobp.2015.11.033
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA DE7KX
UT WOS:000370816500004
PM 26867872
ER
PT J
AU Ngwa, W
Ngoma, T
Zietman, A
Mayr, N
Elzawawy, A
Winningham, TA
Balogun, O
Enwerem-Bromson, N
Ntizimira, C
Olopade, OI
Oluwole, D
Odedina, F
Williams, M
Flanigan, J
Asana, L
Ngwa, K
Avery, S
Pollard, JM
Roland, T
Funwi-gabga, N
Mbarika, V
Hardenbergh, P
Winkfield, K
Pipman, Y
Stefan, C
Ngoma, M
Mohammed, S
Katz, M
Erno, S
Moni, J
Fitzgerald, T
Tonlaar, N
Efstathiou, J
Gierga, D
Ayo, C
Knaul, F
Gospodarowicz, M
Makrigiorgos, GM
Nguyen, PL
AF Ngwa, Wilfred
Ngoma, Twalib
Zietman, Anthony
Mayr, Nina
Elzawawy, Ahmed
Winningham, Thomas A.
Balogun, Onyinye
Enwerem-Bromson, Nelly
Ntizimira, Christian
Olopade, Olufunmilayo I.
Oluwole, Doyin
Odedina, Folakemi
Williams, Makeda
Flanigan, John
Asana, Lydia
Ngwa, Kenneth
Avery, Stephen
Pollard, Julianne M.
Roland, Teboh
Funwi-gabga, Neba
Mbarika, Victor
Hardenbergh, Patricia
Winkfield, Karen
Pipman, Yakov
Stefan, Christina
Ngoma, Mamsau
Mohammed, Sulma
Katz, Matthew
Erno, Sajo
Moni, Janaki
Fitzgerald, Thomas
Tonlaar, Nathan
Efstathiou, Jason
Gierga, David
Ayo, Charles
Knaul, Felicia
Gospodarowicz, Mary
Makrigiorgos, G. Mike
Nguyen, Paul L.
TI Closing the Cancer Divide Through Ubuntu: Information and Communication
Technology-Powered Models for Global Radiation Oncology
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID RADIOTHERAPY; RESPONSIBILITY; COUNTRIES; THERAPY; AFRICA; ACCESS; CARE
C1 [Ngwa, Wilfred; Makrigiorgos, G. Mike; Nguyen, Paul L.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
[Ngwa, Wilfred; Mayr, Nina; Makrigiorgos, G. Mike; Nguyen, Paul L.] Harvard Univ, Sch Med, 75 Francis St, Boston, MA 02115 USA.
[Ngwa, Wilfred; Erno, Sajo] Univ Massachusetts Lowell, Dept Phys & Appl Phys, Lowell, MA USA.
[Ngoma, Twalib] Muhimbili Univ Hlth & Allied Sci, Dept Clin Oncol, Dar Es Salaam, Tanzania.
[Zietman, Anthony; Winkfield, Karen; Efstathiou, Jason; Gierga, David] Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA USA.
[Mayr, Nina] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Elzawawy, Ahmed; Stefan, Christina] African Org Res & Training Canc, Rondebosch, South Africa.
[Winningham, Thomas A.] Hlth First Canc Inst, Titusville, FL USA.
[Balogun, Onyinye] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY USA.
[Enwerem-Bromson, Nelly] IAEA, Program Act Canc Therapy, A-1400 Vienna, Austria.
[Ntizimira, Christian] Kibagabaga Hosp, Kigali City, Rwanda.
[Olopade, Olufunmilayo I.] Univ Chicago, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
[Oluwole, Doyin] Pink Ribbon Red Ribbon, Dallas, TX USA.
[Odedina, Folakemi] Univ Florida, Coll Pharm, Gainesville, FL USA.
[Williams, Makeda; Flanigan, John] NCI, Ctr Global Hlth, Rockville, MD USA.
[Asana, Lydia; Ngwa, Kenneth] African Renaissance Ambassador Corp, Orlando, FL USA.
[Avery, Stephen] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Pollard, Julianne M.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA.
[Roland, Teboh] Johns Hopkins Univ, Dept Radiat Oncol, Baltimore, MD USA.
[Funwi-gabga, Neba] Southern Alberta Inst Technol, Calgary, AB, Canada.
[Mbarika, Victor] Informat & Commun Technol Univ, Baton Rouge, LA USA.
[Hardenbergh, Patricia] Shaw Reg Canc Ctr, Edwards, CO USA.
[Pipman, Yakov] Amer Assoc Physicists Med, Int Educ Activ Comm, College Pk, MD USA.
[Stefan, Christina] South African Med Res Council, Cape Town, South Africa.
[Ngoma, Mamsau] Ocean Rd Canc Inst, Dar Es Salaam, Tanzania.
[Mohammed, Sulma] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA.
[Mohammed, Sulma] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.
[Katz, Matthew] Lowell Gen Hosp, Lowell, MA USA.
[Moni, Janaki; Fitzgerald, Thomas] Univ Massachusetts, Sch Med, Dept Radiat Oncol, Worcester, MA USA.
[Tonlaar, Nathan] Radiating Hope, Salt Lake City, UT USA.
[Ayo, Charles] Covenant Univ, Ota, Nigeria.
[Knaul, Felicia] Harvard Univ, Sch Med, Harvard Global Equ Initiat, Boston, MA USA.
[Gospodarowicz, Mary] Princess Margaret Canc Ctr, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.
[Gospodarowicz, Mary] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada.
RP Ngwa, W (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.; Ngwa, W (reprint author), Harvard Univ, Sch Med, 75 Francis St, Boston, MA 02115 USA.
EM wngwa@lroc.harvard.edu
FU Harvard Radcliffe Institute; Varian Medical Systems; Brigham and Women's
Hospital Center for Community Health and Health Equity
FX This work was supported by Harvard Radcliffe Institute, Varian Medical
Systems, and Brigham and Women's Hospital Center for Community Health
and Health Equity.
NR 26
TC 2
Z9 2
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 1
PY 2016
VL 94
IS 3
BP 440
EP 449
DI 10.1016/j.ijrobp.2015.10.063
PG 10
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA DE7KX
UT WOS:000370816500005
PM 26867873
ER
PT J
AU Sher, DJ
Fidler, MJ
Tishler, RB
Stenson, K
al-Khudari, S
AF Sher, David J.
Fidler, Mary Jo
Tishler, Roy B.
Stenson, Kerstin
al-Khudari, Samer
TI Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral
Robotic Surgery for Human Papillomavirus-Associated, Clinical N2
Oropharyngeal Cancer
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; INTENSITY-MODULATED RADIOTHERAPY;
RADIATION-THERAPY; NECK-CANCER; IMPROVED SURVIVAL; POSITIVE HEAD;
ONCOLOGY; TRIAL; GASTROSTOMY; TOXICITY
AB Purpose: To perform a cost-effectiveness analysis of primary chemoradiation therapy (CRT) versus transoral robotic surgery (TORS) for clinical N2, human papillomavirus (HPV)-positive oropharyngeal carcinoma.
Methods and Materials: We developed a Markov model to describe the health states after treatment with CRT or TORS, followed by adjuvant radiation therapy or CRT in the presence of high-risk pathology (positive margins or extracapsular extension). Outcomes, toxicities, and costs were extracted from the literature. One-way sensitivity analyses (SA) were performed over a wide range of parameters, as were 2-way SA between the key variables. Probabilistic SA and value of information studies were performed over key parameters.
Results: The expected quality-adjusted life years (QALYs)/total costs for CRT and TORS were 7.31/$ 50,100 and 7.29/$62,200, respectively, so that CRT dominated TORS. In SA, primary CRT was almost always cost-effective up to a societal willingness-to-pay of $200,000/QALY, unless the locoregional recurrence risk after TORS was 30% to 50% lower, at which point it became cost effective at a willingness-to-pay of $ 50-100,000/QALY. Probabilistic SA confirmed the importance of locoregional recurrence risk, and the value of information in precisely knowing this parameter was more than $ 7M per year. If the long-term utility after TORS was 0.03 lower than CRT, CRT was cost-effective over nearly any assumption.
Conclusions: Under nearly all assumptions, primary CRT was the cost-effective therapy for HPV-associated, clinical N2 OPC. However, in the hypothetical event of a large relative improvement in LRR with surgery and equivalent long-term utilities, primary TORS would become the higher-value treatment, arguing for prospective, comparative study of the 2 paradigms. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Sher, David J.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, 5801 Lake Forest Rd, Dallas, TX 75390 USA.
[Fidler, Mary Jo] Rush Univ, Med Ctr, Sect Med Oncol, Chicago, IL 60612 USA.
[Tishler, Roy B.] Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
[Tishler, Roy B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Stenson, Kerstin; al-Khudari, Samer] Rush Univ, Med Ctr, Dept Otolaryngol, Chicago, IL 60612 USA.
RP Sher, DJ (reprint author), Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, 5801 Lake Forest Rd, Dallas, TX 75390 USA.
EM david.sher@utsouthwestern.edu
OI Stenson, Kerstin/0000-0002-2643-3053
NR 30
TC 5
Z9 5
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 1
PY 2016
VL 94
IS 3
BP 512
EP 522
DI 10.1016/j.ijrobp.2015.11.006
PG 11
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA DE7KX
UT WOS:000370816500012
PM 26867880
ER
PT J
AU Grover, S
Harkenrider, MM
Cho, LP
Erickson, B
Small, C
Small, W
Viswanathan, AN
AF Grover, Surbhi
Harkenrider, Matthew M.
Cho, Linda P.
Erickson, Beth
Small, Christina
Small, William, Jr.
Viswanathan, Akila N.
TI Image Guided Cervical Brachytherapy: 2014 Survey of the American
Brachytherapy Society
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID HIGH-DOSE-RATE; MAGNETIC-RESONANCE; CANCER BRACHYTHERAPY; VOLUME
PARAMETERS; CONSENSUS GUIDELINES; RECOMMENDATIONS; RADIOTHERAPY;
CARCINOMA; TOMOGRAPHY; IMPACT
AB Purpose: To provide an update of the 2007 American brachytherapy survey on image-based brachytherapy, which showed that in the setting of treatment planning for gynecologic brachytherapy, although computed tomography (CT) was often used for treatment planning, most brachytherapists used point A for dose specification.
Methods and Materials: A 45-question electronic survey on cervical cancer brachytherapy practice patterns was sent to all American Brachytherapy Society members and additional radiation oncologists and physicists based in the United States between January and September 2014. Responses from the 2007 survey and the present survey were compared using the chi(2) test.
Results: There were 370 respondents. Of those, only respondents, not in training, who treat more than 1 cervical cancer patient per year and practice in the United States, were included in the analysis (219). For dose specification to the target (cervix and tumor), 95% always use CT, and 34% always use MRI. However, 46% use point A only for dose specification to the target. There was a lot of variation in parameters used for dose evaluation of target volume and normal tissues. Compared with the 2007 survey, use of MRI has increased from 2% to 34% (P<. 0001) for dose specification to the target. Use of volume-based dose delineation to the target has increased from 14% to 52% (P<. 0001).
Conclusion: Although use of image-based brachytherapy has increased in the United States since the 2007 survey, there is room for further growth, particularly with the use of MRI. This increase may be in part due to educational initiatives. However, there is still significant heterogeneity in brachytherapy practice in the United States, and future efforts should be geared toward standardizing treatment. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Grover, Surbhi] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Harkenrider, Matthew M.; Small, William, Jr.] Loyola Univ, Dept Radiat Oncol, Stritch Sch Med, Chicago, IL 60611 USA.
[Small, Christina] Loyola Univ, Dept Publ Hlth Sci, Stritch Sch Med, Chicago, IL 60611 USA.
[Cho, Linda P.; Viswanathan, Akila N.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
[Erickson, Beth] Froedtert Hosp, Dept Radiat Oncol, Milwaukee, WI USA.
[Erickson, Beth] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
RP Grover, S (reprint author), Univ Penn, Dept Radiat Oncol, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM Surbhi.grover@uphs.upenn.edu
FU National Institutes of Health [R21 167800]
FX A.V. receives support from National Institutes of Health grant R21
167800.
NR 27
TC 9
Z9 9
U1 4
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 1
PY 2016
VL 94
IS 3
BP 598
EP 604
DI 10.1016/j.ijrobp.2015.11.024
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA DE7KX
UT WOS:000370816500022
PM 26867888
ER
PT J
AU Siu, AL
Bibbins-Domingo, K
Grossman, DC
Baumann, LC
Davidson, KW
Ebell, M
Garcia, FAR
Gillman, M
Herzstein, J
Kemper, AR
Krist, AH
Kurth, AE
Owens, DK
Phillips, WR
Phipps, MG
Pignone, MP
AF Siu, Albert L.
Bibbins-Domingo, Kirsten
Grossman, David C.
Baumann, Linda Ciofu
Davidson, Karina W.
Ebell, Mark
Garcia, Francisco A. R.
Gillman, Matthew
Herzstein, Jessica
Kemper, Alex R.
Krist, Alex H.
Kurth, Ann E.
Owens, Douglas K.
Phillips, William R.
Phipps, Maureen G.
Pignone, Michael P.
CA USPSTF
TI Screening for Impaired Visual Acuity in Older Adults US Preventive
Services Task Force Recommendation Statement
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID INTRAOCULAR-LENS IMPLANTATION; RANDOMIZED CONTROLLED-TRIAL; EYE
CATARACT-SURGERY; MACULAR DEGENERATION; UNITED-STATES; CONTRAST
SENSITIVITY; HEALTH-STATUS; PEOPLE; FALLS; RISK
AB DESCRIPTION Update of the US Preventive Services Task Force (USPSTF) recommendation on screening for impaired visual acuity in older adults.
METHODS The USPSTF reviewed the evidence on screening for visual acuity impairment associated with uncorrected refractive error, cataracts, and age-related macular degeneration among adults 65 years or older in the primary care setting; the benefits and harms of screening; the accuracy of screening; and the benefits and harms of treatment of early vision impairment due to uncorrected refractive error, cataracts, and age-related macular degeneration.
POPULATION This recommendation applies to asymptomatic adults 65 years or older who do not present to their primary care clinician with vision problems.
RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults. (I statement)
C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA.
[Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA.
[Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI 53706 USA.
[Davidson, Karina W.] Columbia Univ, New York, NY USA.
[Ebell, Mark] Univ Georgia, Athens, GA 30602 USA.
[Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA.
[Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA.
[Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Kemper, Alex R.] Duke Univ, Durham, NC USA.
[Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA.
[Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA.
[Kurth, Ann E.] NYU, New York, NY USA.
[Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA.
[Phillips, William R.] Univ Washington, Seattle, WA 98195 USA.
[Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA.
[Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA.
RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
EM chair@uspstf.net
OI Phillips, William/0000-0003-2802-4349
FU Agency for Healthcare Research and Quality (AHRQ)
FX The USPSTF is an independent, voluntary body. The US Congress mandates
that the Agency for Healthcare Research and Quality (AHRQ) support the
operations of the USPSTF.
NR 31
TC 1
Z9 1
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 1
PY 2016
VL 315
IS 9
BP 908
EP 914
DI 10.1001/jama.2016.0763
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DF1DB
UT WOS:000371077500021
ER
PT J
AU Ganguli, I
Chang, Y
Weissman, A
Armstrong, K
Metlay, JP
AF Ganguli, Ishani
Chang, Yuchiao
Weissman, Arlene
Armstrong, Katrina
Metlay, Joshua P.
TI Ebola Risk and Preparedness: A National Survey of Internists
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE Ebola; risk communication; physician behavior; medical decision making;
evidence based medicine
ID CARE; HEALTH
AB BACKGROUND: The 2014-2015 Ebola virus disease (Ebola) epidemic centered in West Africa highlighted recurring challenges in the United States regarding risk communication and preparedness during global epidemics.
OBJECTIVE: To investigate perceptions, preparedness, and knowledge among U.S. internists with regard to Ebola risk.
DESIGN: Cross-sectional Web-based national survey distributed by e-mail between December 2014 and January 2015.
PARTICIPANTS: Practicing U.S. internists participating in a research panel representative of American College of Physicians (ACP) membership.
MAIN MEASURES: Respondents' perceptions of Ebola, reported sources of information, and reported management of possible Ebola cases. The primary predictor was the possibility of encountering Ebola (based on respondents' geographic proximity to designated airports or confirmed Ebola cases, or on their patients' travel histories). Pre-specified outcomes included reported management intensity in clinical vignettes involving patients at low risk of symptomatic Ebola as well as reported Ebola preparedness.
KEY RESULTS: The survey response rate was 46.1 %. Among the 202 respondents, 9.9 % (95 % CI 6.2-14.9 %) reported that they had recently evaluated a patient who had traveled to West Africa. Seventy percent (95 % CI 63.0-76.0 %) reported a practice-level protocol. The Centers for Disease Control and Prevention (CDC) was the most popular source for Ebola information (75.2 %, 95 % CI 68.7-81.0 %). Most respondents felt very (45.0 %) or somewhat prepared (52.0 %) to communicate information about or diagnose Ebola, especially those with the possibility of encountering Ebola and those who reported medical journals, professional groups, or government as information sources. One-fifth of respondents (19.8 %, 95% CI 14.5-26.0 %) reported overly intensive management for low-risk patients. Those with the possibility of encountering Ebola were less likely to report overly intensive management (3.1 vs. 22.9 %, p=0.011).
CONCLUSIONS: Internists had wide-ranging views and understanding of Ebola risk; those least likely to encounter Ebola were most likely to be overly aggressive in managing patients at low risk. Our findings underscore the need for better risk communication through various information channels to empower frontline providers in infectious disease outbreaks.
C1 [Ganguli, Ishani; Chang, Yuchiao; Armstrong, Katrina; Metlay, Joshua P.] Massachusetts Gen Hosp, 55 Fruit St Bulfinch 205, Boston, MA 02114 USA.
[Ganguli, Ishani; Chang, Yuchiao; Armstrong, Katrina; Metlay, Joshua P.] Harvard Univ, Sch Med, Boston, MA USA.
[Weissman, Arlene] Amer Coll Physicians, Philadelphia, PA USA.
RP Ganguli, I (reprint author), Massachusetts Gen Hosp, 55 Fruit St Bulfinch 205, Boston, MA 02114 USA.
EM iganguli@partners.org
NR 17
TC 2
Z9 2
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAR
PY 2016
VL 31
IS 3
BP 276
EP 281
DI 10.1007/s11606-015-3493-1
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DF2HE
UT WOS:000371162400007
PM 26289923
ER
PT J
AU Rosenthal, MB
Alidina, S
Friedberg, MW
Singer, SJ
Eastman, D
Li, ZH
Schneider, EC
AF Rosenthal, Meredith B.
Alidina, Shehnaz
Friedberg, Mark W.
Singer, Sara J.
Eastman, Diana
Li, Zhonghe
Schneider, Eric C.
TI A Difference-in-Difference Analysis of Changes in Quality, Utilization
and Cost Following the Colorado Multi-Payer Patient-Centered Medical
Home Pilot
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE patient-centered care; primary care redesign; health care costs; quality
improvement
ID PRIMARY-CARE; HEALTH
AB BACKGROUND: Research on the effects of patient-centered medical homes on quality and cost of care is mixed, so further study is needed to understand how and in what contexts they are effective.
OBJECTIVE: We aimed to evaluate effects of a multi-payer pilot promoting patient-centered medical home implementation in 15 small and medium-sized primary care groups in Colorado.
DESIGN: We conducted difference-in-difference analyses, comparing changes in utilization, costs, and quality between patients attributed to pilot and non-pilot practices.
PARTICIPANTS: Approximately 98,000 patients attributed to 15 pilot and 66 comparison practices 2 years before and 3 years after the pilot launch.
MAIN MEASURES: Healthcare Effectiveness Data and Information Set (HEDIS) derived measures of diabetes care, cancer screening, utilization, and costs to payers.
KEY RESULTS: At the end of two years, we found a statistically significant reduction in emergency department use by 1.4 visits per 1000 member months, or approximately 7.9 % (p=0.02). At the end of three years, pilot practices sustained this difference with 1.6 fewer emergency department visits per 1000 member months, or a 9.3 % reduction from baseline (p=0.01). Emergency department costs were lower in the pilot practices after two (13.9 % reduction, p<0.001) and three years (11.8 % reduction, p=0.001). After three years, compared to control practices, primary care visits in the pilot practices decreased significantly (1.5 % reduction, p=0.02). The pilot was associated with increased cervical cancer screening after two (12.5 % increase, p<0.001) and three years (9.0 % increase, p<0.001), but lower rates of HbA1c testing in patients with diabetes (0.7 % reduction at three years, p=0.03) and colon cancer screening (21.1 % and 18.1% at two and three years, respectively, p<0.001). For patients with two or more comorbidities, similar patterns of association were found, except that there was also a reduction in ambulatory care sensitive inpatient admissions (10.3 %; p=0.05).
CONCLUSION: Our findings suggest that a multi-payer, patient-centered medical home initiative that provides financial and technical support to participating practices can produce sustained reductions in utilization with mixed results on process measures of quality.
C1 [Rosenthal, Meredith B.; Alidina, Shehnaz; Singer, Sara J.; Eastman, Diana; Li, Zhonghe; Schneider, Eric C.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Friedberg, Mark W.; Schneider, Eric C.] RAND Corp, Santa Monica, CA USA.
[Friedberg, Mark W.; Schneider, Eric C.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Friedberg, Mark W.; Singer, Sara J.; Schneider, Eric C.] Harvard Univ, Sch Med, Boston, MA USA.
[Singer, Sara J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rosenthal, Meredith B.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.
RP Rosenthal, MB (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.
EM meredith_rosenthal@harvard.edu
OI Schneider, Eric/0000-0002-1132-5084
FU Commonwealth Fund; Colorado Trust
FX Funding for this research was provided by the Commonwealth Fund and the
Colorado Trust.
NR 20
TC 9
Z9 9
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAR
PY 2016
VL 31
IS 3
BP 289
EP 296
DI 10.1007/s11606-015-3521-1
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DF2HE
UT WOS:000371162400009
PM 26450279
ER
PT J
AU Campbell, JI
Eyal, N
Musiimenta, A
Haberer, JE
AF Campbell, Jeffrey I.
Eyal, Nir
Musiimenta, Angella
Haberer, Jessica E.
TI Ethical Questions in Medical Electronic Adherence Monitoring
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE electronic adherence monitoring; patient adherence; privacy;
confidentiality; personal autonomy; research ethics
ID ANTIRETROVIRAL THERAPY; OBJECTIVE MEASUREMENT; CARE; ACCEPTABILITY;
FEASIBILITY; PERCEPTIONS; ADULTS
AB Electronic adherence monitors (EAMs) record and report an array of health behaviors, ranging from taking daily medications to wearing medical devices. EAMs are utilized in research worldwide and are being investigated for clinical use. However, there is also growing popular concern about the extent to which electronic devices may be used to monitor individuals, including allegations in the media that EAMs represent a move towards "Big Brother" in medicine. Here, we highlight the unique benefits as well as the potential ethical challenges that electronic adherence monitoring generates. These challenges surround autonomy, privacy and confidentiality, trust, and ancillary care obligations. We describe key questions within each of these domains that warrant further investigation, and present potential solutions to many of the concerns raised.
C1 [Campbell, Jeffrey I.] Harvard Univ, Sch Med, Ctr Bioeth, Boston, MA USA.
[Eyal, Nir] Harvard Univ, TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
[Musiimenta, Angella] Mbarara Univ Sci & Technol, Dept Informat Technol, Mbarara, Uganda.
[Haberer, Jessica E.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Haberer, Jessica E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Eyal, N (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
EM nir_eyal@hms.harvard.edu
FU National Institute of Allergy and Infectious Diseases [R21AI108329-01]
FX All authors received support from the National Institute of Allergy and
Infectious Diseases (R21AI108329-01). The study funders had no role in
study design, decision to publish, or preparation of the manuscript.
NR 36
TC 1
Z9 1
U1 4
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAR
PY 2016
VL 31
IS 3
BP 338
EP 342
DI 10.1007/s11606-015-3502-4
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DF2HE
UT WOS:000371162400022
PM 26358284
ER
PT J
AU Barnett, ML
Mehrotra, A
Frolkis, JP
Spinks, M
Steiger, C
Hehir, B
Greenberg, JO
Singh, H
AF Barnett, Michael L.
Mehrotra, Ateev
Frolkis, Joseph P.
Spinks, Melissa
Steiger, Casey
Hehir, Brandon
Greenberg, Jeffrey O.
Singh, Hardeep
TI Implementation Science Workshop: Implementation of an Electronic
Referral System in a Large Academic Medical Center
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
DE health information technology; program evaluation; primary care;
implementation science
ID HEALTH-CARE; FOLLOW-UP; GENERAL-PRACTITIONERS; PATIENT-SAFETY; SPECIALTY
CARE; UNITED-STATES; COMMUNICATION; MODEL; RECORDS; NEIGHBORHOOD
C1 [Barnett, Michael L.; Frolkis, Joseph P.; Greenberg, Jeffrey O.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.
[Steiger, Casey; Hehir, Brandon; Greenberg, Jeffrey O.] Brigham & Womens Phys Org, Boston, MA USA.
[Spinks, Melissa] Par8o Inc, Newton, MA USA.
[Barnett, Michael L.; Mehrotra, Ateev] Harvard Univ, Sch Med, Dept Hlth Care Policy, 180A Longwood Ave, Boston, MA 02115 USA.
[Singh, Hardeep] Houston Vet Affairs Ctr Innovat Qual Effectivenes, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Singh, Hardeep] Baylor Coll Med, Houston, TX 77030 USA.
RP Barnett, ML (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180A Longwood Ave, Boston, MA 02115 USA.
EM mlb748@mail.harvard.edu
FU AHRQ HHS [R01 HS022087, R01HS022087]; PHS HHS [T32-HP10251]
NR 53
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAR
PY 2016
VL 31
IS 3
BP 343
EP 352
DI 10.1007/s11606-015-3516-y
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DF2HE
UT WOS:000371162400023
PM 26556594
ER
PT J
AU Marechal, L
Foong, S
Ding, SY
Wood, KL
Patil, V
Gupta, R
AF Marechal, Luc
Foong, Shaohui
Ding, Shuoyu
Wood, Kristin L.
Patil, Vaibhav
Gupta, Rajiv
TI Design Optimization of a Magnetic Field-Based Localization Device for
Enhanced Ventriculostomy
SO JOURNAL OF MEDICAL DEVICES-TRANSACTIONS OF THE ASME
LA English
DT Article
ID DRAIN PLACEMENT; CATHETER PLACEMENT; TRACKING SYSTEM; HALL SENSORS; HEAD
TRAUMA; ACCURACY; ORIENTATION; RATES
AB The accuracy of many freehand medical procedures can be improved with assistance from real-time localization. Magnetic localization systems based on harnessing passive permanent magnets (PMs) are of great interest to track objects inside the body because they do not require a powered source and provide noncontact sensing without the need for line-of-sight. While the effect of the number of sensors on the localization accuracy in such systems has been reported, the spatial design of the sensing assembly is an open problem. This paper presents a systematic approach to determine an optimal spatial sensor configuration for localizing a PM during a medical procedure. Two alternative approaches were explored and compared through numerical simulations and experimental investigation: one based on traditional grid configuration and the other derived using genetic algorithms (GAs). Our results strongly suggest that optimizing the spatial arrangement has a larger influence on localization performance than increasing the number of sensors in the assembly. We found that among all the optimization schemes, the approach utilizing GA produced sensor designs with the smallest localization errors.
C1 [Marechal, Luc; Foong, Shaohui; Ding, Shuoyu] Singapore Univ Technol & Design, Engn Prod Dev, 8 Somapah Rd, Singapore 487372, Singapore.
[Wood, Kristin L.] Singapore Univ Technol & Design, Pillar Engn Prod Dev, 8 Somapah Rd, Singapore 487372, Singapore.
[Gupta, Rajiv] Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,GRB 273A, Boston, MA 02114 USA.
RP Foong, S (reprint author), Singapore Univ Technol & Design, Engn Prod Dev, 8 Somapah Rd, Singapore 487372, Singapore.
EM foongshaohui@sutd.edu.sg
FU Agency for Science, Technology and Research (A*STAR) [122440002]; Center
for Integration of Medecine and Innovative Technology (CIMIT); SUTD-ZJU
Research Collaboration Grant [SUTDZJU/RES/03/2012]
FX This project was facilitated by the Agency for Science, Technology and
Research (A*STAR) Grant No. 122440002, the Center for Integration of
Medecine and Innovative Technology (CIMIT), and the robotic platform
from the SUTD-ZJU Research Collaboration Grant No. SUTDZJU/RES/03/2012.
The authors were also grateful to Conor J. Walsh from the School of
Engineering and Applied Science of Harvard University and the Mass
General/North Shore Center for Outpatient Care, Danvers, MA.
NR 32
TC 2
Z9 2
U1 1
U2 1
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 1932-6181
EI 1932-619X
J9 J MED DEVICES
JI J. Med. Devices
PD MAR
PY 2016
VL 10
IS 1
AR 011006
DI 10.1115/1.4032614
PG 9
WC Engineering, Biomedical
SC Engineering
GA DF1FU
UT WOS:000371085600007
ER
PT J
AU Scheller, C
Wienke, A
Tatagiba, M
Gharabaghi, A
Ramina, KF
Ganslandt, O
Bischoff, B
Zenk, J
Engelhorn, T
Matthies, C
Westermaier, T
Antoniadis, G
Pedro, MT
Rohde, V
von Eckardstein, K
Kretschmer, T
Kornhuber, M
Steighardt, J
Richter, M
Barker, FG
Strauss, C
AF Scheller, Christian
Wienke, Andreas
Tatagiba, Marcos
Gharabaghi, Alireza
Ramina, Kristofer F.
Ganslandt, Oliver
Bischoff, Barbara
Zenk, Johannes
Engelhorn, Tobias
Matthies, Cordula
Westermaier, Thomas
Antoniadis, Gregor
Pedro, Maria Teresa
Rohde, Veit
von Eckardstein, Kajetan
Kretschmer, Thomas
Kornhuber, Malte
Steighardt, Joerg
Richter, Michael
Barker, Fred G., II
Strauss, Christian
TI Prophylactic nimodipine treatment for cochlear and facial nerve
preservation after vestibular schwannoma surgery: a randomized
multicenter Phase III trial
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE nimodipine; vestibular schwannoma; acoustic neuroma; neuroprotection;
skull base
ID POSTOPERATIVE VASOACTIVE TREATMENT; RECURRENT LARYNGEAL NERVE; ACOUSTIC
NEUROMA SURGERY; HEARING PRESERVATION; PROMOTES REGENERATION; FUNCTIONAL
RECOVERY; RAT; INJURY; MANAGEMENT; RESECTION
AB OBJECTIVE A pilot study of prophylactic nimodipine and hydroxyethyl starch treatment showed a beneficial effect on facial and cochlear nerve preservation following vestibular schwannoma (VS) surgery. A prospective Phase III trial was undertaken to confirm these results.
METHODS An open-label, 2-arm, randomized parallel group and multicenter Phase III trial with blinded expert review was performed and included 112 patients who underwent VS surgery between January 2010 and February 2013 at 7 departments of neurosurgery to investigate the efficacy and safety of the prophylaxis. The was performed after the patients were randomly assigned to one of 2 groups using online randomization. The treatment group (n = 56) received parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%) from the day before surgery until the 7th postoperative day. The control group (n = 56) was not treated prophylactically.
RESULTS Intent-to-treat analysis showed no statistically significant effects of the treatment on either preservation of facial nerve function (35 [67.3%] of 52 [treatment group] compared with 34 [72.3%] of 47 [control group]) (p = 0.745) or hearing preservation (11 [23.4%] of 47 [treatment group] compared with 15 [31.2%] of 48 [control group]) (p = 0.530) 12 months after surgery. Since tumor sizes were significantly larger in the treatment group than in the control group, logistic regression analysis was required. The risk for deterioration of facial nerve function was adjusted nearly the same in both groups (OR 1.07 [95% CI 0.34-3.43], p = 0.91). In contrast, the risk for postoperative hearing loss was adjusted 2 times lower in the treatment group compared with the control group (OR 0.49 [95% CI 0.18-1.30], p = 0.15). Apart from dose dependent hypotension (p < 0.001), no clinically relevant adverse reactions were observed.
CONCLUSIONS There were no statistically significant effects of the treatment. Despite the width of the confidence intervals, the odds ratios may suggest but do not prove a clinically relevant effect of the safe study medication on the preservation of cochlear nerve function after VS surgery. Further study is needed before prophylactic nimodipine can be recommended in VS surgery.
C1 [Scheller, Christian; Strauss, Christian] Univ Halle Wittenberg, Dept Neurosurg, Ernst Grube Str 40, D-06097 Halle, Saale, Germany.
[Kornhuber, Malte] Univ Halle Wittenberg, Dept Neurol, D-06097 Halle, Saale, Germany.
[Wienke, Andreas] Univ Halle Wittenberg, Inst Med Epidemiol Biostat & Informat, D-06097 Halle, Saale, Germany.
[Steighardt, Joerg; Richter, Michael] Univ Halle Wittenberg, Coordinat Ctr Clin Trials, D-06097 Halle, Saale, Germany.
[Scheller, Christian] Univ Leipzig, Translat Ctr Regenerat Med, D-04109 Leipzig, Germany.
[Tatagiba, Marcos; Gharabaghi, Alireza; Ramina, Kristofer F.] Univ Tubingen, Dept Neurosurg, Tubingen, Germany.
[Ganslandt, Oliver; Bischoff, Barbara] Univ Erlangen Nurnberg, Dept Neurosurg, Nurnberg, Germany.
[Zenk, Johannes] Univ Erlangen Nurnberg, Dept Otorhinolaryngol Head & Neck Surg, Nurnberg, Germany.
[Engelhorn, Tobias] Univ Erlangen Nurnberg, Dept Neuroradiol, Nurnberg, Germany.
[Matthies, Cordula; Westermaier, Thomas] Wurzburg Univ Hosp, Dept Neurosurg, Wurzburg, Germany.
[Antoniadis, Gregor; Pedro, Maria Teresa] Univ Ulm, Dept Neurosurg, Bezirkskrankenhaus Gunzburg, D-89069 Ulm, Germany.
[Rohde, Veit; von Eckardstein, Kajetan] Univ Gottingen, Dept Neurosurg, Gottingen, Germany.
[Kretschmer, Thomas] Carl von Ossietzky Univ Oldenburg, Evangel Krankenhaus, Dept Neurosurg, D-26111 Oldenburg, Germany.
[Barker, Fred G., II] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP Scheller, C (reprint author), Univ Halle Wittenberg, Dept Neurosurg, Ernst Grube Str 40, D-06097 Halle, Saale, Germany.
EM christian.scheller@medizin.uni-halle.de
FU Bayer Health Care, Germany; German Federal Ministry of Education and
Research [BMBF 1315883]; Wilhelm-Roux-Program of the Medical Faculty of
the University Halle-Wittenberg, Germany [FKZ 19/07, FKZ 23/26];
Acoustic Neuroma brain tumour (AN) and Interest Group (IGAN),
Switzerland
FX The authors report the following sources of financial and material
support: Bayer Health Care, Germany; the German Federal Ministry of
Education and Research (BMBF 1315883); the Wilhelm-Roux-Program (FKZ
19/07, FKZ 23/26) of the Medical Faculty of the University
Halle-Wittenberg, Germany; and the Acoustic Neuroma brain tumour (AN)
and Interest Group (IGAN), Switzerland.
NR 25
TC 1
Z9 1
U1 1
U2 2
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
EI 1933-0693
J9 J NEUROSURG
JI J. Neurosurg.
PD MAR
PY 2016
VL 124
IS 3
BP 657
EP 664
DI 10.3171/2015.1.JNS142001
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA DE8VQ
UT WOS:000370915200008
PM 26274985
ER
PT J
AU Abedalthagafi, MS
Wu, MP
Merrill, PH
Du, ZM
Woo, T
Sheu, SH
Hurwitz, S
Ligon, KL
Santagata, S
AF Abedalthagafi, Malak S.
Wu, Michael P.
Merrill, Parker H.
Du, Ziming
Woo, Terri
Sheu, Shu-Hsien
Hurwitz, Shelley
Ligon, Keith L.
Santagata, Sandro
TI Decreased FOXJ1 expression and its ciliogenesis programme in aggressive
ependymoma and choroid plexus tumours
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE FOXJ1; ependymoma; choroid plexus; dedifferentiation; stem cells;
subventricular zone; cilia; ciliogenesis
ID LINEAGE-SURVIVAL ONCOGENE; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS;
EPITHELIAL-CELLS; IN-VIVO; TRANSCRIPTION FACTORS; CEREBROSPINAL-FLUID;
ABNORMAL CILIA; RADIAL GLIA; CANCER
AB Well-differentiated human cancers share transcriptional programmes with the normal tissue counterparts from which they arise. These programmes broadly influence cell behaviour and function and are integral modulators of malignancy. Here, we show that the master regulator of motile ciliogenesis, FOXJ1, is highly expressed in cells along the ventricular surface of the human brain. Strong expression is present in cells of the ependyma and the choroid plexus as well as in a subset of cells residing in the subventricular zone. Expression of FOXJ1 and its transcriptional programme is maintained in many well-differentiated human tumours that arise along the ventricle, including low-grade ependymal tumours and choroid plexus papillomas. Anaplastic ependymomas as well as choroid plexus carcinomas show decreased FOXJ1 expression and its associated ciliogenesis programme genes. In ependymomas and choroid plexus tumours, reduced expression of FOXJ1 and its ciliogenesis programme are markers of poor outcome and are therefore useful biomarkers for assessing these tumours. Transitions in ciliogenesis define distinct differentiation states in ependymal and choroid plexus tumours with important implications for patient care. Copyright (c) 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Abedalthagafi, Malak S.; Wu, Michael P.; Merrill, Parker H.; Du, Ziming; Woo, Terri; Ligon, Keith L.; Santagata, Sandro] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Div Neuropathol, Boston, MA 02115 USA.
[Abedalthagafi, Malak S.] King Fahad Med City, Dept Pathol, Riyadh, Saudi Arabia.
[Abedalthagafi, Malak S.] King Abdulaziz City Sci & Technol, Riyadh, Saudi Arabia.
[Abedalthagafi, Malak S.; Sheu, Shu-Hsien; Ligon, Keith L.; Santagata, Sandro] Harvard Univ, Sch Med, Dept Pathol, Boston Childrens Hosp, Boston, MA 02115 USA.
[Hurwitz, Shelley] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Ligon, Keith L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Santagata, Sandro] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
RP Santagata, S (reprint author), Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Med Sch,Dept Canc Biol,Dana Farber Canc Inst,Path, 77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM ssantagata@partners.org
FU NHLBI NIH HHS [T32 HL110852]
NR 69
TC 3
Z9 3
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD MAR
PY 2016
VL 238
IS 4
BP 584
EP 597
DI 10.1002/path.4682
PG 14
WC Oncology; Pathology
SC Oncology; Pathology
GA DE7TQ
UT WOS:000370840000012
PM 26690880
ER
PT J
AU Carroll, S
Rosa, KC
AF Carroll, Stacey
Rosa, Katherine C.
TI Role and Image of Nursing in Children's Literature: A Qualitative Media
Analysis
SO JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES
LA English
DT Article
DE Nursing image; Nursing role; Qualitative media analysis; Children's
literature; Symbolic interactionism
ID STORYBOOKS; NURSES; NOVELS
AB Purpose: Nurses' role and image as portrayed in young children's literature were described and analyzed.
Design and Methods: A total of 30 children's books (pre-kindergarten through grade two audience) written in English were chosen using progressive theoretical sampling. Included were books, both fiction and non-fiction and with varying years of publication, that mentioned nurses and/or were about general healthcare topics. The books were analyzed using the method of qualitative media analysis which is derived from the theoretical framework of symbolic interactionism.
Results: Nurses were generally portrayed positively but simply and inaccurately in this sample of children's literature. The seven themes discovered were labeled as nurse characters using traits evident in the sample: nurse unlikely, nurse minimal, nurse caring, nurse subordination, nurse skillful, nurse diversity, and nurse obvious.
Conclusion: The image of nursing is socially and culturally constructed, and accurate portrayals of nurses and their roles are necessary in all media. Thus, better representation of nurses in children's books is needed as young children's literature is an important first exposure to the art and science of nursing. Practice Implications: Future children's books authored by nurses may more closely reflect accurate contemporary nursing practice and contribute to an improved image of the nursing profession. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Carroll, Stacey] Rush Univ, Armour Acad Ctr, Coll Nursing, Chicago, IL 60612 USA.
[Carroll, Stacey] Anna Maria Coll, Paxton, MA USA.
[Rosa, Katherine C.] Massachusetts Gen Hosp, Clin Res Ctr, Boston, MA 02114 USA.
RP Carroll, S (reprint author), Rush Univ, Armour Acad Ctr, Coll Nursing, Chicago, IL 60612 USA.; Carroll, S (reprint author), Anna Maria Coll, Paxton, MA USA.
EM Smcarroll88@gmail.com
NR 42
TC 0
Z9 0
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0882-5963
J9 J PEDIATR NURS
JI J. Pediatr. Nurs.
PD MAR-APR
PY 2016
VL 31
IS 2
BP 141
EP 151
DI 10.1016/j.pedn.2015.09.009
PG 11
WC Nursing; Pediatrics
SC Nursing; Pediatrics
GA DE7IH
UT WOS:000370808800016
PM 26616685
ER
PT J
AU Sapkota, K
Mao, ZH
Synowicki, P
Lieber, D
Liu, M
Ikezu, T
Gautam, V
Monaghan, DT
AF Sapkota, Kiran
Mao, Zhihao
Synowicki, Paul
Lieber, Dillon
Liu, Meng
Ikezu, Tsuneya
Gautam, Vivek
Monaghan, Daniel T.
TI GluN2D N-Methyl-D-Aspartate Receptor Subunit Contribution to the
Stimulation of Brain Activity and Gamma Oscillations by Ketamine:
Implications for Schizophrenia
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID HIGH-FREQUENCY OSCILLATIONS; THALAMIC NUCLEUS REUNIENS; MEDIAL
PREFRONTAL CORTEX; FREELY MOVING MICE; NMDA RECEPTORS; PREPULSE
INHIBITION; WORKING-MEMORY; MESSENGER-RNAS; NEURODEVELOPMENTAL MODEL;
NETWORK OSCILLATIONS
AB The dissociative anesthetic ketamine elicits symptoms of schizophrenia at subanesthetic doses by blocking N-methyl-D-aspartate receptors (NMDARs). This property led to a variety of studies resulting in the now well-supported theory that hypofunction of NMDARs is responsible for many of the symptoms of schizophrenia. However, the roles played by specific NMDAR subunits in different symptom components are unknown. To evaluate the potential contribution of GluN2D NMDAR subunits to antagonist-induced cortical activation and schizophrenia symptoms, we determined the ability of ketamine to alter regional brain activity and gamma frequency band neuronal oscillations in wild-type (WT) and GluN2D-knockout (GluN2D-KO) mice. In WT mice, ketamine (30 mg/kg, i.p.) significantly increased [C-14]-2-deoxyglucose ([C-14]-2DG) uptake in the medial prefrontal cortex (mPFC), entorhinal cortex and other brain regions, and decreased activity in the somatosensory cortex and inferior colliculus. In GluN2D-KO mice, however, ketamine did not significantly increase [C-14]-2DG uptake in any brain region examined, yet still decreased [C-14]-2DG uptake in the somatosensory cortex and inferior colliculus. Ketamine also increased locomotor activity in WT mice but not in GluN2D-KO mice. In electrocorticographic analysis, ketamine induced a 111% +/- 16% increase in cortical gamma-band oscillatory power in WT mice, but only a 15% +/- 12% increase in GluN2D-KO mice. Consistent with GluN2D involvement in schizophrenia-related neurologic changes, GluN2D-KO mice displayed impaired spatial memory acquisition and reduced parvalbumin (PV)-immunopositive staining compared with control mice. These results suggest a critical role of GluN2D-containing NMDARs in neuronal oscillations and ketamine's psychotomimetic, dissociative effects and hence suggests a critical role for GluN2D subunits in cognition and perception.
C1 [Sapkota, Kiran; Mao, Zhihao; Synowicki, Paul; Lieber, Dillon; Liu, Meng; Monaghan, Daniel T.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
[Ikezu, Tsuneya] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA.
[Ikezu, Tsuneya] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Gautam, Vivek] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Monaghan, DT (reprint author), Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 600 S 42nd St,Box 985800, Omaha, NE 68198 USA.
EM dtmonagh@unmc.edu
FU National Institutes of Health National Institutes of Mental Health
[MH60252]; Edna Ittner Pediatric Research Foundation
FX This study was funded by the National Institutes of Health National
Institutes of Mental Health [Grant MH60252] and the Edna Ittner
Pediatric Research Foundation (DTM).
NR 88
TC 5
Z9 5
U1 1
U2 11
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD MAR
PY 2016
VL 356
IS 3
BP 702
EP 711
DI 10.1124/jpet.115.230391
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DE4PL
UT WOS:000370611700018
PM 26675679
ER
PT J
AU Newell, J
Yesavage, JA
Taylor, JL
Kraemer, HC
Munro, CA
Friedman, L
Rosenberg, PB
Madore, M
Chao, SZ
Devanand, DP
Drye, LT
Mintzer, JE
Pollock, BG
Porsteinsson, AP
Schneider, LS
Shade, DM
Weintraub, D
Lyketsos, CG
Noda, A
AF Newell, Jeffery
Yesavage, Jerome A.
Taylor, Joy L.
Kraemer, Helena C.
Munro, Cynthia A.
Friedman, Leah
Rosenberg, Paul B.
Madore, Michelle
Chao, Steven Z.
Devanand, D. P.
Drye, Lea T.
Mintzer, Jacobo E.
Pollock, Bruce G.
Porsteinsson, Anton P.
Schneider, Lon S.
Shade, David M.
Weintraub, Daniel
Lyketsos, Constantine G.
Noda, Art
CA CitAD Res Grp
TI Sedation mediates part of Citalopram's effect on agitation in
Alzheimer's disease
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Agitation; Sedation; Citalopram
ID DEMENTIA; AGGRESSION; CLINICIAN; TRIAL
AB Background: We found a benefit of citalopram for agitation in the Citalopram for Agitation in Alzheimer's Disease study (CitAD), and wondered if this was mediated by a sedative effect. CitAD was a randomized, placebo-controlled, double-blind, parallel group trial conducted at 8 academic centers in the United States and Canada from August 2009 to January 2013. One hundred sixty-two participants with probable Alzheimer's disease (AD) and clinically significant agitation were analyzed in this study. Participants received a psychosocial intervention and were randomized to receive either citalopram or placebo (approximately half assigned to each group). Participants were rated on the Neurobehavioral Rating Scale Agitation subscale and measures of sedation (i.e., fatigue and somnolence).
Methods: Using the MacArthur Foundation procedures for documenting a mediator effect, we performed a secondary analysis examining whether sedation mediates the effect of treatment on agitation outcome.
Results: We found a statistically significant mediating effect of sedation on agitation outcomes, but the magnitude of the effect was small, only explaining 11% of the variance in agitation, with a significant, but modest effect size of 0.16 (95% CI: 0.08 to 0.22).
Conclusions: The benefit of citalopram was partly due to sedation but largely due to other mechanisms of action. Published by Elsevier Ltd.
C1 [Newell, Jeffery] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
[Yesavage, Jerome A.; Taylor, Joy L.; Madore, Michelle; Chao, Steven Z.] Dept Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA.
[Yesavage, Jerome A.; Taylor, Joy L.; Kraemer, Helena C.; Friedman, Leah; Madore, Michelle; Noda, Art] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Yesavage, Jerome A.; Chao, Steven Z.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
[Munro, Cynthia A.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
[Munro, Cynthia A.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Sch Med, Baltimore, MD 21205 USA.
[Devanand, D. P.] New York State Psychiat Inst & Hosp, Div Geriatr Psychiat, New York, NY 10032 USA.
[Devanand, D. P.] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.
[Drye, Lea T.; Shade, David M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
[Mintzer, Jacobo E.] Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC 29401 USA.
[Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
[Pollock, Bruce G.] Univ Toronto, CAMH, Campbell Inst, Toronto, ON M5S 2S1, Canada.
[Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA.
[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Weintraub, Daniel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Dept Vet Affairs, Philadelphia, PA 19104 USA.
RP Yesavage, JA (reprint author), Palo Alto VA Hlth Care Syst, 3801 Miranda Ave 151Y, Palo Alto, CA 94304 USA.
EM yesavage@stanford.edu
FU NIA and NIMH [R01AG031348]; NIH [AG05142, P50]; Sierra-Pacific Mental
Illness Research, Education, and Clinical Center (MIRECC); Medical
Research Service of Department of Veterans Affairs
FX This work was supported by NIA and NIMH, R01AG031348 and in part by NIH
P50, AG05142 (USC, LSS). and by the Sierra-Pacific Mental Illness
Research, Education, and Clinical Center (MIRECC) and the Medical
Research Service of the Department of Veterans Affairs. The funding
sources had a role in in study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the article for publication.
NR 15
TC 1
Z9 1
U1 2
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD MAR
PY 2016
VL 74
BP 17
EP 21
DI 10.1016/j.jpsychires.2015.12.005
PG 5
WC Psychiatry
SC Psychiatry
GA DE8RS
UT WOS:000370905000004
PM 26736036
ER
PT J
AU Iovieno, N
Nierenberg, AA
Parkin, SR
Kim, DJH
Walker, RSW
Fava, M
Papakostas, GI
AF Iovieno, Nadia
Nierenberg, Andrew A.
Parkin, Susannah R.
Kim, Daniel Ju Hyung
Walker, Rosemary S. W.
Fava, Maurizio
Papakostas, George I.
TI Relationship between placebo response rate and clinical trial outcome in
bipolar depression
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Placebo response; Bipolar depression; Clinical trials
ID PSYCHIATRY WFSBP GUIDELINES; DOUBLE-BLIND; I DEPRESSION; TREATMENTS
METAANALYSIS; BIOLOGICAL TREATMENT; DIAGNOSTIC CRITERIA; WORLD
FEDERATION; ACUTE MANIA; EFFICACY; MONOTHERAPY
AB The aim of this work is to investigate the impact of placebo response rates on the relative risk of response to drug versus placebo in randomized, double-blind, placebo-controlled clinical trials of pharmacological therapy in Bipolar Depression (BPD).
Medline/PubMed publication databases were searched for randomized, double-blind, placebo controlled trials of oral drugs used as monotherapy for the treatment of BPD. The search was limited to articles published between January 1980 and September 2015. Data extracted from 12 manuscripts and one poster with yet unpublished results, representing a total of 17 clinical trials were pooled (n = 6578). Pooled response rates for drug and placebo were 55.1% and 39.2%, corresponding to a risk ratio (RR) for responding to active treatment versus placebo of 1.29 (p < 0.001). Clinical response was defined as a 50% or greater reduction in depression scores, baseline to endpoint. A higher placebo response rate correlated with a significantly lower RR of responding to pharmacotherapy versus placebo (p = 0.002). The pooled drug and placebo response rates for studies with a placebo response rate <= 30% were 50.5% versus 26.6%, while corresponding values from studies with a placebo response rate >30 were 55.0% versus 41.6%.
These results suggest that the relative efficacy of the active drug compared to placebo in clinical trials for BPD is highly heterogeneous across studies with different placebo response rates, with a worse performance in showing a superiority of the drug versus placebo for studies with placebo response rates >30%. It is important to maintain placebo response rates below this critical threshold, since this is one of the most challenging obstacles for new treatment development in BPD. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Iovieno, Nadia; Fava, Maurizio; Papakostas, George I.] Massachusetts Gen Hosp, Clin Trials Network & Inst, One Bowdoin Sq, Boston, MA 02114 USA.
[Nierenberg, Andrew A.; Parkin, Susannah R.; Kim, Daniel Ju Hyung; Walker, Rosemary S. W.; Fava, Maurizio; Papakostas, George I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA.
[Nierenberg, Andrew A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bipolar Clin & Res Program, Boston, MA USA.
RP Iovieno, N (reprint author), Massachusetts Gen Hosp, Clin Trials Network & Inst, One Bowdoin Sq, Boston, MA 02114 USA.
EM niovieno@partners.org
FU AstraZeneca PLC; Bristol Institute/Physicians Myers Squibb Company;
Forest Pharmaceuticals; National Institute of Mental Health; PAMLAB LLC;
Pfizer Inc.; Ridge Di-MGH agnostics; Sunovion Pharmaceuticals; Theracos,
Inc.; Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect
Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.;
Bristol-Myers Squibb; CeNeRx BioPharma; Cepha Ion; Clintara, LLC;
Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.;
Euthymics Bioscience, Inc.; Forest Pharma-ment ceuticals, Inc.; Ganeden
Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute;
Hoffman -LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen
RD, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research
Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; MedAvante; Na
tional Alliance for Research on Schizophrenia & Depression (NAR SAD);
National Center for Complementary and Alternative Medicine (NCCAM);
National Institute of Drug Abuse (NIDA); National Institute of Mental
Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals;
PamLab, LLC.; Pharmacia-Upjohn; Pharmaceutical Research Associates.,
Inc.; Pharmavite(R) LLC; PharmoRx Therapeutics; Photothera; Roche
Pharmaceuticals; RCT Logic, LLC; Sanofi-Aventis US LLC; Shire; Solvay
Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories; AHRQ
Cephalon; Elan; Forest; Mylan; NIMH; PamLabs; Pfizer Pharmaceuticals;
Takeda
FX Dr. Papakostas has served as a consultant for Abbott tories, AstraZeneca
PLC, Avanir Pharmaceuticals, Brainsway Ltd, Bristol-Myers Squibb
Company, Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co.,
GlaxoSmithKline, Evotec AG, H. Lundbeck A/S, Inflabloc Pharmaceuticals,
Jazz Pharmaceuticals, Novartis Pharma AG, Otsuka Pharmaceuticals, PAMLAB
LLC, Pfizer Inc., Pierre Fabre Laboratories, Ridge Diagnostics (formerly
known as Precision Hu-lutions, man Biolaboratories), Shire
Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company
LTD, Theracos, Inc., and Wyeth, Inc. Dr. Papakostas has received
honoraria from Abbott Laboratories, Astra Zeneca PLC, Avanir
Pharmaceuticals, Myers Squibb Company, Brainsway Ltd, Cephalon Inc., Dey
Pharma, LP., Eli Lilly Co., Evotec AG, GlaxoSmithKline, Inflabloc
Pharmaceuticals, Jazz Pharmaceuticals, H. Lundbeck A/S, Novartis Pharma
AG, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer, Pierre Fabre
Laboratories, Ridge Diagnostics, Shire Pharmaceuticals, Sunovion
Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos, Inc.,
Titan Pharmaceuticals, and Wyeth Inc. Dr. Papakos tas has received
research support from AstraZeneca PLC, Bristol Institute/Physicians
Myers Squibb Company, Forest Pharmaceuticals, the National Institute of
Mental Health, PAMLAB LLC, Pfizer Inc., Ridge Di-MGH agnostics (formerly
known as Precision Human Biolaboratories), Sunovion Pharmaceuticals, and
Theracos, Inc. Dr. Papakostas has served (not currently) on the
speaker's bureau for Bris tolMyersSquibb Co and Pfizer, Inc.; Research
Support: Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect
Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.;
Bristol-Myers Squibb; CeNeRx BioPharma; Cepha Ion; Clintara, LLC;
Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.;
Euthymics Bioscience, Inc.; Forest Pharma-ment ceuticals, Inc.; Ganeden
Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute;
Hoffman -LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen
R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research &
Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; MedAvante; Na
tional Alliance for Research on Schizophrenia & Depression (NAR SAD);
National Center for Complementary and Alternative Medicine (NCCAM);
National Institute of Drug Abuse (NIDA); National Institute of Mental
Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals;
PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research
Associates., Inc.; Pharmavite (R) LLC; PharmoRx Therapeutics;
Photothera; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical
Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay
Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories.; Dr.
Nierenberg has consulted for the American Psychiatric Association,
Appliance Computing Inc. (Mindsite), Basliea, Brain Cells, Inc.,
Brandeis University, Bristol Myers Squibb, Clintara, Dey
Pharmaceuticals, Dainippon Sumitomo (now Sunovion), Eli Lilly and
Company, EpiQ, L.P./Mylan Inc., Forest, Novartis, PamLabs, PGx Health,
Shire, Schering-Plough, Sunovion, Takeda Pharmaceuticals, Targacept, and
Teva; consulted through the MGH Clinical Trials Network and Institute
(CTNI) for Astra Zeneca, Brain Cells, Inc, Dianippon Sumitomo/Sepracor,
Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis,
PGx Health, Shire, ScheringPlough, Targacept and Takeda/Lundbeck
Pharmaceuticals; received grant/research support from AHRQ Cephalon,
Elan, Forest, Mylan, NIMH, PamLabs, Pfizer Pharmaceuticals, Shire, and
Takeda; received honoraria from Belvoir Publishing, University of Texas
Southwestern Dallas, Hillside Hospital, American Drug Utilization
Review, American Society for Clinical Psychopharmacology, Baystate
Medical Center, Columbia University, CRICO, Dartmouth Medical School,
IMEDEX, Israel Society for Biological Psychiatry, Johns Hopkins
University, MJ Consulting, New York State, Medscape, MBL Publishing,
National Association of Continuing Education, Physicians Postgraduate
Press, SUNY Buffalo, University of Wisconsin, University of Pisa,
University of Michigan, University of Miami, APSARD, ISBD, SciMed, Slack
Publishing and Wolters Klower Publishing; was currently or formerly on
the advisory boards of Appliance Computing, Inc., Brain Cells, Inc., Eli
Lilly and Company, Johnson and Johnson, Takeda/Lundbeck, Targacept, and
InfoMedic; owns stock options in Appliance Computing, Inc. and Brain
Cells, Inc; has copyrights to the Clinical Positive Affect Scale and the
MGH Structured Clinical Interview for the Montgomery Asberg Depression
Scale exclusively licensed to the MGH Clinical Trials Network and
Institute (CTNI); and has a patent extension application for the
combination of buspirone, bupropion, and melatonin for the treatment of
depression.
NR 46
TC 2
Z9 2
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD MAR
PY 2016
VL 74
BP 38
EP 44
DI 10.1016/j.jpsychires.2015.12.016
PG 7
WC Psychiatry
SC Psychiatry
GA DE8RS
UT WOS:000370905000008
PM 26736040
ER
PT J
AU Barron, E
Sokoloff, NC
Maffazioli, GDN
Ackerman, KE
Woolley, R
Holmes, TM
Anderson, EJ
Misra, M
AF Barron, Elizabeth
Sokoloff, Natalia Cano
Maffazioli, Giovana D. N.
Ackerman, Kathryn E.
Woolley, Ryan
Holmes, Tara M.
Anderson, Ellen J.
Misra, Madhusmita
TI Diets High in Fiber and Vegetable Protein Are Associated with Low Lumbar
Bone Mineral Density in Young Athletes with Oligoamenorrhea
SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS
LA English
DT Article
DE Diet; Athletes; Amenorrhea; Bone density; Adolescents
ID FOOD FREQUENCY QUESTIONNAIRE; FEMALE ATHLETE; ANOREXIA-NERVOSA;
PREMENOPAUSAL WOMEN; ENERGY AVAILABILITY; CONSENSUS STATEMENT;
EXERCISING WOMEN; ADOLESCENT GIRLS; MENSTRUAL STATUS; TRIAD
AB Background Associations of bone mineral density (BMD) with specific food components, including dietary fiber and isoflavones (that have a negative association with serum estrogen), are unclear and need to be determined, particularly in populations more likely to consume large amounts of these nutrients (such as young athletes).
Objective To determine dietary intake of specific food components in athletes with oligoamenorrhea (OA) compared to athletes with eumenorrhea (EA) and nonathletes (NA), and associations of the dietary intake of these nutrients with lumbar spine BMD.
Design and subjects This cross-sectional study evaluated 68 OA, 24 EA, and 26 NA individuals aged 14 to 23 years. Measurements included 4-day food records, a dual x-ray absorptiometry scan evaluating lumbar spine BMD and body composition, and hormone levels. Multivariate analysis was used to estimate associations of nutrients with lumbar spine BMD.
Results Compared with EA and NA, OA had higher intake of fiber, phytic acid, and vegetable protein (all P values <0.0001). Intake of isoflavones, genistein, and daidzein was higher in OA than NA (P=0.003 and P=0.0002, respectively). OA had lower consumption of energy from saturated fatty acids than NA (P=0.002). After controlling for confounders such as body weight, menstrual status (indicative of estrogen status), calcium intake, and serum vitamin D (known BMD determinants), lumbar spine BMD z scores were inversely associated with dietary fiber (beta=-.30; P=0.01), vegetable protein (beta=-.28; P=0.02), phytic acid (beta=-.27; P=0.02), genistein (beta=-.25; P=0.01), and daidzein (beta=-.24; P=0.01), and positively associated with percent energy from fatty acids (beta=.32; P=0.0006).
Conclusions Compared with EA and NA, OA had a higher dietary intake of fiber, vegetable protein, and phytic acid, which were inversely associated with lumbar spine BMD z scores. Further studies are needed to assess dietary recommendations for OA to optimize bone accrual.
C1 [Barron, Elizabeth; Sokoloff, Natalia Cano; Maffazioli, Giovana D. N.; Holmes, Tara M.] Massachusetts Gen Hosp, Harvard Catalyst Clin Res Ctr, Boston, MA 02114 USA.
[Woolley, Ryan] Massachusetts Gen Hosp, Harvard Catalyst Clin Res Ctr, Neuroendocrine Unit, Boston, MA 02114 USA.
[Ackerman, Kathryn E.; Anderson, Ellen J.; Misra, Madhusmita] Harvard Univ, Sch Med, Boston, MA USA.
[Ackerman, Kathryn E.; Misra, Madhusmita] Massachusetts Gen Hosp, Neuroendocrine Unit, 55 Fruit St, Boston, MA 02114 USA.
[Ackerman, Kathryn E.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA.
[Misra, Madhusmita] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA.
RP Misra, M (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, 55 Fruit St, Boston, MA 02114 USA.
EM mmisra@mgh.harvard.edu
OI Holmes, Tara/0000-0003-3613-6391
FU National Institutes of Health [1 UL1 RR025758, 1 UL1 TR001102, 1 R01
HD060827-01A1, K24 HD071843]
FX This work was supported by National Institutes of Health grants 1 UL1
RR025758, 1 UL1 TR001102, 1 R01 HD060827-01A1, and K24 HD071843.
NR 61
TC 3
Z9 3
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-2672
EI 2212-2680
J9 J ACAD NUTR DIET
JI J. Acad. Nutr. Diet.
PD MAR
PY 2016
VL 116
IS 3
BP 481
EP 489
DI 10.1016/j.jand.2015.10.022
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DE6DF
UT WOS:000370723100015
PM 26686817
ER
PT J
AU Blanchard, MG
Kittikulsuth, W
Nair, AV
de Baaij, JHF
Latta, F
Genzen, JR
Kohan, DE
Bindels, RJM
Hoenderop, JGJ
AF Blanchard, Maxime G.
Kittikulsuth, Wararat
Nair, Anil V.
de Baaij, Jeroen H. F.
Latta, Femke
Genzen, Jonathan R.
Kohan, Donald E.
Bindels, Rene J. M.
Hoenderop, Joost G. J.
TI Regulation of Mg2+ Reabsorption and Transient Receptor Potential
Melastatin Type 6 Activity by cAMP Signaling
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID DISTAL CONVOLUTED TUBULE; ALPHA-KINASE DOMAIN; SECONDARY HYPOCALCEMIA;
TRPM6 ACTIVITY; MOLECULAR DETERMINANTS; PARATHYROID-HORMONE; ADENYLYL
CYCLASES; CHANNEL ACTIVITY; HYPOMAGNESEMIA; TRANSPORT
AB The transient receptor potential melastatin type 6 (TRPM6) epithelial Mg2+ channels participate in transcellular Mg2+ transport in the kidney and intestine. Previous reports suggested a hormonal cAMP-dependent regulation of Mg2+ reabsorption in the kidney. The molecular details of this process are, however, unknown. Adenylate cyclase 3 (Adcy3) has been shown to colocalize with the Na+/Cl- cotransporter, a marker of the distal convoluted segment of the kidney, the principal site of TRPM6 expression. Given the critical role of TRPM6 in Mg2+ reabsorption, an inducible kidney-specific Adcy3 deletion mouse model was characterized for blood and urinary electrolyte disturbances under a normal and low Mg2 diet. Increased urinary Mg2+ wasting and Trpm6 mRNA levels were observed in the urine and kidney of Adcy3-deleted animals compared with wild-type controls. Serum Mg2+ concentration was significantly lower in Adcy3-deleted animals at day 7 on the low Mg2+ diet. Using patch clamp electrophysiology, cell surface biotinylation, and total internal reflection fluorescence live cell imaging of transfected HEK293 cells, we demonstrated that cAMP signaling rapidly potentiates TRPM6 activity by promoting TRPM6 accumulation at the plasma membrane and increasing its single-channel conductance. Comparison of electrophysiological data from cells expressing the phosphorylation-deficient S1252A or phosphomimetic S1252D TRPM6 mutants suggests that phosphorylation at this intracellular residue participates in the observed stimulation of channel activity. Altogether, these data support a physiologically relevant magnesiotropic role of cAMP signaling in the kidney by a direct stimulatory action of protein kinase A on the plasma membrane trafficking and function of TRPM6 ion channels.
C1 [Blanchard, Maxime G.; Nair, Anil V.; de Baaij, Jeroen H. F.; Latta, Femke; Bindels, Rene J. M.; Hoenderop, Joost G. J.] Radboud Univ Nijmegen, Med Ctr, Dept Physiol, NL-6525 ED Nijmegen, Netherlands.
[Kittikulsuth, Wararat; Kohan, Donald E.] Univ Utah, Sch Med, Div Nephrol, Salt Lake City, UT USA.
[Genzen, Jonathan R.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA.
[Nair, Anil V.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Nair, Anil V.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Hoenderop, JGJ (reprint author), Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Med Ctr, Dept Physiol, POB 9101, NL-6500 MB Nijmegen, Netherlands.
EM Joost.Hoenderop@radboudumc.nl
RI Bindels, Rene/B-9824-2013; Hoenderop, Joost/H-8047-2014;
OI Bindels, Rene/0000-0003-1167-1339; Blanchard,
Maxime/0000-0001-8955-2239; de Baaij, Jeroen/0000-0003-2372-8486
FU Netherlands Organization for Scientific Research [ALW 818.02.001,
016.130.668]; European Union [305608]
FX This work was supported by grants from the Netherlands Organization for
Scientific Research (Grant ALW 818.02.001 and Vici Grant 016.130.668 to
J.G.J.H.) and EURenOmics funding from the European Union Seventh
Framework Program (FP7/2007-2013, Agreement Number 305608).
NR 51
TC 0
Z9 0
U1 1
U2 4
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAR
PY 2016
VL 27
IS 3
BP 804
EP 813
DI 10.1681/ASN.2014121228
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA DF1LN
UT WOS:000371101400017
PM 26150606
ER
PT J
AU Peralta, CA
Bibbins-Domingo, K
Vittinghoff, E
Lin, F
Fornage, M
Kopp, JB
Winkler, CA
AF Peralta, Carmen A.
Bibbins-Domingo, Kirsten
Vittinghoff, Eric
Lin, Feng
Fornage, Myriam
Kopp, Jeffrey B.
Winkler, Cheryl A.
TI APOL1 Genotype and Race Differences in Incident Albuminuria and Renal
Function Decline
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; AFRICAN-AMERICANS; VARIANTS ASSOCIATE;
RACIAL-DIFFERENCES; UNITED-STATES; RISK; MICROALBUMINURIA;
INSUFFICIENCY; NEPHROPATHY; PROGRESSION
AB Variants in the APOL1 gene are associated with kidney disease in blacks. We examined associations of APOL1 with incident albuminuria and kidney function decline among 3030 young adults with preserved GFR in the Coronary Artery Risk Development in Young Adults (CARDIA) study. eGFR by cystatin C (eGFRcys) and albumin-to-creatinine ratio were measured at scheduled examinations. Participants were white (n=1700), high-risk black (two APOL1 risk alleles, n=176), and low-risk black (zero/one risk allele, n=1154). Mean age was 35 years, mean eGFRcys was 107 ml/min per 1.73 m(2), and 13.2% of blacks had two APOL1 alleles. The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6-22.1) for high-risk blacks, 7.8 (6.4-9.4) for low-risk blacks, and 3.9 (3.1-4.8) for whites. Compared with whites, the odds ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64-8.94) for high-risk blacks and 2.32 (1.73-3.13) for low-risk blacks. Adjustment for risk factors attenuated the difference between low-risk blacks and whites (odds ratio 1.21, 95% confidence interval 0.86-1.71). After adjustment, high-risk blacks had a 0.45% faster yearly eGFRcys decline over 9.3 years compared with whites. Low-risk blacks also had a faster yearly eGFRcys decline compared with whites, but this difference was attenuated after adjustment for risk factors and socioeconomic position. In conclusion, blacks with two APOL1 risk alleles had the highest risk for albuminuria and eGFRcys decline in young adulthood, whereas disparities between low-risk blacks and whites were related to differences in traditional risk factors.
C1 [Peralta, Carmen A.; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Vittinghoff, Eric; Lin, Feng] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
[Kopp, Jeffrey B.] NIDDK, Kidney Dis Branch, Bethesda, MD 20892 USA.
[Winkler, Cheryl A.] Leidos Biomed Inc, Basic Res Lab, Ctr Canc Res, Natl Canc Inst,Frederick Natl Lab, Frederick, MD USA.
RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM carmenalicia.peralta@ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[5R03-DK095877-03]; Robert Wood Johnson Harold Amos Program; NIDDK
Intramural Research Program; National Cancer Institute, National
Institutes of Health (NIH) [HHSN26120080001E]; Intramural Research
Program of the NIH, National Cancer Institute, Center for Cancer
Research; National Heart, Lung, and Blood Institute (NHLBI); University
of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C];
Northwestern University [HHSN268201300027C]; University of Minnesota
[HHSN268201300028C]; Kaiser Foundation Research Institute
[HHSN268201300029C]; Johns Hopkins University School of Medicine
[HHSN268200900041C]; Intramural Research Program of the National
Institute on Aging (NIA); NIA [AG0005]; NHLBI [AG0005]; [R01-DK078124];
[P60006902]; [K24-DK103992]
FX C.P. is funded by grant 5R03-DK095877-03 from National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) and the Robert Wood
Johnson Harold Amos Program.; K.B.D. was funded by R01-DK078124,
P60006902 and K24-DK103992.; J.B.K. was supported by the NIDDK
Intramural Research Program. This project has been funded in whole or in
part with federal funds from the National Cancer Institute, National
Institutes of Health (NIH), under contract HHSN26120080001E.; The
content of this publication does not necessarily reflect the views or
policies of the Department of Health and Human Services, nor does
mention of trade names, commercial products, or organizations imply
endorsement by the US Government. This research was supported in part by
the Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research.; The Coronary Artery Risk Development in
Young Adults Study (CARDIA) is conducted and supported by the National
Heart, Lung, and Blood Institute (NHLBI) in collaboration with the
University of Alabama at Birmingham (HHSN268201300025C and
HHSN268201300026C), Northwestern University (HHSN268201300027C),
University of Minnesota (HHSN268201300028C), Kaiser Foundation Research
Institute (HHSN268201300029C), and Johns Hopkins University School of
Medicine (HHSN268200900041C). CARDIA is also partially supported by the
Intramural Research Program of the National Institute on Aging (NIA) and
an infra-agency agreement between NIA and NHLBI (AG0005). This
manuscript has been reviewed by CARDIA for scientific content.
NR 23
TC 8
Z9 8
U1 1
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAR
PY 2016
VL 27
IS 3
BP 887
EP 893
DI 10.1681/ASN.2015020124
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA DF1LN
UT WOS:000371101400024
PM 26180129
ER
PT J
AU Thadhani, R
Hagmann, H
Schaarschmidt, W
Roth, B
Cingoez, T
Karunnanchi, SA
Wenger, J
Lucchesi, KJ
Tamez, H
Lindner, T
Fridman, A
Thome, U
Kribs, A
Danner, M
Hamacher, S
Mallmann, P
Stepan, H
Benzing, T
AF Thadhani, Ravi
Hagmann, Henning
Schaarschmidt, Wiebke
Roth, Bernhard
Cingoez, Tuelay
Karunnanchi, S. Ananth
Wenger, Julia
Lucchesi, Kathryn J.
Tamez, Hector
Lindner, Tom
Fridman, Alexander
Thome, Ulrich
Kribs, Angela
Danner, Marco
Hamacher, Stefanie
Mallmann, Peter
Stepan, Holger
Benzing, Thomas
TI Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate
Apheresis in Preeclampsia
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DENSITY-LIPOPROTEIN APHERESIS; HOMOZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIA; ANGIOGENIC FACTORS; EXTRACORPOREAL
REMOVAL; FACTOR RECEPTOR-1; RENAL-FUNCTION; MOUSE MODEL; PREGNANCY;
HYPERTENSION
AB Preeclampsia is a devastating complication of pregnancy. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is an antiangiogenic protein believed to mediate the signs and symptoms of preeclampsia. We conducted an open pilot study to evaluate the safety and potential efficacy of therapeutic apheresis with a plasma specific dextran sulfate column to remove circulating sFlt-1 in 11 pregnant women (20-38 years of age) with very preterm preeclampsia (23-32 weeks of gestation, systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg, new onset protein/creatinine ratio >0.30 g/g, and sFlt-1/placental growth factor ratio >85). We evaluated the extent of sFlt-1 removal, proteinuria reduction, pregnancy continuation, and neonatal and fetal safety of apheresis after one (n=6), two (n=4), or three (n=1) apheresis treatments. Mean sFlt-1 levels were reduced by 18% (range 7%-28%) with concomitant reductions of 44% in protein/creatinine ratios. Pregnancy continued for 8 days (range 2-11) and 15 days (range 11-21) in women treated once and multiple times, respectively, compared with 3 days (range 0-14) in untreated contemporaneous preeclampsia controls (n=22). Transient maternal BP reduction during apheresis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration, and reducing blood flow through the apheresis column. Compared with infants born prematurely to untreated women with and without preeclampsia (n=22 per group), no adverse effects of apheresis were observed. In conclusion, therapeutic apheresis reduced circulating sFlt-1 and proteinuria in women with very preterm preeclampsia and appeared to prolong pregnancy without major adverse maternal or fetal consequences. A controlled trial is warranted to confirm these findings.
C1 [Thadhani, Ravi; Wenger, Julia; Lucchesi, Kathryn J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol, 55 Fruit St,1008G Bigelow, Boston, MA USA.
[Hagmann, Henning; Cingoez, Tuelay; Benzing, Thomas] Univ Cologne, Renal Div, D-50931 Cologne, Germany.
[Hagmann, Henning; Cingoez, Tuelay; Benzing, Thomas] Univ Cologne, Dept Med, D-50931 Cologne, Germany.
[Hagmann, Henning; Cingoez, Tuelay; Benzing, Thomas] Univ Cologne, Ctr Mol Med, D-50931 Cologne, Germany.
[Roth, Bernhard; Kribs, Angela; Danner, Marco] Univ Cologne, Dept Neonatol, D-50931 Cologne, Germany.
[Fridman, Alexander; Mallmann, Peter] Univ Cologne, Dept Obstet & Gynecol, D-50931 Cologne, Germany.
[Hamacher, Stefanie] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany.
[Benzing, Thomas] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany.
[Schaarschmidt, Wiebke; Stepan, Holger] Univ Hosp Leipzig, Dept Obstet, Leipzig, Germany.
[Lindner, Tom] Univ Hosp Leipzig, Div Nephrol, Dept Internal Med Neurol & Dermatol, Leipzig, Germany.
[Thome, Ulrich] Univ Hosp Leipzig, Dept Neonatol, Leipzig, Germany.
[Karunnanchi, S. Ananth] Harvard Univ, Sch Med, Dept Med & Obstet & Gynecol, Boston, MA USA.
[Tamez, Hector] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Cardiol, Boston, MA USA.
[Karunnanchi, S. Ananth] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Thadhani, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol, 55 Fruit St,1008G Bigelow, Boston, MA USA.
EM rthadhani@mgh.harvard.edu
FU Kaneka Corporation; Forschungspool Klinische Studien, Faculty of
Medicine, University of Cologne
FX Funding for the study was provided by Kaneka Corporation. Kaneka was not
involved in the design, analysis, and interpretation of results, or the
preparation of the manuscript.; This work was also partly supported by
Forschungspool Klinische Studien, Faculty of Medicine, University of
Cologne.
NR 43
TC 16
Z9 16
U1 5
U2 12
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAR
PY 2016
VL 27
IS 3
BP 903
EP 913
DI 10.1681/ASN.2015020157
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA DF1LN
UT WOS:000371101400026
PM 26405111
ER
PT J
AU Sadeh, N
Spielberg, JM
Logue, MW
Wolf, EJ
Smith, AK
Lusk, J
Hayes, JP
Sperbeck, E
Milberg, WP
McGlinchey, RE
Salat, DH
Carter, WC
Stone, A
Schichman, SA
Humphries, DE
Miller, MW
AF Sadeh, N.
Spielberg, J. M.
Logue, M. W.
Wolf, E. J.
Smith, A. K.
Lusk, J.
Hayes, J. P.
Sperbeck, E.
Milberg, W. P.
McGlinchey, R. E.
Salat, D. H.
Carter, W. C.
Stone, A.
Schichman, S. A.
Humphries, D. E.
Miller, M. W.
TI SKA2 methylation is associated with decreased prefrontal cortical
thickness and greater PTSD severity among trauma-exposed veterans
SO MOLECULAR PSYCHIATRY
LA English
DT Article
ID GLUCOCORTICOID-RECEPTOR; SUICIDE ATTEMPTERS; CORTEX; STRESS; FKBP5;
GENE; BRAIN; DYSFUNCTION; RESPONSES; BEHAVIOR
AB Methylation of the SKA2 (spindle and kinetochore-associated complex subunit 2) gene has recently been identified as a promising biomarker of suicide risk. Based on this finding, we examined associations between SKA2 methylation, cortical thickness and psychiatric phenotypes linked to suicide in trauma-exposed veterans. About 200 trauma-exposed white non-Hispanic veterans of the recent conflicts in Iraq and Afghanistan (91% male) underwent clinical assessment and had blood drawn for genotyping and methylation analysis. Of all, 145 participants also had neuroimaging data available. Based on previous research, we examined DNA methylation at the cytosine guanine locus cg13989295 as well as DNA methylation adjusted for genotype at the methylation-associated single nucleotide polymorphism (rs7208505) in relationship to whole-brain cortical thickness, posttraumatic stress disorder symptoms (PTSD) and depression symptoms. Whole-brain vertex-wise analyses identified three clusters in prefrontal cortex that were associated with genotype-adjusted SI35 years (adjusted hazard ratio [aHR], 2.4; 95% CI, 1.5-3.9), current cigarette smoking (aHR, 1.9; 95% CI, 1.1-3.4), and systemic lupus erythematosus (aHR, 3.5, 95% CI, 1.1-11). Recent diagnosis of uveitis was associated with an increased incidence of NV (compared with patients diagnosed >5 years ago, aHR, 2.4 [95% CI, 1.1-5.0] and aHR, 2.6 [95% CI, 1.2-6.0] for diagnosis within <1 year vs. 1-5 years, respectively). Compared with anterior uveitis, intermediate uveitis (aHR, 3.1; 95% CI, 1.5-6.6), posterior uveitis (aHR, 5.2; 95% CI, 2.5-11), and panuveitis (aHR, 4.3; 95% CI, 2.0-9.3) were associated with a similar degree of increased NV incidence. Active (aHR, 2.1, 95% CI, 1.2-3.7) and slightly active (aHR, 2.4, 95% CI, 1.3-4.4) inflammation were associated with an increased incidence of NV compared with inactive inflammation. Neovascularization incidence also was increased with retinal vascular occlusions (aHR, 10, 95% CI, 3.0-33), retinal vascular sheathing (aHR, 2.6, 95% CI, 1.4-4.9), and exudative retinal detachment (aHR, 4.1, 95% CI, 1.3-13). Diabetes mellitus was associated with a somewhat increased incidence of retinal NV (aHR, 2.3, 95% CI, 1.1-4.9), and systemic hypertension (aHR 1.5, 95% CI, 0.89-2.4) was associated with nonsignificantly increased NV incidence. Results were similar in sensitivity analyses excluding the small minority of patients with diabetes mellitus.
Conclusions: Retinal NV is a rare complication of uveitis, which occurs more frequently in younger patients, smokers, and those with intermediate/posterior/panuveitis, systemic vasculopathy, retinal vascular disease, or active inflammation. Inflammation and retinal NV likely are linked; additional studies are needed to further elucidate this connection. (C) 2016 by the American Academy of Ophthalmology.
C1 [Patel, Apurva K.; Artornsombudh, Pichaporn; Kothari, Srishti; Kempen, John H.] Univ Penn, Scheie Eye Inst, Ophthalmol, Philadelphia, PA 19104 USA.
[Newcomb, Craig W.; Kempen, John H.] Univ Penn, Scheie Eye Inst, Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Kempen, John H.] Univ Penn, Scheie Eye Inst, Ocular Inflammat Serv, Philadelphia, PA 19104 USA.
[Patel, Apurva K.] Retina Northwest PC, Portland, OR USA.
[Liesegang, Teresa L.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Ophthalmol, Portland, OR 97201 USA.
[Rosenbaum, James T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Internal Med, Portland, OR 97201 USA.
[Pujari, Siddharth S.] Om Eye Care Hosp, Belgaum, Karnataka, India.
[Pujari, Siddharth S.; Foster, C. Stephen; Artornsombudh, Pichaporn; Kothari, Srishti] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
[Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Ophthalmol, Baltimore, MD USA.
[Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Epidemiol, Baltimore, MD USA.
[Foster, C. Stephen] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA.
[Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Ophthalmol, New York, NY 10029 USA.
[Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Med, New York, NY 10029 USA.
[Nussenblatt, Robert B.; Sen, H. Nida] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
[Levy-Clarke, Grace A.; Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA.
[Levy-Clarke, Grace A.] Tampa Bay Uveitis Ctr, Safety Harbor, FL USA.
[Artornsombudh, Pichaporn] Chulalongkorn Univ, Div Ophthalmol, Naval Med Dept, Royal Thai Navy,Dept Ophthalmol,Fac Med,Somdech P, Bangkok, Thailand.
RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM john.kempen@uphs.upenn.edu
FU National Eye Institute [EY014943]; Research to Prevent Blindness (RPB);
Paul and Evanina Mackall Foundation; Lois Pope Life Foundation; RPB
James S. Adams Special Scholar Award; R.P.B. Harrington Special Scholar
Award; Research to Prevent Blindness Senior Scientific Investigator
Award; intramural funds of the National Eye Institute; Department of
Veterans' Affairs
FX Supported primarily by National Eye Institute Grant EY014943 (J.H.K.).
Additional support was provided by Research to Prevent Blindness (RPB),
the Paul and Evanina Mackall Foundation, and the Lois Pope Life
Foundation. J.H.K. was an RPB James S. Adams Special Scholar Award
recipient, J.E.T. was an R.P.B. Harrington Special Scholar Award
recipient, and D.A.J. and J.T.R. were Research to Prevent Blindness
Senior Scientific Investigator Award recipients during the course of the
study. G.A.L.-C. was previously supported by and RBN and HNS continues
to be supported by intramural funds of the National Eye Institute.
E.B.S. receives support from the Department of Veterans' Affairs. None
of the sponsors had any role in the design and conduct of the report;
the collection, management, analysis, and interpretation of the data; or
the preparation, review, and approval of this manuscript.
NR 32
TC 1
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2016
VL 123
IS 3
BP 646
EP 654
DI 10.1016/j.ophtha.2015.10.056
PG 9
WC Ophthalmology
SC Ophthalmology
GA DE4UQ
UT WOS:000370626300042
PM 26686964
ER
PT J
AU Bruckel, J
Carballo, V
Kalibatas, O
Soule, M
Wynne, KE
Ryan, MP
Shaw, T
Co, JPT
AF Bruckel, Jeffrey
Carballo, Victoria
Kalibatas, Orinta
Soule, Michael
Wynne, Kathryn E.
Ryan, Megan P.
Shaw, Tim
Co, John Patrick T.
TI Use of spaced education to deliver a curriculum in quality, safety and
value for postgraduate medical trainees: trainee satisfaction and
knowledge
SO POSTGRADUATE MEDICAL JOURNAL
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; SYSTEMS-BASED PRACTICE; ERROR; IMPROVEMENT;
RETENTION; MANAGEMENT; STUDENTS; MEMORY; TEACH; TESTS
AB Purpose Quality, patient safety and value are important topics for graduate medical education (GME). Spaced education delivers case-based content in a structured longitudinal experience. Use of spaced education to deliver quality and safety education in GME at an institutional level has not been previously evaluated.
Objectives To implement a spaced education course in quality, safety and value; to assess learner satisfaction; and to describe trainee knowledge in these areas.
Methods We developed a case-based spaced education course addressing learning objectives related to quality, safety and value. This course was offered to residents and fellows about two-thirds into the academic year (March 2014) and new trainees during orientation (June 2014). We assessed learner satisfaction by reviewing the course completion rate and a postcourse survey, and trainee knowledge by the per cent of correct responses.
Results The course was offered to 1950 trainees. A total of 305 (15.6%) enrolled in the course; 265/305 (86.9%) answered at least one question, and 106/305 (34.8%) completed the course. Fewer participants completed the March programme compared with the orientation programme (42/177 (23.7%) vs 64/128 (50.0%), p<0.001). Completion rates differed by specialty, 80/199 (40.2%) in non-surgical specialties compared with 16/106 (24.5%) in surgical specialties (p=0.008). The proportion of questions answered correctly on the first attempt was 53.2% (95% CI 49.4% to 56.9%). Satisfaction among those completing the programme was high.
Conclusions Spaced education can help deliver and assess learners' understanding of quality, safety and value principles. Offering a voluntary course may result in low completion. Learners were satisfied with their experience and were introduced to new concepts.
C1 [Bruckel, Jeffrey] Massachusetts Gen Hosp, Edward Lawrence Ctr Qual & Safety, Boston, MA 02114 USA.
[Carballo, Victoria; Kalibatas, Orinta] Partners HealthCare, Qual Safety & Value Div, Boston, MA 02114 USA.
[Soule, Michael] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Wynne, Kathryn E.; Co, John Patrick T.] Massachusetts Gen Hosp Children, Dept Pediat, Boston, MA 02114 USA.
[Ryan, Megan P.] Univ Sydney, Cent Coast Local Hlth Dist, Sydney, NSW 2006, Australia.
[Shaw, Tim] Univ Sydney, Workforce Educ & Dev Grp, Sydney, NSW 2006, Australia.
[Co, John Patrick T.] Partners HealthCare, Grad Med Educ, 7 Whittier Pl,Suite 108, Boston, MA 02114 USA.
RP Co, JPT (reprint author), Partners HealthCare, Grad Med Educ, 7 Whittier Pl,Suite 108, Boston, MA 02114 USA.
EM jco@mgh.harvard.edu
FU Partners HealthCare
FX Institutional funds from Partners HealthCare.
NR 38
TC 0
Z9 0
U1 2
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0032-5473
EI 1469-0756
J9 POSTGRAD MED J
JI Postgrad. Med. J.
PD MAR
PY 2016
VL 92
IS 1085
BP 137
EP 144
DI 10.1136/postgradmedj-2015-133446
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DE7PV
UT WOS:000370830100005
PM 26739846
ER
PT J
AU Ghosh, CC
David, S
Zhang, RY
Berghelli, A
Milam, K
Higgins, SJ
Hunter, J
Mukherjee, A
Wei, YY
Tran, M
Suber, F
Kobzik, L
Kain, KC
Lu, SL
Santel, A
Yano, K
Guha, P
Dumont, DJ
Christiani, DC
Parikh, SM
AF Ghosh, Chandra C.
David, Sascha
Zhang, Ruyang
Berghelli, Anthony
Milam, Katelyn
Higgins, Sarah J.
Hunter, Jon
Mukherjee, Aditi
Wei, Yongyue
Tran, Mei
Suber, Freeman
Kobzik, Lester
Kain, Kevin C.
Lu, Shulin
Santel, Ansgar
Yano, Kiichiro
Guha, Prajna
Dumont, Daniel J.
Christiani, David C.
Parikh, Samir M.
TI Gene control of tyrosine kinase TIE2 and vascular manifestations of
infections
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE Tie2; endothelium; infection; angiopoietin; permeability
ID MULTIPLE ORGAN DYSFUNCTION; ACUTE LUNG INJURY; SEVERE SEPSIS; SEPTIC
SHOCK; IN-VIVO; RNA INTERFERENCE; ANGIOPOIETIN 2; CELL; PERMEABILITY;
PROTEIN
AB Ligands of the endothelial-enriched tunica interna endothelial cell kinase 2 (Tie2) are markedly imbalanced in severe infections associated with vascular leakage, yet regulation of the receptor itself has been understudied in this context. Here, we show that TIE2 gene expression may constitute a novel vascular barrier control mechanism in diverse infections. Tie2 expression declined rapidly in wide-ranging models of leak-associated infections, including anthrax, influenza, malaria, and sepsis. Forced Tie2 suppression sufficed to attenuate barrier function and sensitize endothelium to permeability mediators. Rapid reduction of pulmonary Tie2 in otherwise healthy animals attenuated downstream kinase signaling to the barrier effector vascular endothelial (VE)-cadherin and induced vascular leakage. Compared with wild-type littermates, mice possessing one allele of Tie2 suffered more severe vascular leakage and higher mortality in two different sepsis models. Common genetic variants that influence TIE2 expression were then sought in the HapMap3 cohort. Remarkably, each of the three strongest predicted cis-acting SNPs in HapMap3 was also associated with the risk of acute respiratory distress syndrome (ARDS) in an intensive care unit cohort of 1,614 subjects. The haplotype associated with the highest TIE2 expression conferred a 28% reduction in the risk of ARDS independent of other major clinical variables, including disease severity. In contrast, the most common haplotype was associated with both the lowest TIE2 expression and 31% higher ARDS risk. Together, the results implicate common genetic variation at the TIE2 locus as a determinant of vascular leak-related clinical outcomes from common infections, suggesting new tools to identify individuals at unusual risk for deleterious complications of infection.
C1 [Ghosh, Chandra C.; David, Sascha; Berghelli, Anthony; Milam, Katelyn; Higgins, Sarah J.; Hunter, Jon; Mukherjee, Aditi; Tran, Mei; Lu, Shulin; Yano, Kiichiro; Parikh, Samir M.] Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Boston, MA 02215 USA.
[Ghosh, Chandra C.; David, Sascha; Berghelli, Anthony; Milam, Katelyn; Higgins, Sarah J.; Hunter, Jon; Mukherjee, Aditi; Tran, Mei; Lu, Shulin; Yano, Kiichiro; Parikh, Samir M.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Ghosh, Chandra C.; David, Sascha; Berghelli, Anthony; Milam, Katelyn; Higgins, Sarah J.; Hunter, Jon; Mukherjee, Aditi; Tran, Mei; Lu, Shulin; Yano, Kiichiro; Parikh, Samir M.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[David, Sascha] Hannover Med Sch, Div Hypertens & Nephrol, D-30625 Hannover, Germany.
[Zhang, Ruyang; Wei, Yongyue; Christiani, David C.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
[Zhang, Ruyang; Wei, Yongyue; Christiani, David C.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Zhang, Ruyang; Wei, Yongyue; Suber, Freeman; Kobzik, Lester; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Higgins, Sarah J.; Kain, Kevin C.] Univ Toronto, Sandra Rotman Ctr Global Hlth, Univ Hlth Network, 100 Coll St, Toronto, ON M5S 1A1, Canada.
[Higgins, Sarah J.; Kain, Kevin C.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada.
[Santel, Ansgar] Silence Therapeut GmbH, D-13125 Berlin, Germany.
[Guha, Prajna] Roger Williams Med Ctr, Providence, RI 02908 USA.
[Dumont, Daniel J.] Univ Toronto, Sunnybrook Inst, Toronto, ON M4N 3M5, Canada.
RP Ghosh, CC; Parikh, SM (reprint author), Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Boston, MA 02215 USA.; Ghosh, CC; Parikh, SM (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.; Ghosh, CC; Parikh, SM (reprint author), Harvard Univ, Sch Med, Boston, MA 02215 USA.
EM cghosh@bidmc.harvard.edu; sparikh1@bidmc.harvard.edu
FU NIH [HL093234, HL093234-S1, HL125275]; German Research Foundation [DFG
DA1209/1-1]; Canada Research Chair; Canadian Institutes of Health
Research [MOP-115160, 136813, 13721]
FX We thank Prof. Manolis Dermitzakis (University of Geneva) for detailed
advice on cis-eQTL analysis. This study was supported by research
funding from the NIH (Grants HL093234, HL093234-S1, and HL125275 to
S.M.P.). S.D. was supported by the German Research Foundation (Grant DFG
DA1209/1-1). K.C.K. was supported by a Canada Research Chair and grants
from the Canadian Institutes of Health Research (Grants MOP-115160,
136813, and 13721).
NR 53
TC 8
Z9 8
U1 1
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 1
PY 2016
VL 113
IS 9
BP 2472
EP 2477
DI 10.1073/pnas.1519467113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF2WG
UT WOS:000371204500055
PM 26884170
ER
PT J
AU Wong, ASL
Choi, GCG
Cui, CH
Pregernig, G
Milani, P
Adam, M
Perli, SD
Kazer, SW
Gaillard, A
Hermann, M
Shalek, AK
Fraenkel, E
Lu, TK
AF Wong, Alan S. L.
Choi, Gigi C. G.
Cui, Cheryl H.
Pregernig, Gabriela
Milani, Pamela
Adam, Miriam
Perli, Samuel D.
Kazer, Samuel W.
Gaillard, Aleth
Hermann, Mario
Shalek, Alex K.
Fraenkel, Ernest
Lu, Timothy K.
TI Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE CRISPR-Cas; CombiGEM; multifactorial genetics; genetic perturbations;
high-throughput screening
ID HUMAN-CELLS; FUNCTIONAL GENOMICS; COMBINATORIAL GENETICS;
LYMPHOMA-CELLS; CANCER; CAS9; THERAPY; CRISPR/CAS9; INHIBITOR; DISCOVERY
AB The orchestrated action of genes controls complex biological phenotypes, yet the systematic discovery of gene and drug combinations that modulate these phenotypes in human cells is labor intensive and challenging to scale. Here, we created a platform for the massively parallel screening of barcoded combinatorial gene perturbations in human cells and translated these hits into effective drug combinations. This technology leverages the simplicity of the CRISPR-Cas9 system for multiplexed targeting of specific genomic loci and the versatility of combinatorial genetics en masse (CombiGEM) to rapidly assemble barcoded combinatorial genetic libraries that can be tracked with high-throughput sequencing. We applied CombiGEM-CRISPR to create a library of 23,409 barcoded dual guide-RNA (gRNA) combinations and then perform a high-throughput pooled screen to identify gene pairs that inhibited ovarian cancer cell growth when they were targeted. We validated the growth-inhibiting effects of specific gene sets, including epigenetic regulators KDM4C/BRD4 and KDM6B/BRD4, via individual assays with CRISPR-Cas-based knockouts and RNA-interference-based knockdowns. We also tested small-molecule drug pairs directed against our pairwise hits and showed that they exerted synergistic antiproliferative effects against ovarian cancer cells. We envision that the CombiGEM-CRISPR platform will be applicable to a broad range of biological settings and will accelerate the systematic identification of genetic combinations and their translation into novel drug combinations that modulate complex human disease phenotypes.
C1 [Wong, Alan S. L.; Choi, Gigi C. G.; Cui, Cheryl H.; Perli, Samuel D.; Hermann, Mario; Lu, Timothy K.] MIT, Synthet Biol Grp, Synthet Biol Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Wong, Alan S. L.; Choi, Gigi C. G.; Hermann, Mario; Lu, Timothy K.] MIT, Res Lab Elect, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Cui, Cheryl H.] Harvard Univ MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Pregernig, Gabriela; Milani, Pamela; Adam, Miriam; Fraenkel, Ernest; Lu, Timothy K.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Perli, Samuel D.; Lu, Timothy K.] MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Kazer, Samuel W.; Gaillard, Aleth; Shalek, Alex K.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Kazer, Samuel W.; Gaillard, Aleth; Shalek, Alex K.] MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Kazer, Samuel W.; Gaillard, Aleth; Shalek, Alex K.] Ragon Inst Massachusetts Gen Hosp MIT & Harvard U, Cambridge, MA 02139 USA.
[Kazer, Samuel W.; Gaillard, Aleth; Shalek, Alex K.] Broad Inst MIT & Harvard Univ, Cambridge, MA 02142 USA.
RP Lu, TK (reprint author), MIT, Synthet Biol Grp, Synthet Biol Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lu, TK (reprint author), MIT, Res Lab Elect, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lu, TK (reprint author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lu, TK (reprint author), MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM timlu@mit.edu
OI Fraenkel, Ernest/0000-0001-9249-8181
FU NIH [DP2OD008435, P50GM098792, R01 NS089076]; Office of Naval Research
[N00014-13-1-0424]; Defense Threat Reduction Agency [HDTRA1-15-1-0050];
Ellison Foundation New Scholar in Aging Award; Croucher Foundation;
Natural Sciences and Engineering Research Council of Canada
FX We thank members of the T.K.L. laboratory for helpful discussions, T.
Ochiya for OVCAR8-ADR cells, the MIT BioMicro Center for technical
support on Illumina Sequencing, and C. Liu for technical assistance.
This work was supported by the NIH (DP2OD008435, P50GM098792, and R01
NS089076), the Office of Naval Research (N00014-13-1-0424), the Defense
Threat Reduction Agency (HDTRA1-15-1-0050), and the Ellison Foundation
New Scholar in Aging Award. A.S.L.W. and C.H.C. were supported by the
Croucher Foundation and a Natural Sciences and Engineering Research
Council of Canada postgraduate fellowship, respectively.
NR 55
TC 16
Z9 16
U1 9
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 1
PY 2016
VL 113
IS 9
BP 2544
EP 2549
DI 10.1073/pnas.1517883113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF2WG
UT WOS:000371204500067
PM 26864203
ER
PT J
AU Chen, Y
Seepersaud, R
Bensing, BA
Sullam, PM
Rapoport, TA
AF Chen, Yu
Seepersaud, Ravin
Bensing, Barbara A.
Sullam, Paul M.
Rapoport, Tom A.
TI Mechanism of a cytosolic O-glycosyltransferase essential for the
synthesis of a bacterial adhesion protein
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE O-glycosylation; bacterial adhesin; crystal structure; Ser/Thr-rich
repeats; enzymatic mechanism
ID CELLULOSE-BINDING DOMAIN; RICH REPEAT PROTEINS; ACCESSORY SEC LOCUS;
WALL TEICHOIC-ACID; STREPTOCOCCUS-GORDONII; STAPHYLOCOCCUS-AUREUS;
SURFACE PROTEIN; LINKED GLYCOSYLATION; GLCNAC TRANSFERASE; ENZYMATIC
ANALYSIS
AB O-glycosylation of Ser and Thr residues is an important process in all organisms, which is only poorly understood. Such modification is required for the export and function of adhesin proteins that mediate the attachment of pathogenic Gram-positive bacteria to host cells. Here, we have analyzed the mechanism by which the cytosolic O-glycosyltransferase GtfA/B of Streptococcus gordonii modifies the Ser/Thr-rich repeats of adhesin. The enzyme is a tetramer containing two molecules each of GtfA and GtfB. The two subunits have the same fold, but only GtfA contains an active site, whereas GtfB provides the primary binding site for adhesin. During a first phase of glycosylation, the conformation of GtfB is restrained by GtfA to bind substrate with unmodified Ser/Thr residues. In a slow second phase, GtfB recognizes residues that are already modified with N-acetylglucosamine, likely by converting into a relaxed conformation in which one interface with GtfA is broken. These results explain how the glycosyltransferase modifies a progressively changing substrate molecule.
C1 [Chen, Yu; Rapoport, Tom A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Chen, Yu; Rapoport, Tom A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Seepersaud, Ravin; Bensing, Barbara A.; Sullam, Paul M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Seepersaud, Ravin; Bensing, Barbara A.; Sullam, Paul M.] Univ Calif San Francisco, San Francisco, CA 94121 USA.
RP Rapoport, TA (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.; Rapoport, TA (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.; Sullam, PM (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Sullam, PM (reprint author), Univ Calif San Francisco, San Francisco, CA 94121 USA.
EM paul.sullam@ucsf.edu; tom_rapoport@hms.harvard.edu
FU National Institute of General Medical Sciences from the National
Institutes of Health (NIH) [P41 GM103403]; DOE Office of Science by
Argonne National Laboratory [DE-AC02-06CH11357]; Howard Hughes Medical
Institute (HHMI)-Helen Hay Whitney Foundation fellowship; NIH
[GM052586]; Department of Veterans Affairs, NIH [R01-AI041513,
R01-AI106987]; Northern California Institute for Research and Education
FX We thank the staff at the Advanced Photon Source of the Northeastern
Collaborative Access Team (NE-CAT) beamline for help with data
collection; Phil Jeffrey (Princeton University), Surajit Banerjee
(NE-CAT), and Simon Jenni (Harvard Medical School) for help with
crystallographic data merging and anisotropy correction; and Stephen
Harrison for advice on initial backbone tracing. NE-CAT is supported by
National Institute of General Medical Sciences Grant P41 GM103403 from
the National Institutes of Health (NIH). This research used resources of
the Advanced Photon Source, a US Department of Energy (DOE) Office of
Science User Facility operated for the DOE Office of Science by Argonne
National Laboratory under Contract DE-AC02-06CH11357. Y.C. was supported
by a Howard Hughes Medical Institute (HHMI)-Helen Hay Whitney Foundation
fellowship. The work in the T.A.R. laboratory was supported by NIH Grant
GM052586. T.A.R. is an HHMI Investigator. P.M.S. is supported by the
Department of Veterans Affairs, NIH Grants R01-AI041513 and
R01-AI106987, and the Northern California Institute for Research and
Education.
NR 53
TC 2
Z9 2
U1 5
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 1
PY 2016
VL 113
IS 9
BP E1190
EP E1199
DI 10.1073/pnas.1600494113
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF2WG
UT WOS:000371204500011
PM 26884191
ER
PT J
AU Deribe, YL
Shi, YX
Rai, K
Nezi, L
Amin, SB
Wu, CC
Akdemir, KC
Mahdavi, M
Peng, Q
Chang, QE
Hornigold, K
Arold, ST
Welch, HCE
Garraway, LA
Chin, L
AF Deribe, Yonathan Lissanu
Shi, Yanxia
Rai, Kunal
Nezi, Luigi
Amin, Samir B.
Wu, Chia-Chin
Akdemir, Kadir C.
Mahdavi, Mozhdeh
Peng, Qian
Chang, Qing Edward
Hornigold, Kirsti
Arold, Stefan T.
Welch, Heidi C. E.
Garraway, Levi A.
Chin, Lynda
TI Truncating PREX2 mutations activate its GEF activity and alter gene
expression regulation in NRAS-mutant melanoma
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE PREX2; melanoma; Rac1; PI3K/Akt; mouse models of cancer
ID BECKWITH-WIEDEMANN SYNDROME; DEPENDENT KINASE INHIBITOR; NUCLEOTIDE
EXCHANGE FACTOR; FAMILY SMALL GTPASES; BETA-GAMMA-SUBUNITS;
TUMOR-SUPPRESSOR; HOMOLOGY DOMAIN; BREAST-CANCER; IN-VITRO; PTEN
AB PREX2 (phosphatidylinositol-3,4,5-triphosphate-dependent Rac-exchange factor 2) is a PTEN (phosphatase and tensin homolog deleted on chromosome 10) binding protein that is significantly mutated in cutaneous melanoma and pancreatic ductal adenocarcinoma. Here, genetic and biochemical analyses were conducted to elucidate the nature and mechanistic basis of PREX2 mutation in melanoma development. By generating an inducible transgenic mouse model we showed an oncogenic role for a truncating PREX2 mutation (PREX2(E824)*) in vivo in the context of mutant NRAS. Using integrative cross-species gene expression analysis, we identified deregulated cell cycle and cytoskeleton organization as significantly perturbed biological pathways in PREX2 mutant tumors. Mechanistically, truncation of PREX2 activated its Rac1 guanine nucleotide exchange factor activity, abolished binding to PTEN and activated the PI3K (phosphatidyl inositol 3 kinase)/Akt signaling pathway. We further showed that PREX2 truncating mutations or PTEN deletion induces down-regulation of the tumor suppressor and cell cycle regulator CDKN1C (also known as p57(KIP2)). This down-regulation occurs, at least partially, through DNA hypomethylation of a differentially methylated region in chromosome 11 that is a known regulatory region for expression of the CDKN1C gene. Together, these findings identify PREX2 as a mediator of NRAS-mutant melanoma development that acts through the PI3K/PTEN/Akt pathway to regulate gene expression of a cell cycle regulator.
C1 [Deribe, Yonathan Lissanu; Shi, Yanxia; Rai, Kunal; Nezi, Luigi; Amin, Samir B.; Wu, Chia-Chin; Akdemir, Kadir C.; Mahdavi, Mozhdeh; Peng, Qian; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
[Shi, Yanxia] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborate Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China.
[Chang, Qing Edward; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, IACS, Houston, TX 77030 USA.
[Hornigold, Kirsti; Welch, Heidi C. E.] Babraham Inst, Babraham Res Campus, Cambridge CB22 3AT, England.
[Arold, Stefan T.] King Abdullah Univ Sci & Technol, Div Biol & Environm Sci & Engn, Thuwal 239556900, Saudi Arabia.
[Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Garraway, Levi A.] Broad Inst MIT & Harvard, Boston, MA 02141 USA.
RP Deribe, YL; Chin, L (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.; Chin, L (reprint author), Univ Texas MD Anderson Canc Ctr, IACS, Houston, TX 77030 USA.
EM ylissanu@mdanderson.org; lchin@mdanderson.org
OI Amin, Samir/0000-0002-3207-9505
FU Cancer Prevention and Research Institute of Texas (CPRIT); King Abdullah
University of Science and Technology
FX We thank Timothy Heffernan and Trang Tieu of the Institute for Applied
Cancer Science for help with various plasmids, Jim Horner and Erin Paul
of the MD Anderson GEM facility for pronuclear injection of PREX2
transgene, and Chang-Gong Liu of MD Anderson Sequencing and Non-coding
RNA Core Facility for microarray profiling and Denise Spring for
critical reading of the manuscript. L.C is a recipient of the Cancer
Prevention and Research Institute of Texas (CPRIT) Established
Investigator Recruitment Award. S.T.A. was supported by the King
Abdullah University of Science and Technology.
NR 50
TC 7
Z9 7
U1 3
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 1
PY 2016
VL 113
IS 9
BP E1296
EP E1305
DI 10.1073/pnas.1513801113
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF2WG
UT WOS:000371204500022
ER
PT J
AU Greenblatt, MB
Shin, DY
Oh, H
Lee, KY
Zhai, B
Gygi, SP
Lotinun, S
Baron, R
Liu, D
Su, B
Glimcher, LH
Shim, JH
AF Greenblatt, Matthew Blake
Shin, Dong Yeon
Oh, Hwanhee
Lee, Ki-Young
Zhai, Bo
Gygi, Steven P.
Lotinun, Sutada
Baron, Roland
Liu, Dou
Su, Bing
Glimcher, Laurie H.
Shim, Jae-Hyuck
TI MEKK2 mediates an alternative beta-catenin pathway that promotes bone
formation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE osteoblasts; beta-catenin; bone; MEKK2; MAPK
ID DEPENDENT PROTEIN-KINASE; CONTROLS OSTEOBLAST; GROWTH-FACTOR; MICE; WNT;
PHOSPHORYLATION; ACTIVATION; DIFFERENTIATION; RECEPTOR; GENE
AB Proper tuning of beta-catenin activity in osteoblasts is required for bone homeostasis, because both increased and decreased beta-catenin activity have pathologic consequences. In the classical pathway for beta-catenin activation, stimulation with WNT ligands suppresses constitutive phosphorylation of beta-catenin by glycogen synthase kinase 3 beta, preventing beta-catenin ubiquitination and proteasomal degradation. Here, we have found that mitogen-activated protein kinase kinase kinase 2 (MAP3K2 or MEKK2) mediates an alternative pathway for beta-catenin activation in osteoblasts that is distinct from the canonical WNT pathway. FGF2 activates MEKK2 to phosphorylate eta-catenin at serine 675, promoting recruitment of the deubiquitinating enzyme, ubiquitin-specific peptidase 15 (USP15). USP15 in turn prevents the basal turnover of beta-catenin by inhibiting its ubiquitin-dependent proteasomal degradation, thereby enhancing WNT signaling. Analysis of MEKK2-deficient mice and genetic interaction studies between Mekk2- and beta-catenin-null alleles confirm that this pathway is an important physiologic regulator of bone mass in vivo. Thus, an FGF2/MEKK2 pathway mediates an alternative nonclassical pathway for beta-catenin activation, and this pathway is a key regulator of bone formation by osteoblasts.
C1 [Greenblatt, Matthew Blake; Shin, Dong Yeon; Oh, Hwanhee; Shim, Jae-Hyuck] Dept Pathol & Lab Med Weill Cornell Med, New York, NY 10065 USA.
[Lee, Ki-Young] Sungkyunkwan Univ, Dept Mol Cell Biol, Sch Med, Suwon 440746, South Korea.
[Lee, Ki-Young] Sungkyunkwan Univ, Samsung Biomed Res Inst, Sch Med, Suwon 440746, South Korea.
[Zhai, Bo; Gygi, Steven P.] Harvard Univ, Dept Cell Biol, Sch Med, Boston, MA 02115 USA.
[Lotinun, Sutada; Baron, Roland] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Lotinun, Sutada] Chulalongkorn Univ, Dept Physiol, Fac Dent, Bangkok 10330, Thailand.
[Lotinun, Sutada] Chulalongkorn Univ, STAR Craniofacial & Skeletal Disorders, Fac Dent, Bangkok 10330, Thailand.
[Baron, Roland] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02215 USA.
[Baron, Roland] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Liu, Dou; Su, Bing] Yale Univ, Sch Med, Dept Immunobiol, 333 Cedar St, New Haven, CT 06520 USA.
[Liu, Dou; Su, Bing] Yale Univ, Sch Med, Vasc Biol & Therapeut Program, 333 Cedar St, New Haven, CT 06520 USA.
[Su, Bing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Shanghai 200030, Peoples R China.
[Su, Bing] Shanghai Jiao Tong Univ, Sch Med, Dept Immunol & Microbiol, Shanghai 200025, Peoples R China.
[Glimcher, Laurie H.] Weill Cornell Med, Dept Med, New York, NY 10065 USA.
RP Greenblatt, MB; Shim, JH (reprint author), Dept Pathol & Lab Med Weill Cornell Med, New York, NY 10065 USA.; Glimcher, LH (reprint author), Weill Cornell Med, Dept Med, New York, NY 10065 USA.
EM mag3003@med.cornell.edu; lglimche@med.cornell.edu;
jas2060@med.cornell.edu
FU Burroughs Wellcome Fund; NIH [1DP5OD021351]; Musculoskeletal Transplant
Foundation; National Natural Science Foundation of China [31470845,
81430033]
FX We thank Drs. Antonios Aliprantis, Weiguo Zou, and Marc Wein for helpful
discussions; Nicholas Brandy, Yeon-Suk Yang, and Steven Doty for
technical support; and the many individuals who provided valuable
reagents. M.B.G. holds a Career Award for Medical Scientists from the
Burroughs Wellcome Fund and is supported by NIH Director's Early
Independence Award 1DP5OD021351. J.-H.S. is supported by a
Musculoskeletal Transplant Foundation award, and this work is partially
supported by National Natural Science Foundation of China Grants
31470845 and 81430033 (to B.S.).
NR 40
TC 3
Z9 3
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 1
PY 2016
VL 113
IS 9
BP E1226
EP E1235
DI 10.1073/pnas.1600813113
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF2WG
UT WOS:000371204500015
PM 26884171
ER
PT J
AU Japuntich, SJ
Gregor, K
Pineles, SL
Gradus, JL
Street, AE
Prabhala, R
Rasmusson, AM
AF Japuntich, Sandra J.
Gregor, Kristin
Pineles, Suzanne L.
Gradus, Jaimie L.
Street, Amy E.
Prabhala, Rao
Rasmusson, Ann M.
TI Deployment Stress, Tobacco Use, and Postdeployment Posttraumatic Stress
Disorder: Gender Differences
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE deployment; posttraumatic stress disorder; tobacco; trauma; veterans
ID MILITARY DEPLOYMENT; SMOKING; PERSONNEL
AB Objective: Epidemiological research has demonstrated that tobacco use and posttraumatic stress disorder (PTSD) frequently co-occur and are highly prevalent among Veterans; research with female Veterans is limited. Given the increasing numbers of women deployed to combat zones in recent conflicts, the objective of the current study was to examine gender-specific associations between deployment stress, tobacco use and postdeployment PTSD symptoms. Method: Two thousand thirteen Veterans deployed to Afghanistan and Iraq (50.9% female; mean age = 35.53) completed a postdeployment, mailed survey that assessed tobacco use before, during, and after deployment, deployment stressors, and postdeployment PTSD symptoms. Results: Warfare stress was associated with initiation and increases in tobacco use during deployment in both men and women, whereas harassment stress was associated with initiation and increases in tobacco use in women only. Only among women was continued postdeployment tobacco use associated with postdeployment PTSD symptoms. Conclusions: We found a dose-dependent relationship between deployment stress and adoption and escalation of tobacco use; the stressors that provoked initiation and escalation of tobacco use differed by gender. Continued tobacco use after deployment was associated with PTSD in women suggesting that women used tobacco more selectively than men to regulate negative affect. Implications of this work are that training before combat and during combat on healthy means of coping with deployment stress is needed to prevent tobacco use. For women, reducing harassment stress during deployment and early treatment of acute stress and PTSD during and soon after deployment may prevent intractable tobacco use.
C1 [Japuntich, Sandra J.; Gregor, Kristin; Pineles, Suzanne L.; Gradus, Jaimie L.; Street, Amy E.; Rasmusson, Ann M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Japuntich, Sandra J.; Gregor, Kristin; Pineles, Suzanne L.; Gradus, Jaimie L.; Street, Amy E.; Rasmusson, Ann M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA.
[Prabhala, Rao] VA Boston Healthcare Syst, Boston, MA USA.
[Prabhala, Rao] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
RP Japuntich, SJ (reprint author), 150 South Huntington Ave,116B-3, Boston, MA 02130 USA.
EM sandra.japuntich@va.gov
FU United States Department of Veterans Affairs Clinical Sciences Research
and Development Service [1IK2CX000918-01A1]
FX This work was supported in part by Career Development Award (Japuntich)
#1IK2CX000918-01A1 from the United States Department of Veterans Affairs
Clinical Sciences Research and Development Service. The authors declare
that there are no conflicts of interest. The views expressed in this
article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs or the United
States government.
NR 17
TC 0
Z9 0
U1 2
U2 12
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD MAR
PY 2016
VL 8
IS 2
BP 123
EP 126
DI 10.1037/tra0000093
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DF1DU
UT WOS:000371079700001
PM 26654688
ER
PT J
AU Boasso, AM
Steenkamp, MM
Fox, AB
Nash, WP
Larson, JL
Litz, BT
AF Boasso, Alyssa M.
Steenkamp, Maria M.
Fox, Annie B.
Nash, William P.
Larson, Jonathan L.
Litz, Brett T.
TI The Structure of PTSD in Active-Duty Marines Across the Deployment Cycle
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE active-duty; CFA; five-factor model; PTSD
ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; MILITARY
PERSONNEL; VETERANS; SYMPTOMS; SCALE; DSM-5; MODEL; DIMENSIONALITY;
AFGHANISTAN
AB Objective: There has been significant debate about the optimal factor structure of posttraumatic stress disorder (PTSD). In military and veteran samples, most available studies have employed self-report measures, assessed PTSD cross-sectionally, used treatment-seeking samples, and assessed symptoms years after deployment. We extend previous studies by comparing the factor structure of clinician-assessed and self-report Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) PTSD in a nontreatment seeking sample at 4 time points spanning the deployment cycle. Method: The data source for this study was the Marine Resiliency Study (MRS), a longitudinal study of 4 battalion cohorts of active-duty male Marines deployed to Iraq and Afghanistan between 2008 and 2012. We examined the fourth cohort (N = 892), which was evaluated 1 month predeployment, and 1, 5, and 8 months postdeployment. Results: Confirmatory factor analyses (CFA) revealed that the 5-factor solution best fit the data across all time points, and across both interview and self-report assessments. Conclusion: The temporal consistency and convergence demonstrated by our analyses underscores the validity of the 5-factor model among service members exposed to warzone stressors. In particular, the findings suggest that diagnostic criteria for PTSD may benefit from disaggregating hyperarousal symptoms in military samples.
C1 [Boasso, Alyssa M.; Larson, Jonathan L.; Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
[Steenkamp, Maria M.] NYU, Sch Med, New York, NY 10003 USA.
[Fox, Annie B.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA USA.
[Nash, William P.] Boston VA Res Inst Inc, Boston, MA USA.
VA Boston Healthcare Syst, Boston, MA USA.
[Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Boasso, Alyssa M.] Thync Inc, Boston, MA USA.
RP Litz, BT (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave,13-B71, Jamaica Plain, MA 02130 USA.
EM brett.litz@va.gov
FU VA Health Service Research and Development [SDR 09-0128]; U.S. Marine
Corps; Navy Bureau of Medicine and Surgery
FX This study was funded by VA Health Service Research and Development (SDR
09-0128) and by the U.S. Marine Corps and Navy Bureau of Medicine and
Surgery. The authors acknowledge the Marine Resiliency Study (MRS) team
who made this work possible.
NR 49
TC 2
Z9 2
U1 0
U2 4
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD MAR
PY 2016
VL 8
IS 2
BP 127
EP 134
DI 10.1037/tra0000109
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DF1DU
UT WOS:000371079700002
PM 26914679
ER
PT J
AU Fox, AB
Walker, BE
Smith, BN
King, DW
King, LA
Vogt, D
AF Fox, Annie B.
Walker, Brian E.
Smith, Brian N.
King, Daniel W.
King, Lynda A.
Vogt, Dawne
TI Understanding How Deployment Experiences Change Over Time: Comparison of
Female and Male OEF/OIF and Gulf War Veterans
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
ID POSTTRAUMATIC STRESS SYMPTOMATOLOGY; MENTAL-HEALTH; GENDER-DIFFERENCES;
SEXUAL ASSAULT; IRAQI FREEDOM; RISK-FACTORS; RESILIENCE; PERSONNEL;
SUPPORT
AB Despite increased attention to the evolving nature of war, the unique challenges of contemporary deployment, and women's changing role in warfare, few studies have examined differences in deployment stressors across eras of service or evaluated how gender differences in deployment experiences have changed over time. Using data collected from two national survey studies, we examined war cohort and gender differences in veterans' reports of both mission-related and interpersonal stressors during deployment. Although Operation Enduring Freedom and Operation Iraqi Freedom veterans reported more combat experiences and greater preparedness for deployment compared to Gulf War veterans, Gulf War veterans reported higher levels of other mission-related stressors, including difficult living and working environment, perceived threat, and potential exposure to nuclear, biological, and chemical weapons. Gender differences also emerged, with men reporting greater exposure to mission-related stressors and women reporting higher levels of interpersonal stressors. However, the size and nature of gender differences did not differ significantly when comparing veterans of the two eras. By understanding how risk factors for PTSD differ based on war era and gender, veterans' experiences can be better contextualized.
C1 [Fox, Annie B.; Walker, Brian E.; Smith, Brian N.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA.
[Smith, Brian N.; King, Daniel W.; King, Lynda A.; Vogt, Dawne] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02215 USA.
[King, Daniel W.] VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA 02130 USA.
[King, Daniel W.; King, Lynda A.] Boston Univ, Sch Med, Dept Psychol, Boston, MA 02215 USA.
[King, Lynda A.; Vogt, Dawne] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA.
RP Fox, AB (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 3, 150 South Huntington Ave, Boston, MA 02130 USA.
EM annie.fox-galalis@va.gov
FU Department of Veterans Affairs, Health Services Research and Development
Service grant [DHI 09-086]; Department of Defense/Department of Veterans
Affairs [DoD-87]
FX This study was supported by a Department of Veterans Affairs, Health
Services Research and Development Service grant ("Validation of Modified
DRRI Scales in a National Sample of OEF/OIF Veterans," Project DHI
09-086, Dawne Vogt, principal investigator), as well as a Department of
Defense/Department of Veterans Affairs grant ("Measurement and
Validation of Psychosocial Risk and Resilience Factors Associated With
Physical and Mental Health-Related Quality of Life in Persian Gulf War
Veterans," Project DoD-87, Daniel W. King and Lynda A. King,
co-principal investigators).
NR 21
TC 2
Z9 2
U1 4
U2 9
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD MAR
PY 2016
VL 8
IS 2
BP 135
EP 140
DI 10.1037/tra0000033
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DF1DU
UT WOS:000371079700003
PM 25866959
ER
PT J
AU Carlson, EB
Field, NP
Ruzek, JI
Bryant, RA
Dalenberg, CJ
Keane, TM
Spain, DA
AF Carlson, Eve B.
Field, Nigel P.
Ruzek, Josef I.
Bryant, Richard A.
Dalenberg, Constance J.
Keane, Terrence M.
Spain, David A.
TI Advantages and psychometric validation of proximal intensive assessments
of patient-reported outcomes collected in daily life
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Experience sampling method; Ecological momentary assessment; Intensive
longitudinal data; Ambulatory assessment; Traumatic stress;
Patient-reported outcomes
ID POSTTRAUMATIC-STRESS-DISORDER; EXPERIENCE-SAMPLING METHOD; MOMENTARY
ASSESSMENT; DAILY EVENTS; VALIDITY; FEASIBILITY; SCHIZOPHRENIA;
CONSTRUCTION; INDIVIDUALS; RELIABILITY
AB Ambulatory assessment data collection methods are increasingly used to study behavior, experiences, and patient-reported outcomes (PROs), such as emotions, cognitions, and symptoms in clinical samples. Data collected close in time at frequent and fixed intervals can assess PROs that are discrete or changing rapidly and provide information about temporal dynamics or mechanisms of change in clinical samples and individuals, but clinical researchers have not yet routinely and systematically investigated the reliability and validity of such measures or their potential added value over conventional measures. The present study provides a comprehensive, systematic evaluation of the psychometrics of several proximal intensive assessment (PIA) measures in a clinical sample and investigates whether PIA appears to assess meaningful differences in phenomena over time.
Data were collected on a variety of psychopathology constructs on handheld devices every 4 h for 7 days from 62 adults recently exposed to traumatic injury of themselves or a family member. Data were also collected on standard self-report measures of the same constructs at the time of enrollment, 1 week after enrollment, and 2 months after injury.
For all measure scores, results showed good internal consistency across items and within persons over time, provided evidence of convergent, divergent, and construct validity, and showed significant between- and within-subject variability.
Results indicate that PIA measures can provide valid measurement of psychopathology in a clinical sample. PIA may be useful to study mechanisms of change in clinical contexts, identify targets for change, and gauge treatment progress.
C1 [Carlson, Eve B.; Ruzek, Josef I.] Natl Ctr PTSD, Menlo Pk, CA USA.
[Carlson, Eve B.; Ruzek, Josef I.] VA Palo Alto Hlth Care Syst, Dept Vet Affairs, Menlo Pk, CA USA.
[Field, Nigel P.] Palo Alto Univ, Pacific Grad Sch Psychol, Palo Alto, CA USA.
[Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.
[Dalenberg, Constance J.] Alliant Int Univ, San Diego, CA USA.
[Keane, Terrence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Keane, Terrence M.] Boston Univ, Sch Med, Dept Psychol, Boston, MA 02118 USA.
[Keane, Terrence M.] Natl Ctr PTSD, Boston, MA USA.
[Keane, Terrence M.] VA Boston Hlth Care Syst, Dept Vet Affairs, Boston, MA USA.
[Spain, David A.] Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA.
RP Carlson, EB (reprint author), Natl Ctr PTSD, Menlo Pk, CA USA.; Carlson, EB (reprint author), VA Palo Alto Hlth Care Syst, Dept Vet Affairs, Menlo Pk, CA USA.
EM eve.carlson@va.gov
OI Carlson, Eve/0000-0002-4431-2415; Bryant, Richard/0000-0002-9607-819X
FU National Institute of Mental Health [MH69876]
FX This study was funded by the National Institute of Mental Health
(MH69876).
NR 44
TC 3
Z9 3
U1 5
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD MAR
PY 2016
VL 25
IS 3
BP 507
EP 516
DI 10.1007/s11136-015-1170-9
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA DE7EB
UT WOS:000370796700003
PM 26567018
ER
PT J
AU Chusri, P
Kumthip, K
Hong, J
Zhu, CL
Duan, XQ
Jilg, N
Fusco, DN
Brisac, C
Schaefer, EA
Cai, DC
Peng, LF
Maneekarn, N
Lin, WY
Chung, RT
AF Chusri, Pattranuch
Kumthip, Kattareeya
Hong, Jian
Zhu, Chuanlong
Duan, Xiaoqiong
Jilg, Nikolaus
Fusco, Dahlene N.
Brisac, Cynthia
Schaefer, Esperance A.
Cai, Dachuan
Peng, Lee F.
Maneekarn, Niwat
Lin, Wenyu
Chung, Raymond T.
TI HCV induces transforming growth factor beta 1 through activation of
endoplasmic reticulum stress and the unfolded protein response
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HEPATITIS-C-VIRUS; ER STRESS; MESSENGER-RNA; REPLICATION; MEMBRANE;
STAT1; PHOSPHORYLATION; TRANSCRIPTION; PERSISTENCE; EXPRESSION
AB HCV replication disrupts normal endoplasmic reticulum (ER) function and activates a signaling network called the unfolded protein response (UPR). UPR is directed by three ER transmembrane proteins including ATF6, IRE1, and PERK. HCV increases TGF-beta 1 and oxidative stress, which play important roles in liver fibrogenesis. HCV has been shown to induce TGF-beta 1 through the generation of reactive oxygen species (ROS) and p38 MAPK, JNK, ERK1/2, and NF kappa B-dependent pathways. However, the relationship between HCV-induced ER stress and UPR activation with TGF-beta 1 production has not been fully characterized. In this study, we found that ROS and JNK inhibitors block HCV up-regulation of ER stress and UPR activation. ROS, JNK and IRE1 inhibitors blocked HCV-activated NF kappa B and TGF-beta 1 expression. ROS, ER stress, NF kappa B, and TGF-beta 1 signaling were blocked by JNK specific siRNA. Knockdown IRE1 inhibited JFH1-activated NF kappa B and TGF-beta 1 activity. Knockdown of JNK and IRE1 blunted JFH1 HCV up-regulation of NF kappa B and TGF-beta 1 activation. We conclude that HCV activates NF kappa B and TGF-beta 1 through ROS production and induction of JNK and the IRE1 pathway. HCV infection induces ER stress and the UPR in a JNK-dependent manner. ER stress and UPR activation partially contribute to HCV-induced NF-kappa B activation and enhancement of TGF-beta 1.
C1 [Chusri, Pattranuch; Kumthip, Kattareeya; Hong, Jian; Zhu, Chuanlong; Duan, Xiaoqiong; Jilg, Nikolaus; Fusco, Dahlene N.; Brisac, Cynthia; Schaefer, Esperance A.; Cai, Dachuan; Peng, Lee F.; Lin, Wenyu; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Liver Ctr, Boston, MA 02114 USA.
[Chusri, Pattranuch; Kumthip, Kattareeya; Hong, Jian; Zhu, Chuanlong; Duan, Xiaoqiong; Jilg, Nikolaus; Fusco, Dahlene N.; Brisac, Cynthia; Schaefer, Esperance A.; Cai, Dachuan; Peng, Lee F.; Lin, Wenyu; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Div,Dept Med, Boston, MA 02114 USA.
[Chusri, Pattranuch; Kumthip, Kattareeya; Maneekarn, Niwat] Chiang Mai Univ, Fac Med, Dept Microbiol, Chiang Mai 50200, Thailand.
[Zhu, Chuanlong] Nanjing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China.
[Duan, Xiaoqiong] Chinese Acad Med Sci, Inst Blood Transfus, Chengdu, Peoples R China.
[Duan, Xiaoqiong] Peking Union Med Coll, Chengdu, Peoples R China.
[Cai, Dachuan] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing 400010, Peoples R China.
RP Lin, WY; Chung, RT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Liver Ctr, Boston, MA 02114 USA.; Lin, WY; Chung, RT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Div,Dept Med, Boston, MA 02114 USA.
EM wlin1@mgh.harvard.edu; rtchung@mgh.harvard.edu
FU NIH [AI069939, AI082630, DK098079]; NIH-MGH Center for Human Immunology
Pilot/Feasibility Study Grant; Royal Golden Jubilee PhD Program;
Thailand Research Fund; TRF
FX This work was supported by grants NIH AI069939 (RTC), AI082630 (RTC),
DK098079 (RTC), NIH-MGH Center for Human Immunology Pilot/Feasibility
Study Grant (WL), Royal Golden Jubilee PhD Program and the Thailand
Research Fund; TRF (PCH.). We are grateful to Dr. Francis Chisari for
providing Huh7.5.1 cells and Dr. Takaji Wakita for infectious HCV virus
JFH1 DNA construct.
NR 32
TC 3
Z9 3
U1 2
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 1
PY 2016
VL 6
AR 22487
DI 10.1038/srep22487
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF0OK
UT WOS:000371038400003
PM 26927933
ER
PT J
AU Thalin, C
Demers, M
Blomgren, B
Wong, SL
von Arbin, M
von Heijne, A
Laska, AC
Wallen, H
Wagner, DD
Aspberg, S
AF Thalin, Charlotte
Demers, Melanie
Blomgren, Bo
Wong, Siu Ling
von Arbin, Magnus
von Heijne, Anders
Laska, Ann Charlotte
Wallen, Hakan
Wagner, Denisa D.
Aspberg, Sara
TI NETosis promotes cancer-associated arterial microthrombosis presenting
as ischemic stroke with troponin elevation
SO THROMBOSIS RESEARCH
LA English
DT Article
DE Cancer-associated microvascular thrombosis; Neutrophil extracellular
traps; Troponin elevation; Ischemic stroke
ID NEUTROPHIL EXTRACELLULAR TRAPS; VENOUS THROMBOEMBOLISM; DNA TRAPS;
THROMBOSIS; MICE; RISK; RECRUITMENT; CHROMATIN; SWEDEN; COHORT
AB Introduction: Large elevations of high sensitive Troponin T (hsTnT) in ischemic stroke patients is associated with a poor outcome. In a pilot study we found a high prevalence of malignancies among these patients. Since neutrophil extracellular traps (NETs) have been linked to cancer-associated thrombosis, we hypothesized that the concomitant cerebral and myocardial ischemia could be the result of a NET-induced hypercoagulable state.
Materials and methods: Clinical assessments, plasma analyses and autopsies with histopathology (in cases of in-hospital mortality) were performed on ischemic stroke patients with high elevations of hsTnT (N = 12) and normal hsTnT (N = 19).
Results: Patients with hsTnT elevation had an unexpectedly higher prevalence of cancer (p = 0.002), half of which were diagnosed post-mortem. Autopsies of these patients revealed widespread myocardial, cerebral and pulmonary microthrombosis with H3Cit in thrombi. A pro-coagulant state and an increase of the NET specific marker citrullinated histone H3 (H3Cit) was found in plasma of patients with elevated hsTnT compared to patients with normal levels (p < 0.001). Plasma analyses in cancer patients showed even higher H3Cit levels (p < 0.001), and an increase in granulocyte colony-stimulating factor, known to prime neutrophils towards NETosis. H3Cit correlated positively with thrombin-antithrombin complex (p = 0.004) and soluble P-selectin (p < 0.001), further linking NETosis to the pro-thrombotic state.
Conclusions: The high prevalence of known or occult cancer in our study suggests that cancer-associated arterial microthrombosis may be underestimated. By linking the thrombosis to NETs, we suggest markers of NETosis that could aid in revealing cancer in arterial microthrombosis as well as arterial microthrombosis in cancer. Published by Elsevier Ltd.
C1 [Thalin, Charlotte; von Arbin, Magnus; Laska, Ann Charlotte] Karolinska Inst, Dept Clin Sci, Danderyd Hosp, Div Internal Med, Stockholm, Sweden.
[Demers, Melanie; Wong, Siu Ling; Wagner, Denisa D.] Boston Childrens Hosp, Program Cellular & Mol Med, 3 Blackfan Circle,3rd Floor, Boston, MA 02115 USA.
[Demers, Melanie; Wong, Siu Ling; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Blomgren, Bo] Karolinska Inst, Dept Clin Sci, Danderyd Hosp, Dept Oncol Pathol, Stockholm, Sweden.
[von Heijne, Anders] Karolinska Inst, Dept Clin Sci, Danderyd Hosp, Dept Radiol, Stockholm, Sweden.
[Wallen, Hakan; Aspberg, Sara] Karolinska Inst, Dept Clin Sci, Div Cardiovasc Med, Dept Radiol, Stockholm, Sweden.
[Wagner, Denisa D.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
RP Wagner, DD (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, 3 Blackfan Circle,3rd Floor, Boston, MA 02115 USA.
EM denisa.wagner@childrens.harvard.edu
FU National Heart, Lung, and Blood Institute of the National Institutes of
Health [R01HL102101]; Swedish Association of Medicine; Karolinska
Institutet
FX This work was supported by the National Heart, Lung, and Blood Institute
of the National Institutes of Health Grant R01HL102101 (Wagner), the
Swedish Association of Medicine (Aspberg) and Fund 176 and Coagulation
Research Fund 245 of Karolinska Institutet (Thalin).
NR 40
TC 8
Z9 8
U1 5
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD MAR
PY 2016
VL 139
BP 56
EP 64
DI 10.1016/j.thromres.2016.01.009
PG 9
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA DE8II
UT WOS:000370879300009
PM 26916297
ER
PT J
AU Nishino, M
Dahlberg, SE
Fulton, LE
Digumarthy, SR
Hatabu, H
Johnson, BE
Sequist, LV
AF Nishino, Mizuki
Dahlberg, Suzanne E.
Fulton, Linnea E.
Digumarthy, Subba R.
Hatabu, Hiroto
Johnson, Bruce E.
Sequist, Lecia V.
TI Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients
Treated with Erlotinib or Gefitinib
SO ACADEMIC RADIOLOGY
LA English
DT Article
DE Lung cancer; non-small cell; EGFR mutations; tyrosine kinase inhibitors;
tumor volume
ID CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; GROWTH-FACTOR RECEPTOR;
OPEN-LABEL; RECIST PROGRESSION; 1ST-LINE TREATMENT; MUTATIONS;
CHEMOTHERAPY; THERAPY; CRITERIA
AB Rationale and Objectives: The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort of epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and to assess the rate of their volumetric tumor growth after the volume nadir.
Materials and Methods: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir.
Results: In 44 patients with the 8-week follow-up CT, the 8-week tumor volume decrease (%) was significantly associated with longer overall survival when fitted as a continuous variable in a Cox model (P = 0.01). The growth rate of the logarithm of tumor volume (log(e)V), obtained using a linear mixed-effects model adjusting for time since baseline, was 0.096/month (SE: 0.013/month; 95% confidence interval [CI]: 0.071-0.12/month), which was similar to the rate of 0.12/month (SE: 0.015/month; 95%CI: 0.090-0.15/month) observed in the previous report.
Conclusions: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. The volumetric tumor growth rate after the nadir in this cohort was similar to that of the previous cohort, indicating the reproducibility of the observation among different patient cohorts.
C1 [Nishino, Mizuki; Hatabu, Hiroto] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA.
[Nishino, Mizuki; Hatabu, Hiroto; Johnson, Bruce E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
[Dahlberg, Suzanne E.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Londonderry, NH USA.
[Fulton, Linnea E.; Sequist, Lecia V.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA 02215 USA.
[Digumarthy, Subba R.] Harvard Univ, Sch Med, Dept Med, Dept Radiol, Boston, MA 02215 USA.
[Johnson, Bruce E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02215 USA.
[Johnson, Bruce E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
RP Nishino, M (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA.; Nishino, M (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM Mizuki_Nishino@DFCI.HARVARD.EDU
FU NCI [1K23CA157631]; National Institutes of Health [1RO1CA114465-07, 5R21
CA11627-02]; National Cancer Institute Specialized Program of Research
Excellence in Lung Cancer [2P50CA090578-10]; Genentech Inc; Doris and
William Krupp Research Fund in Thoracic Oncology; Gallup Fund in
Thoracic Oncology; American Society of Clinical Oncology Translational
Research Professorship
FX The investigators were supported by Grant No. 1K23CA157631 from NCI
(M.N.), Grant Nos. 1RO1CA114465-07 (B.EJ.) and 5R21 CA11627-02 (H.H.)
from the National Institutes of Health, Grant No. 2P50CA090578-10
(B.EJ.) from the National Cancer Institute Specialized Program of
Research Excellence in Lung Cancer, and a grant from Genentech Inc, as
well as by the Doris and William Krupp Research Fund in Thoracic
Oncology, the Gallup Fund in Thoracic Oncology, and American Society of
Clinical Oncology Translational Research Professorship.
NR 46
TC 4
Z9 4
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1076-6332
EI 1878-4046
J9 ACAD RADIOL
JI Acad. Radiol.
PD MAR
PY 2016
VL 23
IS 3
BP 329
EP 336
DI 10.1016/j.acra.2015.11.005
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DE2PK
UT WOS:000370469000011
PM 26776293
ER
PT J
AU Deitte, LA
Gordon, LL
Zimmerman, RD
Stern, EJ
McLoud, TC
Diaz-Marchan, PJ
Mullins, ME
AF Deitte, Lori A.
Gordon, Leonie L.
Zimmerman, Robert D.
Stern, Eric J.
McLoud, Theresa C.
Diaz-Marchan, Pedro J.
Mullins, Mark E.
TI Entrustable Professional Activities: Ten Things Radiologists Do
SO ACADEMIC RADIOLOGY
LA English
DT Article
DE Entrustable professional activities; medical education; radiology
education; medical assessment; milestones
ID MILESTONES
AB Rationale and Objectives: Learner assessment in medical education has undergone tremendous change over the past two decades. During this time frame, the concept of Entrustable Professional Activities (EPAs) was introduced to guide the faculty when making-competency based decisions on the level of supervision required by trainees. EPAs are gaining momentum in medical education as a basis for decisions related to transitioning from residency training to clinical practice. The purpose of this article is twofold: (1) define EPAs for radiology (EPA-R) and (2) illustrate radiology-specific examples of these EPAs.
Materials and Methods: A multi-institutional work group composed of members of the Alliance of Directors and Vice Chairs of Education in Radiology convened at the 2015 Association of University Radiologists annual meeting to discuss radiology EPAs. The EPAs initially developed by the Accreditation Council for Graduate Medical Education (ACGME) Radiology milestone work group and the resultant ACGME Radiology milestones formed the basis for this discussion.
Results: A total of 10 radiology EPAs and illustrative vignettes were developed to help radiology educators and trainees better understand milestone assessment and how this translates to the necessary skills and responsibilities of practicing radiologists. Examples of EPA mapping to the ACGME subcompetencies and methods of assessment were included.
Conclusions: EPAs offer an opportunity to improve our approach to training by increasing our focus on how we provide appropriate supervision to our residents and assess their progress. In this work, through suggested lists and:vignettes, we have attempted to establish the framework for further discussion and development of EPA-Rs.
C1 [Deitte, Lori A.] Vanderbilt Univ, Med Ctr, Dept Radiol, 1161 21st Ave S CCC-1118 MCN, Nashville, TN 37232 USA.
[Gordon, Leonie L.] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA.
[Zimmerman, Robert D.] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Radiol, New York, NY USA.
[Stern, Eric J.] Univ Washington, Med Ctr, Seattle, WA 98195 USA.
[McLoud, Theresa C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Diaz-Marchan, Pedro J.] Baylor Coll Med, Houston, TX 77030 USA.
[Mullins, Mark E.] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA.
RP Deitte, LA (reprint author), Vanderbilt Univ, Med Ctr, Dept Radiol, 1161 21st Ave S CCC-1118 MCN, Nashville, TN 37232 USA.
EM Lori.a.deitte@vanderbilt.edu
NR 14
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1076-6332
EI 1878-4046
J9 ACAD RADIOL
JI Acad. Radiol.
PD MAR
PY 2016
VL 23
IS 3
BP 374
EP 381
DI 10.1016/j.acra.2015.11.010
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DE2PK
UT WOS:000370469000017
PM 26781203
ER
PT J
AU Toledo, JB
Gopal, P
Raible, K
Irwin, DJ
Brettschneider, J
Sedor, S
Waits, K
Boluda, S
Grossman, M
Van Deerlin, VM
Lee, EB
Arnold, SE
Duda, JE
Hurtig, H
Lee, VMY
Adler, CH
Beach, TG
Trojanowski, JQ
AF Toledo, Jon B.
Gopal, Pallavi
Raible, Kevin
Irwin, David J.
Brettschneider, Johannes
Sedor, Samantha
Waits, Kayla
Boluda, Susana
Grossman, Murray
Van Deerlin, Vivianna M.
Lee, Edward B.
Arnold, Steven E.
Duda, John E.
Hurtig, Howard
Lee, Virginia M. -Y.
Adler, Charles H.
Beach, Thomas G.
Trojanowski, John Q.
TI Pathological alpha-synuclein distribution in subjects with coincident
Alzheimer's and Lewy body pathology
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE Alzheimer disease; Parkinson disease; Dementia with Lewy bodies;
Neuropathology; Diagnosis; Classification
ID SPORADIC PARKINSONS-DISEASE; NEUROPATHOLOGIC ASSESSMENT; ASSOCIATION
GUIDELINES; COGNITIVE IMPAIRMENT; DIAGNOSTIC-CRITERIA; NATIONAL
INSTITUTE; DONATION PROGRAM; DEMENTIA; BRAIN; BODIES
AB We investigated the distribution patterns of Lewy body-related pathology (LRP) and the effect of coincident Alzheimer disease (AD) pathology using a data-driven clustering approach that identified groups with different LRP pathology distributions without any diagnostic or researcher's input in two cohorts including: Parkinson disease patients without (PD, n = 141) and with AD (PD-AD, n = 80), dementia with Lewy bodies subjects without AD (DLB, n = 13) and demented subjects with AD and LRP pathology (Dem-AD-LB, n = 308). The Dem-AD-LB group presented two LRP patterns, olfactory-amygdala and limbic LRP with negligible brainstem pathology, that were absent in the PD groups, which are not currently included in the DLB staging system and lacked extracranial LRP as opposed to the PD group. The Dem-AD-LB individuals showed relative preservation of substantia nigra cells and dopamine active transporter in putamen. PD cases with AD pathology showed increased LRP. The cluster with occipital LRP was associated with non-AD type dementia clinical diagnosis in the Dem-AD-LB group and a faster progression to dementia in the PD groups. We found that (1) LRP pathology in Dem-AD-LB shows a distribution that differs from PD, without significant brainstem or extracranial LRP in initial phases; (2) coincident AD pathology is associated with increased LRP in PD indicating an interaction; (3) LRP and coincident AD pathology independently predict progression to dementia in PD, and (4) evaluation of LRP needs to acknowledge different LRP spreading patterns and evaluate substantia nigra integrity in the neuropathological assessment and consider the implications of neuropathological heterogeneity for clinical and biomarker characterization.
C1 [Toledo, Jon B.; Gopal, Pallavi; Raible, Kevin; Irwin, David J.; Brettschneider, Johannes; Sedor, Samantha; Waits, Kayla; Boluda, Susana; Van Deerlin, Vivianna M.; Lee, Edward B.; Lee, Virginia M. -Y.; Trojanowski, John Q.] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Irwin, David J.; Grossman, Murray; Arnold, Steven E.; Hurtig, Howard] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Brettschneider, Johannes] Univ Ulm, Dept Clin Neuroanat & Neurol, D-89069 Ulm, Germany.
[Arnold, Steven E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Duda, John E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Adler, Charles H.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA.
[Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ USA.
RP Toledo, JB (reprint author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
EM jtoledo@mail.med.upenn.edu
OI Toledo, Jon/0000-0003-4366-9268
FU NIH grants [AG05136, AG006781]; Morris K Udall Center for Parkinson's
disease Research Core grants [P50 NS053488, NS062684]; National
Institute of Neurological Disorders and Stroke (National Brain and
Tissue Resource for Parkinson's Disease and Related Disorders) [U24
NS072026]; National Institute on Aging (Arizona Alzheimer's Disease Core
Center) [P30 AG19610]; Arizona Department of Health Services (Arizona
Alzheimer's Research Center) [211002]; Arizona Biomedical Research
Commission [4001, 0011, 05-901, 1001]; Michael J. Fox Foundation for
Parkinson's Research; [NS088341]
FX This study was supported by NIH grants: AG05136, AG006781 and Morris K
Udall Center for Parkinson's disease Research Core grants P50 NS053488
and NS062684. The Brain and Body Donation Program is supported by the
National Institute of Neurological Disorders and Stroke (U24 NS072026
National Brain and Tissue Resource for Parkinson's Disease and Related
Disorders), the National Institute on Aging (P30 AG19610 Arizona
Alzheimer's Disease Core Center), the Arizona Department of Health
Services (contract 211002, Arizona Alzheimer's Research Center), the
Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and
1001 to the Arizona Parkinson's Disease Consortium) and the Michael J.
Fox Foundation for Parkinson's Research. DJI is supported by NS088341.
Finally, we thank our patients and their families for making this
research possible.
NR 47
TC 7
Z9 7
U1 2
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
EI 1432-0533
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD MAR
PY 2016
VL 131
IS 3
BP 393
EP 409
DI 10.1007/s00401-015-1526-9
PG 17
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA DE7LG
UT WOS:000370817600005
PM 26721587
ER
PT J
AU Binswanger, IA
Stern, MF
Yamashita, TE
Mueller, SR
Baggett, TP
Blatchford, PJ
AF Binswanger, Ingrid A.
Stern, Marc F.
Yamashita, Traci E.
Mueller, Shane R.
Baggett, Travis P.
Blatchford, Patrick J.
TI Clinical risk factors for death after release from prison in Washington
State: a nested case-control study
SO ADDICTION
LA English
DT Article
DE Drug-related mortality; overdose; prison; risk factors
ID CAUSE-SPECIFIC MORTALITY; DRUG-RELATED DEATHS; OPIOID-OVERDOSE;
MEDICAL-RECORDS; DATA LINKAGE; COHORT; SCOTLAND; INMATES; SUICIDE;
METAANALYSIS
AB Background and aimsWhile mortality rates after prison release are high, little is known about clinical risk factors for death. We sought to identify risk and protective factors for all-cause and accidental poisoning (overdose) death.
DesignNested case-control study of people released from prison.
SettingWashington State Department of Corrections, Washington, USA.
ParticipantsCases (699 all-cause deaths, of which 88 were among women, and 196 additional overdose deaths, of which 76 were among women) between 1999 and 2009 matched 1:1 to controls on sex, age and year of release using risk set sampling.
MeasurementsPrison medical charts were abstracted for clinical information. Independent associations between clinical characteristics and all-cause and overdose mortality were assessed using conditional logistic regression.
FindingsKey independent risk factors for all-cause mortality included homelessness [odds ratio (OR)=1.53, 95% confidence interval (CI)=1.06, 2.23], injection drug use (OR=1.54, 95% CI=1.16, 2.06), tobacco use (OR=1.51, 95% CI=1.07, 2.13), cirrhosis (OR=4.42, 95% CI=1.63, 11.98) and psychiatric medications before release (OR=2.38, 95% CI=1.71, 3.30). Independent risk factors for overdose mortality included substance use disorder (OR=2.33, 95% CI=1.32, 4.11), injection drug use (OR=2.43, 95% CI=1.53, 3.86), panic disorder (OR=3.87, 95% CI=1.62, 9.21), psychiatric prescriptions before release (OR=2.44, 95% CI=1.55, 3.85) and problems with opiates/sedatives (OR=2.81, 95% CI=1.40, 5.63). Substance use disorder treatment during the index incarceration was protective for all-cause (OR=0.67, 95% CI=0.49, 0.91) and overdose (OR=0.57, 95% CI=0.36, 0.90) mortality.
ConclusionsInjection drug use and substance use disorders are risk factors for death after release from prison. In-prison substance use disorder treatment services may reduce the risk.
C1 [Binswanger, Ingrid A.; Mueller, Shane R.] Kaiser Permanente, Inst Hlth Res, POB 378066, Denver, CO 80237 USA.
[Binswanger, Ingrid A.; Mueller, Shane R.] Univ Colorado, Sch Med, Div Gen Internal Med, Dept Med, Aurora, CO USA.
[Binswanger, Ingrid A.; Mueller, Shane R.] Univ Colorado, Sch Med, Dept Psychiat, Div Subst Dependence, Aurora, CO USA.
[Binswanger, Ingrid A.] Denver Hlth Med Ctr, Denver, CO USA.
[Stern, Marc F.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Yamashita, Traci E.] Univ Colorado, Sch Med, Undergrad Med Educ, Aurora, CO USA.
[Baggett, Travis P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Baggett, Travis P.] Boston Hlth Care Homeless Program, Boston, MA USA.
[Blatchford, Patrick J.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
RP Binswanger, IA (reprint author), Kaiser Permanente, Inst Hlth Res, POB 378066, Denver, CO 80237 USA.
EM ingrid.a.binswanger@kp.org
FU National Institute on Drug Abuse [R21DA031041, K23DA034008]; Robert Wood
Johnson Foundation
FX Funding for this study was provided by the National Institute on Drug
Abuse (R21DA031041) and the Robert Wood Johnson Foundation. T.P.B. was
supported by the National Institute on Drug Abuse (K23DA034008). The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health or the Robert Wood Johnson Foundation. We wish to acknowledge the
Washington State Department of Corrections, especially Kathryn Lundy
RHIT, Mike Evans and David Daniels. We acknowledge Rick Whisenhunt,
Melanie Arndt and Marcy Fulmer for their assistance in the execution of
this study. We also wish to acknowledge Jason M. Glanz PhD and David
McClure PhD for their thoughtful comments on the design and analysis of
the study.
NR 53
TC 1
Z9 1
U1 3
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD MAR
PY 2016
VL 111
IS 3
BP 499
EP 510
DI 10.1111/add.13200
PG 12
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DD9NI
UT WOS:000370252100016
PM 26476210
ER
PT J
AU Vedak, P
Kroshinsky, D
John, JS
Xavier, RJ
Yajnik, V
Ananthakrishnan, AN
AF Vedak, P.
Kroshinsky, D.
John, J. St.
Xavier, R. J.
Yajnik, V.
Ananthakrishnan, A. N.
TI Genetic basis of TNF- antagonist associated psoriasis in inflammatory
bowel diseases: a genotype-phenotype analysis
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID NECROSIS FACTOR THERAPY; GENOME-WIDE ASSOCIATION; SKIN-LESIONS;
SUSCEPTIBILITY LOCI; CROHNS-DISEASE; COMMON PATHWAYS; SAFETY PROFILE;
ALPHA; IBD; INTERLEUKIN-13
AB BackgroundAnti-tumour necrosis factor (anti-TNF) biologic associated psoriasis has been reported in inflammatory bowel disease (IBD) patients. However, little is known regarding its pathogenesis.
AimTo identify potential genetic predispositions to anti-TNF associated psoriasis in IBD patients.
MethodsThis retrospective chart review included IBD patients enrolled in a prospective registry. Cases of anti-TNF associated psoriasis and idiopathic psoriasis unrelated to anti-TNF exposure were confirmed by an expert dermatologist. All patients were genotyped on the Illumina Immunochip. A weighted genetic risk score ascertaining genetic pre-disposition towards psoriasis was calculated and overall genetic pre-disposition as well as differential distribution of individual polymorphisms was compared across the three groups.
ResultsOur study included 724 IBD patients who initiated anti-TNF therapy and did not develop psoriasis, 35 patients with anti-TNF associated psoriasis, and 38 patients with idiopathic psoriasis. Anti-TNF users who developed psoriasis had a modest but statistically significantly greater psoriasis genetic risk score than anti-TNF controls (mean 0.64 vs. 0.61, P = 0.04), and had a similar genetic risk score as those with idiopathic psoriasis (0.64 vs. 0.62, P = 0.22). Two loci associated with NOS2 and ETS1 genes achieved P < 0.05 when comparing anti-TNF associated psoriasis to anti-TNF controls. Three loci were significantly different between anti-TNF associated psoriasis and idiopathic psoriasis including a polymorphism near NOS2 encoding for inducible nitric oxide synthase that is produced by dendritic cells in skin lesions in psoriasis.
ConclusionPatients with anti-TNF associated psoriasis had a modestly greater genetic pre-disposition towards psoriasis but no single causative polymorphism was identified.
C1 [Vedak, P.; Kroshinsky, D.; John, J. St.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Xavier, R. J.; Yajnik, V.; Ananthakrishnan, A. N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Xavier, R. J.; Yajnik, V.; Ananthakrishnan, A. N.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Yajnik, V; Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA.
EM vyajnik@mgh.harvard.edu; aananthakrishnan@mgh.harvard.edu
FU National Institutes of Health (NIH) [K23 DK097142, P30 DK043351]
FX Ananthakrishnan was supported in part by a grant from the National
Institutes of Health (NIH) (K23 DK097142). This study was also supported
by the National Institutes of Health (P30 DK043351) to the Center for
Study of Inflammatory Bowel Diseases.
NR 35
TC 1
Z9 1
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAR
PY 2016
VL 43
IS 6
BP 697
EP 704
DI 10.1111/apt.13542
PG 8
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA DE5BD
UT WOS:000370644700003
PM 26806281
ER
PT J
AU Kassam, Z
Fabersunne, CC
Smith, MB
Alm, EJ
Kaplan, GG
Nguyen, GC
Ananthakrishnan, AN
AF Kassam, Z.
Fabersunne, C. Cribb
Smith, M. B.
Alm, E. J.
Kaplan, G. G.
Nguyen, G. C.
Ananthakrishnan, A. N.
TI Clostridium difficile associated risk of death score (CARDS): a novel
severity score to predict mortality among hospitalised patients with
C-difficile infection
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; 30-DAY MORTALITY;
ECONOMIC BURDEN; OUTCOMES; IMPACT; DIARRHEA; PREVALENCE; SURVEILLANCE;
VALIDATION
AB BackgroundClostridium difficile infection (CDI) is a public health threat and associated with significant mortality. However, there is a paucity of objectively derived CDI severity scoring systems to predict mortality.
AimTo develop a novel CDI risk score to predict mortality entitled: Clostridium difficile associated risk of death score (CARDS).
MethodsWe obtained data from the United States 2011 Nationwide Inpatient Sample (NIS) database. All CDI-associated hospitalisations were identified using discharge codes (ICD-9-CM, 008.45). Multivariate logistic regression was utilised to identify independent predictors of mortality. Clostridium difficile associated risk of death score was calculated by assigning a numeric weight to each parameter based on their odds ratio in the final logistic model. Predictive properties of model discrimination were assessed using the c-statistic and validated in an independent sample using the 2010 NIS database.
ResultsWe identified 77 776 hospitalisations, yielding an estimate of 374 747 cases with an associated diagnosis of CDI in the US, 8% of whom died in the hospital. The eight severity score predictors were identified on multivariate analysis: age, cardiopulmonary disease, malignancy, diabetes, inflammatory bowel disease, acute renal failure, liver disease and ICU admission, with weights ranging from -1 (for diabetes) to 5 (for ICU admission). The overall risk score in the cohort ranged from 0 to 18. Mortality increased significantly as CARDS increased. CDI-associated mortality was 1.2% with a CARDS of 0 compared to 100% with CARDS of 18. The model performed equally well in our validation cohort.
ConclusionClostridium difficile associated risk of death score is a promising simple severity score to predict mortality among those hospitalised with C. difficile infection.
C1 [Kassam, Z.; Smith, M. B.; Alm, E. J.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Kassam, Z.; Smith, M. B.] OpenBiome, Medford, MA USA.
[Fabersunne, C. Cribb; Ananthakrishnan, A. N.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Fabersunne, C. Cribb] Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
[Kaplan, G. G.] Univ Calgary, Calgary, AB, Canada.
[Nguyen, G. C.] Univ Toronto, Mt Sinai Hosp, Ctr Inflammatory Bowel Dis, Toronto, ON M5G 1X5, Canada.
[Ananthakrishnan, A. N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA.
EM aananthakrishnan@mgh.harvard.edu
OI Kaplan, Gilaad/0000-0003-2719-0556
FU Harvard University Frank Knox Memorial Fellowship; National Institutes
of Health [K23 DK097142]
FX Zain Kassam was supported by a Harvard University Frank Knox Memorial
Fellowship. Ananthakrishnan is supported in part by a grant from the
National Institutes of Health (K23 DK097142).
NR 42
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAR
PY 2016
VL 43
IS 6
BP 725
EP 733
DI 10.1111/apt.13546
PG 9
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA DE5BD
UT WOS:000370644700006
PM 26849527
ER
PT J
AU Wasfy, JH
Rao, SK
Kalwani, N
Chittle, MD
Richardson, CA
Gallen, KM
Isselbacher, EM
Kimball, AB
Ferris, TG
AF Wasfy, Jason H.
Rao, Sandhya K.
Kalwani, Neil
Chittle, Melissa D.
Richardson, Calvin A.
Gallen, Kathleen M.
Isselbacher, Eric M.
Kimball, Alexandra B.
Ferris, Timothy G.
TI Longer-term impact of cardiology e-consults
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ACCOUNTABLE CARE; UNITED-STATES; HEALTH-CARE; SPECIALISTS; EFFICIENCY;
REFERRALS; SYSTEM; GAINS; COSTS
AB Aims Cardiac e-consults may be an effective way to deliver value-oriented outpatient cardiology care in an accountable care organization. Initial results of cardiac e-consults have demonstrated high satisfaction among both patients and referring providers, no known adverse events, and low rates of diagnostic testing. Nevertheless, differences between e-consults and traditional consults, effects of e-consults on traditional consult volume, and whether patients seek traditional consults after e-consults are unknown.
Methods and results We established a cardiac e-consult program on January 13, 2014. We then conducted detailed medical record reviews of all patients with e-consults to detect any adverse clinical events and detect subsequent traditional visits to cardiologists. We also performed 2 comparisons. First, we compared age, gender, and referral reason for e-consults vs traditional consults. Second, we compared changes in volume of referrals to cardiology vs other medical specialties that did not have e-consults. From January 13 to December 31, 2014, 1,642 traditional referrals and 165 e-consults were requested. The proportion of e-consults of all evaluations requested over that period was 9.1%. Gender balance was similar among traditional consults and e-consults (44.8% male for e-consults vs 45.0% for traditional consults, P = .981). E-consult patients were younger than traditional consult patients (55.3 vs 60.4 years, P < .001). After the introduction of cardiac e-consults, the increase in traditional cardiac visit requests was less than the increase in traditional visit requests for control specialties (4.5% vs 10.1%, P < .001). For e-consults with at least 6 months of follow-up, 75.6% patients did not have any type of traditional cardiology visit during the follow-up period.
Conclusion E-consults are an effective and safe mechanism to enhance value in outpatient cardiology care, with low rates of bounceback to traditional consults. E-consults can account for nearly one-tenth of total outpatient consultation volume at 1 year within an accountable care organization and are associated with a reduction in traditional referrals to cardiologists.
C1 [Wasfy, Jason H.; Isselbacher, Eric M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA.
[Wasfy, Jason H.; Rao, Sandhya K.; Richardson, Calvin A.; Kimball, Alexandra B.; Ferris, Timothy G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Massachusetts Gen Phys Org, Boston, MA USA.
[Rao, Sandhya K.; Ferris, Timothy G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Kalwani, Neil] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Chittle, Melissa D.] Massachusetts Gen Hosp, Dept Radiol, Div Intervent Radiol, Boston, MA USA.
[Gallen, Kathleen M.] Massachusetts Gen Hosp, Ctr Heart, Boston, MA 02114 USA.
[Isselbacher, Eric M.] Massachusetts Gen Hosp, Healthcare Transformat Lab, Boston, MA 02114 USA.
[Kimball, Alexandra B.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
RP Wasfy, JH (reprint author), Massachusetts Gen Hosp, Massachusetts Gen Phys Org, BUL 205B,55 Fruit St, Boston, MA 02114 USA.
EM jwasfy@mgh.harvard.edu
NR 15
TC 3
Z9 3
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD MAR
PY 2016
VL 173
BP 86
EP 93
DI 10.1016/j.ahj.2015.11.019
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DE7HO
UT WOS:000370806800011
PM 26920600
ER
PT J
AU Sabatine, MS
Giugliano, RP
Keech, A
Honarpour, N
Wang, H
Liu, T
Wasserman, SM
Scott, R
Sever, PS
Pedersen, TR
AF Sabatine, Marc S.
Giugliano, Robert P.
Keech, Anthony
Honarpour, Narimon
Wang, Huei
Liu, Thomas
Wasserman, Scott M.
Scott, Robert
Sever, Peter S.
Pedersen, Terje R.
TI Rationale and design of the Further cardiovascular OUtcomes Research
with PCSK9 Inhibition in subjects with Elevated Risk trial
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID CORONARY-HEART-DISEASE; PLACEBO-CONTROLLED TRIAL;
LOW-DENSITY-LIPOPROTEIN; PRIMARY-PREVENTION TRIAL; EVOLOCUMAB AMG 145;
STATIN THERAPY; LDL-C; FAMILIAL HYPERCHOLESTEROLEMIA;
MYOCARDIAL-INFARCTION; MONOCLONAL-ANTIBODY
AB Background Despite current therapies, patients with vascular disease remain at high risk for major adverse cardiovascular events. Low-density lipoprotein cholesterol is a well-established modifiable cardiovascular risk factor. Evolocumab is a fully human monoclonal antibody inhibitor of proprotein convertase subtilisin/kexin type 9 that reduces low-density lipoprotein cholesterol by approximately 60% across various populations.
Study design FOURIER is a randomized, placebo-controlled, double-blind, parallel-group, multinational trial testing the hypothesis that adding evolocumab to statin therapy will reduce the incidence of major adverse cardiovascular events in patients with clinically evident vascular disease. The study population consists of 27,564 patients who have had a myocardial infarction (MI), an ischemic stroke, or symptomatic peripheral artery disease and have a low-density lipoprotein >= 70 mg/dL or a non-high-density lipoprotein cholesterol >= 100 mg/dL on an optimized statin regimen. Patients were randomized in a 1: 1 ratio to receive either evolocumab (either 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously every month, according to patient preference) or matching placebo injections. The primary end point is major cardiovascular events defined as the composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary end point is the composite of cardiovascular death, MI, or stroke. The trial is planned to continue until at least 1,630 patients experience the secondary end point, thereby providing 90% power to detect a relative reduction of >= 15% in this end point.
Conclusions FOURIER will determine whether the addition of evolocumab to statin therapy reduces cardiovascular morbidity and mortality in patients with vascular disease.
C1 [Sabatine, Marc S.; Giugliano, Robert P.] Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
[Sabatine, Marc S.; Giugliano, Robert P.] Harvard Univ, Sch Med, Boston, MA USA.
[Keech, Anthony] Univ Sydney, NHMRC Clin Trials Ctr, Sydney Med Sch, Sydney, NSW 2006, Australia.
[Honarpour, Narimon; Wang, Huei; Liu, Thomas; Wasserman, Scott M.; Scott, Robert] Amgen Inc, Thousand Oaks, CA USA.
[Sever, Peter S.] Univ London Imperial Coll Sci Technol & Med, Int Ctr Circulatory Hlth, London, England.
[Pedersen, Terje R.] Oslo Univ Hosp, Ulleval, Norway.
[Pedersen, Terje R.] Univ Oslo, Fac Med, Oslo, Norway.
RP Sabatine, MS (reprint author), Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.; Sabatine, MS (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
FU Amgen
FX FOURIER is funded by Amgen.
NR 38
TC 33
Z9 33
U1 2
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD MAR
PY 2016
VL 173
BP 94
EP 101
DI 10.1016/j.ahj.2015.11.015
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DE7HO
UT WOS:000370806800012
PM 26920601
ER
PT J
AU Acharjee, S
Teo, KK
Jacobs, AK
Hartigan, PM
Barn, K
Gosselin, G
Tanguay, JF
Maron, DJ
Kostuk, WJ
Chaitman, BR
Mancini, GBJ
Spertus, JA
Dada, MR
Bates, ER
Booth, DC
Weintraub, WS
O'Rourke, RA
Boden, WE
AF Acharjee, Subroto
Teo, Koon K.
Jacobs, Alice K.
Hartigan, Pamela M.
Barn, Kulpreet
Gosselin, Gilbert
Tanguay, Jean-Francois
Maron, David J.
Kostuk, William J.
Chaitman, Bernard R.
Mancini, G. B. John
Spertus, John A.
Dada, Marcin R.
Bates, Eric R.
Booth, David C.
Weintraub, William S.
O'Rourke, Robert A.
Boden, William E.
TI Optimal medical therapy with or without percutaneous coronary
intervention in women with stable coronary disease: A pre-specified
subset analysis of the Clinical Outcomes Utilizing Revascularization and
Aggressive druG Evaluation (COURAGE) trial
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ELEVATION MYOCARDIAL-INFARCTION; ARTERY-DISEASE; GENDER-DIFFERENCES;
CONSERVATIVE TREATMENT; UNSTABLE ANGINA; SEX-DIFFERENCES;
YENTL-SYNDROME; HEART-DISEASE; MANAGEMENT; MEN
AB Objectives To determine whether sex-based differences exist in clinical effectiveness of percutaneous coronary intervention (PCI) when added to optimal medical therapy (OMT) in patients with stable coronary artery disease.
Background A prior pre-specified unadjusted analysis from COURAGE showed that women randomized to PCI had a lower rate of death or myocardial infarction during a median 4.6-year follow-up with a trend for interaction with respect to sex.
Methods We analyzed outcomes in 338 women (15%) and 1949 men (85%) randomized to PCI plus OMT versus OMT alone after adjustment for relevant baseline characteristics.
Results There was no difference in treatment effect by sex for the primary end point (death or myocardial infarction; HR, 0.89; 95% CI, 0.77-1.03 for women and HR, 1.02, 95% CI 0.96-1.10 for men; P for interaction = .07). Although the event rate was low, a trend for interaction by sex was nonetheless noted for hospitalization for heart failure, with only women, but not men, assigned to PCI experiencing significantly fewer events as compared to their counterparts receiving OMT alone (HR, 0.59; 95% CI, 0.40-0.84, P < .001 for women and HR, 0.86; 95% CI, 0.74-1.01, P = .47 for men; P for interaction = .02). Both sexes randomized to PCI experienced significantly reduced need for subsequent revascularization (HR, 0.72; 95% CI, 0.62-0.83, P < .001 for women; HR, 0.84; 95% CI, 0.79-0.89, P < .001 for men; P for interaction = .02) with evidence of a sex-based differential treatment effect.
Conclusion In this adjusted analysis of the COURAGE trial, there were no significant differences in treatment effect on major outcomes between men and women. However, women assigned to PCI demonstrated a greater benefit as compared to men, with a reduction in heart failure hospitalization and need for future revascularization. These exploratory observations require further prospective study.
C1 [Acharjee, Subroto] Einstein Med Ctr Philadelphia, Philadelphia, PA USA.
[Teo, Koon K.] Master Univ, Hamilton Gen Hosp, Hamilton, ON, Canada.
[Jacobs, Alice K.] Boston Med Ctr, Boston, MA USA.
[Hartigan, Pamela M.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Barn, Kulpreet] Geisinger Med Ctr, Danville, PA 17822 USA.
[Gosselin, Gilbert; Tanguay, Jean-Francois] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
[Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Kostuk, William J.] London Hlth Sci Ctr, London, ON, Canada.
[Chaitman, Bernard R.] St Louis Univ, Sch Med, St Louis, MT USA.
[Mancini, G. B. John] Vancouver Hosp, Vancouver, BC, Canada.
[Mancini, G. B. John] Hlth Sci Ctr, Vancouver, BC, Canada.
[Spertus, John A.] Mid Amer Heart Inst, Kansas City, MO USA.
[Dada, Marcin R.] Hartford Hosp, Hartford, CT 06115 USA.
[Bates, Eric R.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Booth, David C.] Univ Kentucky, Med Ctr, Lexington, KY USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Weintraub, William S.] Ctr Outcomes Res, Newark, DE USA.
[O'Rourke, Robert A.] South Texas Vet Hlth Care Syst, Audie Murphy Campus, San Antonio, TX USA.
[Boden, William E.] Albany Med Coll, Stratton VA Med Ctr, Albany, NY 12208 USA.
RP Boden, WE (reprint author), Samuel S Stratton VA Med Ctr, 113 Holland Ave, Albany, NY 12208 USA.
EM william.boden@va.gov
FU Amgen Merck Canada; Sanofi; Astra Zeneca; Gilead
FX Dr GB John Mancini: <$10,000 grant, honoraria, speakers bureau: Amgen
Merck Canada, Sanofi, Astra Zeneca.; Dr John Spertus: owns the copyright
to the Seattle Angina Questionnaire, consultant for United Healthcare,
St. Jude Medical, Abbott Vascular and Genentech, research grant from
Gilead.
NR 32
TC 3
Z9 3
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD MAR
PY 2016
VL 173
BP 108
EP 117
DI 10.1016/j.ahj.2015.07.020
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DE7HO
UT WOS:000370806800014
PM 26920603
ER
PT J
AU Levey, AS
Bilous, R
Shlipak, MG
AF Levey, Andrew S.
Bilous, Rudy
Shlipak, Michael G.
TI CKD and Diabetes: What Can We Learn From Their Similarities and
Differences?
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Editorial Material
ID CHRONIC KIDNEY-DISEASE; PROGRESSION; PREVENTION; PREDICTION; COMMUNITY;
HEALTH; MODEL; CARE
C1 [Levey, Andrew S.] Tufts Med Ctr, Boston, MA USA.
[Bilous, Rudy] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
RP Levey, AS (reprint author), Tufts Med Ctr, William B Schwartz Div Nephrol, Box 391,800 Washington St, Boston, MA 02111 USA.
EM alevey@tuftsmedicalcenter.org
NR 21
TC 0
Z9 0
U1 2
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAR
PY 2016
VL 67
IS 3
BP 360
EP 363
DI 10.1053/j.ajkd.2015.12.003
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA DE5UM
UT WOS:000370698100008
PM 26916373
ER
PT J
AU Bhasin, B
Velez, JCQ
AF Bhasin, Bhavna
Velez, Juan Carlos Q.
TI Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Polyuria; water diuresis; solute excretion; urinary osmoles;
hypernatremia
ID NEPHROGENIC DIABETES-INSIPIDUS; SALT WASTING SYNDROME; OSMOTIC DIURESIS;
DIFFERENTIAL-DIAGNOSIS; HYPERNATREMIA; HYPONATREMIA; THERAPY;
VASOPRESSIN; MECHANISMS; CLEARANCE
AB Polyuria, defined as daily urine output in excess of 3.0 to 3.5 L/d, can occur due to solute or water diuresis. Solute-induced polyuria can be seen in hospitalized patients after a high solute load from exogenous protein administration or following relief of urinary obstruction. Similar clinical scenarios are rarely encountered in the outpatient setting. We describe a case of polyuria due to high solute ingestion and excessive water intake leading to a mixed picture of solute and water diuresis. Restriction of the daily solute load and water intake resulted in complete resolution of polyuria. Determination of the daily excreted urinary osmoles may yield important clues to the cause of polyuria and should be included in the routine workup of polyuria. (C) 2016 by the National Kidney Foundation, Inc.
C1 [Bhasin, Bhavna; Velez, Juan Carlos Q.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Velez, Juan Carlos Q.] Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Nephrol Sect, Charleston, SC USA.
RP Bhasin, B (reprint author), 96 Jonathan Lucas St,Clinical Sci Bldg, Charleston, SC 29425 USA.
EM bhasinb@musc.edu
RI Velez, Juan Carlos/N-3782-2016
NR 30
TC 1
Z9 1
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAR
PY 2016
VL 67
IS 3
BP 507
EP 511
DI 10.1053/j.ajkd.2015.10.021
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA DE5UM
UT WOS:000370698100025
PM 26687922
ER
PT J
AU Agenor, M
McCauley, HL
Peitzmeier, SM
Haneuse, S
Gordon, AR
Potter, J
Austin, SB
AF Agenor, Madina
McCauley, Heather L.
Peitzmeier, Sarah M.
Haneuse, Sebastien
Gordon, Allegra R.
Potter, Jennifer
Austin, S. Bryn
TI Sex of Sexual Partners and Human Papillomavirus Vaccination Among US
Girls and Women
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID GENITAL HUMAN-PAPILLOMAVIRUS; HEALTH-CARE ACCESS; SAME-SEX; HPV
VACCINATION; UNITED-STATES; TRANSMITTED INFECTIONS; CERVICAL-CANCER;
NATIONAL-SURVEY; BISEXUAL WOMEN; YOUNG-WOMEN
AB Introduction: Girls and women are at risk of human papillomavirus (HPV) infection and cervical cancer from male and female sexual partners throughout the life course. However, no study has assessed how sex of sexual partners, a dimension of sexual orientation, may relate to HPV vaccination among girls and women.
Methods: In 2014, data from the 2006-2010 National Survey of Family Growth were used to conduct logistic regression analyses estimating the relationship between sex of lifetime and past-year sexual partners and HPV vaccine awareness and initiation among U.S. girls and women aged 15-25 years (N = 3,253).
Results: Among U.S. girls and women aged 15-25 years, the prevalence of HPV vaccine awareness and HPV vaccine initiation was 84.4% and 28.5%, respectively. Adjusting for sociodemographic factors, participants with only female past-year sexual partners had significantly lower odds of initiating HPV vaccination relative to those with only male past-year sexual partners (OR = 0.16, 95% CI = 0.05, 0.55). Similarly, respondents with no lifetime (OR = 0.65, 95% CI = 0.46, 0.92) or past-year (OR = 0.69, 95% CI = 0.50, 0.94) sexual partners had significantly lower adjusted odds of HPV vaccine initiation compared with those with only male sexual partners. No difference was apparent in the odds of initiating HPV vaccination between participants with male and female sexual partners and those with only male sexual partners.
Conclusions: Medical and public health professionals should ensure that girls and women with only female or no sexual partners are included in HPV vaccine education and promotion efforts. (C) 2016 American Journal of Preventive Medicine
C1 [Agenor, Madina; Austin, S. Bryn] Harvard Univ, TH Chan Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave,Kresge Bldg,7th Floor, Boston, MA 02115 USA.
[Agenor, Madina] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[McCauley, Heather L.] Childrens Hosp Pittsburgh, Div Adolescent Med, Pittsburgh, PA 15213 USA.
[McCauley, Heather L.] Univ Pittsburgh, Sch Med, Div Pediat, Pittsburgh, PA USA.
[Peitzmeier, Sarah M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA.
[Haneuse, Sebastien] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Gordon, Allegra R.; Austin, S. Bryn] Boston Childrens Hosp, Div Adolescent & Young Adult Med, Boston, MA USA.
[Gordon, Allegra R.; Austin, S. Bryn] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Potter, Jennifer] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Potter, Jennifer] Fenway Hlth, Womens Hlth Program, Boston, MA USA.
[Potter, Jennifer] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
RP Agenor, M (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave,Kresge Bldg,7th Floor, Boston, MA 02115 USA.
EM magenor@mail.harvard.edu
FU NIH [R25CA057711-20]
FX The authors thank the 2006-2010 National Survey of Family Growth
participants and the National Center for Health Statistics for the data
used in this study. This project was supported by NIH grant
R25CA057711-20, on which M Agenor was a trainee. NIH played no role in
study design; collection, analysis, and interpretation of data; writing
the manuscript; or the decision to submit the manuscript for
publication. M Agenor, S Peitzmeier, S Haneuse, and SB Austin
contributed to the design of the study. M Agenor conducted all data
analyses, and HL McCauley, S Peitzmeier, and SB Austin provided feedback
on data analysis. S Haneuse provided statistical expertise and
consultation. M Agenor, HL McCauley, S Peitzmeier, S Haneuse, AR Gordon,
JE Potter, and SB Austin contributed to the interpretation of the study
results. M Agenor drafted the manuscript, and HL McCauley, S Peitzmeier,
S Haneuse, AR Gordon, JE Potter, and SB Austin provided critical
feedback on the manuscript.
NR 55
TC 2
Z9 2
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD MAR
PY 2016
VL 50
IS 3
BP 318
EP 327
DI 10.1016/j.amepre.2015.08.025
PG 10
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DD9QI
UT WOS:000370260300007
PM 26585049
ER
PT J
AU Montgomery, AE
Dichter, ME
Thomasson, AM
Roberts, CB
AF Montgomery, Ann E.
Dichter, Melissa E.
Thomasson, Arwin M.
Roberts, Christopher B.
TI Services Receipt Following Veteran Outpatients' Positive Screen for
Homelessness
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID MENTAL-ILLNESS; SEXUAL TRAUMA; RISK; VIOLENCE; GENDER; IRAQ
AB Introduction: The Veterans Health Administration seeks to reduce homelessness among Veterans by identifying, and providing prevention and supportive services to, patients with housing concerns. The objectives of this study were to assess the proportion of Veterans Health Administration patients who received homeless or social work services within 6 months of a positive screen for homelessness or risk in the Veterans Health Administration and the demographic and clinical characteristics that predicted services utilization.
Methods: Data were from a cohort of 27,403 Veteran outpatients who screened positive for homelessness or risk between November 1, 2012 and January 31, 2013. During 2013, AORs were calculated using a mixed-effects logistic regression to estimate the likelihood of patients' receipt of VHA homeless or social work services based on demographic and clinical characteristics.
Results: The majority of patients received services within 6 months post-screening; predictors of services utilization varied by gender. Among women, diagnosis of drug abuse and psychosis predicted receipt of services, being unmarried increased the odds of using services among those screening positive for homelessness, and a diagnosis of post-traumatic stress disorder increased the odds of receiving services for at-risk women. Among men, being younger, unmarried, not service-connected/Medicaideligible, and having a medical or behavioral health condition predicted receipt of services.
Conclusions: Receipt of housing support services among Veterans post-homelessness screening differs by patient demographic and clinical characteristics. Future research should investigate the role that primary and secondary prevention interventions play in Veterans' resolution of risk for homelessness and experience of homelessness. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Montgomery, Ann E.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA USA.
[Dichter, Melissa E.; Thomasson, Arwin M.; Roberts, Christopher B.] US Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Thomasson, Arwin M.] Hosp Univ Penn, Penn Transplant Inst, 3400 Spruce St, Philadelphia, PA 19104 USA.
RP Montgomery, AE (reprint author), 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA.
EM ann.montgomery2@va.gov
FU U.S. Department of Veterans Affairs, National Center on Homelessness
Among Veterans; Center for Health Equity Research and Promotion
FX The contents of this article do not necessarily represent the views of
the U.S. Department of Veterans Affairs or the U.S. Government. This
study was funded by the U.S. Department of Veterans Affairs, National
Center on Homelessness Among Veterans, and Center for Health Equity
Research and Promotion.
NR 26
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD MAR
PY 2016
VL 50
IS 3
BP 336
EP 343
DI 10.1016/j.amepre.2015.06.035
PG 8
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DD9QI
UT WOS:000370260300009
PM 26564329
ER
PT J
AU Campbell, JA
Walker, RJ
Egede, LE
AF Campbell, Jennifer A.
Walker, Rebekah J.
Egede, Leonard E.
TI Associations Between Adverse Childhood Experiences, High-Risk Behaviors,
and Morbidity in Adulthood
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID RETROSPECTIVE COHORT; MENTAL-HEALTH; STATES; DISEASE; DISPARITIES;
MORTALITY; IMPACT; DEATH; URBAN; US
AB Introduction: Adverse childhood experiences (ACEs) are associated with early mortality and morbidity. This study evaluated the association among ACEs, high-risk health behaviors, and comorbid conditions, as well as the independent effect of ACE components.
Methods: Data were analyzed on 48,526 U.S. adults from five states in the 2011 Behavioral Risk Factor Surveillance System survey. Exposures included psychological, physical, and sexual forms of abuse as well as household dysfunction such as substance abuse, mental illness, violence, and incarceration. Main outcome measures included risky behaviors and morbidity measures, including binge drinking, heavy drinking, current smoking, high-risk HIV behavior, obesity, diabetes, myocardial infarction, coronary heart disease, stroke, depression, disability caused by poor health, and use of special equipment because of disability. Multiple logistic regression assessed the independent relationship between ACE score categories and risky behaviors/comorbidities in adulthood, and assessed the independent relationship between individual ACE components and risky behaviors/comorbid conditions in adulthood controlling for covariates.
Results: A total of 55.4% of respondents reported at least one ACE and 13.7% reported four or more ACEs. An ACE score >= 4 was associated with increased odds for binge drinking, heavy drinking, smoking, risky HIV behavior, diabetes, myocardial infarction, coronary heart disease, stroke, depression, disability caused by health, and use of special equipment because of disability. In addition, the individual components had different effects on risky behavior and comorbidities.
Conclusions: In addition to having a cumulative effect, individual ACE components have differential relationships with risky behaviors, morbidity, and disability in adulthood after controlling for important confounders. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Campbell, Jennifer A.; Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
[Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA COIN, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU National Institute of Diabetes and Digestive and Kidney Disease
(Principal Investigator, Leonard Egede) [K24DK093699-02]
FX This study was supported by grant K24DK093699-02 from The National
Institute of Diabetes and Digestive and Kidney Disease (Principal
Investigator, Leonard Egede). LEE obtained funding for the study. JAC,
RJW, and LEE designed the study and acquired, analyzed, and interpreted
data. JAC, RJW, and LEE developed analysis, contributed to
interpretation, and critically revised the manuscript for important
intellectual content. All authors approved the final manuscript. This
article represents the views of the authors and not those of NIH,
Veterans Health Administration, or Health Services Research &
Development.
NR 38
TC 6
Z9 6
U1 5
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD MAR
PY 2016
VL 50
IS 3
BP 344
EP 352
DI 10.1016/j.amepre.2015.07.022
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DD9QI
UT WOS:000370260300010
PM 26474668
ER
PT J
AU Vargas, CR
Ricci, JA
Chuang, DJ
Lee, BT
AF Vargas, Christina R.
Ricci, Joseph A.
Chuang, Danielle J.
Lee, Bernard T.
TI Online Patient Resources for Liposuction A Comparative Analysis of
Readability
SO ANNALS OF PLASTIC SURGERY
LA English
DT Article
DE online resources; readability; liposuction
ID COSMETIC BREAST AUGMENTATION; BODY CONTOURING PROCEDURES; HEALTH
LITERACY; DECISION-MAKING; SURGERY; RECONSTRUCTION; SATISFACTION
AB Background
As patients strive to become informed about health care, inadequate functional health literacy is a significant barrier. Nearly half of American adults have poor or marginal health literacy skills and the National Institutes of Health and American Medical Association have recommended that patient information should be written at a sixth grade level. The aim of this study is to identify the most commonly used online patient information about liposuction and to evaluate its readability relative to average American literacy.
Methods
An internet search of "liposuction" was performed and the 10 most popular websites identified. User and location data were disabled and sponsored results excluded. All relevant, patient-directed articles were downloaded and formatted into plain text. Articles were then analyzed using 10 established readability tests. A comparison group was constructed to identify the most popular online consumer information about tattooing. Mean readability scores and specific article characteristics were compared.
Results
A total of 80 articles were collected from websites about liposuction. Readability analysis revealed an overall 13.6 grade reading level (range, 10-16 grade); all articles exceeded the target sixth grade level. Consumer websites about tattooing were significantly easier to read, with a mean 7.8 grade level. These sites contained significantly fewer characters per word and words per sentence, as well as a smaller proportion of complex, long, and unfamiliar words.
Conclusions
Online patient resources about liposuction are potentially too difficult for a large number of Americans to understand. Liposuction websites are significantly harder to read than consumer websites about tattooing. Aesthetic surgeons are advised to discuss with patients resources they use and guide patients to appropriate information for their skill level.
C1 [Vargas, Christina R.; Ricci, Joseph A.; Chuang, Danielle J.; Lee, Bernard T.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Plast & Reconstruct Surg, Dept Surg,Med Sch, Boston, MA 02215 USA.
RP Lee, BT (reprint author), Beth Israel Deaconess Med Ctr, Dept Surg, Div Plast & Reconstruct Surg, 110 Francis St,Suite 5A, Boston, MA 02215 USA.
EM btlee@bidmc.harvard.edu
RI Lee, Bernard/K-1106-2016
OI Lee, Bernard/0000-0002-5533-3166
NR 31
TC 2
Z9 2
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-7043
EI 1536-3708
J9 ANN PLAS SURG
JI Ann. Plast. Surg.
PD MAR
PY 2016
VL 76
IS 3
BP 349
EP 354
DI 10.1097/SAP.0000000000000438
PG 6
WC Surgery
SC Surgery
GA DE2WW
UT WOS:000370489200021
PM 25695442
ER
PT J
AU Smink, DS
Mullen, JT
AF Smink, Douglas S.
Mullen, John T.
TI Calling Is Not a Sign of Weakness
SO ANNALS OF SURGERY
LA English
DT Editorial Material
C1 [Smink, Douglas S.] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.
[Mullen, John T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Smink, Douglas S.; Mullen, John T.] Harvard Univ, Sch Med, Boston, MA USA.
RP Smink, DS (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.
EM dsmink@partners.org
NR 2
TC 0
Z9 0
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD MAR
PY 2016
VL 263
IS 3
BP 427
EP 427
DI 10.1097/SLA.0000000000001611
PG 1
WC Surgery
SC Surgery
GA DD8JJ
UT WOS:000370172400002
PM 26704744
ER
PT J
AU Bojovic, B
AF Bojovic, Branko
TI Commentary on "The First Immediate Face Transplant in the World''
SO ANNALS OF SURGERY
LA English
DT Editorial Material
C1 [Bojovic, Branko] Massachusetts Gen Hosp, Shriners Hosp Children, Boston, MA 02114 USA.
RP Bojovic, B (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Boston, MA 02114 USA.
EM bbojovic@partners.org
NR 3
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD MAR
PY 2016
VL 263
IS 3
BP E40
EP E40
DI 10.1097/SLA.0000000000001598
PG 1
WC Surgery
SC Surgery
GA DD8KH
UT WOS:000370174900002
PM 26720427
ER
PT J
AU Shahian, DM
AF Shahian, David M.
TI The Society of Thoracic Surgeons National Database: "What's Past Is
Prologue"
SO ANNALS OF THORACIC SURGERY
LA English
DT Editorial Material
ID MEASUREMENT TASK-FORCE; ADULT CARDIAC-SURGERY; CLINICAL REGISTRY DATA;
BYPASS GRAFT-SURGERY; HEART-SURGERY; SUCCESSFUL LINKING; COMPOSITE
SCORE; QUALITY; PERFORMANCE
C1 [Shahian, David M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Shahian, David M.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA.
[Shahian, David M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Shahian, DM (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 284, Boston, MA 02114 USA.
EM dshahian@partners.org
NR 28
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAR
PY 2016
VL 101
IS 3
BP 841
EP 845
DI 10.1016/j.athoracsur.2016.01.058
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DE0UF
UT WOS:000370339700012
PM 26897184
ER
PT J
AU Jacobs, JP
Mayer, JE
Mavroudis, C
O'Brien, SM
Austin, EH
Pasquali, SK
Hill, KD
He, X
Overman, DM
St Louis, JD
Karamlou, T
Pizarro, C
Hirsch-Romano, JC
McDonald, D
Han, JM
Dokholyan, RS
Tchervenkov, CI
Lacour-Gayet, F
Backer, CL
Fraser, CD
Tweddell, JS
Elliott, MJ
Walters, H
Jonas, RA
Prager, RL
Shahian, DM
Jacobs, ML
AF Jacobs, Jeffrey P.
Mayer, John E., Jr.
Mavroudis, Constantine
O'Brien, Sean M.
Austin, Erle H., III
Pasquali, Sara K.
Hill, Kevin D.
He, Xia
Overman, David M.
St Louis, James D.
Karamlou, Tara
Pizarro, Christian
Hirsch-Romano, Jennifer C.
McDonald, Donna
Han, Jane M.
Dokholyan, Rachel S.
Tchervenkov, Christo I.
Lacour-Gayet, Francois
Backer, Carl L.
Fraser, Charles D.
Tweddell, James S.
Elliott, Martin J.
Walters, Hal, III
Jonas, Richard A.
Prager, Richard L.
Shahian, David M.
Jacobs, Marshall L.
TI The Society of Thoracic Surgeons Congenital Heart Surgery Database: 2016
Update on Outcomes and Quality
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID SURGICAL REGISTRY DATABASE; EMPIRICALLY BASED TOOL; HEALTH-CARE;
CARDIAC-SURGERY; CASE-MIX; MORTALITY; OPERATIONS; DISEASE;
COMPLICATIONS; NOMENCLATURE
AB The Society of Thoracic Surgeons Congenital Heart Surgery Database is the largest congenital and pediatric cardiac surgical clinical data registry in the world. It is the platform for all activities of The Society of Thoracic Surgeons related to the analysis of outcomes and the improvement of quality in this subspecialty. This article summarizes current aggregate national outcomes in congenital and pediatric cardiac surgery and reviews related activities in the areas of quality measurement, performance improvement, and transparency. The reported data about aggregate national outcomes are exemplified by an analysis of 10 benchmark operations performed from January 2011 to December 2014 and documenting overall discharge mortality (interquartile range among programs with more than 9 cases): off-bypass coarctation, 1.0% (0.0% to 0.9%); ventricular septal defect repair, 0.7% (0.0% to 1.1%); tetralogy of Fallot repair, 1.0% (0.0% to 1.7%); complete atrioventricular canal repair, 3.2% (0.0% to 6.5%); arterial switch operation, 2.7% (0.0% to 5.6%); arterial switch operation plus ventricular septal defect, 5.3% (0.0% to 6.7%); Glenn/hemiFontan, 2.1% (0.0% to 3.8%); Fontan operation, 1.4% (0.0% to 2.4%); truncus arteriosus repair, 9.6% (0.0 % to 11.8%); and Norwood procedure, 15.6% (10.0% to 21.4%). (C) 2016 by The Society of Thoracic Surgeons
C1 [Jacobs, Jeffrey P.; Mavroudis, Constantine; Jacobs, Marshall L.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD 21205 USA.
[Jacobs, Jeffrey P.; Mavroudis, Constantine; Jacobs, Marshall L.] Univ S Florida, All Childrens Hosp, Dept Surg, Div Cardiovasc Surg, St Petersburg, FL 33701 USA.
[Jacobs, Jeffrey P.; Mavroudis, Constantine; Jacobs, Marshall L.] Florida Hosp Children, St Petersburg, FL USA.
[Jacobs, Jeffrey P.; Mavroudis, Constantine; Jacobs, Marshall L.] All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, Dept Surg, Div Cardiovasc Surg, Tampa, FL USA.
[Jacobs, Jeffrey P.; Mavroudis, Constantine; Jacobs, Marshall L.] Florida Hosp Children, Tampa, FL USA.
[Jacobs, Jeffrey P.; Mavroudis, Constantine; Jacobs, Marshall L.] All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, Dept Surg, Div Cardiovasc Surg, Orlando, FL USA.
[Mayer, John E., Jr.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
[O'Brien, Sean M.; Hill, Kevin D.; He, Xia; Dokholyan, Rachel S.] Duke Univ, Durham, NC USA.
[Austin, Erle H., III] Univ Louisville, Kosair Childrens Hosp, Louisville, KY 40292 USA.
[Pasquali, Sara K.; Hirsch-Romano, Jennifer C.] Univ Michigan, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA.
[Overman, David M.] Childrens Hosp & Clin Minnesota, Childrens Heart Clin, Minneapolis, MN USA.
[St Louis, James D.] Univ Missouri, Sch Med, Dept Surg, Kansas City, MO 64108 USA.
[Karamlou, Tara] Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Cardiac Surg, San Francisco, CA 94143 USA.
[Pizarro, Christian] Alfred I duPont Hosp, Nemours, Wilmington, DE USA.
[McDonald, Donna; Han, Jane M.] Soc Thorac Surg, Chicago, IL USA.
[Tchervenkov, Christo I.] McGill Univ, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada.
[Lacour-Gayet, Francois] Royal Hosp, Muscat, Oman.
[Backer, Carl L.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Chicago, IL 60611 USA.
[Fraser, Charles D.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA.
[Tweddell, James S.] Cincinnati Childrens Hosp Med Ctr, Inst Heart, Cincinnati, OH 45229 USA.
[Elliott, Martin J.] Great Ormond St Hosp Sick Children, London, England.
[Walters, Hal, III] Wayne State Univ, Sch Med, Childrens Hosp Michigan, Detroit, MI USA.
[Jonas, Richard A.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Prager, Richard L.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Shahian, David M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Jacobs, JP (reprint author), John Hopkins All Childrens Heart Inst, Div Cardiovasc Surg, 601 Fifth St S, St Petersburg, FL 33701 USA.
EM jeffjacobs@msn.com; jeffjacobs@msn.com
NR 52
TC 6
Z9 6
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAR
PY 2016
VL 101
IS 3
BP 850
EP 862
DI 10.1016/j.athoracsur.2016.01.057
PG 13
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DE0UF
UT WOS:000370339700014
PM 26897186
ER
PT J
AU Tapias, LF
Mathisen, DJ
Wright, CD
Wain, JC
Gaissert, HA
Muniappan, A
Lanuti, M
Donahue, DM
Morse, CR
AF Tapias, Luis F.
Mathisen, Douglas J.
Wright, Cameron D.
Wain, John C.
Gaissert, Henning A.
Muniappan, Ashok
Lanuti, Michael
Donahue, Dean M.
Morse, Christopher R.
TI Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After
Neoadjuvant Therapy
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID CANCER; CHEMORADIOTHERAPY
AB Background. Neoadjuvant therapy is integral in the treatment of locally advanced esophageal cancer. Despite increasing acceptance of minimally invasive approaches to esophagectomy, there remain concerns about the safety and oncologic soundness after neoadjuvant therapy. We examined outcomes in patients undergoing open and minimally invasive (MIE) Ivor Lewis esophagectomy after neoadjuvant therapy.
Methods. This was a retrospective series of 130 consecutive patients with esophageal cancer undergoing Ivor Lewis esophagectomy with curative intention after neoadjuvant therapy at a tertiary academic center (2008 to 2012).
Results. An open procedure was performed in 74 patients (56.9%), and 56 (43.1%) underwent MIE after neoadjuvant therapy. MIE patients had shorter median intensive care unit (p = 0.002) and hospital lengths of stay (p < 0.0001). The incidence of postoperative complications was similar (open: 54.8% vs MIE: 41.1%, p = 0.155). However, observed respiratory complications were significantly reduced after MIE (8.9%) compared with open (29.7%; p = 0.004). Anastomotic leak rates were similar (open: 1.4% vs. MIE: 0%, p = 1.00). Mortality at 30 and 90 days was comparable (open: 2.7% and 4.1% vs MIE: 0% and 1.8%, p = 0.506 and p = 0.634, respectively). Complete resection rates and the number of collected lymph nodes was similar. Overall survival rates at 5 years were similar (open: 61% vs MIE: 50%, p = 0.933). MIE was not a significant predictor of overall survival (hazard ratio, 1.07; 95% confidence interval, 0.61 to 1.87; p = 0.810).
Conclusions. MIE proves its safety after neoadjuvant therapy because it leads to faster progression during the early postoperative period while reducing pulmonary complications. Open and MIE approaches appear equivalent with regards to perioperative oncologic outcomes after neoadjuvant therapy. Long-term outcomes need further validation. (C) 2016 by The Society of Thoracic Surgeons
C1 [Tapias, Luis F.; Mathisen, Douglas J.; Wright, Cameron D.; Wain, John C.; Gaissert, Henning A.; Muniappan, Ashok; Lanuti, Michael; Donahue, Dean M.; Morse, Christopher R.] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA.
RP Morse, CR (reprint author), 55 Fruit St,BLK-1570, Boston, MA 02114 USA.
EM crmorse@partners.org
NR 15
TC 4
Z9 5
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAR
PY 2016
VL 101
IS 3
BP 1097
EP 1103
DI 10.1016/j.athoracsur.2015.09.062
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DE0UF
UT WOS:000370339700046
PM 26652140
ER
PT J
AU Kon, ZN
Pasrija, C
Shah, A
Griffith, BP
Garcia, JP
AF Kon, Zachary N.
Pasrija, Chetan
Shah, Aakash
Griffith, Bartley P.
Garcia, Jose P.
TI Venovenous Extracorporeal Membrane Oxygenation With Atrial Septostomy as
a Bridge to Lung Transplantation
SO ANNALS OF THORACIC SURGERY
LA English
DT Editorial Material
ID VENTRICULAR FAILURE; PULMONARY
AB We report the first successful bridge to lung transplantation using venovenous extracorporeal membrane oxygenation (ECMO) with an atrial septostomy for both pulmonary and right ventricular support. This strategy may provide an alternative to other forms of ECMO support as a bridge to lung transplantation, and potentially allow for ambulation and rehabilitation. (C) 2016 by The Society of Thoracic Surgeons
C1 [Kon, Zachary N.] Univ Maryland, Sch Med, Div Cardiac Surg, 110 S Paca St,7th Flr, Baltimore, MD 21201 USA.
Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA.
RP Kon, ZN (reprint author), Univ Maryland, Sch Med, Div Cardiac Surg, 110 S Paca St,7th Flr, Baltimore, MD 21201 USA.
EM zkon@smail.umaryland.edu
NR 8
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAR
PY 2016
VL 101
IS 3
BP 1166
EP 1169
DI 10.1016/j.athoracsur.2015.03.127
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DE0UF
UT WOS:000370339700057
PM 26897198
ER
PT J
AU Blackmon, SH
Cooke, DT
Whyte, R
Miller, D
Cerfolio, R
Farjah, F
Rocco, G
Blum, M
Hazelrigg, S
Howington, J
Low, D
Swanson, S
Fann, JI
Ikonomidis, JS
Wright, C
Grondin, SC
AF Blackmon, Shanda H.
Cooke, David T.
Whyte, Richard
Miller, Daniel
Cerfolio, Robert
Farjah, Farhood
Rocco, Gaetano
Blum, Matthew
Hazelrigg, Stephen
Howington, John
Low, Donald
Swanson, Scott
Fann, James I.
Ikonomidis, John S.
Wright, Cameron
Grondin, Sean C.
TI The Society of Thoracic Surgeons Expert Consensus Statement: A Tool Kit
to Assist Thoracic Surgeons Seeking Privileging to Use New Technology
and Perform Advanced Procedures in General Thoracic Surgery
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID LICENSURE
C1 [Blackmon, Shanda H.] Mayo Clin, Div Gen Thorac Surg, 200 First St,MA 12-54W, Rochester, MN 55905 USA.
Univ Calif Davis, Davis Med Ctr, Sect Gen Thorac Surg, Sacramento, CA 95817 USA.
Beth Israel Deaconess Med Ctr, Div Thorac Surg, Boston, MA 02215 USA.
WellStar Hlth Syst, Div Thorac Surg, Marietta, GA USA.
Univ Alabama Birmingham, Div Cardiothorac Surg, Birmingham, AL USA.
Univ Washington, Div Cardiothorac Surg, Seattle, WA 98195 USA.
Pascale Fdn, Natl Canc Inst, Naples, Italy.
Mem Hosp Univ Colorado Hlth, Div Thorac Surg, Colorado Springs, CO USA.
So Illinois Univ, Dept Surg, Springfield, IL USA.
NorthShore Univ Hlth Syst, Div Thorac Surg, Evanston, IL USA.
Virginia Mason Med Ctr, Esophageal Ctr Excellence, Seattle, WA 98101 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Div Thorac Surg, 75 Francis St, Boston, MA 02115 USA.
Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA.
Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA.
Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA.
Univ Calgary, Foothills Med Ctr, Div Thorac Surg, Calgary, AB, Canada.
RP Blackmon, SH (reprint author), Mayo Clin, Div Gen Thorac Surg, 200 First St,MA 12-54W, Rochester, MN 55905 USA.
EM blackmon.shanda@mayo.edu
RI Rocco, Gaetano/K-4801-2016
OI Rocco, Gaetano/0000-0003-4150-8604
NR 12
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAR
PY 2016
VL 101
IS 3
BP 1230
EP 1237
DI 10.1016/j.athoracsur.2016.01.061
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DE0UF
UT WOS:000370339700078
PM 27124326
ER
PT J
AU Townsley, E
O'Connor, G
Cosgrove, C
Woda, M
Co, M
Thomas, SJ
Kalayanarooj, S
Yoon, IK
Nisalak, A
Srikiatkhachorn, A
Green, S
Stephens, HAF
Gostick, E
Price, DA
Carrington, M
Alter, G
McVicar, DW
Rothman, AL
Mathew, A
AF Townsley, E.
O'Connor, G.
Cosgrove, C.
Woda, M.
Co, M.
Thomas, S. J.
Kalayanarooj, S.
Yoon, I. -K.
Nisalak, A.
Srikiatkhachorn, A.
Green, S.
Stephens, H. A. F.
Gostick, E.
Price, D. A.
Carrington, M.
Alter, G.
McVicar, D. W.
Rothman, A. L.
Mathew, A.
TI Interaction of a dengue virus NS1-derived peptide with the inhibitory
receptor KIR3DL1 on natural killer cells
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE dengue; HLA; KIR; NK; pathogenesis
ID NK-CELLS; DISEASE SEVERITY; HLA-B; ETHNIC THAIS; T-CELLS;
ANTIBODY-RESPONSE; INFECTION; ASSOCIATIONS; RECOGNITION; CORRELATE
AB Killer immunoglobulin-like receptors (KIRs) interact with human leucocyte antigen (HLA) class I ligands and play a key role in the regulation and activation of NK cells. The functional importance of KIR-HLA interactions has been demonstrated for a number of chronic viral infections, but to date only a few studies have been performed in the context of acute self-limited viral infections. During our investigation of CD8(+) T cell responses to a conserved HLA-B57-restricted epitope derived from dengue virus (DENV) non-structural protein-1 (NS1), we observed substantial binding of the tetrameric complex to non-T/non-B lymphocytes in peripheral blood mononuclear cells (PBMC) from a long-standing clinical cohort in Thailand. We confirmed binding of the NS1 tetramer to CD56(dim) NK cells, which are known to express KIRs. Using depletion studies and KIR-transfected cell lines, we demonstrated further that the NS1 tetramer bound the inhibitory receptor KIR3DL1. Phenotypical analysis of PBMC from HLA-B57(+) subjects with acute DENV infection revealed marked activation of NS1 tetramer-binding natural killer (NK) cells around the time of defervescence in subjects with severe dengue disease. Collectively, our findings indicate that subsets of NK cells are activated relatively late in the course of acute DENV illness and reveal a possible role for specific KIR-HLA interactions in the modulation of disease outcomes.
C1 [Townsley, E.; Woda, M.; Co, M.; Srikiatkhachorn, A.; Green, S.; Mathew, A.] Univ Massachusetts, Med Ctr, Div Infect Dis & Immunol, Worcester, MA USA.
[O'Connor, G.; Carrington, M.; McVicar, D. W.] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Canc & Inflammat Program, Expt Immunol Lab, Frederick, MD USA.
[Cosgrove, C.; Carrington, M.; Alter, G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ragon Inst MGH MIT & Harvard, Boston, MA USA.
[Thomas, S. J.] Walter Reed Army Inst Res, Silver Spring, MD USA.
[Kalayanarooj, S.] Queen Sirikit Natl Inst Child Hlth, Bangkok, Thailand.
[Yoon, I. -K.; Nisalak, A.] Armed Forces Res Inst Med Sci, Dept Virol, Bangkok 10400, Thailand.
[Stephens, H. A. F.] UCL, Ctr Nephrol & Anthony Nolan Trust, Royal Free Campus, London, England.
[Gostick, E.; Price, D. A.] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF10 3AX, S Glam, Wales.
[Price, D. A.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Rothman, A. L.] Univ Rhode Isl, Inst Immunol & Informat, 825 Chalkstone Ave, Providence, RI 02908 USA.
RP Mathew, A (reprint author), Univ Massachusetts, Div Infect Dis & Immunol, Sch Med, S6-862,55 Lake Ave North, Worcester, MA 01655 USA.
EM anuja.mathew@umassmed.edu
RI Price, David/C-7876-2013
OI Price, David/0000-0001-9416-2737
FU National Institutes of Health (NIH) [P01 AI34533, U19 AI57319, R21
AI113479, P30 DK032520]; Frederick National Laboratory for Cancer
Research [HHSN261200800001E]; NIH, Frederick National Laboratory, Center
for Cancer Research
FX We thank the subjects who generously donated peripheral blood samples
for use in our studies, the NIAID Tetramer Core Facility for provision
of the B57-NS126-34 tetramer, Brenda Hartman for expert assistance with
graphics and Dr Suchitra Nimmannitya and staff at the Queen Sirikit
National Institute for Child Health, the Department of Virology, Armed
Forces Research Institute of Medical Sciences and the Department of
Transfusion Medicine, Siriraj Hospital, for patient recruitment, sample
collection and clinical, virological and HLA typing information. This
work was funded by the National Institutes of Health (NIH) via Grants
P01 AI34533, U19 AI57319 and R21 AI113479 with core support from NIH P30
DK032520 and federal funds from the Frederick National Laboratory for
Cancer Research under Contract No. HHSN261200800001E. Additional support
was provided by the Intramural Research Program of the NIH, Frederick
National Laboratory, Center for Cancer Research. The content of this
publication does not necessarily reflect the views or policies of the
Department of Health and Human Services, nor does mention of trade
names, commercial products or organizations imply endorsement by the US
Government. D. A. P. is a Wellcome Trust Senior Investigator.
NR 48
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD MAR
PY 2016
VL 183
IS 3
BP 419
EP 430
DI 10.1111/cei.12722
PG 12
WC Immunology
SC Immunology
GA DD8NU
UT WOS:000370184600011
PM 26439909
ER
PT J
AU Thrift, AP
El-Serag, HB
AF Thrift, Aaron P.
El-Serag, Hashem B.
TI Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma:
Observations and Explanations
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Editorial Material
ID UNITED-STATES; BARRETTS-ESOPHAGUS; CIGARETTE-SMOKING; AFRICAN-AMERICANS;
RISK; WHITES; TRENDS
C1 [Thrift, Aaron P.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[El-Serag, Hashem B.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
RP Thrift, AP (reprint author), Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
NR 16
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD MAR
PY 2016
VL 14
IS 3
BP 330
EP 332
DI 10.1016/j.cgh.2015.10.028
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE1HC
UT WOS:000370376700007
PM 26528803
ER
PT J
AU Kang, XY
Zhao, LN
Leung, F
Luo, H
Wang, LM
Wu, J
Guo, XY
Wang, XP
Zhang, LH
Hui, N
Tao, Q
Jia, H
Liu, ZG
Chen, ZQ
Liu, JJ
Wu, KC
Fan, DM
Pan, YL
Guo, XG
AF Kang, Xiaoyu
Zhao, Lina
Leung, Felix
Luo, Hui
Wang, Limei
Wu, Ji
Guo, Xiaoyang
Wang, Xiangping
Zhang, Linhui
Hui, Na
Tao, Qin
Jia, Hui
Liu, Zhiguo
Chen, Zhangqin
Liu, Junjun
Wu, Kaichun
Fan, Daiming
Pan, Yanglin
Guo, Xuegang
TI Delivery of Instructions via Mobile Social Media App Increases Quality
of Bowel Preparation
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Colon Cancer Screening; Bowel Preparation; ADR
ID ADENOMA DETECTION RATE; COLORECTAL-CANCER; COLONOSCOPY PREPARATION;
PATIENT EDUCATION; VALIDATION; RISK; RECOMMENDATIONS; INDICATORS;
SOCIETY; IMPACT
AB BACKGROUND & AIMS: Bowel preparation is closely linked to the quality of colonoscopy. We investigated whether delivery of instructions via a social media app increases the quality of colonoscopy by improving adequacy of bowel preparation.
METHODS: We performed a prospective study at 3 endoscopic centers in China of 770 colonoscopy outpatients (18-80 years old) with convenient access to Wechat (a widely used mobile social media app) from May through November 2014. Patients were randomly assigned to groups that received standard education along with delivery of interactive information via Wechat (n = 387) or standard education (controls, n = 383). The primary outcome was proportion of patients with adequate bowel preparation (Ottawa score <6). Secondary outcomes included rates of adenoma detection and cecal intubation, cecal intubation time, rates of incomplete compliance with instructions, and patient willingness to repeat bowel preparation.
RESULTS: Demographic features were comparable between the groups. A higher proportion of patients in the group that received social media instruction had adequate bowel preparation than the control group (82.2% vs 69.5%, P < .001). Among patients with successful colonoscopies, the group that received social media instruction had lower mean total and segmental Ottawa scores (P < .05). A higher proportion of patients receiving social media instruction also had cecal intubation (97.2% vs 93.2% in controls, P = .014) and were found to have adenomas (18.6% vs 12.0% in controls, P = .012).
CONCLUSIONS: Instruction via a mobile social media app, in conjunction with regular instruction, increases subjective measures of adequacy of bowel preparation. Use of the app significantly increased the proportion of patients with successful cecal intubation and in whom adenomas were detected, indicating increased quality of colonoscopy. ClinicalTrials.gov number: NCT02140827
C1 [Kang, Xiaoyu; Luo, Hui; Guo, Xiaoyang; Wang, Xiangping; Zhang, Linhui; Hui, Na; Tao, Qin; Jia, Hui; Liu, Zhiguo; Wu, Kaichun; Fan, Daiming; Pan, Yanglin; Guo, Xuegang] Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
[Zhao, Lina] Fourth Mil Med Univ, Xijing Hosp, Dept Radiotherapy, Xian 710032, Shaanxi, Peoples R China.
[Leung, Felix] VA Greater Los Angeles Healthcare Syst, Sepulveda ACC, North Hill, CA USA.
[Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Wang, Limei; Chen, Zhangqin] Shaanxi Second Peoples Hosp, Dept Gastroenterol, Xian, Peoples R China.
[Wu, Ji; Liu, Junjun] Chancheng Cent Hosp Foshan, Dept Gastroenterol, Foshan, Peoples R China.
RP Pan, YL; Guo, XG (reprint author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
EM yanglinpan@hotmail.com; xuegangguo@gmail.com
FU National Natural Science Foundation of China [81172288, 81370585]
FX Supported in part by the National Natural Science Foundation of China
(81172288 and 81370585).
NR 23
TC 4
Z9 4
U1 7
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD MAR
PY 2016
VL 14
IS 3
BP 429
EP +
DI 10.1016/j.cgh.2015.09.038
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE1HC
UT WOS:000370376700021
PM 26492848
ER
PT J
AU Khan, A
Kanwal, F
AF Khan, Anam
Kanwal, Fasiha
TI Treatment of Alcohol Use Disorders: Benchmarking Houston, Texas, and
Philadelphia, Pennsylvania Reply
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Letter
C1 [Khan, Anam] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Kanwal, Fasiha] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[Kanwal, Fasiha] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA.
[Kanwal, Fasiha] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Kanwal, Fasiha] Texas Med Ctr Digest Dis Ctr, Houston, TX USA.
[Kanwal, Fasiha] Dan L Duncan Canc Ctr, Houston, TX USA.
RP Khan, A (reprint author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD MAR
PY 2016
VL 14
IS 3
BP 487
EP 488
DI 10.1016/j.cgh.2015.12.010
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DE1HC
UT WOS:000370376700037
PM 26689902
ER
PT J
AU Ring, D
Bozic, KJ
AF Ring, David
Bozic, Kevin J.
TI Value-based Healthcare: The Value of Considering Patient Preferences and
Circumstances in Orthopaedic Surgery
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Editorial Material
C1 [Ring, David] Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA 02114 USA.
[Bozic, Kevin J.] Univ Texas Austin, Dell Med Sch, Dept Surg & Perioperat Care, 1400 Barbara Jordan Blvd,Suite 1-114, Austin, TX 78723 USA.
RP Bozic, KJ (reprint author), Univ Texas Austin, Dell Med Sch, Dept Surg & Perioperat Care, 1400 Barbara Jordan Blvd,Suite 1-114, Austin, TX 78723 USA.
EM kevin.bozic@austin.utexas.edu
NR 5
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAR
PY 2016
VL 474
IS 3
BP 633
EP 635
DI 10.1007/s11999-015-4648-4
PG 3
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD8BV
UT WOS:000370150000007
PM 26626925
ER
PT J
AU Nazarian, A
Entezari, V
Villa-Camacho, JC
Zurakowski, D
Katz, JN
Hochman, M
Baldini, EH
Vartanians, V
Rosen, MP
Gebhardt, MC
Terek, RM
Damron, TA
Yaszemski, MJ
Snyder, BD
AF Nazarian, Ara
Entezari, Vahid
Villa-Camacho, Juan C.
Zurakowski, David
Katz, Jeffrey N.
Hochman, Mary
Baldini, Elizabeth H.
Vartanians, Vartan
Rosen, Max P.
Gebhardt, Mark C.
Terek, Richard M.
Damron, Timothy A.
Yaszemski, Michael J.
Snyder, Brian D.
TI Does CT-based Rigidity Analysis Influence Clinical Decision-making in
Simulations of Metastatic Bone Disease?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article; Proceedings Paper
CT Symposium of the Musculoskeletal-Tumor-Society
CY OCT 09-11, 2014
CL Houston, TX
SP Musculoskeletal Tumor Soc
ID PATHOLOGICAL FRACTURE; PREDICTING FRACTURE; COMPUTED-TOMOGRAPHY; SCORING
SYSTEM; OF-LIFE; RISK; LESIONS
AB There is a need to improve the prediction of fracture risk for patients with metastatic bone disease. CT-based rigidity analysis (CTRA) is a sensitive and specific method, yet its influence on clinical decision-making has never been quantified.
What is the influence of CTRA on providers' perceived risk of fracture? (2) What is the influence of CTRA on providers' treatment recommendations in simulated clinical scenarios of metastatic bone disease of the femur? (3) Does CTRA improve interobserver agreement regarding treatment recommendations?
We conducted a survey among 80 academic physicians (orthopaedic oncologists, musculoskeletal radiologists, and radiation oncologists) using simulated vignettes of femoral lesions presented as three separate scenarios: (1) no CTRA input (baseline); (2) CTRA input suggesting increased risk of fracture (CTRA+); and (3) CTRA input suggesting decreased risk of fracture (CTRA-). Participants were asked to rate the patient's risk of fracture on a scale of 0% to 100% and to provide a treatment recommendation. Overall response rate was 62.5% (50 of 80).
When CTRA suggested an increased risk of fracture, physicians perceived the fracture risk to be slightly greater (37% +/- 3% versus 42% +/- 3%, p < 0.001; mean difference [95% confidence interval {CI}] = 5% [4.7%-5.2%]) and were more prone to recommend surgical stabilization (46% +/- 9% versus 54% +/- 9%, p < 0.001; mean difference [95% CI] = 9% [7.9-10.1]). When CTRA suggested a decreased risk of fracture, physicians perceived the risk to be slightly decreased (37% +/- 25% versus 35% +/- 25%, p = 0.04; mean difference [95% CI] = 2% [2.74%-2.26%]) and were less prone to recommend surgical stabilization (46% +/- 9% versus 42% +/- 9%, p < 0.03; mean difference [95% CI] = 4% [3.9-5.1]). The effect size of the influence of CTRA on physicians' perception of fracture risk and treatment planning varied with lesion severity and specialty of the responders. CTRA did not increase interobserver agreement regarding treatment recommendations when compared with the baseline scenario (kappa = 0.41 versus kappa = 0.43, respectively).
Based on this survey study, CTRA had a small influence on perceived fracture risk and treatment recommendations and did not increase interobserver agreement. Further work is required to properly introduce this technique to physicians involved in the care of patients with metastatic lesions. Given the number of preclinical and clinical studies outlining the efficacy of this technique, better education through presentations at seminars/webinars and symposia will be the first step. This should be followed by clinical trials to establish CTRA-based clinical guidelines based on evidence-based medicine. Increased exposure of clinicians to CTRA, including its underlying methodology to study bone structural characteristics, may establish CTRA as a uniform guideline to assess fracture risk.
Level III, economic and decision analyses.
C1 [Nazarian, Ara; Entezari, Vahid; Villa-Camacho, Juan C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies,Dept Orthopaed Surg, 330 Brookline Ave,RN 115, Boston, MA 02215 USA.
[Zurakowski, David] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Anesthesiol, Boston, MA 02215 USA.
[Zurakowski, David] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Surg, Boston, MA 02215 USA.
[Katz, Jeffrey N.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Orthoped & Arthrit Ctr Outcomes Res, Boston, MA 02215 USA.
[Hochman, Mary; Rosen, Max P.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
[Baldini, Elizabeth H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA.
[Baldini, Elizabeth H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02215 USA.
[Vartanians, Vartan] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02215 USA.
[Gebhardt, Mark C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, Boston, MA 02215 USA.
[Terek, Richard M.] Brown Univ, Warren Alpert Med Sch, Rhode Isl Hosp, Dept Orthopaed Surg, Providence, RI 02912 USA.
[Damron, Timothy A.] SUNY Upstate Med Univ, Dept Orthopaed Surg, Syracuse, NY 13210 USA.
[Yaszemski, Michael J.] Mayo Clin, Dept Orthopaed Surg, Rochester, MN USA.
[Snyder, Brian D.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Orthopaed Surg, Boston, MA 02215 USA.
RP Nazarian, A (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies,Dept Orthopaed Surg, 330 Brookline Ave,RN 115, Boston, MA 02215 USA.
EM anazaria@bidmc.harvard.edu
OI terek, richard/0000-0002-6322-6790
FU NIAMS NIH HHS [T32 AR055885, L30 AR056606]
NR 17
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAR
PY 2016
VL 474
IS 3
BP 652
EP 659
DI 10.1007/s11999-015-4371-1
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD8BV
UT WOS:000370150000011
PM 26022114
ER
PT J
AU Phukan, R
Herzog, T
Boland, PJ
Healey, J
Rose, P
Sim, FH
Yazsemski, M
Hess, K
Osler, P
DeLaney, TF
Chen, YL
Hornicek, F
Schwab, J
AF Phukan, Rishabh
Herzog, Tyler
Boland, Patrick J.
Healey, John
Rose, Peter
Sim, Franklin H.
Yazsemski, Michael
Hess, Kathryn
Osler, Polina
DeLaney, Thomas F.
Chen, Yen -Lin
Hornicek, Francis
Schwab, Joseph
TI How Does the Level of Sacral Resection for Primary Malignant Bone Tumors
Affect Physical and Mental Health, Pain, Mobility, Incontinence, and
Sexual Function?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article; Proceedings Paper
CT Symposium of the Musculoskeletal-Tumor-Society
CY OCT 09-11, 2014
CL Houston, TX
SP Musculoskeletal Tumor Soc
ID DOSE PHOTON/PROTON RADIOTHERAPY; PROGNOSTIC-FACTORS; SACRECTOMY;
CHORDOMAS; CHONDROSARCOMAS; MANAGEMENT; SPINE; RECONSTRUCTION;
FRACTURES; SACRIFICE
AB En bloc resection for treatment of sacral tumors is the approach of choice for patients with resectable tumors who are well enough to undergo surgery, and studies describe patient survival, postoperative complications, and recurrence rates associated with this treatment. However, most of these studies do not provide patient-reported functional outcomes other than binary metrics for bowel and bladder function postresection.
The purpose of this study was to use validated patient-reported outcomes tools to compare quality of life based on level of sacral resection in terms of (1) physical and mental health; (2) pain; (3) mobility; and (4) incontinence and sexual function.
Our analysis included 33 patients (19 men, 14 women) who had a mean age of 53 years (range, 22-72 years) with a quality-of-life survey administered at a mean postoperative followup of 41 months (range, 6-123 months). The majority of patient-reported quality-of-life outcome surveys for this study were taken from the National Institute of Health's Patient Reported Outcome Measurement Information System (PROMIS) system. To assess physical and mental health, the PROMIS Global Items Survey with physical and mental subscores, Anxiety, and Depression scores were used. Pain outcomes were assessed using PROMIS Pain Intensity and Pain Interference surveys. Patient-reported lower extremity function was assessed using the PROMIS Mobility Survey. Patient-reported quality of life for sexual function was assessed using the PROMIS Sex Interest and Orgasm survey, whereas incontinence was measured using the International Continence Society Voiding and Incontinence scores and the Modified Obstruction and Defecation Score. Surveys were collected prospectively during clinic visits in the postoperative period. Patients were grouped by the level of osteotomy as determined by review of postoperative MRI or CT and half levels were grouped with the more cephalad level. This resulted in the inclusion of total sacrectomy (N = 6), S1 (N = 8), S2 (N = 10), S3 (N = 5), and S4 (N = 4). One-way analysis of variance tests on means or ranks were used to conduct statistical analysis between levels.
Patients with more caudal resections had higher physical health (95% confidence interval [CI] total sacrectomy 36-42 versus S4 50-64, p < 0.001), less intense pain (95% CI total sacrectomy 47-60 versus S4 28-37, p < 0.001), less interference resulting from pain (95% CI total sacrectomy 58-69 versus S4 36-51, p = 0.004), higher mobility (95% CI total sacrectomy 24-46 versus S4 59-59, p = 0.002), and were more functionally able to achieve orgasm (95% CI S1 1-1 versus S4 2.2-5.3, p = 0.043). No difference was found for PROMIS Global Item Mental Health Subscore, Sex Interest, Sex Satisfaction, modified obstruction and defecation score, and International Continence Society Voiding and Incontinence although this could be the result of an inadequate sample size.
Our analysis on patient-reported quality of life based on the level of bony resection in patients who underwent resection for primary sacral tumor indicates that patients with higher resections have more pain and loss of physical function in comparison to patients with lower resections. Additionally, use of the PROMIS outcomes allows for comparisons to normative data.
Level III, therapeutic study.
C1 [Phukan, Rishabh; Herzog, Tyler; Hess, Kathryn; Osler, Polina; Hornicek, Francis; Schwab, Joseph] Massachusetts Gen Hosp, Dept Orthopaed Surg, Yawkey 3A,55 Fruit St, Boston, MA 02114 USA.
[Boland, Patrick J.; Healey, John] Mem Sloan Kettering Canc Ctr, Dept Orthopaed Surg, 1275 York Ave, New York, NY 10021 USA.
[Rose, Peter] Cleveland Clin, Dept Gynecol Oncol, Cleveland, OH 44106 USA.
[Sim, Franklin H.; Yazsemski, Michael] Mayo Clin, Dept Orthopaed Oncol, Rochester, MN USA.
[DeLaney, Thomas F.; Chen, Yen -Lin] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Phukan, R (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Yawkey 3A,55 Fruit St, Boston, MA 02114 USA.
EM rphukan@partners.org
FU NCI NIH HHS [5P01 CA21239-33, P01 CA021239, P30 CA008748]
NR 20
TC 8
Z9 8
U1 3
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAR
PY 2016
VL 474
IS 3
BP 687
EP 696
DI 10.1007/s11999-015-4361-3
PG 10
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD8BV
UT WOS:000370150000017
PM 26013155
ER
PT J
AU Osler, P
Bredella, MA
Hess, KA
Janssen, SJ
Park, CJ
Chen, YL
DeLaney, TF
Hornicek, FJ
Schwab, JH
AF Osler, Polina
Bredella, Miriam A.
Hess, Kathryn A.
Janssen, Stein J.
Park, Christine J.
Chen, Yen Lin
DeLaney, Thomas F.
Hornicek, Francis J.
Schwab, Joseph H.
TI Sacral Insufficiency Fractures are Common After High-dose Radiation for
Sacral Chordomas Treated With or Without Surgery
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID BONE COMPLICATIONS; PELVIC RADIATION; RADIOTHERAPY; IRRADIATION;
MANAGEMENT; THERAPY; PAIN
AB Surgery with high-dose radiation and high-dose radiation alone for sacral chordomas have shown promising local control rates. However, we have noted frequent sacral insufficiency fractures and perceived this rate to be higher than previously reported.
We wished (1) to characterize the incidence of sacral insufficiency fractures in patients with chordomas of the sacrum who received high-dose radiation, and (2) to determine whether patients treated with surgery plus high-dose radiation or high-dose radiation alone are more likely to experience a sacral fracture, and to compare time to fracture in these groups.
Sixty-two patients who received high-dose radiation for sacral chordomas with (n = 44) or without surgical resection (n = 18) between 1992 and 2013 were included in this retrospective study. At our institution, sacral chordomas generally are treated by preoperative radiotherapy, followed by en bloc resection, and postoperative radiotherapy. Radiation alone, with an intent to cure, is offered to patients who otherwise are not good surgical candidates or patients who elect radiotherapy based on tumor location and the anticipated morbidity after surgery (such as sexual, bowel, or bladder dysfunction). MRI and CT scans were evaluated for evidence of sacral insufficiency fractures. Complete followup was available at a minimum of 2 years (or until fracture or death) for all 18 patients who underwent radiation alone, whereas 14% (six of 44 patients) in the surgery plus radiation group (9% [three of 33] after high sacrectomy and 27% [three of 11] after low sacrectomy) were lost to followup before 2 years.
Sacral insufficiency fractures occurred in 29 of the 62 patients (47%). A total of 25 of 33 patients (76%) with high sacrectomy had fractures develop compared with zero of 11 (0%) after low sacrectomy, and four of the 18 patients (22%) who had high-dose radiation alone (p < 0.001). The fracture rate was greater in the high sacrectomy group than in the low sacrectomy group (p < 0.001) and the radiation only group (p < 0.001). There was no difference with the numbers evaluated in fracture probability between patients in the low-sacrectomy group and those treated with radiation alone (p = 0.112). The fracture-free survival probability was 0.99 for the low sacrectomy group at all times as there were no insufficiency fractures in this group; the 1-year fracture-free survival probability was 0.53 (95% CI, 0.35-0.69) after high sacrectomy, 0.83 (95% CI, 0.57-0.94) after radiation alone; the 2-year fracture-free survival probability was 0.36 (95% CI, 0.19-0.52) after high sacrectomy and 0.77 (95% CI, 0.50-0.91) after radiation alone; and the 5-year fracture-free survival probability was 0.14 (95% CI, 0.04-0.30) after high sacrectomy and 0.77 (95% CI, 0.50-0.91) after radiation alone.
Acknowledging the limitations of potential differences in baseline and followup among treatment groups in our study, we found that almost A1/2 of our patients experienced an insufficiency fracture. We found that the fracture rate was greater in the surgery group compared with the radiation alone group and that high sacrectomy accounted for all fractures in the surgery group. These findings can be used to inform patients and also support the need for further research to elucidate the influence of high-dose radiation on bone quality.
Level III, therapeutic study.
C1 [Osler, Polina] Harvard Univ, Sch Med, Boston, MA USA.
[Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Musculoskeletal Imaging & Intervent, Boston, MA 02114 USA.
[Hess, Kathryn A.] Tufts Med Ctr, Dept Orthopaed Surg, Boston, MA USA.
[Janssen, Stein J.; Park, Christine J.; Hornicek, Francis J.; Schwab, Joseph H.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Orthopaed Oncol Serv, 55 Fruit St, Boston, MA 02114 USA.
[Chen, Yen Lin; DeLaney, Thomas F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Janssen, SJ (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Orthopaed Oncol Serv, 55 Fruit St, Boston, MA 02114 USA.
EM steinjanssen@gmail.com
FU Anna Foundation (Oegstgeest, The Netherlands); De Drie Lichten
Foundation (Hilversum, The Netherlands); KWF Kankerbestrijding
(Amsterdam, The Netherlands); Michael van Vloten Foundation (Rotterdam,
The Netherlands); Stryker (Kalamazoo, MI, USA); Biom'up (Saint-Priest,
Lyon, France)
FX One author (SJJ) certifies that he has received, an amount less than USD
10,000 from the Anna Foundation (Oegstgeest, The Netherlands), an amount
less than USD 10,000 from the De Drie Lichten Foundation (Hilversum, The
Netherlands), an amount less than USD 10,000 from the KWF
Kankerbestrijding (Amsterdam, The Netherlands), and an amount less than
USD10,000 from the Michael van Vloten Foundation (Rotterdam, The
Netherlands). One author (JHS) certifies that he or a member of his
family has or may receive payments or benefits, an amount less than USD
10,000 from Stryker (Kalamazoo, MI, USA), and an amount less than USD
10,000 from Biom'up (Saint-Priest, Lyon, France).
NR 24
TC 1
Z9 1
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAR
PY 2016
VL 474
IS 3
BP 766
EP 772
DI 10.1007/s11999-015-4566-5
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD8BV
UT WOS:000370150000028
PM 26400251
ER
PT J
AU van Leeuwen, WF
Janssen, SJ
ter Meulen, DP
Ring, D
AF van Leeuwen, Wouter F.
Janssen, Stein J.
ter Meulen, Dirk P.
Ring, David
TI What Is the Radiographic Prevalence of Incidental Kienbock Disease?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID LICHTMAN CLASSIFICATION; ULNAR VARIANCE; RELIABILITY; LUNATE
AB Kienbock disease is characterized by osteonecrosis of the lunate. Not all patients with radiographic evidence of the disease experience symptoms bothersome enough to consult a doctor. Little research has been performed on the prevalence of Kienbock disease, and the prevalence in the asymptomatic population is unclear. Knowledge of the natural course of the disease and how often patients are not bothered by the symptoms is important, because it might influence the decision as to whether disease-modifying treatment would be beneficial.
(1) What is the prevalence of incidental and symptomatic Kienbock disease? (2) What are the factors associated with incidental and symptomatic Kienbock disease? (3) Are there differences in Lichtman stage distribution between incidentally discovered and symptomatic Kienbock disease?
We retrospectively searched radiology reports of all MRI scans, CT scans, and radiographs that included the wrists of 51,071 patients obtained over an 11-year period at one institution to screen for Kienbock disease and avascular necrosis of the lunate. Corresponding MR images, CT scans, or radiographs were reviewed by an orthopaedic hand surgeon to confirm the presence of Kienbock disease when the report was inconclusive. The medical record was reviewed to determine whether the radiographic Kienbock disease was incidental. Prevalences were calculated for both symptomatic and incidental Kienbock disease. Additionally, we assessed the association of age, sex, and race with incidental and symptomatic Kienbock disease as well as the radiographic severity according to the Lichtman classification and calculated odds ratios.
We identified 51 cases (0.10%) of incidental Kienbock disease and 87 cases (0.17%) of symptomatic Kienbock disease out of 51,071 patients. Patients with incidental Kienbock were older (mean, 54 years; SD, 17; mean difference, -6.1; 95% confidence interval [CI], -11 to -0.96; p = 0.020) and patients with symptomatic Kienbock disease were younger (mean, 43 years; SD, 14; mean difference, 5.1; 95% CI, 1.2-9.0; p = 0.010) compared with the group of patients without Kienbock disease (mean, 48 years; SD, 19). Lunate collapse (Lichtman Stages III and IV) was seen in nine of 51 patients (18%) with incidental Kienbock disease and in 44 of 87 patients (51%) with symptomatic Kienbock disease (odds ratio, 0.21; 95% CI, 0.086-0.51; p < 0.001). Our study did not identify any other factors associated with Kienbock disease.
We found that Kienbock disease is diagnosed on radiographs in a notable number of asymptomatic patients and that asymptomatic patients are more likely to have precollapse stages of the disease. This suggests that symptoms and disability do not correlate with pathophysiology, progression, or activity. Patients and surgeons benefit from awareness that symptoms are not a good indicator of the severity or prognosis of pathophysiology and that lunate osteonecrosis can exist with no or insufficient symptoms. This is important when considering treatment, because we cannot distinguish active disease at risk of collapse that could merit disease-modifying treatment from disease that will not progress.
Level III, prognostic study.
C1 [van Leeuwen, Wouter F.; Janssen, Stein J.; ter Meulen, Dirk P.; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Hand & Upper Extrem Serv, Boston, MA USA.
[Ring, David] Massachusetts Gen Hosp, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
NR 18
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAR
PY 2016
VL 474
IS 3
BP 808
EP 813
DI 10.1007/s11999-015-4541-1
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD8BV
UT WOS:000370150000036
PM 26324836
ER
EF